PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Furth, SL; Hwang, W; Yang, C; Neu, AM; Fivush, BA; Powe, NR				Furth, SL; Hwang, W; Yang, C; Neu, AM; Fivush, BA; Powe, NR			Relation between pediatric experience and treatment recommendations for children and adolescents with kidney failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; AMBULATORY PERITONEAL-DIALYSIS; RESOURCE UTILIZATION; MEDICAL SPECIALTIES; HEMODIALYSIS; CARE; MORTALITY; JUDGMENTS; THERAPY; SYSTEMS	Context Children and adolescent patients with renal failure are frequently cared for by adult subspecialists, While peritoneal dialysis is used in less than 17% of adults with kidney failure, it is the preferred dialysis treatment for children. National data show that 45% of children receiving dialysis are treated with peritoneal dialysis and pediatric nephrologists report its use in 65% of patients receiving dialysis. Whether differences in peritoneal dialysis use among children are due to the pediatric experience of the clinician has not been examined. Objective To assess whether the pediatric experience of nephrologists directly affects treatment recommendations for children with kidney failure. Design Cross-sectional survey using 10 case vignettes per survey based on random combinations of 8 patient characteristics (age, sex, race, distance from facility, cause of renal failure, family structure, education, and compliance). Setting and Participants National random sample of office-, hospital-, and academic medical center-based adult and pediatric nephrologists, stratified by geographic region and conducted June to November 1999. Of 519 eligible physicians, 316 (61%) responded, including 191 adult and 125 pediatric nephrologists. Main Outcome Measure Treatment recommendations for peritoneal dialysis vs hemodialysis, compared based on nephrologists' pediatric experience. Results After controlling for patient characteristics, pediatric nephrologists were 60% more likely than adult nephrologists to recommend peritoneal dialysis for identical patients (odds ratio, 1.61; 95% confidence interval, 1.35-1.92). This was true regardless of dialysis training, years in practice, practice setting, geography, or patient characteristics. Conclusions Our data indicate that pediatric specialization of clinicians influences treatment recommendations for children and adolescents with end-stage renal disease. Referring children to adult subspecialists may lead to differences in treatment choices and processes of care.	Johns Hopkins Med Inst, Dept Pediat, Div Pediat Nephrol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Furth, SL (corresponding author), 600 N Wolfe St,Pk 327, Baltimore, MD 21287 USA.	sfurth@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002586, K24DK002643] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK02586-01A1, K24 DK02643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alloatti S, 2000, J NEPHROL, V13, P331; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BREM AS, 1988, PEDIATR NEPHROL, V2, P460, DOI 10.1007/BF00853442; BROWNBRIDGE G, 1991, PEDIATR NEPHROL, V5, P612, DOI 10.1007/BF00856653; CHURCHILL DN, 1993, KIDNEY INT, V43, pS16; Coyte PC, 1996, AM J KIDNEY DIS, V27, P557, DOI 10.1016/S0272-6386(96)90167-5; Evans ED, 1995, PEDIATR CLIN N AM, V42, P1579; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FINE RN, 1987, PEDIATR CLIN N AM, V34, P789; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; FOX MP, 1993, AM J KIDNEY DIS, V22, P32, DOI 10.1016/0272-6386(93)70179-3; Franks P, 2000, J GEN INTERN MED, V15, P163, DOI 10.1046/j.1525-1497.2000.04079.x; Furth SL, 1997, ARCH PEDIAT ADOL MED, V151, P545, DOI 10.1001/archpedi.1997.02170430011002; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; KAISER BA, 1994, PEDIATR NEPHROL, V8, P733, DOI 10.1007/BF00869106; KRAVITZ RL, 1995, ANNU REV PUBL HEALTH, V16, P431; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; MCFALL SL, 1994, MED CARE, V32, P106, DOI 10.1097/00005650-199402000-00002; Meyer GS, 2000, J GEN INTERN MED, V15, P188, DOI 10.1046/j.1525-1497.2000.06039.x; Murphy SW, 2000, KIDNEY INT, V57, P1720, DOI 10.1046/j.1523-1755.2000.00017.x; NISSENSON AR, 1986, AM J KIDNEY DIS, V7, P229, DOI 10.1016/S0272-6386(86)80009-9; NISSENSON AR, 1993, KIDNEY INT, V43, pS120; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; STABLEIN DM, 2001, N AM PED REN TRANSPL; Stapleton FB, 1997, J AM SOC NEPHROL, V8, pS5; US Renal Data System, 1999, USRDS 1999 ANN DAT R; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; YAGER J, 1986, GEN HOSP PSYCHIAT, V8, P152, DOI 10.1016/0163-8343(86)90073-3	30	27	27	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2001	285	8					1027	1033		10.1001/jama.285.8.1027	http://dx.doi.org/10.1001/jama.285.8.1027			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	403ME	11209173				2023-01-03	WOS:000167046400024
J	Fitchet, A; Neal, R; Bannister, P				Fitchet, A; Neal, R; Bannister, P			Lesson of the week - Splenic trauma complicating cardiopulmonary resuscitation	BRITISH MEDICAL JOURNAL			English	Review									Manchester Royal Infirm, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England; Blackburn Royal Infirm, Blackburn BB2 3LR, Lancs, England; Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Fitchet, A (corresponding author), Manchester Royal Infirm, Manchester Heart Ctr, Oxford Rd, Manchester M13 9WL, Lancs, England.							ADLER SN, 1983, ARCH INTERN MED, V143, P813, DOI 10.1001/archinte.143.4.813; BERNARD SA, 1993, AUST NZ J SURG, V63, P312, DOI 10.1111/j.1445-2197.1993.tb00390.x; KOUWENHOVEN WB, 1984, JAMA-J AM MED ASSOC, V251, P3133, DOI 10.1001/jama.251.23.3133; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; MENZIES D, 1991, BRIT J UROL, V67, P440, DOI 10.1111/j.1464-410X.1991.tb15179.x; NAGEL EL, 1981, CRIT CARE MED, V9, P424, DOI 10.1097/00003246-198105000-00037; Nolan J, 1998, BRIT MED J, V316, P1844; Stallard N, 1997, RESUSCITATION, V35, P171, DOI 10.1016/S0300-9572(97)00054-3; VITELLO JM, 1991, J TRAUMA, V31, P426, DOI 10.1097/00005373-199103000-00023	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 24	2001	322	7284					480	481		10.1136/bmj.322.7284.480	http://dx.doi.org/10.1136/bmj.322.7284.480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	406YD	11222427	Green Published			2023-01-03	WOS:000167243000024
J	Haramburu, F; Miremont-Salame, G; Moore, K				Haramburu, F; Miremont-Salame, G; Moore, K			Good and bad drug prescription in pregnancy	LANCET			English	Editorial Material									Univ Victor Segalen, CHU Pellegrin Carriere, Dept Pharmacol, F-33076 Bordeaux, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Moore, K (corresponding author), Univ Victor Segalen, CHU Pellegrin Carriere, Dept Pharmacol, F-33076 Bordeaux, France.		Miremont-Salame, Ghada/T-2055-2019					BERTHIER M, 1993, THERAPIE, V48, P43; BOETHIUS G, 1977, EUR J CLIN PHARMACOL, V12, P37, DOI 10.1007/BF00561403; BONATI M, 1990, EUR J CLIN PHARMACOL, V38, P325, DOI 10.1007/BF00315569; BROCKLEBANK JC, 1978, AM J OBSTET GYNECOL, V132, P235, DOI 10.1016/0002-9378(78)90887-6; HARAMBURU F, 1995, PHARMACOEPIDEM DR S, V4, pS74; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148, DOI 10.1016/S0002-9378(87)80368-X; Wiebe S, 2000, BMJ-BRIT MED J, V320, P3, DOI 10.1136/bmj.320.7226.3; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V270, P2846	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1704	1704		10.1016/S0140-6736(00)03202-5	http://dx.doi.org/10.1016/S0140-6736(00)03202-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376MX	11095256				2023-01-03	WOS:000165462300007
J	Richter, LJ; Thanavala, Y; Arntzen, CJ; Mason, HS				Richter, LJ; Thanavala, Y; Arntzen, CJ; Mason, HS			Production of hepatitis B surface antigen in transgenic plants for oral immunization	NATURE BIOTECHNOLOGY			English	Article						hepatitis B surface antigen; transgenic plants; edible vaccine; potato; oral vaccine; protein engineering	ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; GENE; EXPRESSION; VACCINE; PATHWAY; REGION; CELLS; LEAF; ER	Here we present data showing oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) in preclinical animal trials. Mice fed transgenic HBsAS potato tubers showed a primary immune response (increases in HBsAg-specific serum antibody) that could be greatly boosted by intraperitoneal delivery of a single subimmunogenic dose of commercial HBsAS vaccine, indicating that plants expressing HBsAg in edible tissues may be a new means for oral hepatitis B immunization. However, attainment of such a goal will require higher HBsAS expression than was observed for the potatoes used in this study. We conducted a systematic analysis of factors influencing the accumulation of HBsAg in transgenic potato, including 5' and 3' flanking elements and protein targeting within plant cells. The most striking improvements resulted from (1) alternative polyadenylation signals, and (2) fusion proteins containing targeting signals designed to enhance integration or retention of HBsAS in the endoplasmic reticulum (ER) of plant cells.	Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Cornell University; Boyce Thompson Institute for Plant Research; Roswell Park Cancer Institute	Mason, HS (corresponding author), Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.		Richter, Lee/N-7730-2016	Richter, Lee/0000-0002-9433-3724; Mason, Hugh/0000-0002-0192-6716	NIAID NIH HHS [AI42836] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042836] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIZPURUA HJ, 1988, J EXP MED, V167, P440; AN GH, 1989, PLANT CELL, V1, P115, DOI 10.1105/tpc.1.1.115; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BEDNAREK SY, 1992, PLANT MOL BIOL, V20, P133, DOI 10.1007/BF00029156; Bruss V, 1996, INTERVIROLOGY, V39, P23, DOI 10.1159/000150471; Chan MT, 1998, P NATL ACAD SCI USA, V95, P6543, DOI 10.1073/pnas.95.11.6543; DEWALD D, 1992, THESIS TEXAS A M U; Dogan B, 2000, BIOTECHNOL PROGR, V16, P435, DOI 10.1021/bp0000454; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; Florence A.T, 1993, DRUGS PHARM SCI, P65; Gomord V, 1997, PLANT J, V11, P313, DOI 10.1046/j.1365-313X.1997.11020313.x; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; JEFFERSON RA, 1987, EMBO J, V6, P3901; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Muraskin William, 1995, WAR HEPATITIS B HIST; MURRAY K, 1984, EMBO J, V3, P645, DOI 10.1002/j.1460-2075.1984.tb01861.x; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; Neuhaus JM, 1998, PLANT MOL BIOL, V38, P127, DOI 10.1023/A:1006032627036; Prevelige PE, 1998, TRENDS BIOTECHNOL, V16, P61, DOI 10.1016/S0167-7799(97)01154-2; SUH SG, 1991, PLANTA, V184, P423, DOI 10.1007/BF00197888; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; WAMPLER DE, 1985, P NATL ACAD SCI USA, V82, P6830, DOI 10.1073/pnas.82.20.6830; WANDELT CI, 1992, PLANT J, V2, P181; WENZLER HC, 1989, PLANT MOL BIOL, V12, P41, DOI 10.1007/BF00017446; World Health Organization (WHO), 1998, WORLD HLTH REP 1998; 1991, MORBIDITY MORTALITY, V40, P1	30	308	378	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2000	18	11					1167	1171		10.1038/81153	http://dx.doi.org/10.1038/81153			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371JV	11062435				2023-01-03	WOS:000165176600021
J	Saltz, LB; Cox, JV; Blanke, C; Rosen, LS; Fehrenbacher, L; Moore, MJ; Maroun, JA; Ackland, SP; Locker, PK; Pirotta, N; Elfring, GL; Miller, LL				Saltz, LB; Cox, JV; Blanke, C; Rosen, LS; Fehrenbacher, L; Moore, MJ; Maroun, JA; Ackland, SP; Locker, PK; Pirotta, N; Elfring, GL; Miller, LL		Irinotecan Study Group	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 13-18, 1999	ATLANTA, GA	Amer Soc Clin Oncol			PHASE-II TRIAL; HEPATIC METASTASES; TOPOISOMERASE-I; CPT-11; CAMPTOTHECIN; CARCINOMA; MODULATION	Background: The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone. Methods: Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival. Results: Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P = 0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P = 0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life. Conclusions: Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival. (N Engl J Med 2000;343:905-14.) (C) 2000, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Gastroenterol Oncol Serv, New York, NY 10021 USA; US Oncol, Dallas, TX USA; Vanderbilt Canc Ctr, Nashville, TN USA; Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; Kaiser Permanente Med Ctr, Vallejo, CA USA; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada; Newcastle Mater Misericordiae Hosp, Waratah, NSW, Australia; Pharmacia Corp, Peapack, NJ USA	Memorial Sloan Kettering Cancer Center; US Oncology Network; Vanderbilt University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Kaiser Permanente; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital Research Institute; Calvary Mater Newcastle Hospital; Pfizer	Saltz, LB (corresponding author), Mem Sloan Kettering Canc Ctr, Gastroenterol Oncol Serv, 1275 York Ave, New York, NY 10021 USA.		Ducreux, Michel/L-7012-2019; Goldberg, Richard M/M-1311-2013; Ackland, Stephen P./G-7460-2013; Goldberg, Richard/O-1871-2017; Messori, Andrea/U-6903-2019; Krieger, Gerhard/D-5164-2012	Ackland, Stephen P./0000-0001-5303-0017; Goldberg, Richard/0000-0003-3713-6895; Krieger, Gerhard/0000-0002-4548-0285; Saltz, Leonard/0000-0001-8353-4670				ABIGERGES D, 1994, J NATL CANCER I, V86, P446, DOI 10.1093/jnci/86.6.446; BUROKER TR, 1994, J CLIN ONCOL, V12, P14, DOI 10.1200/JCO.1994.12.1.14; Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; GANDIA D, 1993, J CLIN ONCOL, V11, P196, DOI 10.1200/JCO.1993.11.1.196; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GREM JL, 1996, CANC CHEMOTHERAPY BI, P149; HSIANG YH, 1989, CANCER RES, V49, P5077; JAXEL C, 1989, CANCER RES, V49, P1465; KAWATO Y, 1991, CANCER RES, V51, P4187; KEMENY N, 1989, CANCER, V63, P742, DOI 10.1002/1097-0142(19890215)63:4<742::AID-CNCR2820630423>3.0.CO;2-T; LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303; MILLER LL, 1998, P AN M AM SOC CLIN, V17, pA297; PAZDUR R, 1997, P AN M AM SOC CLIN, V16, pA260; PETIT RG, 1997, P AN M AM SOC CLIN, V16, pA268; Pitot HC, 1997, J CLIN ONCOL, V15, P2910, DOI 10.1200/JCO.1997.15.8.2910; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Rothenberg ML, 1999, CANCER-AM CANCER SOC, V85, P786, DOI 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9; ROTHENBERG ML, 1998, P AN M AM SOC CLIN, V17, pA284; ROUGIER P, 1995, BRIT J SURG, V82, P1397, DOI 10.1002/bjs.1800821034; Rougier P, 1997, J CLIN ONCOL, V15, P251, DOI 10.1200/JCO.1997.15.1.251; Rougier P, 1998, LANCET, V352, P1634; Saltz LB, 1996, J CLIN ONCOL, V14, P2959, DOI 10.1200/JCO.1996.14.11.2959; SHIMADA Y, 1993, J CLIN ONCOL, V11, P909, DOI 10.1200/JCO.1993.11.5.909; VANCUTSEM E, 1997, P AN M AM SOC CLIN, V16, pA268; VONHOFF DD, 1997, P AN M AM SOC CLIN, V16, pA228	30	2448	2544	1	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	2000	343	13					905	914		10.1056/NEJM200009283431302	http://dx.doi.org/10.1056/NEJM200009283431302			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	357KT	11006366	Bronze			2023-01-03	WOS:000089501400002
J	Morrison, RS; Siu, AL				Morrison, RS; Siu, AL			Survival in end-stage dementia following acute illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; HIP FRACTURE; PREDICTORS; MORTALITY; CARE; EXPERIENCE; PNEUMONIA; ADULTS; TIME	Context Little is known about the prognosis of acutely ill patients with end-stage dementia or about the type of care that these patients receive. If their prognosis is poor, then emphasis should be placed on palliative care for these patients rather than on curative interventions. Objectives To examine survival for patients with end-stage dementia following hospitalization for hip fracture or pneumonia and to com pare their care with that of cognitively intact older adults. Design Prospective cohort study with 6 months of follow-up. Setting and Patients Patients aged 70 years or older who were hospitalized with hip fracture (cognitively intact, n = 59; with end-stage dementia, n = 38) or pneumonia (cognitively intact, n = 39; with end-stage dementia, n = 80) in a large hospital in New York, NY, between September 1, 1996, and March 1, 1998, Main Outcome Measures Mortality, treatments directed at symptoms, and application of distressing and painful procedures in cognitively intact patients vs those with end-stage dementia. Results Six-month mortality for patients with end-stage dementia and pneumonia was 53% (95% confidence interval [CI], 41%-64%) compared with 13% (95% CI, 4%-27%) for cognitively intact patients (adjusted hazard ratio, 4.6; 95% CI, 1.8-11.8), Six month mortality for patients with end-stage dementia and hip fracture was 55% (95% CI, 42%-75%) compared with 12% (95% CI, 5%-24%) for cognitively intact patients (adjusted hazard ratio, 5.8; 95% CI, 1.7-20.4). Patients with end-stage dementia received as many burdensome procedures as cognitively intact patients and only 8 (7%) of 118 patients with end-stage dementia had a documented decision made to forego a life-sustaining treatment other than cardiopulmonary resuscitation, Only 24% of patients with end-stage dementia and hip fracture received a standing order for analgesics. Conclusions In this study, patients with advanced dementia and hip fracture or pneumonia had a very poor prognosis. Given the limited life expectancy of patients with endstage dementia following these illnesses and the burdens associated with their treatment, increased attention should be focused on efforts to enhance comfort in this patient population.	CUNY Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), CUNY Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl, New York, NY 10029 USA.				AHRQ HHS [U18HS09549-0] Funding Source: Medline; NIA NIH HHS [K08AG00833-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R13HS009549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000833] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMANN RJ, 1995, J FAM PRACTICE, V40, P129; Aguero-Torres H, 1998, J AM GERIATR SOC, V46, P444, DOI 10.1111/j.1532-5415.1998.tb02464.x; Bowen JD, 1996, NEUROLOGY, V47, P433, DOI 10.1212/WNL.47.2.433; Claus JJ, 1998, DEMENT GERIATR COGN, V9, P284, DOI 10.1159/000017073; DAVIDSON TI, 1986, INJURY, V17, P12, DOI 10.1016/0020-1383(86)90005-7; FABISZEWSKI KJ, 1990, JAMA-J AM MED ASSOC, V263, P3168, DOI 10.1001/jama.263.23.3168; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Hanrahan P, 1995, Hosp J, V10, P47; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; INCALZI RA, 1994, J TRAUMA, V36, P79; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LUYAO GL, 1994, AM J PUBLIC HEALTH, V84, P1287, DOI 10.2105/AJPH.84.8.1287; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MCGEER A, 1991, AM J INFECT CONTROL, V19, P1, DOI 10.1016/0196-6553(91)90154-5; Morrison RS, 1998, J PAIN SYMPTOM MANAG, V15, P91, DOI 10.1016/S0885-3924(97)00261-3; Muder RR, 1996, ARCH INTERN MED, V156, P2365, DOI 10.1001/archinte.156.20.2365; *OFF TECHN ASS CON, 1990, BURD FAM FIND HELP P; Reisberg B, 1996, Int Psychogeriatr, V8, P291, DOI 10.1017/S1041610296002657; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; ROCCAFORTE WH, 1992, J AM GERIATR SOC, V40, P697, DOI 10.1111/j.1532-5415.1992.tb01962.x; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; Vigano A, 2000, ARCH INTERN MED, V160, P861, DOI 10.1001/archinte.160.6.861; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x	25	262	264	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					47	52		10.1001/jama.284.1.47	http://dx.doi.org/10.1001/jama.284.1.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	328GX	10872012	Bronze			2023-01-03	WOS:000087843000024
J	Young, RK				Young, RK			The old man's friend	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1793	1794		10.1001/jama.283.14.1793	http://dx.doi.org/10.1001/jama.283.14.1793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770128				2023-01-03	WOS:000086248600001
J	Schuurman, PR; Bosch, DA; Bossuyt, PMM; Bonsel, GJ; van Someren, EJW; de Bie, RMA; Merkus, MP; Speelman, JD				Schuurman, PR; Bosch, DA; Bossuyt, PMM; Bonsel, GJ; van Someren, EJW; de Bie, RMA; Merkus, MP; Speelman, JD			A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-BRAIN-STIMULATION; CHRONIC ELECTRICAL-STIMULATION; ADVANCED PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; MOVEMENT-DISORDERS; STEREOTAXIC THALAMOTOMY; SUBTHALAMIC NUCLEUS; CEREBELLAR TREMOR; ACTIVITIES INDEX; STROKE PATIENTS	Background: Deep-brain stimulation through an electrode implanted in the thalamus was developed as an alternative to thalamotomy for the treatment of drug-resistant tremor. Stimulation is thought to be as effective as thalamotomy but to have fewer complications. We examined the effects of these two procedures on the functional abilities of patients with drug-resistant tremor due to Parkinson's disease, essential tremor, or multiple sclerosis. Methods: Sixty-eight patients (45 with Parkinson's disease, 13 with essential tremor, and 10 with multiple sclerosis) were randomly assigned to undergo thalamotomy or thalamic stimulation. The primary outcome measure was the change in functional abilities six months after surgery, as measured by the Frenchay Activities Index. Scores for this index can range from 0 to 60, with higher scores indicating better function. Secondary outcome measures were the severity of tremor, the number of adverse effects, and patients' assessment of the outcome. Results: Functional status improved more in the thalamic-stimulation group than in the thalamotomy group, as indicated by increases in the score for the Frenchay Activities Index (from 31.4 to 36.3 and from 32.0 to 32.5, respectively; difference between groups, 4.4 points; 95 percent confidence interval, 2.0 to 6.9). After adjustment for base-line characteristics, multivariate analysis also showed that the thalamic-stimulation group had greater improvement (difference between groups, 5.1 points; 95 percent confidence interval, 2.3 to 7.9). Tremor was suppressed completely or almost completely in 27 of 34 patients in the thalamotomy group and in 30 of 33 patients in the thalamic-stimulation group. One patient in the thalamic-stimulation group died perioperatively after an intracerebral hemorrhage. With the exception of this incident, thalamic stimulation was associated with significantly fewer adverse effects than thalamotomy. Functional status was reported as improved by 8 patients in the thalamotomy group, as compared with 18 patients in the thalamic-stimulation group (P=0.01). Conclusions: Thalamic stimulation and thalamotomy are equally effective for the suppression of drug-resistant tremor, but thalamic stimulation has fewer adverse effects and results in a greater improvement in function. (N Engl J Med 2000;342:461-8.) (C) 2000, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Netherlands Inst Brain Res, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Speelman, JD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.d.speelman@amc.uva.nl	Van Someren, Eus/AAA-6789-2020; Schuurman, Rick/ABE-9100-2021; Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; de Bie, Rob/0000-0001-5267-0784				ALESCH F, 1995, ACTA NEUROCHIR, V136, P75, DOI 10.1007/BF01411439; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENABID AL, 1993, ACTA NEUROCHIR, P39; Blankensteijn JD, 1998, BRIT J SURG, V85, P1624; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; BOSCH DA, 1986, STEREOTACTIC TECHNIQ; Critchley GR, 1998, BRIT J NEUROSURG, V12, P559, DOI 10.1080/02688699844439; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Fahn S., 1988, PARKINSONS DIS MOVEM, P225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOX MW, 1991, J NEUROSURG, V75, P723, DOI 10.3171/jns.1991.75.5.0723; Geny C, 1996, MOVEMENT DISORD, V11, P489, DOI 10.1002/mds.870110503; GOLDMAN MS, 1992, J NEUROSURG, V76, P924, DOI 10.3171/jns.1992.76.6.0924; Haddow LJ, 1997, NEUROSURG QUART, V7, P23; Hariz GM, 1998, MOVEMENT DISORD, V13, P78, DOI 10.1002/mds.870130117; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Hooper J, 1998, LANCET, V352, P1984, DOI 10.1016/S0140-6736(05)61329-3; Hubble JP, 1996, NEUROLOGY, V46, P1150, DOI 10.1212/WNL.46.4.1150; JANKOVIC J, 1995, NEUROSURGERY, V37, P680, DOI 10.1227/00006123-199510000-00011; KELLY PJ, 1980, J NEUROSURG, V53, P332, DOI 10.3171/jns.1980.53.3.0332; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LENZ FA, 1995, MOVEMENT DISORD, V10, P318, DOI 10.1002/mds.870100315; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; MATSUMOTO K, 1977, APPL NEUROPHYSIOL, V39, P257; NAGASEKI Y, 1986, J NEUROSURG, V65, P296, DOI 10.3171/jns.1986.65.3.0296; Ondo W, 1998, NEUROLOGY, V51, P1063, DOI 10.1212/WNL.51.4.1063; POLLAK P, 1993, ADV NEUROL, V60, P408; Rodriguez MC, 1998, MOVEMENT DISORD, V13, P111; Ryan RM, 1997, ANN ROY COLL SURG, V79, P423; SAMRA K, 1970, J NEUROL NEUROSUR PS, V33, P7, DOI 10.1136/jnnp.33.1.7; SCHALTENBRAND G, 1982, STEREOTAXY HUMAN BRA; Schaltenbrand G, 1977, ATLAS STEREOTAXY HUM; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SELBY G, 1967, J NEUROL SCI, V5, P343, DOI 10.1016/0022-510X(67)90140-2; Shahzadi S, 1995, STEREOT FUNCT NEUROS, V65, P11, DOI 10.1159/000098890; SIEGFRIED J, 1994, STEREOT FUNCT NEUROS, V62, P71, DOI 10.1159/000098599; SPEELMAN JD, 1984, J NEUROL NEUROSUR PS, V47, P596, DOI 10.1136/jnnp.47.6.596; SPEELMAN JD, 1991, THESIS U AMSTERDAM; Tasker RR, 1996, ADV NEUROL, V69, P563; Tasker RR, 1997, ADV STER F, V12, P49; WESTER K, 1990, J NEUROL NEUROSUR PS, V53, P427, DOI 10.1136/jnnp.53.5.427; Whittle IR, 1998, LANCET, V351, P109, DOI 10.1016/S0140-6736(98)24002-5	48	701	725	0	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					461	468		10.1056/NEJM200002173420703	http://dx.doi.org/10.1056/NEJM200002173420703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675426	Green Published			2023-01-03	WOS:000085319100003
J	Himsworth, RL; Goldacre, MJ				Himsworth, RL; Goldacre, MJ			Does time spent in hospital in the final 15 years of life increase with age at death? A population based study	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Cambridge; University of Oxford	Himsworth, RL (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.							GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HENDERSON J, 1990, BRIT MED J, V301, P17, DOI 10.1136/bmj.301.6742.17; vanWeel C, 1997, LANCET, V350, P1159, DOI 10.1016/S0140-6736(97)08312-8; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210	4	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1338	1339		10.1136/bmj.319.7221.1338	http://dx.doi.org/10.1136/bmj.319.7221.1338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567138	Green Published, Bronze			2023-01-03	WOS:000083930200025
J	Oleske, JM; Czarniecki, L				Oleske, JM; Czarniecki, L			Continuum of palliative care: lessons from caring for children infected with HIV-1	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; PERSPECTIVE; MEDICINE; ISSUES; NEEDS; AIDS		Univ Med & Dent New Jersey, Dept Paediat, Div Pulm Allergy Immunol & Infect Dis, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Oleske, JM (corresponding author), Univ Med & Dent New Jersey, Dept Paediat, Div Pulm Allergy Immunol & Infect Dis, Univ Hts, Newark, NJ 07103 USA.		Oleske, James M/C-1951-2016	Oleske, James M/0000-0003-2305-5605				Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BOLAND M, 1995, SEMINARS PEDIAT INFE, V6, P40; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P315; Corner J, 1996, PALLIATIVE MED, V10, P201, DOI 10.1177/026921639601000304; Czarniecki L. M., 1993, PAACNOTES, V5, P492; ELSADR W, 1994, AHCPR PUBLICATION; FERRIS F, 1995, COMPREHENSIVE GUIDE, V4; FOLEY FJ, 1995, J PALLIATIVE CARE, V11, P19, DOI 10.1177/082585979501100204; Futterman D., 1992, AIDS Clinical Care, V4, P95; GROTHE TM, 1995, J PALLIATIVE CARE, V11, P48, DOI 10.1177/082585979501100212; GRUBMAN S, 1995, PEDIATRICS, V95, P657; James L, 1997, J Pediatr Oncol Nurs, V14, P83, DOI 10.1177/104345429701400207; Levetown M, 1996, J PALLIAT CARE, V12, P35, DOI 10.1177/082585979601200308; LEWIS SY, 1994, J DEV BEHAV PEDIATR, V15, pS12; Liben S, 1996, J PALLIAT CARE, V12, P24, DOI 10.1177/082585979601200306; Martinson I, 1996, J PALLIATIVE CARE, V12, P13, DOI 10.1177/082585979601200303; Martinson I M, 1993, J Pediatr Oncol Nurs, V10, P93, DOI 10.1177/104345429301000304; Martinson I M, 1995, Annu Rev Nurs Res, V13, P195; MARTINSON IM, 1986, RES NURS HEALTH, V9, P11, DOI 10.1002/nur.4770090104; Nielsen K, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.4.e4; OLESKE JM, 1995, PEDIATR AIDS HIV INF, V6, P187; Oleske JM, 1996, J NUTR, V126, pS2616, DOI 10.1093/jn/126.suppl_10.2616S; Oleske JM, 1997, HOSP PRACT, V32, P167, DOI 10.1080/21548331.1997.11443514; OLESKE JM, 1994, HOSP PRACT, V29, P81, DOI 10.1080/21548331.1994.11443078; OLESKE JM, 1995, NIH PUBLICATION; Pellegrino ED, 1998, JAMA-J AM MED ASSOC, V279, P1521, DOI 10.1001/jama.279.19.1521; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; Reiter G S, 1996, AIDS Clin Care, V8, P21; Rothpletz-Puglia P., 1997, Topics in Clinical Nutrition, V12, P69; Tasker M., 1992, CAN I TELL YOU SECRE; Trill MD, 1997, ANN NY ACAD SCI, V809, P197, DOI 10.1111/j.1749-6632.1997.tb48083.x; *UN, 1991, CONV RIGHTS CHILDR; VONGUNTEN CF, 1995, J PALLIATIVE CARE, V11, P5, DOI 10.1177/082585979501100202; Welch K, 1998, AIDS PATIENT CARE ST, V12, P125, DOI 10.1089/apc.1998.12.125; *WHO, 1998, REP GLOB HIV AIDS EP; World Health Organization, 1995, WORLD HLTH REP 1995	36	6	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1287	1291		10.1016/S0140-6736(98)12487-X	http://dx.doi.org/10.1016/S0140-6736(98)12487-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243RE	10520650				2023-01-03	WOS:000083010400045
J	Bozzette, SA; Joyce, G; McCaffrey, DF; Leibowitz, AA; Morton, SC; Berry, SH; Rastegar, A; Timberlake, D; Shapiro, MF; Goldman, DP				Bozzette, SA; Joyce, G; McCaffrey, DF; Leibowitz, AA; Morton, SC; Berry, SH; Rastegar, A; Timberlake, D; Shapiro, MF; Goldman, DP		HIV Cost Services Utilization Stud	Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; UNITED-STATES; SERVICES UTILIZATION; MEDICAL-CARE; COSTS; AIDS; PREVALENCE; SAMPLES; ADULTS	Background: The introduction of expensive but very effective antiviral medications has led to questions about the effects on the total use of resources for the care of patients with human immunodeficiency virus (HIV) infection. We examined expenditures for the care of HIV-infected patients since the introduction of highly active antiretroviral therapy. Methods: We interviewed a random sample of 2864 patients who were representative of all American adults receiving care for HIV infection in early 1996, and followed them for up to 36 months. We estimated the average expenditure per patient per month on the basis of self-reported information about care received. Results: The mean expenditure was $1,792 per patient per month at base line, but it declined to $1,359 for survivors in 1997, since the increases in pharmaceutical expenditures were smaller than the reductions in hospital costs. Use of highly active antiretroviral therapy was independently associated with a reduction in expenditures. After adjustments for the interview date, clinical status, and deaths, the estimated annual expenditure declined from $20,300 per patient in 1996 to $18,300 in 1998. Expenditures among subgroups of patients varied by a factor of as much as three. Pharmaceutical costs were lowest and hospital costs highest among underserved groups, including blacks, women, and patients without private insurance. Conclusions: The total cost of care for adults with HIV infection has declined since the introduction of highly active antiretroviral therapy. Expenditures have increased for medications but have declined for other services. However, there are large variations in expenditures across subgroups of patients. (N Engl J Med 2001;344:817-23.) Copyright (C) 2001 Massachusetts Medical Society.	RAND Corp, Hlth, Santa Monica, CA 90407 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	RAND Corporation; University of California System; University of California San Diego; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Bozzette, SA (corresponding author), RAND Corp, Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS008578] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035040] Funding Source: NIH RePORTER; AHRQ HHS [HS08578] Funding Source: Medline; NICHD NIH HHS [R01-HD35040] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRY SH, IN PRESS HCSUC BAS P; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005; Frankel MR, 1999, HEALTH SERV RES, V34, P969; Gebo KA, 1999, AIDS, V13, P963, DOI 10.1097/00002030-199905280-00013; Goldman DP, 2001, MED CARE RES REV, V58, P31, DOI 10.1177/107755870105800102; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; KALTON G, 1983, COMPENSATING MISSING; Keiser P, 1999, J ACQ IMMUN DEF SYND, V20, P28, DOI 10.1097/00042560-199901010-00004; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; LANDON BE, 1999, 16 ANN M ASS HLTH SE, P135; LORD LJ, 1987, US NEWS WORLD R 0615, P16; Moore RD, 2000, PHARMACOECONOMICS, V17, P325, DOI 10.2165/00019053-200017040-00002; Murphy S, 1998, J Health Serv Res Policy, V3, P215; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rabeneck L, 1999, MED CARE, V37, P748, DOI 10.1097/00005650-199908000-00005; Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SCITOVSKY AA, 1990, J ACQ IMMUN DEF SYND, V3, P904; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; SISK JE, 1987, HEALTH AFFAIR, V6, P5, DOI 10.1377/hlthaff.6.2.5; Weissman JS, 1996, AIDS, V10, P775, DOI 10.1097/00002030-199606001-00013	26	208	210	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2001	344	11					817	823		10.1056/NEJM200103153441107	http://dx.doi.org/10.1056/NEJM200103153441107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	410LA	11248159	Green Published			2023-01-03	WOS:000167440400007
J	Bodeker, G				Bodeker, G			Lessons on integration from the developing world's experience	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRADITIONAL MEDICINE; CHINESE MEDICINE; HEALTH		Univ Oxford Green Coll, Commonwealth Working Grp Tradit & Complementary H, Oxford OX2 6HG, England	University of Oxford	Bodeker, G (corresponding author), Univ Oxford Green Coll, Commonwealth Working Grp Tradit & Complementary H, Oxford OX2 6HG, England.	gerry.bodeker@green.ox.ac.uk						Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bannerman R.H., 1983, TRADITIONAL MED HEAL; Bodeker G, 1999, J ALTERN COMPLEM MED, V5, P97; CHI CH, 1994, SOC SCI MED, V39, P307, DOI 10.1016/0277-9536(94)90127-9; Cho HJ, 2000, SOC SCI MED, V50, P123, DOI 10.1016/S0277-9536(99)00284-1; *DEP IND SYST MED, 2000, ANN REP 1999 2000; Easthope G, 1998, MED J AUSTRALIA, V169, P197, DOI 10.5694/j.1326-5377.1998.tb140221.x; Hesketh T, 1997, BRIT MED J, V315, P115, DOI 10.1136/bmj.315.7100.115; HESKETH T, 1994, BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441; Kumar S, 2000, LANCET, V355, P1252, DOI 10.1016/S0140-6736(05)74695-X; OSUIDE GE, 1999, INT C ETHN DRUG DISC; 2000, STRAITS TIMES   1114	12	69	70	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2001	322	7279					164	167		10.1136/bmj.322.7279.164	http://dx.doi.org/10.1136/bmj.322.7279.164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159579	Green Published			2023-01-03	WOS:000166615300034
J	Nahin, RL; Straus, SE				Nahin, RL; Straus, SE			Research into complementary and alternative medicine: problems and potential	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; UNITED-STATES; ACUPUNCTURE; THERAPIES		NIH, Div Extramural Res Training & Review, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Nahin, RL (corresponding author), NIH, Div Extramural Res Training & Review, Natl Ctr Complementary & Alternat Med, 9000 Rockville Pike, Bethesda, MD 20892 USA.			Nahin, Richard/0000-0002-3682-4816				Astin JA, 2000, J GERONTOL A-BIOL, V55, pM4; Birch S, 1998, CLIN J PAIN, V14, P248, DOI 10.1097/00002508-199809000-00012; Brody H, 2000, J FAM PRACTICE, V49, P649; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ellis PM, 2000, ANN ONCOL, V11, P939, DOI 10.1023/A:1008342222205; Eskinazi D, 2000, ALTERN THER HEALTH M, V6, P49; Hammerschlag R, 1998, J ALTERN COMPLEM MED, V4, P159, DOI 10.1089/acm.1998.4.159; Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; *NAT CTR COMPL ALT, 2000, 5 YEAR STRAT PLAN; *NAT CTR COMPL ALT, 2000, LIST THES RES IN; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; Richardson MA, 1998, ANN BEHAV MED, V20, P190, DOI 10.1007/BF02884960; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; VINCENT C, 1995, J ROY SOC MED, V88, P199; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	22	119	123	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					161	164		10.1136/bmj.322.7279.161	http://dx.doi.org/10.1136/bmj.322.7279.161			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	396AZ	11159578	Green Published			2023-01-03	WOS:000166615300033
J	Muramoto, O				Muramoto, O			Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Reg Eth Council, Kaiser Permanente Interstate Med Off E, Portland, OR 97227 USA		Muramoto, O (corresponding author), Reg Eth Council, Kaiser Permanente Interstate Med Off E, Portland, OR 97227 USA.	muramoto@aracnet.com						Bailey R, 1998, ARTIF CELL BLOOD SUB, V26, P571, DOI 10.3109/10731199809117476; Elder L, 2000, J MED ETHICS, V26, P375, DOI 10.1136/jme.26.5.375; GLEDHILL R, 2000, TIMES           0615; LITTLE J, 2000, BBC NEWS        0614; Mullon J, 2000, NEW ENGL J MED, V342, P1638, DOI 10.1056/NEJM200006013422204; Muramoto O, 2000, J MED ETHICS, V26, P381, DOI 10.1136/jme.26.5.381; Muramoto O, 1999, WESTERN J MED, V170, P297; Muramoto O, 1998, J MED ETHICS, V24, P223, DOI 10.1136/jme.24.4.223; Muramoto O, 1998, LANCET, V352, P824, DOI 10.1016/S0140-6736(05)60725-8; Muramoto O, 1999, J MED ETHICS, V25, P463, DOI 10.1136/jme.25.6.463; Ridley DT, 1999, J MED ETHICS, V25, P469, DOI 10.1136/jme.25.6.469; Sharp D, 2000, LANCET, V356, P8, DOI 10.1016/S0140-6736(00)02424-7; *WATCH TOW BIBL TR, 1981, WATCHTOWER      0915, P20; *WATCH TOW BIBL TR, 1987, WATCHTOWER      0901, P12; Watch Tower Bible & Tract Society, 2000, THE WATCHTOWER, P29; Wilcox P, 1999, LANCET, V353, P757, DOI 10.1016/S0140-6736(05)76132-8	16	59	61	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2001	322	7277					37	39		10.1136/bmj.322.7277.37	http://dx.doi.org/10.1136/bmj.322.7277.37			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141155	Green Published			2023-01-03	WOS:000166341400025
J	Mrazek, MF; Mossialos, E				Mrazek, MF; Mossialos, E			Increasing demand while decreasing costs of generic medicines	LANCET			English	Editorial Material							PRESCRIPTION		Univ London London Sch Econ & Polit Sci, LSE Hlth, London WC2A 2AE, England	University of London; London School Economics & Political Science	Mossialos, E (corresponding author), Univ London London Sch Econ & Polit Sci, LSE Hlth, Houghton St, London WC2A 2AE, England.		Mossialos, Elias/ABE-1301-2021					Bussow R., 1996, Formal Methods for Industrial Applications. Specifying and Programming the Steam Boiler Control, P109, DOI 10.1007/BFb0027233; *DEP HLTH UK, 1998, STAT B DEP HLTH UK, V24; *DEP HLTH UK, 2000, GOV RESP HLTH SEL CO; *EUR OBS HLTH CAR, 1999, HLTH CAR SYST TRANS; Giuliani G, 1998, HEALTH POLICY, V44, P73, DOI 10.1016/S0168-8510(98)00012-8; Gosden T, 1997, HEALTH POLICY, V40, P103, DOI 10.1016/S0168-8510(96)00888-3; Hellerstein JK, 1998, RAND J ECON, V29, P108, DOI 10.2307/2555818; Hillman AL, 1999, HEALTH AFFAIR, V18, P189, DOI 10.1377/hlthaff.18.2.189; *HOECHST MAR ROUS, 1998, MAN CAR DIG SER; Hong SH, 1996, CLIN THER, V18, P528, DOI 10.1016/S0149-2918(96)80035-X; *PHARM PRIC REV, 1998, PHARMA PRICING REV, V3, P200; *US DEP HHS, 2000, PRESCR DRUG COV SPEN	12	9	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1784	1785		10.1016/S0140-6736(00)03225-6	http://dx.doi.org/10.1016/S0140-6736(00)03225-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377UY	11117905				2023-01-03	WOS:000165545700004
J	Grinspoon, S; Corcoran, C; Parlman, K; Costello, M; Rosenthal, D; Anderson, E; Stanley, T; Schoenfeld, D; Burrows, B; Hayden, D; Basgoz, N; Klibanski, A				Grinspoon, S; Corcoran, C; Parlman, K; Costello, M; Rosenthal, D; Anderson, E; Stanley, T; Schoenfeld, D; Burrows, B; Hayden, D; Basgoz, N; Klibanski, A			Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NANDROLONE DECANOATE; WEIGHT; BODY	Background: Substantial loss of muscle mass occurs among men with AIDS wasting. Objective: To investigate the independent effects of testosterone therapy and progressive resistance training in eugonadal men with AIDS wasting. Design: Randomized, controlled trial. Setting: University hospital. Patients: 54 eugonadal men with AIDS wasting (weight < 90% ideal body weight or weight loss > 10%). Intervention: In a 2 x 2 factorial design, patients were assigned to receive testosterone enanthate (200 mg/wk) or placebo injections and progressive resistance training (three times weekly) or no training for 12 weeks. Measurements: Cross-sectional muscle area and other indices of muscle mass. Results: Cross-sectional muscle area increased in response to training compared with nontraining (change in arm muscle mass, 499 +/- 349 mm(2) vs. 206 +/- 264 mm(2) [P = 0.004]; change in leg muscle mass, 1106 +/- 854 mm(2) vs. 523 +/- 872 mm(2) [P = 0.045]) and in response to testosterone therapy compared with placebo (change in arm muscle mass, 512 +/- 371 mm(2) vs. 194 +/- 215 mm(2) [P < 0.001]; change in leg muscle mass, 1236 +/- 881 mm(2) vs. 399 +/- 729 mm(2) [P = 0.002]). Levels of high-density lipoprotein cholesterol decreased in response to testosterone therapy compared with placebo (-0.03 +/- 0.13 mmol/L vs. 0.05 +/- 0.13 mmol/L [-1 +/- 5 mg/dL vs. 2 +/- 5 mg/dL]; P = 0.011) and increased in response to training compared with nontraining (0.05 +/- 0.13 mmol/L vs. 0.00 +/- 0.16 mmol/L [2 +/- 5 mg/dL vs. 0 +/- 6 mg/dL]; P = 0.052). Conclusions: In contrast to anabolic therapies that may have adverse effects on metabolic variables, supervised exercise effectively increases muscle mass and is associated with significant positive health benefits in eugonadal men with AIDS wasting.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Vet Adm Med Ctr, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B,55 Fruit St, Boston, MA 02114 USA.		Stanley, Takara/GYV-4488-2022	Stanley, Takara/0000-0002-2336-2958	NCRR NIH HHS [M01-RR01066] Funding Source: Medline; NIDDK NIH HHS [P32-DK07028, R01-DK49302] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049302, T32DK007028] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM COL SPORTS MED, 1980, GUID GRAD EX TEST EX; ANDRES PL, 1986, NEUROLOGY, V36, P937, DOI 10.1212/WNL.36.7.937; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Finison LJ, 1996, ARCH PHYS MED REHAB, V77, P1251; FISHER A, 1998, 12 WORLD AIDS C GEN, P844; GIBERT CL, 1998, 12 WORLD AIDS C GEN, P554; Gold J, 1996, AIDS, V10, P745, DOI 10.1097/00002030-199606001-00008; Grinspoon S, 1999, J CLIN ENDOCR METAB, V84, P201, DOI 10.1210/jc.84.1.201; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; Hortobagyi T, 1997, MED SCI SPORT EXER, V29, P107, DOI 10.1097/00005768-199701000-00015; JORDAN CD, 1992, NEW ENGL J MED, V327, P718; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MUNSAT TL, 1989, PHYSICAL MED REHABIL, V3, P188; RIETSCHEL P, IN PRESS CLIN INFECT; Sattler FR, 1999, J CLIN ENDOCR METAB, V84, P1268, DOI 10.1210/jc.84.4.1268; Silva M, 1998, AIDS, V12, P1645, DOI 10.1097/00002030-199813000-00012; Strawford A, 1999, JAMA-J AM MED ASSOC, V281, P1282, DOI 10.1001/jama.281.14.1282; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422	20	147	149	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					348	355		10.7326/0003-4819-133-5-200009050-00010	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979879				2023-01-03	WOS:000089111900004
J	Rask-Nissila, L; Jokinen, E; Terho, P; Tammi, A; Lapinleimu, H; Ronnemaa, T; Viikari, J; Seppanen, R; Korhonen, T; Tuominen, J; Valimaki, I; Simell, O				Rask-Nissila, L; Jokinen, E; Terho, P; Tammi, A; Lapinleimu, H; Ronnemaa, T; Viikari, J; Seppanen, R; Korhonen, T; Tuominen, J; Valimaki, I; Simell, O			Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; GROWTH; REDUCTION; AGE; ATHEROSCLEROSIS; INTERVENTION; ASSOCIATION; CHILDHOOD	Context Early childhood introduction of nutritional habits aimed at atherosclerosis prevention is compatible with normal growth, but its effect on neurological development is unknown. Objective To analyze how parental counseling aimed at keeping children's diets low in saturated fat and cholesterol influences neurodevelopment during the first 5 years of life. Design Randomized controlled trial conducted between February 1990 and November 1996. Setting Outpatient clinic of a university department in Turku, Finland. Participants A total of 1062 seven-month-old infants and their parents, recruited at well-baby clinics between 1990 and 1992. At age 5 years, 496 children still living in the city of Turku were available to participate in neurodevelopmental testing. Intervention Participants were randomly assigned to receive individualized counseling aimed at limiting the child's fat intake to 30% to 35% of daily energy, with a saturated: monounsaturated:polyunsaturated fatty acid ratio of 1:1:1 and a cholesterol intake of less than 200 mg/d (n = 540) or usual health education (control group, n = 522). Main Outcome Measures Nutrient intake, serum lipid concentrations, and neurological development at 5 years, among children in the intervention vs control groups. Results Absolute and relative intakes of fat, saturated fatty acids, and cholesterol among children in the intervention group were markedly less than the respective values of control children. Mean (SD) percentages of daily energy at age 5 years for the intervention vs control groups were as follows: for total fat, 30.6% (4.5%) vs 33.4% (4.4%) (P<.001); and for saturated fat, 11.7% (2.3%) vs 14.5% (2.4%) (P<.001). Mean intakes of cholesterol were 164.2 mg (60.1 mg) and 192.5 mg (71.9 mg) (P<.001) for the intervention and control groups, respectively Serum cholesterol concentrations were continuously 3% to 5% lower in children in the intervention group than in children in the control group. At age 5 years, mean (SD) serum cholesterol concentration of the intervention group was 4.27 (0.63) mmol/L (165 [24] mg/dL) and of the control group, 4.41 (0.74) mmol/L (170 [29] mg/dL) (P=.04). Neurological development of children in the intervention group was at least as good as that of children in the control group. Relative risks for children in the intervention group to fail tests of speech and language skills, gross motor functioning plus perception, and visual motor skills were 0.95 (90% confidence interval [CI], 0.60-1.49), 0.95 (90% CI, 0.58-1.55), and 0.65 (90% CI, 0.39-1.08), respectively (P=.85, .86, and .16, respectively, vs control children). Conclusion Our data indicate that repeated child-targeted dietary counseling of parents during the first 5 years of a child's life lessens age-associated increases in children's serum cholesterol and is compatible with normal neurological development.	Univ Turku, Cardiovasc Res Unit, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Univ Turku, Dept Med, FIN-20520 Turku, Finland; Univ Turku, Dept Biostat, FIN-20520 Turku, Finland; Univ Turku, Dept Child Psychiat & Psychol, FIN-20520 Turku, Finland; City Turku, Social Insurance Inst, Res & Dev Unit, Turku, Finland; City Turku, Child & Adolescent Hlth Care, Turku, Finland; Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Helsinki	Rask-Nissila, L (corresponding author), Univ Turku, Cardiovasc Res Unit, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	leena.rask-nissila@utu.fi	Lapinleimu, Helena/AAT-8415-2021					AGGETT PJ, 1994, J PEDIATR GASTR NUTR, V19, P261; Altman DG., 1995, PRACTICAL STAT MED R; American Academy of Pediatrics. Committee on Nutrition, 1998, Pediatrics, V101, P141; [Anonymous], 1995, JAMA, V273, P1429; AYRES JA, 1980, SO CALIFORNIA SENSOR; BAX M, 1987, DEV MED CHILD NEUROL, V29, P40; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BOULTON TJC, 1995, ACTA PAEDIATR, V84, P146, DOI 10.1111/j.1651-2227.1995.tb13597.x; DiGeorge AM., 1996, NELSON TXB PEDIAT, P1640; *EUR AG EV MED PRO, 2000, POINTS CONS BIOST ME; Fisher EA, 1997, CIRCULATION, V95, P2332, DOI 10.1161/01.CIR.95.9.2332; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN G, 1976, PEDIATRICS, V58, P655; GALLER JR, 1987, J PEDIATR GASTR NUTR, V6, P847, DOI 10.1097/00005176-198711000-00005; Hakala P, 1996, FOOD CHEM, V57, P71, DOI 10.1016/0308-8146(96)00077-5; HAND D, 1996, PRACTICAL LONGITUDIN; Harris, 1963, CHILDRENS DRAWINGS M; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KOPPITZ EM, 1963, BENDER GESTALT TEST; LAPINLEIMU H, 1995, LANCET, V345, P471, DOI 10.1016/S0140-6736(95)90580-4; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; LIUKSILA PR, 1993, TURUN KAUPUNGIN TERV, V8, P1; Miller L. J, 1988, MILLER ASSESSMENT PR; NEURINGER M, 1994, J PEDIATR-US, V125, pS39, DOI 10.1016/S0022-3476(06)80735-3; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; Niinikoski H, 1997, PEDIATRICS, V99, P687, DOI 10.1542/peds.99.5.687; Niinikoski H, 1997, PEDIATRICS, V100, P810, DOI 10.1542/peds.100.5.810; Niinikoski H, 1996, CIRCULATION, V94, P1386, DOI 10.1161/01.CIR.94.6.1386; POLONSKY SM, 1993, PEDIATRICS, V91, P92; PUGLIESE MT, 1987, PEDIATRICS, V80, P175; RASTAS M, 1993, NUTR COMP FOODS; Salo P, 1999, EUR J CLIN NUTR, V53, P927, DOI 10.1038/sj.ejcn.1600872; SAS, 1996, SAS STAT SOFTW CHANG; SHANNON BM, 1994, PEDIATRICS, V94, P923; SHEA S, 1993, PEDIATRICS, V92, P579; Stott D.H., 1984, TEST MOTOR IMPAIRMEN; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291	40	61	62	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2000	284	8					993	1000		10.1001/jama.284.8.993	http://dx.doi.org/10.1001/jama.284.8.993			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344PX	10944645				2023-01-03	WOS:000088769000026
J	Avorn, J; Solomon, DH				Avorn, J; Solomon, DH			Cultural and economic factors that (Mis)Shape antibiotic use: The nonpharmacologic basis of therapeutics	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RANDOMIZED CONTROLLED TRIAL; DAY-CARE-CENTER; ACUTE BRONCHITIS; DECISION-SUPPORT; DRUG-RESISTANCE; VANCOMYCIN USE; ORDER FORM; PHYSICIANS; IMPACT	The use of antibiotics in both ambulatory and inpatient settings is heavily shaped by cultural and economic factors as well as by microbiological considerations. These nonpharmacologic factors are relevant to clinicians and policymakers because of the clinical and fiscal toll of inappropriate antibiotic prescribing, including excessive use, preventable adverse effects, and the increasing prevalence of resistant organisms. An understanding of the determinants of antibiotic consumption is critical to explain current patterns of use and to devise programs to reduce inappropriate use. Patient motivations include the desire for a tangible product of the clinical encounter coupled with incorrect perceptions of the effectiveness of antibiotics, particularly in viral infections. Physician behavior can be explained by such factors as lack of information, a desire to satisfy patient demand, and pressure from managed care organizations to speed throughput. Marketing campaigns directed at both physicians and patients further serve to increase demand, especially for newer, costlier products. Studies of antibiotic use patterns in inpatient and outpatient care consistently demonstrate considerable inappropriate prescribing, which is likely to exacerbate the emergence of resistant organisms. Several approaches have been shown to improve the rationality of antibiotic use. Computer-based algorithms or reminders can prompt physicians to improve antibiotic choices at the time of prescribing; paper-based order entry forms can achieve the same goal. Interactive educational outreach ("academic detailing") is a practical implementation of social marketing principles to improve antibiotic use. Public education programs directed at consumers can help to reduce the inappropriate patient demand that helps to drive much improper antibiotic prescribing.	Brigham & Womens Hosp, Div Pharmaco Epidemiol & Pharmacoeconom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Avorn, J (corresponding author), Brigham & Womens Hosp, Div Pharmaco Epidemiol & Pharmacoeconom, 221 Longwood Ave,BLI-341, Boston, MA 02115 USA.							Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; AVOM J, 1987, REV INFECT DIS, V9, pS286; AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; ECHOLS RM, 1984, J INFECT DIS, V150, P803, DOI 10.1093/infdis/150.6.803; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; FARYNA A, 1987, J GEN INTERN MED, V2, P102, DOI 10.1007/BF02596306; Freidson E., 1970, PROFESSION MED STUDY; Gonzales R, 1998, J GEN INTERN MED, V13, P541, DOI 10.1046/j.1525-1497.1998.00165.x; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KATON W, 1980, RELEVANCE SOCIAL SCI, P253; Levy S.B., 1992, ANTIBIOTIC PARADOX H; Lipsky BA, 1999, AM J INFECT CONTROL, V27, P84, DOI 10.1016/S0196-6553(99)70086-6; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; McIsaac WJ, 2000, MED DECIS MAKING, V20, P33, DOI 10.1177/0272989X0002000104; Metlay JP, 1998, ARCH INTERN MED, V158, P1813, DOI 10.1001/archinte.158.16.1813; *OFF TECHN ASS, 1995, IMP ANT RES BACT; OSLER W, 1920, AECQUANIMITAS, P254; Parsons T, 1951, SOCIAL SYSTEM, P428; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; RADETSKY MS, 1981, LANCET, V2, P771; RAY WA, 1985, JAMA-J AM MED ASSOC, V253, P1774, DOI 10.1001/jama.253.12.1774; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROBINSBROWNE RM, 1984, J HYG-CAMBRIDGE, V93, P9, DOI 10.1017/S0022172400060873; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; Starr P., 1982, SOCIAL TRANSFORMATIO; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; UTTLEY AHC, 1988, LANCET, V1, P57; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Wilson AA, 1999, J GEN INTERN MED, V14, P658, DOI 10.1046/j.1525-1497.1999.08118.x; ZENNI MK, 1995, J PEDIATR-US, V127, P533, DOI 10.1016/S0022-3476(95)70108-7	47	196	197	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2000	133	2					128	135		10.7326/0003-4819-133-2-200007180-00012	http://dx.doi.org/10.7326/0003-4819-133-2-200007180-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	335RL	10896639				2023-01-03	WOS:000088258500006
J	Sharp, D				Sharp, D			Jehovah's Witnesses' blood policy	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), The Lancet, London WC1X 8RR, England.							GILLIES P, 2000, TIMES           0621; GLEDHILL R, 2000, TIMES           0614	2	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					8	8		10.1016/S0140-6736(00)02424-7	http://dx.doi.org/10.1016/S0140-6736(00)02424-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892756				2023-01-03	WOS:000087933400006
J	Halliday, HL				Halliday, HL			Towards earlier neonatal extubation	LANCET			English	Editorial Material									Queens Univ Belfast, Nuffield Dept Child Hlth, Belfast BT12 6BJ, Antrim, North Ireland	Queens University Belfast	Halliday, HL (corresponding author), Queens Univ Belfast, Nuffield Dept Child Hlth, Belfast BT12 6BJ, Antrim, North Ireland.			Halliday, Henry/0000-0001-7978-4992				Bancalari Eduardo, 1992, P200; DAVIES MW, 2000, COCHRANE LIB; DAVIS PG, 2000, COCHRANE LIB; Dimitriou G, 2000, BRIT J RADIOL, V73, P156, DOI 10.1259/bjr.73.866.10884728; FLENADY VJ, 2000, COCHRANE LIB; HENDERSONSMART DJ, 2000, COCHRANE LIB; SPENCE K, 2000, COCHRANE LIB; Verder H, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e24	8	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 17	2000	355	9221					2091	2092		10.1016/S0140-6736(00)02372-2	http://dx.doi.org/10.1016/S0140-6736(00)02372-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	325QD	10902619				2023-01-03	WOS:000087687100005
J	Ferner, RE; Aronson, JK				Ferner, RE; Aronson, JK			Medication errors, worse than a crime	LANCET			English	Editorial Material									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX1 2JD, England	University of Birmingham; Radcliffe Infirmary; University of Oxford	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.			Ferner, Robin/0000-0003-3769-1346				Ashraf H, 2000, LANCET, V355, P471, DOI 10.1016/S0140-6736(00)82021-8; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Ferner RE, 1999, BRIT J CLIN PHARMACO, V47, P581; FERNER RE, 1999, SIDE EFFECTS DRUGS A, P22; Firth-Cozens J, 1993, MED ACCIDENTS, P131; Kohn LT., 2000, ERR IS HUMAN BUILDIN; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; Reason J., 1990, HUMAN ERROR; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P506, DOI 10.1177/0310057X9302100506; TEAHON K, 1993, BRIT MED J, V307, P605, DOI 10.1136/bmj.307.6904.605; Walley T, 1997, BRIT J CLIN PHARMACO, V44, P171, DOI 10.1046/j.1365-2125.1997.00668.x	11	46	48	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					947	948		10.1016/S0140-6736(00)99025-1	http://dx.doi.org/10.1016/S0140-6736(00)99025-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YH	10768430				2023-01-03	WOS:000086054000006
J	Kemeny, N; Huang, Y; Cohen, AM; Shi, WJ; Conti, JA; Brennan, MF; Bertino, JR; Turnbull, ADM; Sullivan, D; Stockman, J; Blumgart, LH; Fong, YM				Kemeny, N; Huang, Y; Cohen, AM; Shi, WJ; Conti, JA; Brennan, MF; Bertino, JR; Turnbull, ADM; Sullivan, D; Stockman, J; Blumgart, LH; Fong, YM			Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 13-18, 1999	ATLANTA, GA	Amer Soc Clin Oncol			PROSPECTIVE RANDOMIZED TRIAL; LIVER METASTASES; INTRAARTERIAL FLOXURIDINE; SURGICAL RESECTION; CARCINOMA; SURVIVAL; FLUORODEOXYURIDINE; 5-FLUOROURACIL; LIFE	Background: Two years after undergoing resection of liver metastases from colorectal cancer, about 65 percent of patients are alive and 25 percent are free of detectable disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection. Methods: We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone. Patients were stratified according to previous treatment and the number of liver metastases identified at operation. The study end points were overall survival, survival without recurrence of hepatic metastases, and survival without any metastases at two years. Results: The actuarial rate of overall survival at two years was 86 percent in the group treated with combined therapy and 72 percent in the group given monotherapy alone (P = 0.03). The median survival was 72.2 months in the combined-therapy group and 59.3 months in the monotherapy group, with a median follow-up of 62.7 months. After two years, the rates of survival free of hepatic recurrence were 90 percent in the combined-therapy group and 60 percent in the monotherapy group (P < 0.001), and the respective rates of progression-free survival were 57 percent and 42 percent (P = 0.07). At two years, the risk ratio for death was 2.34 among patients treated with systemic therapy alone, as compared with patients who received combined therapy (95 percent confidence interval, 1.10 to 4.98; P = 0.027), after adjustment for important variables. The rates of adverse effects of at least moderate severity were similar in the two groups, except for a higher frequency of diarrhea and hepatic effects in the combined-therapy group. Conclusions: For patients who undergo resection of liver metastases from colorectal cancer, postoperative treatment with a combination of hepatic arterial infusion of floxuridine and intravenous fluorouracil improves the outcome at two years. (N Engl J Med 1999;341:2039-48.) (C)1999, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kemeny, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [R01 CA61524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN NB, 1974, SURGERY, V75, P589; ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647; ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; AUGUST DA, 1985, ANN SURG, V201, P210, DOI 10.1097/00000658-198502000-00013; CADY B, 1992, ARCH SURG-CHICAGO, V127, P561; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; COX DR, 1972, J R STAT SOC B, V34, P187; DOCI R, 1991, BRIT J SURG, V78, P797, DOI 10.1002/bjs.1800780711; ENSMINGER WD, 1983, SEMIN ONCOL, V10, P176; FEGIZ G, 1991, J SURG ONCOL, P144; Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; FORTNER JG, 1988, AM J SURG, V155, P378, DOI 10.1016/S0002-9610(88)80086-2; FOSTER JH, 1978, AM J SURG, V135, P389, DOI 10.1016/0002-9610(78)90072-7; GILBERT HA, 1976, FUNDAMENTAL ASPECTS, P385; Gorlick R, 1998, J CLIN ONCOL, V16, P1465, DOI 10.1200/JCO.1998.16.4.1465; HOHN DC, 1989, J CLIN ONCOL, V7, P1646, DOI 10.1200/JCO.1989.7.11.1646; HUGHES K, 1989, SURG CLIN N AM, V69, P339; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMENY MM, 1999, P AN M AM SOC CLIN, V18, P1012; KEMENY N, 1992, CANCER, V69, P327, DOI 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U; KEMENY N, 1993, CANCER-AM CANCER SOC, V71, P1964, DOI 10.1002/1097-0142(19930315)71:6<1964::AID-CNCR2820710607>3.0.CO;2-T; KEMENY N, 1987, ANN INTERN MED, V107, P459, DOI 10.7326/0003-4819-107-4-459; KEMENY N, 1994, SURG LIVER BILIARY T, V2, P1473; KEMENY NE, 1999, CURRENT CLIN ONCOLOG, P5; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEICHMAN L, 1995, EUR J CANCER, V31A, P1306, DOI 10.1016/0959-8049(95)00326-E; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; SCHEELE J, 1990, BRIT J SURG, V77, P1241, DOI 10.1002/bjs.1800771115; SIGURDSON ER, 1991, P AN M AM SOC CLIN, V10, P140; VANOOIJEN B, 1992, CANCER-AM CANCER SOC, V70, P28, DOI 10.1002/1097-0142(19920701)70:1<28::AID-CNCR2820700105>3.0.CO;2-9; WAGMAN LD, 1990, J CLIN ONCOL, V8, P1885, DOI 10.1200/JCO.1990.8.11.1885; YOUNES RN, 1991, ANN SURG, V214, P107, DOI 10.1097/00000658-199108000-00003	36	686	701	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2039	2048		10.1056/NEJM199912303412702	http://dx.doi.org/10.1056/NEJM199912303412702			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	271BR	10615075				2023-01-03	WOS:000084573300002
J	Bodenheimer, T				Bodenheimer, T			Long-term care for frail elderly people - The On Lok model	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROGRAM											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; Binstock RH, 1997, HEALTH SERV RES, V32, P715; CHATTERJI P, 1998, IMPACT PACE PARTICIP; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Eng C., 1996, CURR CONCEPTS GERIAT, V2, P4; Fisher Ian, 1998, N Y Times Web, P30; GRUENBERG L, 1993, ANAL EXPECTED MED CO; HARRINGTON C, 1991, JAMA-J AM MED ASSOC, V266, P3023, DOI 10.1001/jama.266.21.3023; IRVIN CV, 1999, NEW ENGL J MED, V340, P1283; Kassirer JP, 1998, NEW ENGL J MED, V339, P1925, DOI 10.1056/NEJM199812243392609; KUNZ E, 1996, AM J MANAGE CARE, V2, P301; Levit KR, 1998, HEALTH AFFAIR, V17, P35, DOI 10.1377/hlthaff.17.1.35; MCLEOD D, 1998, AARP B           APR; NEWCOMER R, 1996, ANNU REV GERONTOL, V16, P1; RIMER S, 1998, NY TIMES        0315, P1; Vladeck B.C., 1980, UNLOVING CARE NURSIN; White A.J., 1998, EFFECT PACE COSTS ME; [No title captured]; [No title captured]	19	78	82	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1324	1328		10.1056/NEJM199910213411722	http://dx.doi.org/10.1056/NEJM199910213411722			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247NF	10528046				2023-01-03	WOS:000083226300034
J	Siskind, LJ; Colombini, M				Siskind, LJ; Colombini, M			The lipids C-2- and C-16-ceramide form large stable channels - Implications for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MEMBRANE-FUSION; CYTOCHROME-C; CERAMIDE; MITOCHONDRIAL; GENERATION; ACTIVATION; STABILITY; RELEASE	We report that physiological concentrations of both short- and long-chain ceramides, despite being lipids, form large stable pores in membranes. Some of these pores should be large enough to allow cytochrome c to permeate. Dihydroceramide differs from ceramide by the reduction of one double bond, and yet both its apoptogenic and channel-forming activities are greatly reduced. A structural model provides insight into how ceramides might form pores. According to a mathematical model, both the individual conductance of the channels and the overall membrane conductance are directly related to the overall concentration of ceramide in the membrane. Slight changes in concentration have dramatic effects on the size of the channels formed, providing an easy way for rapidly altering membrane permeability by changing the activity of local synthetic and catabolic enzymes. A possible role for these channels in apoptosis is discussed.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	mc34@umail.umd.edu	Colombini, Marco/A-1540-2014	Siskind, Leah/0000-0001-5026-5187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042467] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS042467-01, F31 NS042467] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ariga T, 1998, J LIPID RES, V39, P1; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Castedo M, 1996, J IMMUNOL, V157, P512; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Huang HW, 1998, EUR BIOPHYS J BIOPHY, V27, P361, DOI 10.1007/s002490050143; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PASCHER I, 1976, BIOCHIM BIOPHYS ACTA, V455, P433, DOI 10.1016/0005-2736(76)90316-3; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	33	231	237	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38640	38644		10.1074/jbc.C000587200	http://dx.doi.org/10.1074/jbc.C000587200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11027675	Green Accepted, hybrid			2023-01-03	WOS:000165739800068
J	Kravitz, RL				Kravitz, RL			Direct-to-consumer advertising of prescription drugs: Implications for the patient-physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Davis, CA 95616 USA	University of California System; University of California Davis	Kravitz, RL (corresponding author), Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Davis, CA 95616 USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				Bell RA, 1999, J FAM PRACTICE, V48, P446; EVERETT SE, 1991, J ADVERTISING RES, V31, P43; Hoffman JR, 1999, BRIT MED J, V318, P1301, DOI 10.1136/bmj.318.7194.1301; Holmer AF, 1999, JAMA-J AM MED ASSOC, V281, P380, DOI 10.1001/jama.281.4.380; Lipsky MS, 1997, J FAM PRACTICE, V45, P495; MAGUIRE P, 1999, ACP ASIM OBSERVER, P1; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110	7	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2244	2244		10.1001/jama.284.17.2244	http://dx.doi.org/10.1001/jama.284.17.2244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	367GD	11056603	hybrid			2023-01-03	WOS:000090052600039
J	Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA				Rothbard, JB; Garlington, S; Lin, Q; Kirschberg, T; Kreider, E; McGrane, PL; Wender, PA; Khavari, PA			Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation	NATURE MEDICINE			English	Article							EPIDERMAL PERMEABILITY BARRIER; ALLERGIC CONTACT-DERMATITIS; ATOPIC-DERMATITIS; DRUG-DELIVERY; ALOPECIA-AREATA; DOUBLE-BLIND; PSORIASIS; EFFICACY; SKIN; PROTEINS	Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7-CsA. In contrast to unmodified cyclosporin A,which fails to penetrate skin, topically applied R7-CsA was efficiently transported into cells in mouse and human skin. R7-CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.	CellGate, Sunnyvale, CA 94086 USA; Vet Adm Palo Alto, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Khavari, PA (corresponding author), CellGate, Sunnyvale, CA 94086 USA.	Khavari@cmgm.stanford.edu	Chen, Yao/AAJ-2409-2020					Bach M, 1998, EUR J PHARM BIOPHARM, V46, P1, DOI 10.1016/S0939-6411(97)00149-5; BAUMANN L, 1999, TOPICAL GLUCOCORTICO, P2713; BerthJones J, 1996, BRIT J DERMATOL, V135, P775; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; DEPROST Y, 1986, LANCET, V2, P803; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Doering T, 1999, J BIOL CHEM, V274, P11038, DOI 10.1074/jbc.274.16.11038; DUNCAN JI, 1993, ACTA DERM-VENEREOL, V73, P84; Furlanut M, 1996, PHARMACOL RES, V33, P349, DOI 10.1006/phrs.1996.0048; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gilbertson EO, 1998, J AM ACAD DERMATOL, V38, P318, DOI 10.1016/S0190-9622(98)70573-0; GILHAR A, 1989, ACTA DERM-VENEREOL, V69, P252; Hadgraft J, 1998, J Investig Dermatol Symp Proc, V3, P131; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Ho VC, 1999, BRIT J DERMATOL, V141, P283; Kim DT, 1997, J IMMUNOL, V159, P1666; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Koo J, 1998, BRIT J DERMATOL, V139, P88; MIYACHI Y, 1982, ARCH DERMATOL, V118, P451, DOI 10.1001/archderm.118.7.451; MROWIETZ U, 1992, ACTA DERM-VENEREOL, V72, P321; Naeyaert JM, 1999, DERMATOLOGY, V198, P145, DOI 10.1159/000018091; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oikarinen A, 1998, BRIT J DERMATOL, V139, P1106; Powles AV, 1998, BRIT J DERMATOL, V138, P443; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; RANADE VV, 1991, J CLIN PHARMACOL, V31, P401, DOI 10.1002/j.1552-4604.1991.tb01895.x; Roberts MS, 1997, CLIN EXP PHARMACOL P, V24, P874, DOI 10.1111/j.1440-1681.1997.tb02708.x; SCHMOOK FP, 1993, SKIN PHARMACOL, V6, P116; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; SIEG P, 1995, BRIT J DERMATOL, V132, P790; Simpson J, 1998, THER DRUG MONIT, V20, P294, DOI 10.1097/00007691-199806000-00009; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SURBER C, 1992, CONTACT DERMATITIS, V26, P116, DOI 10.1111/j.1600-0536.1992.tb00895.x; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	38	533	623	5	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2000	6	11					1253	1257		10.1038/81359	http://dx.doi.org/10.1038/81359			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062537				2023-01-03	WOS:000165114800033
J	Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM				Pector, V; Backmann, J; Maes, D; Vandenbranden, M; Ruysschaert, JM			Biophysical and structural properties of DNA center dot diC(14)-amidine complexes - Influence of the DNA/lipid ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPOSOME COMPLEXES; VIVO GENE-TRANSFER; IN-VIVO; DNA COMPLEXES; CRYOELECTRON MICROSCOPY; MAMMALIAN-CELLS; LIPID VESICLES; FUSION; DELIVERY; THERAPY	Cationic liposomes are used as vectors for gene delivery both in vitro and in vivo. Comprehension of both DNA/liposome interactions on a molecular level and a description of structural modifications involved, are prerequisites to an optimization of the transfection protocol and, thus, successful application in therapy. Formation and stability of a DNA/cationic liposome complex were investigated here at different DNA:lipid molar ratios (rho). Isothermal titration calorimetry (ITC) of cationic liposomes with plasmid DNA was used to characterize the DNA-lipid interaction. Two processes were shown to be involved in the complex formation. A fast exothermic process was attributed to the electrostatic binding of DNA to the liposome surface. A subsequent slower endothermic reaction is likely to be caused by the fusion of the two components and their rearrangement into a new structure. Fluorescence and differential scanning calorimetry confirmed this interpretation. A kinetic model analyzes the ITC profile in terms of DNA/cationic liposome interactions.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; Free Univ Brussels, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pector, V (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, Campus Plaine CP 206-2, B-1050 Brussels, Belgium.			Backmann, Jan/0000-0002-3323-8838				ALI M, 1994, GENE THER, V1, P367; Battersby BJ, 1998, BBA-BIOMEMBRANES, V1372, P379, DOI 10.1016/S0005-2736(98)00062-5; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ElOuahabi A, 1996, FEBS LETT, V380, P108, DOI 10.1016/0014-5793(96)00038-5; ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3; EPAND RM, 1995, BIOSCIENCE REP, V15, P151, DOI 10.1007/BF01207455; Felgner JH, 1997, PHARMACEUT RES, V14, P1269, DOI 10.1023/A:1012131613160; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; Fortunati E, 1996, BBA-GENE STRUCT EXPR, V1306, P55, DOI 10.1016/0167-4781(95)00217-0; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUNZBURG WH, 1995, MOL MED TODAY, V1, P410, DOI 10.1016/S1357-4310(95)90771-8; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; KENNETH WCM, 1997, BIOPHYS J, V73, P2534; KERENZUR M, 1989, BIOCHIM BIOPHYS ACTA, V983, P253, DOI 10.1016/0005-2736(89)90241-1; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; Pires P, 1999, BBA-BIOMEMBRANES, V1418, P71, DOI 10.1016/S0005-2736(99)00023-1; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; RUYSSCHAERT JM, 1994, BIOCHEM BIOPH RES CO, V203, P1622, DOI 10.1006/bbrc.1994.2372; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Sternberg B, 1998, BBA-BIOMEMBRANES, V1375, P23, DOI 10.1016/S0005-2736(98)00129-1; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; TAKEHARA T, 1995, HEPATOLOGY, V21, P746, DOI 10.1002/hep.1840210323; THOMAS PG, 1993, BIOCHEM J, V291, P397, DOI 10.1042/bj2910397; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yang JP, 1998, GENE THER, V5, P380, DOI 10.1038/sj.gt.3300596; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	39	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29533	29538		10.1074/jbc.M909996199	http://dx.doi.org/10.1074/jbc.M909996199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10896680	hybrid			2023-01-03	WOS:000089439800048
J	Fayrer-Hosken, RA; Grobler, D; Van Altena, JJ; Bertschinger, HJ; Kirkpatrick, JF				Fayrer-Hosken, RA; Grobler, D; Van Altena, JJ; Bertschinger, HJ; Kirkpatrick, JF			Immunocontraception of African elephants - A humane method to control elephant populations without behavioural side effects.	NATURE			English	Article							PORCINE ZONA-PELLUCIDA		Univ Georgia, Coll Vet Med, Athens, GA 30602 USA; Kruger Natl Pk, ZA-1350 Skukuza, South Africa; Univ Pretoria, Dept Theriogenol, ZA-0110 Onderstepoort, South Africa; ZooMontana, Billings, MT 59106 USA	University System of Georgia; University of Georgia; University of Pretoria	Fayrer-Hosken, RA (corresponding author), Univ Georgia, Coll Vet Med, Athens, GA 30602 USA.							AYRERHOSKEN RA, 1997, THERIOGENOLOGY, V47, P397; Fayrer-Hosken RA, 1999, THERIOGENOLOGY, V52, P835, DOI 10.1016/S0093-691X(99)00176-4; FayrerHosken RA, 1997, WILDLIFE SOC B, V25, P18; Kirkpatrick JF, 1997, REPROD FERT DEVELOP, V9, P105, DOI 10.1071/R96052; WILLIS P, 1994, J EQUINE VET SCI, V14, P364, DOI 10.1016/S0737-0806(06)81753-3	5	88	101	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	2000	407	6801					149	149		10.1038/35025136	http://dx.doi.org/10.1038/35025136			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352VX	11001042	Bronze			2023-01-03	WOS:000089241000032
J	Churchill, D; Allen, J; Pringle, M; Hippisley-Cox, J; Ebdon, D; Macpherson, M; Bradley, S				Churchill, D; Allen, J; Pringle, M; Hippisley-Cox, J; Ebdon, D; Macpherson, M; Bradley, S			Consultation patterns and provision of contraception in general practice before teenage pregnancy: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENTS; CARE	Objectives To determine patterns of consultation in general practice and provision of contraception before teenage pregnancy. Design Case-control study, with retrospective analysis of case notes. Setting 14 general practices in Trent region. Subjects 240 registered patients (cases) with a recorded conception before the age of 20. Three controls per case were matched by age and practice. Main outcome measures Consultations in general practice and provision of contraception in the 12 months before conception and recorded provision of contraception at any time before conception. Results Overall, 223 cases (93%) had consulted a health professional at least once in the year before conception, 171 (71%) had discussed contraception in this time, and 121 (50%) had been prescribed oral contraception. Cases were more likely to have consulted in the year before: conception than controls (odds ratio 2.70, 95% confidence interval 1.56 to 4.66). (odds ratio 2.70, 95% confidence interval 1.56 to 4.66). Most Of the difference was owing to consultation for contraception. Overall, 53 cases (22%,) resulted in a termination of pregnancy. Cases whose pregnancy ended in a termination were more likely to have received emergency contraception than either their controls (3.21, 1.32 to 7.79) or cases resulting in other outcomes (3.01, 1.06 to 8.51). Conclusions Most teenagers who became pregnant attended general practice in the year before pregnancy, and many had sought contraceptive advice. The reluctance of teenagers to attend general practice for contraception may be less than previously supposed. The association between provision of emergency contraception and pregnancy ending in termination emphasises the need for continuing follow up of teenagers consulting for this form of contraception.	Univ Nottingham, Sch Med, Queens Med Ctr, Div Gen Practice, Nottingham NG7 2UH, England; Univ Nottingham, Dept Geog, Nottingham NG7 2RD, England; Queens Med Ctr, Dept Obstet & Gynaecol, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Nursing, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Churchill, D (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Div Gen Practice, Nottingham NG7 2UH, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Churchill, Richard/0000-0003-0049-8200; Bethea, Jane/0000-0003-0297-0468				COLEMAN J, 1999, KEY DATA ADOLESCENCE; Donovan C, 1997, BRIT J GEN PRACT, V47, P715; JACOBSON LD, 1994, FAM PRACT, V11, P296, DOI 10.1093/fampra/11.3.296; JACOBSON LD, 1994, BRIT J GEN PRACT, V44, P420; Kramer T, 1997, BRIT J GEN PRACT, V47, P327; MELVILLE AWT, 1989, FAM PRACT, V6, P245, DOI 10.1093/fampra/6.4.245; NHS Centre for Reviews and Dissemination University of York, 1997, EFFECTIVE HLTH CARE, V3, P1; PEARSON VAH, 1995, J ROY SOC MED, V88, P384; PEARSON VAH, 1995, BRIT J FAM PLAN, V21, P45; *SECR STAT HLTH, 1992, HLTH NAT; *SOC EXCL UN, 1999, CMND 4342; Stevenson J, 1996, BRIT J FAM PLAN, V22, P75	12	42	45	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	2000	321	7259					486	489		10.1136/bmj.321.7259.486	http://dx.doi.org/10.1136/bmj.321.7259.486			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347MC	10948031	Green Published, Bronze			2023-01-03	WOS:000088932800023
J	Aebi, S; Gelber, S; Castiglione-Gertsch, M; Gelber, RD; Collins, J; Thurlimann, B; Rudenstam, CM; Lindtner, J; Crivellari, D; Cortes-Funes, H; Simoncini, E; Werner, ID; Coates, AS; Goldhirsch, A				Aebi, S; Gelber, S; Castiglione-Gertsch, M; Gelber, RD; Collins, J; Thurlimann, B; Rudenstam, CM; Lindtner, J; Crivellari, D; Cortes-Funes, H; Simoncini, E; Werner, ID; Coates, AS; Goldhirsch, A		IBCSG	Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?	LANCET			English	Article							AGE; CARCINOMA; PROGNOSIS; SURVIVAL; TUMOR	Background The prognosis of breast cancer in very young women is generally considered to be unfavourable. Therefore, the outcome of adjuvant therapy was analysed in a population of young (<35 years) premenopausal patients treated in four randomised controlled trials. Methods Between 1978 and 1993 the International Breast Cancer Study Group (IBCSG) treated 3700 premenopausal and perimenopausal patients with various timing and duration of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF with or without low-dose prednisone and oophorectomy). 314 of these women were less than 35 years old at randomisation. Findings Relapse and death occurred earlier and more often in younger (<35 years) than in older (greater than or equal to 35) patients with a 10-year disease-free survival of 35% (SE 3) versus 47% (1) (hazard ratio 1.41 [95% CI 1.22-1.62], p<0.001) and overall survival of 49% (3) versus 62% (1) (1.50 [1.28-1.77], p<0.001). Younger patients with oestrogen-receptor positive tumours had a significantly worse disease-free survival than younger patients with oestrogen-receptor negative tumours. By contrast, among older patients the disease-free survival was similar irrespective of oestrogen-receptor status. Interpretation Young premenopausal breast cancer patients treated with adjuvant CMF chemotherapy had higher risk of relapse and death than older premenopausal patients, especially if their tumours expressed oestrogen receptors. The endocrine effects of chemotherapy alone are insufficient for the younger age group and these patients should strongly consider additional endocrine therapies (tamoxifen or ovarian ablation) if their tumours express oestrogen receptors.	Univ Hosp Inselspital, Bern, Switzerland; Frontier Sci & Technol Res Fdn Inc, Brookline, MA USA; IBCSG Coordinating Ctr, Bern, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Anticanc Council Victoria, Melbourne, Vic, Australia; Kantonsspital, CH-9007 St Gallen, Switzerland; SU Molndals Hosp, Dept Surg, Molndal, Sweden; Inst Oncol, Ljubljana, Slovenia; Ctr Riferimento Oncol, I-33081 Aviano, Italy; Hosp Seguridad Social 12 Octubre, Madrid, Spain; Spedali Civil Brescia, I-25125 Brescia, Italy; Fdn Beretta, Brescia, Italy; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Univ Sydney, Australian Canc Soc, Sydney, NSW 2006, Australia; European Inst Oncol, Milan, Italy	University of Bern; University Hospital of Bern; Frontier Science Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Sahlgrenska University Hospital; Institute of Oncology - Slovenia; IRCCS Aviano (CRO); Hospital Universitario 12 de Octubre; Hospital Spedali Civili Brescia; University of Cape Town; University of Sydney; IRCCS European Institute of Oncology (IEO)	Aebi, S (corresponding author), Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland.	aebi@insel.ch	Aebi, Stefan/F-2004-2010	Aebi, Stefan/0000-0002-3383-9449	NCI NIH HHS [CA75362] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; CastiglioneGertsch M, 1996, J CLIN ONCOL, V14, P1885; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; Clarke M, 1998, LANCET, V351, P1451; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; COX DR, 1972, J R STAT SOC B, V34, P187; Donegan WL, 1997, CA-CANCER J CLIN, V47, P28, DOI 10.3322/canjclin.47.1.28; GARNIER HS, 1995, EUR J CANCER, V31, P1851; GERTSCH MC, 1994, ANN ONCOL, V5, P717; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677; Greenwood M., 1926, NATURAL DURATION CAN; Holli K, 1997, EUR J CANCER, V33, P425; JORDAN VC, 1983, EUR J CANCER CLIN ON, V19, P357, DOI 10.1016/0277-5379(83)90133-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Ludwig Breast Cancer Study Group, 1985, Cancer Res, V45, P4454; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; NOYES RD, 1982, CANCER, V49, P1302, DOI 10.1002/1097-0142(19820315)49:6<1302::AID-CNCR2820490638>3.0.CO;2-0; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; QUIET CA, 1995, J CLIN ONCOL, V13, P1144, DOI 10.1200/JCO.1995.13.5.1144; RIBEIRO GG, 1981, CLIN RADIOL, V32, P231, DOI 10.1016/S0009-9260(81)80168-7; Swanson G M, 1994, J Natl Cancer Inst Monogr, P69; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Winchester DP, 1996, CANCER-AM CANCER SOC, V78, P1838, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y; 1992, P229 SAS I INC	32	203	210	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1869	1874		10.1016/S0140-6736(00)02292-3	http://dx.doi.org/10.1016/S0140-6736(00)02292-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866443				2023-01-03	WOS:000087306500014
J	McKeganey, N; Norrie, J				McKeganey, N; Norrie, J			Association between illegal drugs and weapon carrying in young people in Scotland: schools' survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH SCHOOLCHILDREN; VIOLENT BEHAVIOR; SAMPLE; ADOLESCENTS; STUDENTS	Objectives To identify the type and extent of weapons being carried among young people in Scotland, and to determine the relation between use of illegal drugs and weapon carrying. Design Questionnaire school survey. Setting Independent schools in central Scotland and schools in Lanarkshire and Perth and Kinross. Participants 3121 students aged 11 to 16 in 20 schools. Main outcome measures Self completion questionnaire reporting history of drug use and weapon carrying. Results Overall, 34.1% of males and 8.6% of females reported having carried a weapon (P < 0.0001), ranging From 29.2% of boys aged 11-13 (classes S1 to S2) to 39.3% of boys aged 13-15 (S3 to S4). These values are higher than those in a recent survey of young people in England. Weapon carrying in Lanarkshire was 70% higher for males than in the rural area of Perth and Kinross. Both males and females who had taken drugs were more likely to carry weapons (63.5% of male drug users versus 20.5%, of non-users and 22.8% of female drug users versus 3.7% of non-users; both P < 0.0001). The proportions of males carrying weapons who used none, one, two, three or four, or five or more illegal drugs were 21%, 52%, 68% 74%, and 92% respectively. A similar trend was found among females. Conclusions Better information is needed on the nature and extent of weapon carrying by young people in the United Kingdom, and better educational campaigns are needed warning of the dangers of carrying weapons.	Univ Glasgow, Ctr Drug Misuse Res, Glasgow G12 8SQ, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	McKeganey, N (corresponding author), Univ Glasgow, Ctr Drug Misuse Res, Glasgow G12 8SQ, Lanark, Scotland.	gkua27@udcf.gla.ac.uk						BALDING J, 1996, CASH CARRY YOUNG PEO; Barnard M, 1996, DRUG-EDUC PREV POLIC, V3, P81, DOI 10.3109/09687639609019313; Barnard M, 1998, ADDICT RES, V6, P421, DOI 10.3109/16066359809026060; DuRant RH, 1997, ARCH PEDIAT ADOL MED, V151, P360, DOI 10.1001/archpedi.1997.02170410034004; Forsyth A, 1998, DRUG-EDUC PREV POLIC, V5, P157, DOI 10.3109/09687639809006681; Friedman AS, 1998, AGGRESS VIOLENT BEH, V3, P339, DOI 10.1016/S1359-1789(97)00012-8; Komro KA, 1998, J CHILD ADOLES SUBST, V8, P77; Lowry R, 1998, AM J PREV MED, V14, P122, DOI 10.1016/S0749-3797(97)00020-2; McKeganey N, 1996, BRIT MED J, V313, P401; McKeganey N, 1999, ADDICT RES, V7, P493, DOI 10.3109/16066359909004402; Presley CA, 1997, J AM COLL HEALTH, V46, P3, DOI 10.1080/07448489709595580; VALOIS RF, 1995, J ADOLESCENT HEALTH, V16, P26, DOI 10.1016/1054-139X(95)94070-O; Wagner EF, 1996, AGGRESS VIOLENT BEH, V1, P375, DOI 10.1016/S1359-1789(96)00008-0	13	30	30	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2000	320	7240					982	984		10.1136/bmj.320.7240.982	http://dx.doi.org/10.1136/bmj.320.7240.982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303XP	10753152	Bronze, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000086453100024
J	Reich, MR				Reich, MR			The global drug cap	SCIENCE			English	Article							COMMUNITY; HEALTH	Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional-capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Reich, MR (corresponding author), Harvard Univ, Sch Publ Hlth, 667 Huntington Ave, Boston, MA 02115 USA.							[Anonymous], 1993, WORLD DEV REP 1993 I; Bond P, 1999, INT J HEALTH SERV, V29, P765, DOI 10.2190/4MA6-53E3-LE1X-C1YY; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; FUJISAKI T, 1997, ASSESSMENT TDRS CONT; *IMS, 1999, IMS HLTH; Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865; KREMER M, 1999, PURCHASE PRECOMMITME; Lanjouw J.O., 1999, 6366 NAT BUR EC RES; Management Sciences for Health, 1997, MAN DRUG SUPPL; MCPAKE B, 1993, SOC SCI MED, V36, P1383, DOI 10.1016/0277-9536(93)90381-D; Milstien JB, 1998, DRUG INF J, V32, P175, DOI 10.1177/009286159803200125; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; Parry E, 1997, THORAX, V52, P589, DOI 10.1136/thx.52.7.589; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Reich M.R., 1998, DAP RES SERIES; REICH MR, 1987, HEALTH POLICY, V8, P39, DOI 10.1016/0168-8510(87)90129-1; Reich MR, 1999, B WORLD HEALTH ORGAN, V77, P675; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; *UNDP WORLD BANK W, 1995, TROP DIS RES PROGR 1; Wehrwein P, 1999, HARV PUBLIC HLTH SUM, P32; *WHO EXP COMM, 1998, WHO TECHN REP SER, V882; 1999, GUIDELINES DRUG DONA; 1999, SUPPLY DIVISION ANN; 1998, AIDS EPIDEMIC UPDATE	24	50	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1979	1981		10.1126/science.287.5460.1979	http://dx.doi.org/10.1126/science.287.5460.1979			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755953				2023-01-03	WOS:000085902800051
J	Nuttin, B; Cosyns, P; Demeulemeester, H; Gybels, J; Meyerson, B				Nuttin, B; Cosyns, P; Demeulemeester, H; Gybels, J; Meyerson, B			Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder	LANCET			English	Article								Chronic electrical stimulation instead of bilateral capsulotomy was done in four selected patients with long-standing treatment-resistant obsessive-compulsive disorder. In three of them beneficial effects were observed.	Katholieke Univ Leuven, Dept Neurosurg, Lab Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium; Univ Instelling Antwerp, Dept Psychiat, Antwerp, Belgium; Karolinska Inst Hosp, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden	KU Leuven; Universite Catholique Louvain; University of Antwerp; Karolinska Institutet; Karolinska University Hospital	Nuttin, B (corresponding author), Katholieke Univ Leuven, Dept Neurosurg, Lab Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium.							Cosyns P, 1994, Adv Tech Stand Neurosurg, V21, P239; Lippitz BE, 1999, NEUROSURGERY, V44, P452, DOI 10.1097/00006123-199903000-00005; McNair D.M., 1971, MANUAL PROFILES MOOD; MEYERSON BA, 1998, TXB STEREOTACTIC FUN, P1955	4	506	548	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1526	1526		10.1016/S0140-6736(99)02376-4	http://dx.doi.org/10.1016/S0140-6736(99)02376-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551504				2023-01-03	WOS:000083411300018
J	Armstrong, K; Schwartz, JS; Asch, DA				Armstrong, K; Schwartz, JS; Asch, DA			Direct sale of sildenafil (Viagra) to consumers over the Internet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL INFORMATION; QUALITY		Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Armstrong, K (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X	NCI NIH HHS [CA73619] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger A, 1998, BMJ, V317, P824; CAPPASSO T, 1999, STATE J REGISTE 0506, P9; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; Dorozynski A, 1996, BRIT MED J, V313, P1033; DOULIN T, 1999, COLUMBUS DISPA 0513, pA1; Dyer C, 1996, BRIT MED J, V313, P645; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Greenaway NJ, 1999, LANCET, V353, P330, DOI 10.1016/S0140-6736(05)74889-3; HADDON J, 1999, MORNING EDITION 0511; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LEE TH, 1999, HARVARD HEART LETT, V9, P7; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P975, DOI 10.1001/jama.281.11.975; McDonald CJ, 1998, JAMA-J AM MED ASSOC, V280, P1325, DOI 10.1001/jama.280.15.1325; OSTROM CM, 1999, SEATTLE TIMES   0512, pA1; PERRIN J, 1998, PHARM J, V260, P707; Seaboldt JA, 1997, AM J HEALTH-SYST PH, V54, P1732, DOI 10.1093/ajhp/54.15.1732; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P1723; SLIVKA J, 1999, SEATTLE POST IN 0507, pC1; TAYLOR C, 1999, TIME            0524, P73; Wang T, 1997, Methods Mol Biol, V72, P1	22	69	71	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1389	1392		10.1056/NEJM199910283411810	http://dx.doi.org/10.1056/NEJM199910283411810			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536133				2023-01-03	WOS:000083357800010
J	Di Blasi, Z; Harkness, E; Ernst, E; Georgiou, A; Kleijnen, J				Di Blasi, Z; Harkness, E; Ernst, E; Georgiou, A; Kleijnen, J			Influence of context effects on health outcomes: a systematic review	LANCET			English	Review							INFORMED CONSENT; POWERFUL PLACEBO; CLINICAL-TRIAL; PATIENT; SIDE; INSTRUCTIONS; EXPECTATIONS; CARE	Background Throughout history, doctor-patient relationships have been acknowledged as having an important therapeutic effect, irrespective of any prescribed drug or treatment. We did a systematic review to determine whether there was any empirical evidence to support this theory. Methods A comprehensive search strategy was developed to include 11 medical, psychological, and sociological electronic databases. The quality of eligible trials was objectively assessed by two reviewers, and the type of nontreatment care given in each trial was categorised as cognitive or emotional. Cognitive care aims to influence patients' expectations about the illness or the treatment, whereas emotional care refers to the style of the consultation (eg, warm, empathic), and aims to reduce negative feelings such as anxiety and fear. Findings We identified 25 eligible randomised controlled trials. 19 examined the effects of influencing patients' expectations about treatment, half of which found significant effects. None of the studies examined the effects of emotional care alone, but four trials assessed a combination of both cognitive and emotional care. Three of these studies showed that enhancing patients' expectations through positive information about the treatment or the illness, while providing support or reassurance, significantly influenced health outcomes. Interpretation There is much inconsistency regarding emotional and cognitive care, although one relatively consistent finding is that physicians who adopt a warm, friendly, and reassuring manner are mor effective than those who keep consultations formal and do not offer reassurance.	Univ York, Dept Hlth Sci & Clin Evaluat, York YO10 5DD, N Yorkshire, England; Univ York, NHS Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England; Univ Exeter, Dept Complementary Med, Exeter EX4 4QJ, Devon, England; Univ Leeds, Div Publ Hlth, Leeds LS2 9JT, W Yorkshire, England	University of York - UK; University of York - UK; University of Exeter; University of Leeds	Di Blasi, Z (corresponding author), Univ York, Dept Hlth Sci & Clin Evaluat, York YO10 5DD, N Yorkshire, England.	zdb1@york.ac.uk		Harkness, Elaine/0000-0001-6625-7739; Di Blasi, Zelda/0000-0001-8950-4958	PHS HHS [026ROO286 01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRAS WS, 1982, PSYCHOSOM MED, V44, P389; AMIGO I, 1993, J HYPERTENS, V11, P293, DOI 10.1097/00004872-199303000-00010; BALINT M, 1955, LANCET, V1, P683; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; BERK SN, 1977, J CONSULT CLIN PSYCH, V45, P612, DOI 10.1037/0022-006X.45.4.612; BUTLER C, 1986, BRIT J CLIN PSYCHOL, V25, P173, DOI 10.1111/j.2044-8260.1986.tb00693.x; COOPER WD, 1983, BRIT J CLIN PRACT, V37, P99; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; DAHAN R, 1986, BRIT MED J, V293, P363, DOI 10.1136/bmj.293.6543.363; de Craen AJM, 2000, J NEUROL, V247, P183, DOI 10.1007/s004150050560; de Craen AJM, 1999, BRIT J CLIN PHARMACO, V48, P853, DOI 10.1046/j.1365-2125.1999.00094.x; deCraen AJM, 1996, BRIT MED J, V313, P1624, DOI 10.1136/bmj.313.7072.1624; DECRAEN AJM, 1998, THESIS U AMSTERDAM; DEEKS J, 1994, UNDERTAKING SYSTEMAT; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; DEVINE EC, 1992, PATIENT EDUC COUNS, V19, P129, DOI 10.1016/0738-3991(92)90193-M; FREUND J, 1972, CLIN PHARMACOL THER, V13, P172; GRYLL SL, 1978, PSYCHOPHARMACOLOGY, V57, P253, DOI 10.1007/BF00426747; KALDOR A, 1973, BMJ-BRIT MED J, V1, P352, DOI 10.1136/bmj.1.5849.352-b; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kienle GS, 1997, J CLIN EPIDEMIOL, V50, P1311, DOI 10.1016/S0895-4356(97)00203-5; Kincheloe J E, 1991, Quintessence Int, V22, P311; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LAPORTE JR, 1994, LANCET, V344, P1206, DOI 10.1016/S0140-6736(94)90515-0; LEVENTHAL H, 1982, PSYCHOSOCIAL EPIDEMI, V3, P55; LINDEN W, 1989, CAN MED ASSOC J, V141, P409; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; NEILD JE, 1985, BRIT MED J, V290, P674, DOI 10.1136/bmj.290.6469.674; Novack Dennis, 1995, MED INTERVIEW CLIN C, P32; OConnor AM, 1996, J CLIN EPIDEMIOL, V49, P1271, DOI 10.1016/S0895-4356(96)00177-1; OLSSON B, 1989, FAM PRACT, V6, P188, DOI 10.1093/fampra/6.3.188; REDELMEIER DA, 1995, LANCET, V345, P1131, DOI 10.1016/S0140-6736(95)90975-3; ROSE S, 1993, AM J GASTROENTEROL, V88, P20; SHAPIRO AK, 1984, BEHAV HLTH; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1978, BRIT MED J, V1, P1327, DOI 10.1136/bmj.1.6123.1327; THOMAS KB, 1994, LANCET, V344, P1066, DOI 10.1016/S0140-6736(94)91716-7; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; VANWEEL C, 1985, FAM PRACT, V2, P147, DOI 10.1093/fampra/2.3.147; WIED G L, 1953, Arztl Wochensch, V8, P623; 1923, HIPPOCRATES, V2	43	849	855	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2001	357	9258					757	762		10.1016/S0140-6736(00)04169-6	http://dx.doi.org/10.1016/S0140-6736(00)04169-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	409TC	11253970				2023-01-03	WOS:000167400900014
J	Mills, SY				Mills, SY			Regulation in complementary and alternative medicine	BRITISH MEDICAL JOURNAL			English	Article									Sch Educ, Dept Lifelong Learning, Complementary Hlth Studies Programme, Exeter EX1 2LU, Devon, England		Mills, SY (corresponding author), Sch Educ, Dept Lifelong Learning, Complementary Hlth Studies Programme, Exeter EX1 2LU, Devon, England.			Mills, Simon/0000-0001-7729-5300				DICKINSON D, 1995, COMPLEMENT THER MED, V3, P9; Ernst E., 1995, COMPLEMENT THER MED, V3, P6; *F INT MED, 1998, INT HEALTHC WAY NEXT; *HOUS LORDS SEL CO, 2000, COMPL ALT MED SESS 1; Mills S., 1997, PROFESSIONAL ORG COM; MILLS S, 2000, PROFESSIONAL ORG COM; Mills S. Y., 1996, COMPLEMENT THER MED, V4, P48; SHIFFIN K, 1993, COMPLEMENTARY THERAP, V1, P91; STONE J, 1996, COMPLEMENTARY MED LA; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207	10	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					158	160		10.1136/bmj.322.7279.158	http://dx.doi.org/10.1136/bmj.322.7279.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159577	Green Published			2023-01-03	WOS:000166615300032
J	Girou, E; Schortgen, F; Delclaux, C; Brun-Buisson, C; Blot, F; Lefort, Y; Lemaire, F; Brochard, L				Girou, E; Schortgen, F; Delclaux, C; Brun-Buisson, C; Blot, F; Lefort, Y; Lemaire, F; Brochard, L			Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	International Conference of the American-Thoracic-Society	APR 23-28, 1999	SAN DIEGO, CALIFORNIA	Amer Thoracic Soc			ACUTE RESPIRATORY-FAILURE; POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE PULMONARY-DISEASE; INTENSIVE-CARE UNIT; MECHANICAL VENTILATION; FACE MASK; AIRWAY PRESSURE; ATTRIBUTABLE MORTALITY; SUPPORT VENTILATION; ACUTE EXACERBATIONS	Context Invasive life-support techniques are a major risk factor for nosocomial infection. Noninvasive ventilation (NIV) can be used to avoid endotracheal intubation and may reduce morbidity among patients in intensive care units (ICUs). Objective To determine whether the use of NIV is associated with decreased risk of nosocomial infections and improved survival in everyday clinical practice among patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) or hypercapnic cardiogenic pulmonary edema (CPE). Design and setting Matched case-control study conducted in the medical ICU of a French university hospital from January 1996 through March 1998, Patients fifty patients with acute exacerbation of COPD or severe CPE who were treated with NIV for at least 2 hours and 50 patients treated with mechanical ventilation between 1993 and 1998 (controls), matched on diagnosis, Simplified Acute Physiology Score II, Logistic Organ Dysfunction score, age, and no contraindication to NIV. Main Outcome Measures Rates of nosocomial infections, antibiotic use, lengths of ventilatory support and of ICU stay, ICU mortality, compared between cases and controls, Results Rates of nosocomial infections and of nosocomial pneumonia were significantly lower in patients who received NIV than those treated with mechanical ventilation (18% vs 60% and 8% vs 22%; P<.001 and P=.04, respectively). Similarly, the daily risk of acquiring an infection (19 vs 39 episodes per 1000 patient-days; P=.05), proportion of patients receiving antibiotics for nosocomial infection (8% vs 26%, P=.01), mean (SD) duration of ventilation (6 [6] vs 10 [12] days; P=.01), mean (SD) length of ICU stay (9 [7] vs 15 [14] days; P=.02), and crude mortality (4% vs 26%; P=.002) were all lower among patients who received NIV than those treated with mechanical ventilation, Conclusions Use of NIV instead of mechanical ventilation is associated with a lower risk of nosocomial infections, less antibiotic use, shorter length of ICU stay, and lower mortality.	Assistance Publ Hop Paris, Hop Henri Mondor, Unite Hyg & Prevent Infect, F-94010 Creteil, France; Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, F-94010 Creteil, France; Assistance Publ Hop Paris, Hop Henri Mondor, INSERM, U492, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Girou, E (corresponding author), Assistance Publ Hop Paris, Hop Henri Mondor, Unite Hyg & Prevent Infect, F-94010 Creteil, France.			Schortgen, Frederique/0000-0003-1756-7508				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; Confalonieri M., 1998, European Respiratory Journal, V12, p128S; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Girou E, 1998, AM J RESP CRIT CARE, V157, P1151, DOI 10.1164/ajrccm.157.4.9701129; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; Guerin C, 1998, INTENS CARE MED, V24, P27, DOI 10.1007/s001340050510; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; MAKI DG, 1989, ARCH INTERN MED, V149, P30, DOI 10.1001/archinte.149.1.30; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Nourdine K, 1999, INTENS CARE MED, V25, P567, DOI 10.1007/s001340050904; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Rusterholtz T, 1999, INTENS CARE MED, V25, P21, DOI 10.1007/s001340050782; Sznajder M, 1998, INTENS CARE MED, V24, P582, DOI 10.1007/s001340050619; TEASDALE G, 1974, LANCET, V2, P81; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	37	267	288	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2361	2367		10.1001/jama.284.18.2361	http://dx.doi.org/10.1001/jama.284.18.2361			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066187	Bronze			2023-01-03	WOS:000165074500031
J	Billings, JA				Billings, JA			Recent advances - Palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ILL HOSPITALIZED-PATIENTS; TERMINALLY ILL; DEATH; LIFE; END; MANAGEMENT; ONCOLOGY; OUTCOMES; SUPPORT; TRIAL		Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Billings, JA (corresponding author), Massachusetts Gen Hosp, Palliat Care Serv, Founders 600,55 Fruit St, Boston, MA 02114 USA.	JBillings@partners.org			NCI NIH HHS [R25 CA066818, R25 CA 66818-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA066818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; BACKONJA M, 1988, JAMA-J AM MED ASSOC, V280, P1831; Baile WF, 1999, CANCER-AM CANCER SOC, V86, P887, DOI 10.1002/(SICI)1097-0142(19990901)86:5<887::AID-CNCR27>3.0.CO;2-X; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Bruera E, 1998, CAN MED ASSOC J, V158, P1717; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; DAVIS C, 1995, EUR J PALLIAT CARE, V2, P9; Desbiens NA, 1999, J PAIN SYMPTOM MANAG, V17, P248, DOI 10.1016/S0885-3924(98)00149-3; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Foley KM, 1999, ARCH NEUROL-CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krakauer E L, 2000, Oncologist, V5, P53, DOI 10.1634/theoncologist.5-1-53; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; Mazzocato C, 2000, SUPPORT CARE CANCER, V8, P89, DOI 10.1007/s005200050021; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Rabow MW, 2000, JAMA-J AM MED ASSOC, V283, P771, DOI 10.1001/jama.283.6.771; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Volicer L, 1998, HOSPICE CARE PATIENT; Wineberg H, 2000, ARCH INTERN MED, V160, P21, DOI 10.1001/archinte.160.1.21	40	36	37	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					555	558		10.1136/bmj.321.7260.555	http://dx.doi.org/10.1136/bmj.321.7260.555			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968822	Green Published			2023-01-03	WOS:000089174100024
J	Hambrecht, R; Gielen, S; Linke, A; Fiehn, E; Yu, JT; Walther, C; Schoene, N; Schuler, G				Hambrecht, R; Gielen, S; Linke, A; Fiehn, E; Yu, JT; Walther, C; Schoene, N; Schuler, G			Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; MYOCARDIAL-INFARCTION; DYSFUNCTION; CAPACITY	Context Exercise training in patients with chronic heart failure improves work capacity by enhancing endothelial function and skeletal muscle aerobic metabolism, but effects on central hemodynamic function are not well established. Objective To evaluate the effects of exercise training on left ventricular (LV) function and hemodynamic response to exercise in patients with stable chronic heart failure. Design Prospective randomized trial conducted in 1994-1999. Setting University department of cardiology/outpatient clinic in Germany. Patients Consecutive sample of 73 men aged 70 years or younger with chronic heart failure (with LV ejection fraction of approximately 0.27). Intervention Patients were randomly assigned to 2 weeks of in-hospital ergometer exercise for 10 minutes 4 to 6 times per day, followed by 6 months of home-based ergometer exercise training for 20 minutes per day at 70% of peak oxygen uptake (n=36) or to no intervention (control group; n=37). Main Outcome Measures Ergospirometry with measurement of central hemodynamics by thermodilution at rest and during exercise; echocardiographic determination of LV diameters and volumes, at baseline and 6-month follow-up, for the exercise training vs control groups. Results After 6 months, patients in the exercise training group had statistically significant improvements compared with controls in New York Heart Association functional class, maximal ventilation, exercise time, and exercise capacity as well as decreased resting heart rate and increased stroke volume at rest. In the exercise training group, an increase from baseline to 6-month follow-up was observed in mean (SD) resting LV ejection fraction (0.30 [0.08] vs 0.35 [0.09]; P=.003). Mean (SD) total peripheral resistance (TPR) during peak exercise was reduced by 157 (306) dyne/s/cm(-5) in the exercise training group vs an increase of 43 (148) dyne/s/cm-5 in the control group (P=.03), with a concomitant increase in mean (SD) stroke volume of 14 (22) mt vs 1 (19) mL in the control group (P=.03). There was a small but significant reduction in mean (SD) LV end diastolic diameter of 4 (6) mm vs an increase of 1 (4) mm in the control group (P<.001). Changes from baseline in resting TPR for both groups were correlated with changes in stroke volume (r=-0.76; P<.001) and in LV end diastolic diameter (r=0.45; P<.001). Conclusions In patients with stable chronic heart failure, exercise training is associated with reduction of peripheral resistance and results in small but significant improvements in stroke volume and reduction in cardiomegaly.	Univ Leipzig, Kardiol Klin, Herzzentrum GmbH, D-7010 Leipzig, Germany	Heart Center Leipzig GMBH; Leipzig University	Hambrecht, R (corresponding author), Univ Leipzig, Herzzentrum Gmbh, Klin Innere Med Kardiol, Russenstr 19, D-04289 Leipzig, Germany.							ADAMOPOULOS S, 1993, J AM COLL CARDIOL, V21, P1101, DOI 10.1016/0735-1097(93)90231-O; BELARDINELLI R, 1995, CIRCULATION, V91, P2775, DOI 10.1161/01.CIR.91.11.2775; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; Demopoulos L, 1997, J AM COLL CARDIOL, V29, P597, DOI 10.1016/S0735-1097(96)00526-8; Dubach P, 1997, CIRCULATION, V95, P2060, DOI 10.1161/01.CIR.95.8.2060; Giannuzzi P, 1997, CIRCULATION, V96, P1790, DOI 10.1161/01.CIR.96.6.1790; Hambrecht R, 1997, J AM COLL CARDIOL, V29, P1067, DOI 10.1016/S0735-1097(97)00015-6; Hambrecht R, 1998, CIRCULATION, V98, P2709, DOI 10.1161/01.CIR.98.24.2709; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Hornig B, 1996, CIRCULATION, V93, P210, DOI 10.1161/01.CIR.93.2.210; JUGDUTT BI, 1988, J AM COLL CARDIOL, V12, P362, DOI 10.1016/0735-1097(88)90407-X; Katz SD, 1997, J APPL PHYSIOL, V82, P1488, DOI 10.1152/jappl.1997.82.5.1488; Katz SD, 1996, J AM COLL CARDIOL, V28, P585, DOI 10.1016/0735-1097(96)00204-5; KUBO SH, 1991, CIRCULATION, V84, P1589, DOI 10.1161/01.CIR.84.4.1589; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236, DOI 10.1152/jappl.1973.35.2.236; WEICKER H, 1986, LAB MED, V33, P122; Wilson JR, 1996, CIRCULATION, V94, P1567, DOI 10.1161/01.CIR.94.7.1567	21	461	485	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2000	283	23					3095	3101		10.1001/jama.283.23.3095	http://dx.doi.org/10.1001/jama.283.23.3095			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PV	10865304	Bronze			2023-01-03	WOS:000087574900034
J	Connolly, SJ; Kerr, CR; Gent, M; Roberts, RS; Yusuf, S; Gillis, AM; Sami, MH; Talajic, M; Tang, ASL; Klein, GJ; Lau, C; Newman, DM				Connolly, SJ; Kerr, CR; Gent, M; Roberts, RS; Yusuf, S; Gillis, AM; Sami, MH; Talajic, M; Tang, ASL; Klein, GJ; Lau, C; Newman, DM		Canadian Trial of Physl Pacing Inv	Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICK-SINUS SYNDROME; DUAL-CHAMBER; RANDOMIZED TRIAL; ATRIAL; LIFE	Background: Evidence suggests that physiologic pacing (dual-chamber or atrial) may be superior to single-chamber (ventricular) pacing because it is associated with lower risks of atrial fibrillation, stroke, and death. These benefits have not been evaluated in a large, randomized, controlled trial. Methods: At 32 Canadian centers, patients without chronic atrial fibrillation who were scheduled for a first implantation of a pacemaker to treat symptomatic bradycardia were eligible for enrollment. We randomly assigned patients to receive either a ventricular pacemaker or a physiologic pacemaker and followed them for an average of three years. The primary outcome was stroke or death due to cardiovascular causes. Secondary outcomes were death from any cause, atrial fibrillation, and hospitalization for heart failure. Results: A total of 1474 patients were randomly assigned to receive a ventricular pacemaker and 1094 to receive a physiologic pacemaker. The annual rate of stroke or death due to cardiovascular causes was 5.5 percent with ventricular pacing, as compared with 4.9 percent with physiologic pacing (reduction in relative risk, 9.4 percent; 95 percent confidence interval, -10.5 to 25.7 percent [the negative value indicates an increase in risk]; P = 0.33). The annual rate of atrial fibrillation was significantly lower among the patients in the physiologic-pacing group (5.3 percent) than among those in the ventricular-pacing group (6.6 percent), for a reduction in relative risk of 18.0 percent (95 percent confidence interval, 0.3 to 32.6 percent; P = 0.05). The effect on the rate of atrial fibrillation was not apparent until two years after implantation. The observed annual rates of death from all causes and of hospitalization for heart failure were lower among the patients with a physiologic pacemaker than among those with a ventricular pacemaker, but not significantly so (annual rates of death, 6.6 percent with ventricular pacing and 6.3 percent with physiologic pacing; annual rates of hospitalization for heart failure, 3.5 percent and 3.1 percent, respectively). There were significantly more perioperative complications with physiologic pacing than with ventricular pacing (9.0 percent vs. 3.8 percent, P < 0.001). Conclusions: Physiologic pacing provides little benefit over ventricular pacing for the prevention of stroke or death due to cardiovascular causes. (N Engl J Med 2000;342:1385-91.) (C)2000, Massachusetts Medical Society.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Inst Cardiol Montreal, Montreal, PQ, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	McMaster University; McMaster University; University of British Columbia; University of Calgary; McGill University; Universite de Montreal; Institut de Cardiologie de Montreal; University of Ottawa; Western University (University of Western Ontario); University of Toronto	Connolly, SJ (corresponding author), Hamilton Hlth Sci, Gen Site,McMaster Clin Rm 501,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	connostu@hhsc.ca	Tang, Anthony S/E-6203-2014; Klein, George/G-3313-2011	Talajic, Mario/0000-0001-8469-4748; Yusuf, Salim/0000-0003-4776-5601				ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Connolly SJ, 1996, CIRCULATION, V94, P578, DOI 10.1161/01.CIR.94.3.578; COX DR, 1972, J R STAT SOC B, V34, P187; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRISTENSSON BE, 1985, PACE, V8, P73, DOI 10.1111/j.1540-8159.1985.tb05726.x; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LINDEEDELSTAM C, 1992, PACE, V15, P905, DOI 10.1111/j.1540-8159.1992.tb03081.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MENOZZI C, 1990, PACE, V13, P1816, DOI 10.1111/j.1540-8159.1990.tb06896.x; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; Wharton JM, 1998, CIRCULATION, V98, P494	14	504	531	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1385	1391		10.1056/NEJM200005113421902	http://dx.doi.org/10.1056/NEJM200005113421902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805823	Bronze			2023-01-03	WOS:000086940600002
J	Ostermann, ME; Keenan, SP; Seiferling, RA; Sibbald, WJ				Ostermann, ME; Keenan, SP; Seiferling, RA; Sibbald, WJ			Sedation in the intensive care unit - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CRITICALLY-ILL PATIENTS; LONG-TERM SEDATION; OPEN-HEART-SURGERY; CARDIAC-SURGERY; MECHANICAL VENTILATION; COST-EFFECTIVENESS; MYOCARDIAL-ISCHEMIA; PROLONGED SEDATION; MIDAZOLAM; PROPOFOL	Context Sedation has become an integral part of critical care practice in minimizing patient discomfort; however, sedatives have adverse effects and the potential to prolong mechanical ventilation, which may increase health care costs. Objective To determine which form of sedation is associated with optimal sedation, the shortest time to extubation, and length of intensive care unit (ICU) stay. Data Sources A key word search of MEDLINE, EMBASE, and the Cochrane Collaboration databases and hand searches of 6 anesthesiology journals from 1980 to June 1998. Experts and industry representatives were contacted, personal files were searched, and reference lists of relevant primary and review articles were reviewed. Study Selection Studies included were randomized controlled trials enrolling adult patients receiving mechanical ventilation and requiring short-term or long-term sedation. At least 2 sedative agents had to be compared and the quality of sedation, time to extubation, or length of ICU stay analyzed. Data Extraction Data on population, intervention, outcome, and methodological quality were extracted in duplicate by 2 of 3 investigators using 8 validity criteria. Data Synthesis Of 49 identified randomized controlled trials, 32 met our selection criteria; 20 studied short-term sedation and 14, long-term sedation. Of these, 20 compared propofol with midazolam. Most trials were not double-blind and did not report or standardize important cointerventions. Propofol provides at least as effective sedation as midazolam and results in a faster time to extubation, with an increased risk of hypotension and higher cost. Insufficient data exist to determine effect on length of stay in the ICU. Isoflurane demonstrated some advantages over midazolam, and ketamine had a more favorable hemodynamic profile than fentanyl in patients with head injuries. Conclusion Considering the widespread use of sedation for critically ill patients, more large, high-quality, randomized controlled trials of the effectiveness of different agents for short-term and long-term sedation are warranted.	St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6M 2N8, Canada; Univ Western Ontario, Dept Med, Div Crit Care, London, ON, Canada; London Hlth Sci Ctr, Richard Ivey Crit Care Trauma Ctr, London, ON, Canada; London Hlth Sci Ctr, Dept Pharm, London, ON, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	St. Paul's Hospital; University of Saskatchewan; Western University (University of Western Ontario); London Health Sciences Centre; London Health Sciences Centre; University of British Columbia	Keenan, SP (corresponding author), St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, 620B-1081 Burrard, Vancouver, BC V6M 2N8, Canada.		Ostermann, Marlies/AAH-8160-2021; Ostermann, Marlies/B-8777-2015	Ostermann, Marlies/0000-0001-9500-9080				ADAMS HA, 1991, ANAESTHESIST, V40, P238; ADAMS HA, 1988, ANAESTHESIST, V37, P268; AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BERGER I, 1995, AM FAM PHYSICIAN, V51, P166; BEYER R, 1992, ANAESTHESIST, V41, P335; BOYD O, 1993, CAN J ANAESTH, V40, P1142, DOI 10.1007/BF03009603; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Cernaianu AC, 1996, CRIT CARE MED, V24, P222, DOI 10.1097/00003246-199602000-00007; Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010; CHAUDHRI S, 1992, BRIT J ANAESTH, V68, P98, DOI 10.1093/bja/68.1.98; COOK S, 1989, J DRUG DEV S2, V4, P65; Costa J, 1994, Clin Intensive Care, V5, P17; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; CRIPPEN DW, 1994, CRIT CARE CLIN, V10, P733, DOI 10.1016/S0749-0704(18)30103-9; DASTA JF, 1994, CRIT CARE MED, V22, P974, DOI 10.1097/00003246-199406000-00016; DEJONGHE B, IN PRESS INTENSIVE C; Durbin C G Jr, 1994, New Horiz, V2, P64; ENGELMAN RM, 1994, ANN THORAC SURG, V58, P1742, DOI 10.1016/0003-4975(94)91674-8; EWART MC, 1992, ANAESTHESIA, V47, P146, DOI 10.1111/j.1365-2044.1992.tb02015.x; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Hall RI, 1997, ANESTH ANALG, V85, P971, DOI 10.1097/00000539-199711000-00004; Hall S, 1996, CULT STUD, V10, P12, DOI 10.1080/09502389600490431; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; HARDING J, 1994, CHEST, V106, P194, DOI 10.1378/chest.106.1.194; HARPER SJ, 1991, EUR J ANAESTH, V8, P157; HARRIS CE, 1990, ANAESTHESIA, V45, P366, DOI 10.1111/j.1365-2044.1990.tb14777.x; Heinrichs W, 1992, Anaesthesiol Reanim, V17, P77; HEINRICHS W, 1992, ANAESTHESIOL REANIM, V17, P82; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; KONG KL, 1989, BRIT MED J, V298, P1277, DOI 10.1136/bmj.298.6683.1277; KONG KL, 1990, BRIT J ANAESTH, V64, P159, DOI 10.1093/bja/64.2.159; KOVARIK WD, 1996, CLIN INTENSIVE CARE, V7, P248; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; KRESS JP, 1997, J CRIT ILLNESS, V12, P287; LEDINGHAM I M, 1988, Resuscitation, V16, pS69, DOI 10.1016/0300-9572(88)90008-1; Louvelle J M, 1995, Can J Hosp Pharm, V48, P344; Manley NM, 1997, PHARMACOECONOMICS, V12, P247, DOI 10.2165/00019053-199712020-00015; MATHEWS HML, 1987, BRIT J ANAESTH, V59, P557, DOI 10.1093/bja/59.5.557; MAZZEO AJ, 1995, CRIT CARE CLIN, V11, P937, DOI 10.1016/S0749-0704(18)30047-2; McLeod G, 1997, INTENS CARE MED, V23, P428, DOI 10.1007/s001340050352; MCMURRAY TJ, 1990, ANAESTHESIA, V45, P322, DOI 10.1111/j.1365-2044.1990.tb14743.x; MENDEL PR, 1993, INT ANESTHESIOL CLIN, V31, P185, DOI 10.1097/00004311-199331020-00012; MILLER DR, 1994, CAN J ANAESTH, V41, P782, DOI 10.1007/BF03011584; O'Connor M, 1992, Acta Anaesthesiol Belg, V43, P235; Plunkett JJ, 1997, ANESTHESIOLOGY, V86, P785, DOI 10.1097/00000542-199704000-00008; POHLMAN AS, 1994, CRIT CARE MED, V22, P1241, DOI 10.1097/00003246-199408000-00007; POLSTER MR, 1993, BRIT J ANAESTH, V70, P612, DOI 10.1093/bja/70.6.612; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REEVE WG, 1991, CARE CRIT ILL, V7, P238; REVES JG, 1994, DRUG INFUSION SEDATI; RHONEY DH, 1998, CRIT CARE MED, V26, pA24; Roekaerts P M, 1993, J Cardiothorac Vasc Anesth, V7, P142, DOI 10.1016/1053-0770(93)90206-Z; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; Searle NR, 1997, CAN J ANAESTH, V44, P629, DOI 10.1007/BF03015447; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Sherry KM, 1996, ANAESTHESIA, V51, P312, DOI 10.1111/j.1365-2044.1996.tb07738.x; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SNELLEN F, 1990, INTENS CARE MED, V16, P312, DOI 10.1007/BF01706356; SPENCER EM, 1992, INTENS CARE MED, V18, P415, DOI 10.1007/BF01694344; STOLTZFUS DP, 1995, CRIT CARE CLIN, V11, P903, DOI 10.1016/S0749-0704(18)30045-9; TreggiariVenzi M, 1996, INTENS CARE MED, V22, P1186, DOI 10.1007/BF01709334; TUNG A, 1995, CRIT CARE CLIN, V11, P791, DOI 10.1016/S0749-0704(18)30039-3; VINIK H R, 1991, Intensive Care Medicine, V17, pS20, DOI 10.1007/BF01731150; Wahr JA, 1996, ANESTHESIOLOGY, V84, P1350, DOI 10.1097/00000542-199606000-00011; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WESTPHAL LM, 1987, ANESTHESIOLOGY, V67, P257, DOI 10.1097/00000542-198708000-00020; WEYLAND W, 1993, ANAESTHESIST, V42, P391; WHEELER AP, 1993, CHEST, V104, P566, DOI 10.1378/chest.104.2.566; YATE PM, 1986, BRIT J ANAESTH, V58, P1091, DOI 10.1093/bja/58.10.1091	76	255	267	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1451	1459		10.1001/jama.283.11.1451	http://dx.doi.org/10.1001/jama.283.11.1451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732935	Bronze			2023-01-03	WOS:000085696700030
J	Coulehan, J				Coulehan, J			Attention must be paid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					976	976		10.1001/jama.283.8.976	http://dx.doi.org/10.1001/jama.283.8.976			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697044				2023-01-03	WOS:000085308600001
J	Landi, F; Gambassi, G; Cocchi, A; Bernabei, R				Landi, F; Gambassi, G; Cocchi, A; Bernabei, R			Therapy for stroke patients living at home	LANCET			English	Letter							OCCUPATIONAL-THERAPY; TRIAL; CARE		Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Inst Med Interna & Geriatr, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Landi, F (corresponding author), Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Inst Med Interna & Geriatr, I-00168 Rome, Italy.		Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X				Bernabei R, 1998, BMJ-BRIT MED J, V316, P1348, DOI 10.1136/bmj.316.7141.1348; Clark F, 1997, JAMA-J AM MED ASSOC, V278, P1321, DOI 10.1001/jama.278.16.1321; Landi F, 1997, AM J PHYS MED REHAB, V76, P38, DOI 10.1097/00002060-199701000-00007; LANDI F, 1996, EUR J PHYS MED REHAB, V6, P1; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	5	1	1	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1731	1731		10.1016/S0140-6736(05)76719-2	http://dx.doi.org/10.1016/S0140-6736(05)76719-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568600				2023-01-03	WOS:000083652800057
J	Baird, DT; Glasier, AF				Baird, DT; Glasier, AF			Science, medicine, and the future - Contraception	BRITISH MEDICAL JOURNAL			English	Review							MIFEPRISTONE RU-486; ESTROGEN; ANDROGEN		Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland; Edinburgh Primary Care NHS Trust, Edinburgh, Midlothian, Scotland	University of Edinburgh	Baird, DT (corresponding author), Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9EW, Midlothian, Scotland.	dtbaird@ed.ac.uk						ALEXANDER NJ, 1995, SCI AM, V273, P136; BAIRD D, 1965, BMJ-BRIT MED J, V2, P1141, DOI 10.1136/bmj.2.5471.1141; BAIRD DT, 1993, CLIN APPL MIFEPRISTO, P148; Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; GEMZELLDANIELSSON K, 1993, HUM REPROD, V8, P870, DOI 10.1093/oxfordjournals.humrep.a138157; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GRIFFIN D, 1990, CONRAD W S, P501; HARRISON PF, 1996, CONTRACEPTIVE RES DE, P125; HERR JC, 1996, CONTRACEPTIVE RES DE, P401; LESSEY BA, 1994, FERTIL STERIL, V61, P812; MARTIN CW, 1997, ACTA OBSTET GYNE S76, V167; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Meriggiola MC, 1997, J ANDROL, V18, P240; NIESCHLAG E, 1996, PHARM BIOL CLIN APPL, P395; NORMAN J, 1995, HUM REPROD, V10, P308; RIMMER C, 1992, HUM REPROD, V7, P608, DOI 10.1093/oxfordjournals.humrep.a137705; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUNDARAM K, 1993, ANN MED, V25, P199, DOI 10.3109/07853899309164168; Swahn ML, 1999, HUM REPROD, V14, P485, DOI 10.1093/humrep/14.2.485; *WHO, 1998, WORLD HLTH REP 1998, P120	20	24	25	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					969	972		10.1136/bmj.319.7215.969	http://dx.doi.org/10.1136/bmj.319.7215.969			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514161	Green Published			2023-01-03	WOS:000083111700028
J	Rodriguez, C; Patel, AV; Calle, EE; Jacob, EJ; Thun, MJ				Rodriguez, C; Patel, AV; Calle, EE; Jacob, EJ; Thun, MJ			Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STATES CASE-CONTROL; UNITED-STATES; COLLABORATIVE ANALYSIS; RISK-FACTORS; WHITE WOMEN; CARCINOMA; DETERMINANTS; PATHOGENESIS; PROGESTINS; MENOPAUSE	Context Postmenopausal estrogen use is associated with increased risk of endometrial and breast cancer, 2 hormone-related cancers. The effect of postmenopausal estrogen use on ovarian cancer is not established. Objectives To examine the association between postmenopausal estrogen use and ovarian cancer mortality and to determine whether the association differs according to duration and recency of use. Design and Setting The American Cancer Society's Cancer Prevention Study II, a prospective US cohort study with mortality follow-up from 1982 to 1996. Participants A total of 211581 postmenopausal women who completed a baseline questionnaire in 1982 and had no history of cancer, hysterectomy, or ovarian surgery at enrollment. Main Outcome Measure Ovarian cancer mortality, compared among never users, users at baseline, and former users as well as by total years of use of estrogen replacement therapy (ERT). Results A total of 944 ovarian cancer deaths were recorded in 14 years of follow-up. Women who were using ERT at baseline had higher death rates from ovarian cancer than never users (rate ratio [RR], 1.51; 95% confidence interval [CI], 1.16-1.96). Risk was slightly but not significantly increased among former estrogen users (RR, 1.16; 95 % CI, 0.99-1.37). Duration of use was associated with increased risk in both baseline and former users, Baseline users with 10 or more years of use had an RR of 2.20 (95% CI, 1.53-3.17), while former users with 10 or more years of use had an RR of 1.59 (95 % CI, 1.13-2.25). Annual age-adjusted ovarian cancer death rates per 100000 Women were 64.4 for baseline users with 10 or more years of use, 38.3 for former users with 10 or more years of use, and 26.4 for never users. Among former users with 10 or more years of use, risk decreased with time since last use reported at study entry (RR for last use <15 years ago, 2.05; 95% CI, 1.29-3.25; RR for last use <greater than or equal to>15 years ago, 1.31;95% CI, 0.79-2.17). Conclusions In this population, postmenopausal estrogen use for 10 or more years was associated with increased risk of ovarian cancer mortality that persisted up to 29 years after cessation of use.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Rodriguez, C (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.							ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; CHIEN CH, 1994, MOL CELL ENDOCRINOL, V99, P11; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; DAVIDSON NE, 1995, NEW ENGL J MED, V332, P1638, DOI 10.1056/NEJM199506153322409; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; GORSKY RD, 1994, OBSTET GYNECOL, V83, P161; HARLOW BL, 1988, CANCER RES, V48, P5849; HARRIS R, 1992, AM J EPIDEMIOL, V136, P1204, DOI 10.1093/oxfordjournals.aje.a116428; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HELZLSOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926, DOI 10.1001/jama.274.24.1926; Hempling RE, 1997, OBSTET GYNECOL, V89, P1012, DOI 10.1016/S0029-7844(97)00118-X; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HOOVER R, 1977, LANCET, V2, P533; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; KAUFMAN DW, 1989, AM J EPIDEMIOL, V130, P1142, DOI 10.1093/oxfordjournals.aje.a115441; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; LARSSONCOHN U, 1977, BRIT J OBSTET GYNAEC, V85, P367; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; LEE NC, 1986, AGING REPROD CLIMACT; Markman M, 1996, GYNECOL ONCOL, V62, P4, DOI 10.1006/gyno.1996.0181; Negri E, 1999, INT J CANCER, V80, P848; PARAZZINI F, 1994, INT J CANCER, V57, P135, DOI 10.1002/ijc.2910570124; POLYCHRONOPOULOU A, 1993, INT J CANCER, V55, P402, DOI 10.1002/ijc.2910550312; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Ries L. A. G., 1999, SEER CANC STAT REV 1; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; RISCH HA, 1996, GYNECOL ONCOL, V63, P533; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; Rodriguez C, 1998, LANCET, V352, P1354, DOI 10.1016/S0140-6736(05)60745-3; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; TZONOU A, 1984, EUR J CANC CLIN ONCO, V20, P2045; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1212, DOI 10.1093/oxfordjournals.aje.a116429; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; *WHO, 1979, INT CLASS DIS MAN ST; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226; ZEIL HK, 1975, NEW ENGL J MED, V293, P1167	43	301	318	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2001	285	11					1460	1465		10.1001/jama.285.11.1460	http://dx.doi.org/10.1001/jama.285.11.1460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410VQ	11255422	Bronze			2023-01-03	WOS:000167462100028
J	Beattie, TF				Beattie, TF			To blow or not to blow?	LANCET			English	Editorial Material							NASAL FOREIGN-BODIES		Royal Hosp Sick Children, Dept Accid & Emergency, Edinburgh EH9 1LF, Midlothian, Scotland		Beattie, TF (corresponding author), Royal Hosp Sick Children, Dept Accid & Emergency, Edinburgh EH9 1LF, Midlothian, Scotland.							Botma P, 2000, J LARYNGOL OTOL, V114, P598; GUAZZO E, 1985, NEW ENGL J MED, V312, P725; Kadish HA, 1997, AM J EMERG MED, V15, P54, DOI 10.1016/S0735-6757(97)90049-8; Kalan A, 2000, POSTGRAD MED J, V76, P484, DOI 10.1136/pmj.76.898.484; Tong MCF, 1996, INT J PEDIATR OTORHI, V35, P207, DOI 10.1016/0165-5876(95)01305-9	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 27	2001	357	9252					250	250		10.1016/S0140-6736(00)03609-6	http://dx.doi.org/10.1016/S0140-6736(00)03609-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397JW	11214125				2023-01-03	WOS:000166693400007
J	Stern, V				Stern, V			Operations: spinal versus general anaesthetics - a patient's view	BRITISH MEDICAL JOURNAL			English	Article											Stern, V (corresponding author), 30 Goldhurst Terrace, London NW6 3HU, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1606	1607		10.1136/bmj.321.7276.1606	http://dx.doi.org/10.1136/bmj.321.7276.1606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124198	Green Published			2023-01-03	WOS:000166134500034
J	von Gunten, CF; Ferris, FD; Emanuel, LL				von Gunten, CF; Ferris, FD; Emanuel, LL			Ensuring competency in end-of-life care - Communication and relational skills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; ADVANCE DIRECTIVES; EUTHANASIA; DEATH; ATTITUDES; FUTILITY; REQUESTS	Physician competence in end-of-life care requires skill in communication, decision making, and building relationships, yet these skills were not taught to the majority of physicians during their training. This article presents a 7-step approach for physicians for structuring communication regarding care at the end of life. Physicians should prepare for discussions by confirming medical facts and establishing an appropriate environment; establish what the patient (and family) knows by using open-ended questions; determine how information is to be handled at the beginning of the patient-physician relationship; deliver the information in a sensitive but straightforward manner; respond to emotions of the patients, parents, and families; establish goals for care and treatment priorities when possible; and establish an overall plan. These 7 steps can be used in situations such as breaking bad news, setting treatment goals, advance care planning, withholding or withdrawing therapy, making decisions in sudden life-threatening illness, resolving conflict around medical futility, responding to a request for physician-assisted suicide, and guiding patients and families through the last hours of living and early stages after death. Effective application as part of core end-of-life care competencies is likely to improve patients' and families' experiences of care. It may also enhance physicians' professional fulfillment from satisfactory relationships with their patients and patients' families.	Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, EPEC Project, Chicago, IL 60611 USA; San Diego Hospice, Ctr Palliat Studies, San Diego, CA USA	Northwestern University	Emanuel, LL (corresponding author), Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, EPEC Project, 750 N Lake Shore Dr,Suite 601, Chicago, IL 60611 USA.	lemanuel@epec.net						[Anonymous], 1989, Ann Intern Med, V110, P734; [Anonymous], 1991, JAMA, V265, P1868; *ASP REF GROUP, 1999, PALL CAR PAT FAM COU; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BREITBART W, 1998, TXB PSYCHOONCOLOGY, P437; Buckman R, 1992, BREAK BAD NEWS GUIDE, P65, DOI 10.3138/9781487596989; CASSEM NH, 1976, ACUTE GRIEF FUNERAL; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; CHOCHINOV HM, 1998, PSYCHO-ONCOLOGY, P1016; *COUN ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P41; *COUNC ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P46; *COUNC ETH JUD AFF, 1998, COUNC ETH JUD AFF RE, P30; *COUNC ETH JUD AFF, 1998, REP END LIF CAR, P52; COUSINS N, 1985, NEW ENGL J MED, V313, P1422, DOI 10.1056/NEJM198511283132227; Doyle D., 1998, OXFORD TXB PALLIATIV, P957; ELLERSHAW JE, 1995, J PAIN SYMPTOM MANAG, V10, P192, DOI 10.1016/0885-3924(94)00123-3; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1993, J CLIN ETHIC, V4, P8; Emanuel L. L., 1998, REGULATING WE DIE ET; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 2000, EPEC CURRICULUM ED P; Emanuel LL, 1998, PRINCIPLES PRACTICE, P791; Evans Alison, 1994, Palliative Medicine, V8, P159, DOI 10.1177/026921639400800211; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; *HOSP I FLOR SUNC, 1996, CAR TIM DEATH HOSP R; *HOSP I FLOR SUNC, 1996, GRIEF BER HOSP TRAIN; HUDSON T, 1994, HOSP HEALTH NETWORK, V68, P26; HUDSON T, 1994, HOSP HEALTH NETWORK, V68, P32; IRVINE P, 1985, NEW ENGL J MED, V312, P1704, DOI 10.1056/NEJM198506273122608; Janson L J, 1991, J Palliat Care, V7, P51; Laine C, 1996, ANN INTERN MED, V125, P640, DOI 10.7326/0003-4819-125-8-199610150-00003; MARTINEZ J, 1997, CANC NURSING PRINCIP; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; O'Gorman SM, 1998, J ADV NURS, V27, P1127, DOI 10.1046/j.1365-2648.1998.00659.x; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN R, 1992, YOUR LIFE YOUR CHOIC; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; ROY DJ, 1998, OXFORD TXB PALLIATIV, P112; SHELDON F, 1993, MANAGEMENT TERMINAL, P29; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; Teno JM, 1996, J CLIN ETHIC, V7, P205; The Council for Environmental Education, 1998, COUNCIL ENV ED AGEND, P1; TODRES ID, 1994, PEDIATR CLIN N AM, V41, P1395; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; *U TOR JOINT CTR B, 1999, JOINT CTR BIOETH CAN; VACHON MLS, 1982, AM J PSYCHIAT, V139, P998; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; von Gunten C F, 2000, J Palliat Med, V3, P157, DOI 10.1089/10966210050085223; Weber M, 1998, J PALLIATIVE CARE, V14, P34, DOI 10.1177/082585979801400406; Yancey D, 1990, J Palliat Care, V6, P24; YOUNGNER SJ, 1994, J AM GERIATR SOC, V42, P887, DOI 10.1111/j.1532-5415.1994.tb06565.x	62	166	167	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3051	3057		10.1001/jama.284.23.3051	http://dx.doi.org/10.1001/jama.284.23.3051			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382VC	11122596	Bronze			2023-01-03	WOS:000165847200034
J	Weiner, LM; Adams, GP				Weiner, LM; Adams, GP			New approaches to antibody therapy	ONCOGENE			English	Article						antibody therapy; radioimmunotherapy; bispecific antibodies	SINGLE-CHAIN FV; BISPECIFIC MONOCLONAL-ANTIBODY; PHASE-I TRIAL; B-CELL LYMPHOMA; ENZYME PRODRUG THERAPY; FUSION PROTEIN; RADIOLABELED-ANTIBODY; TARGETING C-ERBB-2; OVARIAN-CARCINOMA; COLORECTAL-CANCER	Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effecters. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induct adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Adams, Gregory/ABE-8245-2020		NATIONAL CANCER INSTITUTE [P30CA006927, R01CA050633, R01CA065559] Funding Source: NIH RePORTER; NCI NIH HHS [CA65559, CA06927, CA50633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 1998, CANCER RES, V58, P485; ADAMS GP, 1993, CANCER RES, V53, P4026; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; ADAMS GP, 1995, CANCER IMMUNOL IMMUN, V40, P299, DOI 10.1007/BF01519629; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; ANDERSON WT, 1987, NATL CANCER I MONOGR, V3, P149; Axworthy D, 1996, TUMOR TARGET, V2, P156; Bagshawe K D, 1993, Adv Pharmacol, V24, P99, DOI 10.1016/S1054-3589(08)60935-7; BAGSHAWE KD, 1991, DIS MARKERS, V9, P233; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; CANEVARI S, 1995, JNCI-J NATL CANCER I, V87, P1463, DOI 10.1093/jnci/87.19.1463; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COLCHER D, 1988, CANCER RES, V48, P4597; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; DEPALAZZO IG, 1990, CANCER RES, V50, P7123; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GALLINGER S, 1993, CANCER RES, V53, P271; Giantonio BJ, 1997, J CLIN ONCOL, V15, P1994, DOI 10.1200/JCO.1997.15.5.1994; GILLIES SD, 1992, P NATL ACAD SCI USA, V89, P1428, DOI 10.1073/pnas.89.4.1428; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOODWIN DA, 1988, J NUCL MED, V29, P226; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAIN RK, 1987, CANCER RES, V47, P3039; JUWEID M, 1992, CANCER RES, V52, P5144; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 2000, CLIN CANCER RES, V6, P406; KUDO T, 1991, J IMMUNOL METHODS, V145, P119, DOI 10.1016/0022-1759(91)90317-9; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; LI S, 1986, J IMMUNOL, V137, P3378; LINK BK, 1993, BLOOD, V81, P3343; Link BK, 1998, INT J CANCER, V77, P251, DOI 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.3.CO;2-O; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MALONEY DG, 1994, BLOOD, V84, P2457; Martin J, 1997, CANCER CHEMOTH PHARM, V40, P189, DOI 10.1007/s002800050646; NITTA T, 1990, LANCET, V335, P368, DOI 10.1016/0140-6736(90)90205-J; OBRIST R, 1988, BIOCHEM BIOPH RES CO, V155, P1139, DOI 10.1016/S0006-291X(88)81259-2; ORDER SE, 1986, INT J RADIAT ONCOL, V12, P277, DOI 10.1016/0360-3016(86)90110-0; PAGANELLI G, 1988, INT J CANCER, P121; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; RENNER C, 1995, EUR J IMMUNOL, V25, P2027, DOI 10.1002/eji.1830250734; SABZEVARI H, 1994, P NATL ACAD SCI USA, V91, P9626, DOI 10.1073/pnas.91.20.9626; SCHEINBERG DA, 1991, J CLIN ONCOL, V9, P478, DOI 10.1200/JCO.1991.9.3.478; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHIER R, 1995, IMMUNOTECHNOLOGY, V1, P73, DOI 10.1016/1380-2933(95)00007-0; SCONOCCHIA G, 1994, J IMMUNOL, V153, P5473; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; Siemers NO, 1997, BIOCONJUGATE CHEM, V8, P510, DOI 10.1021/bc9700751; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; SILVERSTEIN AM, 1994, CELL IMMUNOL, V158, P1, DOI 10.1006/cimm.1994.1253; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA377; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Thomas MC, 1998, HUM GENE THER, V9, P835, DOI 10.1089/hum.1998.9.6-835; TIBBEN JG, 1993, J NATL CANCER I, V85, P1003, DOI 10.1093/jnci/85.12.1003; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; Valerius T, 1997, BLOOD, V90, P4485, DOI 10.1182/blood.V90.11.4485.4485_4485_4492; VALONE FH, 1995, J CLIN ONCOL, V13, P2281, DOI 10.1200/JCO.1995.13.9.2281; WEINER GJ, 1994, J IMMUNOL, V152, P2385; WEINER LM, 1995, CANCER RES, V55, P4586; WEINER LM, 1993, CANCER RES, V53, P94; WEINER LM, 1993, J IMMUNOL, V151, P2877; WEINER LM, 1995, TUMOR TARGET, V1, P51; Weinstein S., 1986, MODERN MED, V1, P5; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5	72	77	85	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6144	6151		10.1038/sj.onc.1204000	http://dx.doi.org/10.1038/sj.onc.1204000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156528				2023-01-03	WOS:000166121400008
J	Ferner, RE				Ferner, RE			Medication errors that have led to manslaughter charges	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.			Ferner, Robin/0000-0003-3769-1346				[Anonymous], 2000, ORG MEMORY REPORT EX; CLOUGH S, 1999, COMMUNICATION   0106; DYER C, 1975, BRIT MED J, V3, P108; Fenn P, 2000, BRIT MED J, V320, P1567, DOI 10.1136/bmj.320.7249.1567; HALLE M, 1994, OBSERVER        0213, P7; Kohn LT, 1999, ERR IS HUMAN BUILDIN; NELSONJONES R, 1995, MED NEGLIGENCE CASE, pA511; Reason J., 1990, HUMAN ERROR; STOKES P, 1998, COMMUNICATION   1128; STOKES P, 1999, COMMUNICATION   1005; TAYLOR JL, 1970, DOCTOR LAW; 1925, BMJ, V1, P1022; 1978, TIMES           0428, P4; 1982, TIMES           0707, P3; 1995, GUARDIAN        0307, P2; 1986, TIMES           1205, P2; 1994, GUARDIAN        0304, P3; 1990, GUARDIAN        0731, P6; 1994, GUARDIAN        0507, P8; 1978, TIMES           1031, P4; 1982, TIMES           0715, P4	21	40	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1212	1216		10.1136/bmj.321.7270.1212	http://dx.doi.org/10.1136/bmj.321.7270.1212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073516	Green Published			2023-01-03	WOS:000165357100033
J	Henney, JE				Henney, JE			Challenges in regulating direct-to-consumer advertising	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Washington, DC 20204 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, Washington, DC 20204 USA.							Bradley LR, 1997, MED CARE, V35, P86, DOI 10.1097/00005650-199701000-00008; Food and Drug Administration Center for Drug Evaluation and Research (CDER), 1999, FED REG, V64, P43197; *FOOD DRUG ADM, 1997, DRAFT GUID IND CONS; *FOOD DRUG ADM, 1984, PRESCR DRUG ADV CONS; WILES MS, 2000, HLTH AFF MILLWOOD, V10, P110; 1999, FED REG, V50, P36677	6	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2242	2242		10.1001/jama.284.17.2242	http://dx.doi.org/10.1001/jama.284.17.2242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367GD	11056601	hybrid			2023-01-03	WOS:000090052600037
J	Speed, CA; Shapiro, LM				Speed, CA; Shapiro, LM			Exercise prescription in cardiac disease	LANCET			English	Editorial Material							SUDDEN STRENUOUS EXERCISE; CORONARY-ARTERY DISEASE		Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England; Addenbrookes Hosp, Dept Rheumatol & Sports & Exercise Med, Cambridge, England	Papworth Hospital; Addenbrooke's Hospital; University of Cambridge	Shapiro, LM (corresponding author), Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England.							BARNARD RJ, 1973, CIRCULATION, V48, P936, DOI 10.1161/01.CIR.48.5.936; BARNARD RJ, 1973, J APPL PHYSIOL, V34, P833, DOI 10.1152/jappl.1973.34.6.833; BETHELL HJN, 1999, BENEFITS HAZARDS EXE, P339; Burrows S, 1999, BRIT J SPORT MED, V33, P287; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; FOSTER C, 1981, CIRCULATION, V63, P592, DOI 10.1161/01.CIR.63.3.592; FRANKLIN BA, 1992, AM J CARDIOL, V69, P1426, DOI 10.1016/0002-9149(92)90895-6; OBERMAN A, 1995, AM J CARDIOL, V76, P643, DOI 10.1016/S0002-9149(99)80189-1; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1975, ARCH PHYS MED REHAB, V56, P141; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; POLLOCK ML, 1996, US PRESIDENTS COUNCI, V2; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; SIRE S, 1987, EUR HEART J, V8, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062195; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; Swan L, 2000, HEART, V83, P685, DOI 10.1136/heart.83.6.685	16	9	10	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1208	1210		10.1016/S0140-6736(00)02778-1	http://dx.doi.org/10.1016/S0140-6736(00)02778-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072933				2023-01-03	WOS:000089724900004
J	Larson, DG; Tobin, DR				Larson, DG; Tobin, DR			End-of-life conversations - Evolving practice and theory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; PALLIATIVE MEDICINE; DECISION-MAKING; SELF-EFFICACY; CARE; CANCER; COMMUNICATION; PERSPECTIVES; QUALITY	This article examines the evolution of and need for "end-of-life conversations." Barriers to end-of-life discussions that have been identified in patients and families, health care professionals, and health cave systems can seriously interfere with the quality of remaining life for terminally ill patients. Strategies for enhancing end-of-life discussions are most productively linked to (1) physicians' interpersonal communication skills, (2) a patient-centered model of care, (3) a focus on quality of remaining life, and (4) innovative clinical models for implementing these discussions earlier in the care process. We conclude that end-of-life conversations must become a routine, structured intervention in health care and that advance care planning is best viewed as one component in a series of ongoing end-of-life discussions. Randomized trials are needed to examine new approaches and models for enhancing end-of-life conversations.	Vet Affairs Hlth Care Network Upstate New York, Albany, NY 12208 USA; Santa Clara Univ, Dept Counseling Psychol, Santa Clara, CA 95053 USA	Santa Clara University	Tobin, DR (corresponding author), Vet Affairs Hlth Care Network Upstate New York, 113 Holland Ave,111T, Albany, NY 12208 USA.	daniel.tobin@med.va.gov						Bandura A, 1997, EFFICACY EXERCISE CO; Becker E., 1973, DENIAL DEATH; Beckham JC, 1997, BEHAV MED, V23, P138, DOI 10.1080/08964289709596370; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Buckman R., 1992, BREAK BAD NEWS GUIDE; BURGER JM, 1989, J PERS SOC PSYCHOL, V56, P246, DOI 10.1037/0022-3514.56.2.246; Byock I, 1997, DYING WELL PROSPECT; Byock IR, 1996, CLIN GERIATR MED, V12, P237; CASSEL EJ, 1989, NEW ENGL J MED, V306, P639; Chen A., 2000, BEST PRACTICES COORD; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Connor S, 1998, HOSPICE PRACTICE PIT; Connor S R, 1999, Hosp J, V14, P193; Cugliari AM, 1999, AM J HEALTH BEHAV, V23, P105, DOI 10.5993/AJHB.23.2.3; EMANUEL L, 1999, ED PHYSICIANS END LI; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1995, STRUCTURED DELIBRA S; EPSTEIN RM, 1993, J FAM PRACTICE, V37, P377; FAULKNER A, 1991, PATIENT EDUC COUNS, V18, P3, DOI 10.1016/0738-3991(91)90073-E; Field MJ, 1997, APPROACHING DEATH IM; Fins JJ, 1999, J PAIN SYMPTOM MANAG, V17, P6, DOI 10.1016/S0885-3924(98)00109-2; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Gallagher TH, 1999, TEACH LEARN MED, V11, P142, DOI 10.1207/S15328015TL110304; GERTEIS M, 1993, PATIENTS EYES, P1; GOLDSTEIN MG, 1998, HDB HLTH BEHAV CHANG, P85; Greene MG, 1996, RES AGING, V18, P84, DOI 10.1177/0164027596181006; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HAVERMANS T, 1994, CHILD CARE HLTH DEV, V20, P309, DOI 10.1111/j.1365-2214.1994.tb00393.x; Heaven CM, 1997, PALLIATIVE MED, V11, P283, DOI 10.1177/026921639701100404; Hinton J, 1998, J PALLIATIVE CARE, V14, P15, DOI 10.1177/082585979801400305; Hockley JM, 1998, HOSP BASED PALLIATIV; JARRETT N, 1995, J ADV NURS, V22, P72, DOI 10.1046/j.1365-2648.1995.22010072.x; Kleinman A., 1988, ILLNESS NARRATIVES; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Larson D. G., 1993, HELPERS JOURNEY WORK; Larson Dale G., 1993, Journal of Psychosocial Oncology, V11, P1; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; Lynn J, 2000, J AM GERIATR SOC, V48, pS214, DOI 10.1111/j.1532-5415.2000.tb03135.x; MCCANN R, 1998, GERONTOL GERIATR ED, V18, P3; Merluzzi TV, 1997, HEALTH PSYCHOL, V16, P163, DOI 10.1037/0278-6133.16.2.163; Morrison M.F., 1998, END OF LIFE DECISION, P109; Murphy P, 2000, J AM GERIATR SOC, V48, pS154, DOI 10.1111/j.1532-5415.2000.tb03125.x; National Hospice Organization Standards and Accreditation Committee, 1997, PATHW PAT FAM FAC TE; PEARLMAN RA, 1995, PATIENT EDUC COUNS, V26, P353, DOI 10.1016/0738-3991(95)00739-M; Rabow MW, 2000, JAMA-J AM MED ASSOC, V283, P771, DOI 10.1001/jama.283.6.771; Rando T, 2000, CLIN DIMENSIONS ANTI; ROTER D, 1998, PSYCHO-ONCOLOGY, P1074; ROTHCHILD E, 1994, GEN HOSP PSYCHIAT, V16, P251, DOI 10.1016/0163-8343(94)90004-3; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SMITH RA, 1984, J PERS SOC PSYCHOL, V47, P415, DOI 10.1037/0022-3514.47.2.415; Solomon M Z, 1993, J Law Med Ethics, V21, P231, DOI 10.1111/j.1748-720X.1993.tb01245.x; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P75, DOI 10.1016/S0885-3924(98)00134-1; TOBIN DR, 2000, ADV ILLNES COORDINAT; TOBIN DR, 1999, PEACEFUL DYING; TOBIN DR, 1999, PATIENT FAMILY ED MA, P193; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; Weissman DE, 1998, J PAIN SYMPTOM MANAG, V15, P195, DOI 10.1016/S0885-3924(97)00265-0; Weissman DE, 1998, J PAIN SYMPTOM MANAG, V15, P82, DOI 10.1016/S0885-3924(97)00253-4; Wilkinson A M, 1998, Hosp J, V13, P165; Yuen K, 1998, J PALLIATIVE CARE, V14, P79, DOI 10.1177/082585979801400316; Zuckerman C, 1999, Hosp J, V14, P85; [No title captured]	67	185	187	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	2000	284	12					1573	1578		10.1001/jama.284.12.1573	http://dx.doi.org/10.1001/jama.284.12.1573			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	355HF	11000655	Bronze			2023-01-03	WOS:000089379700037
J	Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS				Baulard, AR; Betts, JC; Engohang-Ndong, J; Quan, S; McAdam, RA; Brennan, PJ; Locht, C; Besra, GS			Activation of the pro-drug ethionamide is regulated in mycobaeteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID RESISTANCE; CATALASE PEROXIDASE; GENE; BIOACTIVATION; OXIDATION; TARGET	The anti-tuberculosis drug ethionamide (ETH), which is a structural analog of isoniazid (INH), is known to strongly inhibit mycolic acid synthesis in Mycobacterium tuberculosis. Although several targets have been identified for INH, only speculative information is available concerning ETH, Mutations within the promoter and the coding region of enoyl-acyl carrier protein reductase (InhA) were found to confer resistance to both drugs, thus leading to the impression that INR and ETH may: share a common mode of action. However, a notable distinction between the two drugs Lies in the lack of cross-resistance in clinical isolates. This may be attributed in part to the fact that the pro-drug INH must be activated via KatG, and no activation step for ETH has yet been described. Here we report the identification of an activator for ETH, The ETH activator (Rv3854c), which we have termed EthA, was found to be homologous to various monooxygenases and induced ETR sensitivity when overexpressed in mycobacteria, Interestingly, the neighboring open reading frame (Rv3855), which was found homologous to transcriptional repressors of the tetR family, led to ETH resistance when overexpressed. In addition, chromosomal inactivation of this gene by transposition led to ETH hypersensitivity. These data strongly suggest that Rv3855, which me have termed EthR, regulates the production of EthA, which subsequently activates the pro-drug ETH, This study opens up new avenues of research relating to ETR activation in mycobacteria, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.	Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Inst Pasteur, Inst Biol, INSERM, U447, F-59019 Lille, France	Newcastle University - UK; Colorado State University; GlaxoSmithKline; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Besra, GS (corresponding author), Newcastle Univ, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.s.besra@newcastle.ac.uk	Baulard, Alain R/E-6830-2017; Locht, Camille/L-3516-2018	Baulard, Alain R/0000-0002-0150-5241; Besra, Gurdyal/0000-0002-5605-0395; Betts, Joanna/0000-0003-1729-1839	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087, R01AI033706, R22AI018357, R01AI018357, R37AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33706, AI-18357, AI-38087] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Barry CE, 1998, DRUG RESIST UPDATE, V1, P128, DOI 10.1016/S1368-7646(98)80028-9; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; BECK CF, 1988, MICROBIOL REV, V52, P318, DOI 10.1128/MMBR.52.3.318-326.1988; CHIELI E, 1985, BIOCHEM PHARMACOL, V34, P395, DOI 10.1016/0006-2952(85)90056-5; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; DELENCASTRE H, 1983, J GEN MICROBIOL, V129, P3203; ESPINAL M, 1999, 260 WHO; Fattorini L, 1999, MICROB DRUG RESIST, V5, P265, DOI 10.1089/mdr.1999.5.265; GUYER MS, 1978, J MOL BIOL, V126, P347, DOI 10.1016/0022-2836(78)90045-1; Heym B., 1999, Tubercle and Lung Disease, V79, P267, DOI 10.1054/tuld.1998.0208; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; LIU J, 1999, MYCOBACTERIA MOL BIO; Loewen PC, 2000, ASM NEWS, V66, P76; QUEMARD A, 1992, ANTIMICROB AGENTS CH, V36, P1316, DOI 10.1128/AAC.36.6.1316; RIST NOEL, 1960, ADVANCES TUBERC RES, V10, P69; Rollier R, 1972, Maroc Med, V52, P148; RUSE MJ, 1991, BIOCHEM SOC T, V19, pS233, DOI 10.1042/bst019233s; RUSE MJ, 1991, TOXICOL LETT, V58, P37, DOI 10.1016/0378-4274(91)90188-C; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAYAMA K, 1974, ANN NY ACAD SCI, V235, P426, DOI 10.1111/j.1749-6632.1974.tb43281.x; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WANG L, 1972, ANTIMICROB AGENTS CH, V2, P438, DOI 10.1128/AAC.2.6.438; Wards BJ, 1996, FEMS MICROBIOL LETT, V145, P101, DOI 10.1016/0378-1097(96)00394-1; WATERS MFR, 1989, BIOL MYCOBACTERIA, V3, P405; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	244	266	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28326	28331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10869356				2023-01-03	WOS:000089197100105
J	Weiss, SC				Weiss, SC			Parental decisions and physician responsibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Asch A, 1997, HASTINGS CENT REP, V27, P17; 1974, NY TIMES        0612, pA18	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1142	1142		10.1001/jama.284.9.1142	http://dx.doi.org/10.1001/jama.284.9.1142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974697				2023-01-03	WOS:000089037200018
J	Mant, J; Carter, J; Wade, DT; Winner, S				Mant, J; Carter, J; Wade, DT; Winner, S			Family support for stroke: a randomised controlled trial	LANCET			English	Article							SPECIALIST NURSE SUPPORT; QUESTIONNAIRE; INTERVENTION; VERSION; CONSENT; PEOPLE; INDEX; SF-36	Background Attention is currently focused on family care of stroke survivors, but the effectiveness of support services is unclear. We did a single-blind, randomised, controlled trial to assess the impact of family support on stroke patients and their carers. Methods Patients with acute stroke admitted to hospitals in Oxford. UK, were assigned family support or normal care within 6 weeks of stroke. After 6 months, we assessed, for carers, knowledge about stroke, Frenchay activities index, general health questionnaire-28 scores, caregiver strain index, Dartmouth co-op charts, short form 36 (SF-36), and satisfaction scores, and, for patients, knowledge about stroke and use of services, Barthel index, Rivermead mobility index. Frenchay activities index, London handicap scale, hospital anxiety and depression scales, Dartmouth co-op charts, and satisfaction. Findings 323 patients and 267 carers were followed up. Carers in the intervention group had significantly better Frenchay activities indices (p=0.03), SF-36 scores (energy p=0.02. mental health p=0.004, pain p=0.03, physical function p=0.025, and general health perception p=0.02), quality of life on the Dartmouth co-op chart (p=0.01), and satisfaction with understanding of stroke (82 vs 71.%, p=0.04) than those in the control group. Patients' knowledge about stroke, disability, handicap, quality of life, and satisfaction with services and understanding of stroke did not differ between groups. Fewer patients in the intervention group than in the control group saw a physiotherapist after discharge (44 vs 56%, p=0.04), but use of other services was similar. Interpretation Family support significantly increased social activities and improved quality of life for carers, with no significant effects on patients.	Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Rivermead Rehabil Ctr, Oxford OX1 4XD, England; Radcliffe Infirm, Dept Clin Geratol, Oxford OX2 6HE, England	University of Birmingham; Radcliffe Infirmary	Mant, J (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.		Tanne, David/F-2560-2010	Tanne, David/0000-0002-6699-2220; Wade, Derick/0000-0002-1188-8442				BOSANQUET N, 1998, STROKE CARE REDUCING; CARNWATH TCM, 1987, BMJ-BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Carter J, 1997, CLIN REHABIL, V11, P131, DOI 10.1177/026921559701100206; CHRISTIE D, 1984, COMMUNITY HEALTH ST, V8, P26; Dennis M, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077; Dennis M, 1998, STROKE, V29, P1867, DOI 10.1161/01.STR.29.9.1867; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Dorman PJ, 1999, STROKE, V30, P2146, DOI 10.1161/01.STR.30.10.2146; Dowswell G, 1997, CLIN REHABIL, V11, P293, DOI 10.1177/026921559701100405; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; FRIEDLAND JF, 1992, ARCH PHYS MED REHAB, V73, P573; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; Harwood RH, 1995, MANUAL LONDON HANDIC; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Mant J, 1998, CLIN REHABIL, V12, P465, DOI 10.1191/026921598668972226; MANT J, 1998, HLTH TRENDS, V29, P96; McLean S, 1997, BRIT MED J, V314, P1076, DOI 10.1136/bmj.314.7087.1076; POUND P, 1993, J EPIDEMIOL COMMUN H, V47, P500, DOI 10.1136/jech.47.6.500; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; ROWAN K, 1994, MEASURING HLTH MED O; *STROK ASS, 1997, FAM SUPP OV APR 1996; TOWLE D, 1989, CLIN REHABIL, V3, P89; Trigg R, 1997, BRIT MED J, V315, P607; Wade D T, 1988, Int Disabil Stud, V10, P64; Wade DT., 1992, MEASUREMENT NEUROLOG; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	166	171	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 2	2000	356	9232					808	813		10.1016/S0140-6736(00)02655-6	http://dx.doi.org/10.1016/S0140-6736(00)02655-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350LF	11022928				2023-01-03	WOS:000089101800011
J	Herrington, DM; Reboussin, DM; Brosnihan, KB; Sharp, PC; Shumaker, SA; Snyder, TE; Furberg, CD; Kowalchuk, GJ; Stuckey, TD; Rogers, WJ; Givens, DH; Waters, D				Herrington, DM; Reboussin, DM; Brosnihan, KB; Sharp, PC; Shumaker, SA; Snyder, TE; Furberg, CD; Kowalchuk, GJ; Stuckey, TD; Rogers, WJ; Givens, DH; Waters, D			Effects of estrogen replacement on the progression of coronary-artery atherosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-REACTIVE PROTEIN; POSTMENOPAUSAL WOMEN; 17-BETA ESTRADIOL; HEART-DISEASE; THERAPY; CHOLESTEROL; RISK; ENDOTHELIUM; PREVENTION; PROGESTIN	Background: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. Methods: We randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (+/-SD) of 3.2+/-0.6 years. Base-line and follow-up coronary angiograms were analyzed by quantitative methods. Results: Estrogen and estrogen plus medroxyprogesterone acetate produced significant reductions in low-density lipoprotein cholesterol levels (9.4 percent and 16.5 percent, respectively) and significant increases in high-density lipoprotein cholesterol levels (18.8 percent and 14.2 percent, respectively); however, neither treatment altered the progression of coronary atherosclerosis. After adjustment for measurements at base line, the mean (+/-SE) minimal coronary-artery diameters at follow-up were 1.87+/-0.02 mm, 1.84+/-0.02 mm, and 1.87+/-0.02 mm in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively. The differences between the values for the two active-treatment groups and the value for the placebo group were not significant. Analyses of several secondary angiographic outcomes and subgroups of women produced similar results. The rates of clinical cardiovascular events were also similar among the treatment groups. Conclusions: Neither estrogen alone nor estrogen plus medroxyprogesterone acetate affected the progression of coronary atherosclerosis in women with established disease. These results suggest that such women should not use estrogen replacement with an expectation of cardiovascular benefit. (N Engl J Med 2000;343:522-9.) (C)2000, Massachusetts Medical Society.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Family & Community Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27157 USA; Carolinas Med Ctr, Dept Cardiol, Charlotte, NC 28203 USA; LeBauer Cardiovasc Associates, Greensboro, NC USA; Univ Alabama, Div Cardiol, Birmingham, AL USA; Winston Salem Cardiol Associates, Winston Salem, NC USA; San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Carolinas Medical Center; LeBauer-Brodie Center for Cardiovascular Research & Education; University of Alabama System; University of Alabama Birmingham; San Francisco General Hospital Medical Center	Herrington, DM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NCRR NIH HHS [M01 RR07122] Funding Source: Medline; NHLBI NIH HHS [U01 HL-45488] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Azen SP, 1996, CIRCULATION, V93, P34, DOI 10.1161/01.CIR.93.1.34; Brown BG, 1998, CIRCULATION, V98, P635; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; Bush TL, 1998, J WOMENS HEALTH, V7, P781, DOI 10.1089/jwh.1998.7.781; Cushman M, 1999, ARTERIOSCL THROM VAS, V19, P893, DOI 10.1161/01.ATV.19.4.893; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, NEW ENGL J MED, V335, P1406; Grundy Scott M., 1994, Circulation, V89, P1329; Grundy SM, 1997, CIRCULATION, V95, P2329, DOI 10.1161/01.CIR.95.9.2329; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; Hanke H, 1999, ATHEROSCLEROSIS, V147, P123, DOI 10.1016/S0021-9150(99)00182-3; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P257, DOI 10.1016/S0197-2456(00)00054-4; Herrington DM, 1999, ANN INTERN MED, V131, P463, DOI 10.7326/0003-4819-131-6-199909210-00012; HERRINGTON DM, 1997, HORMONAL METABOLIC C, P175; Holm P, 1999, CIRCULATION, V100, P1727, DOI 10.1161/01.CIR.100.16.1727; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; LEUNG WH, 1991, CATHETER CARDIO DIAG, V24, P121, DOI 10.1002/ccd.1810240211; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Ong PJL, 1999, JAMA-J AM MED ASSOC, V281, P794; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; SMITH SC, 1995, CIRCULATION, V92, P2; van Baal WM, 1999, THROMB HAEMOSTASIS, V81, P925, DOI 10.1055/s-0037-1614600; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; VOGEL RA, 1999, TXB INTERVENTIONAL C, P111; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WENGER NK, 1998, PREV CARDIOL, V1, P9; WILLIAMS JK, 1995, ARTERIOSCL THROM VAS, V15, P827, DOI 10.1161/01.ATV.15.7.827	35	926	948	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2000	343	8					522	529		10.1056/NEJM200008243430801	http://dx.doi.org/10.1056/NEJM200008243430801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346QM	10954759				2023-01-03	WOS:000088882600001
J	Farmer, RDT; Williams, TJ; Simpson, EL; Nightingale, AL				Farmer, RDT; Williams, TJ; Simpson, EL; Nightingale, AL			Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective To compare the incidence of venous rhromboembolism among women taking combined oral contraceptives before and after the October 1995 pill scare. Design Analysis of General Practice Research Database. Setting United Kingdom, January 1993 to December 1998. Subjects Women aged 15-49 taking combined oral contraceptives. Main outcome measures Incidence of venous thromboembolism. Results Use of so called "third generation" combined oral contraceptives fell from 53% during January 1993 to October 1995 to 14% during November 1995 to December 1998. There was no significant change in the incidence of venous thromboembolism between the two periods after age was adjusted for (incidence ratio 1.04, 95%, confidence interval 0.78 to 1.39). Conclusions The findings are not compatible with the assertion that third generation oral contraceptives are associated with a twofold increase in risk of venous thromboembolism compared with older progestogens.	Univ Surrey, Postgrad Med Sch, Guildford GU2 7DJ, Surrey, England	University of Surrey	Farmer, RDT (corresponding author), Univ Surrey, Postgrad Med Sch, Guildford GU2 7DJ, Surrey, England.	r.farmer@surrey.ac.uk		Nightingale, Alison/0000-0001-8611-2940				Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; Committee on the Safety of Medicines, 1995, COMB OR CONTR THROMB; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Lawrenson RA, 1999, BRIT MED J, V319, P387, DOI 10.1136/bmj.319.7206.387; Lewis MA, 1999, HUM REPROD, V14, P1493, DOI 10.1093/humrep/14.6.1493; Lidegaard O, 1998, CONTRACEPTION, V57, P291, DOI 10.1016/S0010-7824(98)00033-X; Mayor S, 1999, BRIT MED J, V318, P1026, DOI 10.1136/bmj.318.7190.1026a; Mellemkjaer L, 1999, BRIT MED J, V319, P820, DOI 10.1136/bmj.319.7213.820; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; POULTER NR, 1995, LANCET, V346, P1575; Spitzer WO, 1996, BRIT MED J, V312, P83; *STAT CORP, 1997, STAT STAT SOFTW REL; Suissa S, 1998, CONTRACEPTION, V57, P64	17	53	53	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2000	321	7259					477	479		10.1136/bmj.321.7259.477	http://dx.doi.org/10.1136/bmj.321.7259.477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347MC	10948026	Bronze, Green Published			2023-01-03	WOS:000088932800019
J	Berek, JS				Berek, JS			Interferon plus chemotherapy for primary treatment of ovarian cancer	LANCET			English	Editorial Material							RECOMBINANT GAMMA-INTERFERON; GYNECOLOGIC-ONCOLOGY-GROUP; TUMOR-NECROSIS-FACTOR; ALPHA-INTERFERON; CARCINOMA CELLS; EXPRESSION; CISPLATIN; TRIAL		Univ Calif Los Angeles, Sch Med, Div Gynecol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berek, JS (corresponding author), Univ Calif Los Angeles, Sch Med, Div Gynecol Oncol, Los Angeles, CA 90095 USA.							ALLAVENA P, 1990, CANCER RES, V50, P7318; BEREK JS, 1990, J CLIN ONCOL, V8, P1610, DOI 10.1200/JCO.1990.8.10.1610; Berek JS, 1999, GYNECOL ONCOL, V74, P48, DOI 10.1006/gyno.1999.5455; BEREK JS, 1992, EUR J CANCER, V28A, P719, DOI 10.1016/0959-8049(92)90100-G; BEREK JS, 1991, GYNECOL ONCOL, V40, P237; Berek JS, 1999, GYNECOL ONCOL, V75, P10, DOI 10.1006/gyno.1999.5532; BEREK JS, 2000, PRACTICAL GYNECOLOGI, P457; COLOMBO N, 1992, INT J CANCER, V51, P42, DOI 10.1002/ijc.2910510109; DACQUISTO R, 1988, J CLIN ONCOL, V6, P689, DOI 10.1200/JCO.1988.6.4.689; Duda DG, 2000, CANCER RES, V60, P1111; MARKMAN M, 1992, INT J GYNECOL CANCER, V2, P30; MARTH C, 1990, CANCER RES, V50, P7037; Marth C, 1997, BRIT J CANCER, V76, P1328, DOI 10.1038/bjc.1997.556; Marth C, 1996, INT J CANCER, V67, P826, DOI 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#; NARDI M, 1990, J CLIN ONCOL, V8, P1036, DOI 10.1200/JCO.1990.8.6.1036; NEHME A, 1994, EUR J CANCER, V30A, P520, DOI 10.1016/0959-8049(94)90430-8; PujadeLauraine E, 1996, J CLIN ONCOL, V14, P343, DOI 10.1200/JCO.1996.14.2.343; SAITO T, 1986, CANCER RES, V46, P1142; WILLEMSE PHB, 1990, EUR J CANCER, V26, P353, DOI 10.1016/0277-5379(90)90233-J; Windbichler GH, 2000, BRIT J CANCER, V82, P1138	20	16	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					6	7		10.1016/S0140-6736(00)02422-3	http://dx.doi.org/10.1016/S0140-6736(00)02422-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892754				2023-01-03	WOS:000087933400004
J	Stott, S				Stott, S			Recent advances - Recent advances in intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RESPIRATORY-DISTRESS-SYNDROME; INHALED NITRIC-OXIDE; PERCUTANEOUS DILATATIONAL TRACHEOSTOMY; PULMONARY-ARTERY CATHETER; CRITICALLY ILL PATIENTS; DILATIONAL TRACHEOSTOMY; VENTILATION STRATEGY; PARENTERAL-NUTRITION; BEDSIDE PROCEDURE; SYNDROME ARDS		Grampian Univ Hosp Trust, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Stott, S (corresponding author), Grampian Univ Hosp Trust, Aberdeen AB25 2ZN, Scotland.	s.a.stott@abdn.ac.uk						Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Atkinson S, 1998, CRIT CARE MED, V26, P1164, DOI 10.1097/00003246-199807000-00013; BEALE RJ, IN PRESS CRIT CARE M; BENNETT D, 1991, INTENS CARE MED, V17, pR1, DOI 10.1007/BF01704735; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Blok WL, 1996, J NUTR, V126, P1515, DOI 10.1093/jn/126.6.1515; BRITTENDEN J, 1994, SURGERY, V115, P205; Cariou A, 1998, CRIT CARE MED, V26, P2066, DOI 10.1097/00003246-199812000-00043; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; Cobean R, 1996, ARCH SURG-CHICAGO, V131, P265; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cuthbertson BH, 1997, INTENS CARE MED, V23, P1212, DOI 10.1007/s001340050488; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Flaatten H, 1998, ACTA ANAESTH SCAND, V42, P329, DOI 10.1111/j.1399-6576.1998.tb04925.x; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; Germann P, 1998, ANESTHESIOLOGY, V89, P1401, DOI 10.1097/00000542-199812000-00017; Griffiths RD, 1997, NUTRITION, V13, P295; HEFFNER JE, 1986, CHEST, V14, P742; Hill BB, 1996, J TRAUMA, V41, P238, DOI 10.1097/00005373-199608000-00007; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; Papazian L, 1998, AM J RESP CRIT CARE, V157, P580, DOI 10.1164/ajrccm.157.2.9705046; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; PINSKY MR, 1994, INTENS CARE MED, V20, P1, DOI 10.1007/BF02425045; Poelaert J, 1999, ANAESTHESIA, V54, P128, DOI 10.1046/j.1365-2044.1999.00666.x; Sandham JD, 1998, CRIT CARE MED, V26, P1288, DOI 10.1097/00003246-199807000-00037; SCHACHNER A, 1989, CRIT CARE MED, V17, P1052, DOI 10.1097/00003246-198910000-00017; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; WINKLER WB, 1994, INTENS CARE MED, V20, P476, DOI 10.1007/BF01711898; Zwissler B, 1996, AM J RESP CRIT CARE, V154, P1671, DOI 10.1164/ajrccm.154.6.8970353	37	5	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					358	361		10.1136/bmj.320.7231.358	http://dx.doi.org/10.1136/bmj.320.7231.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657335	Green Published			2023-01-03	WOS:000085211400029
J	Griffiths, TL; Burr, ML; Campbell, IA; Lewis-Jenkins, V; Mullins, J; Shiels, K; Turner-Lawlor, PJ; Payne, N; Newcombe, RG; Lonescu, AA; Thomas, J; Tunbridge, J				Griffiths, TL; Burr, ML; Campbell, IA; Lewis-Jenkins, V; Mullins, J; Shiels, K; Turner-Lawlor, PJ; Payne, N; Newcombe, RG; Lonescu, AA; Thomas, J; Tunbridge, J			Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; LONG-TERM BENEFITS; EXERCISE TOLERANCE; RESPIRATORY REHABILITATION; DISEASE; COPD; PROGRAM; HOME; QUESTIONNAIRE; IMPROVES	Background Pulmonary rehabilitation seems to be an effective intervention in patients with chronic obstructive pulmonary disease. We undertook a randomised controlled trial to assess the effect of outpatient pulmonary rehabilitation on use of health care and patients' wellbeing over 1 year. Methods 200 patients with disabling chronic lung disease (the majority with chronic obstructive pulmonary disease) were randomly assigned a 6-week multidisciplinary rehabilitation programme (18 visits) or standard medical management. Use of health services was assessed from hospital and general-practice records. Analysis was by intention to treat. Findings There was no difference between the rehabilitation (n=99) and control (n=101) groups in the number of patients admitted to hospital (40 vs 41) but the number of days these patients spent in hospital differed significantly (mean 10.4 [SD 9.7] vs 21.0 [20.7], p=0.022). The rehabilitation group had more primary-care consultations at the general-practitioner's premises than did the control group (8.6 [6.8] vs 7.3 [8.3], p=0.033) but fewer primary-care home visits (1.5 [2.8] vs 2.8 [4.6], p=0.037). Compared with control, the rehabilitation group also showed greater improvements in walking ability and in general and disease-specific health status. Interpretation For patients chronically disabled by obstructive pulmonary disease, an intensive, multidisciplinary, outpatient programme of rehabilitation is an effective intervention, in the short term and the long term, that decreases use of health services.	Cardiff Univ, Dept Med, Sect Resp Med, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales; Cardiff Univ, Dept Publ Hlth Med, Cardiff CF4 4XN, S Glam, Wales; Cardiff Univ, Dept Med Comp & Stat, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Hosp, Penarth, S Glam, Wales; Llandough Hosp NHS Trust, Penarth, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Griffiths, TL (corresponding author), Cardiff Univ, Dept Med, Sect Resp Med, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales.	griffithsti@cf.ac.uk	Newcombe, Robert G/B-4897-2009					American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; Bendstrup KE, 1997, EUR RESPIR J, V10, P2801, DOI 10.1183/09031936.97.10122801; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Cotes JE, 1975, LUNG FUNCTION; Foglio K, 1999, EUR RESPIR J, V13, P125, DOI 10.1183/09031936.99.13112599; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Harper R, 1997, THORAX, V52, P879, DOI 10.1136/thx.52.10.879; HUDSON LD, 1976, CHEST, V70, P606, DOI 10.1378/chest.70.5.606; JOHNSON HR, 1980, RESP THER, V3, P15; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Ketelaars CAJ, 1997, CHEST, V112, P363, DOI 10.1378/chest.112.2.363; Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8; MAHLER DA, 1995, CHEST, V107, P1585, DOI 10.1378/chest.107.6.1585; Pearson MG, 1997, THORAX, V52, pS1; PETTY TL, 1969, ANN INTERN MED, V70, P1109, DOI 10.7326/0003-4819-70-6-1109; Ries AL, 1997, CHEST, V112, P1363, DOI 10.1378/chest.112.5.1363; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Singh SJ, 1998, RESP MED, V92, P1146, DOI 10.1016/S0954-6111(98)90410-3; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; VALE F, 1993, CHEST, V103, P42, DOI 10.1378/chest.103.1.42; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1994, PHYSICAL MENTAL HLTH; Wedzicha JA, 1998, EUR RESPIR J, V12, P363, DOI 10.1183/09031936.98.12020363; White RJ, 1997, J ROY COLL PHYS LOND, V31, P541; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; WIJKSTRA PJ, 1995, THORAX, V50, P824, DOI 10.1136/thx.50.8.824; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	608	626	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					362	368		10.1016/S0140-6736(99)07042-7	http://dx.doi.org/10.1016/S0140-6736(99)07042-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665556				2023-01-03	WOS:000085122100012
J	Izurieta, HS; Thompson, WW; Kramarz, P; Shay, DK; Davis, RL; DeStefano, F; Black, S; Shinefield, H; Fukuda, K				Izurieta, HS; Thompson, WW; Kramarz, P; Shay, DK; Davis, RL; DeStefano, F; Black, S; Shinefield, H; Fukuda, K			Influenza and the rates of hospitalization for respiratory disease among infants and young children.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; MYCOPLASMA-PNEUMONIAE; SYNCYTIAL VIRUS; EPIDEMICS; VACCINE; IMPACT; PARAINFLUENZA; INFECTION	Background: Young children may be at increased risk for serious complications from influenzavirus infection. However, in population-based studies it has been difficult to separate the effects of influenzavirus from those of respiratory syncytial virus. Respiratory syncytial virus often circulates with influenzaviruses and is the most frequent cause of hospitalization for lower respiratory tract infections in infants and young children. We studied the rates of hospitalization for acute respiratory disease among infants and children during periods when the circulation of influenzaviruses predominated over the circulation of respiratory syncytial virus. Methods: For each season from October to May during the period from 1992 to 1997, we used local viral surveillance data to define periods in Washington State and northern California when the circulation of influenzaviruses predominated over that of respiratory syncytial virus. We calculated the rates of hospitalization for acute respiratory disease, excess rates attributable to influenzavirus, and incidence-rate ratios for all infants and children younger than 18 years of age who were enrolled in either the Kaiser Permanente Medical Care Program of Northern California or the Group Health Cooperative of Puget Sound. Results: The rates of hospitalization for acute respiratory disease among children who did not have conditions that put them at high risk for complications of influenza (e.g., asthma, cardiovascular diseases, or premature birth) and who were younger than two years of age were 231 per 100,000 person-months at Northern California Kaiser sites (from 1993 to 1997) and 193 per 100,000 person-months at Group Health Cooperative sites (from 1992 to 1997). These rates were approximately 12 times as high as the rates among children without high-risk conditions who were 5 to 17 years of age (19 per 100,000 person-months at Northern California Kaiser sites and 16 per 100,000 person-months at Group Health Cooperative sites) and approached the rates among children with chronic health conditions who were 5 to 17 years of age (386 per 100,000 person-months and 216 per 100,000 person-months, respectively). Conclusions: Infants and young children without chronic or serious medical conditions are at increased risk for hospitalization during influenza seasons. Routine influenza vaccination should be considered in these children. (N Engl J Med 2000;342:232-9.) (C)2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Influenza Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Epidemiol & Surveillance Div, Atlanta, GA 30333 USA; Grp Hlth Cooperat, Seattle, WA USA; No Calif Kaiser Permanente, Oakland, CA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Group Health Cooperative; Kaiser Permanente	Thompson, WW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Influenza Branch, Mailstop A 32,1600 Clifton Rd, Atlanta, GA 30333 USA.		Kramarz, Piotr/U-9442-2019	Fukuda, Keiji/0000-0002-9598-9565; Shay, David/0000-0001-9619-4820				*ADV COMM IMM PRAC, 1999, MMWR-MORBID MORTAL W, V4, P1; [Anonymous], 1997, MMWR RECOMM REP, V46, P1; AVILA M, 1990, REV INFECT DIS S, V8, P974; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; CAUL EO, 1976, J HYG-CAMBRIDGE, V77, P383, DOI 10.1017/S0022172400055765; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; COONEY MK, 1975, AM J EPIDEMIOL, V101, P532, DOI 10.1093/oxfordjournals.aje.a112125; *CYT SOFTW, 1995, STATX 3 WIND US MAN; *DEP HLTH HUM SERV, 1980, DHHS PUBL PHS; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; Fishman PA, 1999, MED CARE, V37, P874, DOI 10.1097/00005650-199909000-00004; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GILCHRIST S, 1994, J INFECT DIS, V170, P986, DOI 10.1093/infdis/170.4.986; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1990, PEDIATR ANN, V19, P535, DOI 10.3928/0090-4481-19900901-09; GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; HALL CB, 1998, TXB PEDIAT INFECT DI, V2, P2084; HAYDEN GF, 1995, PEDIATR INFECT DIS J, V14, P895, DOI 10.1097/00006454-199510000-00015; KILBOURNE ED, 1987, INFLUENZA; KRAMARZ P, 1998, PHARMACOEPIDEMIOL S2, V7, P113; Marx A, 1997, J INFECT DIS, V176, P1423, DOI 10.1086/514137; MUFSON MA, 1970, AM J EPIDEMIOL, V91, P192, DOI 10.1093/oxfordjournals.aje.a121128; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; NOBLE GR, 1982, BASIC APPL INFLUENZA, P11; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; PETER G, 1997, 1997 RED BOOK REPORT, P307; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SIMONSEN L, 1996, OPTIONS CONTROL INFL, V3, P26; 1996, MMWR MORB MORTAL WKL, V46, P173; 1995, MMWR MORB MORTAL WKL, V44, P292; 1996, MMWR MORB MORTAL WKL, V45, P326	36	761	806	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					232	239		10.1056/NEJM200001273420402	http://dx.doi.org/10.1056/NEJM200001273420402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648764				2023-01-03	WOS:000084941000002
J	Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB				Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB			Impact of respiratory virus infections on persons with chronic underlying conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNCYTIAL VIRUS; AIR-POLLUTION; DISEASE HOSPITALIZATIONS; INFLUENZA EPIDEMICS; VIRAL-INFECTIONS; ASTHMA; CHILDREN; ADULTS; ILLNESS; VACCINE	Context While hospitalization rates have declined overall, hospitalizations for acute lower respiratory tract infections have increased steadily since 1980. Development of new approaches for prevention of acute respiratory tract conditions requires studies of the etiologies of infections and quantification of the risk of hospitalization for vulnerable patients. Objective To determine the frequency of specific virus infections associated with acute respiratory tract conditions leading to hospitalization of chronically ill patients. Design Analysis of viral etiology of patients hospitalized with acute respiratory tract conditions between July 1991 and June 1995. Setting Four large clinics and related hospitals serving diverse populations representative of Harris County, Texas. Patients A total of 1029 patients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations of asthma or chronic obstructive pulmonary disease, and/or congestive heart failure. Main Outcome Measure Virus infection, defined by culture, antigen detection, and significant rise in serum antibodies, by underlying condition; hospitalization rates by low- vs middle-income status. Results Ninety-three percent of patients older than 5 years had a chronic underlying condition; a chronic pulmonary condition was most common. Patients with chronic pulmonary disease from low-income populations were hospitalized at a rate of 398.6 per 10 000, almost 8 times higher than the rate for patients from middle-income groups (52.2 per 10 000; P<.001). Of the 403 patients (44.4% of adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respiratory tract virus infections were detected in 181 (44.9%). influenza, parainfluenza, and respiratory syncytial virus (RSV) infections accounted for 75% of all virus infections. Conclusions Our study suggests that respiratory virus infections commonly trigger serious acute respiratory conditions that result in hospitalization of patients with chronic underlying conditions, highlighting the need for development of effective vaccines for these viruses, especially for parainfluenza and RSV.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Glezen, WP (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	wglezen@bcm.tmc.edu	Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015103] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15103] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON M, 1994, J ASTHMA, V31, P367, DOI 10.3109/02770909409061316; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BUSSE WW, 1993, ASTHMA, P345; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FRANK AL, 1979, J CLIN MICROBIOL, V10, P32, DOI 10.1128/JCM.10.1.32-36.1979; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HALFON N, 1993, PEDIATRICS, V91, P56; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pamuk E., 1998, SOCIOECONOMIC STATUS; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; PHILIT F, 1992, REV MAL RESPIR, V9, P191; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WOOD PR, 1993, PEDIATRICS, V91, P62	42	386	402	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					499	505		10.1001/jama.283.4.499	http://dx.doi.org/10.1001/jama.283.4.499			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659876	Bronze			2023-01-03	WOS:000084879800029
J	Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R				Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R			Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; WOMEN	Context Whether menopausal hormone replacement therapy using a combined estrogen-progestin regimen increases risk of breast cancer beyond that associated with estrogen alone is unknown. Objective To determine whether increases in risk associated with the estrogen-progestin regimen are greater than those associated with estrogen alone. Design Cohort study of follow-up data for 1980-1995 from the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine screening centers throughout the United States. Participants A total of 46 355 postmenopausal women (mean age at start of followup, 58 years). Main Outcome Measure Incident breast cancers by recency, duration, and type of hormone use. Results During follow-up, 2082 cases of breast cancer were identified. Increases in risk with estrogen only and estrogen-progestin only were restricted to use within the previous 4 years (relative risk [RR], 1.2 [95% confidence interval {CI}, 1.0-1.4] and 1.4 [95% CI, 1.1-1.8], respectively); the relative risk increased by 0.01 (95% CI, 0.002-0.03) with each year of estrogen-only use and by 0.08 (95% CI, 0.02-0.16) with each year of estrogen-progestin-only use among recent users, after adjustment for mammographic screening, age at menopause, body mass index (BMI), education, and age. The P value associated with the test of homogeneity of these estimates was .02. Among women with a BMI of 24.4 kg/m(2) or less, increases in RR with each year of estrogen-only use and estrogen-progestin-only use among recent users were 0.03 (95% CI, 0.01-0.06) and 0.12 (95% CI, 0.02-0.25), respectively. These associations were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease. Risk in heavier women did not increase with use of estrogen only or estrogen-progestin only. Conclusion Our data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Social & Sci Syst Inc, Bethesda, MD USA; Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Social & Scientific Systems; University of Massachusetts System; University of Massachusetts Amherst	Schairer, C (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS Room 7080,MSC 7234, Rockville, MD 20852 USA.		Brinton, Louise A/G-7486-2015	Brinton, Louise A/0000-0003-3853-8562	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010113] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1987, STAT METHODS CANC RE; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Greendale GA, 1997, AM J EPIDEMIOL, V146, P763; Hargreaves DF, 1998, BRIT J CANCER, V78, P945, DOI 10.1038/bjc.1998.606; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; PRESTON DL, 1996, EPICURE SOFTWARE REL; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264	15	786	821	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					485	491		10.1001/jama.283.4.485	http://dx.doi.org/10.1001/jama.283.4.485			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659874	Bronze			2023-01-03	WOS:000084879800027
J	Conroy, S; Choonara, I; Impicciatore, P; Mohn, A; Arnell, H; Rane, AR; Knoeppel, C; Seyberth, H; Pandolfini, C; Raffaelli, MP; Rocchi, F; Bonati, M; 't Jong, G; de Hoog, M; van den Anker, J				Conroy, S; Choonara, I; Impicciatore, P; Mohn, A; Arnell, H; Rane, AR; Knoeppel, C; Seyberth, H; Pandolfini, C; Raffaelli, MP; Rocchi, F; Bonati, M; 't Jong, G; de Hoog, M; van den Anker, J		European Network Drug Invest Child	Survey of unlicensed and off label drug use in paediatric wards in European countries	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the extent of use of unlicensed and off label drugs in children in hospital in five European countries. Design Prospective study of drugs administered to children in general paediatric medical wards over four weeks. Setting Children's wards in five hospitals tone each in the United Kingdom, Sweden, Germany, Italy, and the Netherlands). Subjects Children aged 4 days to 16 years admitted to general paediatric medical wards. Main outcome measure Proportion of drugs that were used in an unlicensed or off label manner. Results 2262 drug prescriptions were administered to 624 children in the five hospitals. Almost half of all drug prescriptions (1036; 46%) were either unlicensed or off label. Of these 1036, 872 were off label and 164 were unlicensed. Over half of the patients (421; 67%) received an unlicensed or off label drug prescription. Conclusions Use of off label or unlicensed drugs to treat children is widespread. This problem is likely to affect children throughout Europe and requires European action.	Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ Nottingham, Derbushire Childrens Hosp, Acad Div Child Hlth, Derby DE22 3NE, England; Univ Uppsala Hosp, Uppsala, Sweden; Univ Marburg, Childrens Hosp, Marburg, Germany; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; University of Nottingham; Uppsala University; Uppsala University Hospital; Philipps University Marburg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Choonara, I (corresponding author), Univ Nottingham, Derbushire Childrens Hosp, Acad Div Child Hlth, Derby DE22 3NE, England.		Pandolfini, Chiara/K-5693-2016; Choonara, Imti/I-3559-2019; Bonati, Maurizio/K-8980-2016; de Hoog, Matthijs/A-3882-2013	Pandolfini, Chiara/0000-0001-9809-2991; Choonara, Imti/0000-0002-3069-6323; Bonati, Maurizio/0000-0003-3997-3726; 				Bonati M, 1999, LANCET, V353, P1625, DOI 10.1016/S0140-6736(05)75752-4; BONATI M, 1994, J CLIN PHARMACOL, V34, P300, DOI 10.1002/j.1552-4604.1994.tb01997.x; Choonara I, 1998, ARCH DIS CHILD, V78, P402, DOI 10.1136/adc.78.5.402; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Cote CJ, 1996, PEDIATRICS, V98, P118; *EMEA, 1997, NOT GUID CLIN INV ME; Impicciatore P, 1999, BRIT J CLIN PHARMACO, V48, P15, DOI 10.1046/j.1365-2125.1999.00981.x; NAHATA MC, 1997, PAEDIAT PERINAT DRUG, V1, P50; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Turner S, 1996, LANCET, V347, P549, DOI 10.1016/S0140-6736(96)91182-4; Turner S, 1999, ACTA PAEDIATR, V88, P965, DOI 10.1080/08035259950168469; Turner S, 1998, BRIT MED J, V316, P343, DOI 10.1136/bmj.316.7128.343; TURNER S, 1997, PAEDIAT PERINAT DRUG, V1, P152	13	488	522	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					79	82		10.1136/bmj.320.7227.79	http://dx.doi.org/10.1136/bmj.320.7227.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625257	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000084746600014
J	Sloan, EP; Koenigsberg, M; Gens, D; Cipolle, M; Runge, J; Mallory, MN; Rodman, G				Sloan, EP; Koenigsberg, M; Gens, D; Cipolle, M; Runge, J; Mallory, MN; Rodman, G		DCLHb Traumatic Hemorrhagic Shoc	Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock - A randomized controlled efficacy trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DELAYED FLUID RESUSCITATION; MULTIPLE ORGAN FAILURE; UNCONTROLLED HEMORRHAGE; BASE DEFICIT; EMERGENCY RESEARCH; HYPERTONIC SALINE; INFORMED CONSENT; BLOOD SUBSTITUTE; VASCULAR INJURY; SCORE	Context Severe, uncompensated, traumatic hemorrhagic shock causes significant morbidity and mortality, but resuscitation with an oxygen-carrying fluid might improve patient outcomes. Objective To determine if the infusion of up to 1000 mt of diaspirin cross-linked hemoglobin (DCLHb) during the initial hospital resuscitation could reduce 28-day mortality in traumatic hemorrhagic shock patients. Design and Setting Multicenter, randomized, controlled, single-blinded efficacy trial conducted between February 1997 and January 1998 at 18 US trauma centers selected for their high volume of critically injured trauma patients, but 1 did not enroll patients. Patients A total of 112 patients with traumatic hemorrhagic shock and unstable vital signs or a critical base deficit, who had a mean (SD) patient age of 39 (20) years. Of the infused patients, 79% were male and 56% were white. An exception to informed consent was used when necessary. Intervention All patients were to be infused with 500 mL of DCLHb or saline solution. Critically ill patients who still met entry criteria could have received up to an additional 500 mt during the 1-hour infusion period. Main Outcome Measures Twenty-eight day mortality, 28-day morbidity, 48-hour mortality, and 24-hour lactate levels. Results Of the 112 patients, 98 (88%) were infused with DCLHb or saline solution. At 28 days, 24 (46%) of the 52 patients infused with DCLHb died, and 8 (17%) of the 46 patients infused with the saline solution died (P =.003). At 48 hours, 20 (38%) of the 52 patients infused with DCLHb died and 7 (15%) of the 46 patients infused with the saline solution died (P = .01). The 28-day morbidity rate, as measured by the multiple organ dysfunction score, was 72% higher in the DCLHb group (P =.03). There was no difference in adverse event rates or the 24-hour lactate levels. Conclusions Mortality was higher for patients treated with DCLHb. Although further analysis should investigate whether the mortality difference was solely due to a direct treatment effect or to other factors, DCLHb does not appear to be an effective resuscitation fluid.	Univ Illinois, Coll Med, Dept Emergency Med, Chicago, IL 60612 USA; Univ Maryland, Ctr Shock Trauma, Baltimore, MD 21201 USA; Lehigh Valley Hosp Ctr, Allentown, PA USA; Carolinas Med Ctr, Charlotte, NC 28203 USA; Univ Louisville Hosp, Louisville, KY USA; Methodist Hosp Indiana, Indianapolis, IN 46202 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Maryland; University of Maryland Baltimore; Lehigh Valley Hospital; Carolinas Medical Center; University of Louisville; Indiana University System	Sloan, EP (corresponding author), Univ Illinois, Coll Med, Dept Emergency Med, Mail Code 724 Room,471H CME,808 S Wood ST, Chicago, IL 60612 USA.							BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Biros MH, 1998, ACAD EMERG MED, V5, P359, DOI 10.1111/j.1553-2712.1998.tb02722.x; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; COHN SM, 1995, J TRAUMA, V39, P210, DOI 10.1097/00005373-199508000-00005; COX D, 1992, J R STAT SOC B, P187; DAVIS JW, 1988, J TRAUMA, V28, P1464, DOI 10.1097/00005373-198810000-00010; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DeAngeles DA, 1997, J TRAUMA, V42, P406, DOI 10.1097/00005373-199703000-00007; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Frankel HL, 1996, J TRAUMA, V40, P231, DOI 10.1097/00005373-199602000-00010; GERVIN AS, 1984, J TRAUMA, V24, P327, DOI 10.1097/00005373-198404000-00008; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; Gulati A, 1998, SHOCK, V9, P65, DOI 10.1097/00024382-199801000-00010; Gulati A, 1997, AM J PHYSIOL-HEART C, V273, pH827, DOI 10.1152/ajpheart.1997.273.2.H827; Hart JL, 1997, J LAB CLIN MED, V129, P356, DOI 10.1016/S0022-2143(97)90184-0; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; JESCH FH, 1982, CRIT CARE MED, V10, P270, DOI 10.1097/00003246-198204000-00007; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; LAMY M, 1997, CLIN BENEFITS DCLHB; Leppaniemi A, 1996, J SURG RES, V63, P413, DOI 10.1006/jsre.1996.0285; Leppaniemi A, 1996, J TRAUMA, V40, P242, DOI 10.1097/00005373-199602000-00011; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOORE EE, 1981, J TRAUMA, V21, P439; NELSON D, 1992, BIOMAT ARTIF CELL IM, V20, P423, DOI 10.3109/10731199209119662; OWENS TM, 1995, J TRAUMA, V39, P200, DOI 10.1097/00005373-199508000-00004; Patel MJ, 1998, BLOOD, V91, P710, DOI 10.1182/blood.V91.2.710.710_710_716; PRZYBELSKI R, 1998, AM J CRIT CARE MED, V157, pA295; PRZYBELSKI R, 1991, CRIT CARE MED, V22, pA231; Przybelski RJ, 1996, CRIT CARE MED, V24, P1993, DOI 10.1097/00003246-199612000-00011; Przybelski RJ, 1997, TRANSFUSION, V37, P749, DOI 10.1046/j.1537-2995.1997.37797369452.x; Reah G, 1997, CRIT CARE MED, V25, P1480, DOI 10.1097/00003246-199709000-00014; Reppucci AJ, 1997, TRANSFUSION, V37, P1143, DOI 10.1046/j.1537-2995.1997.37111298088043.x; ROUMEN RMH, 1993, J TRAUMA, V35, P349, DOI 10.1097/00005373-199309000-00004; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; SCHILLER HJ, 1993, CURR SURG THER, P1067; SCHULTZ SC, 1993, J TRAUMA, V35, P619, DOI 10.1097/00005373-199310000-00019; SCHULTZ SC, 1994, J TRAUMA, V37, P408, DOI 10.1097/00005373-199409000-00013; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; SLOAN EP, 1995, ACAD EMERG MED, V2, P364; SPRUNG J, 1995, CRIT CARE MED, V23, P1540, DOI 10.1097/00003246-199509000-00015; Standl T, 1997, ANAESTHESIST, V46, P763, DOI 10.1007/s001010050466; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Vignali A, 1996, VOX SANG, V71, P170, DOI 10.1046/j.1423-0410.1996.7130170.x; 1996, FED REG, P51528	61	336	345	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1857	1864		10.1001/jama.282.19.1857	http://dx.doi.org/10.1001/jama.282.19.1857			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573278	Bronze			2023-01-03	WOS:000083615700030
J	Wade, DT; Johnston, C				Wade, DT; Johnston, C			The permanent vegetative state: practical guidance on diagnosis and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVEMENT		Rivermead Rehabil Ctr, Oxford OX1 4XD, England; Supreme Court, London W2A 1DD, England		Wade, DT (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.	derick.wade@dial.pipex.com		Wade, Derick/0000-0002-1188-8442				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 1995, Neurology, V45, P1012; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; HARRIS P, 1996, FAM LAW REP, V2, P375; HINCHCLIFFE M, 1996, NEW LAW J, P1579; Jennett B, 1997, BMJ-BRIT MED J, V314, P1621, DOI 10.1136/bmj.314.7094.1621; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; LIU GT, 1992, J CLIN NEURO-OPHTHAL, V12, P47; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043	18	46	47	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					841	844		10.1136/bmj.319.7213.841	http://dx.doi.org/10.1136/bmj.319.7213.841			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496834	Green Published			2023-01-03	WOS:000082865200032
J	Smirlis, D; Muangmoonchai, R; Edwards, M; Phillips, IR; Shephard, EA				Smirlis, D; Muangmoonchai, R; Edwards, M; Phillips, IR; Shephard, EA			Orphan receptor promiscuity in the induction of cytochromes P450 by xenobiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-RESPONSIVE ENHANCER; NUCLEAR; CAR; GENES; IDENTIFICATION; DEFINES; ELEMENT; TARGET	The mechanisms by which different classes of chemicals induce the same cytochrome P450 (CYP) or the same chemical differentially induces more than one CYP are not well understood. We show that in primary hepatocytes and in vivo in liver (transfected by particle-mediated delivery) two orphan nuclear receptors, constitutive androstane receptor and pregnane X receptor (PXR1), transactivate a CYP gene via the same response element in a xenobiotic-specific manner. The constitutive androstane receptor mediates the barbiturate activation of expression of CYP2B1 and CYP3A1. PXR1 activates both genes in response to synthetic steroids. To exert their effect the receptors bind to the same direct repeat site (DR4) within the phenobarbital response element of the CYP2B1 promoter and to the same DR3 site in the pregnane X response element of CYP3A1. The receptors are therefore promiscuous with respect to DNA binding but not ligand binding. Differences in enhancer half-site spacing may influence the efficiency of interactions between the receptor and the transcription machinery and hence form the basis for the differential induction of CYP2B1 and CYP3A1 in response to barbiturates and synthetic steroids.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; Queen Mary University London; University of London; University College London	Phillips, IR (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	I.R.Phillips@qmw.ac.uk; e.shephard@ucl.ac.uk	Phillips, Ian R/A-7337-2008	Smirlis, Despina/0000-0003-4996-2879				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Dell H, 1998, Methods Mol Biol, V107, P381; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V2; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Kassam A, 2000, J BIOL CHEM, V275, P4345, DOI 10.1074/jbc.275.6.4345; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; ONATE SA, 1995, SCIENCE, V270, P1354; PHILLIPS IR, 1985, DRUG METABOLISM MOL, P93; Quattrochi LC, 1998, ARCH BIOCHEM BIOPHYS, V349, P251, DOI 10.1006/abbi.1997.0467; Rastinejad Fraydoon, 1998, P105; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112	30	86	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12822	12826		10.1074/jbc.M005930200	http://dx.doi.org/10.1074/jbc.M005930200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11278292	hybrid			2023-01-03	WOS:000168198600051
J	Tsomides, T				Tsomides, T			Reflections on a death	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Maine Med Ctr, Dept Med, Portland, ME 04102 USA	Maine Medical Center	Tsomides, T (corresponding author), Maine Med Ctr, Dept Med, 22 Bramhall St, Portland, ME 04102 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2001	134	3					246	248		10.7326/0003-4819-134-3-200102060-00017	http://dx.doi.org/10.7326/0003-4819-134-3-200102060-00017			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397KR	11177339				2023-01-03	WOS:000166695300010
J	Kay, AB				Kay, AB			Advances in immunology - Allergy and allergic diseases - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GRASS-POLLEN IMMUNOTHERAPY; FC-EPSILON-RI; MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; CHRONIC URTICARIA; CONTROLLED TRIAL; RECEPTOR; ASTHMA; PHASE; AUTOANTIBODIES		Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	Imperial College London	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England.							Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allsopp CEM, 1996, EUR J IMMUNOL, V26, P1951, DOI 10.1002/eji.1830260841; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CRETICOS PS, 1986, J CLIN INVEST, V78, P1421; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; LECKIE MJ, IN PRESS LANCET; Lipper GM, 2000, JAMA-J AM MED ASSOC, V283, P175, DOI 10.1001/jama.283.2.175; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; Slater JW, 1999, DRUGS, V57, P31, DOI 10.2165/00003495-199957010-00004; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	33	228	247	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					109	113		10.1056/NEJM200101113440206	http://dx.doi.org/10.1056/NEJM200101113440206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150362				2023-01-03	WOS:000166281100006
J	Kollef, MH				Kollef, MH			Non-invasive ventilation for chronic obstructive pulmonary disease	LANCET			English	Editorial Material							POSITIVE PRESSURE VENTILATION; MECHANICAL VENTILATION; TRIAL		Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kollef, MH (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.							Burdet L, 1997, AM J RESP CRIT CARE, V156, P1800, DOI 10.1164/ajrccm.156.6.9704142; Fridkin SK, 1996, INFECT CONT HOSP EP, V17, P150; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; THORENS JB, 1995, CRIT CARE MED, V23, P1807, DOI 10.1097/00003246-199511000-00004; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339	11	3	3	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 16	2000	356	9234					956	957		10.1016/S0140-6736(00)02708-2	http://dx.doi.org/10.1016/S0140-6736(00)02708-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	353UJ	11041392				2023-01-03	WOS:000089293600005
J	Taylor, MA; Reilly, D; Llewellyn-Jones, RH; McSharry, C; Aitchison, TC				Taylor, MA; Reilly, D; Llewellyn-Jones, RH; McSharry, C; Aitchison, TC			Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; FLOW-RATE; METAANALYSIS; HOMEOPATHT; PATENCY	Objective To test the hypothesis that homoeopathy is a placebo by examining its effect in patients with allergic rhinitis and so contest the evidence from three previous trials in this series. Design Randomised, double blind, placebo controlled, parallel group, multicentre study. Setting Four general practices and a hospital ear, nose, and throat outpatient department. Participants 51 patients with perennial allergic rhinitis. Intervention Random assignment to an oral 30c homoeopathic preparation of principal inhalant allergen or to placebo. Main outcome measures Changes from baseline in nasal inspiratory peak now and symptom visual analogue scale score over third and fourth weeks after randomisation. Results Fifty patients completed the study. The homoeopathy group had a significant objective improvement in nasal airflow compared with the placebo group (mean difference 19.8 1/min, 95% confidence interval 10.4 to 29.1, P = 0.0001). Both groups reported improvement in symptoms, with patients taking homoeopathy reporting more improvement in all but one of the centres, which had more patients with aggravations. On average no significant difference between the groups was seen on visual analogue scale scores. Initial aggravations of rhinitis symptoms were more common with homoeopathy than placebo (7 (30%) v 2 (7%), P = 0.04). Addition of these results to those of three previous trials (n = 253) showed a mean symptom reduction on visual analogue scores of 28% (10.9 mm) for homoeopathy compared with 3% (1.1 mm) for placebo (95% confidence interval 4.2 to 15.4, P = 0.0007). Conclusion The objective results reinforce earlier evidence that homoeopathic dilutions differ from placebo.	Univ Glasgow, Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland; Univ Sydney, Dept Med Psychol, Sydney, NSW 2006, Australia; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Stat, Glasgow G12 8QQ, Lanark, Scotland	Royal Infirmary of Edinburgh; University of Glasgow; University of Sydney; University of Glasgow; University of Glasgow	Reilly, D (corresponding author), Glasgow Homoeopath Hosp, Acad Dept, Glasgow G12 0XQ, Lanark, Scotland.	davidreilly1@compuserve.com	Reilly, David/AAG-9067-2020	McSharry, Charles/0000-0003-4758-9038				Aby JS, 1996, ANN ALLERG ASTHMA IM, V76, P348, DOI 10.1016/S1081-1206(10)60036-1; BELLAVITE P, 1995, HOMOEOPATHY; Bracken Michael B., 1992, P13; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FAIRLEY JW, 1993, CLIN OTOLARYNGOL, V18, P19, DOI 10.1111/j.1365-2273.1993.tb00803.x; GLEESON MJ, 1986, CLIN OTOLARYNGOL, V11, P99, DOI 10.1111/j.1365-2273.1986.tb00114.x; HAHNEMANN H, 1796, HUFELANDS J, V2, P391; HAHNEMANN H, 1796, HUFELANDS J, V2, P465; HOLMSTROM M, 1990, Rhinology (Utrecht), V28, P191; *HOM MED RES GROUP, 1994, REP EUR COMM DIR GEN, V1, P16; JONES AS, 1991, CLIN OTOLARYNGOL, V16, P206, DOI 10.1111/j.1365-2273.1991.tb01978.x; Kiene H, 1996, Altern Ther Health Med, V2, P74; Kiene H, 1996, Altern Ther Health Med, V2, P59; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KNIPSCHILD P, 1991, J CLIN EPIDEMIOL, V44, P461, DOI 10.1016/0895-4356(91)90208-Q; KRAYENBUHL MC, 1988, CLIN ALLERGY, V18, P157, DOI 10.1111/j.1365-2222.1988.tb02855.x; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MALMBERG H, 1991, Rhinology (Utrecht), V29, P137; Mygind N., 1979, NASAL ALLERGY, p224 ; Pocock S, 1983, CLIN TRIALS; REIL GH, 1985, Z KARDIOL, V74, P65; REILLY, 1994, LANCET, V344, P1506; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SHAPIRO AK, 1997, POWERFUL PLACEBO, P226; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657; VITHOULKAS G, 1985, HOMOEOPATHY, P72; WIHL JA, 1988, ANN ALLERGY, V61, P50; Youlten LJ., 1980, ALLERGOL IMMUNOPATH, V8, P344	33	107	109	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2000	321	7259					471	476		10.1136/bmj.321.7259.471	http://dx.doi.org/10.1136/bmj.321.7259.471			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347MC	10948025	Green Published, Green Accepted			2023-01-03	WOS:000088932800017
J	Pouyanne, P; Haramburu, F; Imbs, JL; Begaud, B				Pouyanne, P; Haramburu, F; Imbs, JL; Begaud, B		French Pharmacovigliance Centres	Admissions to hospital caused by adverse drug reactions: cross sectional incidence study	BRITISH MEDICAL JOURNAL			English	Article									Univ Victor Segalen, CHU, Ctr Pharmacovigilance, Dept Pharmacol, F-33076 Bordeaux, France; Hop Univ, Serv Pharmacol Clin, Ctr Reg Pharmacovigilance Alsace, F-67091 Strasbourg, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; CHU Strasbourg	Haramburu, F (corresponding author), Univ Victor Segalen, CHU, Ctr Pharmacovigilance, Dept Pharmacol, F-33076 Bordeaux, France.							EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Imbs JL, 1999, THERAPIE, V54, P21; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Roughead EE, 1998, MED J AUSTRALIA, V168, P405, DOI 10.5694/j.1326-5377.1998.tb138996.x; *WHO, 1996, WHO TECHN REP SER, V425	5	281	296	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1036	1036		10.1136/bmj.320.7241.1036	http://dx.doi.org/10.1136/bmj.320.7241.1036			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764362	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000086675700021
J	Snyder, L; Caplan, AL				Snyder, L; Caplan, AL			Assisted suicide: Finding common ground	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org						Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Doerflinger RM, 1999, HASTINGS CENT REP, V29, P52	2	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					468	469		10.7326/0003-4819-132-6-200003210-00007	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733446				2023-01-03	WOS:000085834700006
J	Stender, IM; Na, RH; Fogh, H; Gluud, C; Wulf, HC				Stender, IM; Na, RH; Fogh, H; Gluud, C; Wulf, HC			Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial	LANCET			English	Article							5-AMINOLEVULINIC ACID; VIRAL WARTS; TOPICAL APPLICATION; PROTOPORPHYRIN; CRYOTHERAPY; CONDYLOMATA; COMMON; TUMORS	Background Photodynamic therapy (PDT) with topical 5-aminolaevulinic acid (ALA) followed by irradiation with incoherent light (ALA-PDT) for recalcitrant warts have had beneficial results, Therefore, we undertook a randomised, parallel, double-blind clinical trial of ALA-PDT versus placebo-PDT for recalcitrant foot and hand warts. Methods Recalcitrant foot and hand warts were randomly assigned to six repetitive ALA-PDT or placebo-PDT interventions combined with standard treatment encompassing paring followed by a keratolytic (Verucid), Standardised photographs of each wart were taken before, during (week 7) and after treatment (weeks 14 and 18). The area of each wart compared with entry area was the primary outcome variable, measured from photographs by arl evaluator unaware of treatment allocation for intervention. Pain intensity immediately and 24 h after each intervention was assessed by a five-point scale. Findings A total of 232 foot and hand warts in 45 patients were entered into the trial: 117 warts were allocated to ALA-PDT and 115 warts to placebo-PDT. In week 14, the median relative reduction in wart area was 98% in the ALA-PDT group (interquartile range 100%, 55%) versus 52% (100%, 0) in the placebo group (p = 0.0006,), In week 18, the median relative reduction in wart area wa!; 100% in the ALA-PDT group (100%, 57%) versus 71% (100%, 0) in the placebo-PDT arm (p = 0.008). Both the number of vanishing warts and the difference in relative wart area of persisting warts at week 14 and 18 were significant (p < 0.05) in favour of ALA-PDT, Significantly more ALA-PDT warts were graded at a higher pain intensity after treatment than placebo-PDT warts. Interpretation ALA-PDT is superior to placebo-PDT when both wart area and number of vanishing warts are considered.	Bispebjerg Hosp, Dept Dermatol, Copenhagen NV, Denmark; Copenhagen Univ Hosp, Kommunehosp, Inst Prevent Med, Ctr Clin Intervent Res,Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Stender, IM (corresponding author), Bispebjerg Hosp, Dept Dermatol, Copenhagen NV, Denmark.		Gluud, Christian/HGB-3191-2022; Gluud, Christian/AAY-1027-2021	Gluud, Christian/0000-0002-8861-0799				BOURKE JF, 1995, BRIT J DERMATOL, V132, P433, DOI 10.1111/j.1365-2133.1995.tb08678.x; BUNNEY MH, 1976, BRIT J DERMATOL, V94, P667, DOI 10.1111/j.1365-2133.1976.tb05167.x; Fehr MK, 1996, AM J OBSTET GYNECOL, V174, P951, DOI 10.1016/S0002-9378(96)70332-0; Frank RGJ, 1996, GENITOURIN MED, V72, P70; Fritsch C, 1998, ARCH DERMATOL, V134, P207, DOI 10.1001/archderm.134.2.207; JETTE C, 1993, BEADV C COP DENM, P28; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P260, DOI 10.1111/j.1365-2230.1990.tb02085.x; KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9; Kilkenny M, 1998, BRIT J DERMATOL, V138, P840; Kloek J, 1998, PHOTOCHEM PHOTOBIOL, V67, P150; Morton CA, 1996, BRIT J DERMATOL, V135, P766, DOI 10.1111/j.1365-2133.1996.tb03887.x; OHNHAUS EE, 1975, PAIN, V1, P379, DOI 10.1016/0304-3959(75)90075-5; ORENSTEIN A, 1995, CANCER LETT, V93, P227, DOI 10.1016/0304-3835(95)03814-D; PENQ Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235; PENQ Q, 1997, CANCER, V79, P2282; Ross EV, 1997, BRIT J DERMATOL, V137, P736; Smetana Z, 1997, LASER SURG MED, V21, P351, DOI 10.1002/(SICI)1096-9101(1997)21:4<351::AID-LSM6>3.0.CO;2-P; Stender IM, 1999, CLIN EXP DERMATOL, V24, P154, DOI 10.1046/j.1365-2230.1999.00441.x; Stender IM, 1999, ACTA DERM-VENEREOL, V79, P400, DOI 10.1080/000155599750010463; SVANBERG K, 1994, BRIT J DERMATOL, V130, P743, DOI 10.1111/j.1365-2133.1994.tb03412.x	20	170	175	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					963	966		10.1016/S0140-6736(00)90013-8	http://dx.doi.org/10.1016/S0140-6736(00)90013-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768434				2023-01-03	WOS:000086054000010
J	Michota, FA				Michota, FA			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; DEEP-VEIN THROMBOSIS; VENA-CAVA FILTERS; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; ENTEROCOCCUS; INFECTIONS; BACTEREMIA; MANAGEMENT; OUTCOMES		Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Michota, FA (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Altkorn D, 1999, ANN INTERN MED, V131, P199, DOI 10.7326/0003-4819-131-3-199908030-00007; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; FINCH R, 1993, BRIT J HOSP MED, V49, P346; Fine MJ, 1997, ARCH INTERN MED, V157, P36, DOI 10.1001/archinte.157.1.36; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; Greenberger NJ, 1999, ANN INTERN MED, V131, P445, DOI 10.7326/0003-4819-131-6-199909210-00010; GULLBERG RM, 1989, REV INFECT DIS, V11, P74; GUNTUPALLI KK, 1999, ANN INTERN MED, V131, P28; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; JOLLEY AE, 1992, RESP MED, V86, P503, DOI 10.1016/S0954-6111(96)80011-4; Karnik AM, 1999, ANN INTERN MED, V131, P596, DOI 10.7326/0003-4819-131-8-199910190-00009; Katz PR, 1996, J AM GERIATR SOC, V44, P1118; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Lave JR, 1996, J GEN INTERN MED, V11, P415, DOI 10.1007/BF02600189; Leizorovicz A, 1996, DRUGS, V52, P30, DOI 10.2165/00003495-199600527-00006; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MAGNANT JG, 1992, J VASC SURG, V16, P701; MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173, DOI 10.1093/clinids/14.6.1173; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; NOSKIN GA, 1995, CLIN INFECT DIS, V20, P296, DOI 10.1093/clinids/20.2.296; PATTERSON JA, 1995, J AM GERIATR SOC, V43, P919, DOI 10.1111/j.1532-5415.1995.tb05538.x; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Rawlins MD, 1991, TXB ADVERSE DRUG REA; *WHO, 1966, TECHN REP SER WHO, V425; 1997, HLTH CARE FINANC R S, V18, P73	27	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2000	132	5					384	390		10.7326/0003-4819-132-5-200003070-00008	http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KY	10691589				2023-01-03	WOS:000085563000007
J	Quill, TE; Byock, IR				Quill, TE; Byock, IR		ACP-ASIM End Life Care Consensus P	Responding to intractable terminal suffering: The role of terminal sedation and voluntary refusal of food and fluids	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN-ASSISTED SUICIDE; SLOW EUTHANASIA; ACTIVE EUTHANASIA; PATIENT REQUESTS; SUPREME-COURT; UNITED-STATES; DEATH; CARE; LIFE; MANAGEMENT	When provided by a skilled, multidisciplinary team, palliative care is highly effective at addressing the physical, psychological, social, and spiritual needs of dying patients and their families. However, some patients who have witnessed harsh death want reassurance that they can escape if their suffering becomes intolerable. In addition, a small percentage of terminally ill patients receiving comprehensive care reach a point at which their suffering becomes severe and unacceptable despite unrestrained palliative efforts; some of these patients request that death be hastened. This paper presents terminal sedation and voluntary refusal of hydration and nutrition as potential last resorts that can be used to address the needs of such patients. These two practices allow clinicians to address a much wider range of intractable end-of-life suffering than physician-assisted suicide (even if it were legal) and can also provide alternatives for patients, families, and clinicians who are morally opposed to physician-assisted suicide. This paper will define the two practices, distinguish them from more standard palliative care interventions and from physician-assisted suicide, illustrate them with a real clinical scenario, provide potential guidelines and practicalities, and explore their moral and legal status. Although medicine cannot sanitize dying or provide perfect answers for all challenging end-of-life clinical problems, terminal sedation and voluntary refusal of hydration and nutrition substantially increase patients' choices at this inherently challenging time.			Quill, TE (corresponding author), Care Of Snyder L, Amer Coll Phys, Amer Soc Internal Med, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BRODY H, 1993, J CLIN ETHIC, V4, P112; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Brody H, 1996, J PALLIATIVE CARE, V12, P38, DOI 10.1177/082585979601200406; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Byock I, 1995, Am J Hosp Palliat Care, V12, P9; BYOCK I, 1997, DYING WELL PROSPECTS; Byock I R, 1993, J Palliat Care, V9, P25; Byock I R, 1994, J Palliat Care, V10, P8; Byock IR, 1996, CLIN GERIATR MED, V12, P237; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Cherny N I, 1994, J Palliat Care, V10, P31; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DOYLE D, 1998, OXFORD TXB PALLIATIV, P945; DUNLOP RJ, 1989, PALLIATIVE MED, V3, P65; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; ENCK RE, 1994, MED CARE TERMINALLY; ENCK RE, 1994, MED CARE TERMINALLY, P166; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; Frankel V. E., 1955, DOCTOR SOUL PSYCHOTH; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KASTING GA, 1994, PHYSICIAN ASSISTED D, P25; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; Moyle J, 1995, J PAIN SYMPTOM MANAG, V10, P643, DOI 10.1016/0885-3924(95)00125-5; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T, 1996, MIDWIFE DYING PROCES; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; Saunders C., 1993, MANAGEMENT TERMINAL, P1; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIA OTHER MED, V2; Ventafridda V, 1990, J Palliat Care, V6, P7; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008	61	195	198	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 7	2000	132	5					408	414		10.7326/0003-4819-132-5-200003070-00012	http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288KY	10691593				2023-01-03	WOS:000085563000011
J	Lyons, RA; Wareham, K; Hutchings, HA; Major, E; Ferguson, B				Lyons, RA; Wareham, K; Hutchings, HA; Major, E; Ferguson, B			Population requirement for adult critical-care beds: a prospective quantitative and qualitative study	LANCET			English	Article								Background The provision of adult critical-care facilities is not based on a rational or scientific assessment of need. We aimed to define the numbers of adult critical-care beds required for a population of 500 000. Methods In five hospitals in Wales, UK, we classified patients who might be suitable for critical care in intensive-care or high-dependency units. On every 12th day for 1 calendar year, we counted the numbers of such patients admitted in a defined geographical population. A panel of ten intensivists made consensus decisions about whether individual patients were in the appropriate unit. The data were used to predict the numbers of beds and units required for the population. Findings 4058 patients were suitable for critical care, of whom 3028 lived in the study area. 56.4% were in general wards, 22.3% in high-dependency units, and 21.3% in intensive-care units. The mean risk of death was 22.0% and the in-hospital death rate 17.3%. According to the masked consensus, 41.3% of patients required high-dependency beds and 21.5% intensive-care beds. Mean risk of death increased from general wards (14.7%) to high-dependency units (19.2%) to intensive care (37.0%). Based on the consensus decisions, the average daily requirement of intensive-care beds was 21 and of high-dependency beds 43; to meet needs 95% of times required 30 and 55 beds, respectively, in a single critical-care unit. Interpretation We estimated, scientifically, numbers of adult critical-care beds required to meet population needs. Studies are necessary periodically to track changes in admissions requiring critical care.	Univ Wales Coll Med, Dept Epidemiol & Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Morriston Hosp, Sch Postgrad Studies Med & Hlth Care, Clin Res Unit, Swansea, W Glam, Wales; Prince Wales Hosp, Bridgend, Wales	Cardiff University; Morriston Hospital; Swansea University	Lyons, RA (corresponding author), Univ Wales Coll Med, Dept Epidemiol & Publ Hlth, Swansea SA1 1LT, W Glam, Wales.		Hutchings, Hayley A/C-9944-2013; Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X; Hutchings, Hayley Anne/0000-0003-4155-1741				Audit Commission, 1999, CRIT SUCC PLAC EFF E; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; METCALF A, 1993, STUDY PROVISION INTE; *NAT HLTH SERV WAL, 1999, CLIN IND NHS 1995 19; Townsend PP., 1988, HLTH DEPRIVATION INE; *WORK GROUP GUID A, 1996, DISCH INT CAR HIGH D	7	61	61	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					595	598		10.1016/S0140-6736(00)01265-4	http://dx.doi.org/10.1016/S0140-6736(00)01265-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696978				2023-01-03	WOS:000085615400009
J	Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W				Truog, RD; Burns, JP; Mitchell, C; Johnson, J; Robinson, W			Pharmacologic paralysis and withdrawal of mechanical ventilation at the end of life.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; CRITICALLY ILL PATIENTS; CLINICAL MANAGEMENT; DYING PATIENTS; STRATEGY; CARE		Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Truog, RD (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.		Burns, Jeffrey P/AAW-8474-2021					Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; BURNS JP, IN PRESS CRIT CARE M; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; Domino KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Field MJ, 1997, APPROACHING DEATH IM; Hatherill M, 1998, BMJ-BRIT MED J, V317, P80, DOI 10.1136/bmj.317.7150.80a; Hoyt J W, 1994, New Horiz, V2, P48; HUNTER JM, 1995, NEW ENGL J MED, V332, P1691, DOI 10.1056/NEJM199506223322507; KIRKLAND L, 1994, J CLIN ETHIC, V5, P38; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LOPER KA, 1989, PAIN, V37, P315, DOI 10.1016/0304-3959(89)90196-6; MEISEL A, 1995, RIGHT DIE; RIDDICK CA, 1994, J CLIN ETHIC, V5, P41; Rushton C H, 1995, Am J Crit Care, V4, P112; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SOTTILE FD, 1995, CHEST, V108, P887, DOI 10.1378/chest.108.3.887-a; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	24	55	56	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2000	342	7					508	511		10.1056/NEJM200002173420712	http://dx.doi.org/10.1056/NEJM200002173420712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284FA	10675435				2023-01-03	WOS:000085319100012
J	Henney, JE				Henney, JE			First drug device to treat actinic keratoses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2023-01-03	WOS:000084956500006
J	Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N				Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N			Psychiatric illness and risk factors for suicide in Denmark	LANCET			English	Article							PREVENTING SUICIDE; ATTRIBUTABLE RISK; SWEDISH SUICIDE; UNEMPLOYMENT; MORTALITY	Background Several risk factors for suicide have been identified, We assessed the relative risks and population attributable risks of suicide associated with various socioeconomic factors and with previous mental illness that necessitated hospital admission. Our aim was to assist in the choice of potential strategies for preventing suicide in the general population. Methods We did a population-based nested case-control study based on register data. Data were collected on a random 5% sample of the Danish population aged 16-78 years during a 15-year period (1980-94) and analysed with conditional logistic regression. Findings 811 cases of suicide were found and 79 871 controls were chosen in this population. Unemployment, tow income, being single, and a history of mental illness necessitating hospital admission were associated With increased risk of suicide. However, in the multivariate analysis, the strongest risk factor was mental illness necessitating hospital admission; risk of suicide was especially high during admission (relative risk 62.6 [95% CI 41.1-95.4]) and during the year after discharge (6.51 [5.03-8.44]). The effect of socioeconomic variables decreased after adjustment for history of mental illness. The population attributable risk associated with mental illness necessitating admission to hospital was 44.6% (43.6-45.5); the attributable risks associated with the other factors were 3.0% (1.4-6.6) for unemployment and 10.3% (6.13-16.9) for being single. Interpretation Suicide prevention aimed at patients who are admitted to hospital with mental disorders and improved detection and treatment of mental disorders in the general population may be the most efficient strategy to decrease risk of suicide. Reports of high relative risk and attributable risk associated with unemployment and other socioeconomic risk factors may be confounded and overestimated owing to the lack of adjustment for the association with mental disorders.	Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Univ Aarhus, Ctr Labour Market & Social Res, Aarhus, Denmark	Aarhus University; Aarhus University	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark.		Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012	Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; Eriksson, Tor/0000-0001-9309-5499				Agresti A., 1990, CATEGORICAL DATA ANA; Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; BARNDORFFNIELSE.OE, 1989, ASYMPTOMATIC TECHNIQ; BARNERASMUSSEN P, 1986, ACTA PSYCHIAT SCAND, V73, P449, DOI 10.1111/j.1600-0447.1986.tb02710.x; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; FerradaNoli M, 1997, ACTA PSYCHIAT SCAND, V96, P108, DOI 10.1111/j.1600-0447.1997.tb09914.x; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldberg DP, 1992, COMMON MENTAL DISORD; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hills, 1993, STAT MODELS EPIDEMIO; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; Johansson LM, 1997, SOC PSYCH PSYCH EPID, V32, P165; KREITMAN N, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P73; KURITZ SJ, 1988, BIOMETRICS, V44, P355, DOI 10.2307/2531850; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Lewis G, 1997, BRIT J PSYCHIAT, V171, P351, DOI 10.1192/bjp.171.4.351; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Rosenman SJ, 1998, MED J AUSTRALIA, V169, P100, DOI 10.5694/j.1326-5377.1998.tb140193.x; *SUNDH, 1992, DODS 1990 CAUS DEATH; WESTERGARDNIELS.N, 1984, STUDIES LABOR MARKET, P267; *WHO, 1967, MAN INT CLASS DIS IC; WILKINSON G, 1994, BRIT MED J, V309, P860, DOI 10.1136/bmj.309.6958.860; World Health Organization, 1992, ICD 10 CLASS MENT BE; 1993, LANCET, V342, P381	30	253	260	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					9	12		10.1016/S0140-6736(99)06376-X	http://dx.doi.org/10.1016/S0140-6736(99)06376-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279MU	10615884				2023-01-03	WOS:000085049200009
J	Spanagel, R				Spanagel, R			Is there a pharmacological basis for therapy with rapid opioid detoxification?	LANCET			English	Editorial Material							RECEPTOR BLOCKADE; ADDICTED PATIENTS; ANESTHESIA		Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany	Max Planck Society	Spanagel, R (corresponding author), Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany.							Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Kienbaum P, 1998, ANESTHESIOLOGY, V88, P1154, DOI 10.1097/00000542-199805000-00004; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Maldonado R, 1996, NEUROBIOLOGICAL MECH; Miotto K, 1997, DRUG ALCOHOL DEPEN, V45, P131, DOI 10.1016/S0376-8716(97)01348-3; MORRIS BJ, 1988, J PHARMACOL EXP THER, V247, P729; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Roizen MF, 1998, ANESTHESIOLOGY, V88, P1142, DOI 10.1097/00000542-199805000-00002; Seoane A, 1997, BRIT J PSYCHIAT, V171, P340, DOI 10.1192/bjp.171.4.340; Spanagel R, 1998, DRUG ALCOHOL DEPEN, V52, P251, DOI 10.1016/S0376-8716(98)00106-9; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2	13	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2017	2018		10.1016/S0140-6736(99)90248-9	http://dx.doi.org/10.1016/S0140-6736(99)90248-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636363				2023-01-03	WOS:000084183300006
J	Bloom, BS; Iannacone, RC				Bloom, BS; Iannacone, RC			Internet availability of prescription pharmaceuticals to the public	ANNALS OF INTERNAL MEDICINE			English	Article						Internet; prescriptions, drug; health services accessibility; costs and cost analysis; conflict of interest		Background: The Internet holds great but uncertain promise for increased access and cost control in health care. Objective: To determine access to and cost of prescription pharmaceuticals over the Internet. Design: An Internet search conducted during February and March 1999. Setting: The Philadelphia region. Measurements: Data were collected on availability and cost of medications and physician Internet visits, requirements for physician prescriptions, and geographic location of Web-based companies and consulting physicians. Costs of comparable physician visits were obtained from Medicare and managed care organizations in the Philadelphia region. Costs of medications came from five Philadelphia community pharmacies. Results: Forty-six Web sites were identified. Thirty-seven sites (33 based in the United States and 4 based outside the United States) required a prescription from a personal physician or from an Internet physician consultation. Nine sites based outside of the United States did not require a prescription or physician consultation. The median cost of an Internet physician visit was $70 (range, $20 to $90), more than 15% higher than that for a genera I practice visit in the Philadelphia region. Quality of physician consultation, physician qualifications and specialty, and geographic location were unknown. Median price per pill of the two most commonly offered medications was 10% higher on the Internet (before shipping charges) than at Philadelphia pharmacies ($5.49 and $4.50 for sildenafil; $1.94 and $1.83 for finasteride). Conclusions: The Internet may expand patient access to health-related services but at overall increased cost. In addition, the quality of physician Internet care is uncertain, and potential for serious abuse exists. Patients can easily provide incorrect or false information to obtain medications. Furthermore, conflict of interest exists for Web-based firms because they profit from selling medications and physician consultations.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Bloom, BS (corresponding author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA.								0	57	58	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					830	+		10.7326/0003-4819-131-11-199912070-00005	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610627				2023-01-03	WOS:000084053200004
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine and the patient	BRITISH MEDICAL JOURNAL			English	Review									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Res Council Complementary Med, London, England	Memorial Sloan Kettering Cancer Center								Benson Herbert, 1996, TIMELESS HEALING POW; BISHOP B, 1996, TIME HEL; SHARMA U, 1995, COMPLEMENTARY MED TO	3	40	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1486	1489		10.1136/bmj.319.7223.1486	http://dx.doi.org/10.1136/bmj.319.7223.1486			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582937	Green Published			2023-01-03	WOS:000084129200026
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Herbal medicine	BRITISH MEDICAL JOURNAL			English	Article									Res Council Complementary Med, London, England									Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; MELCHART D, 1999, COCHRANE COLLABORATI; Mills S., 1993, ESSENTIAL BOOK HERBA; Newall CA, 1996, HERBAL MED GUIDE HLT; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	6	107	112	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1050	1053		10.1136/bmj.319.7216.1050	http://dx.doi.org/10.1136/bmj.319.7216.1050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521203	Green Published			2023-01-03	WOS:000083210100032
J	Robertson, MC; Devlin, N; Gardner, MM; Campbell, AJ				Robertson, MC; Devlin, N; Gardner, MM; Campbell, AJ			Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE UTILIZATION; COST-EFFECTIVENESS; OLDER PERSONS; COMMUNITY; WOMEN; RISK; BALANCE; POPULATION; STRENGTH; INJURIES	Objectives To assess the effectiveness of a trained district nurse individually prescribing a home based exercise programme to reduce falls and injuries in elderly people and to estimate the cost effectiveness of the programme. Design Randomised controlled trial with one year's follow up. Setting Community health service at a New Zealand hospital. Participants 240 women and men aged 75 years and older. Intervention 121 participants received the exercise programme (exercise group) and 119 received usual care (control group); 90% (211 of 233) completed the trial. Main outcome measures Number of falls, number of injuries resulting from falls, costs of implementing the programme, and hospital costs as a result of falls. Results Falls were reduced by 46% (incidence rate ratio 0.54, 95% confidence interval 0.32 to 0.90). Five hospital admissions were due to injuries caused by falls in the control group and none in the exercise group. The programme cost $NZ1803 (pound 523) (at 1998 prices) per fall prevented for delivering the programme and $NZ155 per fall prevented when hospital costs averted were considered. Conclusion A home exercise programme, previously shown to be successful when delivered by a physiotherapist, was also effective in reducing falls when delivered by a trained nurse from within a home health service. Serious injuries and hospital admissions due to falls were also reduced. The programme was cost effective in participants aged 80 years and older compared with younger participants.	Otago Med Sch, Dept Med & Surg Sci, Dunedin, New Zealand; Univ Otago, Dept Econ, Dunedin, New Zealand	University of Otago; University of Otago	Robertson, MC (corresponding author), Otago Med Sch, Dept Med & Surg Sci, POB 913, Dunedin, New Zealand.		Robertson, Mary Clare/A-3964-2009					BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; *CROWN CO MON ADV, 1999, HOSP HLTH SERV PERF; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; KIEL DP, 1991, MED CARE, V29, P221; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; MacRae PG, 1994, J AGING PHYS ACTIV, V2, P127, DOI DOI 10.1123/JAPA.2.2.127; McMurdo MET, 1997, BRIT MED J, V314, P569, DOI 10.1136/bmj.314.7080.569; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; Rizzo JA, 1998, MED CARE, V36, P1174, DOI 10.1097/00005650-199808000-00006; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; Robertson MC, 2001, BRIT MED J, V322, P701, DOI 10.1136/bmj.322.7288.701; ROBERTSON MC, 2001, IN PRESS J EPIDEMIOL; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; Salkeld G, 2000, AUST NZ J PUBL HEAL, V24, P265, DOI 10.1111/j.1467-842X.2000.tb01566.x; *STAT CORP, 1999, STAT STAT SOFTW; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	27	315	325	0	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 24	2001	322	7288					697	701		10.1136/bmj.322.7288.697	http://dx.doi.org/10.1136/bmj.322.7288.697			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	416GB	11264206	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000167771000022
J	Silberstein, LE; Toy, P				Silberstein, LE; Toy, P			Research opportunities in transfusion medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODIFIED DENDRITIC CELLS; BLOOD; HYPORESPONSIVENESS; REQUIREMENTS; INACTIVATION	In recent years, the translation of basic research in transfusion medicine has led to development of novel cellular therapies using well-characterized cell populations isolated from either bone marrow or blood (eg, hematopoietic stem and progenitor cells, T lymphocytes, dendritic cells). Refinements in cell therapies will make possible optimal stem cell engraftment, gene therapy, immunotherapy of cancer and infectious disease, and even solid organ regeneration. Moreover, the immune consequences of transfusion therapy are better appreciated and opportunities are at hand to prevent or blunt unwanted immune responses, such as platelet refractoriness and graft-vs-host disease. Transfusion medicine has become a broad, multidisciplinary field that has evolved beyond issues related to blood procurement and storage. The next series of advances in transfusion medicine will complement the current approaches of donor blood screening and viral/bacterial inactivation steps to ensure a safe and adequate blood supply.	Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Silberstein, LE (corresponding author), Childrens Hosp, Dana Farber Canc Inst, Joint Program Transfus Med, Bader 4,300 Longwood Ave, Boston, MA 02115 USA.							Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Armstrong B, 2000, CYTOMETRY, V40, P102, DOI 10.1002/(SICI)1097-0320(20000601)40:2<102::AID-CYTO3>3.3.CO;2-W; Blajchman MA, 1999, TRANSFUSION, V39, P665, DOI 10.1046/j.1537-2995.1999.39070665.x; BLAKESLEE S, 2000, NY TIMES        0725; Daniels G, 1999, BLOOD REV, V13, P14, DOI 10.1016/S0268-960X(99)90020-6; GULNAN EC, 1999, NEW ENGL J MED, V340, P1704; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HOROWITZ MM, 1990, BLOOD, V75, P555; Kirk CJ, 2000, HUM GENE THER, V11, P797, DOI 10.1089/10430340050015419; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; Klein HG, 2000, NEW ENGL J MED, V342, P1666, DOI 10.1056/NEJM200006013422211; KLEINMAN S, 2000, NEW ASPECTS BLOOD TR; Landsteiner K, 1936, SPECIFICITY SEROLOGI; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; MCCULLOUGH J, 1995, TRANSFUSION, V35, P374, DOI 10.1046/j.1537-2995.1995.35595259145.x; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; Murphy WJ, 1999, CURR OPIN IMMUNOL, V11, P509, DOI 10.1016/S0952-7915(99)00002-3; Niimi M, 1998, J IMMUNOL, V161, P5331; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; REED WF, 1999, CURR OPIN HEMATOL, P6432; Reid ME, 2000, TRANSFUSION, V40, P48, DOI 10.1046/j.1537-2995.2000.40010048.x; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; SIENA S, 1989, BLOOD, V74, P1905; SKYES M, 1988, BONE MARROW TRANSPL, V3, P379; Taylor PA, 2000, J IMMUNOL, V164, P612, DOI 10.4049/jimmunol.164.2.612; Thurer RL, 2000, TRANSFUSION, V40, P751, DOI 10.1046/j.1537-2995.2000.40060751.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; YANKEE RA, 1969, NEW ENGL J MED, V281, P1208, DOI 10.1056/NEJM196911272812202; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0	29	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	2001	285	5					577	580		10.1001/jama.285.5.577	http://dx.doi.org/10.1001/jama.285.5.577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397TV	11176862				2023-01-03	WOS:000166714200015
J	Grodstein, F; Manson, JE; Colditz, GA; Willett, WC; Speizer, FE; Stampfer, MJ				Grodstein, F; Manson, JE; Colditz, GA; Willett, WC; Speizer, FE; Stampfer, MJ			A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT THERAPY; MYOCARDIAL-INFARCTION; FOLLOW-UP; RISK; STROKE; USERS; PROGESTIN; WOMEN	Background: Most primary prevention studies have found that long-term users of postmenopausal hormone therapy are at lower risk for coronary events, but numerous questions remain. An adverse influence of hormone therapy on cardiovascular risk has been suggested during the initial year of use; however, few data are available on short-term hormone therapy. In addition, the cardiovascular effects of daily doses of oral conjugated estrogen lower than 0.625 mg are unknown, and few studies have examined estrogen plus progestin in this regard. Objective: To investigate duration, dose, and type of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Design: Prospective, observational cohort study. Setting: Nurses' Health Study, with follow-up from 1976 to 1996. Patients: 70 533 postmenopausal women, in whom 1258 major coronary events (nonfatal myocardial infarction or fatal coronary disease) and 767 strokes were identified. Measurements: Details of postmenopausal hormone use were ascertained by using biennial questionnaires. Cardiovascular disease was established by using a questionnaire and was confirmed by medical record review. Logistic regression models were used to calculate relative risks and 95% Cls, adjusted for confounders. Results: When all cardiovascular risk factors were considered, the risk for major coronary events was lower among current users of hormone therapy, including short-term users, compared with never-users (relative risk, 0.61 [95% CI, 0.52 to 0.71]). Among women taking oral conjugated estrogen, the risk for coronary events was similarly reduced in those currently taking 0.625 mg daily (relative risk, 0.54 [CI, 0.44 to 0.67]) and those taking 0.3 mg daily (relative risk, 0.58 [CI, 0.37 to 0.92]) compared with never-users. However, the risk for stroke was statistically significantly increased among women taking 0.625 mg or more of oral conjugated estrogen daily (relative risk, 1.35 [CI, 1.08 to 1.68] for 0.625 mg/d and 1.63 [CI, 1.18 to 2.26] for greater than or equal to1.25 mg/d) and those taking estrogen plus progestin (relative risk, 1.45 [CI, 1.10 to 1.92]). Overall, little relation was observed between combination hormone therapy and risk for cardiovascular disease (major coronary heart disease plus stroke) (relative risk, 0.91 [CI, 0.75 to 1.11]). Conclusions: Postmenopausal hormone use appears to decrease risk for major coronary events in women without previous heart disease. Furthermore, 0.3 mg of oral conjugated estrogen daily is associated with a reduction similar to that seen with the standard dose of 0.625 mg. However, estrogen at daily doses of 0.625 mg or greater and in combination with progestin may increase risk for stroke.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; GANGAR KF, 1996, EUR MENOPAUSE J, V3, P147; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; GRODSTEIN F, 2000, CIRCULATION S, V100, P18; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HERNANDEZ AM, 1990, EPIDEMIOLOGY, V1, P128; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; Rothman K, 1979, NIH PUBL; Rothman K, 1986, MODERN EPIDEMIOLOGY; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SARREL PM, 1992, AM J OBSTET GYNECOL, V167, P467, DOI 10.1016/S0002-9378(11)91431-8; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Walker AE, 1981, STROKE S1, V12, P13; *WHO, 1971, IHD REGISTER REPORT; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598	37	761	790	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					933	941		10.7326/0003-4819-133-12-200012190-00008	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119394				2023-01-03	WOS:000165952300001
J	Kronzon, I				Kronzon, I			The department of card tricks and close magic	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU Med Ctr, New York, NY 10016 USA	New York University	Kronzon, I (corresponding author), NYU Med Ctr, 560 1st Ave, New York, NY 10016 USA.	Itzhak.Kronzon@med.nyu.edu							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					1005	1007		10.7326/0003-4819-133-12-200012190-00018	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119404				2023-01-03	WOS:000165952300011
J	Davies, L; Wilkinson, M; Bonner, S; Calverley, PMA; Angus, RM				Davies, L; Wilkinson, M; Bonner, S; Calverley, PMA; Angus, RM			"Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES	Objectives To compare "hospital at home" and hospital care as an inpatient in acute exacerbations of chronic obstructive pulmonary disease. Design Prospective randomised controlled trial with three months' follow up. Setting University teaching hospital offering secondary care service to 350 000 patients. Patients Selected patients with an exacerbation of chronic obstructive pulmonary disease where hospital admission had been recommended after medical assessment. Interventions Nurse administered home care was provided as an alternative to inpatient admission. Main outcome measures Readmission rates at two weeks and three months, changes in forced expiratory volume in one second (FEV1) from baseline at these times and mortality. Results 583 patients with chronic obstructive pulmonary disease referred for admission were assessed. 192 met the criteria for home care, and 42 refused to enter the trial. 100 were randomised to home care and 50 to hospital care. On admission, FEV1 after use of a bronchodilator was 36.1% (95% confidence interval 2.4% to 69.8%) predicted in home care and 35.1% (6.3% to 63.9%) predicted in hospital care. No significant difference was found in FEV1 after se of a bronchodilator at two weeks (42.6%, 3.4% to 81.8% versus 42.1%, 5.1% to 79.1%) or three months (41.5%, 8.2% to 74.8% versus 41.9%, 6.2% to 77.6%) between the groups. 37% of patients receiving home care and 34% receiving hospital care were readmitted at three months. No significant difference was found in mortality between the groups at three months (9% versus 8%). Conclusions Hospital at home care is a practical alternative to emergency admission in selected patients with exacerbations of chronic obstructive pulmonary disease.	Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England; Univ Hosp Aintree, Dept Accid & Emergency, ACTRITF Team, Liverpool L9 7AL, Merseyside, England; Univ Hosp Aintree, Dept Med, Liverpool L9 7AL, Merseyside, England	University of Liverpool	Angus, RM (corresponding author), Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England.							ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; *BRIT THOR SOC, 1998, THORAX, V53, pA70; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; DAVIES L, 1998, THORAX S4, V53, pA71; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; HAGGERTY MC, 1991, CHEST, V100, P607, DOI 10.1378/chest.100.3.607; JEFFREY AA, 1992, THORAX, V47, P37; National Health Service Executive, 1996, BURD DIS DISC DOC; Osman LM, 1997, THORAX, V52, P67; ROBERTS CM, 2000, IN PRESS EUR RESP J; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	13	129	129	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1265	1268		10.1136/bmj.321.7271.1265	http://dx.doi.org/10.1136/bmj.321.7271.1265			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082090	Green Published, Bronze			2023-01-03	WOS:000165445800028
J	Morrow, J				Morrow, J			Making mortal decisions at the beginning of life: The case of impaired and imperiled infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BABY DOE		Univ Texas, Med Branch, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Morrow, J (corresponding author), Univ Texas, Med Branch, Galveston, TX 77550 USA.							Affleck G., 1991, INFANTS CRISIS PAREN; AMUNDSEN DW, 1987, EUTHANASIA NEWBORN, P10; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; Dworkin R., 1993, LIFES DOMINION; Jones G E, 1990, Pediatrician, V17, P87; KOOP CE, 1989, HASTINGS CENT REP, V19, pS2; MCMILLAN RC, 1987, EUTHANASIA NEWBORN, pR14; More ES, 1994, EMPATHIC PRACTITIONE; MOSKOP JC, 1986, HASTINGS CENT REP, V16, P8, DOI 10.2307/3563084; NOLAN K, 1990, HASTINGS CENT REP, V20, P3; REISER SJ, 1986, J HEALTH POLIT POLIC, V11, P199, DOI 10.1215/03616878-11-2-199; RHODEN NK, 1985, MILBANK FUND Q, V63, P18, DOI 10.2307/3349897; SINCLAIR JC, 1987, EUTHANASIA NEWBORN, P169; Singer P., 1993, PRACTICAL ETHICS; WEIR R, 1992, COMPELLED COMPASSION, P10	15	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1146	1147		10.1001/jama.284.9.1146	http://dx.doi.org/10.1001/jama.284.9.1146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	349GK	10974700				2023-01-03	WOS:000089037200021
J	Kress, JP; Pohlman, AS; O'Connor, MF; Hall, JB				Kress, JP; Pohlman, AS; O'Connor, MF; Hall, JB			Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNIT; PERMISSIVE HYPERCAPNIA; RESPIRATORY-FAILURE; MIDAZOLAM; PROPOFOL; COST; COMPLICATIONS; EXTUBATIONS; MULTICENTER	Background: Continuous infusions of sedative drugs in the intensive care unit may prolong the duration of mechanical ventilation, prolong the length of stay in the intensive care unit and the hospital, impede efforts to perform daily neurologic examinations, and increase the need for tests to assess alterations in mental status. Whether regular interruption of such infusions might accelerate recovery is not known. Methods: We conducted a randomized, controlled trial involving 128 adult patients who were receiving mechanical ventilation and continuous infusions of sedative drugs in a medical intensive care unit. In the intervention group, the sedative infusions were interrupted until the patients were awake, on a daily basis; in the control group, the infusions were interrupted only at the discretion of the clinicians in the intensive care unit. Results: The median duration of mechanical ventilation was 4.9 days in the intervention group, as compared with 7.3 days in the control group (P=0.004), and the median length of stay in the intensive care unit was 6.4 days as compared with 9.9 days, respectively (P=0.02). Six of the patients in the intervention group (9 percent) underwent diagnostic testing to assess changes in mental status, as compared with 16 of the patients in the control group (27 percent, P=0.02). Complications (e.g., removal of the endotracheal tube by the patient) occurred in three of the patients in the intervention group (4 percent) and four of the patients in the control group (7 percent, P=0.88). Conclusions: In patients who are receiving mechanical ventilation, daily interruption of sedative-drug infusions decreases the duration of mechanical ventilation and the length of stay in the intensive care unit. (N Engl J Med 2000;342:1471-7.) (C)2000, Massachusetts Medical Society.	Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hall, JB (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, MC 6026, Chicago, IL 60637 USA.							BIDANI A, 1994, JAMA-J AM MED ASSOC, V272, P957, DOI 10.1001/jama.272.12.957; Boulain T, 1998, AM J RESP CRIT CARE, V157, P1131, DOI 10.1164/ajrccm.157.4.9702083; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010; CHENG EY, 1995, CRIT CARE CLIN, V11, P1005, DOI 10.1016/S0749-0704(18)30050-2; Christensen MJ, 1996, AUSTRALAS PLANT PATH, V25, P186, DOI 10.1071/AP96032; COX DR, 1972, J R STAT SOC B, V34, P187; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; GUNDLACH CA, 1991, HOSP FORMUL, V26, P132; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; INDECK M, 1988, J TRAUMA, V28, P1020, DOI 10.1097/00005373-198807000-00018; JACOBS JR, 1991, INT ANESTHESIOL CLIN, V29, P23, DOI 10.1097/00004311-199102940-00004; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RIKER RR, 1994, CRIT CARE MED, V22, P433, DOI 10.1097/00003246-199403000-00013; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Shelly MP, 1999, INTENS CARE MED, V25, P137, DOI 10.1007/s001340050805; SIVAM SP, 1985, LIFE SCI, V37, P199, DOI 10.1016/0024-3205(85)90645-9; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; VASSAL T, 1993, INTENS CARE MED, V19, P340, DOI 10.1007/BF01694708; WOOD LDH, 1998, PRINCIPLES CRITICAL, P499; 1998, 1999 NY TIMES ALMANA, P316	29	1775	1877	3	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	2000	342	20					1471	1477		10.1056/NEJM200005183422002	http://dx.doi.org/10.1056/NEJM200005183422002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314QT	10816184				2023-01-03	WOS:000087068200002
J	Reed, JL; Lyne, R				Reed, JL; Lyne, R			Inpatient care of mentally ill people in prison: results of a year's programme of semistructured inspections	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DISORDER	Objective To investigate the facilities for inpatient care of mentally disordered people in prison. Design Semistructured inspections conducted by doctor and nurse. Expected standards were based on healthcare quality standards published by the Prison Service or the NHS. Setting 13 prisons with inpatient beds in England and Wales subject to the prison inspectorate's routine inspection programme during 1997-8. Main outcomes measures Appraisals of quality of care against published standards. Results The 13 prisons had 348 beds, 20% of all beds in prisons. Inpatient units had between 3 and 75 beds. No doctor in charge of inpatients had completed specialist psychiatric training. 24% of nursing staff had mental health training; 32% were non-nursing trained healthcare officers. Only one prison had occupational therapy input; two had input from a clinical psychologist Most patients were unlocked for about 3.5 hours a day and none for more than nine hours a day. Four prisons provided statistics on the use of seclusion. The average length of an episode of seclusion was 50 hours. Conclusion The quality of services for mentally ill prisoners fell far below the standards in the NHS. Patients' lives were unacceptably restricted and therapy limited. The present policy dividing inpatient care of mentally disordered prisoners between the prison service and the NHS needs reconsideration.	HM Inspectorate Prisons, Home Off, London SW1H 9AT, England		Reed, JL (corresponding author), HM Inspectorate Prisons, Home Off, London SW1H 9AT, England.							Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; *DEP HLTH, 1998, IN PAT FORM DET HOSP; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; Hargreaves D, 1997, J FORENSIC PSYCHIATR, V8, P62, DOI 10.1080/09585189708411994; Health Advisory Committee for the Prison Service, 1997, PROV MENT HLTH CAR P; *HER MAJ INSP PRIS, 1999, REP FULL INSP HMYOI; *HER MAJ PRIS SERV, 1993, HLTH CAR STAND PRIS; *HER MAJ PRIS SERV, 1999, FUT ORG PRIS HLTH CA; *HER MAJ PRIS SERV, 1991, STAND ORD 13 HLTH CA; *HOM OFF, 1991, CUST CAR JUST WAY AH; MELTZER H, 1994, PREVALENCE PSYCHIAT; *PRIS SERV, 1997, REP DIR HLTH CAR 199; *PRIS SERV, 1998, REP DIR HLTH CAR 199; Reed J, 1997, BRIT MED J, V315, P1420, DOI 10.1136/bmj.315.7120.1420; Singleton N., 1998, PSYCHIAT MORBIDITY P; Smith Richard, 1984, PRISON HLTH CARE; THOMLINSON L, 1998, BMA NEWS REV     OCT; WILLIAMS J, 1999, PHARM J, V263, P634	19	38	38	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1031	1034		10.1136/bmj.320.7241.1031	http://dx.doi.org/10.1136/bmj.320.7241.1031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764360	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000086675700018
J	Gilbertson, L; Langhorne, P; Walker, A; Allen, A; Murray, GD				Gilbertson, L; Langhorne, P; Walker, A; Allen, A; Murray, GD			Domiciliary occupational therapy for patients with stroke discharged from hospital: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION	Objective To establish if a brief programme of domiciliary occupational therapy could improve the recovery of patients with stroke discharged from hospital. Design Single blind randomised controlled trial. Setting Two hospital sites within a UK teaching hospital. Subjects 138 patients with stroke with a definite plan for discharge home from hospital. Intervention Six week domiciliary occupational therapy or routine follow up. Main outcome measures Nottingham extended activities of daily living score and "global outcome" (deterioration according to the Barthel activities of daily living index, or death). Results By eight weeks the mean Nottingham extended activities of daily living score in the intervention group was 4.8 points (95% confidence interval -0.5 to 10.0, P = 0.08) greater than that of the control group. Overall, 16 (24%) intervention patients had a poor global outcome compared with 30 (42%) control patients (odds ratio 0.43, 0.21 to 0.89, P = 0.02). These patterns persisted at six months but were not statistically significant Patients in the intervention group were more likely to report satisfaction with a range of aspects of services. Conclusion The functional outcome and satisfaction of patients with stroke can be improved by a brief occupational therapy programme carried out in the patient's home immediately after discharge. Major benefits may not, however, be sustained.	Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Glasgow Royal Infirm, Dept Occupat Therapy, Glasgow G4 0SF, Lanark, Scotland; Greater Glasgow Hlth Board, Glasgow G3 8YU, Lanark, Scotland; Univ Edinburgh, Dept Community Hlth Sci, Med Stat Unit, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Glasgow; University of Glasgow; University of Edinburgh	Langhorne, P (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.			Murray, Gordon/0000-0001-9866-4734				Corr S, 1995, CLIN REHABIL, V9, P291; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; GILBERTSON L, 1998, THESIS U GLASGOW; Gladman J, 1996, BRIT MED J, V312, P1623, DOI 10.1136/bmj.312.7047.1623; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Rodgers H, 1997, CLIN REHABIL, V11, P280, DOI 10.1177/026921559701100403; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; Wade DT., 1992, MEASUREMENT NEUROLOG; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	11	88	90	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	2000	320	7235					603	606		10.1136/bmj.320.7235.603	http://dx.doi.org/10.1136/bmj.320.7235.603			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291NH	10698876	Green Published, Green Submitted, Bronze, Green Accepted			2023-01-03	WOS:000085742600022
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine in conventional practice	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									Coates JR, 1998, J ALTERN COMPLEM MED, V4, P209, DOI 10.1089/acm.1998.4.209; Fulder S., 1996, HDB ALTERNATIVE COMP, V3rd; SHARMA U, 1995, COMPLEMENTARY MED TO; STONE J, 1996, COMPLEMENTARY MED LA; 1993, COMPLEMENTARY MED NE	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					901	904		10.1136/bmj.319.7214.901	http://dx.doi.org/10.1136/bmj.319.7214.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506051	Green Published			2023-01-03	WOS:000082975600030
J	Owen, DK; Lewith, G; Stephens, CR				Owen, DK; Lewith, G; Stephens, CR			Can doctors respond to patients' increasing interest in complementary and alternative medicine?	BRITISH MEDICAL JOURNAL			English	Article									Winchester Homeopath Practice, Winchester SO22 6RL, Hants, England; Southampton Gen Hosp, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Owen, DK (corresponding author), Homeopath Phys Teaching Grp Oxford, Oxford OX1 2NP, England.			Lewith, George/0000-0002-2364-3960				BARBERIS L, IN PRESS J ALTERNATI; Barker S, 2000, MED EDUC, V34, P159, DOI 10.1046/j.1365-2923.2000.00617.x; Berman B M, 1995, J Am Board Fam Pract, V8, P361; *BMA HOUS, 1999, REP M DIFF MED SCH P; British Medical Association, 1993, COMPL MED NEW APPR G; CARSTON M, 1997, FAM MED, V29, P559; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FREEMAN R, 1998, MENTORING GEN PRACTI, P103; FURNHAM A, 1993, COMPLEMENTARY THERAP, V1, P120; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; GRIFFITHS M, 1992, J EDUC TEACHING, V18, P69, DOI 10.1080/0260747920180107; Hawkins P., 2000, SUPERVISION HELPING; LEWITH G, IN PRESS J R COLL PH; Lewith GT, 2000, COMPLEMENT THER MED, V8, P202, DOI 10.1054/ctim.2000.0377; Morgan D., 1998, COMPLEMENT THER MED, V6, P64; OWEN D, IN PRESS J MED ED; Rampes H, 1997, J ROY SOC MED, V90, P19, DOI 10.1177/014107689709000107; REILLY D, 1987, DEV INTEGRATED MED R; THOMAS K, 1995, NATL SURVEY ACCESS C; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; Zollman C, 2000, ABC COMPLEMENTARY ME	23	63	65	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					154	157		10.1136/bmj.322.7279.154	http://dx.doi.org/10.1136/bmj.322.7279.154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159576	Green Published			2023-01-03	WOS:000166615300030
J	Rodgers, A; Walker, N; Schug, S; McKee, A; Kehlet, H; van Zundert, A; Sage, D; Futter, M; Saville, G; Clark, T; MacMahon, S				Rodgers, A; Walker, N; Schug, S; McKee, A; Kehlet, H; van Zundert, A; Sage, D; Futter, M; Saville, G; Clark, T; MacMahon, S			Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TOTAL HIP-REPLACEMENT; DEEP-VEIN THROMBOSIS; TRANS-URETHRAL RESECTION; AORTOCORONARY BYPASS-SURGERY; ABDOMINAL AORTIC-SURGERY; GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; METABOLIC-RESPONSE; BLOOD-LOSS; PULMONARY COMPLICATIONS	Objectives To obtain reliable estimates of the effects of neuraxial blockade with epidural or spinal anaesthesia on postoperative morbidity and mortality. Design Systematic review of all trials with randomisation to intraoperative neuraxial blockade or not Studies 141 trials including 9559 patients for which data were available before 1 January 1997. Trials were eligible irrespective of their primary aims, concomitant use of general anaesthesia, publication status, or language. Trials were identified by extensive search methods, and substantial amounts of data were obtained or confirmed by correspondence with trialists. Main outcome measures. All cause mortality. deep vein thrombosis, pulmonary embolism, myocardial infarction, transfusion requirements, pneumonia, other infections, respiratory depression, and renal failure. Results Overall mortality was reduced by about a third in patients allocated to neuraxial blockade (103 deaths/4871 patients versus 144/4688 patients, odds ratio = 0.70, 95% confidence interval 0.54 to 0.90. P = 0.006). Neuraxial blockade reduced the odds of deep vein thrombosis by 44%, pulmonary embolism by 55%, transfusion requirements by 50%, pneumonia by 39%, and respiratory depression by 59% (all P < 0.001). There were also reductions in myocardial infarction and renal failure. Although there was limited power to assess subgroup effects, the proportional reductions in mortality did not clearly differ by surgical group, type of blockade (epidural or spinal), or in those trials in which neuraxial blockade was combined with general anaesthesia compared with trials in which neuraxial blockade was used alone. Conclusions Neuraxial blockade reduces postoperative mortality and other serious complications. The size of some of these benefits remains uncertain, and further research is required to determine whether these effects are due solely to benefits of neuraxial blockade or partly to avoidance of general anaesthesia. Nevertheless, these findings support more widespread use of neuraxial blockade.	Univ Auckland, Dept Med, Clin Trials Res Unit, Auckland, New Zealand; Univ Auckland, Div Anaesthesiol, Auckland 1, New Zealand; Green Lane Hosp, Dept Anaesthet, Auckland 1003, New Zealand; Hvidovre Univ Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Catharina Hosp, Dept Anesthesiol Intens Care & Pain Therapy, NL-5623 EJ Eindhoven, Netherlands; Auckland Hosp, Dept Anaesthesia, Auckland, New Zealand; Starship Hosp, Dept Anaesthesia, Auckland, New Zealand; Royal Cornwall Hosp, Dept Anaesthesia, Treliske TR1 3LJ, Truro, England; Univ Sydney, Inst Int Hlth, Sydney, NSW 1585, Australia	University of Auckland; University of Auckland; University of Copenhagen; Catharina Hospital; Auckland City Hospital; Starship Children's Hospital; Royal Cornwall Hospital; University of Sydney	Rodgers, A (corresponding author), Univ Auckland, Dept Med, Clin Trials Res Unit, Private Bag 92019, Auckland, New Zealand.	a.rodgers@ctru.auckland.ac.nz	van Zundert, Andre/D-6938-2012; Clark, Taane G./AAM-2570-2020; Schug, Stephan/G-1432-2010; Van Zundert, Andre A/G-2436-2015	Clark, Taane G./0000-0001-8985-9265; Schug, Stephan/0000-0002-0302-2315; Van Zundert, Andre A/0000-0001-5483-5941; MacMahon, Stephen/0000-0003-2064-7699; Rodgers, Anthony/0000-0003-1282-1896				ABBOUD TK, 1985, ANESTH ANALG, V64, P996; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ASBJORN J, 1989, ACTA ANAESTH SCAND, V33, P369, DOI 10.1111/j.1399-6576.1989.tb02925.x; ASOH T, 1983, ACTA ANAESTH SCAND, V27, P233, DOI 10.1111/j.1399-6576.1983.tb01942.x; ASOH T, UNPUB POSTOPERATIVE; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; BERGGREN D, 1987, ANESTH ANALG, V66, P497; BIGLER D, 1985, ANAESTHESIA, V40, P672, DOI 10.1111/j.1365-2044.1985.tb10949.x; BLUNNIE WP, 1983, BRIT J ANAESTH, V55, P611, DOI 10.1093/bja/55.7.611; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Bonnet F, 1989, Ann Vasc Surg, V3, P214, DOI 10.1016/S0890-5096(07)60026-0; BONNET F, 1982, BRIT J ANAESTH, V54, P29, DOI 10.1093/bja/54.1.29; BOROVSKIKH NA, 1990, VESTN KHIR IM GREKOV, V145, P95; BOTTIGLIERI T, 1992, REGION ANESTH S, V17, P95; BRANDT MR, 1978, BRIT MED J, V1, P1106, DOI 10.1136/bmj.1.6120.1106; BREDAHL C, 1991, ACTA ANAESTH SCAND, V35, P548, DOI 10.1111/j.1399-6576.1991.tb03346.x; BREDBACKA S, 1986, ACTA ANAESTH SCAND, V30, P204, DOI 10.1111/j.1399-6576.1986.tb02397.x; BRESLOW MJ, 1993, ANESTHESIOLOGY, V79, P1202, DOI 10.1097/00000542-199312000-00010; BRICHON PY, 1994, EUR J CARDIO-THORAC, V8, P482, DOI 10.1016/1010-7940(94)90019-1; BROMAGE PR, 1971, SURG GYNECOL OBSTETR, V132, P1051; BROWN AG, 1994, ANAESTH INTENS CARE, V22, P150, DOI 10.1177/0310057X9402200205; BUCKLEY FP, 1982, BRIT J ANAESTH, V54, P325, DOI 10.1093/bja/54.3.325; CHIN SP, 1982, BRIT J ANAESTH, V54, P491, DOI 10.1093/bja/54.5.491; CHRISTENSEN P, 1982, BRIT J ANAESTH, V54, P23, DOI 10.1093/bja/54.1.23; CHRISTENSEN T, 1986, ACTA CHIR SCAND, V152, P407; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; CHUNG F, 1987, ANESTHESIOLOGY, V67, P422, DOI 10.1097/00000542-198709000-00026; CHUNG FF, 1989, CAN J ANAESTH, V36, P382, DOI 10.1007/BF03005334; COOK PT, 1986, ANAESTH INTENS CARE, V14, P373, DOI 10.1177/0310057X8601400409; COUDERC E, 1977, ANESTH ANALG REANIM, V34, P987; COUSINS M, 1988, NEURAL BLOCKADE CLIN; CUSCHIERI RJ, 1985, BRIT J SURG, V72, P495, DOI 10.1002/bjs.1800720631; DAHL JB, 1990, BRIT J ANAESTH, V64, P178, DOI 10.1093/bja/64.2.178; Damask M C, 1990, J Clin Anesth, V2, P71, DOI 10.1016/0952-8180(90)90056-9; DARLING JR, 1994, ANESTH ANALG, V78, P706; DAVIES MJ, 1993, ANAESTH INTENS CARE, V21, P790, DOI 10.1177/0310057X9302100607; DAVIS FM, 1987, BRIT J ANAESTH, V59, P561, DOI 10.1093/bja/59.5.561; DAVIS FM, 1980, BRIT MED J, V281, P1528, DOI 10.1136/bmj.281.6254.1528; DAVIS FM, 1987, BRIT J ANAESTH, V59, P1080, DOI 10.1093/bja/59.9.1080; DAVIS FM, 1987, BRIT J ANAESTH, V59, P725, DOI 10.1093/bja/59.6.725; DAVIS FM, 1981, ANAESTH INTENS CARE, V9, P352, DOI 10.1177/0310057X8100900406; DAVIS FM, 1989, ANAESTH INTENS CARE, V17, P136, DOI 10.1177/0310057X8901700203; DAVIS FM, 1989, J BONE JOINT SURG BR, V71, P181, DOI 10.1302/0301-620X.71B2.2925731; DEKOCK M, 1993, ANESTHESIOLOGY, V79, P525, DOI 10.1097/00000542-199309000-00016; DICK W, 1992, EUR J ANAESTH, V9, P15; DICKERSIN K, 1995, ESTABLISHING MAINTAI; DOBSON PMS, 1994, BRIT J ANAESTH, V72, P267, DOI 10.1093/bja/72.3.267; DONADONI R, 1988, REGION ANESTH, V13, P55; EDWARDS ND, 1995, BRIT J ANAESTH, V74, P368, DOI 10.1093/bja/74.4.368; FLEISHER LA, 1994, ANESTH ANALG, V79, P165; FOATE JA, 1985, ANAESTH INTENS CARE, V13, P383, DOI 10.1177/0310057X8501300409; FRANK SM, 1994, ANESTHESIOLOGY, V80, P502, DOI 10.1097/00000542-199403000-00005; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; FREDIN H, 1986, EUR J ANAESTH, V3, P273; Garnett RL, 1996, CAN J ANAESTH, V43, P769, DOI 10.1007/BF03013027; GELMAN S, 1980, ANESTH ANALG, V59, P902; GHONEIM MM, 1988, ANESTHESIOLOGY, V69, P507, DOI 10.1097/00000542-198810000-00010; Go AS, 1996, ANESTHESIOLOGY, V84, P1, DOI 10.1097/00000542-199601000-00001; GODFREY PJ, 1981, BRIT J SURG, V68, P587, DOI 10.1002/bjs.1800680820; GOERTZ AW, 1993, ACTA ANAESTH SCAND, V37, P38, DOI 10.1111/j.1399-6576.1993.tb03595.x; GOLD MS, 1994, ANESTH ANALG, V78, P225, DOI 10.1213/00000539-199402000-00006; GOTTLIEB A, 1988, REGION ANESTH PAIN M, V13, P69; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P300, DOI 10.1093/oxfordjournals.aje.a117250; Gregoretti S M, 1985, Minerva Anestesiol, V51, P87; HAKANSSON E, 1983, ACTA ANAESTH SCAND, V27, P78; HALEVY S, 1978, BRIT J ANAESTH, V50, P1053, DOI 10.1093/bja/50.10.1053; Haljamae H, 1988, Eur J Vasc Surg, V2, P395, DOI 10.1016/S0950-821X(88)80018-5; HASENBOS M, 1985, ACTA ANAESTH SCAND, V29, P577, DOI 10.1111/j.1399-6576.1985.tb02257.x; HASENBOS M, 1985, ACTA ANAESTH SCAND, V29, P572, DOI 10.1111/j.1399-6576.1985.tb02256.x; HEDENSTIERNA G, 1985, ACTA ANAESTH SCAND, V29, P55, DOI 10.1111/j.1399-6576.1985.tb02159.x; HENDOLIN H, 1981, ACTA CHIR SCAND, V147, P425; HENDOLIN H, 1982, International Urology and Nephrology, V14, P399, DOI 10.1007/BF02081981; HENDOLIN H, 1987, ANN CHIR GYNAECOL FE, V76, P234; HENDOLIN H, 1982, ACTA CHIR SCAND, V148, P405; HENDOLIN H, 1982, ANN CLIN RES, V14, P181; HENDOLIN H, 1987, ACTA ANAESTH SCAND, V31, P645, DOI 10.1111/j.1399-6576.1987.tb02637.x; HENNY CP, 1986, BRIT J ANAESTH, V58, P301, DOI 10.1093/bja/58.3.301; HESSELVIK F, 1987, SCAND J CLIN LAB INV, V47, P435; HJORTSO NC, 1985, BRIT J ANAESTH, V57, P400, DOI 10.1093/bja/57.4.400; HJORTSO NC, 1985, ACTA ANAESTH SCAND, V29, P790, DOI 10.1111/j.1399-6576.1985.tb02302.x; HJORTSO NC, 1984, ACTA ANAESTH SCAND, V28, P128, DOI 10.1111/j.1399-6576.1984.tb02027.x; HOLDCROFT A, 1979, ANAESTHESIA, V34, P758, DOI 10.1111/j.1365-2044.1979.tb06408.x; HOLE A, 1980, ACTA ANAESTH SCAND, V24, P279, DOI 10.1111/j.1399-6576.1980.tb01549.x; HOLE A, 1983, ACTA ANAESTH SCAND, V27, P135, DOI 10.1111/j.1399-6576.1983.tb01923.x; HOLE A, 1984, ACTA ANAESTH SCAND, V28, P296, DOI 10.1111/j.1399-6576.1984.tb02064.x; HOLE A, 1984, ACTA ANAESTH SCAND, V28, P287, DOI 10.1111/j.1399-6576.1984.tb02062.x; HOLE A, 1982, ACTA ANAESTH SCAND, V26, P301, DOI 10.1111/j.1399-6576.1982.tb01771.x; HOMANN B, 1984, ANAESTHESIST, V33, P145; Horlocker TT, 1997, ANESTH ANALG, V84, P578, DOI 10.1097/00000539-199703000-00021; HOUWELING PL, 1993, EUR J ANAESTH, V10, P403; JAKOBSEN BW, 1986, ACTA ANAESTH SCAND, V30, P668, DOI 10.1111/j.1399-6576.1986.tb02498.x; JAYR C, 1993, ANESTHESIOLOGY, V78, P666, DOI 10.1097/00000542-199304000-00009; JAYR C, 1988, SURGERY, V104, P57; JAYR C, 1988, REGION ANESTH, V13, P6; JENKINS J, 1983, ANAESTHESIA, V38, P748, DOI 10.1111/j.1365-2044.1983.tb12197.x; JENSEN BH, 1977, ACTA ANAESTH SCAND, V21, P395, DOI 10.1111/j.1399-6576.1977.tb01238.x; JENSEN CH, 1980, ACTA ANAESTH SCAND, V24, P472, DOI 10.1111/j.1399-6576.1980.tb01586.x; JIA N, 1991, ACTA ACAD MED SIN, V13, P112; JIA N, 1985, CHIN MED J, V65, P30; JONES MJT, 1990, BRIT MED J, V300, P1683, DOI 10.1136/bmj.300.6741.1683; JORDANOV K, 1985, AKUSH GINEKOL SOFIA, V24, P31; JORGENSEN LN, 1991, BRIT J ANAESTH, V66, P8, DOI 10.1093/bja/66.1.8; KAUSALYA R, 1994, ANAESTH INTENS CARE, V22, P161, DOI 10.1177/0310057X9402200207; Kehlet H., 1988, NEURAL BLOCKADE CLIN, P145; KEITH I, 1977, ANAESTHESIA, V32, P444, DOI 10.1111/j.1365-2044.1977.tb09981.x; KOKHNOVER S, 1982, AKUSH GINEKOL SOFIA, V6, P48; KOSSMANN B, 1982, REGIONAL ANESTH, V7, P107; LEHTINEN AM, 1987, J IN VITRO FERTIL EM, V4, P23, DOI 10.1007/BF01555431; LICKER M, 1994, EUR J ANAESTH, V11, P193; MANN RAM, 1983, ANAESTHESIA, V38, P1185, DOI 10.1111/j.1365-2044.1983.tb12523.x; MAURETTE P, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P305, DOI 10.1016/S0750-7658(88)80033-9; MCGOWAN SW, 1980, ANAESTHESIA, V35, P847, DOI 10.1111/j.1365-2044.1980.tb03941.x; MCKENZIE PJ, 1985, BRIT J ANAESTH, V57, P853, DOI 10.1093/bja/57.9.853; MCKENZIE PJ, 1984, BRIT J ANAESTH, V56, P581, DOI 10.1093/bja/56.6.581; MCKENZIE PJ, 1980, BRIT J ANAESTH, V52, P49, DOI 10.1093/bja/52.1.49; MCLAREN AD, 1978, ANAESTHESIA, V33, P10, DOI 10.1111/j.1365-2044.1978.tb08270.x; MCLAREN AD, 1982, REG ANAESTH S, V7, pS172; MELLBRING G, 1983, ACTA CHIR SCAND, V149, P263; MELSEN N C, 1987, Ugeskrift for Laeger, V149, P150; MERHAV H, 1993, INT SURG, V78, P257; MITCHELL D, 1991, CLIN ORTHOP RELAT R, V269, P109; MODIG J, 1983, ANESTH ANALG, V62, P174; MODIG J, 1980, ACTA ANAESTH SCAND, V24, P305, DOI 10.1111/j.1399-6576.1980.tb01553.x; MODIG J, 1980, Anesthesiology (Hagerstown), V53, pS34, DOI 10.1097/00000542-198009001-00034; MODIG J, 1987, EUR J ANAESTH, V4, P345; MODIG J, 1981, ACTA CHIR SCAND, V147, P125; MODIG J, 1988, ACTA CHIR SCAND    S, V550, P95; MODIG J, 1986, REGION ANESTH PAIN M, V11, P72; MOINICHE S, 1992, REGION ANESTH S, V17, P2; Murakami M, 1987, Masui, V36, P583; NAESH O, 1994, EUR J ANAESTH, V11, P169; NAESH O, 1994, ACTA ANAESTH SCAND, V38, P820, DOI 10.1111/j.1399-6576.1994.tb04012.x; NIELSEN K K, 1987, International Urology and Nephrology, V19, P287, DOI 10.1007/BF02549865; NIELSEN TH, 1989, EUR J ANAESTH, V6, P409; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; Ogata M, 1985, Masui, V34, P1358; Ogata M, 1988, Masui, V37, P163; PARKER MJ, 2000, COCHRANE LIB; Pedersen J, 1986, Ugeskr Laeger, V148, P1819; PEDERSEN J, 1987, Ugeskrift for Laeger, V149, P1463; PERHONIEMI V, 1986, EUR UROL, V12, P244; PLANES A, 1991, J BONE JOINT SURG BR, V73, P418, DOI 10.1302/0301-620X.73B3.1670442; POIKOLAINEN E, 1983, ACTA CHIR SCAND, V149, P361; POLL J, 1988, REGION ANESTH, V13, P4; RADE J, 1986, ANN FR ANESTH, V5, P24; RAVIN MB, 1971, ANESTHESIOLOGY, V35, P319, DOI 10.1097/00000542-197109000-00018; REINHART K, 1989, ANESTH ANALG, V69, P360; REM J, 1980, LANCET, V1, P283; RICKFORD JK, 1988, ANN ROY COLL SURG, V70, P69; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Rodgers A, 1996, ANAESTH INTENS CARE, V24, P79, DOI 10.1177/0310057X9602400114; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; ROSBERG B, 1982, ACTA ANAESTH SCAND, V26, P189, DOI 10.1111/j.1399-6576.1982.tb01751.x; ROSENFELD BA, 1993, ANESTHESIOLOGY, V79, P435, DOI 10.1097/00000542-199309000-00005; ROSSEEL P, 1985, Acta Anaesthesiologica Belgica, V36, P345; RUTBERG H, 1984, BRIT J ANAESTH, V56, P233, DOI 10.1093/bja/56.3.233; RYAN P, 1992, EUR J SURG, V158, P45; SCHEININ B, 1982, ACTA ANAESTH SCAND, V26, P474, DOI 10.1111/j.1399-6576.1982.tb01802.x; SEELING W, 1990, ANAESTHESIST, V39, P33; SEELING W, 1986, ANAESTHESIST, V35, P80; SEELING W, 1985, ANAESTHESIST, V34, P217; SEELING W, 1991, ANAESTHESIST, V40, P614; SEELING W, 1985, ANAESTHESIST, V34, P417; SEITZ W, 1985, ANASTH INTENSIV NOTF, V20, P119, DOI 10.1055/s-2007-1003097; Sharrock NE, 1992, REGIONAL ANESTHES S3, V17, P94; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; SHIRASAKA C, 1986, BRIT J SURG, V73, P142, DOI 10.1002/bjs.1800730224; SIMPSON PJ, 1982, ANAESTHESIA, V37, P3, DOI 10.1111/j.1365-2044.1982.tb00985.x; SLINGER P, 1995, J CARDIOTHOR VASC AN, V9, P128, DOI 10.1016/S1053-0770(05)80182-X; SMEETS HJ, 1993, WORLD J SURG, V17, P601, DOI 10.1007/BF01659119; SORENSON RM, 1992, ANESTHESIOLOGY, V77, P1095, DOI 10.1097/00000542-199212000-00009; STATHOPOULOU T, 1992, REGION ANESTH S, V17, P181; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P834, DOI 10.1111/j.1399-6576.1994.tb04014.x; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P826, DOI 10.1111/j.1399-6576.1994.tb04013.x; STJERNSTROM H, 1985, ACTA ANAESTH SCAND, V29, P743, DOI 10.1111/j.1399-6576.1985.tb02293.x; TANAKA K, 1993, REGION ANESTH, V18, P34; TARKKILA PJ, 1991, REGION ANESTH, V16, P101; TRAYNOR C, 1982, BRIT J ANAESTH, V54, P319, DOI 10.1093/bja/54.3.319; TSUJI H, 1983, BRIT J SURG, V70, P437, DOI 10.1002/bjs.1800700716; TSUJI H, 1983, BRIT J SURG, V70, P122, DOI 10.1002/bjs.1800700223; TULLA H, 1992, ACTA ANAESTH SCAND, V36, P101, DOI 10.1111/j.1399-6576.1992.tb03431.x; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; UCHIDA I, 1988, BRIT J SURG, V75, P557, DOI 10.1002/bjs.1800750618; VALENTIN N, 1986, BRIT J ANAESTH, V58, P284, DOI 10.1093/bja/58.3.284; WALLACE DH, 1995, OBSTET GYNECOL, V86, P193, DOI 10.1016/0029-7844(95)00139-I; WATTERS JM, 1993, CAN J ANAESTH, V40, P314, DOI 10.1007/BF03009628; WATTWIL M, 1987, ACTA ANAESTH SCAND, V31, P529, DOI 10.1111/j.1399-6576.1987.tb02616.x; WESSEN A, 1994, J CLIN ANESTH, V6, P193, DOI 10.1016/0952-8180(94)90058-2; WHELAN P, 1982, CLIN EXP IMMUNOL, V48, P611; WHITE IWC, 1980, ANAESTHESIA, V35, P1107, DOI 10.1111/j.1365-2044.1980.tb05053.x; WICKSTROM I, 1982, ACTA ANAESTH SCAND, V26, P607, DOI 10.1111/j.1399-6576.1982.tb01825.x; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; WilliamsRusso P, 1996, CLIN ORTHOP RELAT R, P199, DOI 10.1097/00003086-199610000-00028; WORSLEY MH, 1988, BRIT J ANAESTH, V60, P836, DOI 10.1093/bja/60.7.836; Wust H J, 1980, Anasth Intensivther Notfallmed, V15, P87, DOI 10.1055/s-2007-1005128; XONISHI M, 1989, MASUI, V38, P329; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZWARTS SJ, 1989, REGION ANESTH, V14, P183	202	1174	1239	3	54	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1493	1497		10.1136/bmj.321.7275.1493	http://dx.doi.org/10.1136/bmj.321.7275.1493			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118174	Green Published, Bronze			2023-01-03	WOS:000165994700023
J	Hainer, MI; Tsai, N; Komura, ST; Chiu, CL				Hainer, MI; Tsai, N; Komura, ST; Chiu, CL			Fatal hepatorenal failure associated with hydrazine sulfate	ANNALS OF INTERNAL MEDICINE			English	Article							CELL LUNG-CANCER; MEDICAL PROGRESS; WEIGHT-LOSS; CACHEXIA; BIOLOGY	Background: The Internet has revolutionized the manner in which patients obtain information about health care. This technology has also allowed patients to obtain directly both prescription and nonprescription therapies. Objective: To report a case of fulminant hepatorenal failure associated with the use of hydrazine sulfate, an unregulated alternative remedy for cancer marketed on the Internet. Design: Case report. Setting: Academic medical center. Patient: A 55-year-old man with maxillary sinus cancer. Intervention: Self-medication with hydrazine sulfate. Measurements: serum liver and renal function tests; histologic evaluation of liver and kidney tissue. Results: The patient developed hepatic encephalopathy, renal failure, and profound coagulopathy. He died after severe gastrointestinal hemorrhage developed. Autopsy revealed autolysis of the kidneys and submassive bridging necrosis of the liver. Conclusion: Fatal hepatorenal failure may occur after the use of hydrazine sulfate. This fatal complication must be considered in anyone taking or contemplating the use of hydrazine sulfate.	Moncrief Army Community Hosp, Dept Internal Med, Ft Jackson, SC 29207 USA; St Francis Med Ctr, Honolulu, HI USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	University of Hawaii System	Hainer, MI (corresponding author), Moncrief Army Community Hosp, Dept Internal Med, Ft Jackson, SC 29207 USA.	mark.hainer@se.amedd.army.mil						CHLEBOWSKI RT, 1990, J CLIN ONCOL, V8, P9, DOI 10.1200/JCO.1990.8.1.9; CHLEBOWSKI RT, 1987, CANCER, V59, P406, DOI 10.1002/1097-0142(19870201)59:3<406::AID-CNCR2820590309>3.0.CO;2-W; CHLEBOWSKI RT, 1984, CANCER RES, V44, P857; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gold J, 1998, J NATL CANCER I, V90, P1101, DOI 10.1093/jnci/90.14.1101; GOLD J, 1975, ONCOLOGY, V32, P1; GOLD J, 1987, Nutrition and Cancer, V9, P59; KOSTY MP, 1994, J CLIN ONCOL, V12, P1113, DOI 10.1200/JCO.1994.12.6.1113; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P1126, DOI 10.1200/JCO.1994.12.6.1126; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P1121, DOI 10.1200/JCO.1994.12.6.1121; MICHELOT D, 1989, J TOXICOL CLIN EXPER, V9, P83; SOTANIEMI E, 1971, ANN CLIN RES, V3, P30; *SYR CANC RES I, 2000, HYDR SULF GEN INF; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; Wheeler BM, 1998, J NATL CANCER I, V90, P628, DOI 10.1093/jnci/90.8.628; WOO J, 1992, J MED, V23, P51	19	46	47	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					877	880		10.7326/0003-4819-133-11-200012050-00011	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103057				2023-01-03	WOS:000165585800006
J	Fainsinger, RL				Fainsinger, RL			A century of progress in palliative care	LANCET			English	Article									Royal Alexandra Hosp, Palliat Cre Program, Edmonton, AB T5H 3V9, Canada	Royal Alexandra Hospital	Fainsinger, RL (corresponding author), Royal Alexandra Hosp, Palliat Cre Program, Edmonton, AB T5H 3V9, Canada.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S24	S24		10.1016/S0140-6736(00)92010-5	http://dx.doi.org/10.1016/S0140-6736(00)92010-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191480				2023-01-03	WOS:000166074900026
J	Brill-Edwards, P; Ginsberg, JS; Gent, M; Hirsh, J; Burrows, R; Kearon, C; Geerts, W; Kovacs, M; Weitz, JI; Robinson, KS; Whittom, R; Couture, G				Brill-Edwards, P; Ginsberg, JS; Gent, M; Hirsh, J; Burrows, R; Kearon, C; Geerts, W; Kovacs, M; Weitz, JI; Robinson, KS; Whittom, R; Couture, G		Recurrence Clot Pregnancy Study Gr	Safety of withholding heparin in pregnant women with a history of venous thromboembolism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULANT-THERAPY; PROTEIN-C; RECURRENT THROMBOEMBOLISM; PULMONARY-EMBOLISM; MATERNAL MORTALITY; ASSAY; THROMBOPROPHYLAXIS; PROPHYLAXIS; PUERPERIUM	Background: Women with a history of venous thromboembolism may be at increased risk for venous thromboembolic events during pregnancy. In these women, the decision to give or withhold heparin in the antepartum period is controversial, because accurate estimates of the frequency of recurrent thromboembolic events if antepartum heparin is withheld are not available. Methods: We prospectively studied 125 pregnant women with a single previous episode of venous thromboembolism. Antepartum heparin was withheld, but anticoagulant therapy was given for four to six weeks post partum. Our primary objective was to determine the rate of antepartum recurrence of venous thromboembolism. Laboratory studies were performed to identify thrombophilia in 95 women. Results: Three of the 125 women (2.4 percent) had an antepartum recurrence of venous thromboembolism (95 percent confidence interval, 0.2 to 6.9 percent). There were no recurrences in the 44 women who had no evidence of thrombophilia and who also had a previous episode of thrombosis that was associated with a temporary risk factor. Among the 51 women with abnormal laboratory results or a previous episode of idiopathic thrombosis, or both, 3 (5.9 percent) had an antepartum recurrence of venous thromboembolism (95 percent confidence interval, 1.2 to 16.2 percent). Conclusions: The risk of recurrent antepartum venous thromboembolism in women with a history of venous thromboembolism is low, and therefore routine antepartum prophylaxis with heparin is not warranted. (N Engl J Med 2000;343:1439-44.) (C) 2000, Massachusetts Medical Society.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; Monash Med Ctr, Clayton, Vic 3168, Australia; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; London Hlth Sci Ctr, London, ON, Canada; Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; Univ Quebec St Francois dAssise, Ctr Hosp, Quebec City, PQ, Canada	McMaster University; Monash University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Universite de Montreal; Laval University; University of Quebec	Ginsberg, JS (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,HSC-3X28, Hamilton, ON L8N 3Z5, Canada.		ginsberg, jeffrey s/ABC-1065-2020; Kovacs, Michael/G-3315-2011; Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; ANDERSSON NE, 1991, THROMB HAEMOSTASIS, V65, P912; BADARACC.MA, 1974, BRIT MED J, V1, P215, DOI 10.1136/bmj.1.5901.215; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; COLVIN BT, 1993, J CLIN PATHOL, V46, P97, DOI 10.1136/jcp.46.2.97; DAHLMAN T, 1990, BRIT J OBSTET GYNAEC, V97, P221, DOI 10.1111/j.1471-0528.1990.tb01785.x; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DESWIET M, 1987, BRIT J HOSP MED, V38, P264; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; FAUGHT W, 1995, AM J OBSTET GYNECOL, V172, P147, DOI 10.1016/0002-9378(95)90104-3; Ginsberg JS, 1998, CHEST, V114, p524S, DOI 10.1378/chest.114.5_Supplement.524S; HOWELL R, 1983, BRIT J OBSTET GYNAEC, V90, P1124, DOI 10.1111/j.1471-0528.1983.tb06458.x; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; LAO TT, 1985, BRIT J OBSTET GYNAEC, V92, P202, DOI 10.1111/j.1471-0528.1985.tb01082.x; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; MATERNAL A, 1993, J CLIN PATHOL, V46, P489; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; TENGBORN L, 1989, AM J OBSTET GYNECOL, V160, P90, DOI 10.1016/0002-9378(89)90095-1; THIAGARAJAN P, 1986, BLOOD, V68, P869; TRIPLETT DA, 1993, THROMB HAEMOSTASIS, V70, P787; WARWICK R, 1989, J ROY SOC MED, V82, P591, DOI 10.1177/014107688908201008	30	303	311	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1439	1444		10.1056/NEJM200011163432002	http://dx.doi.org/10.1056/NEJM200011163432002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078768				2023-01-03	WOS:000165271300002
J	Ernst, E				Ernst, E			The role of complementary and alternative medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Millennium Festival of Medicine Conference	NOV 06-10, 2000	LONDON, ENGLAND				METAANALYSIS; THERAPY		Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.	E.Ernst@ex.ac.uk						Astin JA, 2000, ANN INTERN MED, V132, P903, DOI 10.7326/0003-4819-132-11-200006060-00009; Bronfort G, 1999, NEUROL CLIN, V17, P91, DOI 10.1016/S0733-8619(05)70116-X; Cooke B, 2000, BRIT J GEN PRACT, V50, P493; Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1; Ernst E, 2000, BRIT MED J, V321, P707; Ernst E, 1997, CIRCULATION, V96, P1031; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; ERNST E, 1995, BRIT J GEN PRACT, V45, P506; Ernst E, 1999, ANN INTERN MED, V131, P230, DOI 10.7326/0003-4819-131-3-199908030-00021; Ernst E, 2000, ARCH OPHTHALMOL-CHIC, V118, P120; Ernst E, 1999, Complement Ther Med, V7, P250, DOI 10.1016/S0965-2299(99)80011-9; ERNST E, IN PRESS COMPLEMENTA; ERNST E, 1997, EUR J GEN PRACT, V3, P52; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; LINDE K, 1997, COCHRANE LIB; LINDE K, 2000, COCHRANE LIB; Pittler MH, 2000, AM J MED, V108, P276, DOI 10.1016/S0002-9343(99)00454-4; Vickers A, 2000, BRIT J GEN PRACT, V50, P444; Vickers A, 1997, INT J TECHNOL ASSESS, V13, P111, DOI 10.1017/S0266462300010278; White AR, 2000, COMPLEMENT THER MED, V8, P111, DOI 10.1054/ctim.2000.0356; WHITE AR, 1997, COMPLEMENT THER MED, V5, P210; Williams JW, 2000, ANN INTERN MED, V132, P743, DOI 10.7326/0003-4819-132-9-200005020-00011	24	152	156	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	2000	321	7269					1133	1135		10.1136/bmj.321.7269.1133	http://dx.doi.org/10.1136/bmj.321.7269.1133			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	372DT	11061738	Green Published			2023-01-03	WOS:000165219600029
J	Eisenberg, MS				Eisenberg, MS			Is it time for over-the-counter defibrillators?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATIC EXTERNAL DEFIBRILLATOR; HOSPITAL CARDIAC-ARREST; VENTRICULAR-FIBRILLATION; SURVIVAL; CPR; RESUSCITATION; PROFESSIONALS; INSTRUCTION; COMMUNITY		Univ Washington, Med Ctr, Dept Med, Div Emergency Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eisenberg, MS (corresponding author), Univ Washington, Med Ctr, Dept Med, Div Emergency Med, Box 356123, Seattle, WA 98195 USA.							Atkins DL, 1998, PEDIATRICS, V101, P393, DOI 10.1542/peds.101.3.393; BANDINI F, 1997, G ITAL CARDIOL, V11, P1121; Becker L, 1999, Prehosp Emerg Care, V3, P353, DOI 10.1080/10903129908958968; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Braslow A, 1997, RESUSCITATION, V34, P207, DOI 10.1016/S0300-9572(97)01096-4; CHADDA KD, 1987, AM J CARDIOL, V60, P732, DOI 10.1016/0002-9149(87)90396-1; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG M, 1995, ANN EMERG MED, V25, P198, DOI 10.1016/S0196-0644(95)70324-1; EISENBERG MS, 1989, AM J CARDIOL, V63, P443, DOI 10.1016/0002-9149(89)90316-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Stolberg S G, 2000, N Y Times Web, pA15; Todd KH, 1998, ANN EMERG MED, V31, P364, DOI 10.1016/S0196-0644(98)70348-8; WEAVER WD, 1990, PROGR CLIN PACING 19, P47; WEINSTEIN MC, 1995, VALUING HLTH CARE CO, P77, DOI DOI 10.1017/CBO9780511625817.005; 2000, EM TODAY        0614, P1	22	21	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1435	1438		10.1001/jama.284.11.1435	http://dx.doi.org/10.1001/jama.284.11.1435			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989409				2023-01-03	WOS:000089242500041
J	Mangrum, JM; DiMarco, JP				Mangrum, JM; DiMarco, JP			Primary care: The evaluation and management of bradycardia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SICK-SINUS SYNDROME; 24-HOUR AMBULATORY ELECTROCARDIOGRAPHY; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; HEART-RATE; ATRIAL-FIBRILLATION; OPERATIONAL DEFINITION; ACC/AHA GUIDELINES; PACEMAKER THERAPY; SLEEP-APNEA		Univ Virginia Hlth Syst, Dept Med, Div Cardiovasc, Cardiac Electrophysiol Lab, Charlottesville, VA 22908 USA	University of Virginia	DiMarco, JP (corresponding author), Univ Virginia Hlth Syst, Dept Med, Div Cardiovasc, Cardiac Electrophysiol Lab, Box 158, Charlottesville, VA 22908 USA.							ABBOTT JA, 1977, AM J MED, V62, P330, DOI 10.1016/0002-9343(77)90829-4; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Benditt DG, 1996, J AM COLL CARDIOL, V28, P263, DOI 10.1016/0735-1097(96)00236-7; Benditt DG, 1997, PACE, V20, P832, DOI 10.1111/j.1540-8159.1997.tb03916.x; Bergfeldt L, 1996, J CARDIOVASC ELECTR, V7, P95, DOI 10.1111/j.1540-8167.1996.tb00504.x; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BOUMAN LN, 1986, EUR HEART J, V7, P94, DOI 10.1093/oxfordjournals.eurheartj.a062047; BRODSKY M, 1977, AM J CARDIOL, V39, P390, DOI 10.1016/S0002-9149(77)80094-5; CLARKE M, 1991, BRIT HEART J, V66, P185; CORBELLI R, 1990, PACE, V13, P179, DOI 10.1111/j.1540-8159.1990.tb05068.x; Crawford MH, 1999, J AM COLL CARDIOL, V34, P912, DOI 10.1016/S0735-1097(99)00354-X; DEMOULIN JC, 1978, BRIT HEART J, V40, P1384; DICKINSON DF, 1984, BRIT HEART J, V51, P179; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; EVANS R, 1977, BRIT HEART J, V39, P778; Farshi R, 1999, J AM COLL CARDIOL, V33, P304, DOI 10.1016/S0735-1097(98)00561-0; FERRER MI, 1968, J AMER MED ASSOC, V206, P645, DOI 10.1001/jama.206.3.645; FLEG JL, 1982, CHEST, V81, P302, DOI 10.1378/chest.81.3.302; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; GUILLEMINAULT C, 1983, AM J CARDIOL, V52, P490, DOI 10.1016/0002-9149(83)90013-9; HANNEPAPARO N, 1976, CARDIOLOGY, V61, P267, DOI 10.1159/000169770; HOLDEN W, 1978, BRIT HEART J, V40, P923; JOSE AD, 1970, CARDIOVASC RES, V4, P160, DOI 10.1093/cvr/4.2.160; KANTELIP JP, 1986, AM J CARDIOL, V57, P398, DOI 10.1016/0002-9149(86)90760-5; Krahn AD, 1999, CIRCULATION, V99, P406, DOI 10.1161/01.CIR.99.3.406; LEV M, 1954, J GERONTOL, V9, P1; NORTHCOTE RJ, 1989, BRIT HEART J, V61, P155; PITCHER D, 1986, BRIT MED J, V292, P594, DOI 10.1136/bmj.292.6520.594; POLLAK A, 1993, AM HEART J, V125, P824, DOI 10.1016/0002-8703(93)90177-B; RASMUSSEN K, 1981, EUR HEART J, V2, P455, DOI 10.1093/oxfordjournals.eurheartj.a061236; RUBENSTEIN JJ, 1972, CIRCULATION, V46, P5, DOI 10.1161/01.CIR.46.1.5; SCHEINMAN MM, 1982, AM J CARDIOL, V50, P1316, DOI 10.1016/0002-9149(82)90469-6; SCHEINMAN MM, 1979, J ELECTROCARDIOL, V12, P211, DOI 10.1016/S0022-0736(79)80031-X; SCOTT O, 1980, BRIT HEART J, V44, P304; SHAW DB, 1987, BRIT HEART J, V58, P598; SOUTHALL DP, 1981, BRIT HEART J, V45, P281; SPODICK DH, 1992, AM J CARDIOL, V69, P1245, DOI 10.1016/0002-9149(92)90947-W; SPODICK DH, 1993, AM J CARDIOL, V72, P487, DOI 10.1016/0002-9149(93)91153-9; Spodick DH, 1996, SOUTHERN MED J, V89, P666, DOI 10.1097/00007611-199607000-00003; Stegman SS, 1996, PACE, V19, P899, DOI 10.1111/j.1540-8159.1996.tb03385.x; VIITASALO MT, 1982, BRIT HEART J, V47, P213; WIENS RD, 1984, AM J CARDIOL, V54, P74, DOI 10.1016/0002-9149(84)90306-0; Zimetbaum PJ, 1999, ANN INTERN MED, V130, P848, DOI 10.7326/0003-4819-130-10-199905180-00020; ZIPES DP, 1995, CIRCULATION, V92, P673	46	159	167	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2000	342	10					703	709		10.1056/NEJM200003093421006	http://dx.doi.org/10.1056/NEJM200003093421006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ZW	10706901				2023-01-03	WOS:000085708800006
J	Katzan, IL; Furlan, AJ; Lloyd, LE; Frank, JI; Harper, DL; Hinchey, JA; Hammel, JP; Qu, A; Sila, CA				Katzan, IL; Furlan, AJ; Lloyd, LE; Frank, JI; Harper, DL; Hinchey, JA; Hammel, JP; Qu, A; Sila, CA			Use of tissue-type plasminogen activator for acute ischemic stroke - The Cleveland area experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COOPERATIVE ACUTE STROKE; FIRST-LINE TREATMENT; THROMBOLYTIC THERAPY; INTRAVENOUS THROMBOLYSIS; T-PA; QUALITY; MORTALITY; ICD-9-CM; CARE	Context Little is known regarding outcomes after intravenous tissue-type plasminogen activator (IV tPA) therapy for acute ischemic stroke outside a trial setting. Objective To assess the rate of IV tPA use, the incidence of symptomatic intracerebral hemorrhage (ICH), and in-hospital patient outcomes throughout a large urban community. Design Historical prospective cohort study conducted from July 1997 through June 1998. Setting Twenty-nine hospitals in the Cleveland, Ohio, metropolitan area. Patients A total of 3948 patients admitted to a study hospital with a primary diagnosis of ischemic stroke (International Classification of Diseases, Ninth Revision, Clinical Modification code 434 or 436). Main Outcome Measures Rate of IV tPA use and occurrence of symptomatic ICH among patients treated with tPA; proportion of patients receiving tPA whose treatment deviated from national guidelines; in-hospital mortality among patients receiving tPA compared with that among ischemic stroke patients not receiving tPA and with mortality predicted by a model. Results Seventy patients (1.8%) admitted with ischemic stroke received IV tPA. Of those, 11 patients (15.7%; 95% confidence interval [CI], 8.1%-26.4%) had a symptomatic ICH (of which 6 were fatal) and 50% (95% CI, 37.8%-62.2%) had deviations from national treatment guidelines. In-hospital mortality was significantly higher among patients treated with tPA (15.7%) compared with patients not receiving tPA (5.1%, P<.001) and compared with the model's prediction (7.9%; P<.006). Conclusions A small proportion of patients admitted with acute ischemic stroke in Cleveland received tPA; they experienced a high rate of ICH. Cleveland community experience with tPA for acute ischemic stroke may differ from that reported in clinical trials.	Cleveland Clin Fdn, Cerebrovasc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Qual Informat Management Corp, Cleveland, OH USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Rochester, Dept Neurol, Rochester, NY USA; Oregon State Univ, Dept Stat, Corvallis, OR 97331 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Chicago; University of Chicago; University of Rochester; Oregon State University	Katzan, IL (corresponding author), Cleveland Clin Fdn, Cerebrovasc Ctr, S91,9500 Euclid Ave, Cleveland, OH 44195 USA.							*ACEP, 1996, ACEP NEWS, P15; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; Adams HP, 1996, NEUROLOGY, V47, P835; ALBERS WA, 1999, 51 ANN M AM AC NEUR; Benesch C, 1997, NEUROLOGY, V49, P660, DOI 10.1212/WNL.49.3.660; Brott T, 1996, ARCH NEUROL-CHICAGO, V53, P1305, DOI 10.1001/archneur.1996.00550120117025; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; CUMMINS RO, 1997, ADV CARDIAC LIFE SUP, P1; Demchuk AM, 1999, STROKE, V30, P34, DOI 10.1161/01.STR.30.1.34; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Goldstein LB, 1998, STROKE, V29, P1602, DOI 10.1161/01.STR.29.8.1602; Grond M, 1998, STROKE, V29, P1544, DOI 10.1161/01.STR.29.8.1544; Grotta J, 1997, NEW ENGL J MED, V337, P1310; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANSON SK, 1998, 50 ANN M AM AC NEUR; Hinchey JA, 1998, NEUROLOGY, V50, P619, DOI 10.1212/WNL.50.3.619; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; KARBALAI H, 1999, 24 AM HEART ASS INT; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; Lopez-Yunez AM, 1999, STROKE, V30, P264, DOI 10.1161/01.STR.30.11.2495; MANLY BF, 1998, RANDOMIZATION BOOTST, pCH3; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARLER JR, 1997, NIH PUBLICATION; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; Scott PA, 1999, STROKE, V30, P244; Tanne D, 1999, NEUROLOGY, V53, P424, DOI 10.1212/WNL.53.2.424; Tanne D, 1999, STROKE, V30, P248; Tilley BC, 1997, ARCH NEUROL-CHICAGO, V54, P1466, DOI 10.1001/archneur.1997.00550240020008; Zweifler RM, 1998, NEUROLOGY, V50, P501, DOI 10.1212/WNL.50.2.501	34	479	493	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1151	1158		10.1001/jama.283.9.1151	http://dx.doi.org/10.1001/jama.283.9.1151			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703777	Bronze			2023-01-03	WOS:000085424100024
J	Sandin, RH; Enlund, G; Samuelsson, P; Lennmarken, C				Sandin, RH; Enlund, G; Samuelsson, P; Lennmarken, C			Awareness during anaesthesia: a prospective case study	LANCET			English	Article							GENERAL-ANESTHESIA; RECALL; PROPOFOL	Background Patients who are given general anaesthesia are not guaranteed to remain unconscious during surgery. Knowledge about the effectiveness of current protective measures is scarce, as is our understanding of patients' responses to this complication. We did a prospective case study to assess conscious awareness during anaesthesia. Methods 11 785 patients who had undergone general anaesthesia were interviewed for awareness on three occasions: before they left the post-anaesthesia care unit, and 1-3 days and 7-14 days after the operation. Findings We identified 18 cases of awareness and one case of inadvertent muscle blockade that had occurred before unconsciousness. Incidence of awareness was 0.18% in cases in which neuromuscular blocking drugs were used, and 0.10% in the absence of such drugs. 17 cases of awareness were identified at the final interview, but no more than 11 would have been detected if an interview had been done only when the patients left the post-anaesthesia care unit. Four non-paralysed patients recalled intraoperative events, but none had anxiety during wakefulness or had delayed neurotic symptoms. This finding contrasts with anaesthesia with muscle relaxants, during which 11 of 14 patients had pain, anxiety, or delayed neurotic symptoms, After repeated discussion and information, the delayed neurotic symptoms resolved within 3 weeks in all patients. Analysis of individual cases suggests that a reduced incidence of recall of intraoperative events would not be achieved by monitoring of end-tidal anaesthetic gas concentration or by more frequent use of benzodiazepines. Interpretation The inability to prevent awareness by conventional measures may advocate monitoring of cerebral activity by neurophysiological techniques. However, the sensitivity of such techniques is not known, and in the light of our findings, at least 861 patients would need to be monitored to avoid one patient from suffering due to awareness during relaxant anaesthesia.	Lanssjukhuset, Dept Anaesthesia & Intens Care, S-39185 Kalmar, Sweden; Vrinnevisjukhuset, Dept Anaesthesia & Intens Care, Norrkoping, Sweden		Sandin, RH (corresponding author), Lanssjukhuset, Dept Anaesthesia & Intens Care, S-39185 Kalmar, Sweden.	rolfs@ltkalmar.se	garcia, waynice np/K-3914-2015					BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; Klafta JM, 1996, ANESTH ANALG, V83, P1314, DOI 10.1097/00000539-199612000-00031; LIU WHD, 1991, ANAESTHESIA, V46, P435, DOI 10.1111/j.1365-2044.1991.tb11677.x; Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383; Nordstrom O, 1996, BRIT J ANAESTH, V76, P699, DOI 10.1093/bja/76.5.699; Nordstrom O, 1997, ACTA ANAESTH SCAND, V41, P978, DOI 10.1111/j.1399-6576.1997.tb04823.x; Pomfrett CJD, 1999, BRIT J ANAESTH, V82, P659, DOI 10.1093/bja/82.5.659; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Ranta SOV, 1998, ANESTH ANALG, V86, P1084, DOI 10.1097/00000539-199805000-00035	9	418	450	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	2000	355	9205					707	711		10.1016/S0140-6736(99)11010-9	http://dx.doi.org/10.1016/S0140-6736(99)11010-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703802				2023-01-03	WOS:000085615600012
J	Paul, C				Paul, C			Internal and external morality of medicine: lessons from New Zealand	BRITISH MEDICAL JOURNAL			English	Article								The stories we tell about failures of good medical practice, such as about the Bristol case and the New Zealand cervical cancer study, can restrict our thinking about solutions In New Zealand, the stories told in the report of the judicial inquiry and by women's health advocacy groups were shaped by a concentration on external morality-the view from the outside, reflecting the ethos of the wider society and of bioethics Internal morality-those values, norms, and rules that are intrinsic to the practice of medicine-was ignored or even denigrated; external controls were proposed as solutions The story that best fits the facts is that it was doctors acting in accord with their traditional obligations who brought the problem to light and limited the harm to patients We conclude that external controls are blunt instruments for finding the solutions ill particular cases and require a functioning internal morality to interpret them.	Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago	Paul, C (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.							Cartwright Silvia, 1988, REPORT COMMITTEE ENQ; DELMONTHE T, 1998, BRIT MED J, V316, P1757	2	30	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					499	502		10.1136/bmj.320.7233.499	http://dx.doi.org/10.1136/bmj.320.7233.499			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	288KP	10678869	Green Published			2023-01-03	WOS:000085562200031
J	Checkley, W; Epstein, LD; Gilman, RH; Figueroa, D; Cama, RI; Patz, JA; Black, RE				Checkley, W; Epstein, LD; Gilman, RH; Figueroa, D; Cama, RI; Patz, JA; Black, RE			Effects of El Nino and ambient temperature on hospital admissions for diarrhoeal diseases in Peruvian children	LANCET			English	Article							SOUTHERN OSCILLATION; RURAL BANGLADESH; INFECTION; CLIMATE; GROWTH	Introduction To investigate whether the El Nino phenomenon and ambient temperature had an effect on the epidemiology of childhood diarrhoea, we analysed data on daily number of admissions of children with diarrhoea to the Oral Rehydration Unit of the Institute de Salud del Nino in Lima, Peru, between January, 1993, and November, 1998. Methods We obtained daily data on hospital admissions from the Oral Rehydration Unit, and meteororological data from the Peruvian Weather Service, and used time-series linear regression models to assess the effects of the 1997-98 El Nino event on admissions for diarrhoea. Findings 57 331 children under 10 years old were admitted to the unit during the study. During the 1997-98 El Nino episode, mean ambient temperature in Lima increased up to 5 degrees C above normal, and the number of daily admissions for diarrhoea increased to 200% of the previous rate. 6225 excess admissions were attributable to El Nino, and these cost US$277 000. During the period before the El Nino episode, admissions for diarrhoea increased by 8% per 1 degrees C increase in mean ambient temperature. The effects of El Nino and ambient temperature on the number of admissions for diarrhoea were greatest during the winter months. Interpretation El Nino had an effect on hospital admissions greater than that explained by the regular seasonal variability in ambient temperature. The excess increase in ambient temperature was the main environmental variable affecting admissions. If our findings are reproducible in other regions, diarrhoeal diseases may increase by millions of cases worldwide with each degree of increase in ambient temperature above normal.	Johns Hopkins Univ, Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Proyectos Informat Salud Med & Agr, Lima, Peru; Catholic Univ Chile, Dept Estadist, Santiago, Chile; Inst Natl Salud Nino, Unidad Rehidratac Oral, Lima, Peru	Johns Hopkins University; Johns Hopkins University; Pontificia Universidad Catolica de Chile	Gilman, RH (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Room W3503, Baltimore, MD 21205 USA.			Black, Robert/0000-0001-9926-7984; Checkley, William/0000-0003-1106-8812	NICHD NIH HHS [F31-HD08488] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F31HD008488] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armitage P, 1996, STAT METHODS MED RES; Bell GD, 1998, B AM METEOROL SOC, V79, pS1, DOI 10.1175/1520-0477-79.5s.S1; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; Black Robert E., 1995, P13; Bouma MJ, 1997, JAMA-J AM MED ASSOC, V278, P1772, DOI 10.1001/jama.278.21.1772; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; Cama RI, 1999, J INFECT DIS, V179, P1139, DOI 10.1086/314701; Checkley W, 1998, AM J EPIDEMIOL, V148, P497, DOI 10.1093/oxfordjournals.aje.a009675; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Diggle P. J., 1995, TIME SERIES BIOSTATI; GILLES HM, 1993, BRUCECHWATTS ESSENTI; GUERRANT RL, 1983, J INFECT DIS, V148, P986, DOI 10.1093/infdis/148.6.986; GUERRANT RL, 1996, EDGE DEV HLTH CRISIS, P91; Hales S, 1999, ENVIRON HEALTH PERSP, V107, P99, DOI 10.2307/3434364; HALES S, 1996, LANCET, V348, P1665; KONNO T, 1983, J INFECT DIS, V147, P125, DOI 10.1093/infdis/147.1.125; Madico G, 1996, J CLIN MICROBIOL, V34, P2968, DOI 10.1128/JCM.34.12.2968-2972.1996; Madico G, 1997, CLIN INFECT DIS, V24, P977, DOI 10.1093/clinids/24.5.977; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; *PAN HLTH ORG, 1994, HLTH COND AM SCI PUB, V549; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; Rice JA, 1988, MATH STAT DATA ANAL; SalazarLindo E, 1997, LANCET, V350, P1597, DOI 10.1016/S0140-6736(05)64013-5; Tibshirani R., 1995, GEN ADDITIVE MODELS; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; *WHO, 1996, CLI CHANG HUM HLTH; World Health Organization, 1995, 854 WHO	29	303	315	3	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2000	355	9202					442	450						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZW	10841124				2023-01-03	WOS:000085306800010
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 44-year-old woman with severe pain at the end of life, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Parker RA, 1999, JAMA-J AM MED ASSOC, V281, P1937, DOI 10.1001/jama.281.20.1937	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2354	2354		10.1001/jama.282.24.2354	http://dx.doi.org/10.1001/jama.282.24.2354			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612324				2023-01-03	WOS:000084261700030
J	Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A				Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A			Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Aldemoor Hlth Ctr, Acad Dept Primary Med Care, Southampton SO9 5NH, Hants, England; Univ Southampton, Southampton Gen Hosp, Dept Med Stat, Southampton SO9 5NH, Hants, England; Queen Alexandra Hosp, Postgrad Med Sch, Portsmouth PO6 3LY, Hants, England; Sch Nursing, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	George, S (corresponding author), Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	pluto@soton.ac.uk	Moore, Michael/C-3447-2011; Smith, Helen E/M-2449-2016	Moore, Michael/0000-0002-5127-4509; Smith, Helen E/0000-0003-1883-6124; Turnbull, Joanne/0000-0002-5006-4438				Brogan C, 1998, BRIT MED J, V316, P524, DOI 10.1136/bmj.316.7130.524; *COLL HLTH, 1998, DEV NHS DIR; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054	4	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1408	1408		10.1136/bmj.319.7222.1408	http://dx.doi.org/10.1136/bmj.319.7222.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574857	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000083995200028
J	Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK				Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK			The mechanism of membrane insertion for a cholesterol-dependent cytolysin: A novel paradigm for pore-forming toxins	CELL			English	Article							PERFRINGOLYSIN-O; PROTECTIVE ANTIGEN; THETA-TOXIN; BINDING; IDENTIFICATION; HEMOLYSIN; BILAYERS; DOMAIN	Perfringolysin O (PFO), a water-soluble monomeric cytolysin secreted by pathogenic Clostridium perfringens, oligomerizes and forms large pores upon encountering cholesterol-containing membranes. Whereas all pore-forming bacterial toxins examined previously have been shown to penetrate the membrane using a single amphipathic beta hairpin per polypeptide, cysteine-scanning mutagenesis and multiple independent fluorescence techniques here reveal that each PFO monomer contains a second domain involved in pore formation, and that each of the two amphipathic a hairpins completely spans the membrane. In the soluble monomer, these transmembrane segments are folded into six alpha helices. The insertion of two transmembrane hairpins per toxin monomer and the major change in secondary structure are striking and define a novel paradigm far the mechanism of membrane insertion by a cytolytic toxin.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Vincents Inst Med Res, Ian Potter Fdn, Prot Crystallog Lab, Fitzroy, Vic 3065, Australia	Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St. Vincent's Institute of Medical Research	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Johnson, Arthur E/G-3457-2012; Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138	NIAID NIH HHS [AI37657, R01 AI037657] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207	16	288	292	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					293	299		10.1016/S0092-8674(00)81660-8	http://dx.doi.org/10.1016/S0092-8674(00)81660-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555145	Bronze			2023-01-03	WOS:000083440600007
J	Psaty, BM; Smith, NL; Lemaitre, RN; Vos, HL; Heckbert, SR; LaCroix, AZ; Rosendaal, FR				Psaty, BM; Smith, NL; Lemaitre, RN; Vos, HL; Heckbert, SR; LaCroix, AZ; Rosendaal, FR			Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTOR-V-LEIDEN; CORONARY HEART-DISEASE; ACTIVATED PROTEIN-C; GENE-ENVIRONMENT INTERACTION; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; 3'-UNTRANSLATED REGION; VASCULAR-DISEASE; YOUNG-WOMEN; FACTOR-II	Context Estrogens are known to be prothrombotic, and findings from the Heart and Estrogen/progestin Replacement Study suggest that in women with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with early harm and late benefit in terms of coronary events. Objective To assess whether, as hypothesized, prothrombotic mutations modify the association between HRT use and incidence of first myocardial infarction (MI). Design and Setting Population-based, case-control study conducted in a Seattle-based health maintenance organization. Participants Cases were 232 postmenopausal women aged 30 to 79 years who had their first nonfatal MI between 1995 and 1998. Controls were a stratified random sample of 723 postmenopausal women without MI who were frequency-matched to cases by age. calendar year, and hypertension status. Main Outcome Measure Risk of first nonfatal MI based on current use of HRT and the presence or absence of coagulation factor V Leiden and prothrombin 20210 G-->A variants among cases and controls, stratified by hypertension. Results One hundred eight MI cases and 387 controls had hypertension and 124 MI cases and 336 controls did not. Among hypertensive women, the prothrombin variant was a risk factor for MI (odds ratio [OR], 4.32; 95% confidence interval [CI], 1.52-12.1) and, in this stratum, there was also a significant interaction between use of HRT and presence of the prothrombin variant on risk of Mi. Compared with nonusers of HRT with wild-type genotype, women who were current users and who had the prothrombin variant (n=8) had a nearly Ii-fold increase in risk of a nonfatal MI (OR, 10.9; 95% CI, 2.15-55.2). The interaction with the prothrombin variant was more pronounced in analyses assuming 100% compliance than in those assuming 80% compliance with HRT, The interaction was absent among nonhypertensive women and was less pronounced if hypertensive and nonhypertensive women were combined into 1 group. No interaction was found for factor V Leiden in either hypertensive or nonhypertensive women. Among hypertensive women, the estimates were affected only in trivial ways by adjustment, and the interaction with the prothrombin variant was specific to HRT. Conclusions Our results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without. the prothrombin 20210 G-->A variant. If these findings are confirmed in other studies. screening for the prothrombin variant may permit a better assessment of the risks and benefits associated with HRT in postmenopausal women.	Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA; Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Group Health Cooperative; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060739, R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43201, HL60739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1970, JAMA, V214, P1303; Arruda VR, 1998, CARDIOVASC RES, V37, P42, DOI 10.1016/S0008-6363(97)00211-3; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BARRETTCONNOR E, 1998, ANNU REV PUBL HEALTH, V19, P35; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Cushman M, 1998, THROMB HAEMOSTASIS, V79, P912; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Doggen CJM, 1998, CIRCULATION, V97, P1037, DOI 10.1161/01.CIR.97.11.1037; Franco RF, 1999, BRIT J HAEMATOL, V104, P50, DOI 10.1046/j.1365-2141.1999.01149.x; Gardemann A, 1999, THROMB HAEMOSTASIS, V81, P208; Glueck CJ, 1999, AM J CARDIOL, V84, P549, DOI 10.1016/S0002-9149(99)00375-6; GRADY D, 1992, ANN INTERN MED, V117, P1038; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Lip GYH, 2000, HYPERTENSION, V36, P975, DOI 10.1161/01.HYP.36.6.975; Lowe G, 2000, THROMB HAEMOSTASIS, V83, P530; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; PEARCE N, 1993, INT J EPIDEMIOL, V22, P1189, DOI 10.1093/ije/22.6.1189; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; PSATY BM, 1993, ARCH INTERN MED, V153, P1421, DOI 10.1001/archinte.153.12.1421; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1991, STAT MED, V10, P653, DOI 10.1002/sim.4780100416; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; Redondo M, 1999, ARTERIOSCL THROM VAS, V19, P1020, DOI 10.1161/01.ATV.19.4.1020; Ridker PM, 1999, CIRCULATION, V99, P999, DOI 10.1161/01.CIR.99.8.999; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Sechi LA, 2000, HYPERTENSION, V36, P978, DOI 10.1161/01.HYP.36.6.978; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; SOTANIEMI EA, 1975, SCAND J UROL NEPHROL, V9, P89, DOI 10.3109/00365597509180912; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	43	123	127	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					906	913		10.1001/jama.285.7.906	http://dx.doi.org/10.1001/jama.285.7.906			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402BE	11180734	Bronze			2023-01-03	WOS:000166965500028
J	Schwetz, BA				Schwetz, BA			New treatment for eczema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2023-01-03	WOS:000166817200005
J	Dove, A				Dove, A			Betting on biogenerics	NATURE BIOTECHNOLOGY			English	Article								With patents on several blockbuster therapeutic proteins soon to expire and several companies pondering whether to manufacture their own versions of these medicines, can a commercially viable business be based on biogenerics?.											0	15	17	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2001	19	2					117	120		10.1038/84365	http://dx.doi.org/10.1038/84365			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	398KB	11175723				2023-01-03	WOS:000166754700015
J	Lee, NLS; Yuen, KY; Kumana, CR				Lee, NLS; Yuen, KY; Kumana, CR			beta-lactam antibiotic and beta-lactamase inhibitor combinations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHARMACOKINETIC PROPERTIES; PIPERACILLIN-TAZOBACTAM; ANTIBACTERIAL ACTIVITY; AMPICILLIN-SULBACTAM; IN-VITRO; ENDOCARDITIS; PNEUMONIAE; EFFICACY		Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Kumana, CR (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Professorial Block 4-F,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Lee, Nelson/B-6418-2008; Yuen, Kwok Yung/C-4465-2009	Lee, Nelson/0000-0002-0783-6607; Yuen, Kwok-yung/0000-0002-2083-1552				AKYUREK N, 1997, BRIT J SURG, V84, P880; Backo M, 1999, ANTIMICROB AGENTS CH, V43, P2565, DOI 10.1128/AAC.43.10.2565; Bradley SJ, 1999, J ANTIMICROB CHEMOTH, V43, P261, DOI 10.1093/jac/43.2.261; Brun-Buisson C, 1998, CLIN INFECT DIS, V26, P346, DOI 10.1086/516294; Chaibi EB, 1999, J ANTIMICROB CHEMOTH, V43, P447, DOI 10.1093/jac/43.4.447; Corbella X, 1998, J ANTIMICROB CHEMOTH, V42, P793, DOI 10.1093/jac/42.6.793; Craig WA, 1997, DIAGN MICR INFEC DIS, V27, P49, DOI 10.1016/S0732-8893(97)00022-9; DAVEY PG, 1994, EUR J SURG S, V573, P67; de la Pena A, 1999, INT J CLIN PHARM TH, V37, P63; Goldstein FW, 1999, J ANTIMICROB CHEMOTH, V44, P141, DOI 10.1093/jac/44.2.141; Gould IM, 1999, J ANTIMICROB CHEMOTH, V43, P459, DOI 10.1093/jac/43.4.459; Jaccard C, 1998, ANTIMICROB AGENTS CH, V42, P2966, DOI 10.1128/AAC.42.11.2966; Kaye KS, 2000, ANTIMICROB AGENTS CH, V44, P1004, DOI 10.1128/AAC.44.4.1004-1009.2000; Lister PD, 1999, ANTIMICROB AGENTS CH, V43, P882, DOI 10.1128/AAC.43.4.882; Munoz P, 1996, INT J ANTIMICROB AG, V7, pS9, DOI 10.1016/0924-8579(96)00313-5; PARFITT K, 1999, MARTINDALE COMPLETE; PEFANIS A, 1993, ANTIMICROB AGENTS CH, V37, P507, DOI 10.1128/AAC.37.3.507; Pitts N E, 1989, APMIS Suppl, V5, P23; Prabhakaran K, 1999, INT J ANTIMICROB AG, V13, P133, DOI 10.1016/S0924-8579(99)00101-6; Quenzer RW, 1997, AM J MANAG C, V3, P1027; Rice LB, 1996, CLIN INFECT DIS, V23, P118, DOI 10.1093/clinids/23.1.118; Settle CD, 1998, ALIMENT PHARM THER, V12, P1217; SIROT D, 1995, J ANTIMICROB CHEMOTH, V36, P19, DOI 10.1093/jac/36.suppl_A.19; TODD PA, 1990, DRUGS, V39, P264, DOI 10.2165/00003495-199039020-00008; Virk A, 2000, MAYO CLIN PROC, V75, P200; Williams JD, 1997, CLIN INFECT DIS, V24, P494, DOI 10.1093/clinids/24.3.494; Wright AJ, 1999, MAYO CLIN PROC, V74, P290, DOI 10.4065/74.3.290	27	18	20	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2001	285	4					386	388		10.1001/jama.285.4.386	http://dx.doi.org/10.1001/jama.285.4.386			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394CG	11242403				2023-01-03	WOS:000166506000002
J	Luczak, J; Hunter, GP				Luczak, J; Hunter, GP			Hospice care in eastern Europe	LANCET			English	Article									Palliat Care Dept Poznan, PL-61878 Poznan, Poland		Luczak, J (corresponding author), Palliat Care Dept Poznan, Ul Lakowa 1-2, PL-61878 Poznan, Poland.								0	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S23	S23		10.1016/S0140-6736(00)92009-9	http://dx.doi.org/10.1016/S0140-6736(00)92009-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191479				2023-01-03	WOS:000166074900025
J	Henney, JE				Henney, JE			New treatment for leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2178	2178		10.1001/jama.284.17.2178	http://dx.doi.org/10.1001/jama.284.17.2178			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367GD	11056574				2023-01-03	WOS:000090052600007
J	Vernia, P; Fracasso, PL; Casale, V; Villotti, G; Marcheggiano, A; Stigliano, V; Pinnaro, P; Bagnardi, V; Caprilli, R				Vernia, P; Fracasso, PL; Casale, V; Villotti, G; Marcheggiano, A; Stigliano, V; Pinnaro, P; Bagnardi, V; Caprilli, R			Topical butyrate for acute radiation proctitis: randomised, crossover trial	LANCET			English	Article							CHAIN FATTY-ACIDS; ULCERATIVE-COLITIS; INJURY; MUCOSA; BOWEL; RAT	Background No available therapy has, as yet, proven effective to treat acute radiation proctitis (ARP) following radiation therapy for malignant pelvic disease. We assessed whether sodium butyrate enemas, at a dose of 80 mmol/L (80 mL/24 h), might offer effective treatment for this condition. Methods 20 patients presenting with ARP after completing a cycle of 35-52 Gy external-beam radiation therapy for pelvic malignant disease, were treated for 3 weeks with topical sodium butyrate and saline enemas according to a randomised, double-blind, crossover protocol. Clinical, endoscopic, and histological findings were assessed at enrolment, at week 3, and then at the end of the study. Data were analysed by two-tailed t test for paired data (continuous variables) and a logistic-regression model with variable multiple response for ordered categorical data. Findings Topical butyrate, but not saline, led to remission of symptoms (clinical score from 8.2 [SE 1.6] to 1.5 [0.7] vs 7.9 [1.8] to 8.1 [3.4]). When the treatment regimen was switched, eight out of nine of the previously placebo-treated patients went into remission, whereas three patients relapsed when switched to saline. The advantage of butyrate over placebo, expressed as CI, odds ratio, and p value was significant for almost all the clinical, endoscopic and histological factors taken into consideration. Interpretation Topical sodium butyrate, unlike other therapeutic regimens used so far, proved effective in the treatment of ARP.	Univ Rome La Sapienza, Dipartimento Sci Clin, Cattedra Gastroenterol 1, I-00161 Rome, Italy; Ist Regina Elena, I-00161 Rome, Italy; Univ Milan, Dipartimento Stat, I-20122 Milan, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan	Vernia, P (corresponding author), Univ Rome La Sapienza, Dipartimento Sci Clin, Cattedra Gastroenterol 1, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Vernia, Piero/AAM-4267-2020; Pinnarò, Paola/H-8862-2017; Fracasso, Pierluigi/ABD-9575-2021	Pinnarò, Paola/0000-0003-3049-7380; Fracasso, Pierluigi/0000-0003-4265-9981				AlSabbagh R, 1996, AM J GASTROENTEROL, V91, P1814; Babb RR, 1996, AM J GASTROENTEROL, V91, P1309; Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P19, DOI 10.1016/S0936-6555(05)80689-2; CASALE V, 1993, ITAL J GASTROENTEROL, V25, P41; DARGENIO G, 1994, GASTROENTEROLOGY, V106, P399, DOI 10.1016/0016-5085(94)90598-3; DELANEY JP, 1994, RADIAT RES, V137, P405, DOI 10.2307/3578717; DUBRAY BM, 1994, RADIOTHER ONCOL, V33, P41, DOI 10.1016/0167-8140(94)90084-1; Kim YI, 1998, NUTR REV, V56, P17; Kochhar R, 1999, DIGEST DIS SCI, V44, P973, DOI 10.1023/A:1026612731210; KVIETYS PR, 1981, GASTROENTEROLOGY, V80, P962; MCKENNA KJ, 1994, SURGERY, V115, P626; Miller AR, 1999, INT J RADIAT ONCOL, V43, P817, DOI 10.1016/S0360-3016(98)00485-4; MORTENSEN FV, 1990, GUT, V31, P1391, DOI 10.1136/gut.31.12.1391; NUSSBAUM ML, 1993, CLIN PLAST SURG, V20, P573; SAKATA T, 1991, SHORT CHAIN FATTY AC, P63; SENN S, 1993, CROSS OVER TRIALS CL; VERNIA P, 1995, ALIMENT PHARM THERAP, V9, P309; Wang CJ, 1998, INT J RADIAT ONCOL, V40, P85, DOI 10.1016/S0360-3016(97)00560-9; Zimmermann FB, 1998, STRAHLENTHER ONKOL, V174, P85	19	77	80	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1232	1235		10.1016/S0140-6736(00)02787-2	http://dx.doi.org/10.1016/S0140-6736(00)02787-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072942				2023-01-03	WOS:000089724900013
J	Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC				Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC			Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity	FASEB JOURNAL			English	Article						asialoglycoprotein; HBV; HSV-1; drug targeting; liver	CHRONIC HEPATITIS-B; LOW-DENSITY-LIPOPROTEIN; HERPES-SIMPLEX VIRUS; POLY-L-LYSINE; ASIALOGLYCOPROTEIN RECEPTOR; LIVER-CELLS; HIGH-AFFINITY; LAMIVUDINE RESISTANCE; CLUSTER GALACTOSIDES; LIPOPHILIC PRODRUG	The device of new hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine (PMEA) with specificity for the asialoglycoprotein receptor on parenchymal liver cells is described. PMEA was conjugated to bi- and trivalent cluster glycosides (K(GN)(2) and K-2 (GN)(3), respectively) with nanomolar affinity for the asialoglycoprotein receptor. The liver uptake of the PMEA prodrugs was more than 10-fold higher than that of the parent drug (52+/-6% and 62+/-3% vs. 4.8+/-0.7% of the injected dose for PMEA) and could be attributed for 90% to parenchymal cells. Accumulation of the PMEA prodrugs in extrahepatic tissue (e.g., kidney, skin) was substantially reduced. The ratio of parenchymal liver cell-to-kidney uptake-a measure of the prodrugs therapeutic window-was increased from 0.058 +/- 0.01 for PMEA to 1.86 +/- 0.57 for K(GN)(2)-PMEA and even 2.69 +/- 0.24 for K-2 (GN)(3)-PMEA. Apparently both glycosides have a similar capacity to redirect (antiviral) drugs to the liver. After cellular uptake, both PMEA prodrugs were converted into the parent drug, PMEA, during acidification of the lysosomal milieu (t(1/2) approximate to 100 min), and the released PMEA was rapidly translocated into the cytosol. The antiviral activity of the prodrugs in vitro was dramatically enhanced as compared to the parent drug (5- and 52-fold for K(GN)(2)-PMEA and K-2 (GN)(3)-PMEA, respectively). Given the 15-fold enhanced liver uptake of the prodrugs, we anticipate that the potency in vivo will be similarly increased. We conclude that PMEA prodrugs have been developed with greatly improved pharmacokinetics and therapeutic activity against viral infections that implicate the liver parenchyma (e.g., HBV). In addition, the significance of the above prodrug concept also extends to drugs that intervene in other liver disorders such as cholestasis and dyslipidemia.	Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Leiden, Netherlands; Leiden Univ, LIC, Dept Bioorgan Chem, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Wassenaarseweg 72, Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021; de Vrueh, Remco/ABE-3053-2020					ABRAHAMS PJ, 1984, MOL CELL BIOL, V4, P2341, DOI 10.1128/MCB.4.11.2341; Angus PW, 1997, J GASTROEN HEPATOL, V12, P217, DOI 10.1111/j.1440-1746.1997.tb00411.x; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Atkins M, 1998, J HEPATOL, V28, P169, DOI 10.1016/S0168-8278(98)80219-5; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1994, J HEPATOL, V21, P806, DOI 10.1016/S0168-8278(94)80243-2; Bijsterbosch MK, 1996, BIOCHEM PHARMACOL, V52, P113, DOI 10.1016/0006-2952(96)00170-0; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BISCHOFBERGER N, 1994, ANTIMICROB AGENTS CH, V38, P2387, DOI 10.1128/AAC.38.10.2387; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; Cerenzia MT, 1996, HEPATOLOGY, V23, P657, DOI 10.1002/hep.510230401; CIHLAR T, 1995, ANTIMICROB AGENTS CH, V39, P117, DOI 10.1128/AAC.39.1.117; de Vrueh RLA, 1999, PHARMACEUT RES, V16, P1179, DOI 10.1023/A:1018933126885; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; EISENBERG C, 1991, J HEPATOL, V13, P305, DOI 10.1016/0168-8278(91)90073-K; ENRIQUEZ PM, 1995, BIOCONJUGATE CHEM, V6, P195, DOI 10.1021/bc00032a007; FIUME L, 1995, HEPATOLOGY, V22, P1072, DOI 10.1002/hep.1840220409; Fiume L, 1997, J VIRAL HEPATITIS, V4, P363, DOI 10.1046/j.1365-2893.1997.00067.x; FIUME L, 1986, BIOCHEM PHARMACOL, V35, P967, DOI 10.1016/0006-2952(86)90084-5; FOSTER SA, 1991, J BIOL CHEM, V266, P238; Hangeland JJ, 1997, ANTISENSE NUCLEIC A, V7, P141, DOI 10.1089/oli.1.1997.7.141; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Hoofnagle JH, 1997, J VIRAL HEPATITIS, V4, P41, DOI 10.1111/j.1365-2893.1997.tb00159.x; JANSEN RW, 1993, HEPATOLOGY, V18, P146, DOI 10.1016/0270-9139(93)90518-R; KROGSGAARD K, 1994, J HEPATOL, V21, P646, DOI 10.1016/S0168-8278(94)80114-2; KRUINING J, 1995, J HEPATOL, V22, P263, DOI 10.1016/0168-8278(95)80277-0; Kuznetsova E V, 1995, Mol Biol (Mosk), V29, P415; Lee RT, 1997, BIOCONJUGATE CHEM, V8, P762, DOI 10.1021/bc9700796; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; MIDOUX P, 1990, BIOCHEM BIOPH RES CO, V167, P1044, DOI 10.1016/0006-291X(90)90628-Z; MYERS BM, 1995, HEPATOLOGY, V22, P1519, DOI 10.1016/0270-9139(95)90160-4; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NAESENS L, 1992, DRUG METAB DISPOS, V20, P747; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; RAHIL J, 1981, J AM CHEM SOC, V103, P1723, DOI 10.1021/ja00397a024; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; SCHALM SW, 1995, J HEPATOL, V22, P52; Smeijsters LJJW, 1996, ANTIMICROB AGENTS CH, V40, P1584, DOI 10.1128/AAC.40.7.1584; Valentijn ARPM, 1997, TETRAHEDRON, V53, P759, DOI 10.1016/S0040-4020(96)01018-6; Van Berkel Theo J. C., 1994, Current Opinion in Lipidology, V5, P331, DOI 10.1097/00041433-199410000-00004; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	47	15	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1784	1792		10.1096/fj.99-0887com	http://dx.doi.org/10.1096/fj.99-0887com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973928	Bronze			2023-01-03	WOS:000089212400018
J	Kidane, G; Morrow, RH				Kidane, G; Morrow, RH			Teaching mothers to provide home treatment of malaria in Tigray, Ethiopa: a randomised trial	LANCET			English	Article							TREATED BED NETS; RURAL AREA; VERBAL AUTOPSIES; HEALTH-CARE; MORTALITY; CHILDREN; MORBIDITY; BEDNETS; PROGRAM; AFRICA	Background No satisfactory strategy for reducing high child mortality from malaria has yet been established in tropical Africa. We compared the effect on under-5 mortality of leaching mothers to promptly provide antimalarials to their sick children at home, with the present community health worker approach. Methods Of 37 tabias (cluster of villages) in two districts with hyperendemic to holoendemic malaria, tabias reported to have the highest malaria morbidity were selected. A census was done which included a maternity history to determine under-5 mortality. Tabias (population 70 506) were paired according to under-5 mortality rates. One tabia from each pair was allocated by random number to an intervention group and the other was allocated to the control group. In the intervention tabias, mother coordinators were trained to teach other local mothers to recognise symptoms of malaria in their children and to promptly give chloroquine. In both intervention and control tabias, all births and deaths of under-5s were recorded monthly. Findings From January to December 1997, 190 of 6383 (29.8 per 1000) children under-5 died in the intervention tabias compared with 366 of 7294 (50.2 per 1000) in the control tabias. Under-5 mortality was reduced by 40% in the intervention localities (95% CI from 29.2-50.6; paired t test, p<0.003). For every third child who died, a structured verbal autopsy was undertaken to ascribe cause of mortality as consistent with malaria or possible malaria, or not consistent with malaria. Of the 190 verbal autopsies, 13 (19%) of 70 in the intervention tabias were consistent with possible malaria compared with 68 (57%) of 120 in the control tabias, Interpretation A major reduction in under-5 mortality can be achieved in holoendemic malaria areas through training local mother coordinators to teach mothers to give under-5 children antimalarial drugs.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Morrow, RH (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; Barnabas G A, 1997, Health Policy Plan, V12, P38, DOI 10.1093/heapol/12.1.38; Binka FN, 1996, TROP MED INT HEALTH, V1, P147; D'Alessandro U, 1997, T ROY SOC TROP MED H, V91, P638, DOI 10.1016/S0035-9203(97)90502-2; DABIS F, 1989, B WORLD HEALTH ORGAN, V67, P675; Engers HD, 1998, PARASITOL TODAY, V14, P56, DOI 10.1016/S0169-4758(97)01184-8; GHEBREYESUS TA, 1996, ACTA TROP, V61, P45; Grant James P., 1995, STATE WORLDS CHILDRE; KASEJE D C O, 1987, Annals of Tropical Medicine and Parasitology, V81, P111; Kloos H, 1998, SOC SCI MED, V46, P505, DOI 10.1016/S0277-9536(97)00194-9; MENON A, 1988, J TROP MED HYG, V91, P49; MENON A, 1990, T R SOC TROP MED HYG, V84, P968; MORROW RH, 2000, INFECT DIS EPIDEMIOL; MWABU GM, 1986, SOC SCI MED, V22, P315, DOI 10.1016/0277-9536(86)90129-2; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7; PLASEK P, 1997, QUAL HEALTH CARE, V6, P40; Quigley MA, 1996, B WORLD HEALTH ORGAN, V74, P147; RUEBUSH TK, 1995, B WORLD HEALTH ORGAN, V73, P229; SALUM FM, 1994, ACTA TROP, V58, P29, DOI 10.1016/0001-706X(94)90119-8; SMITH PG, 1991, METHODS FIELD TRIALS; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; *WHO, 1984, WHO STUD GROUP TECHN, V712; [WHO] World Health Organization, 1993, WHO TECHN REP SER	26	275	276	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2000	356	9229					550	555		10.1016/S0140-6736(00)02580-0	http://dx.doi.org/10.1016/S0140-6736(00)02580-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	345MY	10950232				2023-01-03	WOS:000088820800012
J	Sesmilo, G; Biller, BMK; Llevadot, J; Hayden, D; Hanson, G; Rifai, N; Klibanski, A				Sesmilo, G; Biller, BMK; Llevadot, J; Hayden, D; Hanson, G; Rifai, N; Klibanski, A			Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency - A randomized, controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							C-REACTIVE PROTEIN; CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; PLACEBO-CONTROLLED TRIAL; INTIMA-MEDIA THICKNESS; RECOMBINANT HUMAN GH; NESTED CASE-CONTROL; MYOCARDIAL-INFARCTION; BODY-COMPOSITION; HYPOPITUITARY ADULTS	Background: Growth hormone-deficient adults have increased cardiovascular mortality. Growth hormone replacement may affect cardiovascular risk. Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events. Objective: To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors. Design: Randomized, single-blind, placebo-controlled trial. Patients: 40 men with adult-onset growth hormone deficiency. Intervention: Growth hormone or placebo given for 18 months at a dose adjusted for normal serum insulin-like growth factor I level. Measurements: Anthropometric, hemoglobin A(1c), and central fat values were assessed every 6 months. Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months. C-reactive protein, serum amyloid polypeptide A, interleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months. Results: C-reactive protein and interleukin-6 levels decreased in growth hormone recipients compared with placebo recipients (differences between groups, -1.9+/-0.6 mg/L [P=0.0027] and -1.3+/-0.5 ng/L [P=0.013], respectively). Changes in serum amyloid polypeptide A levels between groups did not reach statistical significance (difference between groups, -2.4+/-1.2 mg/L; P = 0.056). Serum cholesterol levels, low-density lipoprotein cholesterol levels, and ratios of total cholesterol to high-density lipoprotein cholesterol decreased in growth hormone recipients in the first 3 months compared with placebo recipients (differences between groups, -0.86 +/- 0.17 mmol/L [-33.2 +/- 6.6 mg/dL] [P < 0.001], -0.63 +/- 0.20 mmol/L [-24.5 +/- 5.9 mg/dL] [P < 0.001], and -0.56 +/- 0.26 [P = 0.040], respectively), but the decrease was not maintained from month 6 to month 18. Lipoprotein(a) levels increased (difference between groups, 22.0 +/- 8.0 mg/L; P = 0.0096). Short-term increases occurred in glucose levels, insulin levels, and insulin-to-glucose ratios (differences between groups, 0.54 +/- 0.16 mmol/L [9.6 +/- 2.8 mg/dL] [P = 0.0018], 37.9 +/- 9.6 pmol/L [P < 0.001], and 6.0 +/- 1.8 [P = 0.0025], respectively), but only the increase in glucose level was maintained over the long term (difference between groups, 0.56 +/- 0.17 mmol/L [10.0 +/- 3.1 mg/dL]; P = 0.0026). Hemoglobin A,, values did not change. Truncal fat-to-total fat ratios decreased (difference between groups, -0.018 +/- 0.007; P = 0.0087), Conclusions: Long-term growth hormone replacement in men reduces levels of inflammatory cardiovascular risk markers, decreases central fat, and increases lipoprotein(a) and glucose levels without affecting lipid levels.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	Klibanski, A (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St,Bulfinch 457B, Boston, MA 02114 USA.				NCRR NIH HHS [RR 1066] Funding Source: Medline; NIDDK NIH HHS [DK08783] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008783] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; AUEMHAMMER CJ, 1995, EUR J ENDOCRINOL, V133, P635; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Beshyah SA, 1999, CLIN ENDOCRINOL, V50, P1, DOI 10.1046/j.1365-2265.1999.00682.x; BESHYAH SA, 1995, J CLIN ENDOCR METAB, V80, P356, DOI 10.1210/jc.80.2.356; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; Borson-Chazot F, 1999, J CLIN ENDOCR METAB, V84, P1329, DOI 10.1210/jc.84.4.1329; Bozzola M, 1997, ACTA PAEDIATR, V86, P84; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; Capaldo B, 1997, J CLIN ENDOCR METAB, V82, P1378, DOI 10.1210/jc.82.5.1378; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; Cuneo RC, 1998, J CLIN ENDOCR METAB, V83, P107, DOI 10.1210/jc.83.1.107; CUNEO RC, 1993, METABOLISM, V42, P1519, DOI 10.1016/0026-0495(93)90145-E; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; EDEN S, 1993, ARTERIOSCLER THROMB, V13, P296, DOI 10.1161/01.ATV.13.2.296; Evans LM, 1999, CLIN ENDOCRINOL, V50, P457; Florkowski CM, 1996, CLIN ENDOCRINOL, V45, P769, DOI 10.1046/j.1365-2265.1996.830895.x; FOWELIN J, 1993, METABOLISM, V42, P1443, DOI 10.1016/0026-0495(93)90197-V; Fyfe AI, 1997, CIRCULATION, V96, P2914, DOI 10.1161/01.CIR.96.9.2914; Geffner M, 1997, ACTA PAEDIATR, V86, P76; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hadigan C, 1999, J CLIN ENDOCR METAB, V84, P1932, DOI 10.1210/jc.84.6.1932; HANSEN PS, 1995, METABOLISM, V44, P725, DOI 10.1016/0026-0495(95)90184-1; Hwu CM, 1997, J CLIN ENDOCR METAB, V82, P3285, DOI 10.1210/jc.82.10.3285; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; INOUE L, 1995, ARCH SURG-CHICAGO, V130, P1115; Jarrar D, 1997, ARCH SURG-CHICAGO, V132, P1171; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JOHANNSSON G, 1995, ARTERIOSCL THROM VAS, V15, P2142, DOI 10.1161/01.ATV.15.12.2142; JOHANSSON JO, 1995, METABOLISM, V44, P1126, DOI 10.1016/0026-0495(95)90004-7; JORGENSEN JOL, 1989, LANCET, V1, P1221; JORGENSEN JOL, 1994, CLIN ENDOCRINOL, V41, P609, DOI 10.1111/j.1365-2265.1994.tb01826.x; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kratz A, 1998, NEW ENGL J MED, V339, P1063, DOI 10.1056/NEJM199810083391508; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Libby P, 1999, CIRCULATION, V100, P1148, DOI 10.1161/01.CIR.100.11.1148; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lucidi P, 1998, J CLIN ENDOCR METAB, V83, P353, DOI 10.1210/jc.83.2.353; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; Nolte W, 1997, EUR J ENDOCRINOL, V137, P459, DOI 10.1530/eje.0.1370459; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; Renier G, 1996, ENDOCRINOLOGY, V137, P4611, DOI 10.1210/en.137.11.4611; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSEN T, 1993, ACTA ENDOCRINOL-COP, V129, P195, DOI 10.1530/acta.0.1290195; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rus HG, 1996, ATHEROSCLEROSIS, V127, P263, DOI 10.1016/S0021-9150(96)05968-0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; Serri O, 1999, J CLIN ENDOCR METAB, V84, P58, DOI 10.1210/jc.84.1.58; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; WEAVER JU, 1995, J CLIN ENDOCR METAB, V80, P153, DOI 10.1210/jc.80.1.153; Webster JM, 1997, ATHEROSCLEROSIS, V133, P115, DOI 10.1016/S0021-9150(97)00110-X; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; WUSTER C, 1991, KLIN WOCHENSCHR, V69, P769, DOI 10.1007/BF01797616	67	218	226	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2000	133	2					111	122		10.7326/0003-4819-133-2-200007180-00010	http://dx.doi.org/10.7326/0003-4819-133-2-200007180-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335RL	10896637				2023-01-03	WOS:000088258500004
J	Seto, TB; Kwiat, D; Taira, DA; Douglas, PS; Manning, WJ				Seto, TB; Kwiat, D; Taira, DA; Douglas, PS; Manning, WJ			Physicians' recommendations to patients for use of antibiotic prophylaxis to prevent endocarditis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MITRAL-VALVE PROLAPSE; AMERICAN-HEART-ASSOCIATION; BACTERIAL-ENDOCARDITIS; INFECTIVE ENDOCARDITIS; GUIDELINES; ECHOCARDIOGRAPHY; EPIDEMIOLOGY; NETHERLANDS; MANAGEMENT; AWARENESS	Context The American Heart Association recommendations for infectious endocarditis (IE) prophylaxis, published in June 1997, sought to improve patient and physician compliance by simplifying the dosing regimen and clarifying endocarditis risk. Adherence to these updated recommendations in patients with echocardiographic verification of their endocarditis risk profile is unknown. Objective To determine the recommended and actual use of IE prophylaxis as reported by patients undergoing echocardiography. Design, Setting, and Participants All patients who underwent outpatient transthoracic echocardiography at a university-based tertiary hospital in Boston, Mass, during December 1997 were contacted 6 to 9 months rater to respond to a survey, completed by 218 (80%) eligible subjects. Main Outcome Measure Patients' report of their physicians' instructions on actual use of IE prophylaxis in accordance with patient risk category, determined by echocardiographic data. Results One hundred eight patients (49.5%) had clinical or echocardiographic findings for which prophylaxis was indicated. Of these 108 patients, 71 (65.7%) reported that they were instructed to take IE prophylaxis. Sixteen high-risk patients (88.9%) but only 55 moderate-risk patients (61.1%) reported that they were instructed to take prophylaxis. Among the 110 negligible-risk patients, 29 (26.4%) reported that they had been instructed to take IE prophylaxis. Overall, 100 patients (45.9%) reported that they received physician instructions to take IE prophylaxis. Of those who subsequently underwent a procedure for which IE prophylaxis was indicated (n = 68), 9 (13.2%) elected not to follow their physician's advice to take prophylaxis. Conclusions We found that although most patients reported receiving instructions for IE prophylaxis use consistent with American Heart Association guidelines, IE prophylaxis overuse among negligible-risk patients and underuse among moderate-risk patients was common. Continued physician and patient education may lead to improved adherence to the current American Heart Association recommendations.	Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Harvard Thorndike Lab,Charles A Dana Res Lab, Boston, MA 02215 USA; Queens Med Ctr, Ctr Best Healthcare Practices, Honolulu, HI USA; Univ Hawaii, Dept Med, Div Cardiol, Honolulu, HI 96822 USA; Univ Hawaii, Div Clin Epidemiol, John A Burns Sch Med, Honolulu, HI 96822 USA; Hawaii Med Serv Assoc, Honolulu, HI USA	Harvard University; Beth Israel Deaconess Medical Center; The Queen's Medical Center; University of Hawaii System; University of Hawaii System	Manning, WJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Harvard Thorndike Lab,Charles A Dana Res Lab, 330 Brookline Ave, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049				BAYLISS R, 1983, BRIT HEART J, V50, P506, DOI 10.1136/hrt.50.6.506; BOR DH, 1984, AM J MED, V76, P711, DOI 10.1016/0002-9343(84)90300-0; BROOKS SL, 1980, J AM DENT ASSOC, V101, P41, DOI 10.14219/jada.archive.1980.0361; CLEMENS JD, 1984, J CHRON DIS, V37, P531, DOI 10.1016/0021-9681(84)90004-3; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Delahaye F, 1999, J AM COLL CARDIOL, V33, P788, DOI 10.1016/S0735-1097(98)00624-X; DURACK DT, 1995, NEW ENGL J MED, V332, P38, DOI 10.1056/NEJM199501053320107; ELKODT AG, 1995, ANN INTERN MED, V122, P277; HASHWAY T, 1982, CIRCULATION, V66, P1110, DOI 10.1161/01.CIR.66.5.1110; Heidenreich PA, 1997, AM J MED, V102, P337, DOI 10.1016/S0002-9343(97)00084-3; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; Meyers DG, 1997, AM J PREV MED, V13, P45, DOI 10.1016/S0749-3797(18)30224-1; Muhlestein JB, 1999, J AM COLL CARDIOL, V33, P794; NELSON CL, 1989, J AM DENT ASSOC, V118, P169, DOI 10.14219/jada.archive.1989.0215; OLIVE KE, 1990, J GEN INTERN MED, V5, P470, DOI 10.1007/BF02600871; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; RETCHIN SM, 1985, MED CARE, V23, P1156, DOI 10.1097/00005650-198510000-00004; SADOWSKY D, 1989, J AM DENT ASSOC, V118, P175, DOI 10.14219/jada.archive.1989.0242; Tomos MP, 1992, ANN INTERN MED, V117, P567; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1869, DOI 10.1001/archinte.152.9.1869; VANDERMEER JTM, 1992, J ANTIMICROB CHEMOTH, V29, P187, DOI 10.1093/jac/29.2.187; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863	25	25	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					68	71		10.1001/jama.284.1.68	http://dx.doi.org/10.1001/jama.284.1.68			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872015	Bronze			2023-01-03	WOS:000087843000027
J	Sheikh, A; Alves, B				Sheikh, A; Alves, B			Hospital admissions for acute anaphylaxis: time trend study	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England	Imperial College London	Sheikh, A (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.		Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; Ewan PW, 1998, BRIT MED J, V316, P1442, DOI 10.1136/bmj.316.7142.1442; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; *NHS CTR COD CLASS, 1995, GUID US TABL EQ ICD; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	5	138	142	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1441	1441		10.1136/bmj.320.7247.1441	http://dx.doi.org/10.1136/bmj.320.7247.1441			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10827045	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000087414700025
J	Callahan, D				Callahan, D			Death and the research imperative.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hastings Ctr, Garrison, NY 10524 USA		Callahan, D (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.							AMUNDSEN DW, 1978, HASTINGS CENT REP, V8, P23, DOI 10.2307/3560974; Aries P, 1981, HOUR OUR DEATH; FISHER LM, 1999, NY TIMES        0829; Larson E. J., 1997, WAKE FOREST LAW REV, V32, P349; SCHWARTZ WB, 1998, LIFE DIS PURSUIT MED; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506	6	104	114	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	2000	342	9					654	656		10.1056/NEJM200003023420910	http://dx.doi.org/10.1056/NEJM200003023420910			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288QV	10699168				2023-01-03	WOS:000085575500010
J	Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA				Ganzini, L; Nelson, HD; Schmidt, TA; Kraemer, DF; Delorit, MA; Lee, MA			Physicians' experiences with the Oregon Death with Dignity Act.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSISTED SUICIDE; TERMINALLY ILL; EUTHANASIA; DESIRE; CARE	Background: Physician-assisted suicide was legalized in Oregon in October 1997. There are data on patients who have received prescriptions for lethal medications and died after taking the medications. There is little information, however, on physicians' experiences with requests for assistance with suicide. Methods: Between February and August 1999, we mailed a questionnaire to physicians who were eligible to prescribe lethal medications under the Oregon Death with Dignity Act. Results: Of 4053 eligible physicians, 2649 (65 percent) returned the survey. Of the respondents, 144 (5 percent) had received a total of 221 requests for prescriptions for lethal medications since October 1997. We received information on the outcome in 165 patients (complete information for 143 patients and partial for an additional 22). The mean age of the patients was 68 years; 76 percent had an estimated life expectancy of less than six months. Thirty-five percent requested a prescription from another physician. Twenty-nine patients (18 percent) received prescriptions, and 17 (10 percent) died from taking the prescribed medication. Twenty percent of the patients had symptoms of depression; none of these patients received a prescription for a lethal medication. In the case of 68 patients, including 11 who received prescriptions and 8 who died by taking the prescribed medication, the physician implemented at least one substantive palliative intervention, such as control of pain or other symptoms, referral to a hospice program, a consultation, or a trial of antidepressant medication. Forty-six percent of the patients for whom substantive interventions were made changed their minds about assisted suicide, as compared with 15 percent of those for whom no substantive interventions were made (P<0.001). Conclusions: Our data indicate that in Oregon, physicians grant about 1 in 6 requests for a prescription for a lethal medication and that 1 in 10 requests actually results in suicide. Substantive palliative interventions lead some -- but not all -- patients to change their minds about assisted suicide. (N Engl J Med 2000;342:557-63.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Portland, OR USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence Hlth Syst, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Div Mental Hlth, P-7-1DMH,POB 1034, Portland, OR 97207 USA.							Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1995, ACAD MED, V70, P583; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; EMANUEL EJ, 1998, 1997 98 ASCO SURVEY; Faber-Langendoen K, 1998, CANCER-AM CANCER SOC, V82, P35, DOI 10.1002/(SICI)1097-0142(19980101)82:1<35::AID-CNCR4>3.3.CO;2-#; Fisher LD., 1997, BIOMETRICS, V53, P1182; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Henriksson MM, 1995, J AFFECT DISORDERS, V36, P11, DOI 10.1016/0165-0327(95)00047-X; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; *OR HLTH DIV, 1997, OR VIT STAT ANN REP, V12; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L	19	275	275	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					557	563		10.1056/NEJM200002243420806	http://dx.doi.org/10.1056/NEJM200002243420806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684915				2023-01-03	WOS:000085422400006
J	Christakis, NA; Lamont, EB				Christakis, NA; Lamont, EB			Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX HELP; PREFERENCES; SURVIVAL; CANCER; UNCERTAINTY; PREDICTIONS; ACCURACY; CARE	Objective To describe doctors' prognostic accuracy in terminally ill patients and to evaluate the determinants of that accuracy. Design Prospective cohort study. Setting Five outpatient hospice programmes in Chicago. Participants 343 doctors provided survival estimates for 468 terminally ill patients at the time of hospice referral. Main outcome measures Patients' estimated and actual survival. Results Median survival was 24 days. Only 20% (92/468) of predictions were accurate (within 33% of actual survival); 63% (295/468) were overoptimistic and 17% (81/468) were over-pessimistic. Overall, doctors overestimated survival by a factor of 5.3. Few patient or doctor characteristics were associated with prognostic accuracy. Male patients were 58% less likely to have over-pessimistic predictions. Non-oncology medical specialists were 326% more likely than general internists to make overpessimistic predictions. Doctors in the upper quartile of practice experience were the most accurate. As duration of doctor-patient relationship increased and time since last contact decreased, prognostic accuracy decreased. Conclusion Doctors are inaccurate in their prognoses for terminally ill patients and the error is systematically optimistic The inaccuracy is, in general, not restricted to certain kinds of doctors or patients. These phenomena may be adversely affecting the quality of care given to patients near the end of life.	Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Med Ctr, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	Christakis, NA (corresponding author), Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA.		Christakis, Nicholas A/C-3205-2009; Christakis, Nicholas A/B-6690-2008; Ram, Prem/K-4511-2012	Lamont, Elizabeth/0000-0001-6604-678X				ADDINGTONHALL JM, 1990, BRIT J CANCER, V62, P695, DOI 10.1038/bjc.1990.360; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 1997, SOC SCI MED, V44, P301, DOI 10.1016/S0277-9536(96)00100-1; Christakis NA, 1999, DEATH FORETOLD PROPH; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EVANS C, 1985, LANCET, V1, P1204; FLETCHER SW, 1981, BIOMEDICAL INNOVATIO; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; HEVSEMOORE LH, 1987, PALLIATIVE MED, V1, P165; IWASHYNA TJ, 1998, PALLIATIVE MED, V1, P241; LYNN J, 1995, WESTERN J MED, V163, P250; Mackillop WJ, 1997, J CLIN EPIDEMIOL, V50, P21, DOI 10.1016/S0895-4356(96)00316-2; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; PEARLMAN RA, 1988, ARCH INTERN MED, V148, P2537, DOI 10.1001/archinte.148.12.2537; POSES RM, 1991, CRIT CARE MED, V19, P1533, DOI 10.1097/00003246-199112000-00016; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Zubrod C.G., 1960, J CHRON DIS, V11, P7	21	908	915	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					469	472		10.1136/bmj.320.7233.469	http://dx.doi.org/10.1136/bmj.320.7233.469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678857	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000085562200018
J	Bhalla, P; Eaton, FE; Coulter, JBS; Amegavie, FL; Sills, JA; Abernethy, LJ				Bhalla, P; Eaton, FE; Coulter, JBS; Amegavie, FL; Sills, JA; Abernethy, LJ			Lesson of the week - Hyponatraemic seizures and excessive intake of hypotonic fluids in young children	BRITISH MEDICAL JOURNAL			English	Review							SQUASH DRINKING SYNDROME; HIGH-ENERGY FLUIDS; WATER-INTOXICATION; NORMAL INFANTS; MORBIDITY		Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England; Whiston Hosp, Prescot, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Whiston Hospital	Coulter, JBS (corresponding author), Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England.							Arieff AI, 1999, PEDIATRICS, V103, P1292, DOI 10.1542/peds.103.6.1292; Corneli H M, 1985, Pediatr Emerg Care, V1, P190, DOI 10.1097/00006565-198512000-00005; CRUMPACK.RW, 1973, NEUROLOGY, V23, P1251, DOI 10.1212/WNL.23.11.1251; DAVID R, 1981, PEDIATRICS, V68, P349; DUGAN S, 1967, PEDIATRICS, V39, P418; EASTON J, 1992, LANCET, V339, P808; FINBERG L, 1991, AM J DIS CHILD, V145, P981, DOI 10.1001/archpedi.1991.02160090033016; GORDILLO G, 1957, PEDIATRICS, V20, P303; HOPE SA, 1995, ARCH DIS CHILD, V73, P277, DOI 10.1136/adc.73.3.277-b; HOURIHANE JOB, 1995, ARCH DIS CHILD, V72, P141, DOI 10.1136/adc.72.2.141; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; NICKMAN SL, 1968, PEDIATRICS, V41, P149; PARTRIDGE JC, 1981, AM J DIS CHILD, V135, P38, DOI 10.1001/archpedi.1981.02130250026009; PETTER LPM, 1995, ARCH DIS CHILD, V72, P137, DOI 10.1136/adc.72.2.137; ROWE JW, 1979, KIDNEY INT, V16, P729, DOI 10.1038/ki.1979.189; Sandhu BK, 1997, J PEDIATR GASTR NUTR, V24, P522, DOI 10.1097/00005176-199705000-00006; SCHAEFFER AV, 1991, AM J DIS CHILD, V145, P27, DOI 10.1001/archpedi.1991.02160010029006; Schwartz ID, 1998, ARCH PEDIAT ADOL MED, V152, P1037; Sharf R E, 1993, Arch Fam Med, V2, P647, DOI 10.1001/archfami.2.6.647; 1992, LANCET, V339, P153	20	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1554	1557		10.1136/bmj.319.7224.1554	http://dx.doi.org/10.1136/bmj.319.7224.1554			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591722	Green Published			2023-01-03	WOS:000084245600028
J	Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T				Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T			Reversible molecular adsorption based on multiple-point interaction by shrinkable gels	SCIENCE			English	Article							N-ISOPROPYLACRYLAMIDE	A general approach is presented for creating polymer-gels that can recognize and capture a target molecule by multiple-point interaction and that can reversibly change their affinity to the target by more than one order of magnitude. The polymers consist of majority monomers that make the gel reversibly swell and shrink and minority monomers that constitute multiple-point adsorption centers for the target molecule, Multiple-point interaction is experimentally proven by power Laws found between the affinity and the concentration of the adsorbing monomers within the gels.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, George R Harrison Spect Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oya, T (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Takeoka, Yukikazu/I-6785-2014; Grosberg, Alexander Y/O-2122-2015; Grosberg, Alexander/AAD-9614-2019; yilmaz, yasar/D-6190-2014; Takeoka, Yukikazu/W-9627-2019	Takeoka, Yukikazu/0000-0002-1406-0704; Grosberg, Alexander Y/0000-0002-4230-8690; Grosberg, Alexander/0000-0002-4230-8690; yilmaz, yasar/0000-0003-2352-4723; Takeoka, Yukikazu/0000-0002-1406-0704				HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; RICKA J, 1985, MACROMOLECULES, V18, P83, DOI 10.1021/ma00143a013; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Tanaka T, 1995, FARADAY DISCUSS, V101, P201, DOI 10.1039/fd9950100201; YAMATO M, 1999, CONNECT TISSUE, V31, P13	5	179	186	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1543	1545		10.1126/science.286.5444.1543	http://dx.doi.org/10.1126/science.286.5444.1543			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567256				2023-01-03	WOS:000083768300052
J	Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC				Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC			Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; CEREBRAL BLOOD-FLOW; TOTAL HEPATECTOMY; BODY-TEMPERATURE; CONTROLLED TRIAL; BRAIN EDEMA; GLUTAMINE; RAT; METABOLISM; AMMONIA	Background Increased intracranial pressure as a complication of acute liver failure has a mortality of about 90% in patients who do not respond to treatment with mannitol and ultrafiltration. We investigated the safety and efficacy of moderate hypothermia for uncontrolled increase in intracranial pressure in patients with acute liver failure. Methods We studied seven consecutive patients aged 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver failure who fulfilled criteria for poor-prognosis liver failure and had increased intracranial pressure that was unresponsive to two treatments with mannitol and ultrafiltration. We used cooling blankets to lower the patients' core temperature to 32-33 degrees C. Patients who were not suitable candidates for OLT (patients 1-3) were cooled for 8 h and then gradually rewarmed over 1 h to 8 baseline temperature of 37 degrees C. Patients who were suitable candidates for OLT (patients 4-7) were cooled before and during the OLT procedure; We measured cerebral blood flow and metabolic indices before and after cooling. Findings The four patients who were candidates for OLT were successfully maintained until transplantation with 13 (range 10-14) h of hypothermia. The three patients who were unsuitable candidates for OLT died after rewarming. Intracranial pressure before cooling was 45 (25-49) mm Hg and was reduced in all patients to 16 (13-17) mm Hg (p<0.05). Cerebral blood flow decreased from 103 (25-134) mt 100 g(-1) min(-1) before cooling to 44 (24-75) mt 100 g(-1) min(-1) after cooling (p<005). The corresponding changes for cerebral perfusion pressure was an increase from 45 (37-56) mm Hg to 70 (60-78) mm Hg (p<0.05) and for cardiac index a decrease from 9.8 (7-13) to 5.1 (4.3-6.1) L per min per m(2) of body surface area. During hypothermia there was no significant relapse of increased intracranial pressure. Arterial ammonia and cerebral uptake of ammonia were significantly reduced with cooling. No adverse effects of hypothermia were observed. Interpretation Moderate hypothermia is useful in the treatment of uncontrolled increase in intracranial pressure in patients with acute liver failure and may serve as a bridge to OLT.	Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Scottish Liver Transplantat Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Dept Anaesthet, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Intens Care Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Maastricht Univ, Dept Surg, Maastricht, Netherlands	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Maastricht University	Jalan, R (corresponding author), Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Deutz, Nicolaas E/J-5200-2012; Damink, Steven WM Olde/U-7919-2019	Damink, Steven WM Olde/0000-0002-5202-9345; Deutz, Nicolaas/0000-0001-5845-6447	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGARWAL S, 1994, HEPATOLOGY, V19, P80, DOI 10.1002/hep.1840190114; ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEJONG CHC, 1993, J CLIN INVEST, V92, P2834, DOI 10.1172/JCI116903; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; Eguchi S, 1996, HEPATOLOGY, V24, P1452; EJLERSEN E, 1994, TRANSPLANT P, V26, P1794; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1016/0270-9139(95)90434-4; JACOBSEN M, 1989, J CEREB BLOOD FLOW M, V9, P717; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Larsen FS, 1996, SEMIN LIVER DIS, V16, P281, DOI 10.1055/s-2007-1007241; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCONNELL JR, 1995, HEPATOLOGY, V22, P69, DOI 10.1016/0270-9139(95)90354-2; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OLAFSSON S, 1995, GASTROENTEROLOGY, V108, P1097, DOI 10.1016/0016-5085(95)90208-2; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; Philips BJ, 1998, HEPATOLOGY, V27, P369, DOI 10.1002/hep.510270209; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; TAKAHASHI H, 1991, AM J PHYSIOL, V261, P825; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trey C, 1970, Prog Liver Dis, V3, P282; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9	30	255	265	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1164	1168		10.1016/S0140-6736(98)12440-6	http://dx.doi.org/10.1016/S0140-6736(98)12440-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513710				2023-01-03	WOS:000082954100012
J	Hensher, M; Edwards, N; Stokes, R				Hensher, M; Edwards, N; Stokes, R			The hospital of the future - International trends in the provision and utilisation of hospital care	BRITISH MEDICAL JOURNAL			English	Article									NHS Federat, London SE1P 4ND, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Consumers Assoc, London NW1 4DF, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, N (corresponding author), NHS Federat, London SE1P 4ND, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827				AlexanderWilliams J, 1996, PRACTITIONER, V240, P152; Barnum H., 1993, PUBLIC HOSP DEV COUN; *GOV STAT SERV, 1992, STAT B HOSP ACT STAT, P1997; *MIN SANT PUBL REP, 1998, RAPP ANN SIT SAN 199; *ORG EC COOP DEV, 1997, OECD HLTH 1997 SOFTW; *ORG EC COOP DEV, 1993, OECD HLTH SYST FACTS; SALUNAN RB, 1997, WHO REGIONAL PUBLICA, V72; *WHO, 1997, HLTH IND DAT 1997; *WORLD BANK, 1996, SOC IND DEV 1996	9	35	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					845	848		10.1136/bmj.319.7213.845	http://dx.doi.org/10.1136/bmj.319.7213.845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496836	Green Published			2023-01-03	WOS:000082865200034
J	Khan, LK; Serdula, MK; Bowman, BA; Williamson, DF				Khan, LK; Serdula, MK; Bowman, BA; Williamson, DF			Use of prescription weight loss pills among US adults in 1996-1998	ANNALS OF INTERNAL MEDICINE			English	Article							PREVALENCE	Background: Pharmacotherapy is recommended for the treatment of obese persons with a body mass index of 30 kg/m(2) or higher or a body mass index of at least 27 kg/m(2) plus an obesity-related comorbid condition. Objective: To estimate the prevalence of use of prescription weight loss pills in the United States in 1996-1998. Design: 1998 Behavioral Risk Factor Surveillance System, a nationally representative telephone survey. Setting: United States. Participants: 139 779 adults 18 years of age and older. Measurements: Self-reported pill use for 1996-1998, body mass index (current and before pill use), age, sex, and race or ethnicity. Results: The 2-year prevalence of pill use was 2.5% (95% CI, 2.1% to 2.9%); or 4.6 million U.S. adults. Use was higher in women than in men (4.0% vs. 0.9%, respectively) and highest among Hispanic respondents (3.2%). Of pill users, 25% were not overweight (body mass index < 27 kg/m(2)) before using pills. Conclusions: Nearly 5 million U.S. adults used prescription weight loss pills in 1996-1998. However, one quarter of users were not overweight. suggesting that weight loss pills may be inappropriately used, especially among women, white persons, and Hispanic persons.	Ctr Dis Control & Prevent, Div Nutr & Phys Activ, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Khan, LK (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Activ, 4770 Buford Highway NE,Mailstop K29, Atlanta, GA 30341 USA.	LDK7@cdc.gov						Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; *IMS AM LTD NAT PR, 1997, BAS DAT REP IMS AM L; LUMPKIN MM, 1997, FDA B, V27, P2; McKee MD, 1999, J FAM PRACTICE, V48, P993; *MMWR, 1997, MMWR-MORBID MORTAL W, V46, P1061; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; NELSON DE, 1998, P SECT SURV METH AM; ORADELL NJ, 1997, MED EC; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Shah BV, 1997, SUDAAN USERS MANUAL	14	34	34	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2001	134	4					282	286		10.7326/0003-4819-134-4-200102200-00011	http://dx.doi.org/10.7326/0003-4819-134-4-200102200-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NW	11182838				2023-01-03	WOS:000167050200004
J	Schellenberg, R				Schellenberg, R			Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN SECRETION; TENSION SYNDROME; SCALES	Objectives To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome. Design Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles. Setting General medicine community clinics. Participants 178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days. Interventions Agnus castus(dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles. Main outcome measured Main efficacy variable: change from baseline to end point (end of third cycle) in women's self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk of benefit) and responder rate (50% reduction in symptoms). Results Improvement in the main variable was greater in the active group compared wit placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment. Conclusions Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.	Inst Hlth Care & Sci, D-35625 Huttenberg, Germany		Schellenberg, R (corresponding author), Inst Hlth Care & Sci, D-35625 Huttenberg, Germany.							American Psychiatric Association, 1997, DIAGN STAT MAN MENT; BERGER D, 1999, Z PHYTOTHER, V20, P140; BRICKELL C, 1989, ROYAL HORTICULTURAL; Brugisser R, 1999, Z PHYTOTHERAPIE, V20, P140; CARROLL BJ, 1978, PSYCHONEUROENDOCRINO, V3, P171, DOI 10.1016/0306-4530(78)90005-7; CASPER RF, 1986, AM J OBSTET GYNECOL, V155, P862, DOI 10.1016/S0002-9378(86)80040-0; Chuong CJ, 1988, PREMENSTRUAL SYNDROM, P75; DUMEC G, 1993, AUST J MED HERBALISM, V5, P63; Guy E, 1976, ECDEU ASS MAN PSYCH, P217; HOBBS C, 1991, PHARM HIST, V23, P19; JARRY H, 1994, EXP CLIN ENDOCRINOL, V102, P448, DOI 10.1055/s-0029-1211317; JARRY H, 1991, Z PHYTOTHER, V12, P77; Kupper C, 1996, DTSCH APOTHEKER ZEIT, V136, P23; Lauritzen C, 1997, PHYTOMEDICINE, V4, P183, DOI 10.1016/S0944-7113(97)80066-9; MACHIN D, 1987, STAT TABLES DESIGN C, P81; Medina JH, 1998, PHYTOMEDICINE, V5, P235, DOI 10.1016/S0944-7113(98)80034-2; Merz PG, 1996, EXP CLIN ENDOCR DIAB, V104, P447, DOI 10.1055/s-0029-1211483; MILEWICZ A, 1993, ARZNEIMITTEL-FORSCH, V43-2, P752; PETERSWELTE C, 1994, TW GYNAKOLOGIE, V7, P49; ROEDER D, 1994, Z PHYTOTHER, V15, P155; SAMOCHOWIEC I, 1998, ARZTEZEITSCHR NATURH, V39, P213; Shiah IS, 1998, LIFE SCI, V63, P1289, DOI 10.1016/S0024-3205(98)00241-0; SLIUTZ G, 1993, HORM METAB RES, V25, P253, DOI 10.1055/s-2007-1002090; Smith S, 1994, MODERN MANAGEMENT PR, P46; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; WINTERHOFF H, 1991, Z PHYTOTHERAPIE, V12, P175; Wuttke W, 1995, PHYTOPHARMAKA FORSCH, P81	28	160	169	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					134	137		10.1136/bmj.322.7279.134	http://dx.doi.org/10.1136/bmj.322.7279.134			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159568	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000166615300023
J	Chintu, C; Mwaba, P				Chintu, C; Mwaba, P			Striving for global drug availability	LANCET			English	Article									UNZA UCLMS, Project HIV AIDS & TB Res & Training, Lusaka, Zambia; Univ Teaching Hosp, Lusaka, Zambia; Minist Hlth, Lusaka, Zambia	University of Zambia; University of Zambia	Chintu, C (corresponding author), UNZA UCLMS, Project HIV AIDS & TB Res & Training, POB 50110, Lusaka, Zambia.		Mwaba, Peter/V-6017-2019						0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S5	S5		10.1016/S0140-6736(00)91991-3	http://dx.doi.org/10.1016/S0140-6736(00)91991-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191508	Bronze			2023-01-03	WOS:000166074900007
J	Bergh, J; Wiklund, T; Erikstein, B; Lidbrink, E; Lindman, H; Malmstrom, P; Kellokumpu-Lehtinen, P; Bengtsson, NO; Soderlund, G; Anker, G; Wist, E; Ottosson, S; Salminen, E; Ljungman, P; Holte, H; Nilsson, J; Blomqvist, C; Wilking, N				Bergh, J; Wiklund, T; Erikstein, B; Lidbrink, E; Lindman, H; Malmstrom, P; Kellokumpu-Lehtinen, P; Bengtsson, NO; Soderlund, G; Anker, G; Wist, E; Ottosson, S; Salminen, E; Ljungman, P; Holte, H; Nilsson, J; Blomqvist, C; Wilking, N		Scandinavian Breast Grp 9401 Study	Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial	LANCET			English	Article							ANTICANCER DRUGS; CELL SUPPORT; TOXICITY; LEUKEMIA; THERAPY; CMF; PHARMACOKINETICS; METHOTREXATE; EFFICACY; REGIMEN	Background Chemotherapy drug distribution varies greatly among individual patients. Therefore, we developed an individualised fluorouracil. epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer. We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support. Methods 525 women younger than 60 years of age with highrisk primary breast cancer were randomised after surgery to receive nine cycles of tailored FEC to haematological equitoxicity with granulocyte colony-stimulating factor (G-CSF) support (n=251), or three cycles of FEC at standard doses followed by high-dose chemotherapy with cyctophosphamide, thiotepa, and carboplatin (CTCb), and peripheral-blood stem-cell or bone-marrow support (n=274). Both groups received locoregional radiation therapy and tamoxifen for 5 years. The primary outcome measure was relapse-free survival, and analysis was by intention to treat. Findings At a median follow-up of 34.3 months, there were 81 breast-cancer relapses in the tailored FEC group versus 113 in the CTCb group (double triangular method p=0.04). 60 deaths occurred in the tailored FEC group and 82 in the CTCb group (log-rank p=0.12). Patients in the CTCb group experienced more grade 3 or 4 acute toxicity compared with the tailored FEC group (p<0.0001). Two treatment-related deaths (0.7%) occurred in the CTCb group. Six patients in the tailored FEC group developed acute myeloid leukaemia and three developed myelodysplastic syndrome. Interpretation Tailored FEC with G-CSF support resulted in a significantly improved relapse-free survival and fewer grade 3 and 4 toxicities compared with marrow-supported high-dose chemotherapy with CTCb as adjuvant therapy of women with high-risk primary breast cancer.	Karolinska Hosp, Radiumhemmet, S-10401 Stockholm, Sweden; Univ Helsinki Hosp, Helsinki, Finland; Norwegian Radium Hosp, Oslo, Norway; Soder Sjukhuset, S-10064 Stockholm, Sweden; Univ Uppsala, Akad Sjukhuset, Dept Oncol, Uppsala, Sweden; Univ Hosp, Lund, Sweden; Tampere Univ Hosp, Tampere, Finland; Univ Hosp, Umea, Sweden; Univ Hosp, Linkoping, Sweden; Haukeland Univ Hosp, N-5021 Bergen, Norway; Ulluval Univ Hosp, Gothenburg, Sweden; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Turku Univ Hosp, FIN-20520 Turku, Finland; Huddinge Univ Hosp, Uppsala, Sweden; Reg Oncol Ctr, Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Oslo; Sodersjukhuset Hospital; Uppsala University; Uppsala University Hospital; Lund University; Skane University Hospital; Tampere University; Tampere University Hospital; Umea University; University of Bergen; Haukeland University Hospital; Sahlgrenska University Hospital; University of Turku; Karolinska Institutet	Bergh, J (corresponding author), Karolinska Hosp & Inst, Radiumhemmet, Dept Oncol, S-17176 Stockholm, Sweden.		Holte, Harald/AAO-5647-2020; Ljungman, Per/M-4946-2019	Blomqvist, Carl/0000-0003-3041-1938; Wiklund, Tom/0000-0002-9384-9614; Bergh, Jonas/0000-0001-5526-1847				AJANI JA, 1990, CANCER INVEST, V8, P147, DOI 10.3109/07357909009017560; [Anonymous], 1992, DESIGN ANAL SEQUENTI; ANTMAN K, 1988, ANN INTERN MED, V108, P570, DOI 10.7326/0003-4819-108-4-570; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; Bastholt L, 1996, J CLIN ONCOL, V14, P1146, DOI 10.1200/JCO.1996.14.4.1146; Bergh J, 1998, RECENT RES CANCER, V152, P328; Bergh J, 2000, LANCET, V355, P944, DOI 10.1016/S0140-6736(00)90007-2; BONNETERRE J, 1998, P 34 ANN M AM SOC CL; Colleoni M, 1998, EUR J CANCER, V34, P1693, DOI 10.1016/S0959-8049(98)00209-3; DECILLIS A, 1997, P 33 ANN M AM SOC CL; Diamandidou E, 1996, J CLIN ONCOL, V14, P2722, DOI 10.1200/JCO.1996.14.10.2722; EVANS WE, 1989, CLIN PHARMACOKINET, V16, P327, DOI 10.2165/00003088-198916060-00001; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; Fisher B, 1997, J CLIN ONCOL, V15, P1858, DOI 10.1200/JCO.1997.15.5.1858; Fossati R, 1998, J CLIN ONCOL, V16, P3439, DOI 10.1200/JCO.1998.16.10.3439; Gurney H, 1996, J CLIN ONCOL, V14, P2590, DOI 10.1200/JCO.1996.14.9.2590; Gurney HP, 1998, J CLIN ONCOL, V16, P2299, DOI 10.1200/JCO.1998.16.7.2299; HENDERSON I, 1998, P 34 ANN M AM SOC CL; Hortobagyi GN, 2000, JNCI-J NATL CANCER I, V92, P225, DOI 10.1093/jnci/92.3.225; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Lindman H, 1999, ACTA ONCOL, V38, P239; PedersenBjergaard J, 1995, ANN ONCOL, V6, P751, DOI 10.1093/oxfordjournals.annonc.a059310; PETERS W, 1999, P 35 ANN M AM SOC CL; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; Poikonen P, 1999, BRIT J CANCER, V80, P1763, DOI 10.1038/sj.bjc.6690594; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; RODENHUIS S, 2000, P 36 ANN M AM SOC CL; ROSTI G, 1997, SOLID TUMOURS WORKIN, P41; Saarto T, 1997, BRIT J CANCER, V75, P301, DOI 10.1038/bjc.1997.49; Sandstrom M, 1996, J CLIN ONCOL, V14, P1581, DOI 10.1200/JCO.1996.14.5.1581; Stadtmauer EA, 2000, NEW ENGL J MED, V342, P1069, DOI 10.1056/NEJM200004133421501; TRAVIS L, 1999, P 35 ANN M AM SOC CL; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; van Os R, 1998, BLOOD, V92, P1950, DOI 10.1182/blood.V92.6.1950.418k21_1950_1956	35	209	212	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 21	2000	356	9239					1384	1391		10.1016/S0140-6736(00)02841-5	http://dx.doi.org/10.1016/S0140-6736(00)02841-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	365XQ	11052580				2023-01-03	WOS:000089976100011
J	Wei, P; Zhang, J; Egan-Hafley, M; Liang, SG; Moore, DD				Wei, P; Zhang, J; Egan-Hafley, M; Liang, SG; Moore, DD			The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism	NATURE			English	Article							GENE; 1,4-BIS<2-(3,5-DICHLOROPYRIDYLOXY)>BENZENE; HEPATOTOXICITY; CARCINOGENS; EXPRESSION; LIVER; PXR	Organisms encounter a wide range of foreign compounds-or 'xenobiotics'-with potentially harmful consequences. The cytochrome P450 (CYP) enzymes metabolize xenobiotics and thus are a primary defence against these compounds. Increased expression of specific CYP genes in response to particular xenobiotics is a central component of this defence(1), although such induction can also increase production of toxic metabolites. Here we show that the nuclear receptor CAR mediates the response evoked by a class of xenobiotics known as the 'phenobarbital-like inducers'. The strong activation of Cyp2b10 gene expression by phenobarbital, or by the more potent TCPOBOP, is absent in mice lacking the CAR gene. These animals also show decreased metabolism of the classic CYP substrate zoxazolamine and a complete loss of the liver hypertrophic and hyperplastic responses to these inducers. Cocaine causes acute hepatotoxicity in wild-type mice previously exposed to phenobarbital-like inducers and this toxicity is also absent in the CAR-deficient animals. Thus, loss of CAR function alters sensitivity to toxins, increasing or decreasing it depending on the compound. Modulation of CAR activity in humans may significantly affect metabolism of drugs and other xenobiotics.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bornheim LM, 1998, TOXICOL APPL PHARM, V150, P158, DOI 10.1006/taap.1998.8403; Carthew P, 1998, TOXICOL SCI, V44, P46, DOI 10.1006/toxs.1998.2473; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Code EL, 1997, DRUG METAB DISPOS, V25, P985; Cunningham ML, 1996, MUTAT RES-REV GENET, V365, P59, DOI 10.1016/S0165-1110(96)90012-3; HEUBEL F, 1989, BIOCHEM PHARMACOL, V38, P1293, DOI 10.1016/0006-2952(89)90336-5; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liang HCL, 1996, P NATL ACAD SCI USA, V93, P1671, DOI 10.1073/pnas.93.4.1671; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; POLAND A, 1980, MOL PHARMACOL, V18, P571; ROBINSON JR, 1974, MOL PHARMACOL, V10, P484; Selim K, 1999, HEPATOLOGY, V29, P1347, DOI 10.1002/hep.510290535; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	22	551	576	3	41	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 19	2000	407	6806					920	923		10.1038/35038112	http://dx.doi.org/10.1038/35038112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	364PZ	11057673				2023-01-03	WOS:000089901900056
J	Saito, M; Korsmeyer, SJ; Schlesinger, PH				Saito, M; Korsmeyer, SJ; Schlesinger, PH			BAX-dependent transport of cytochrome c reconstituted in pure liposomes	NATURE CELL BIOLOGY			English	Article							PORE FORMATION; MARKER MOLECULES; CELL-DEATH; RELEASE; MITOCHONDRIA; MEMBRANES; APOPTOSIS; KINETICS; BCL-2; MELITTIN		Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Schlesinger, PH (corresponding author), Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA.		Schlesinger, Paul H/C-6049-2012					Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BADLEY RA, 1976, MODERN FLUORESCENCE, V2, P112; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HILLE B, 1968, J GEN PHYSIOL, V51, P199, DOI 10.1085/jgp.51.2.199; LEVITT DG, 1984, CURR TOP MEMBR TRANS, V21, P181; MILLER C, 1984, ANNU REV PHYSIOL, V46, P549, DOI 10.1146/annurev.ph.46.030184.003001; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; RENKIN EM, 1954, J GEN PHYSIOL, V38, P225; Rex S, 1996, BIOPHYS CHEM, V58, P75, DOI 10.1016/0301-4622(95)00087-9; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SCHWARZ G, 1990, BIOPHYS J, V58, P577, DOI 10.1016/S0006-3495(90)82401-2; SCHWARZ G, 1992, BIOCHIM BIOPHYS ACTA, V1110, P97, DOI 10.1016/0005-2736(92)90299-2; SCHWARZ G, 1992, BIOPHYS CHEM, V42, P291, DOI 10.1016/0301-4622(92)80021-V; Segel I., 1975, ENZYME KINETICS, P371; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	26	389	405	1	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					553	555		10.1038/35019596	http://dx.doi.org/10.1038/35019596			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934477				2023-01-03	WOS:000088605000022
J	Xie, W; Barwick, JL; Downes, M; Blumberg, B; Simon, CM; Nelson, MC; Neuschwander-Tetri, BA; Bruntk, EM; Guzelian, PS; Evans, RM				Xie, W; Barwick, JL; Downes, M; Blumberg, B; Simon, CM; Nelson, MC; Neuschwander-Tetri, BA; Bruntk, EM; Guzelian, PS; Evans, RM			Humanized xenobiotic response in mice expressing nuclear receptor SXR	NATURE			English	Article							SMALL-BOWEL ENTEROCYTES; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; TRANSGENIC MICE; ADULT-RAT; INDUCTION; CYTOCHROME-P-450; CYP3A4; LIVER; IDENTIFICATION	The cytochrome CYP3A gene products, expressed in mammalian liver, are essential for the metabolism of lipophilic substrates, including endogenous steroid hormones and prescription drugs(1,2). CYP3A enzymes are extremely versatile and are inducible by many of their natural and xenobiotic substrates. Consequently, they form the molecular basis for many clinical drug-drug interactions(3). The induction of CYP3A enzymes is species-specific(4,5), and we have postulated that it involves one or more cellular factors, or receptor-like xeno-sensors(6). Here we identify one such factor unequivocally as the nuclear receptor pregnenolone X receptor (PXR)(7,8) and its human homologue, steroid and xenobiotic receptor (SXR)(8-10). We show that targeted disruption of the mouse PXR gene abolishes induction of CYP3A by prototypic inducers such as dexamethasone or pregnenolone-16 alpha-carbonitrile. In transgenic mice, an activated form of SXR causes constitutive upregulation of CYP3A gene expression and enhanced protection against toxic xenobiotic compounds. Furthermore, we show that the species origin of the receptor, rather than the promoter structure of CYP3A genes, dictates the species-specific pattern of CYP3A inducibility. Thus, we can generate 'humanized' transgenic mice that are responsive to human-specific inducers such as the antibiotic rifampicin. We conclude that SXR/PXR genes encode the primary species-specific xeno-sensors that mediate the adaptive hepatic response, and may represent the critical biochemical mechanism of human xenoprotection.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; St Louis Univ, Sch Med, Dept Pathol, Kansas City, MO 64108 USA; St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, Kansas City, MO 64108 USA	Howard Hughes Medical Institute; Salk Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Irvine; Saint Louis University; Saint Louis University	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Xie, Wen/M-1768-2016	Evans, Ronald/0000-0002-9986-5965; 				Barwick JL, 1996, MOL PHARMACOL, V50, P10; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; BOCHERDING SM, 1992, ARCH INTERN MED, V152, P711; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P11; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; HEBERT MF, 1992, CLIN PHARMACOL THER, V52, P453, DOI 10.1038/clpt.1992.171; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; KIMURA S, 1984, NUCLEIC ACIDS RES, V12, P2917, DOI 10.1093/nar/12.6.2917; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KOLARS JC, 1992, J CLIN INVEST, V90, P1871, DOI 10.1172/JCI116064; KOLARS JC, 1994, GASTROENTEROLOGY, V106, P433, DOI 10.1016/0016-5085(94)90602-5; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; WRIGHTON SA, 1985, MOL PHARMACOL, V28, P312; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YANAGIMOTO T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P329, DOI 10.1016/0167-4781(92)90447-8	30	561	593	6	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 27	2000	406	6794					435	439		10.1038/35019116	http://dx.doi.org/10.1038/35019116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337WC	10935643				2023-01-03	WOS:000088383800053
J	Swan, SK; Rudy, DW; Lasseter, KC; Ryan, CF; Buechel, KL; Lambrecht, LJ; Pinto, MB; Dilzer, SC; Obrda, O; Sundblad, KJ; Gumbs, CP; Ebel, DL; Quan, H; Larson, PJ; Schwartz, JI; Musliner, TA; Gertz, BJ; Brater, DC; Yao, SL				Swan, SK; Rudy, DW; Lasseter, KC; Ryan, CF; Buechel, KL; Lambrecht, LJ; Pinto, MB; Dilzer, SC; Obrda, O; Sundblad, KJ; Gumbs, CP; Ebel, DL; Quan, H; Larson, PJ; Schwartz, JI; Musliner, TA; Gertz, BJ; Brater, DC; Yao, SL			Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLOMERULAR-FILTRATION RATE; SODIUM-BALANCE; H SYNTHASE; INSUFFICIENCY; INDOMETHACIN; PROSTAGLANDINS; HOMEOSTASIS; ISOFORM; ASPIRIN	Background: Most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1), whose inhibition is associated with gastrointestinal ulceration, and COX-2, whose inhibition is associated with therapeutic benefits. Although agents that do not produce COX-1 activity may have fewer adverse effects, targeted disruption of the COX-2 allele in mice has resulted in severe renal problems, suggesting that COX-2 inhibition may also produce adverse effects. Objective: To determine the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients. Design: A randomized, three-period, single-dose crossover study and a randomized, parallel-group, multiple-dose study. Setting: Clinical research units. Patients: 75 patients 60 to 80 years of age. Intervention: In the first study, single doses of rofecoxib, 250 mg (about Ei-fold to 20-fold the recommended dose); indomethacin, 75 mg; and placebo were administered to 15 patients. In the second study, multiple doses of rofecoxib, 12.5 or 25 mg/d; indomethacin, 50 mg three times daily; or placebo were administered to 60 patients. Patients in both studies received a low-sodium diet Measurements: Glomerular filtration rate, creatinine clearance, and urinary and serum sodium and potassium values. Results: Compared with placebo, single doses of rofecoxib and indomethacin decreased the glomerular filtration rate by 0.23 mL/s (P < 0.001) and 0.18 mL/s (P = 0.003), respectively. In contrast, respective decreases of 0.14, 0.13, and 0.10 mL/s were observed after multiple doses of rofecoxib, 12.5 mg/d (P = 0.019); rofecoxib, 25 mg (P = 0.029), and indomethacin (P = 0.086) were administered. Changes in creatinine clearance and serum and urinary sodium and potassium were less pronounced. Conclusions: The effects of COX-2 inhibition on renal function are similar to those observed with nonselective NSAIDs. Thus, COX-2 seems to play an important role in human renal function.	Hennepin Cty Med Ctr, Div Nephrol, Minneapolis, MN 55415 USA; Total Renal Res Inc, Minneapolis, MN USA; Indiana Univ, Indianapolis, IN 46204 USA; Clin Pharmacol Associates, Miami, FL USA; PPD, Austin, TX USA; Merck Res Labs, Rahway, NJ USA	Hennepin County Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company	Yao, SL (corresponding author), Hennepin Cty Med Ctr, Div Nephrol, 701 Pk Ave, Minneapolis, MN 55415 USA.	siulong_yao@merck.com						BRATER DC, 1985, CLIN PHARMACOL THER, V38, P674, DOI 10.1038/clpt.1985.244; BRATER DC, 1979, CLIN PHARMACOL THER, V25, P322; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002-9343(98)00091-6; DONKER AJM, 1976, NEPHRON, V17, P288, DOI 10.1159/000180733; DUSING R, 1982, KLIN WOCHENSCHR, V60, P1229, DOI 10.1007/BF01716728; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; FJELDBO W, 1968, J LAB CLIN MED, V72, P353; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Komhoff M, 1997, AM J PHYSIOL-RENAL, V272, pF460, DOI 10.1152/ajprenal.1997.272.4.F460; KRAMER HJ, 1985, CLIN SCI, V68, P387, DOI 10.1042/cs0680387; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Murray MD, 1997, AM J MED SCI, V314, P80, DOI 10.1097/00000441-199708000-00009; MURRAY MD, 1992, BRIT J CLIN PHARMACO, V33, P385, DOI 10.1111/j.1365-2125.1992.tb04056.x; MURRAY MD, 1995, AM J MED SCI, V310, P188, DOI 10.1097/00000441-199511000-00003; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; MUTHER RS, 1981, ANN INTERN MED, V94, P317, DOI 10.7326/0003-4819-94-3-317; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; SIGMAN EM, 1966, J NUCL MED, V7, P60; SIGMAN EUGENE M., 1965, INVEST UROL, V2, P432; SIROIS J, 1992, J BIOL CHEM, V267, P11586; TOTO RD, 1986, KIDNEY INT, V30, P760, DOI 10.1038/ki.1986.253	25	274	287	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					1	9		10.7326/0003-4819-133-1-200007040-00002	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877734				2023-01-03	WOS:000087923100001
J	Fields, SA; Usatine, R; Steiner, E				Fields, SA; Usatine, R; Steiner, E			Teaching medical students in the ambulatory setting - Strategies for success	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMMUNITY PRECEPTORS; CARE; PARTICIPATION; EDUCATION		Oregon Hlth Sci Univ, Dept Family Med, Portland, OR 97201 USA; Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA	Oregon Health & Science University; University of California System; University of California Los Angeles	Fields, SA (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							*ASS AM MED COLL, 1999, MED TEACH PHYS DOC I; BROOK RH, 1996, JAMA-J AM MED ASSOC, V276, P479; Devera-Sales A, 1999, ACAD MED, V74, P550, DOI 10.1097/00001888-199905000-00024; Ferenchick G, 1997, ACAD MED, V72, P277, DOI 10.1097/00001888-199704000-00011; Fields SA, 1998, ACAD MED, V73, P95, DOI 10.1097/00001888-199801000-00019; Fields SA, 1998, ACAD MED, V73, P25, DOI 10.1097/00001888-199801000-00008; Hunt CE, 1999, ARCH PEDIAT ADOL MED, V153, P297; KALET A, 1997, ACAD MED, V72, P766; Lawrence SL, 1999, ACAD MED, V74, P715, DOI 10.1097/00001888-199906000-00020; Ludmerer KM, 1999, TIME HEAL; Neher J O, 1992, J Am Board Fam Pract, V5, P419; Seifer SD, 1998, ACAD MED, V73, P273, DOI 10.1097/00001888-199803000-00015; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; STANGL S, 1995, ACAD MED, V70, P459, DOI 10.1097/00001888-199505000-00066; USATINE R, IN PRESS ACAD MED; Usatine R P, 1995, Fam Med, V27, P566; Vinson DC, 1996, J FAM PRACTICE, V42, P243; Wilkes MS, 1998, ACAD MED, V73, P32, DOI 10.1097/00001888-199801000-00009	18	26	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	2000	283	18					2362	2364		10.1001/jama.283.18.2362	http://dx.doi.org/10.1001/jama.283.18.2362			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310CD	10815060				2023-01-03	WOS:000086808200002
J	Roses, AD				Roses, AD			Pharmacogenetics and future drug development and delivery	LANCET			English	Editorial Material							DISEASE; POLYMORPHISM; DEMENTIA		Glaxo Wellcome plc, Genet Directorate, Greenford, Middx, England; Duke Univ, Med Ctr, Durham, NC USA	GlaxoSmithKline; Duke University	Roses, AD (corresponding author), Glaxo Wellcome Res & Dev Ltd, 5 Moore Dr,5-5616, Res Triangle Pk, NC 27709 USA.							AITMAN TJ, 1995, BAILLIERE CLIN ENDOC, V9, P631, DOI 10.1016/S0950-351X(95)80655-5; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Fijal BA, 2000, CONTROL CLIN TRIALS, V21, P7, DOI 10.1016/S0197-2456(99)00039-2; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Mather DB, 1999, AM J MANAG CARE, V5, P277; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; *NHS, 1999, FAST ACC MOD TREATM; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; ROSES AD, 1994, CURR NEUROL, V14, P111; Scott WK, 1999, JAMA-J AM MED ASSOC, V281, P513, DOI 10.1001/jama.281.6.513; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512	15	149	155	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1358	1361		10.1016/S0140-6736(00)02126-7	http://dx.doi.org/10.1016/S0140-6736(00)02126-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776762				2023-01-03	WOS:000086829400042
J	Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G				Groenewoud, JH; van der Heide, A; Onwuteaka-Philipsen, BD; Willems, DL; van der Maas, PJ; van der Wal, G			Clinical problems with the performance of euthanasia and physician-assisted suicide in the netherlands.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; ATTITUDES; LIFE; END; ONCOLOGISTS; DECISIONS; OREGON; DEATH	Background and Methods: The characteristics and frequency of clinical problems with the performance of euthanasia and physician-assisted suicide are uncertain. We analyzed data from two studies of euthanasia and physician-assisted suicide in the Netherlands (one conducted in 1990 and 1991 and the other in 1995 and 1996), with a total of 649 cases. We categorized clinical problems as technical problems, such as difficulty inserting an intravenous line; complications, such as myoclonus or vomiting; or problems with completion, such as a longer-than-expected interval between the administration of medications and death. Results: In 114 cases, the physician's intention was to provide assistance with suicide, and in 535, the intention was to perform euthanasia. Problems of any type were more frequent in cases of assisted suicide than in cases of euthanasia. Complications occurred in 7 percent of cases of assisted suicide, and problems with completion (a longer-than-expected time to death, failure to induce coma, or induction of coma followed by awakening of the patient) occurred in 16 percent of the cases; complications and problems with completion occurred in 3 percent and 6 percent of cases of euthanasia, respectively. The physician decided to administer a lethal medication in 21 of the cases of assisted suicide (18 percent), which thus became cases of euthanasia. The reasons for this decision included problems with completion (in 12 cases) and the inability of the patient to take all the medications (in 5). Conclusions: There may be clinical problems with the performance of euthanasia and physician-assisted suicide. In the Netherlands, physicians who intend to provide assistance with suicide sometimes end up administering a lethal medication themselves because of the patient's inability to take the medication or because of problems with the completion of physician-assisted suicide. (N Engl J Med 2000;342:551-6.) (C)2000, Massachusetts Medical Society.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Social Med, Amsterdam, Netherlands	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Groenewoud, JH (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; *GEN BOARD RDMA, 1996, EUTH NETH; Gevers S, 1996, BRIT MED BULL, V52, P326; *KON NED MAATSCH B, 1994, TOEP BER EUTH SGRAV; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LEGEMAATE J, 1995, CAMB Q HEALTHC ETHIC, V4, P112; Matzo M L, 1997, Oncol Nurs Forum, V24, P1725; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MULLER MT, 1992, VOX HOSP, V16, P3; Onwuteaka-Philipsen B D, 1995, Arch Fam Med, V4, P951, DOI 10.1001/archfami.4.11.951; OnwuteakaPhilipsen BD, 1997, J AM GERIATR SOC, V45, P1208, DOI 10.1111/j.1532-5415.1997.tb03771.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Wal G, 1992, Ned Tijdschr Geneeskd, V136, P1299; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; *WET I NED AP, 1998, MED CONTACT, V53, P1366; Woolfrey J, 1998, HASTINGS CENT REP, V28, P9, DOI 10.2307/3528645	28	123	123	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					551	556		10.1056/NEJM200002243420805	http://dx.doi.org/10.1056/NEJM200002243420805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684914	Green Published, Bronze			2023-01-03	WOS:000085422400005
J	McPhillips, M; Hepper, PG; Mulhern, G				McPhillips, M; Hepper, PG; Mulhern, G			Effects of replicating primary-reflex movements on specific reading difficulties in children: a randomised, double-blind, controlled trial	LANCET			English	Article							DYSLEXIA; DISABILITIES; INFANTS	Background Children with specific reading difficulties have problems that extend beyond the range of underlying language-related deficits leg, they have difficulties with balance and mote, control). We investigated the role of persistent primary reflexes (Which are closely linked in the earliest months of life to the balance system) in disrupting the development of reading skills. Methods We assessed the efficacy of an intervention programme based on replicating the movements generated by the primary-reflex system during fetal and neonatal life. A randomised, individually matched, double-blind, placebo-controlled design was used and children (aged 8-11 years) with persistent primary reflexes and a poor standard of reading were enrolled into one of three treatment groups: experimental (children were given a specific movement sequence); placebo control (children were given non-specific movements); and control (no movements). Findings From an initial sample of 98 children, 60 children, 20 in each group were matched on age, sex, verbal intelligence quotient (IQ), reading ability, and persistent asymmetrical tonic neck reflex. For asymmetrical tonic neck-reflex levels there was a significant (group by time) interaction (p<0.001). The experimental group showed a significant decrease in the level of persistent reflex over the course of the study (mean change -1.8 [95% CI -2.4 to -1.2], p<0.001), whereas the changes in the placebo-control and control groups were not significant (-0.2 [-0.9 to 0.6] and -0.4 [-0.9 to 0.2]). Interpretation This study provides further evidence of a link between: reading difficulties and control of movement in children. In particular, our study highlights how the educational functioning of children may be linked to interference from an early neurodevelopmental system (the primary-reflex system). A new approach to the treatment of children with reading difficulties is proposed involving assessment of underlying neurological functioning, and appropriate remediation.	Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast	McPhillips, M (corresponding author), Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland.		hepper, peter/D-1478-2009	McPhillips, Martin/0000-0003-0233-6619				BEARD R, 1993, TEACHING LIT BALANCI; BOBATH B, 1975, MOTOR DEV DIFFERENT; BOOKBINDER GE, 1976, MANUAL SALFORD SENTE; Bradley L., 1985, RHYME REASON READING; BRAITHWAITE GR, 1975, LANCHESTER SHORT STA; Capute A. J., 1981, LANGUAGE BEHAV INFAN, P157; CARTE E, 1984, J DEV BEHAV PEDIATR, V5, P189; CORNELISSEN P, 1995, VISION RES, V35, P1483, DOI 10.1016/0042-6989(95)98728-R; EDEN GF, 1994, VISION RES, V34, P1345, DOI 10.1016/0042-6989(94)90209-7; Fawcett AJ, 1996, ANN DYSLEXIA, V46, P259, DOI 10.1007/BF02648179; FAWCETT AJ, 1995, J MOTOR BEHAV, V27, P235, DOI 10.1080/00222895.1995.9941713; Frederickson N., 1995, PHONOLOGICAL ASSESSM; HASLUM MN, 1989, IRISH J PSYCHOL, V10, P622, DOI 10.1080/03033910.1989.10557776; Holt K. S., 1991, CHILD DEV DIAGNOSIS; Illingworth RS, 1987, DEV INFANT YOUNG CHI, V9th; KIBEL M, 1994, READING DEVELOPMENT AND DYSLEXIA, P105; LOVEGROVE W, 1991, VISUAL DYSLEXIA VISI, V13; Morrison D. C., 1985, NEUROBEHAVIOURAL PER; NEALE MD, 1989, NEALE ANAL READING A; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; Olson R., 1990, READING ITS DEV COMP, P261; PAINE R S, 1964, Dev Med Child Neurol, V6, P345; Prechtl H., 1984, CONTINUITY NEURAL FU, P1; RILEY J, 1996, TEACHING READING; Rust J, 1993, WECHSLER OBJECTIVE R; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SEIDEL UP, 1975, DEV MED CHILD NEUROL, V17, P563; SHAYWITZ SE, 1996, SCI AM, V275, P78; Snowling M., 2005, DYSLEXIA COGNITIVE D, V17, P4; STANOVICH KE, 1988, J LEARN DISABIL-US, V21, P590, DOI 10.1177/002221948802101003; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; Stein JF, 1995, IRISH J PSYCHOL, V16, P220, DOI 10.1080/03033910.1995.10558058; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; THELEN E, 1983, J MOTOR BEHAV, V15, P353; THELEN E, 1979, ANIM BEHAV, V27, P699, DOI 10.1016/0003-3472(79)90006-X; YOUNG D, 1989, NONREADING INTELLIGE	36	66	67	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2000	355	9203					537	541		10.1016/S0140-6736(99)02179-0	http://dx.doi.org/10.1016/S0140-6736(99)02179-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	287CN	10683004				2023-01-03	WOS:000085487400012
J	Chang, TW				Chang, TW			The pharmacological basis of anti-IgE therapy	NATURE BIOTECHNOLOGY			English	Review						immunoglobulin E; anti-IgE; allergy; asthma; humanized antibodies; Fc epsilon RI; immune complexes	FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; CHIMERIC MONOCLONAL-ANTIBODY; HUMAN-IMMUNOGLOBULIN-E; HUMAN BASOPHILS; BINDING-SITE; B-CELLS; IN-VIVO; EXPRESSION; ASTHMA	The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II and III human clinical studies. The therapeutic efficacy of this approach is attributable to several pharmacological mechanisms. In addition to the expected effects of these monoclonal antibodies in neutralizing free IgE and inhibiting IgE production by B cells, several indirect biochemical and cellular effects have been uncovered during the course of the clinical trials. These include the accumulation of potentially beneficial IgE-anti-IgE immune complexes and the downregulation of the high-affinity IgE Fc receptors (Fc epsilon RI) on basophils and mast cells. This article analyzes the structural basis of the specificity of the anti-IgE antibodies and pertinent results from in vitro experiments, animal model studies, and human clinical trials in an attempt to provide a cogent pharmacological interpretation of the therapeutic effects of anti-IgE therapy in both the near- and long term. The development of anti-IgE therapy over the past 10 years provides an interesting example of the emergence of a conceptually new, biotechnology-produced pharmaceutical.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan	National Tsing Hua University	Chang, TW (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan.	twchang@life.nthu.edu.tw	Chang, Tse Wen/H-5955-2011					ADELROTH E, 1999, 20 NORD C ALL OSL NO; Barnes PJ, 1999, NEW ENGL J MED, V341, P2006, DOI 10.1056/NEJM199912233412610; BIALY H, 1990, BIO-TECHNOL, V8, P96; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; CARTER SE, 1998, CURR OPIN PEDIATR, V10, P594; CELIS E, 1984, SCIENCE, V224, P297, DOI 10.1126/science.6231724; CHANG TW, 1990, BIO-TECHNOL, V8, P122, DOI 10.1038/nbt0290-122; Chen HD, 1996, ALLERGY ASTHMA PROC, V17, P143, DOI 10.2500/108854196779165058; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825, DOI 10.1164/ajrccm.155.6.9196081; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; ERAY M, 1994, INT IMMUNOL, V6, P1817, DOI 10.1093/intimm/6.12.1817; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; HABA S, 1994, J IMMUNOL, V152, P51; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Heusser CH, 1997, INT ARCH ALLERGY IMM, V113, P231, DOI 10.1159/000237555; HOOK WA, 1991, MOL IMMUNOL, V28, P631, DOI 10.1016/0161-5890(91)90132-4; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Juniper EF, 1997, ALLERGY, V52, P971, DOI 10.1111/j.1398-9995.1997.tb02416.x; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; KOLBINGER F, 1993, PROTEIN ENG, V6, P971, DOI 10.1093/protein/6.8.971; Lantz CS, 1997, J IMMUNOL, V158, P2517; Liu CL, 1996, CELL IMMUNOL, V167, P188, DOI 10.1006/cimm.1996.0026; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAHONEY DG, 1997, J CLIN ONCOL, V15, P3266; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAURER D, 1995, J IMMUNOL, V154, P6285; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; OGAWA M, 1971, AM J MED, V51, P193, DOI 10.1016/0002-9343(71)90238-5; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; PEETERS SH, 1981, IMMUNOLOGY, V43, P25; PENG C, 1992, J IMMUNOL, V148, P129; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Racine-Poon A, 1997, CLIN PHARMACOL THER, V62, P675, DOI 10.1016/S0009-9236(97)90087-4; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; Sechi S, 1996, J BIOL CHEM, V271, P19256, DOI 10.1074/jbc.271.32.19256; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; STAMPFLI MR, 1994, EUR J IMMUNOL, V24, P2161, DOI 10.1002/eji.1830240934; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WARNER GL, 1991, J IMMUNOL, V146, P2185; Wright JD, 1998, PROTEIN ENG, V11, P421, DOI 10.1093/protein/11.6.421; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	59	218	252	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					157	162		10.1038/72601	http://dx.doi.org/10.1038/72601			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657120				2023-01-03	WOS:000085146900021
J	Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR				Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR			The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCYTIAL VIRUS-INFECTION; RESPIRATORY-DISEASE; YOUNG-CHILDREN; OTITIS-MEDIA; A-VIRUS; IMPACT; VACCINE; EPIDEMIOLOGY; MORTALITY; AGE	Background: Despite high annual rates of influenza in children, influenza vaccines are given to children infrequently. We measured the disease burden of influenza in a large cohort of healthy children in the Tennessee Medicaid program who were younger than 15 years of age. Methods: We determined the rates of hospitalization for acute cardiopulmonary conditions, outpatient visits, and courses of antibiotics over a period of 19 consecutive years. Using the differences in the rates of these events when influenzavirus was circulating and the rates from November through April when there was no influenza in the community, we calculated morbidity attributable to influenza. There was a total of 2,035,143 person-years of observation. Results: During periods when influenzavirus was circulating, the average number of hospitalizations for cardiopulmonary conditions in excess of the expected number was 104 per 10,000 children per year for children younger than 6 months of age, 50 per 10,000 per year for those 6 months to less than 12 months, 19 per 10,000 per year for those 1 year to less than 3 years, 9 per 10,000 per year for those 3 years to less than 5 years, and 4 per 10,000 per year for those 5 years to less than 15 years. For every 100 children, an annual average of 6 to 15 outpatient visits and 3 to 9 courses of antibiotics were attributable to influenza. In winter, 10 to 30 percent of the excess number of courses of antibiotics occurred during periods when influenzavirus was circulating. Conclusions: Healthy children younger than one year of age are hospitalized for illness attributable to influenza at rates similar to those for adults at high risk for influenza. The rate of hospitalization decreases markedly with age. Influenza accounts for a substantial number of outpatient visits and courses of antibiotics in children of all ages. (N Engl J Med 2000; 342:225-31.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	University of Washington; University of Washington Seattle; Vanderbilt University; Vanderbilt University; Vanderbilt University	Neuzil, KM (corresponding author), Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, 1660 S Columbian Way, Seattle, WA 98108 USA.	kneuzil@u.washington.edu			PHS HHS [U50/CCU41398-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Clements ML, 1996, J INFECT DIS, V173, P44, DOI 10.1093/infdis/173.1.44; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Fisher RG, 1997, PEDIATRICS, V99, pE71, DOI 10.1542/peds.99.2.e7; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; FOY HM, 1973, AM J EPIDEMIOL, V97, P93, DOI 10.1093/oxfordjournals.aje.a121493; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; GLEZEN WP, 1982, J INFECT DIS, V146, P313, DOI 10.1093/infdis/146.3.313; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; KARRON RA, 1995, PEDIATR INFECT DIS J, V14, P10, DOI 10.1097/00006454-199501000-00002; KIM HW, 1979, AM J EPIDEMIOL, V109, P464, DOI 10.1093/oxfordjournals.aje.a112704; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; LONGINI IM, 1982, AM J EPIDEMIOL, V115, P736, DOI 10.1093/oxfordjournals.aje.a113356; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT 10, V193; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Piper J M, 1991, Paediatr Perinat Epidemiol, V5, P402, DOI 10.1111/j.1365-3016.1991.tb00726.x; PUCK JM, 1980, J INFECT DIS, V142, P844, DOI 10.1093/infdis/142.6.844; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Simonsen L, 1997, EPIDEMIOLOGY, V8, P390, DOI 10.1097/00001648-199707000-00007; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; WRIGHT PF, 1980, AM J EPIDEMIOL, V112, P814, DOI 10.1093/oxfordjournals.aje.a113053; WRIGHT PF, 1977, NEW ENGL J MED, V296, P829, DOI 10.1056/NEJM197704142961501	36	830	868	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					225	231		10.1056/NEJM200001273420401	http://dx.doi.org/10.1056/NEJM200001273420401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648763				2023-01-03	WOS:000084941000001
J	Jones, J; Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Parker, G				Jones, J; Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Parker, G			Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY DISCHARGE; MINIMIZATION ANALYSIS; SCHEME; HIP	Objectives To compare the costs of admission to a hospital at home scheme with those of acute hospital admission. Design Cost minimisation analysis within a pragmatic randomised controlled trial. Setting Hospital at home scheme in Leicester and the city's three acute hospitals. Participants 199 consecutive patients assessed as being suitable for admission to hospital at home for acute care during the 18 month trial period (median age 84 years). Intervention Hospital at home or hospital inpatient care. Main outcome measures Costs to NHS, social services, patients, and families during the initial episode of treatment and the three months after admission. Results Mean (median) costs per episode (including any transfer from hospital at home to hospital) were similar when analysed by intention to treat-hospital at home pound f2569 (pound 1655), hospital ward pound 2881 (pound 2031), bootstrap mean difference -305 (95% confidence interval -1112 to 448). When analysis was restricted to those who accepted their allocated place of care, hospital at home was significantly cheaper-hospital at home pound 2557 (pound 1710), hospital ward pound 3660 (pound 2903), bootstrap mean difference - 1071 (-1843 to -246). At thee months the cost differences were sustained. Costs with all cases included were hospital at home pound 3671 (pound 2491), hospital ward pound 3877 (pound 3405), bootstrap mean difference -210 (-1025 to 635). When only those accepting allocated care were included the costs were hospital at home pound 3698 (pound 2493), hospital ward pound 4761 (pound 3940), bootstrap mean difference -1063 (-2044 to -163); P = 0.009. About 25% of the costs for episodes of hospital at home were incurred through transfer to hospital. Costs per day of care were higher in the hospital at home arm (mean pound 207 v pound 134 in the hospital arm, excluding refusers, P < 0.001). Conclusions Hospital at home can deliver care at similar or lower cost than an equivalent admission to an acute hospital.	Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England; Univ Leicester, Nuffield Community Care Studies Unit, Leicester LE1 6TP, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester; University of Leicester	Wilson, A (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England.	AW7@le.ac.uk		Jagger, Carol/0000-0002-6377-9926; Parker, Gillian Mary/0000-0002-2221-6748				Briggs AH, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/HTA3020; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, IN PRESS J HLTH SERV; Edwards N, 1998, BRIT MED J, V317, P135, DOI 10.1136/bmj.317.7151.135; Efron B., 1986, STAT SCI, P54; FARNWORTH MG, 1994, AGE AGEING, V23, P190, DOI 10.1093/ageing/23.3.190; Hensher M, 1999, BRIT MED J, V319, P1127, DOI 10.1136/bmj.319.7217.1127; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; Lilford RJ, 1998, BRIT MED J, V317, P1651; NETTEN A, 1996, PERSONAL SOCIAL SERV; OCATHAIN A, 1994, J PUBLIC HEALTH MED, V16, P205, DOI 10.1093/oxfordjournals.pubmed.a042958; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; Wilson A, 1999, BRIT MED J, V319, P1542, DOI 10.1136/bmj.319.7224.1542	15	71	79	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1547	1550		10.1136/bmj.319.7224.1547	http://dx.doi.org/10.1136/bmj.319.7224.1547			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591720	Bronze, Green Published			2023-01-03	WOS:000084245600026
J	Posnett, J				Posnett, J			The hospital of the future - Is bigger better? Concentration in the provision of secondary care	BRITISH MEDICAL JOURNAL			English	Editorial Material							VOLUME		Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England	University of York - UK	Posnett, J (corresponding author), Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ALETRAS V, 1997, CONCENTRATION CHOICE, P23; Bentham G, 1995, Soc Sci Med, V40, P131, DOI 10.1016/0277-9536(94)E0048-W; Carr-Hill R, 1997, CONCENTRATION CHOICE, P37; *EFF HLTH CAR B, 1996, HOSP VOL HLTH CAR OU; GODDARD M, 1997, HLTH EC SERIES; HOWLAND G, 1997, IHSM HLTH SOCIAL SER; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; SOWDEN A, 1997, CONCENTRATION CHOICE, P9; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151	9	55	57	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1063	1065		10.1136/bmj.319.7216.1063	http://dx.doi.org/10.1136/bmj.319.7216.1063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521207	Green Published			2023-01-03	WOS:000083210100037
J	Waterlow, J				Waterlow, J			Treatment of children with malnutrition and diarrhoea	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Waterlow, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.							Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SMITH R, 1963, LANCET, V1, P771; WATERLOW JC, 1978, NUTRITION CLIN MANAG, P49; Waterlow JC, 1992, PROTEIN ENERGY MALNU; WATERLOW JC, 1992, NUTR CLIN MANAGEMENT; World Health Organization, 1999, MAN SEV MALN MAN PHY	7	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1142	1142		10.1016/S0140-6736(99)00329-3	http://dx.doi.org/10.1016/S0140-6736(99)00329-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513705				2023-01-03	WOS:000082954100007
J	Buhr, A; Wagner, C; Fuchs, K; Sieghart, W; Sigel, E				Buhr, A; Wagner, C; Fuchs, K; Sieghart, W; Sigel, E			Two novel residues in M2 of the gamma-aminobutyric acid type A receptor affecting gating by GABA and picrotoxin affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; ION CHANNELS; BINDING-SITE; A RECEPTOR; AMINO-ACID; SUBUNIT; ALPHA(1); IDENTIFICATION; PHARMACOLOGY; EXPRESSION	An amino acid residue was found in M2 of gamma -aminobutyric acid (GABA) type A receptors that has profound effects on the binding of picrotoxin to the receptor and therefore may form part of its binding pocket. In addition, it strongly affects channel gating. The residue is located N-terminally to residues suggested so far to be important for channel gating. Point mutated alpha (1)beta (3) receptors were expressed in Xenopus oocytes and analyzed using the electrophysiological techniques. Coexpression of the alpha (1) subunit with the mutated beta (3) subunit beta (3)L253F led to spontaneous picrotoxin-sensitive currents in the absence of GABA. Nanomolar concentrations of GABA further promoted channel opening. Upon washout of picrotoxin, a huge transient inward current was observed. The reversal potential of the inward current was indicative of a chloride ion selectivity. The amplitude of the inward current was strongly dependent on the picrotoxin concentration and on the duration of its application. There was more than a 100-fold decrease in picrotoxin affinity. A kinetic model is presented that mimics the gating behavior of the mutant receptor. The point mutation in the neighboring residue beta (3)A252V resulted in receptors that displayed an about 6-fold increased apparent affinity to GABA and an about 10-fold reduced sensitivity to picrotoxin.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Vienna, Brain Res Inst, Sect Biochem & Mol Biol, A-1090 Vienna, Austria	University of Bern; University of Vienna	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Sieghart, Werner/A-4877-2013; Sigel, Erwin/F-7736-2015	Sieghart, Werner/0000-0002-0443-0302; 				Barnard EA, 1998, PHARMACOL REV, V50, P291; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; HILL TL, 1977, FREE ENERGY TRANSDUC, P193; Jursky F, 2000, J NEUROCHEM, V74, P1310; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; Krishek BJ, 1996, MOL PHARMACOL, V49, P494; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Tierney ML, 1996, J MEMBRANE BIOL, V154, P11, DOI 10.1007/s002329900128; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	31	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7775	7781		10.1074/jbc.M008907200	http://dx.doi.org/10.1074/jbc.M008907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114302	hybrid			2023-01-03	WOS:000167474900016
J	Breitbart, W; Rosenfeld, B; Pessin, H; Kaim, M; Funesti-Esch, J; Galietta, M; Nelson, CJ; Brescia, R				Breitbart, W; Rosenfeld, B; Pessin, H; Kaim, M; Funesti-Esch, J; Galietta, M; Nelson, CJ; Brescia, R			Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; ATTITUDES; QUESTIONNAIRE; EUTHANASIA; ONCOLOGY; CARE	Context Understanding why some terminally ill patients desire a hastened death has become an important issue in palliative care and the debate regarding legalization of assisted suicide. Objectives To assess the prevalence of desire for hastened death among terminally ill cancer patients and to identify factors corresponding to desire for hastened death. Design Prospective survey conducted in a 200-bed palliative care hospital in New York, NY. Patients Ninety-two terminally ill cancer patients (60% female; 70% white; mean age, 65.9 years) admitted between June 1998 and January 1999 for end-of-life care who passed a cognitive screening test and provided sufficient data to permit analysis. Main Outcome Measure Scores on the Schedule of Attitudes Toward Hastened Death (SAHD), a self-report measure assessing desire for hastened death among individuals with life-threatening medical illness. Results Sixteen patients (17%) were classified as having a high desire for hastened death based on the SAHD and 15 (16%) of 89 patients met criteria for a current major depressive episode. Desire for hastened death was significantly associated with a clinical diagnosis of depression (P =.001) as well as with measures of depressive symptom severity (P<.001) and hopelessness (P<.001), In multivariate analyses, depression (P=.003) and hopelessness (P<.001) provided independent and unique contributions to the prediction of desire for hastened death, while social support (P=.05) and physical functioning (P=.02) added significant but smaller contributions. Conclusions Desire for hastened death among terminally ill cancer patients is not uncommon. Depression and hopelessness are the strongest predictors of desire for hastened death in this population and provide independent and unique contributions. Interventions addressing depression, hopelessness, and social support appear to be important aspects of adequate palliative care, particularly as it relates to desire for hastened death.	Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10021 USA; Fordham Univ, Dept Psychol, Bronx, NY USA; Calvary Hosp, Palliat Care Inst, Bronx, NY USA	Memorial Sloan Kettering Cancer Center; Fordham University	Breitbart, W (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1242 2nd Ave, New York, NY 10021 USA.							BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Brady MJ, 1999, PSYCHO-ONCOLOGY, V8, P417, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<417::AID-PON398>3.3.CO;2-W; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GLOCK SD, 2000, ANN INTERN MED, V132, P209; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HENDIN H, 1993, AM J PSYCHIAT, V150, P143; Karnofsky DA, 1949, CLIN EVALUATION CHEM, P191; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Moorey S, 1998, PSYCHO-ONCOL, V7, P218, DOI 10.1002/(SICI)1099-1611(199805/06)7:3<218::AID-PON308>3.3.CO;2-4; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rosenfeld B, 2000, CANCER, V88, P2868, DOI 10.1002/1097-0142(20000615)88:12<2868::AID-CNCR30>3.0.CO;2-K; Rosenfeld B, 1999, AM J PSYCHIAT, V156, P94, DOI 10.1176/ajp.156.1.94; ROSENFELD B, IN PRESS PSYCHOL PUB; Rousseau P, 2000, J CLIN ONCOL, V18, P2000, DOI 10.1200/JCO.2000.18.9.2000; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SPIEGEL D, 1995, SUPPORT CARE CANCER, V3, P252; Spitzer R.L., 1996, STRUCTURED CLIN INTE; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822	29	640	651	5	115	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2907	2911		10.1001/jama.284.22.2907	http://dx.doi.org/10.1001/jama.284.22.2907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147988	Bronze			2023-01-03	WOS:000165717000031
J	Quillen, K				Quillen, K			Hypotensive transfusion reactions in patients taking angiotensin-converting-enzyme inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Boston Med Ctr, Boston, MA 02118 USA	Boston Medical Center	Quillen, K (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.			Quillen, Karen/0000-0002-4243-0864				*AM ASS BLOOD BANK, 1998, AABB WKLY REP, V4, P1; Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606; Hume HA, 1996, TRANSFUSION, V36, P904, DOI 10.1046/j.1537-2995.1996.361097017178.x; KLEIN HG, 1998, HEMATOLOGY 1998, P158; Sweeney JD, 1998, TRANSFUSION, V38, P410, DOI 10.1046/j.1537-2995.1998.38498257382.x	5	19	19	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1422	1423		10.1056/NEJM200011093431918	http://dx.doi.org/10.1056/NEJM200011093431918			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183892				2023-01-03	WOS:000165152800033
J	Cohen, J				Cohen, J			Combination antibiotic therapy for severe peritonitis	LANCET			English	Editorial Material							INFECTIONS; NETILMICIN; GENTAMICIN		Hammersmith Hosp, Imperial Coll Sch Med, Dept Infect Dis & Microbiol, London W12 0NN, England	Imperial College London	Cohen, J (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Dept Infect Dis & Microbiol, London W12 0NN, England.							COMETTA A, 1994, ANTIMICROB AGENTS CH, V38, P1309, DOI 10.1128/AAC.38.6.1309; Del Favero A, 1999, 39 INT C ANT AG CHEM, P722; DONNELLY JP, 1985, J INFECTION, V11, P205, DOI 10.1016/S0163-4453(85)93063-4; Dupont H, 2000, ANTIMICROB AGENTS CH, V44, P2028, DOI 10.1128/AAC.44.8.2028-2033.2000; Falagas ME, 1996, EUR J CLIN MICROBIOL, V15, P913, DOI 10.1007/BF01690508; Johnson CC, 1997, CLIN INFECT DIS, V24, P1035, DOI 10.1086/513658; MARTINO P, 1985, EUR J CANCER CLIN ON, V21, P439, DOI 10.1016/0277-5379(85)90034-3; MOSDELL DM, 1991, ANN SURG, V214, P543, DOI 10.1097/00000658-199111000-00001; ROTSTEIN OD, 1985, REV INFECT DIS, V7, P151; SAUNDERS NJ, 1995, J ANTIMICROB CHEMOTH, V36, P729, DOI 10.1093/jac/36.4.729; VANDERAUWERA P, 1985, J ANTIMICROB CHEMOTH, V16, P581, DOI 10.1093/jac/16.5.581	11	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1539	1540		10.1016/S0140-6736(00)03120-2	http://dx.doi.org/10.1016/S0140-6736(00)03120-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075763				2023-01-03	WOS:000165134500005
J	Steiner, JF; Earnest, MA				Steiner, JF; Earnest, MA			Lingua medica - The language of medication-taking	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; ADHERENCE; THERAPY; PATIENT; HYPERTENSION; INTERVENTIONS; PERSPECTIVES; GUIDELINES; EFFICACY		Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Steiner, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.							Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015; ARLUKE A, 1980, HUM ORGAN, V39, P84, DOI 10.17730/humo.39.1.ln604545vgw68x32; Carleton RA, 1997, ANN INTERN MED, V126, P589, DOI 10.7326/0003-4819-126-7-199704010-00031; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; DIXON WM, 1957, LANCET, V2, P871; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; Earnest M. A., 1999, JGIM, V14, P26; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FEINSTEIN AR, 1990, ARCH INTERN MED, V150, P1377, DOI 10.1001/archinte.150.7.1377; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; Haynes RB, 1996, LANCET, V348, P383; HAYNES RB, 1976, COMPLIANCE THERAPEUT, P193; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; INUI TS, 1981, MED CARE, V19, P1061, DOI 10.1097/00005650-198110000-00008; JENKINS B W, 1954, GP, V9, P66; KRAVITZ RL, 1993, ARCH INTERN MED, V153, P1869, DOI 10.1001/archinte.153.16.1869; KRUSE W, 1990, EUR J CLIN PHARMACOL, V38, P561, DOI 10.1007/BF00278582; KRUSE W, 1994, INT J CLIN PHARM TH, V32, P452; Lerner BH, 1998, ANN INTERN MED, V129, P573, DOI 10.7326/0003-4819-129-7-199810010-00012; Leslie Charles, 1976, HIST E AFRICA, P1, DOI DOI 10.1016/S0070-4571(08)71123-3; LEVENTHAL H, 1987, PATIENT EDUC COUNS, V10, P117, DOI 10.1016/0738-3991(87)90093-0; MARKOWITZ M, 1970, CIRCULATION, V41, P1077, DOI 10.1161/01.CIR.41.6.1077; MATERSON BJ, 1978, CLIN PHARMACOL THER, V24, P192; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; NORRBY SR, 1990, REV INFECT DIS, V12, P458; PATERSON D, 1999, 6 C RETR OPP INF FEB; PITMAN ER, 1959, DIS CHEST, V36, P1; PRICKMAN LE, 1958, JAMA-J AM MED ASSOC, V167, P1451, DOI 10.1001/jama.1958.02990290005002; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1979, COMPLIANCE HLTH CARE; SHEINER LB, 1995, CLIN PHARMACOL THER, V57, P6, DOI 10.1016/0009-9236(95)90260-0; Smith MY, 1997, J GEN INTERN MED, V12, P216, DOI 10.1007/s11606-006-5043-3; STEELE DJ, 1990, J FAM PRACTICE, V30, P294; STEINER JF, 1991, J CLIN EPIDEMIOL, V44, P1361, DOI 10.1016/0895-4356(91)90097-S; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Stone VE, 1998, J GEN INTERN MED, V13, P586, DOI 10.1046/j.1525-1497.1998.00180.x; TEMPLE R, 1989, INT CONGR SER, V808, P145; TROSTLE JA, 1988, SOC SCI MED, V27, P1299, DOI 10.1016/0277-9536(88)90194-3; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; WAGNER EH, 1981, J CHRON DIS, V34, P519, DOI 10.1016/0021-9681(81)90014-X; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WEINTRAUB M, 1984, DRUG TREATMENT ELDER, P43	49	94	96	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					926	930		10.7326/0003-4819-132-11-200006060-00026	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00026			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836931				2023-01-03	WOS:000087334900022
J	Morrison, LJ; Verbeck, PR; McDonald, AC; Sawadsky, BV; Cook, DJ				Morrison, LJ; Verbeck, PR; McDonald, AC; Sawadsky, BV; Cook, DJ			Mortality and prehospital thrombolysis for acute myocardial infarction - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Royal-College-of-Physicians-and-Surgeons-of-Canada	SEP 16-27, 1998	TORONTO, CANADA	Royal Coll Physicians & Surgeons Canada			TISSUE PLASMINOGEN-ACTIVATOR; RANDOMIZED TRIALS; CLINICAL-TRIALS; THERAPY; MANAGEMENT; SURVIVAL; ELECTROCARDIOGRAM; METAANALYSIS; GUIDELINES; EMERGENCY	Context Early administration of thrombolysis for acute myocardial infarction (AMI) may improve survival if safely and appropriately delivered. No systematic reviews that have comprehensively examined this topic exist in the literature. Objective To perform a meta-analysis of randomized controlled trials of prehospital vs in-hospital thrombolysis for AMI measuring in-hospital mortality. Data Sources The Cochrane search strategy was used to search MEDLINE, EMBASE, and the Science Citation Index (1982-1999); Dissertation Abstracts (1987-1999); and Current Contents (1994-1999) for the terms thrombolysis, thrombolysis therapy, prehospital, and acute myocardial infarction. In addition, text and journal article bibliographies were hand searched, the National Institutes of Health Web site was reviewed, and primary authors and thrombolytic drug manufacturers were contacted for unpublished studies. Study Selection Randomized controlled trials of prehospital vs in-hospital thrombolysis for AMI measuring all-cause hospital mortality were included. Two authors independently reviewed 175 citations by title, abstract, or complete article. After exclusion of 30 duplicate citations, 145 studies remained, of which 6 studies and 3 follow-up studies met the inclusion criteria. Data Extraction Independent data abstraction by 2 reviewers blinded to the journal, title, and author was confirmed by consensus. Trial quality was independently assessed by 2 other coauthors, blinded to the author, title, journal, introduction, and discussion. Data Synthesis The results of the 6 randomized trials (n=6434) were pooled and indicated significantly decreased all-cause hospital mortality among patients treated with prehospital thrombolysis compared with in-hospital thrombolysis (odds ratio, 0.83; 95% confidence interval, 0.70-0.98). Results were similar regardless of trial quality or training and experience of the provider. Estimated (SE) time to thrombolysis was 104 (7) minutes for the prehospital group and 162 (16) minutes for the in-hospital thrombolysis group (P = .007). Conclusions Our meta-analysis suggests that prehospital thrombolysis for AMI significantly decreases the time to thrombolysis and all-cause hospital mortality.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Emergency Serv, Toronto, ON M4N 3M5, Canada; McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Morrison, LJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Emergency Serv, 2075 Bayview Ave,Suite BG-20, Toronto, ON M4N 3M5, Canada.	l.morrison@utoronto.ca	Morrison, Laurie Jean/A-6325-2012	Morrison, Laurie Jean/0000-0001-8369-9774				ANDERSON JL, 1992, J INTERV CARDIOL, V5, P127, DOI 10.1111/j.1540-8183.1992.tb00417.x; [Anonymous], 1990, LANCET, V336, P65; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Boersma H, 1996, EUR HEART J, V17, P64; BOISSEL JP, 1995, INT J CARDIOL, V49, pS29, DOI 10.1016/0167-5273(95)02336-U; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; Brouwer MA, 1996, AM J CARDIOL, V78, P497, DOI 10.1016/S0002-9149(96)00352-9; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; Carlsson J, 1997, ANAESTHESIST, V46, P829, DOI 10.1007/s001010050476; CASTAIGNE AD, 1987, DRUGS, V33, P231, DOI 10.2165/00003495-198700333-00042; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; FathOrdoubadi F, 1996, HEART, V75, P169; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GERSH BJ, 1993, CIRCULATION, V88, P296, DOI 10.1161/01.CIR.88.1.296; GOTSMAN M, 1996, KARDIOLOGIA POLSKA, V44, P6; GROVER A, 1995, CURR OPIN CARDIOL, V10, P361, DOI 10.1097/00001573-199507000-00004; GRUNEWALD M, 1994, FIBRINOLYSIS, V8, P67, DOI 10.1016/S0268-9499(05)80023-2; HUNT D, 1992, LANCET, V339, P753; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; Julian DG, 1996, EUR HEART J, V17, P43; KENNEDY JW, 1987, HEART LUNG, V16, P740; KOWALENKO T, 1992, AM HEART J, V123, P181, DOI 10.1016/0002-8703(92)90764-M; LEFEUVRE C, 1993, AM J CARDIOL, V72, pG145, DOI 10.1016/0002-9149(93)90121-R; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MCALEER B, 1992, CARDIOVASC DRUG THER, V6, P369, DOI 10.1007/BF00054183; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; MULROW CD, 1997, COCHRANE COLLABORATI; Myers RBH, 1998, CAN J CARDIOL, V14, P1231; Nee PA, 1997, J ACCID EMERG MED, V14, P2; ORNATO JP, 1990, CLIN CARDIOL, V13, P27; ORNATO JP, 1995, AM J EMERG MED, V13, P58; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; Rawles JM, 1997, CLIN CARDIOL, V20, P6, DOI 10.1002/clc.4960201404; RISENFORS M, 1991, J INTERN MED, V229, P3; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; ROZENMAN Y, 1995, INT J CARDIOL, V49, pS21, DOI 10.1016/0167-5273(95)02335-T; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; Selig MB, 1996, AM J EMERG MED, V14, P209, DOI 10.1016/S0735-6757(96)90135-7; Selker HP, 1997, ANN EMERG MED, V29, P310; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1994, HOSP PRACT, V29, P77, DOI 10.1080/21548331.1994.11443004; WOO KS, 1994, CURR OPIN CARDIOL, V9, P471	50	385	411	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2686	2692		10.1001/jama.283.20.2686	http://dx.doi.org/10.1001/jama.283.20.2686			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	314FP	10819952				2023-01-03	WOS:000087046000037
J	Ernst, E; White, AR				Ernst, E; White, AR			Acupuncture may be associated with serious adverse events	BRITISH MEDICAL JOURNAL			English	Letter									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							Ernst E, 1999, BRIT MED J, V318, P536, DOI 10.1136/bmj.318.7182.536; Ernst E, 1997, BRIT MED J, V314, P1362; Onizuka T, 1998, Kansenshogaku Zasshi, V72, P776; Vickers A, 1999, BRIT MED J, V319, P973, DOI 10.1136/bmj.319.7215.973	4	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					513	514		10.1136/bmj.320.7233.513	http://dx.doi.org/10.1136/bmj.320.7233.513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10678876	Green Published			2023-01-03	WOS:000085562200046
J	Guntupalli, KK; Fromm, RE				Guntupalli, KK; Fromm, RE			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Review							TRIALS		Ben Taub Gen Hosp, Baylor Coll Med, Dept Pulm, Houston, TX 77030 USA	Baylor College of Medicine	Guntupalli, KK (corresponding author), Ben Taub Gen Hosp, Baylor Coll Med, Dept Pulm, 1502 Taub Loop, Houston, TX 77030 USA.							D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2000	132	4					288	295		10.7326/0003-4819-132-4-200002150-00007	http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285CY	10681284				2023-01-03	WOS:000085372900006
J	Henney, JE				Henney, JE			Sertraline approved for posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2023-01-03	WOS:000084956500007
J	Sloan, FA; Taylor, DH				Sloan, FA; Taylor, DH			Private and public choices in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRENDS		Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA	Duke University	Sloan, FA (corresponding author), Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA.							COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Gramelspacher GP, 1997, J GEN INTERN MED, V12, P346, DOI 10.1007/s11606-006-5082-9; *I MED, 1997, APPR DEATH IMPR CAR; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	8	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2078	2078		10.1001/jama.282.21.2078	http://dx.doi.org/10.1001/jama.282.21.2078			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591394	hybrid			2023-01-03	WOS:000083908700031
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Massage therapies	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									VICKERS A, 1998, MASSAGE AROMATHERAPY	1	63	64	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1254	1257		10.1136/bmj.319.7219.1254	http://dx.doi.org/10.1136/bmj.319.7219.1254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550095	Green Published			2023-01-03	WOS:000083625600031
J	Evans, WE; Relling, MV				Evans, WE; Relling, MV			Pharmacogenomics: Translating functional genomics into rational therapeutics	SCIENCE			English	Review							CONVERTING ENZYME GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMORPHIC DRUG-METABOLISM; RECEPTOR GENE; THIOPURINE METHYLTRANSFERASE; TARDIVE-DYSKINESIA; P-GLYCOPROTEIN; DIHYDROPYRIMIDINE DEHYDROGENASE; ESSENTIAL-HYPERTENSION; POOR METABOLIZERS	Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications. Pharmacogenomic studies are rapidly elucidating the inherited nature of these differences in drug disposition and effects, thereby enhancing drug discovery and providing a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Coll Pharm, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322	NATIONAL CANCER INSTITUTE [R01CA078224, R37CA036401, R01CA051001] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51001, R37 CA36401, R01 CA78224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; Benetos A, 1996, HYPERTENSION, V28, P1081, DOI 10.1161/01.HYP.28.6.1081; Black AJ, 1998, ANN INTERN MED, V129, P716, DOI 10.7326/0003-4819-129-9-199811010-00007; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BROSEN K, 1989, EUR J CLIN PHARMACOL, V36, P537, DOI 10.1007/BF00637732; Caraco Y, 1996, J PHARMACOL EXP THER, V278, P1165; CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a; Chen CH, 1997, BIOL PSYCHIAT, V41, P827, DOI 10.1016/S0006-3223(96)00543-4; Cohen J, 1997, SCIENCE, V275, P776, DOI 10.1126/science.275.5301.776; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; DESMEULES J, 1991, EUR J CLIN PHARMACOL, V41, P23, DOI 10.1007/BF00280101; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; ESSEN GGV, 1996, LANCET, V347, P94; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GONZALEZ FJ, 1995, TRENDS PHARMACOL SCI, V16, P325, DOI 10.1016/S0165-6147(00)89065-3; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Haas M, 1998, KIDNEY BLOOD PRESS R, V21, P66, DOI 10.1159/000025845; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Henrion D, 1998, J VASC RES, V35, P356, DOI 10.1159/000025605; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Kapitany T, 1998, SCHIZOPHR RES, V32, P101, DOI 10.1016/S0920-9964(98)00038-3; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; LEE JT, 1990, NEW ENGL J MED, V322, P1764, DOI 10.1056/NEJM199006213222502; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; Lennard L, 1998, THER DRUG MONIT, V20, P527, DOI 10.1097/00007691-199810000-00014; LENNARD MS, 1983, CLIN PHARMACOL THER, V34, P732, DOI 10.1038/clpt.1983.242; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Lipworth BJ, 1999, CHEST, V115, P324, DOI 10.1378/chest.115.2.324; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; Marshall A, 1997, NAT BIOTECHNOL, V15, P954, DOI 10.1038/nbt1097-954; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756; Mizuiri S, 1997, NEPHRON, V75, P310, DOI 10.1159/000189554; NAKAMURA H, 1995, J PHARMACOL EXP THER, V274, P1099; Nakano Y, 1997, AM J HYPERTENS, V10, P1064, DOI 10.1016/S0895-7061(97)00279-3; Nebert DW, 1997, AM J HUM GENET, V60, P265; O'Toole L, 1998, J CARDIOVASC PHARM, V32, P988, DOI 10.1097/00005344-199812000-00017; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Poulsen L, 1996, EUR J CLIN PHARMACOL, V51, P289, DOI 10.1007/s002280050200; Priori SG, 1999, CIRCULATION, V99, P674, DOI 10.1161/01.CIR.99.5.674; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Ratain MJ, 1996, PHARMACOGENETICS, V6, P93, DOI 10.1097/00008571-199602000-00008; Rebbeck TR, 1998, J NATL CANCER I, V90, P1225, DOI 10.1093/jnci/90.16.1225; Relling MV, 1999, BLOOD, V93, P2817; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; Sasaki M, 1996, J HYPERTENS, V14, P1403, DOI 10.1097/00004872-199612000-00003; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Schuetz EG, 1999, J BIOCHEM MOL TOXIC, V13, P219; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SINDRUP SH, 1993, PAIN, V53, P335, DOI 10.1016/0304-3959(93)90229-I; Spielberg SP, 1996, J PHARMACOKINET BIOP, V24, P509, DOI 10.1007/BF02353477; Steen VM, 1997, MOL PSYCHIATR, V2, P139, DOI 10.1038/sj.mp.4000249; Steward DJ, 1997, PHARMACOGENETICS, V7, P361, DOI 10.1097/00008571-199710000-00004; Tyndale RF, 1997, PHARMACOGENETICS, V7, P375, DOI 10.1097/00008571-199710000-00006; vanderKleij FGH, 1997, NEPHROL DIAL TRANSPL, V12, P42; vanderKleij FGH, 1997, KIDNEY INT, pS23; WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270; ZHOU HH, 1989, NEW ENGL J MED, V320, P565, DOI 10.1056/NEJM198903023200905	71	1759	1921	5	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					487	491		10.1126/science.286.5439.487	http://dx.doi.org/10.1126/science.286.5439.487			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521338				2023-01-03	WOS:000083121200050
J	Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH				Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH			Safety of early discharge for Medicaid newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL READMISSION; STAY	Context Neonates are being discharged from the hospital more rapidly, but the risks associated with this practice, especially for low-income populations, are unclear. Objective To determine the impact of decreasing postnatal length of stay on rehospitalization rates in the immediate postdischarge period for Medicaid neonates. Design and Setting Retrospective, population-based cohort study using Ohio Medicaid claims data linked to vital statistics files from July 1, 1991, to June 15, 1995. Participants A total of 102 678 full-term neonates born to mothers receiving Medicaid for at least 30 days after birth. Main Outcome Measures Rehospitalization rates within 7 and 14 days of discharge, postdischarge health care use, and regional variations in length of stay and rehospitalization. Results The proportion of neonates who were discharged following a short stay (less than 1 day after vaginal delivery, less than 2 days after cesarean birth) increased 185%, from 21 % to 59.8% (P<.001) and the mean (SD) length of stay decreased 27%, from 2.2 (1.0) to 1.6 (0.9) days (P<.001), over the course of the study, The proportion of neonates who received a primary care visit within 14 days of birth increased 117% (P = .001). Rehospitalization rates within 7 and 14 days of discharge decreased by 23 %, from 1.3 % to 1.0% (P = .01), and by 19%, from 2.1% to 1.7% (P = .03), respectively. Short stay across the 6 regions of the state varied significantly over time (P<.001), Factors significantly associated with increased likelihood of rehospitalization within both 7 and 14 days of discharge were white race, shorter gestation, primiparity, earlier year of birth, lower 5-minute Apgar score, vaginal delivery, married mother, and region of the state. Conclusion Our data suggest that reductions in length of stay for full-term Medicaid newborns in Ohio have not resulted in an increase in rehospitalization rates in the immediate postnatal period.	Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Neonatol, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA; Ohio Dept Human Serv, Bur Medicaid Policy, Columbus, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kotagal, UR (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							ADEBONOJO FO, 1973, CLIN PEDIATR, V12, P644, DOI 10.1177/000992287301201107; Bragg EJ, 1997, OBSTET GYNECOL, V89, P930, DOI 10.1016/S0029-7844(97)85764-X; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; CATZ C, 1995, PEDIATRICS, V96, P743; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; COOPER WO, 1995, PEDIATRICS, V96, P957; COTTRELL DG, 1983, J AM OSTEOPATH ASSOC, V83, P216; Czarnecki M T, 1996, J Nurs Care Qual, V10, P1; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; Fox M H, 1995, Am J Med Qual, V10, P206, DOI 10.1177/0885713X9501000407; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; Kotagal UR, 1996, J PEDIATR GASTR NUTR, V22, P402, DOI 10.1097/00005176-199605000-00012; KRAMER MS, 1991, PEDIATRICS, V87, P399; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; *NAT CTR HLTH STAT, 1995, HLTH PEOPL 2000 REV; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; *OH DEP HLTH, 1977, STAT PER GUID; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; Pruett S H, 1996, Am J Med Qual, V11, pS39; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; RYAN AS, 1991, PEDIATRICS, V88, P719; Smith R D, 1988, Pediatr Emerg Care, V4, P107, DOI 10.1097/00006565-198806000-00005; SPONG FW, 1997, INPATIENT CARE MOTHE	27	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1150	1156		10.1001/jama.282.12.1150	http://dx.doi.org/10.1001/jama.282.12.1150			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501118				2023-01-03	WOS:000082596200030
J	Daoud, R; Julien, M; Gros, P; Georges, E				Daoud, R; Julien, M; Gros, P; Georges, E			Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; CONJUGATE EXPORT PUMP; QUINOLINE-BASED DRUG; LEUKOTRIENE C-4; VINCRISTINE TRANSPORT; INCREASED SENSITIVITY; DEPENDENT TRANSPORT; EPITOPE INSERTION; TUMOR-CELLS; GLUTATHIONE	MRP1 is an ABC (or ATP binding cassette) membrane transport protein shown to confer resistance to structurally dissimilar drugs, Studies of MRP1 topology suggested the presence of a hydrophobic N-domain with five potential membrane-spanning domains linked to an MDR1-like core (MSD1-NBD1-L1-MSD2-NBD2) by an intracellular linker domain (LO). MRP1-mediated multidrug resistance is thought to be due to enhanced drug efflux. However, little is known about MRP1-drug interaction and its drug binding site(s). We previously developed several photoreactive probes to study MRP1-drug interactions. In this report, we have used eight MRP1-HA variants that were modified to have hemagglutinin A (HA) epitopes inserted at different sites in MRP1 sequence. Exhaustive in-gel digestion of all IAARh123 photoaffinity-labeled MRP1-HA variants revealed the same profile of photolabeled peptides as seen for wild type MRP1. Photolabeling of the different MRP1-HA variants followed by digestion with increasing concentrations of trypsin or Staphylococcus aureus V8 protease (1:800 to 1:5 w/w) and immunoprecipitation with anti-HA mAb identified two small photolabeled peptides (similar to6-7 kDa) from MRP1-HA(574) and MRP1-HA(1222). Based on the location of the HA epitopes in the latter variants together with molecular masses of the two peptides, the photolabeled amino acid residues were localized to MRP1 sequences encoding transmembranes 10 and 11 of MSD1 (Ser(542)-Arg(593)) and transmembranes 16 and 17 of MSD2 (Cys(1205)-Glu(1253)). Interestingly, the same sequences in MRP1 were also photolabeled with a structurally different photoreactive drug, IACI, confirming the significance of transmembranes 10, 11, 16 and 17 in MRP1 drug binding. Taken together, the results in this study provide the first delineation of the drug binding site(s) of MRP1. Furthermore, our findings suggest the presence of common drug binding site(s) for structurally dissimilar drugs.	McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, Dept Biochem, Ste Anne De Bellevue, PQ H9X 3V9, Canada	McGill University; McGill University	Georges, E (corresponding author), McGill Univ, Inst Parasitol, 21111 Lakeshore Rd, Ste Anne De Bellevue, PQ H9X 3V9, Canada.	Elias.Georges@McGill.CA						Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Draper MP, 1997, EUR J BIOCHEM, V243, P219, DOI 10.1111/j.1432-1033.1997.0219a.x; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Jedlitschky G, 1996, CANCER RES, V56, P988; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 1999, BIOCHEMISTRY-US, V38, P5124, DOI 10.1021/bi982525y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; RAO US, 1994, MOL PHARMACOL, V45, P773; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Shapiro AB, 1998, ACTA PHYSIOL SCAND, V163, P227; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2; Vezmar M, 2000, BIOCHEM PHARMACOL, V59, P1245, DOI 10.1016/S0006-2952(00)00270-7; Vezmar M, 1997, BIOCHEM BIOPH RES CO, V241, P104, DOI 10.1006/bbrc.1997.7634; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	48	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12324	12330		10.1074/jbc.M009782200	http://dx.doi.org/10.1074/jbc.M009782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11152467	hybrid			2023-01-03	WOS:000168081800118
J	Nenner, F				Nenner, F			Listen to the voices	BRITISH MEDICAL JOURNAL			English	Editorial Material									Lutheran Med Ctr, Eth Comm, Brooklyn, NY 11220 USA		Nenner, F (corresponding author), Lutheran Med Ctr, Eth Comm, Brooklyn, NY 11220 USA.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					372	372		10.1136/bmj.322.7282.372	http://dx.doi.org/10.1136/bmj.322.7282.372			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159672	Green Published			2023-01-03	WOS:000167050000072
J	Angus, DC; Kelley, MA; Schmitz, RJ; White, A; Popovich, J				Angus, DC; Kelley, MA; Schmitz, RJ; White, A; Popovich, J		Comm Manpower Pulm Critical Care	Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease - Can we meet the requirements of an aging population?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; HEALTH-CARE; PHYSICIAN WORKFORCE; UNITED-STATES; INTERNATIONAL COMPARISONS; RESOURCE UTILIZATION; MEDICARE; OUTCOMES; SURGERY; SYSTEM	Context Two important areas of medicine, care of the critically ill and management of pulmonary disease, are likely to be influenced by the aging of the US population. Objective To estimate current and future requirements for adult critical care and pulmonary medicine physicians in the United States. Design, Setting, and Participants Analysis of existing population, patient, and hospital data sets and prospective, nationally representative surveys of intensive care unit (ICU) directors (n=393) and critical care specialists (intensivists) and pulmonary specialists (pulmonologists) (n=421), conducted from 1996 to 1999. Main Outcome Measures Influence of patient, physician, regional, hospital, and payer characteristics on current practice patterns; forecasted future supply of and demand for specialist care through 2030. Separate models for critical care and pulmonary disease. Base-case projections with sensitivity analyses to estimate the impact of future changes in training and retirement, disease prevalence and management, and health care reform initiatives. Results In 1997, intensivists provided care to 36.8% of all ICU patients, Care in the ICU was provided more commonly by intensivists in regions with high managed care penetration, The current ratio of supply to demand is forecast to remain in rough equilibrium until 2007, Subsequently, demand will grow rapidly while supply will remain near constant, yielding a shortfall of specialist hours equal to 22% of demand by 2020 and 35% by 2030, primarily because of the aging of the US population. Sensitivity analyses suggest that the spread of current health care reform initiatives will either have no effect or worsen this shortfall. A shortfall of pulmonologist time will also occur before 2007 and increase to 35% by 2020 and 46% by 2030, Conclusions We forecast that the proportion of care provided by intensivists and pulmonologists in the United States will decrease below current standards in less than 10 years. While current health care reform initiatives and modification of existing practice patterns may temporarily forestall this problem, most anticipated effects are minor in comparison with the growing disease burden created by the aging US population.	Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA; Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA; ABT Associates Inc, Math Policy Res, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Henry Ford Health System; Henry Ford Hospital; ABT Associates; Mathematica	Angus, DC (corresponding author), Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Room 604,Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	angusdc@anes.upmc.edu	Angus, Derek C/E-9671-2012					*AG HLTH CAR POL R, 1996, HEALTHC COST UT PROJ; Akaike H., 1973, INFORM THEORY EXTENS, P267; Amemiya T., 1985, ADV ECONOMETRICS; Angus DC, 1997, CRIT CARE CLIN, V13, P389, DOI 10.1016/S0749-0704(05)70317-1; Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; Bion JF, 1998, INTENS CARE MED, V24, P372, DOI 10.1007/s001340050584; Butler Margaret A., 1993, RURAL URBAN CONTINUU; CALLAHAN D, 1998, FALSE HOPE WHY AM QU; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; Collett D., 1994, MODELING SURVIVAL DA; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; *COUNC GRAD MED ED, 1996, 8US DEP HHS COUNC GR; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Fuchs VR, 1999, HEALTH AFFAIR, V18, P11, DOI 10.1377/hlthaff.18.1.11; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Guntupalli KK, 1996, INTENS CARE MED, V22, P625, DOI 10.1007/BF01709737; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Hart IG, 1997, HEALTH AFFAIR, V16, P55, DOI 10.1377/hlthaff.16.1.55; HINES FK, 1975, AER272 USDA EC RES S; *HLTH RES SERV ADM, 1991, HLTH PERS US; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; JONASSON O, 1995, JAMA-J AM MED ASSOC, V274, P731; KVETAN V, 1997, INT PERSPECTIVES CRI; LOHR KN, 1996, NATIONS PHYSICIAN WO; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P689, DOI 10.1001/jama.276.9.689; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Neilson EG, 1997, J AM SOC NEPHROL, V8, pS1; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; Reinhardt UE, 1999, JAMA-J AM MED ASSOC, V281, P462, DOI 10.1001/jama.281.5.462; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; SCHROEDER SA, 1994, INQUIRY-J HEALTH CAR, V31, P266; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; Theil H., 1971, APPL EC FORECASTING; Vladeck BC, 1999, NEW ENGL J MED, V340, P1503, DOI 10.1056/NEJM199905133401911; Weiner DM, 1997, UROLOGY, V49, P335, DOI 10.1016/S0090-4295(96)00492-X; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; White J, 1999, HEALTH AFFAIR, V18, P63, DOI 10.1377/hlthaff.18.1.63; 1997, JAMA, V278, P775	49	716	737	2	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2762	2770		10.1001/jama.284.21.2762	http://dx.doi.org/10.1001/jama.284.21.2762			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105183				2023-01-03	WOS:000165509500031
J	Catlin, DH; Leder, BZ; Ahrens, B; Starcevic, B; Hatton, CK; Green, GA; Finkelstein, JS				Catlin, DH; Leder, BZ; Ahrens, B; Starcevic, B; Hatton, CK; Green, GA; Finkelstein, JS			Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; 19-NORANDROSTERONE; EXCRETION	Context Several anabolic steroids are sold over-the-counter (OTC) in the United States, and their production is not regulated by the US Food and Drug Administration. Reports have suggested that use of these supplements can cause positive urine test results for metabolites of the prohibited steroid nandrolone. Objectives To assess the content and purity of OTC androstenedione and to determine if androstenedione and 19-norandrostenedione administration causes positive urine test results for 19-norandrosterone, a nandrolone metabolite. Design Randomized controlled trial of androstenedione, open-label trial of 19-norandrostenedione, and mass spectrometry of androstenedione preparations, conducted between October 1998 and April 2000. Setting Outpatient facility of a university hospital. Participants A total of 41 healthy men aged 20 to 44 years. Intervention Participants were randomly assigned to receive oral androstenedione, 100 mg/d (n = 13) or 300 mg/d (n = 11) for 7 days, or no androstenedione (n = 13); in addition, 4 patients received 10 mug of 19-norandrostenedione. Main Outcome Measures Content of OTC androstenedione preparations; level of 19-norandrosterone in urine samples, determined by mass spectrometry, compared among the 3 randomized groups at day 1 and day 7, and among the participants who received 19-norandrostenedione from October 1998 to April 2000, Results All urine samples from participants treated with androstenedione contained 19-norandrosterone, while no samples from the no-androstenedione group did, Urinary concentrations were averaged for day 1 vs day 7 measurements; mean (SD) 19-norandrosterone concentrations in the 100-mg/d and 300-mg/d groups were 3.8 (2.5) ng/mL and 10,2 (6.9) ng/mL, respectively (P = .006),The 19-norandrosterone content exceeded the cut-off for reporting positive cases (>2.0 ng/mL) in 20 of 24. The androstenedione preparation used was pure at a sensitivity of 0.1%, but at 0.001% 19-norandrostenedione was found. For the 4 participants to whom 10 mug of 19-norandrostenedione was administered, 19-norandrosterone was found in all urine samples. Of 7 brands of androstenedione analyzed at the 1% level, 1 contained no androstenedione, 1 contained 10 mg of testosterone, and 4 more contained 90% or less of the amount stated on the label, Conclusion Our study suggests that trace contamination of androstenedione with 19-norandrostenedione is sufficient to cause urine test results positive for 19-norandrosterone, the standard marker for nandrolone use. Oral steroid doses as small as 10 mug are absorbed and excreted in urine. Some brands of androstenedione are grossly mislabeled. Careful analysis of androstenedione preparations is recommended in all studies of its biological effects.	Univ Calif Los Angeles, Olymp Analyt Lab, Dept Mol & Med Pharmacol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90025 USA; Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital	Catlin, DH (corresponding author), Univ Calif Los Angeles, Olymp Analyt Lab, Dept Mol & Med Pharmacol, 2122 Granville Ave, Los Angeles, CA 90025 USA.		Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002759] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [DK02759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Catlin DH, 1996, JAMA-J AM MED ASSOC, V276, P231, DOI 10.1001/jama.276.3.231; CATLIN DH, 1987, CLIN CHEM, V33, P319; CIARDI M, 1999, RECENT ADV DOPING AN, P97; COPPEN JJW, 1979, TROP SCI, V21, P125; DEHENNIN L, 1987, J STEROID BIOCHEM, V26, P399, DOI 10.1016/0022-4731(87)90107-5; Dehennin L, 1999, J CHROMATOGR B, V721, P301, DOI 10.1016/S0378-4347(98)00480-0; FISHMAN J, 1982, CANC RES B, V42; Le Bizec B, 1999, J CHROMATOGR B, V723, P157, DOI 10.1016/S0378-4347(98)00541-6; Leder BZ, 2000, JAMA-J AM MED ASSOC, V283, P779, DOI 10.1001/jama.283.6.779; Merkli A, 1997, PLANT CELL REP, V16, P632, DOI [10.1007/s002990050292, 10.1007/BF01275505]; REZNIK Y, 1987, J CLIN ENDOCR METAB, V64, P1086, DOI 10.1210/jcem-64-5-1086; Uralets VP, 1999, J ANAL TOXICOL, V23, P357, DOI 10.1093/jat/23.5.357; US Department of Health and Human Services, 1999, GUID IND ANDAS IMP D; *US PHARM DI 2000, 1998, MICROMEDEX, V3; ZORPETTE G, 1999, SCI AM PRESENTS, V10, P52; 1999, CONSUMER REPORTS, V64, P44	17	97	99	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2618	2621		10.1001/jama.284.20.2618	http://dx.doi.org/10.1001/jama.284.20.2618			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086369				2023-01-03	WOS:000165296200036
J	Silveira, MJ; DiPiero, A; Gerrity, MS; Feudtner, C				Silveira, MJ; DiPiero, A; Gerrity, MS; Feudtner, C			Patients' knowledge of options at the end of life - Ignorance in the face of death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-DETERMINATION ACT; ADVANCE DIRECTIVES; ELDERLY OUTPATIENTS; MEDICAL-CARE; ATTITUDES; PHYSICIANS	Context Effectiveness of legislation promoting advance directives and legalizing physician-assisted suicide depends on patients' understanding their legal options about end-of-life care. However, outpatients' understanding of their legal options at the end of life has not been studied. Objectives To estimate the percentage of outpatients who are informed about 4 areas relevant to end-of-life care: refusal and withdrawal of lifesaving treatments, physician-assisted suicide, active euthanasia, and double effect; and to determine whether authoring advance directives, experiencing illness, acting as a proxy for health care decisions, and caring for an ill loved one are associated with better knowledge in end-of-life care. Design Cross-sectional survey. Setting and Participants One thousand consecutive English-speaking, adult patients attending 1 university-based internal medicine clinic and 3 community-based, university-affiliated, mixed internal medicine and family practice clinics in Oregon during May and June 1999. Main Outcome Measures Percentage of correct responses in the 4 topic areas and total knowledge score, adjusted for demographic (eg, age, race, educational level, income level, marital status) and experiential (eg, health, proxy decision making, advance directives, and death of a loved one) factors. Results Of the 1000 patients invited to participate, 728 (73 %) consented and completed the questionnaire and were included in the analysis. A total of 69% of respondents answered correctly regarding refusal of treatment, 46% for withdrawal of treatment, 23% for assisted suicide, 32% for active euthanasia, and 41% for double effect. Sixty-two percent of respondents did not distinguish between assisted suicide and euthanasia. After adjustment for other covariates, better knowledge was significantly associated with white race (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.3-4.2), having at least a college degree (OR, 3.0; 95% CI, 1.4-6.7), and having been a proxy for health care decisions (OR, 1.8, 95% CI, 1.2-2.6). Personal experience with illness (OR, 1.0; 95% CI, 0.6-1.5), death or illness of a loved one (OR, 1.6; 95% CI; 1.0-2.7), and authoring an advance directive (OR,1,3; 95% CI, 0.9-2.0) were not associated with better knowledge. Conclusions A significant proportion of outpatients at university-affiliated clinics in Oregon appear to misunderstand options in end-of-life care. Our results suggest that greater public knowledge about end-of-life care is needed, and advance care planning must be preceded by education about options in end-of-life care.	Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Dept Gen Internal Med, Portland, OR 97201 USA	University of Washington; University of Washington Seattle; Oregon Health & Science University	Silveira, MJ (corresponding author), Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Box 357183, Seattle, WA 98195 USA.		Silveira, Maria J/E-9802-2013; Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Gerrity, Martha/0000-0002-8772-4591; Silveira, Maria/0000-0002-6600-8633				*AMA POLL, 1997, AM MED NEWS     0113, P3; EDINGER W, 1992, J FAM PRACTICE, V35, P650; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1991, HASTINGS CENT REP, V21, pS6, DOI 10.2307/3562901; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Kane R J, 1991, J Health Hosp Law, V24, P373; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; MEISEL A, 1995, RIGHT DIE; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; Smucker W D, 1993, J Am Board Fam Pract, V6, P473; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; WHITE ML, 1991, JAMA-J AM MED ASSOC, V266, P410, DOI 10.1001/jama.1991.03470030110035; 1994, TRENDS HLTH CARE LAW, V9, P29	20	127	127	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2483	2488		10.1001/jama.284.19.2483	http://dx.doi.org/10.1001/jama.284.19.2483			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371MY	11074778	Bronze			2023-01-03	WOS:000165183800022
J	van Craaikamp, JCJ; Oosting, ME				van Craaikamp, JCJ; Oosting, ME			Netherlands: IVF for unmarried women, euthanasia	LANCET			English	Article								Most physicians in Europe, if asked what is very different about medicine and the law in the Netherlands, would choose euthanasia. We will discuss recent developments there but begin with a different topic-equality of access to in vitro fertilisation.	CMS Derks Star Busmann Hanotiau, Transnatl Legal Serv, NL-3584 BB Utrecht, Netherlands		Oosting, ME (corresponding author), CMS Derks Star Busmann Hanotiau, Transnatl Legal Serv, Pythagoraslaan 2, NL-3584 BB Utrecht, Netherlands.							BREWAEYS AMA, 1997, THESIS U LEIDEN; ENLERT U, 1994, HUM REPROD, V9, P1969; FORDER CJ, 1998, LEGAL POSITION SPERM; *HLTH COUNC COMM R, 1997, HLTH COUNC PUBL, V103; VERHULST FC, 1998, ADOPTION FOREIGN CHI	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1512	1513		10.1016/S0140-6736(00)02887-7	http://dx.doi.org/10.1016/S0140-6736(00)02887-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081550				2023-01-03	WOS:000090067300041
J	Shah, JL				Shah, JL			Lesson of the week - Postoperative pressure sores after epidural anaesthesia	BRITISH MEDICAL JOURNAL			English	Review							ANALGESIA; SURGERY		City Hosp, Dept Anaesthet, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Shah, JL (corresponding author), Queen Elizabeth Hosp, Dept Anaesthet, Birmingham B15 2TH, W Midlands, England.							ABUOWN A, 1995, EUR J VASC ENDOVASC, V9, P327, DOI 10.1016/S1078-5884(05)80139-X; Bliss M, 1999, BMJ-BRIT MED J, V319, P863, DOI 10.1136/bmj.319.7214.863; BLISS MR, 1995, AGE AGEING, V24, P297, DOI 10.1093/ageing/24.4.297; Buggy DJ, 1999, BMJ-BRIT MED J, V319, P530, DOI 10.1136/bmj.319.7209.530; Gebhardt K S, 1996, J Wound Care, V5, P116; KOSIAK M, 1961, Arch Phys Med Rehabil, V42, P19; KROUSKOP TA, 1978, MED HYPOTHESES, V4, P37, DOI 10.1016/0306-9877(78)90025-7; PUNT CD, 1991, ANESTH ANALG, V73, P657; REULER JB, 1981, ANN INTERN MED, V94, P661, DOI 10.7326/0003-4819-94-5-661; Smet IGG, 1996, REGION ANESTH, V21, P338; Waltman N L, 1991, Oncol Nurs Forum, V18, P867	11	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	2000	321	7266					941	942		10.1136/bmj.321.7266.941	http://dx.doi.org/10.1136/bmj.321.7266.941			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	365XE	11030688	Green Published			2023-01-03	WOS:000089975100027
J	Haverkate, I; Onwuteaka-Philipsen, BD; van der Heide, A; Kostense, PJ; van der Wal, G; van der Maas, PJ				Haverkate, I; Onwuteaka-Philipsen, BD; van der Heide, A; Kostense, PJ; van der Wal, G; van der Maas, PJ			Refused and granted requests for euthanasia and assisted suicide in the Netherlands: interview study with structured questionnaire	BRITISH MEDICAL JOURNAL			English	Article									Vrije Univ Amsterdam, Inst Res Extramural Med, Dept Social Med, NL-1081 BT Amsterdam, Netherlands; Erasmus Univ, Dept Publ Hlth, NL-3000 DK Rotterdam, Netherlands; Vrije Univ Amsterdam, Inst Res Extramural Med, Dept Epidemiol & Biostat, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Vrije Universiteit Amsterdam	Haverkate, I (corresponding author), Vrije Univ Amsterdam, Inst Res Extramural Med, Dept Social Med, van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.							Breitbart W, 1996, AM J PSYCHIAT, V153, P238; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERWAL PJ, 1996, EUTHANASIA OTHER MED	4	54	54	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	2000	321	7265					865	866		10.1136/bmj.321.7265.865	http://dx.doi.org/10.1136/bmj.321.7265.865			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VC	11021864	Bronze, Green Published			2023-01-03	WOS:000089857500022
J	Stevinson, C; Pittler, MH; Ernst, E				Stevinson, C; Pittler, MH; Ernst, E			Garlic for treating hypercholesterolemia - A meta-analysis of randomized clinical trials	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-LIPIDS; ALLIUM-SATIVUM; TOTAL CHOLESTEROL; PLASMA-LIPIDS; SERUM-LIPIDS; METAANALYSIS; BIAS; LIPOPROTEINS; QUALITY	Purpose: To investigate the effect of garlic on total cholesterol level in persons with elevated levels by conducting a metaanalysis of randomized, double-blind, placebo-controlled trials. Data Sources: Systematic literature searches were conducted on the MEDLINE, EMBASE, BIOSIS, Cochrane Library, AMED, and CISCOM databases. Manufacturers of commercial garlic preparations and experts in the field were asked about published or unpublished trials. Study Selection: Selected trials were required to state that they were randomized, double-blind, and placebo-controlled; use garlic monopreparations; include persons with mean total cholesterol levels of at least 5.17 mmol/L (200 mg/dL); and report total cholesterol level as an end point There were no language restrictions. Data Extraction: Two reviewers, blinded to key identifiers of each paper, independently extracted data in a standardized manner and assessed methodologic quality by using the Jadad scale. Discrepancies were settled through discussion. Data Synthesis: In the 13 trials included in the meta-analysis, garlic reduced total cholesterol level from baseline significantly more than placebo (P < 0.01); the weighted mean difference was -0.41 mmol/L (95% CI, -0.66 to -0.15 mmol/L) (-15.7 mg/dL [CI, -25.6 to -5.7 mg/dL]). Six diet-controlled trials with the highest scores for methodologic quality revealed a nonsignificant difference between garlic and placebo groups; the weighted mean difference was -0.11 mmol/L(CI, -0.30 to 0.08 mmol/L) (-4.3 mg/dL ICI, -11.7 to 3.1 mg/dL]). Conclusions: The available data suggest that garlic is superior to placebo in reducing total cholesterol levels. However, the size of the effect is modest, and the robustness of the effect is debatable. The use of garlic for hypercholesterolemia is therefore of questionable value.	Univ Exeter, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Dept Complementary Med, 25 Victoria Pk Rd, Exeter EX2 4NT, Devon, England.	E.Ernst@exeter.ac.uk						Adler AJ, 1997, AM J CLIN NUTR, V65, P445, DOI 10.1093/ajcn/65.2.445; Auer W, 1990, Br J Clin Pract Suppl, V69, P3; BARRIE SA, 1987, J ORTHOMOL MED, V2, P15; Berthold HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/jama.279.23.1900; BHUSHAN S, 1979, Indian Journal of Physiology and Pharmacology, V23, P211; BIMMERMANN A, 1988, THERAPIEWOCHE, V38, P3885; BORDIA A, 1975, ATHEROSCLEROSIS, V21, P15, DOI 10.1016/0021-9150(75)90091-X; Bordia A, 1998, PROSTAG LEUKOTR ESS, V58, P257, DOI 10.1016/S0952-3278(98)90034-5; BORDIA A, 1981, AM J CLIN NUTR, V34, P2100, DOI 10.1093/ajcn/34.10.2100; Bordia A, 1982, Indian Heart J, V34, P86; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; ERNST E, 1987, PHARMATHERAPEUTICA, V5, P83; ERNST E, 1986, COMPTES RENDUS THERA, V4, P4; ERNST E, 1986, ARZTLICHE PRAXIS, V51, P3; Gadkari J V, 1991, J Postgrad Med, V37, P128; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HOLZGARTNER H, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1473; Isaacsohn JL, 1998, ARCH INTERN MED, V158, P1189, DOI 10.1001/archinte.158.11.1189; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; Kandziora J., 1988, ARZTL FORSCH, V35, P3; KIESEWETTER H, 1991, INT J CLIN PHARM TH, V29, P151; Kiesewetter H, 1990, Br J Clin Pract Suppl, V69, P24; Koscielny J, 1999, ATHEROSCLEROSIS, V144, P237, DOI 10.1016/S0021-9150(99)00060-X; Lash JP, 1998, TRANSPLANT P, V30, P189, DOI 10.1016/S0041-1345(97)01227-X; LAU BHS, 1987, NUTR RES, V7, P139, DOI 10.1016/S0271-5317(87)80026-X; LAWSON LD, 1998, Q REV NAT MED    FAL, P187; LEWIS B, 1987, EUR HEART J, V8, P77; LULEY C, 1986, ARZNEIMITTEL-FORSCH, V36-1, P766; Lutomski J, 1984, Z PHYTOTHER, V5, P938; MADER FH, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1111; McCrindle BW, 1998, ARCH PEDIAT ADOL MED, V152, P1089; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MULROW CD, 1997, CONDUCT SYSTEMATIC R; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; Nieminen P, 1999, LANCET, V353, P1592, DOI 10.1016/S0140-6736(99)00415-8; PHELPS S, 1993, LIPIDS, V28, P475, DOI 10.1007/BF02535949; Pittler MH, 2000, J CLIN EPIDEMIOL, V53, P485, DOI 10.1016/S0895-4356(99)00220-6; PLENGVIDHYA C, 1988, Journal of the Medical Association of Thailand, V71, P248; PYORALA K, 1994, EUR HEART J, V15, P1300; REUTER HD, 1996, GARLIC SCI THERAPEUT; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; ROTZSCH W, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1223; SANTOS OSD, 1993, BR J CLIN RES, V4, P27; Saradeth T, 1994, Phytomedicine, V1, P183, DOI 10.1016/S0944-7113(11)80062-0; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz V, 1998, RATIONAL PHYTOTHERAP; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; Steiner M, 1998, J CARDIOVASC PHARM, V31, P904, DOI 10.1097/00005344-199806000-00014; Steiner M, 1996, AM J CLIN NUTR, V64, P866, DOI 10.1093/ajcn/64.6.866; STEVINSON C, 2000, FOCUS ALTERNATIVE CO, V5, P23; SUCUR M, 1980, Diabetologia Croatica, V9, P323; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; Vorberg G, 1990, Br J Clin Pract Suppl, V69, P7; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009; Zimmermann W, 1990, Br J Clin Pract Suppl, V69, P20	64	210	218	2	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					420	429		10.7326/0003-4819-133-6-200009190-00009	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975959				2023-01-03	WOS:000089329700003
J	de Matteis, A; Nuzzo, F; Rossi, E; Landi, G; Perrone, F				de Matteis, A; Nuzzo, F; Rossi, E; Landi, G; Perrone, F			Intestinal side-effects of docetaxel/vinorelbine combination	LANCET			English	Letter									Natl Canc Inst, Div Med Oncol Endocrinol C, I-80131 Naples, Italy; Natl Canc Inst, Clin Trials Off, I-80131 Naples, Italy	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Perrone, F (corresponding author), Natl Canc Inst, Div Med Oncol Endocrinol C, I-80131 Naples, Italy.		Perrone, Francesco/AAB-8283-2022	Perrone, Francesco/0000-0002-9738-0526				Fumoleau P, 1997, Oncology (Williston Park), V11, P29; Ibrahim NK, 2000, LANCET, V355, P281, DOI 10.1016/S0140-6736(99)06195-4; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9	4	8	8	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1098	1099		10.1016/S0140-6736(05)72219-4	http://dx.doi.org/10.1016/S0140-6736(05)72219-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744113				2023-01-03	WOS:000086380800049
J	Tulsky, JA; Ciampa, R; Rosen, EJ				Tulsky, JA; Ciampa, R; Rosen, EJ		Univ Pennsylvania	Responding to legal requests for physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							WASHINGTON-STATE; PATIENT REQUESTS; EUTHANASIA; ATTITUDES; CARE; AUTONOMY; PERSPECTIVE; CHOICE; WILL; DIE	In 1998, 15 terminally ill Oregon residents ended their lives with overdoses of medications supplied legally by their physicians. Many more people consider this possibility. This paper examines the ways in which the physician's response to requests for assisted suicide may change in an era of legalization, articulates some of the resulting conceptual challenges, and provides practical advice to physicians facing such requests. In areas where it is legal, assisted dying becomes one of the many options that can be freely considered for terminally ill patients with extreme suffering. Some patients even view assisted death as a right that can be expected on demand. We consider the ethical implications of disclosing assisted dying to patients as an option of last resort: and suggest that physicians working in environments where assisted dying is legal are obliged to do so. However, we conclude that physicians should not encourage patients to hasten death even when practicing in jurisdictions that allow assisted dying. Furthermore, without abandoning the model, we suggest that strict informed consent does not fully address patients' needs at this time. Physicians must also focus on patients' broader biopsychosocial concerns and help them identify solutions through empathic listening and emotional support. We provide a framework and vocabulary for physicians to use when responding to requests for assisted suicide. Physicians should clarify the request, explore and address the patient's concerns, achieve a shared understanding of the goals of treatment, search for less harmful alternatives, express to the patient what they are willing to do, discuss the relevant legal issues, and share their decision making with colleagues.	Vet Affairs Med Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Durham, NC USA; Hosp Univ Penn, Philadelphia, PA 19104 USA; Family Inst Westchester, Scarsdale, NY USA; Phelps Mem Hospice, Scarsdale, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University of Pennsylvania; Northwell Health	Tulsky, JA (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.							APPELBAUM P, 1987, INFORMED CONSENT LEG; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BRODY H, 1992, HEALERS POWER; Byock I, 1997, DYING WELL PROSPECT; CAPLAN AL, 1993, PRESCRIBING OUR FUTU, P149; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Cole Roger M., 1993, Palliative Medicine, V7, P139, DOI 10.1177/026921639300700208; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Dunn PM, 1996, J GEN INTERN MED, V11, P689, DOI 10.1007/BF02600161; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1999, ED PHYSICIANS END OF; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Rose PG, 1998, J CLIN ONCOL, V16, P405, DOI 10.1200/JCO.1998.16.2.405; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Teno JM, 1996, J CLIN ETHIC, V7, P205; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683	34	18	18	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					494	499		10.7326/0003-4819-132-6-200003210-00012	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733451				2023-01-03	WOS:000085834700011
J	Merz, CNB; Paul-Labrador, M; Vongvanich, P				Merz, CNB; Paul-Labrador, M; Vongvanich, P			Time to reevaluate risk stratification guidelines for medically supervised exercise training in patients with coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; MULTIFACTORIAL INTERVENTION PROGRAM; CARDIAC REHABILITATION; SUDDEN DEATHS; REDUCTION; TRIALS		Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Prevent & Rehabil Cardiac Ctr, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Merz, CNB (corresponding author), Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Prevent & Rehabil Cardiac Ctr, 444 S San Vicente Blvd,Suite 901, Los Angeles, CA 90048 USA.	merz@cshs.org						*AG HLTH CAR POL R, 1995, CARD REH GUID; *AM ASS CARD PULM, 1995, GUID CARD REH PROGR; *ANT TRIAL COLL, 1983, BMJ-BRIT MED J, V296, P320; BONDESTAM E, 1995, AM J CARDIOL, V75, P767, DOI 10.1016/S0002-9149(99)80408-1; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Dorn J, 1999, CIRCULATION, V100, P1764, DOI 10.1161/01.CIR.100.17.1764; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; Gordon NF, 1997, AM J CARDIOL, V80, pH69, DOI 10.1016/S0002-9149(97)00825-4; HAMALAINEN H, 1989, EUR HEART J, V10, P55; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; KALLIO V, 1979, LANCET, V2, P1091; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; LEVIN LA, 1991, J INTERN MED, V230, P427, DOI 10.1111/j.1365-2796.1991.tb00468.x; Merz CNB, 1996, AM HEART J, V132, P418; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PASHKOW FJ, 1993, J AM COLL CARDIOL, V21, P822, DOI 10.1016/0735-1097(93)90116-I; Paul-Labrador M, 1999, J Cardiopulm Rehabil, V19, P118, DOI 10.1097/00008483-199903000-00006; PAULLABRADOR M, 1994, J CARDIOPULM REHABIL, V14, P328; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHULER G, 1988, CIRCULATION, V77, P172, DOI 10.1161/01.CIR.77.1.172; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; Vongvanich P, 1996, AM J CARDIOL, V77, P1383, DOI 10.1016/S0002-9149(96)00215-9; Vongvanich P, 1996, J Cardiopulm Rehabil, V16, P233, DOI 10.1097/00008483-199607000-00004; Wenger N K, 1992, Ann Acad Med Singap, V21, P141; WHITE LJ, 1988, ANN INTERN MED, V109, P671, DOI 10.7326/0003-4819-109-8-671; [No title captured]	31	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1476	1478						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732938				2023-01-03	WOS:000085696700033
J	Henney, JE				Henney, JE			Complications related to vascular hemostasis devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2023-01-03	WOS:000083908700004
J	Sinderby, C; Navalesi, P; Beck, J; Skrobik, Y; Comtois, N; Friberg, S; Gottfried, SB; Lindstrom, L				Sinderby, C; Navalesi, P; Beck, J; Skrobik, Y; Comtois, N; Friberg, S; Gottfried, SB; Lindstrom, L			Neural control of mechanical ventilation in respiratory failure	NATURE MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; END-EXPIRATORY PRESSURE; CONTRACTILE PROPERTIES; AIRWAY PRESSURE; HUMAN DIAPHRAGM; INTRINSIC PEEP; SUPPORT; HYPERINFLATION; DYSPNEA; WORK		Univ Montreal, Maisonneuve Rosemont Hosp, Dept Med, Guy Bernier Res Ctr,Intens Care Div, Montreal, PQ, Canada; Univ Gothenburg, Sahlgrenska Hosp, Inst Clin Neurosci, Gothenburg, Sweden; Osped Valduce, Pulm Unit, Rehabil Ctr Villa Beretta, Costamasnaga, LC, Italy; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Gothenburg, Sahlgrens Hosp, Dept Clin Physiol, Gothenburg, Sweden; McGill Univ, Ctr Hlth, Div Resp Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Crit Care Med, Montreal, PQ, Canada	Universite de Montreal; Sahlgrenska University Hospital; University of Gothenburg; McGill University; McGill University; Sahlgrenska University Hospital; University of Gothenburg; McGill University; McGill University	Sinderby, C (corresponding author), Univ Montreal, Maisonneuve Rosemont Hosp, Dept Med, Guy Bernier Res Ctr,Intens Care Div, Montreal, PQ, Canada.		Navalesi, Paolo/I-9584-2019; Navalesi, Paolo/F-9559-2010; Skrobik, Yoanna/K-8165-2014; Skrobik, Yoanna/J-6393-2013	Navalesi, Paolo/0000-0002-3733-3453; Navalesi, Paolo/0000-0002-3733-3453; Skrobik, Yoanna/0000-0002-5315-6020; 				APPENDINI L, 1994, AM J RESP CRIT CARE, V149, P1069, DOI 10.1164/ajrccm.149.5.8173743; ARGOV Z, 1979, NEW ENGL J MED, V301, P409, DOI 10.1056/NEJM197908233010805; AYRES SM, 1969, AM J MED, V46, P495, DOI 10.1016/0002-9343(69)90069-2; Beck J, 1996, J APPL PHYSIOL, V81, P1434, DOI 10.1152/jappl.1996.81.3.1434; Beck J, 1998, J APPL PHYSIOL, V85, P1123, DOI 10.1152/jappl.1998.85.3.1123; BERNSTEIN G, 1993, AM REV RESPIR DIS, V148, P358, DOI 10.1164/ajrccm/148.2.358; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Drinker P, 1929, J AMER MED ASSOC, V92, P1658, DOI 10.1001/jama.1929.02700460014005; GOTTFRIED SB, 1995, THORAX, P2471; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; KLIBURN KH, 1966, ANN INTERN MED, V65, P977; Konyukov YA, 1996, INTENS CARE MED, V22, P363, DOI 10.1007/BF01700461; LEBOURDELLES G, 1994, AM J RESP CRIT CARE, V149, P1539, DOI 10.1164/ajrccm.149.6.8004310; LESSARD MR, 1995, AM J RESP CRIT CARE, V151, P562, DOI 10.1164/ajrccm.151.2.7842221; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; LOURENCO RV, 1966, J APPL PHYSIOL, V21, P527, DOI 10.1152/jappl.1966.21.2.527; MACKLEM PT, 1984, AM REV RESPIR DIS, V129, P1; MALTAIS F, 1994, AM J RESP CRIT CARE, V150, P1318, DOI 10.1164/ajrccm.150.5.7952559; MARINI JJ, 1992, CRIT CARE MED, V20, P1604, DOI 10.1097/00003246-199211000-00020; MARINI JJ, 1998, AM REV RESPIR DIS, V140, P1; Martin RJ, 1994, PRINCIPLES PRACTICE, P511; NAVA S, 1995, INTENS CARE MED, V21, P871, DOI 10.1007/BF01712327; NINANE V, 1993, AM REV RESPIR DIS, V148, P1037, DOI 10.1164/ajrccm/148.4_Pt_1.1037; Parthasarathy S, 1998, AM J RESP CRIT CARE, V158, P1471, DOI 10.1164/ajrccm.158.5.9802014; PETROF BJ, 1990, AM REV RESPIR DIS, V141, P281, DOI 10.1164/ajrccm/141.2.281; QVIST J, 1975, ANESTHESIOLOGY, V42, P45, DOI 10.1097/00000542-197501000-00009; RANIERI VM, 1993, AM REV RESPIR DIS, V147, P5, DOI 10.1164/ajrccm/147.1.5; REMMERS JE, 1976, J APPL PHYSIOL, V41, P252, DOI 10.1152/jappl.1976.41.2.252; SIMILOWSKI T, 1991, NEW ENGL J MED, V325, P917, DOI 10.1056/NEJM199109263251304; Sinderby C, 1998, J APPL PHYSIOL, V85, P2146, DOI 10.1152/jappl.1998.85.6.2146; Sinderby CA, 1997, J APPL PHYSIOL, V82, P1370, DOI 10.1152/jappl.1997.82.4.1370; TOBIN MJ, 1994, PRINCIPLES PRACTICE, P1149; YOUNES M, 1992, AM REV RESPIR DIS, V145, P114, DOI 10.1164/ajrccm/145.1.114	33	405	450	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1433	1436		10.1038/71012	http://dx.doi.org/10.1038/71012			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581089	Bronze			2023-01-03	WOS:000084049700046
J	Emanuel, EJ; Fairclough, DL; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Emanuel, LL			Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ONCOLOGY PATIENTS; CARE GIVERS; FAMILIES; HEALTH; BURDEN; DEATH	Context Euthanasia and physician-assisted suicide (PAS) are highly controversial is' sues. While there are studies of seriously ill patients' interest in euthanasia and PAS, there are no data on the attitudes and desires of terminally ill patients regarding these issues. Objective To determine the attitudes of terminally ill patients toward euthanasia and PAS, whether they seriously were considering euthanasia and PAS for themselves, the stability of their desires, factors associated with their desires, and the proportion of patients who die from these interventions. Design Prospective cohort of terminally ill patients and their primary caregivers surveyed twice between March 1996 and July 1997. Setting Outpatient settings in 5 randomly selected metropolitan statistical areas and 1 rural county. Participants A total of 988 patients identified by their physicians to be terminally ill with any disease except for human immunodeficiency virus infection (response ratel 87.4%) and 893 patient-designated primary caregivers (response rate, 97.6%). Main Outcome Measures Support for euthanasia or PAS in standard scenarios; patient-expressed considerations and discussions of their desire for euthanasia or PAS; hoarding of drugs for suicide; patient death by euthanasia or PAS; and patient-reported sociodemographic factors and symptoms related to these outcomes. Results Of the 988 terminally ill patients, a total of 60.2% supported euthanasia or PAS in a hypothetical situation, but only 10.6% reported seriously considering euthanasia or PAS for themselves. Factors associated with being less likely to consider euthanasia or PAS were feeling appreciated (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.52-0.82), being aged 65 years or older (OR, 0.52; 95% CI, 0.34-0.82), and being African American (OR, 0.39; 95 % CI, 0.18-0.84). Factors associated with being more likely to consider euthanasia or PAS were depressive symptoms (OR, 1.25; 95 % Clr 1.05-1.49), substantial caregiving needs (OR, 1.09; 95 % CI, 1.01 - 1.17), and pain (OR, 1.26; 95% CI, 1.02-1.56). At the follow-up interview, half of the terminally ill patients who had considered euthanasia or PAS for themselves changed their minds, while an almost equal number began considering these interventions. Patients with depressive symptoms (OR, 5.29; 95% CI, 1.21-23.2) and dyspnea (OR, 1.68; 95% CI, 1.26-2.22) were more likely to change their minds to consider euthanasia or PAS. According to the caregivers of the 256 decedents, 14 patients (5.6%) had discussed asking the physician for euthanasia or PAS and 6 (2.5%) had hoarded drugs. Ultimately, of the 256 decedents 1 (0.4%) died by euthanasia or PAS, 1 unsuccessfully attempted suicide, and 1 repeatedly requested for her life to be ended but the family and physicians refused. Conclusions In this survey, a small proportion of terminally ill patients seriously considered euthanasia or PAS for themselves. Over a few months, half the patients changed their minds. Patients with depressive symptoms were more likely to change their minds;about desiring euthanasia or PAS.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, Chicago, IL USA	National Institutes of Health (NIH) - USA; Northwestern University	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Brown J, 1995, AM J PSYCHIAT, V152, P1185; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 1999, ETHICS, V109, P629, DOI 10.1086/233925; EMANUEL L, IN PRESS J PALLIAT M; EPSTEIN AM, 1995, INQUIRY-J HEALTH CAR, V32, P211; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Koenig HG, 1996, ARCH INTERN MED, V156, P2240, DOI 10.1001/archinte.156.19.2240; Nuland SB, 2000, NEW ENGL J MED, V342, P583, DOI 10.1056/NEJM200002243420811; Owen C., 1992, PSYCHO-ONCOLOGY, V1, P79, DOI [10.1002/pon.2960010205, DOI 10.1002/PON.2960010205]; Quill TE, 1993, DEATH DIGNITY MAKING; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; Rosenfeld B, 1999, AM J PSYCHIAT, V156, P94, DOI 10.1176/ajp.156.1.94; SHERBOURNE CD, 1993, SOC SCI MED, V12, P164; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; SuarezAlmazor ME, 1997, J CLIN ONCOL, V15, P418, DOI 10.1200/JCO.1997.15.2.418; SUBROD C, 1960, J CHRON DIS, V11, P7; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; Ware J. E., 1993, SF36 HLTH SURVEY MAN; Willems DL, 2000, ARCH INTERN MED, V160, P63, DOI 10.1001/archinte.160.1.63; Wolfe J, 1999, J CLIN ONCOL, V17, P1274, DOI 10.1200/JCO.1999.17.4.1274; [No title captured]	38	235	236	1	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2460	2468		10.1001/jama.284.19.2460	http://dx.doi.org/10.1001/jama.284.19.2460			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074775	Bronze			2023-01-03	WOS:000165183800019
J	Steinhauser, AE; Christakis, NA; Clipp, EC; McNeilly, M; McIntyre, L; Tulsky, JA				Steinhauser, AE; Christakis, NA; Clipp, EC; McNeilly, M; McIntyre, L; Tulsky, JA			Factors considered important at the end of life by patients, family, physicians, and other care providers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINING TREATMENTS; PREFERENCES; SAMPLE; PEOPLE; DEATH	Context A clear understanding of what patients, families, and health care practitioners view as important at the end of life is integral to the success of improving care of dying patients. Empirical evidence de fining such factors, however, is lacking. Objective To determine the factors considered important at the end of life by patients, their families, physicians, and other care providers. Design and Setting Cross-sectional, stratified random national survey conducted in March-August 1999. Participants Seriously ill patients (n = 340), recently bereaved family (n = 332), physicians (n = 361), and other care providers (nurses, social workers, chaplains, and hospice volunteers; n = 429). Main Outcome Measures Importance of 44 attributes of quality at the end of life (5-point scale) and rankings of 9 major attributes, compared in the 4 groups. Results Twenty-six items consistently were rated as being important (>70% responding that item is important) across all 4 groups, including pain and symptom management, preparation for death, achieving a sense of completion, decisions about treatment preferences, and being treated as a "whole person." Eight items received strong importance ratings from patients but less from physicians (P<.001), including being mentally aware, having funeral arrangements planned, not being a burden, helping others, and coming to peace with Clod. Ten items had broad variation within as well as among the 4 groups, including decisions about life-sustaining treatments, dying at home, and talking about the meaning of death. Participants ranked freedom from pain most important and dying at home least important among 9 major attributes. Conclusions Although pain and symptom management, communication with;one's physician, preparation for death, and the opportunity to achieve a sense of completion are important to most, other factors important to quality at the end of life differ by role and by individual. Efforts to evaluate and improve patients' and families' experiences at the end of life must account for diverse perceptions of quality.	Program Med Encounter & Palliat Care, Durham, NC USA; Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; Duke Univ, Inst Care End Life, Durham, NC USA; Inst Multiculturalism, Durham, NC USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Sociol, Chicago, IL 60637 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University; University of Chicago; University of Chicago	Steinhauser, AE (corresponding author), Vet Affairs Med Ctr 152, 508 Fulton St, Durham, NC 27705 USA.	karensteinhauser@mindspring.com	Christakis, Nicholas A/C-3205-2009; Christakis, Nicholas A/B-6690-2008	McIntyre, Lauren/0000-0002-0077-3359				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; [Anonymous], 1997, APPROACHING DEATH, DOI [10.17226/5801, DOI 10.17226/5801]; CHILDERS TL, 1979, J MARKETING RES, V16, P429, DOI 10.2307/3150720; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis Nicholas, 1999, DEATH FORETOLD PROPH; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Erikson E.H., 1982, LIFE CYCLE COMPLETED; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GARVIN J, 1995, W J MED, V163, P268; GIBSON R, 1998, J PALLIAT MED, V1, P415; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HENDRICK C, 1972, PSYCHON SCI, V26, P349; KING DE, 1994, J FAM PRACTICE, V39, P349; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; *NAT HOSP ORG, 1996, NEW FINDINGS ADDRESS; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; SCHMIDT TA, 1995, ACAD EMERG MED, V2, P513, DOI 10.1111/j.1553-2712.1995.tb03250.x; SEALE C, 1991, SOC SCI MED, V32, P943, DOI 10.1016/0277-9536(91)90249-C; SEALE C, 1995, SOC SCI MED, V40, P589, DOI 10.1016/0277-9536(94)E0119-D; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; TULSKY J, 1997, J CLIN ETHIC, V126, P381; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306	27	1610	1630	11	107	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2476	2482		10.1001/jama.284.19.2476	http://dx.doi.org/10.1001/jama.284.19.2476			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074777	Green Published			2023-01-03	WOS:000165183800021
J	Hauer, KE; Winawer, N				Hauer, KE; Winawer, N			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							ELDERLY PATIENTS; CARE; QUALITY		Univ Calif San Francisco, San Francisco, CA 94143 USA; Emory Univ, Atlanta, GA 30322 USA	University of California System; University of California San Francisco; Emory University	Hauer, KE (corresponding author), Univ Calif San Francisco, Box 0320,400 Parnassus Ave, San Francisco, CA 94143 USA.	karenha@itsa.ucsf.edu						CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437; Lurie JD, 1999, AM J MED, V106, P441, DOI 10.1016/S0002-9343(99)00045-5; Navasa M, 1997, Semin Gastrointest Dis, V8, P200; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	12	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					707	713		10.7326/0003-4819-133-9-200011070-00013	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074904				2023-01-03	WOS:000165075300006
J	Phillips, DM				Phillips, DM			JCAHO pain management standards are unveiled	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	387	396	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	2000	284	4					428	429		10.1001/jama.284.4.428	http://dx.doi.org/10.1001/jama.284.4.428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335QB	10904487				2023-01-03	WOS:000088254200005
J	Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB				Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB			Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappa B, AP-1, JNK, MAPKK and apoptosis	ONCOGENE			English	Article						anethole; TNF; NF-kappa B; AP-1; JNK; apoptosis	LIPID-PEROXIDATION; TRANSCRIPTION FACTOR; POTENT INHIBITOR; TERMINAL KINASE; COLON-CANCER; ACTIVATION; EUGENOL; CELLS; CHEMOPREVENTION; OVEREXPRESSION	Anethole, a chief constituent of anise, camphor, and fennel, has been shown to block both inflammation and carcinogenesis, but just how these effects are mediated is not known, One possibility is TNF-mediated signaling, which has also been associated with both inflammation and carcinogenesis. In the present report we show that anethole is a potent inhibitor of TNF-induced NF-kappa B activation (an early response) as monitored by electrophoretic mobility shift assay I kappa B alpha phosphorylation and degradation, and NF-kappa B reporter gene expression. Suppresaon of I kappa B alpha phosphorylation and NF-kappa B reporter gene expression induced by TRAF2 and NIK, suggests that anethole acts on I kappa B alpha kinase, Anethole also blocked the NF-kappa B activation induced by a variety of other inflammatory agents. Besides NF-kappa B, anethole also suppressed TNF-induced activation of the transcription factor AP-1, c-jun N-terminal kinase and MAPK-kinase, In addition, anethole abrogated TNF-induced apoptosis as measured by both caspase activation and cell viability. The anethole analogues eugenol and isoeugenol also blocked TNF signaling. Anethole suppressed TNF-induced both lipid peroxidation and ROI generation. Overall, our results demonstrate that anethole inhibits TNF-induced cellular responses,,which mag explain its role in suppression of inflammation and carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Chainy, Gagan B N/G-7020-2012; Aggarwal, Bharat B/G-3388-2013	Chainy, Gagan B N/0000-0002-6418-0480; 				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALHARBI MM, 1995, EUR J CANCER PREV, V4, P307, DOI 10.1097/00008469-199508000-00006; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Bouthillier L, 1996, TOXICOL APPL PHARM, V139, P177, DOI 10.1006/taap.1996.0156; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Budavari S., 1996, MERCK INDEX, P108; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drukarch B, 1997, EUR J PHARMACOL, V329, P259, DOI 10.1016/S0014-2999(97)89187-X; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanna S, 1998, BIOCHEM PHARMACOL, V56, P61, DOI 10.1016/S0006-2952(98)00113-0; KO FN, 1995, BBA-LIPID LIPID MET, V1258, P145; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LUBET RA, 1997, INT J CANCER, P7295; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MANSUY D, 1986, BIOCHEM BIOPH RES CO, V135, P1015, DOI 10.1016/0006-291X(86)91029-6; NAGABABU E, 1994, FREE RADICAL RES, V20, P253, DOI 10.3109/10715769409147521; NAIDU KA, 1995, PROSTAG LEUKOTR ESS, V53, P381, DOI 10.1016/0952-3278(95)90060-8; RAJAKUMAR DV, 1993, BIOCHEM PHARMACOL, V46, P2067, DOI 10.1016/0006-2952(93)90649-H; Reddy BS, 1996, PREV MED, V25, P48, DOI 10.1006/pmed.1996.0017; Reddy BS, 1997, ADV EXP MED BIOL, V400, P931; REDDY BS, 1993, CANCER RES, V53, P3493; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; ROMPELBERG CJM, 1993, FOOD CHEM TOXICOL, V31, P637, DOI 10.1016/0278-6915(93)90046-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SHARMA JN, 1994, PHARMACOLOGY, V49, P314, DOI 10.1159/000139248; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; STOHS SJ, 1986, MECH AGEING DEV, V37, P137, DOI 10.1016/0047-6374(86)90071-0; Suganuma M, 1996, CANCER RES, V56, P3711; TAIRA J, 1992, FREE RADICAL RES COM, V16, P197, DOI 10.3109/10715769209049172; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	40	146	150	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2943	2950		10.1038/sj.onc.1203614	http://dx.doi.org/10.1038/sj.onc.1203614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871845				2023-01-03	WOS:000087544500008
J	Vickers, A				Vickers, A			Use of hypericum as antidepressant - Use of placebo in depression trial was unethical	BRITISH MEDICAL JOURNAL			English	Letter									Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Vickers, A (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.			Vickers, Andrew/0000-0003-1525-6503				Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1142	1142						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10836816				2023-01-03	WOS:000086782800029
J	Simini, B				Simini, B			Awareness of awareness during general anaesthesia	LANCET			English	Editorial Material							ANESTHESIA; RECALL		Ospedale, I-55100 Lucca, Italy		Simini, B (corresponding author), Ospedale, I-55100 Lucca, Italy.							Aitkenhead AR, 1996, CAN J ANAESTH, V43, P206, DOI 10.1007/BF03011735; Bailey AR, 1997, ANAESTHESIA, V52, P460, DOI 10.1111/j.1365-2044.1997.133-az0134.x; BRIGHOUSE D, 1992, BRIT MED J, V304, P1327, DOI 10.1136/bmj.304.6838.1327; LEVINSON BW, 1965, BRIT J ANAESTH, V37, P544, DOI 10.1093/bja/37.7.544; LIU WHD, 1991, ANAESTHESIA, V46, P435, DOI 10.1111/j.1365-2044.1991.tb11677.x; Peduto V A, 1994, Minerva Anestesiol, V60, P1; Ranta SOV, 1998, ANESTH ANALG, V86, P1084, DOI 10.1097/00000539-199805000-00035; REYNOLDS F, 1986, ANAESTHESIA, V41, P652, DOI 10.1111/j.1365-2044.1986.tb13069.x; SANDIN R, 1993, BRIT J ANAESTH, V71, P782, DOI 10.1093/bja/71.6.782; Schwender D, 1998, BRIT J ANAESTH, V80, P133, DOI 10.1093/bja/80.2.133; 1986, LANCET, V2, P1019; 1973, LANCET, V2, P1305	12	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 26	2000	355	9205					672	674		10.1016/S0140-6736(00)00080-5	http://dx.doi.org/10.1016/S0140-6736(00)00080-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HZ	10703797				2023-01-03	WOS:000085615600006
J	Foley, K				Foley, K			Dismantling the barriers: Providing palliative and pain care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; CANCER PAIN; ATTITUDES		Cornell Univ, Coll Med, New York, NY 10021 USA	Cornell University	Foley, K (corresponding author), Cornell Univ, Coll Med, New York, NY 10021 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Carron A T, 1999, Ann Intern Med, V130, P82; Foley Kathleen M., 1997, P2807; FOLEY KM, 1995, PAIN FORUM, V4, P163; *GALL I, 1997, SPIR BEL DYING PROC; *I MED DIV HLTH CA, 1997, APPROACHING DEATH IM; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEVIN DN, 1985, CANCER, V56, P2337, DOI 10.1002/1097-0142(19851101)56:9<2337::AID-CNCR2820560935>3.0.CO;2-W; MEIER DE, 1997, ANN INTERN MED, V127, P3; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; World Health Organization, 1990, CANC PAIN REL PALL C	12	19	19	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					115	115		10.1001/jama.283.1.115	http://dx.doi.org/10.1001/jama.283.1.115			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632292	hybrid			2023-01-03	WOS:000084514400037
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL			Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED ADULTS; ALZHEIMERS-DISEASE; MENTAL-HEALTH; BURDEN; CANCER; NEEDS	Background In addition to medical care, dying patients often need many types of assistance, including help with transportation, nursing care, homemaking services, and personal care. We interviewed terminally ill adults and their care givers in six randomly selected areas of the United States (five metropolitan areas and one rural county) to determine how their needs for assistance were met and the frequency with which they received such assistance from family members and paid and volunteer care givers. Methods The patients, whose physicians estimated them to have less than six months to live and who had clinically significant illness other than human immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the study by their physicians. Of the 1131 eligible patients, 988 (87.4 percent) consented to a detailed in-person interview conducted in English, as did 893 of the 915 eligible primary care givers (97.6 percent). Results Of the 988 terminally ill patients, 59.4 percent: were over the age of 65 years, and 51.5 percent were women; The most frequent terminal illness was cancer (in 51.8 percent of the patients), followed by heart disease (18.0 percent) and chronic obstructive pulmonary disease (10.9 percent). Four percent of the patients were in an institution, such as a nursing home, residential hospice, or hospital; the rest were living in a private residence. A need for assistance was reported by 86.8 percent of the patients; they required help with transportation (reported by 62.0 percent), homemaking services (55.2 percent), nursing care (28.7 percent), and personal care (26.0 percent). Of the care givers, 72.1 percent were women. Primary care givers were family members in 96.0 percent of cases; only 4.0 percent were unrelated. Most patients relied completely on family members and friends for assistance. A total of 15.5 percent of patients relied only on paid assistance for more than half of the types of care that they needed. Volunteers (that is, unpaid helpers who were not family members or friends) provided less than 3 percent of all care. Conclusions In our survey of terminally ill patients, family members, usually women, provided the majority of assistance with nonmedical care. Although many people received assistance from paid care givers, very few had assistance from volunteers; (N Engl J Med 1999;341:956-63.) (C) 1999, Massachusetts Medical Society.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Vital Sci & Hlth, Newtonville, MA USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ., 1997, APPROACHING DEATH IM, P50; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HEINRICH RL, 1984, J CLIN PSYCHOL, V40, P972, DOI 10.1002/1097-4679(198407)40:4<972::AID-JCLP2270400417>3.0.CO;2-W; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; Kleinbaum D. G., 1988, STUDENTS PARTIAL SOL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MAX W, 1995, J AGING HEALTH, V7, P179, DOI 10.1177/089826439500700202; Meyer H, 1997, HOSP HEALTH NETWORK, V71, P26; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; US Bureau of the Census, 1998, STAT ABSTR US 1998; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Zubrod C.G., 1960, J CHRON DIS, V11, P7; 1998, WASHINGTON POST 0304, pA13; [No title captured]; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	30	240	246	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					956	963		10.1056/NEJM199909233411306	http://dx.doi.org/10.1056/NEJM199909233411306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498492				2023-01-03	WOS:000082658100006
J	Zhu, YX; King, MA; Schuller, AGP; Nitsche, JF; Reidl, M; Elde, RP; Unterwald, E; Pasternak, GW; Pintar, JE				Zhu, YX; King, MA; Schuller, AGP; Nitsche, JF; Reidl, M; Elde, RP; Unterwald, E; Pasternak, GW; Pintar, JE			Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice	NEURON			English	Article							PHARMACOLOGICAL CHARACTERIZATION; MESSENGER-RNA; EXPRESSION; DEPENDENCE; SUBTYPES; BINDING; MOUSE; ANTINOCICEPTION; NALTRINDOLE; WITHDRAWAL	Gene targeting was used to delete exon 2 of mouse DOR-1, which encodes the delta opioid receptor. Essentially all 3H-[D-Pen(2),D-Pen(5)]enkephalin (H-3-DPDPE) and 3H-[D-Ala(2),D-Glu(4)]deltorphin (H-3-deltorphin-2) binding is absent from mutant mice, demonstrating that DOR-1 encodes both delta(1) and delta(2) receptor subtypes. Homozygous mutant mice display markedly reduced spinal 6 analgesia, but peptide 6 agonists retain supraspinal analgesic potency that is only partially antagonized by naltrindole. Retained DPDPE analgesia is also demonstrated upon formalin testing, while the nonpeptide 6 agonist BW373U69 exhibits enhanced activity in DOR-l mutant mice. Together, these findings suggest the existence of a second delta-like analgesic system. Finally, DOR-1 mutant mice do not develop analgesic tolerance to morphine, genetically demonstrating a central role for DOR-1 in this process.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Univ Minnesota, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Pintar, JE (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007242, R01DA009040, R37DA007242] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00220, DA-09040, DA-07242] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ARVIDSSON U, 1995, J NEUROSCI, V15, P1215; CALCAGNETTI DJ, 1988, EUR J PHARMACOL, V153, P117, DOI 10.1016/0014-2999(88)90595-X; CHANG KJ, 1993, J PHARMACOL EXP THER, V267, P852; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; Ellison Neil M., 1993, P185; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Hepburn MJ, 1997, J PHARMACOL EXP THER, V281, P1350; HERZ A, 1993, HDB EXPT PHARM, V114; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; HEYMAN JS, 1988, TRENDS PHARMACOL SCI, V9, P134, DOI 10.1016/0165-6147(88)90195-2; Hiller JM, 1996, BRAIN RES, V719, P85, DOI 10.1016/0006-8993(96)00090-X; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Kest B, 1996, BRAIN RES BULL, V39, P185, DOI 10.1016/0361-9230(95)02092-6; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; LUKE MC, 1988, LIFE SCI, V43, P1249, DOI 10.1016/0024-3205(88)90215-9; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MANSOUR A, 1993, J CHEM NEUROANAT, V6, P351, DOI 10.1016/0891-0618(93)90010-2; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MATTIA A, 1991, J PHARMACOL EXP THER, V258, P583; MATTIA A, 1992, J PHARMACOL EXP THER, V260, P518; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Olianas MC, 1995, J PHARMACOL EXP THER, V275, P1560; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; RAPAKA RS, 1991, PHARM RES-DORDR, V8, P1, DOI 10.1023/A:1015809702296; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Rossi GC, 1997, BRAIN RES, V753, P176, DOI 10.1016/S0006-8993(97)00081-4; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; STANDIFER KM, 1994, NEURON, V12, P805, DOI 10.1016/0896-6273(94)90333-6; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; TISEO PJ, 1993, EUR J PHARMACOL, V236, P89, DOI 10.1016/0014-2999(93)90230-F; UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018; WILD KD, 1993, J PHARMACOL EXP THER, V267, P858; ZHENG M, 1995, METH NEUROSCI, V23, P45; Zhu YX, 1998, BIOL REPROD, V59, P925, DOI 10.1095/biolreprod59.4.925; Zhu YX, 1998, J NEUROSCI, V18, P2538	44	333	349	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	SEP	1999	24	1					243	252		10.1016/S0896-6273(00)80836-3	http://dx.doi.org/10.1016/S0896-6273(00)80836-3			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	241QC	10677041	Bronze			2023-01-03	WOS:000082893200023
J	Robertson, MC; Gardner, MM; Devlin, N; McGee, R; Campbell, AJ				Robertson, MC; Gardner, MM; Devlin, N; McGee, R; Campbell, AJ			Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 2: Controlled trial in multiple centres	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; PEOPLE; WOMEN; OLDER	Objectives To assess the effectiveness of trained nurses based in general practices individually prescribing a home exercise programme to reduce falls and injuries in elderly people and to estimate the cost effectiveness of the programme. Design Controlled trial with one year's follow up. Setting 32 general practices in seven southern New Zealand centres. Participants 450 women and men aged 80 years and older. Intervention 330 participants received the exercise programme (exercise centres) and 120 received usual care (control centres); 87% (371 of 426) completed the trial. Main outcome measures Number of falls, number of injuries resulting from falls, costs of implementing the programme, and hospital costs as a result of falls. Results Falls were reduced by 30% in the exercise centres (incidence rate ratio 0.70, 95% confidence interval 0.59 to 0.84). The programme was equally effective in men and women. The programme cost $NZ418 (pound 121) (at 1998 prices) per person to deliver for one year or $NZ1519 (pound 441) per fall prevented. Fewer participants had falls resulting in injuries, but there was no difference in the number who had serious injuries and no difference in hospital costs resulting from falls in exercise centres compared with control centres. Conclusions An individually tailored exercise programme, delivered by trained nurses from within general practices, was effective in reducing falls in three different centres, This strategy should be combined with other successful interventions to form part of home programmes to prevent falls in elderly people.	Otago Med Sch, Dept Med & Surg Sci, Dunedin, New Zealand; Univ Otago, Dept Econ, Dunedin, New Zealand; Otago Med Sch, Dept Prevent & Social Med, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago	Robertson, MC (corresponding author), Otago Med Sch, Dept Med & Surg Sci, POB 913, Dunedin, New Zealand.		Robertson, Mary Clare/A-3964-2009	McGee, Rob/0000-0003-2429-6304				Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; Campbell AJ, 1999, J AM GERIATR SOC, V47, P850, DOI 10.1111/j.1532-5415.1999.tb03843.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; *STAT, 1999, STAT STAT SOFTW; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301	11	180	184	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 24	2001	322	7288					701	704		10.1136/bmj.322.7288.701	http://dx.doi.org/10.1136/bmj.322.7288.701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	416GB	11264207	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000167771000023
J	Slamon, DJ; Leyland-Jones, B; Shak, S; Fuchs, H; Paton, V; Bajamonde, A; Fleming, T; Eiermann, W; Wolter, J; Pegram, M; Baselga, J; Norton, L				Slamon, DJ; Leyland-Jones, B; Shak, S; Fuchs, H; Paton, V; Bajamonde, A; Fleming, T; Eiermann, W; Wolter, J; Pegram, M; Baselga, J; Norton, L			Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; OVARIAN-CANCER; NEU ONCOGENE; PHASE-II; CELLS; THERAPY; PROTOONCOGENE; AMPLIFICATION; EXPRESSION; DISEASE	Background: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Methods: We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women). Results: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), longer survival (median survival, 25.1 vs. 20.3 months; P=0.046), and a 20 percent reduction in the risk of death. The most important adverse event was cardiac dysfunction, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone. Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management. Conclusions: Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2. (N Engl J Med 2001;344:783-92.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Genentech Inc, Med Affairs, S San Francisco, CA 94080 USA; IntraBiotics, Mt View, CA USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Frauenklin vom Roten Kreuz, Dept Obstet & Gynecol, Munich, Germany; Rush Presbyterian St Lukes Med Ctr, Dept Oncol, Chicago, IL 60612 USA; Hosp Gen Univ Vall Dhebron, Dept Oncol, Barcelona, Spain; Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10021 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McGill University; Roche Holding; Genentech; University of Washington; University of Washington Seattle; Rush University; Hospital Universitari Vall d'Hebron; Memorial Sloan Kettering Cancer Center	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, 11-244 Factor Bldg,10833 Le Conte, Los Angeles, CA 90095 USA.		Wilson, Matthew H/K-3193-2013; Mieszkowska, Magdalena/O-6753-2017	Norton, Larry/0000-0003-3701-9250				AHERN RP, 1993, BRIT J CANCER, V67, P801, DOI 10.1038/bjc.1993.146; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; Baselga J, 1999, CANCER RES, V59, P2020; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fossati R, 1998, J CLIN ONCOL, V16, P3439, DOI 10.1200/JCO.1998.16.10.3439; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Konecny G., 1999, Breast Cancer Research and Treatment, V57, P114; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Pietras RJ, 1999, CANCER RES, V59, P1347; PRESS MF, 1993, CANCER RES, V53, P4960; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLEDGE GW, 1997, P AN M AM SOC CLIN, V16, P1; Smith G, 1996, SEMIN ONCOL, V23, P506; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710	33	8201	8701	51	1262	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2001	344	11					783	792		10.1056/NEJM200103153441101	http://dx.doi.org/10.1056/NEJM200103153441101			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410LA	11248153				2023-01-03	WOS:000167440400001
J	Diggory, P; Fernandez, C; Humphrey, A; Jones, V; Murphy, M				Diggory, P; Fernandez, C; Humphrey, A; Jones, V; Murphy, M			Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine whether elderly people can learn to use the inhaler used to deliver zanamivir (Relenza Diskhaler) as effectively as the Turbohaler and to identify which aspects of inhaler technique are most problematic. Design Randomised, controlled, intervention study. Setting Wards for acute elderly care in a large district general hospital. Participants 73 patients who were unfamiliar with the use of an inhaler, aged 71 to 99 (mean 83) years. Main outcome measures Initial scores and changes in scores 24 hours later using a 10 point scoring system of five aspects of inhaler technique. Results 38 patients were allocated the Relenza Diskhaler and 35 the Turbohaler. The mean total score was significantly greater in the Turbohaler than Diskhaler groups both initially (8.74 v 7.05) and after 24 hours (8.28 v 5.43). The major difference between inhalers was in loading and priming. After tuition 50% (19 of 38) of patients allocated the Diskhaler were unable to load and prime the device and 65% (24 of 37) were unable to do so 24 hours later. Of those allocated the Turbohaler, two patients were unable to load and prime the device after initial review and one after 24 hours. Conclusion Most elderly people cannot use the inhaler device used to deliver the anti-influenza drug zanamivir. Treatment with this drug is unlikely to be effective in elderly people unless the delivery system is improved.	Mayday Hosp, Dept Elderly Care Med, Croydon CR7 7YE, England; Mayday Hosp, Dept Clin Audit, Croydon CR7 7YE, England	Croydon University Hospital; Croydon University Hospital	Diggory, P (corresponding author), Mayday Hosp, Dept Elderly Care Med, Croydon CR7 7YE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen SC, 1997, AGE AGEING, V26, P83, DOI 10.1093/ageing/26.2.83; ARMITAGE JM, 1988, AGE AGEING, V17, P275, DOI 10.1093/ageing/17.4.275; *DEP HLTH, 1996, IMM INF DIS, P120; DIGGORY P, 1991, AGE AGEING, V20, P379, DOI 10.1093/ageing/20.5.379; ELIZABETH JE, 1988, GERIATR MED, V18, P11; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HODGKINSON HM, 1972, AGE AGEING, V1, P233; Jones V, 1999, AGE AGEING, V28, P481, DOI 10.1093/ageing/28.5.481; PESSON G, 1986, EUR RESPIR J, V1, P681; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; 1996, EFFECTIVENESS MATTER, V2, P1	11	66	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 10	2001	322	7286					577	579		10.1136/bmj.322.7286.577	http://dx.doi.org/10.1136/bmj.322.7286.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	411KU	11238150	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000167499900020
J	Ledergerber, B; Mocroft, A; Reiss, P; Furrer, H; Kirk, O; Bickel, M; Uberti-Foppa, C; Pradier, C; Monforte, AD; Schneider, MME; Lundgren, JD				Ledergerber, B; Mocroft, A; Reiss, P; Furrer, H; Kirk, O; Bickel, M; Uberti-Foppa, C; Pradier, C; Monforte, AD; Schneider, MME; Lundgren, JD		Eight European Study Grp	Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	7th Conference on Retroviruses and Opportunistic Infections	JAN 29-FEB 03, 2000	SAN FRANCISCO, CA				ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; OPPORTUNISTIC INFECTIONS; AEROSOLIZED PENTAMIDINE; HIV-1-INFECTED PATIENTS; COTRIMOXAZOLE; PROGRESSION; PREVENTION; MUTATIONS; MORTALITY	Background: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known. Methods: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight prospective European cohorts. Between October 1996 and January 2000, these patients discontinued secondary prophylaxis during treatment with at least three anti-HIV drugs after they had at least one peripheral-blood CD4 cell count of more than 200 cells per cubic millimeter. Results: Secondary prophylaxis was discontinued at a median CD4 cell count of 350 per cubic millimeter; the median nadir CD4 cell count had been 50 per cubic millimeter. The median duration of the increase in the CD4 cell count to more than 200 per cubic millimeter after discontinuation of secondary prophylaxis was 11 months. The median follow-up period after discontinuation of secondary prophylaxis was 13 months, yielding a total of 374 person-years of follow-up; for 355 of these person-years, CD4 cell counts remained at or above 200 per cubic millimeter. No cases of recurrent P. carinii pneumonia were diagnosed during this period; the incidence was thus 0 per 100 patient-years (99 percent confidence interval, 0 to 1.2 per 100 patient-years, on the basis of the entire follow-up period, and 0 to 1.3 per 100 patient-years, on the basis of the follow-up period during which CD4 cell counts remained at or above 200 per cubic millimeter). Conclusions: It is safe to discontinue secondary prophylaxis against P. carinii pneumonia in patients with HIV infection who have an immunologic response to highly active antiretroviral therapy. (N Engl J Med 2001;344:168-74.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; UCL Royal Free & Univ Coll Med Sch, London, England; Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland; Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; Goethe Univ Frankfurt, Ctr Internal Med, D-6000 Frankfurt, Germany; Hosp San Raffaele, Dept Infect Dis, I-20132 Milan, Italy; Hop Archet, Trop & Infect Dis Dept, Nice, France; Univ Milan, Inst Infect & Trop Dis, Milan, Italy; Univ Utrecht, Med Ctr, Dept Internal Med, Div Infect Dis & AIDS, Utrecht, Netherlands	University of Zurich; University Zurich Hospital; University of London; University College London; UCL Medical School; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Bern; University Hospital of Bern; University of Copenhagen; Goethe University Frankfurt; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; CHU Nice; University of Milan; Utrecht University	Ledergerber, B (corresponding author), Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland.	infled@usz.unizh.ch	Mocroft, Amanda/C-1527-2008; Ledergerber, Bruno/B-5656-2009; Foppa, Caterina Uberti/ABH-3089-2020; Furrer, Hansjakob/G-6768-2013; Mocroft, Amanda/G-8748-2011; Pradier, Christian/AFE-8255-2022; Pradier, Christian/AAE-9669-2022; Lundgren, Jens/AAE-6876-2019; kirk, ole/ABB-4746-2021	Ledergerber, Bruno/0000-0002-6881-4401; Foppa, Caterina Uberti/0000-0001-5271-9138; Furrer, Hansjakob/0000-0002-1375-3146; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; LUNDGREN JD, 1995, CLIN INFECT DIS, V21, P106, DOI 10.1093/clinids/21.1.106; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft AJ, 1997, INT J EPIDEMIOL, V26, P400, DOI 10.1093/ije/26.2.400; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; Navin TR, 2000, J INFECT DIS, V181, P158, DOI 10.1086/315196; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; Pradier C, 1997, AIDS, V11, P832; Rizzardi GP, 1996, J INFECTION, V32, P123, DOI 10.1016/S0163-4453(96)91312-2; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SHELHAMER JH, 1984, AM REV RESPIR DIS, V130, P1161; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	38	109	112	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					168	174		10.1056/NEJM200101183440302	http://dx.doi.org/10.1056/NEJM200101183440302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	392GF	11188837	Green Published, Bronze			2023-01-03	WOS:000166402800002
J	Jones, A; Pill, R; Adams, S				Jones, A; Pill, R; Adams, S			Qualitative study of views of health professionals and patients on guided self management plans for asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To explore the views held by general practitioners, practice nurses, and patients about the role of guided self management plans in asthma care. Design Qualitative study using nine focus groups that each met on two occasions. Setting South Wales. Subjects 13 asthma nurses, 11 general practitioners (six with an interest in asthma), and 32 patients (13 adults compliant with treatment, 12 non-compliant adults, and seven teenagers). Results Neither health professionals nor patients were enthusiastic about guided self management plans, and, although for different reasons, almost all participants were ambivalent about their usefulness or relevance. Most professionals opposed their use. Few patients reported sustained use, and most felt that plans were largely irrelevant to them. The attitudes associated with these views reflect the gulf between the professionals' concept of the "responsible asthma patient" and the patients' view. Conclusions Attempts to introduce self guided management plans in primary care are unlikely to be successful. A more patient centred, patient negotiated plan is needed for asthma care in the community.	Cardiff Univ, Ctr Hlth, Dept Gen Practice, Cardiff CF26 9PN, S Glam, Wales; Univ Swansea, Sch Social Sci & Int Dev, Swansea SA2 8PP, W Glam, Wales	Cardiff University; Swansea University	Jones, A (corresponding author), Princess St Surg, Swansea SA4 2US, W Glam, Wales.	research@gors.freeserve.co.uk						Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; [Anonymous], 1993, BRIT MED J, V306, P776; Ayres JG, 1996, EUR RESPIR J, V9, P886, DOI 10.1183/09031936.96.09050886; GIBSON PG, 2000, COCHRANE LIB; Guba E.G., 1989, 4 GENERATION EVALUAT; HAUGHNEY J, 1997, AIRWAYS, V4, P2; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; Lahdensuo A, 1999, BMJ-BRIT MED J, V319, P759, DOI 10.1136/bmj.319.7212.759; LEVY M, 1999, ED SELF MANAGEMENT A, P63; Neville RG, 1999, THORAX, V54, P813, DOI 10.1136/thx.54.9.813; Partridge MR, 1990, RES CLIN FORUMS, V15, P65; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; YOON R, 1993, THORAX, V48, P1110, DOI 10.1136/thx.48.11.1110	13	103	104	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2000	321	7275					1507	1510		10.1136/bmj.321.7275.1507	http://dx.doi.org/10.1136/bmj.321.7275.1507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GF	11118179	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000165994700027
J	Lawlor, PG; Fainsinger, RL; Bruera, ED				Lawlor, PG; Fainsinger, RL; Bruera, ED			Delirium at the end of life - Critical issues in clinical practice and research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ELDERLY HOSPITALIZED-PATIENTS; ILL CANCER-PATIENTS; COGNITIVE FAILURE; PREDICTIVE MODEL; MEDICAL PATIENTS; DIAGNOSIS; SUBTYPES; PAIN		Grey Nuns Community Hlth Ctr & Hosp, Edmonton Reg Palliat Care Program, Edmonton, AB T6L 5X8, Canada; Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Dept Symptom Control & Palliat Care, Houston, TX 77030 USA	University of Alberta; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lawlor, PG (corresponding author), Grey Nuns Community Hlth Ctr & Hosp, Edmonton Reg Palliat Care Program, Room 5211,1100 Youville Dr W, Edmonton, AB T6L 5X8, Canada.	plawlor@gpu.srv.ualberta.ca	Bruera, Eduardo/AAA-1550-2022					AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P123; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; Bruera E, 1990, J Pain Symptom Manage, V5, P218, DOI 10.1016/0885-3924(90)90014-B; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P192, DOI 10.1016/0885-3924(92)90074-R; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P267, DOI 10.1016/0885-3924(92)90060-U; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Cole MG, 1998, J GERIATR PSYCH NEUR, V11, P126, DOI 10.1177/089198879801100303; Fainsinger R, 1991, J Palliat Care, V7, P5; Fainsinger R L, 1993, J Palliat Care, V9, P4; FAINSINGER RL, 2000, TOPICS PALLIATIVE CA, V4, P261; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Lawlor PG, 2000, CANCER, V88, P2859, DOI 10.1002/1097-0142(20000615)88:12<2859::AID-CNCR29>3.3.CO;2-K; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LEVKOFF SE, 1988, J AM GERIATR SOC, V36, P1099, DOI 10.1111/j.1532-5415.1988.tb04396.x; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPTZIN B, 1992, BRIT J PSYCHIAT, V161, P843, DOI 10.1192/bjp.161.6.843; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; Meagher DJ, 1996, BRIT J PSYCHIAT, V168, P512, DOI 10.1192/bjp.168.4.512; Minagawa H, 1996, CANCER, V78, P1131, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1131::AID-CNCR26>3.0.CO;2-2; Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P47, DOI 10.1001/jama.284.1.47; O'Keeffe ST, 1999, AGE AGEING, V28, P115, DOI 10.1093/ageing/28.2.115; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; Walker P, 1997, ANN ONCOL, V8, P915, DOI 10.1023/A:1008274608267	32	53	53	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2427	2429		10.1001/jama.284.19.2427	http://dx.doi.org/10.1001/jama.284.19.2427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074759				2023-01-03	WOS:000165183800002
J	Rebagliato, M; Cuttini, M; Broggin, L; Berbik, I; de Vonderweid, U; Hansen, G; Kaminski, M; Kollee, LAA; Kucinskas, A; Lenoir, S; Levin, A; Persson, J; Reid, M; Saracci, R				Rebagliato, M; Cuttini, M; Broggin, L; Berbik, I; de Vonderweid, U; Hansen, G; Kaminski, M; Kollee, LAA; Kucinskas, A; Lenoir, S; Levin, A; Persson, J; Reid, M; Saracci, R		EURONIC Study Grp	Neonatal end-of-life decision making - Physicians' attitudes and relationship with self-reported practices in 10 European countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTREMELY PREMATURE NEWBORNS; INTENSIVE-CARE; ETHICAL DECISIONS; DANISH PHYSICIANS; MORTALITY; SUPPORT; NURSERY; UNITS	Context The ethical issues surrounding end-of-life decision making for infants with adverse prognoses are controversial. Little empirical evidence is available on the attitudes and values that underlie such decisions in different countries and cultures. Objective To explore the variability of neonatal physicians' attitudes among 10 European countries and the relationship between such attitudes and self-reported practice of end-of-life decisions. Design and Setting Survey conducted during 1996-1997 in 10 European countries (France, Germany, Italy, the Netherlands, Spain, Sweden, the United Kingdom, Estonia, Hungary, and Lithuania). Participants A total of 1391 physicians (response rate, 89%) regularly employed in 142 neonatal intensive care units (NICUs). Main Outcome Measures Scores on an attitude scale, which measured views regarding absolute value of life (score of 0) vs value of quality of life (score of 10); self-report of having ever set limits to intensive neonatal interventions in cases of poor neurological prognosis. Results Physicians more likely to agree with statements consistent with preserving life at any cost were from Hungary (mean attitude scores, 5.2 [95% confidence interval {CI}, 4.9-5.5]), Estonia (4.9 [95% CI, 4.3-5.5]), Lithuania (5.5 [95% CI, 4.8-6.1]), and Italy (5.7 [95% CI, 5.3-6.0]), while physicians more likely to agree with the idea that quality of life must be taken into account were from the United Kingdom (attitude scores, 7.4 [95% CI, 7.1-7.7]), the Netherlands (7.3 [95% CI, 7.1-7.5]), and Sweden (6.8 [95% CI, 6.4-7.3]). Other factors associated with having a pro-quality-of-life view were being female, having had no children, being Protestant or having no religious background, considering religion as not important, and working in an NICU with a high number of very low-birth-weight newborns. Physicians with scores reflecting a more quality-of-life view were more likely to report that in their practice, they had set limits to intensive interventions in cases of poor neurological prognosis, with an adjusted odds ratio of 1.5 (95% CI, 1.3-1.7) per unit change in attitude score. Conclusions In our study, physicians' likelihood of reporting setting limits to intensive neonatal interventions in cases of poor neurological prognosis is related to their attitudes. After adjusting for potential confounders, country remained the most important predictor of physicians' attitudes and practices.	Miguel Hernandez Univ, Dept Publ Hlth, Alicante 03550, Spain; Burlo Garofolo Childrens Hosp, Epidemiol Unit, Trieste, Italy; Burlo Garofolo Childrens Hosp, Neonatal Intens Care Unit, Trieste, Italy; Natl Res Council, IFC, Div Epidemiol, Pisa, Italy; Vaszary Kolos Hosp, Dept Obstet & Gynaecol, Tergoti, Hungary; Univ Halle Wittenberg, Dept Pediat, Halle, Germany; Inst Gustave Roussy, INSERM, U149, Epidemiol Res Unit Perinatal & Womens Hlth, F-94805 Villejuif, France; Fac Med Toulouse, INSERM, Unit Res Reprod, F-31073 Toulouse, France; Univ Nijmegen Hosp, Dept Neonatol, NL-6500 HB Nijmegen, Netherlands; Vilnius State Univ, Neonatal Clin, Vilnius, Lithuania; Tallinn Hosp, Newborn & Premature Childrens Dept, Tallinn, Estonia; Linkoping Univ, Ctr Med Technol Assessment, Linkoping, Sweden; Univ Glasgow, Dept Publ Hlth, Glasgow, Lanark, Scotland	Universidad Miguel Hernandez de Elche; IRCCS Burlo Garofolo; IRCCS Burlo Garofolo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Martin Luther University Halle Wittenberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Radboud University Nijmegen; Vilnius University; Linkoping University; University of Glasgow	Rebagliato, M (corresponding author), Miguel Hernandez Univ, Dept Publ Hlth, Campus San Juan,Ctra Valencia,Km 87, Alicante 03550, Spain.		Cuttini, Marina/AAI-1987-2019; Kollee, L.A.A./L-4443-2015; Rebagliato, Marisa/L-6116-2018	Cuttini, Marina/0000-0002-3284-6874; Rebagliato, Marisa/0000-0001-5825-0190				CANDEE D, 1982, PEDIATR RES, V16, P846, DOI 10.1203/00006450-198210000-00009; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; Cuttini M, 1999, ARCH DIS CHILD-FETAL, V81, pF84, DOI 10.1136/fn.81.2.F84; Cuttini M, 1997, PAEDIATR PERINAT EP, V11, P461, DOI 10.1046/j.1365-3016.1997.d01-29.x; Davis Alison, 1994, P629; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; Garel M, 1997, ARCH PEDIATRIE, V4, P662, DOI 10.1016/S0929-693X(97)83370-2; GREELY HT, 1995, ETHICS PERINATOLOGY, P296; KOHRMAN A, 1994, PEDIATRICS, V93, P532; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; Kuhse H, 1985, SHOULD BABY LIVE PRO; LANTOS JD, 1994, ARCH DIS CHILD-FETAL, V71, pF218, DOI 10.1136/fn.71.3.F218; Lemeshow S, 1998, AM J EPIDEMIOL, V148, P298; LEVIN BW, 1990, SOC SCI MED, V30, P901, DOI 10.1016/0277-9536(90)90218-H; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; MCHAFFIE HE, 1996, LIFE DEATH DECISIONS; Norup M, 1998, ACTA PAEDIATR, V87, P896, DOI 10.1080/080352598750013707; Norup M, 1999, ACTA PAEDIATR, V88, P438, DOI 10.1080/08035259950169846; O'Shea TM, 1998, PEDIATRICS, V101, P642, DOI 10.1542/peds.101.4.642; Oppenheim A.N, 2000, QUESTIONNAIRE DESIGN; Payer L., 1988, MED CULTURE VARIETIE; PHILIP AGS, 1995, J PEDIATR-US, V126, P427, DOI 10.1016/S0022-3476(95)70463-9; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; RHODEN NK, 1986, HASTINGS CENT REP, V34, P42; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; Sanders M R, 1995, J Perinatol, V15, P494; SHELP EE, 1986, BORN DIE DECIDING FA; SILVERMAN WA, 1992, PEDIATRICS, V90, P971; *STAT CORP, 1999, STAT STAT SOFTW COMP; TODRES ID, 1977, PEDIATRICS, V60, P197; Tough SC, 2000, J PEDIATR-US, V136, P618, DOI 10.1067/mpd.2000.105132; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; 1999, CORRIERE SERA   0316; 2000, LANCET, V355, P79	39	168	169	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2451	2459		10.1001/jama.284.19.2451	http://dx.doi.org/10.1001/jama.284.19.2451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074774	Bronze			2023-01-03	WOS:000165183800018
J	Emanuel, EJ; Fairclough, D; Clarridge, BC; Blum, D; Bruera, E; Penley, WC; Schnipper, LE; Mayer, RJ				Emanuel, EJ; Fairclough, D; Clarridge, BC; Blum, D; Bruera, E; Penley, WC; Schnipper, LE; Mayer, RJ			Attitudes and practices of US oncologists regarding euthanasia and physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							WASHINGTON-STATE; REQUESTS; DEATH	Background: The practices of euthanasia and physician-assisted suicide remain controversial. Objective: To achieve better understanding of attitudes and practices regarding euthanasia and physician-assisted suicide in the context of end-of-life care. Design: Cohort study. Setting: United States. Participants: 3299 oncologists who are members of the American Society of Clinical Oncology. Measurements: Responses to survey questions on attitudes toward euthanasia and physician-assisted suicide for a terminally ill patient with prostate cancer who has unremitting pain, requests for and performance of euthanasia and physician-assisted suicide, and sociodemographic characteristics. Results: Of U.S. oncologists surveyed, 22.5% supported the use of physician-assisted suicide for a terminally ill patient with unremitting pain and 6.5% supported euthanasia Oncologists who were reluctant to increase the dose of intravenous morphine for terminally ill patients in excruciating pain (odds ratio [OR], 0.61 [95% CI, 0.48 to 0.77]) and had sufficient time to talk to dying patients about end-of-life care issues (OR, 0.79 [CI, 0.71 to 0.87]) were less likely to support euthanasia or physician-assisted suicide. During their career, 3.7% of surveyed oncologists had performed euthanasia and 10.8% had performed physician-assisted suicide. Oncologists who were reluctant to increase the morphine dose for patients in excruciating pain (OR, 0.58 [CI, 0.43 to 0.79]) and those who believed that they had received adequate training in end-of-life care (OR, 0.86 [CI, 0.79 to 0.95]) were less likely to have performed euthanasia or physician-assisted suicide. Oncologists who reported not being able to obtain all the care that a dying patient needed were more likely to have performed euthanasia (P = 0.001). Conclusions: Requests for euthanasia and physician-assisted suicide are likely to decrease as training in end-of-life care improves and the ability of physicians to provide this care to their patients is enhanced.	Dana Farber Canc Inst, Dept Med Adult Oncol, Boston, MA 02115 USA; NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; AMC Canc Res Ctr, Denver, CO USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Canc Care Inc, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Baptist Hosp, Nashville, TN USA	Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; AMC Cancer Research Center; University of Massachusetts System; University of Massachusetts Boston; Harvard University; Beth Israel Deaconess Medical Center; University of Texas System; UTMD Anderson Cancer Center; Saint Thomas Hospital	Mayer, RJ (corresponding author), Dana Farber Canc Inst, Dept Med Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Bruera, Eduardo/AAA-1550-2022					Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DiMola G, 1996, ANN ONCOL, V7, P907, DOI 10.1093/oxfordjournals.annonc.a010792; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Wolfe J, 1999, J CLIN ONCOL, V17, P1274, DOI 10.1200/JCO.1999.17.4.1274	17	115	115	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 3	2000	133	7					527	532		10.7326/0003-4819-133-7-200010030-00011	http://dx.doi.org/10.7326/0003-4819-133-7-200010030-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	360QG	11015165				2023-01-03	WOS:000089678300004
J	Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ				Rabow, MW; Hardie, GE; Fair, JM; McPhee, SJ			End-of-life care content in 50 textbooks from multiple specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Conference on Improving End-of-Life Care - A Conference of Nursing and Medical Textbook Publishers	MAR 12, 1999	OPEN SOC INST, NEW YORK, NY	Robert Wood Johnson Fdn, Last Acts Program	OPEN SOC INST		MEDICAL-EDUCATION; PALLIATIVE CARE; DYING PATIENTS; CHALLENGE; MODEL	Context Prior reviews of small numbers of medical textbooks suggest that end-of-life care is not well covered in textbooks. No broad study of end-of-life care content analysis has been performed on textbooks across a wide range of medical, pediatric, psychiatric, and surgical specialties. Objective To determine the quantity and rate the adequacy of information on end-of-life care in textbooks from multiple medical disciplines. Design and Sources A 1998 review of 50 top-selling textbooks from multiple specialties (cardiology, emergency medicine, family and primary care medicine, geriatrics, infectious disease and acquired immunodeficiency syndrome [AIDS], internal medicine, neurology, oncology and hematology, pediatrics, psychiatry, pulmonary medicine, and surgery) for the presence and adequacy of content in 13 end-of-life care domains. Main Outcome Measures Chapters on diseases commonly causing death and those devoted to end-of-life care were identified, read, rated, and compared by textbook specialty, chapter, and domain for the presence of helpful information in the 13 domains. Content for each domain was rated as absent, minimally present, or helpful. Textbook indexes were analyzed for the number of pages relevant to end-of-life care. Results Overall, helpful information was provided in 24.1% (range, 8.7%-44.2%) of the expected end-of-life content domains; in 19.1% (range, 6.2%-38.5%), expected content received minimal attention; and in 56.9% (range, 23.1%-77.9%), expected content was absent. As a group, the textbooks with the highest percentages of absent content were in surgery (71.8%), infectious diseases and AIDS (70%), and oncology and hematology (61.9%). Textbooks with the highest percentage of helpful end-of-life care content were in family medicine (34.4%), geriatrics (34.4%), and psychiatry (29.6%), In internal medicine textbooks, the content domains with the greatest amount of helpful information were epidemiology and natural history. Content domains covered least well were social, spiritual, ethical, and family issues, as well as physician after-death responsibilities. On average, textbook indexes cited 2% of their total pages as pertinent to end-of-life care. Conclusion Top-selling textbooks generally offered little helpful information on caring for patients at the end of life. Most disease-oriented chapters had no or minimal end-of-life care content. Specialty textbooks with information about particular diseases often did not contain helpful information on caring for patients dying from those diseases.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rabow, MW (corresponding author), Univ Calif San Francisco, Mt Zion, 1701 Divisadero St,5th Floor, San Francisco, CA 94115 USA.	mrabow@medicine.ucsf.edu						American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLANCHARD CG, 1981, CANCER, V47, P2756, DOI 10.1002/1097-0142(19810601)47:11<2756::AID-CNCR2820471135>3.0.CO;2-G; Block S D, 1998, J Palliat Med, V1, P347, DOI 10.1089/jpm.1998.1.347; Carron A T, 1999, Ann Intern Med, V130, P82; *CDCP, 1998, 10 LEAD CAUS DEATH U; Emanuel EJ, 1997, LANCET, V349, P1714, DOI 10.1016/S0140-6736(05)62952-2; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Ferrell B R, 1999, J Palliat Med, V2, P161, DOI 10.1089/jpm.1999.2.161; GIBSON R, 1998, J PALLIAT MED, V1, P415; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; Hill Wendy C., 1998, Pediatric Research, V43, p111A; HOLLEMAN WL, 1994, TEACH LEARN MED, V6, P260; *I MED COMM CAR EN, 1997, APPR DEATH IMPR CAR; Kaye J M, 1991, J Cancer Educ, V6, P21; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; *LOG BROTH CO INC, 1997, ORD FORM MOST POP TI; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MACDONALD N, 1991, CANADIAN PALLIATIVE; MCWHINNEY IR, 1994, CAN FAM PHYSICIAN, V40, P240; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Quill TE, 1998, ANN INTERN MED, V129, P590, DOI 10.7326/0003-4819-129-7-199810010-00026; Rabow M W, 1999, J Palliat Med, V2, P153, DOI 10.1089/jpm.1999.2.153; RAPPAPORT W, 1993, SURGERY, V113, P163; *RW JOHNS FDN LAST, 1999, C NURS MED TXB PUBL; SCHEIDERMAMN LJ, 1997, J FAM PRACTICE, V45, P259; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinmetz D, 1993, Arch Fam Med, V2, P753, DOI 10.1001/archfami.2.7.753; von Gunten C F, 1995, Am J Hosp Palliat Care, V12, P38, DOI 10.1177/104990919501200413; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Woods NF., 1988, NURSING RES THEORY P; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	34	125	126	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2000	283	6					771	778		10.1001/jama.283.6.771	http://dx.doi.org/10.1001/jama.283.6.771			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	280XL	10683056				2023-01-03	WOS:000085129000029
J	Orentlicher, D; Caplan, A				Orentlicher, D; Caplan, A			The Pain Relief Promotion Act of 1999 - A serious threat to palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTED SUICIDE; SUPREME-COURT	Recent educational efforts in the US medical community have begun to address the critical issue bf palliative care for terminally ill patients. However, a newly introduced bill in; Congress, the Pain Relief Promotion Act of 1999 (PRPA), could dramatically hinder these efforts if enacted. The act criminally punishes the use of controlled substances to cause-or assist in causing-a patient's death. The primary purposes of PRPA are to override the physician-assisted suicide law currently in effect in Oregon and prohibit other states from enacting similar laws, The act also includes valuable provisions for better research and education in palliative care, but the benefits of those provisions are outweighed by the punitive sections of the act. Under PRPA, the quality of palliative care in the United States could be compromised when physicians, fearing criminal prosecution, err on the side of caution rather than risk their patients' deaths by using highly aggressive pain treatments. Furthermore,PRPA would put Drug Enforcement Administration officials, who have no medical expertise, in the position of regulating medical decisions. The act also would interfere with individual states' long-standing authority over medical practice. Finally, PRPA would discourage physicians from engaging in experimentation and innovation in palliative care, again out of concern for crossing the line between relief of suffering and physician-assisted suicide. Other bills have been introduced that go much further than PRPA to encourage palliative care, without its problematic provisions. Regardless of the controversy surrounding physician-assisted suicide in the United States, the need for quality end-of-life care will be far better sewed if Congress enacts one of these bills rather than PRPA.	Indiana Univ, Sch Law, Ctr Law & Hlth, Indianapolis, IN 46202 USA; Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Pennsylvania; Pennsylvania Medicine	Orentlicher, D (corresponding author), Indiana Univ, Sch Law, Ctr Law & Hlth, 735 W New York St, Indianapolis, IN 46202 USA.							Alpers A, 1998, J LAW MED ETHICS, V26, P308, DOI 10.1111/j.1748-720X.1998.tb01678.x; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; *BNA, 1999, BNA HLTH LAW RE 0624, V8, P1027; Brody H, 1998, J Palliat Med, V1, P329, DOI 10.1089/jpm.1998.1.329; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; JORANSON DE, 1994, PSYCHIAT PRACTICE FI, P173; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Meisel A, 1999, ARCH INTERN MED, V159, P1089, DOI 10.1001/archinte.159.10.1089; Noble Holcomb B, 1999, N Y Times Web, pA13; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Quill T E, 1998, J Palliat Med, V1, P333, DOI 10.1089/jpm.1998.1.333	14	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					255	258		10.1001/jama.283.2.255	http://dx.doi.org/10.1001/jama.283.2.255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634344				2023-01-03	WOS:000084661400034
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Homoeopathy	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									LECKRIDGE B, 1997, HOMOEPATHY PRIMARY C; SWAYNE J, 1998, HOMOEOPATHIC METHOD	2	40	41	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1115	1118		10.1136/bmj.319.7217.1115	http://dx.doi.org/10.1136/bmj.319.7217.1115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531108	Green Published			2023-01-03	WOS:000083419500031
J	de Quiros, JCLB; Miro, JM; Pena, JM; Podzamczer, D; Alberdi, JC; Martinez, E; Cosin, J; Claramonte, X; Gonzalez, J; Domingo, P; Casado, JL; Ribera, E				de Quiros, JCLB; Miro, JM; Pena, JM; Podzamczer, D; Alberdi, JC; Martinez, E; Cosin, J; Claramonte, X; Gonzalez, J; Domingo, P; Casado, JL; Ribera, E		Grp Estudio SIDA 04 98	A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 26-29, 1999	SAN FRANCISCO, CA				TRIMETHOPRIM-SULFAMETHOXAZOLE; OPPORTUNISTIC INFECTIONS; AEROSOLIZED PENTAMIDINE; VIRUS; AIDS; CHEMOPROPHYLAXIS; PREVENTION; ZIDOVUDINE; MORTALITY; DAPSONE	Background: Prophylaxis against Pneumocystis carinii pneumonia is indicated in patients with human immunodeficiency virus (HIV) infection who have less than 200 CD4 cells per cubic millimeter and in those with a history of P. carinii pneumonia. However, it is not clear whether prophylaxis can be safely discontinued after CD4 cell counts increase in response to highly active antiretroviral therapy. Methods: We conducted a randomized trial of the discontinuation of primary or secondary prophylaxis against P. carinii pneumonia in HIV-infected patients with a sustained response to antiretroviral therapy, defined by a CD4 cell count of 200 or more per cubic millimeter and a plasma HIV type 1 (HIV-1) RNA level of less than 5000 copies per milliliter for at least three months. Prophylactic treatment was restarted if the CD4 cell count declined to less than 200 per cubic millimeter. Results: The 474 patients receiving primary prophylaxis had a median CD4 cell count at entry of 342 per cubic millimeter, and 38 percent had detectable HIV-1 RNA. After a median follow-up period of 20 months (388 person-years), there had been no episodes of P. carinii pneumonia in the 240 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 0.85 episode per 100 person-years). For the 113 patients receiving secondary prophylaxis, the median CD4 cell count at entry was 355 per cubic millimeter, and 24 percent had detectable HIV-1 RNA. After a median follow-up period of 12 months (65 person-years), there had been no episodes of P. carinii pneumonia in the 60 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 4.57 episodes per 100 person-years). Conclusions: In HIV-infected patients receiving highly active antiretroviral therapy, primary and secondary prophylaxis against P. carinii pneumonia can be safely discontinued after the CD4 cell count has increased to 200 or more per cubic millimeter for more than three months. (N Engl J Med 2001;344:159-67.) Copyright (C) 2001 Massachusetts Medical Society.	Hosp Gen Gregorio Maranon, Div Infect Dis, E-28007 Madrid, Spain; Inst Invest Biomed August Pi I Sunyer, Barcelona, Spain; Hosp Clin Univ, Barcelona, Spain; Ciudad Sanitaria Seguridad Social La Paz, Madrid, Spain; Bellvitge Hosp, Barcelona, Spain; Consejeria Sanidad Comunidad Autonoma Madrid, Madrid, Spain; Hosp Santa Creu & Sant Pau, Barcelona, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; Hosp Univ Vall dHebron, Barcelona, Spain; Hosp Univ Gregorio Maranon, Madrid, Spain	General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Hospital of Santa Creu i Sant Pau; Hospital Universitario Ramon y Cajal; Hospital Universitari Vall d'Hebron; General University Gregorio Maranon Hospital	de Quiros, JCLB (corresponding author), Hosp Gen Gregorio Maranon, Div Infect Dis, Doctor Esquerdo 46, E-28007 Madrid, Spain.	juanclopez@retemail.es	Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Montejo, Jose Miguel/E-1755-2012	Domingo, Pere/0000-0003-1138-5770; Casado, Jose Luis/0000-0002-7639-8591; Ribera, Esteban/0000-0002-3752-8808				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Atzori C, 2000, J INFECT DIS, V181, P1629, DOI 10.1086/315437; BOZZETTE SA, 1995, AM J MED, V98, P177, DOI 10.1016/S0002-9343(99)80401-X; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CARCELAIN G, 1999, AIDS REV, V1, P51; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Gea-Banacloche JC, 1999, AIDS, V13, pS25; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HUANG L, 1999, MED MANAGEMENT AIDS, P305; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; KAPLAN JE, 1999, 39 INT C ANT AG CHEM, P124; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; Ledergerber B, 2001, NEW ENGL J MED, V344, P168, DOI 10.1056/NEJM200101183440302; LOPEZ JC, 1999, 6 C RETR OPP INF CHI, P206; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; Masur H, 1999, NEW ENGL J MED, V340, P1356, DOI 10.1056/NEJM199904293401709; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, SCIENCE, V275, P14; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; MOORE RD, 1999, 5 C RETR OPP INF CHI, P113; Mussini C, 2000, J INFECT DIS, V181, P1635, DOI 10.1086/315471; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; RAVIGLIONE MC, 1990, LANCET, V336, P180, DOI 10.1016/0140-6736(90)91701-B; Romeu J, 1999, SCAND J INFECT DIS, V31, P37, DOI 10.1080/00365549950161862; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELIK RM, 1987, AIDS, V1, P175; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; Stansell JD, 1997, AM J RESP CRIT CARE, V155, P60, DOI 10.1164/ajrccm.155.1.9001290; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; VALDEZ H, 1999, 6 C RETR OPP INF CHI, P130; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; 1989, JAMA, V262, P335	44	109	113	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					159	167		10.1056/NEJM200101183440301	http://dx.doi.org/10.1056/NEJM200101183440301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	392GF	11172138	Green Published, Green Submitted			2023-01-03	WOS:000166402800001
J	Johnson, C; Glover, G; Arias, J				Johnson, C; Glover, G; Arias, J			Regulation of DNA binding and trans-activation by a xenobiotic stress-activated plant transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TISSUE-SPECIFIC EXPRESSION; SALICYLIC-ACID; INTRAMOLECULAR INHIBITION; GENE PROMOTER; FACTOR ASF-1; OCS-ELEMENT; AUXIN; INDUCTION; PROTEIN	As-1-type cis-elements augment transcription of both nuclear and pathogen genes in response to stress and defense cues in plants. Basic/leucine zipper proteins termed "TGA factors" that specifically bind as-1 elements are likely candidates for mediating these transcription activities. Our earlier work has shown that 2,4-dichlorophenoxyacetic acid-induced xenobiotic stress enhances trans-activation by a chimeric fusion protein of the yeast Gal4 binding domain and TGA1a, a TGA factor of tobacco. Here we demonstrate that xenobiotic stress also enhances the ability of native TGA1a to bind as-1 and activate transcription of a known target gene. In addition, the previously identified xenobiotic stress-responsive domain of TGA1a was found to inhibit this factor's trans-activation potential by a mechanism that appears to involve stimulus-reversible interactions with a nuclear repressor protein. Results from these and other studies can now be placed in the context of a working model to explain basal and xenobiotic stress-induced activities of TGA1a through its cognate cis-acting element.	Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, College Pk, MD 20742 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Arias, J (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.	arias@umbi.umd.edu						AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; ARIAS JA, 1993, PLANT CELL, V5, P485, DOI 10.1105/tpc.5.4.485; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; Harlow E., 1988, ANTIBODIES LAB MANUA, Vfirst; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KIM YH, 1994, PLANT MOL BIOL, V24, P105, DOI 10.1007/BF00040578; Klinedinst S, 2000, PLANT MOL BIOL, V42, P679, DOI 10.1023/A:1006332708388; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Koehler SM, 1996, PLANT MOL BIOL, V31, P595, DOI 10.1007/BF00042232; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU XJ, 1994, J BIOL CHEM, V269, P668; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; Niggeweg R, 2000, J BIOL CHEM, V275, P19897, DOI 10.1074/jbc.M909267199; Pascuzzi P, 1998, J BIOL CHEM, V273, P26631, DOI 10.1074/jbc.273.41.26631; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; Zhang B, 1995, PLANT CELL, V7, P2241, DOI 10.1105/tpc.7.12.2241; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	33	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					172	178		10.1074/jbc.M005143200	http://dx.doi.org/10.1074/jbc.M005143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034999	hybrid			2023-01-03	WOS:000166280700025
J	Sacks, FM; Svetkey, LP; Vollmer, WM; Appel, LJ; Bray, GA; Harsha, D; Obarzanek, E; Conlin, PR; Miller, ER; Simons-Morton, DG; Karanja, N; Lin, PH				Sacks, FM; Svetkey, LP; Vollmer, WM; Appel, LJ; Bray, GA; Harsha, D; Obarzanek, E; Conlin, PR; Miller, ER; Simons-Morton, DG; Karanja, N; Lin, PH		DASH-Sodium Collaborative Res Grp	Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HYPERTENSION; CLINICAL-TRIAL; RESTRICTION; POTASSIUM; PATTERNS; CATECHOLAMINES; POPULATION; REDUCTION; CALCIUM; WHITES	Background: The effect of dietary composition on blood pressure is a subject of public health importance. We studied the effect of different levels of dietary sodium, in conjunction with the Dietary Approaches to Stop Hypertension (DASH) diet, which is rich in vegetables, fruits, and low-fat dairy products, in persons with and in those without hypertension. Methods: A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet. Within the assigned diet, participants ate foods with high, intermediate, and low levels of sodium for 30 consecutive days each, in random order. Results: Reducing the sodium intake from the high to the intermediate level reduced the systolic blood pressure by 2.1 mm Hg (P<0.001) during the control diet and by 1.3 mm Hg (P = 0.03) during the DASH diet. Reducing the sodium intake from the intermediate to the low level caused additional reductions of 4.6 mm Hg during the control diet (P<0.001) and 1.7 mm Hg during the DASH diet (P<0.01). The effects of sodium were observed in participants with and in those without hypertension, blacks and those of other races, and women and men. The DASH diet was associated with a significantly lower systolic blood pressure at each sodium level; and the difference was greater with high sodium levels than with low ones. As compared with the control diet with a high sodium level, the DASH diet with a low sodium level led to a mean systolic blood pressure that was 7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension. Conclusions: The reduction of sodium intake to levels below the current recommendation of 100 mmol per day and the DASH diet both lower blood pressure substantially, with greater effects in combination than singly. Long-term health benefits will depend on the ability of people to make long-lasting dietary changes and the increased availability of lower-sodium foods. (N Engl J Med 2001;344:3-10.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Duke Univ, Sch Med, Sarah W Stedman Ctr Nutr Studies, Durham, NC USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Pennington Biomed Res Ctr, Baton Rouge, LA USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University; Kaiser Permanente; Johns Hopkins University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Appel, Larry/GLT-2608-2022		NHLBI NIH HHS [U01-HL57173, U01-HL57114, U01-HL57190] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL057114, U01HL057173, U01HL057190] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CHAPMAN CB, 1950, NEW ENGL J MED, V243, P899, DOI 10.1056/NEJM195012072432301; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; ELLIOTT P, 1988, BRIT MED J, V297, P319; FLACK JM, 1991, HYPERTENSION S1, V17, P115; GILL JR, 1988, HYPERTENSION, V11, P312, DOI 10.1161/01.HYP.11.4.312; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; GRIMM RH, 1990, NEW ENGL J MED, V322, P569, DOI 10.1056/NEJM199003013220901; HATCH FT, 1954, AM J MED, V17, P499, DOI 10.1016/0002-9343(54)90125-4; HOLM S, 1979, SCAND J STAT, V6, P65; Karanja NM, 1999, J AM DIET ASSOC, V99, pS19, DOI 10.1016/S0002-8223(99)00412-5; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; KRISHNA GG, 1989, NEW ENGL J MED, V320, P1177, DOI 10.1056/NEJM198905043201804; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LAW MR, 1991, BRIT MED J, V302, P939; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT FC, 1979, CIRCULATION, V59, P643, DOI 10.1161/01.CIR.59.4.643; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; MATTES RD, 1991, J AM COLL NUTR, V10, P383; MILLER JZ, 1987, J CHRON DIS, V40, P245, DOI 10.1016/0021-9681(87)90160-3; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; NEATON JD, 1991, ARCH INTERN MED, V151, P1413, DOI 10.1001/archinte.151.7.1413; PARFREY PS, 1981, BRIT MED J, V283, P94, DOI 10.1136/bmj.283.6284.94; RICH GM, 1991, AM J HYPERTENS, V4, pS642, DOI 10.1093/ajh/4.11S.642S; SAITO K, 1989, HYPERTENSION, V13, P219, DOI 10.1161/01.HYP.13.3.219; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Svetkey LP, 1999, ARCH INTERN MED, V159, P285, DOI 10.1001/archinte.159.3.285; Svetkey LP, 1999, J AM DIET ASSOC, V99, pS96, DOI 10.1016/S0002-8223(99)00423-X; *US SEN, 1977, DIET GOALS US; VOORS AW, 1983, AM J CLIN NUTR, V37, P583, DOI 10.1093/ajcn/37.4.583; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; ZEMEL MB, 1986, J HYPERTENS, V4, pS343	39	3312	3401	13	346	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					3	10		10.1056/NEJM200101043440101	http://dx.doi.org/10.1056/NEJM200101043440101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136953	Bronze			2023-01-03	WOS:000166160400001
J	Knipschild, P				Knipschild, P			Alternative treatments: do they work?	LANCET			English	Article									Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Maastricht University	Knipschild, P (corresponding author), Maastricht Univ, Dept Gen Practice, POB 616, NL-6200 MD Maastricht, Netherlands.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S4	S4		10.1016/S0140-6736(00)91990-1	http://dx.doi.org/10.1016/S0140-6736(00)91990-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191497				2023-01-03	WOS:000166074900006
J	Henney, JE				Henney, JE			Clarification on buprenorphine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2178	2178		10.1001/jama.284.17.2178	http://dx.doi.org/10.1001/jama.284.17.2178			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367GD	11056574				2023-01-03	WOS:000090052600005
J	Dodd, ME; Kellet, F; Davis, A; Simpson, JCG; Webb, AK; Haworth, CS; Niven, RM				Dodd, ME; Kellet, F; Davis, A; Simpson, JCG; Webb, AK; Haworth, CS; Niven, RM			Audit of oxygen prescribing before and after the introduction of a prescription chart	BRITISH MEDICAL JOURNAL			English	Article							NASAL		Manchester Univ Hosp NHS Trust, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England	University of Manchester	Dodd, ME (corresponding author), Manchester Univ Hosp NHS Trust, NW Lung Ctr, Manchester M23 9LT, Lancs, England.			Niven, Robert/0000-0003-2249-960X				Bateman NT, 1998, BRIT MED J, V317, P798, DOI 10.1136/bmj.317.7161.798; BAZUAYE EA, 1992, THORAX, V47, P609, DOI 10.1136/thx.47.8.609; DAVIES RJO, 1989, BRIT MED J, V299, P43, DOI 10.1136/bmj.299.6690.43; SMALL D, 1992, AM J MED, V92, P591, DOI 10.1016/0002-9343(92)90775-7; 1999, BRIT NATL FORMULARY, V37, P153	5	44	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	2000	321	7265					864	865		10.1136/bmj.321.7265.864	http://dx.doi.org/10.1136/bmj.321.7265.864			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VC	11021863	Green Published, Bronze			2023-01-03	WOS:000089857500021
J	Roberts, JM				Roberts, JM			Recent advances - Obstetrics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-BIRTH-WEIGHT; CEREBRAL-PALSY; DELIVERY; PREECLAMPSIA; PREVENTION; TRANSMISSION; HYPERTENSION; CHILDBIRTH; INFECTION; WOMEN		Magee Womens Res Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Roberts, JM (corresponding author), Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.	rsislm@mail.magee.edu	Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; BARKER DJP, 1989, LANCET, V2, P577; Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392; CAREY J, IN PRESS N ENGL J ME; CAREY J, 2000, AM J OBSTET GYNECOL, V182; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Cotch MF, 1997, SEX TRANSM DIS, V24, P353, DOI 10.1097/00007435-199707000-00008; Gluckman PD, 1997, ACTA PAEDIATR, V86, P69; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Hall MH, 1999, LANCET, V354, P776, DOI 10.1016/S0140-6736(05)76016-5; Hudson CN, 1999, LANCET, V353, P1030, DOI 10.1016/S0140-6736(99)00066-5; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Klebanoff MA, 1999, ARCH INTERN MED, V159, P1607, DOI 10.1001/archinte.159.14.1607; Langley-Evans SC, 1999, BIOCHEM SOC T, V27, P88, DOI 10.1042/bst0270088; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; Paneth N, 1996, J HYPERTENS, V14, pS121; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Paterson-Brown S, 1998, BMJ-BRIT MED J, V317, P462; PHELAN JP, 1998, CURR OPIN OBSTET GYN, V53, P662; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Stringer JSA, 1999, JAMA-J AM MED ASSOC, V281, P1946, DOI 10.1001/jama.281.20.1946; Sultan AH, 1997, CURR OPIN OBSTET GYN, V9, P320; Sultan AH, 1996, BRIT J HOSP MED, V55, P575; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301	29	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					33	35		10.1136/bmj.321.7252.33	http://dx.doi.org/10.1136/bmj.321.7252.33			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875834	Green Published			2023-01-03	WOS:000088030100026
J	Grady, D; Wenger, NK; Herrington, D; Khan, S; Furberg, C; Hunninghake, D; Vittinghoff, E; Hulley, S				Grady, D; Wenger, NK; Herrington, D; Khan, S; Furberg, C; Hunninghake, D; Vittinghoff, E; Hulley, S		Heart Estrogen Progestin Replacem	Postmenopausal hormone therapy increases risk for venous thromboembolic disease - The heart and estrogen/progestin replacement study	ANNALS OF INTERNAL MEDICINE			English	Article						estrogen replacement therapy; venous thrombosis; thrombophlebitis; thromboembolism; progestin	ORAL-CONTRACEPTIVES; PULMONARY-EMBOLISM; VASCULAR-DISEASE; RANDOMIZED TRIAL; BREAST-CANCER; WOMEN; ESTROGEN; THROMBOSIS; PREVENTION; POPULATION	Background: Oral contraceptive use increases risk for venous thromboembolism, but data on the effect of postmenopausal hormone therapy are limited. Objective: To determine the effect of therapy with estrogen plus progestin on risk for venous thromboembolic events in postmenopausal women. Design: Randomized, double-blind, placebo-controlled trial. Setting: 20 clinical centers in the United States. Participants: 2763 postmenopausal women younger than 80 years of age (mean age, 67 years) who had coronary heart disease but no previous Venous thromboembolism and had not had a hysterectomy. Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in one tablet (n = 1380) or placebo that was identical in appearance (n = 1383). Measurements: Documented deep venous thrombosis or pulmonary embolism. Results: During an average of 4.1 years of follow-up, 34 women in the hormone therapy group and 13 in the placebo group experienced Venous thromboembolic events (relative hazard, 2.7 [95% CI, 1.4 to 5.0] [P = 0.003]; excess risk, 3.9 per 1000 woman-years [CI, 1.4 to 6.4 per 1000 woman-years]; number needed to treat for harm, 256 [CI, 157 to 692]). In multivariate analysis, the risk for venous thromboembolism was increased among women who had lower-extremity fractures (relative hazard, 18.1 [CI, 5.4 to 60.4]) or cancer (relative hazard, 3.9 [Cl, 1.6 to 9.4]) and for 90 days after inpatient surgery (relative hazard, 4.9 [CI, 2.4 to 9.8]) or nonsurgical hospitalization (relative hazard, 5.7 [Ct, 3.0 to 10.8]). Risk was decreased with aspirin (relative hazard, 0.5 [CI, 0.2 to 0.8]) or statin use (relative hazard, 0.5 [CI, 0.2 to 0.9]). Conclusions: Postmenopausal therapy with estrogen plus progestin increases risk for venous thromboembolism in women with coronary heart disease. This risk should be considered when the risks and benefits of therapy are being weighed.	Univ Calif San Francisco, San Francisco, CA 94105 USA; Emory Univ, Sch Med, Atlanta, GA USA; Wake Forest Univ, Sch Med, Winston Salem, NC USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Minnesota, Minneapolis, MN USA	University of California System; University of California San Francisco; Emory University; Wake Forest University; Cedars Sinai Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Grady, D (corresponding author), Univ Calif San Francisco, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	bhudson@mail.acponline.org						[Anonymous], 1997, ARCH INTERN MED, V157, P1237; [Anonymous], 1974, NEW ENGL J MED, V290, P15; Carr BR, 1997, CONTRACEPTION, V55, P267, DOI 10.1016/S0010-7824(97)00029-2; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; Meilahn E N, 1992, Ann Epidemiol, V2, P445; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1995, LANCET, V346, P1575; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; Wilkes HC, 1996, BRIT MED J, V312, P473	28	555	563	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					689	+		10.7326/0003-4819-132-9-200005020-00002	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787361				2023-01-03	WOS:000086734100001
J	Bauchner, H; Wise, PH				Bauchner, H; Wise, PH			Antibiotics without prescription: "bacterial or medical resistance"?	LANCET			English	Editorial Material									Boston Univ, Boston Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Boston Med Ctr, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA	Boston Medical Center; Boston University; Boston Medical Center; Boston University	Bauchner, H (corresponding author), Boston Univ, Boston Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA.			Bauchner, Howard/0000-0002-8368-9805				BAUCHNER H, 2000, PED AC SOC M MAY BOS, pA173; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; Reeves DS, 1999, J ANTIMICROB CHEMOTH, V44, P163, DOI 10.1093/jac/44.2.163; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Wood MJ, 1999, J ANTIMICROB CHEMOTH, V44, P149, DOI 10.1093/jac/44.2.149	7	23	23	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1480	1480		10.1016/S0140-6736(00)02160-7	http://dx.doi.org/10.1016/S0140-6736(00)02160-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801167				2023-01-03	WOS:000086830100007
J	Pappas, GD				Pappas, GD			Fine structure of host-graft relationships between transplanted chromaffin cells and CNS	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		RAT PERIAQUEDUCTAL GRAY; CHRONIC PAIN; CANCER PAIN; SURVIVAL; IMPLANTS	Our laboratory studies have shown that transplantation of adrenal medullary tissue or isolated chromaffin cells into central nervous system (CNS) pain modulatory regions (i.e., periaqueductal gay and subarachnoid lumbar spinal cord) can reduce pain sensitivity of rats in both acute and chronic pain. The analgesia produced by these transplants is thought to result from release of both opiate peptides and catecholamines, Morphologically, these animal studies also suggest that there is no development of tolerance over long periods of time, and the transplanted chromaffin cells appear to be robust and well integrated with the host tissue. In our initial clinical studies, where allografts of adrenal medullary tissue were transplanted intrathecally to relieve intractable cancer pain, patients obtained significant and long-lasting pain relief. Increased cerebrospinal fluid (CSF) levels of metenkephalin were correlated with the decreased pain scores. Histology of;autopsy tissue obtained from two patients with 1 year transplants revealed viable transplanted chromaffin cells. Because of the limited availability of human adrenal glands, sources of xenogeneic chromaffin cells will need to be identified if effective transplantation therapy for chronic pain is to be developed further.	Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pappas, GD (corresponding author), Univ Illinois, Inst Psychiat, Dept Psychiat, 1601 W Taylor St M-C 912, Chicago, IL 60612 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028931] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-28931] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bes JC, 1998, CELL TRANSPLANT, V7, P227, DOI 10.1016/S0963-6897(97)00161-9; Czech KA, 1997, EXP NEUROL, V147, P66, DOI 10.1006/exnr.1997.6589; Lazorthes Y, 1995, ADV STER F, V11, P97; Lazorthes Y, 1991, Adv Tech Stand Neurosurg, V18, P143; Michalewicz P., 1997, Society for Neuroscience Abstracts, V23, P1455; Ortega J D, 1992, Cell Transplant, V1, P33; ORTEGA JD, 1994, J NEURAL TRANSP PLAS, V5, P31, DOI 10.1155/NP.1994.31; ORTEGA JD, 1992, J COMP NEUROL, V323, P13, DOI 10.1002/cne.903230103; Pappas G. D., 1998, ADRENAL CHROMAFFIN C, P343; Pappas GD, 1997, NEUROL RES, V19, P71; PAPPAS GD, 1988, PROG BRAIN RES, V78, P513; SAGEN J, 1990, J NEUROCYTOL, V19, P697, DOI 10.1007/BF01188038; SAGEN J, 1987, ANN NY ACAD SCI, V495, P306, DOI 10.1111/j.1749-6632.1987.tb23683.x; SAGEN J, 1990, PAIN, V42, P69, DOI 10.1016/0304-3959(90)91093-X; Unsicker K, 1996, PROG NEUROBIOL, V48, P307, DOI 10.1016/0301-0082(95)00045-3; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WASFIE T, 1991, TRANSPLANT P, V23, P378; WILSON SP, 1982, J NEUROSCI, V2, P1150; WINNIE AP, 1993, ANESTHESIOLOGY, V79, P644, DOI 10.1097/00000542-199310000-00004	19	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S277	S280		10.1096/fasebj.13.9002.S277	http://dx.doi.org/10.1096/fasebj.13.9002.S277			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619143				2023-01-03	WOS:000084390200021
J	Furberg, CD; Herrington, DM; Psaty, BM				Furberg, CD; Herrington, DM; Psaty, BM			Are drugs within a class interchangeable?	LANCET			English	Editorial Material							CHRONIC HEART-FAILURE; BETA-BLOCKERS; SURVIVAL; STATINS		Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA USA	Wake Forest University; Wake Forest University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Furberg, CD (corresponding author), Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA.							CUSHMAN DW, 1989, BR J CLIN PHARM, V28, P115; *DIV DRUG MARK ADV, 1999, FDA WARN LETT NOV PH; Furberg CD, 1999, CIRCULATION, V99, P185, DOI 10.1161/01.CIR.99.2.185; Packer M, 1998, EUR HEART J, V19, pB40; PITT B, 1994, CIRCULATION, V90, P1550, DOI 10.1161/01.CIR.90.3.1550; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Soriano JB, 1997, PROG CARDIOVASC DIS, V39, P445, DOI 10.1016/S0033-0620(97)80039-4; Thomas M, 1998, LANCET, V352, P1830, DOI 10.1016/S0140-6736(05)79893-7; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; VENNING GR, 1983, BRIT MED J, V286, P289, DOI 10.1136/bmj.286.6361.289; WOLFE SM, 1995, DIFFERENCES NUMBER D; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1980, FED REG, V45, P76356	13	90	92	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1202	1204		10.1016/S0140-6736(99)03190-6	http://dx.doi.org/10.1016/S0140-6736(99)03190-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513728				2023-01-03	WOS:000082954100046
J	Nicolelis, MAL				Nicolelis, MAL			Actions from thoughts	NATURE			English	Article							MOTOR CORTEX; STIMULATION; PLASTICITY; SEIZURES; NEURONS	Real-time direct interfaces between the brain and electronic and mechanical devices could one day be used to restore sensory and motor functions lost through injury or disease. Hybrid brain-machine interfaces also have the potential to enhance our perceptual, motor and cognitive capabilities by revolutionizing the way we use computers and interact with remote environments.	Duke Univ, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Dept Expt Psychol, Durham, NC 27710 USA; Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Nicolelis, MAL (corresponding author), Duke Univ, Dept Neurobiol, Durham, NC 27710 USA.	nicoleli@neuro.duke.edu						BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; CHAPIN KJ, 2000, NEURLA PROSTHESES RE; Fanselow EE, 2000, J NEUROSCI, V20, P8160; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Ghazanfar AA, 1999, TRENDS COGN SCI, V3, P377, DOI 10.1016/S1364-6613(99)01379-0; Hahnloser RHR, 2000, NATURE, V405, P947, DOI 10.1038/35016072; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Laubach M, 2000, NATURE, V405, P567, DOI 10.1038/35014604; Martinerie J, 1998, NAT MED, V4, P1173, DOI 10.1038/2667; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; MEAD C, 1989, ANAL VLSI NEURAL SYS; MERZENICH MM, 1974, LARYNGOSCOPE, V84, P1887, DOI 10.1002/lary.5540841105; MOXON KA, 2000, NEURAL PROSTHESES RE; Nicolelis MAL, 1998, NAT NEUROSCI, V1, P621, DOI 10.1038/2855; Pfingst BE, 2001, METH NE FRO NEUROSCI, P3; Polley DB, 1999, NEURON, V24, P623, DOI 10.1016/S0896-6273(00)81117-4; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413; SCHMIDT EM, 1980, ANN BIOMED ENG, V8, P339, DOI 10.1007/BF02363437; Schutz S, 1999, NATURE, V398, P298, DOI 10.1038/18585; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; SRINIVASAN MA, 1994, VIRTUAL REALITY SCI, P161; UTHMAN BM, 1990, EPILEPSIA, V31, pS44, DOI 10.1111/j.1528-1157.1990.tb05849.x; Webber WRS, 1996, ELECTROEN CLIN NEURO, V98, P250, DOI 10.1016/0013-4694(95)00277-4; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; WOLPAW JR, 1991, ELECTROEN CLIN NEURO, V78, P252, DOI 10.1016/0013-4694(91)90040-B; Wu CWH, 1999, J NEUROSCI, V19, P7679, DOI 10.1523/JNEUROSCI.19-17-07679.1999; ZABARA J, 1992, EPILEPSIA, V33, P1005, DOI 10.1111/j.1528-1157.1992.tb01751.x	30	454	480	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2001	409	6818					403	407		10.1038/35053191	http://dx.doi.org/10.1038/35053191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	392VY	11201755	Bronze			2023-01-03	WOS:000166434300063
J	Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A				Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A			Effect of heme iron valence state on the conformation of cytochrome c and its association witt membrane interfaces - A CD and EPR investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CASPASE ACTIVATION; INDUCED APOPTOSIS; RELEASE; PEROXIDATION; CARDIOLIPIN; MECHANISM; OXIDATION	Recently cytochrome c has been mentioned as an important mediator in the events of cellular oxidative stress and apoptosis, To investigate the influence of charged interfaces on the conformation of cytochrome c, the CD and magnetic circular dichroic behavior of ferric and ferrous cytochrome c in homogeneous medium and in phosphatidylcholine/phosphatidylethanolamine/cardiolipin and dicetylphosphate liposomes was studied in the 300-600 and 200-320 nm wavelength region. EPR spectra demonstrate that the association of cytochrome c with membranes promotes alterations of the crystal field symmetry and spin state of the heme Fe3+. The studies also include the effect of P-i, NaCl, and CaCl2. Magnetic circular dichroism and CD results show that the interaction of both ferrous and ferric cytochrome c with charged interfaces promotes conformational changes in the cy-helix content, tertiary structure, and heme iron spin state. Moreover, the association of cytochrome c with different liposomes is sensitive to the heme iron valence state. The more effective association with membranes occurs with ferrous cytochrome c. Dicetylphosphate liposomes, as a negatively charged membrane model, promoted a more pronounced conformational modification in the cytochrome c structure. A decrease in the lipid/protein association is detected in the presence of increasing amounts of CaCl2, NaCl, and P-i, in response to the increase of the ionic strength.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; UMC, Diretoria Pesquisa & Posgrad, CIIB, BR-08780911 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis Sao Carlos, Grp Biofis, BR-13560970 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Mogi das Cruzes; Universidade de Sao Paulo	Faljoni-Alario, A (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26077, BR-05513970 Sao Paulo, Brazil.		Nantes, Iseli Lourenço/B-9517-2012; DO ROSARIO ZUCCHI, MARIA/AAG-7660-2021	Nantes, Iseli Lourenço/0000-0003-1434-3154; 				Almeida AM, 1999, FREE RADICAL BIO MED, V27, P744, DOI 10.1016/S0891-5849(99)00136-7; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CILENTO G, 1995, FREE RADICAL BIO MED, V19, P103, DOI 10.1016/0891-5849(95)00002-F; Eaton W A, 1981, Methods Enzymol, V76, P175; GALLARDO H, 1984, BIOCHIM BIOPHYS ACTA, V789, P57, DOI 10.1016/0167-4838(84)90060-8; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Iwase H, 1996, BIOCHEM BIOPH RES CO, V222, P83, DOI 10.1006/bbrc.1996.0701; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; MORTARA RA, 1978, BIOCHEM BIOPH RES CO, V81, P1080, DOI 10.1016/0006-291X(78)91246-9; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PINHEIRO TJT, 1994, BIOCHIMIE, V76, P489, DOI 10.1016/0300-9084(94)90173-2; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STOREY BT, 1973, BIOCHIM BIOPHYS ACTA, V292, P554, DOI 10.1016/0005-2728(73)90004-2; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VINCENT JS, 1987, BIOCHEMISTRY-US, V26, P2312, DOI 10.1021/bi00382a036; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	85	88	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					153	158		10.1074/jbc.M006338200	http://dx.doi.org/10.1074/jbc.M006338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027687	hybrid			2023-01-03	WOS:000166280700022
J	Lee, KY; Peters, MC; Anderson, KW; Mooney, DJ				Lee, KY; Peters, MC; Anderson, KW; Mooney, DJ			Controlled growth factor release from synthetic extracellular matrices	NATURE			English	Article							PROTEIN DELIVERY; POLYMER MATRICES; TISSUE; HYDROGELS; INVIVO	Polymeric matrices can be used to grow new tissues and organs(1,2), and the delivery of growth factors from these matrices is one method to regenerate tissues(3,4). A problem with engineering tissues that exist in a mechanically dynamic environment, such as bone, muscle and blood vessels(5,6), is that most drug delivery systems have been designed to operate under static conditions. We thought that polymeric matrices, which release growth factors in response to mechanical signals, might provide a new approach to guide tissue formation in mechanically stressed environments. Critical design features for this type of system include the ability to undergo repeated deformation, and a reversible binding of the protein growth factors to polymeric matrices to allow for responses to repeated stimuli. Here we report a model delivery system that can respond to mechanical signalling and upregulate the release of a growth factor to promote blood vessel formation. This approach may rnd a number of applications, including regeneration and engineering of new tissues and more general drug-delivery applications.	Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.			Lee, Kuen Yong/0000-0002-5759-5952; Mooney, David/0000-0001-6299-1194				Baldwin SP, 1998, ADV DRUG DELIVER REV, V33, P71, DOI 10.1016/S0169-409X(98)00021-0; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; EDELMAN ER, 1987, J BIOMED MATER RES, V21, P339, DOI 10.1002/jbm.820210307; Jen AC, 1996, BIOTECHNOL BIOENG, V50, P357, DOI 10.1002/(SICI)1097-0290(19960520)50:4<357::AID-BIT2>3.3.CO;2-F; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Putnam AJ, 1996, NAT MED, V2, P824, DOI 10.1038/nm0796-824; Ripamonti U, 1997, CRIT REV ORAL BIOL M, V8, P154, DOI 10.1177/10454411970080020401; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; Williams B, 1998, J HYPERTENS, V16, P1921, DOI 10.1097/00004872-199816121-00011	20	433	459	3	125	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					998	1000		10.1038/35050141	http://dx.doi.org/10.1038/35050141			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140690	Green Published			2023-01-03	WOS:000165951100056
J	White, HD				White, HD			Thrombolytic therapy in the elderly	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; OLDER; ANGIOPLASTY; TRIALS; AGE		Green Lane Hosp, Cardiovasc Res Unit, Auckland 1030, New Zealand		White, HD (corresponding author), Green Lane Hosp, Cardiovasc Res Unit, Private Bag 92189, Auckland 1030, New Zealand.							[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Ayanian JZ, 2000, CIRCULATION, V101, P2224, DOI 10.1161/01.CIR.101.19.2224; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Berger AK, 2000, J AM COLL CARDIOL, V36, P366, DOI 10.1016/S0735-1097(00)00723-3; Berger AK, 1999, JAMA-J AM MED ASSOC, V282, P341, DOI 10.1001/jama.282.4.341; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Holmes DR, 1999, J AM COLL CARDIOL, V33, P412, DOI 10.1016/S0735-1097(98)00579-8; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lesnefsky EJ, 1996, J AM COLL CARDIOL, V28, P331, DOI 10.1016/0735-1097(96)00148-9; Lundergan CF, 1998, J AM COLL CARDIOL, V32, P641, DOI 10.1016/S0735-1097(98)00278-2; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Thiemann DR, 2000, CIRCULATION, V101, P2239, DOI 10.1161/01.CIR.101.19.2239; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	16	113	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2028	2030		10.1016/S0140-6736(00)03397-3	http://dx.doi.org/10.1016/S0140-6736(00)03397-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145486				2023-01-03	WOS:000165994300006
J	Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C				Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C			The saposin-like domain of the plant aspartic proteinase precursor is a potent inducer of vesicle leakage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYNARA-CARDUNCULUS L; NK-LYSIN; PHOSPHOLIPID-MEMBRANES; CRYSTAL-STRUCTURE; BARLEY; GRANULYSIN; PEPTIDES; CARDOSIN; BINDING; FUSION	A unique feature of plant aspartic proteinase precursors is the presence of an internal domain, known as plant-specific insert, whose function is not completely understood. The three-dimensional structure of the plant-specific insert resembles that of saposin-like proteins, a group of lipid-binding proteins involved in a variety of physiological processes. Here we show that recombinant plant-specific insert is able to interact with phospholipid vesicles and to induce leakage of their contents in a pH- and lipid-dependent manner. The leakage activity is higher at pH 4.5 and requires the presence of acidic phospholipids such as phosphatidylserine. To determine whether the same effect could be observed when the plant-specific insert is part of the precursor form, procardosin A and a mutant form lacking this specific domain were produced and characterized. Procardosin A displays a similar activity profile, whereas the mutant without the plant-specific insert shows only residual activity. These findings indicate that the plant-specific insert domain of plant aspartic proteinases mediates an interaction of their precursors with phospholipid membranes and induces membrane permeabilization. It is therefore possible that the plant-specific insert, alone or in conjunction with the proteolytic activity of plant aspartic proteinases, may function either as a defensive weapon against pathogens or in late autolysis of plant cells.	Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Univ Coimbra, Dept Bioquim, Fac Ciencias & Tecnol, P-3001401 Coimbra, Portugal; Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Egas, C (corresponding author), Ctr Neurociencias Coimbra, Dept Biol Mol & Biotecnol, Inst Biomed Invest Luz & Imagem, Azinhaga Santa Comba, P-3000 Coimbra, Portugal.	cve@imagem.ibili.uc.pt	Resende, Rosa/F-4610-2010; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Resende, Rosa/AFU-7705-2022; Egas, Conceição/K-4866-2014	Resende, Rosa/0000-0002-0504-5756; de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Egas, Conceição/0000-0002-2307-5414; Brito, Rui/0000-0001-9128-2557; Faro, Carlos/0000-0002-0480-8379; Pires, Euclides/0000-0002-5853-0165				Andreu D, 1999, BIOCHEM J, V344, P845, DOI 10.1042/0264-6021:3440845; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beck DC, 2000, J BIOL CHEM, V275, P3365, DOI 10.1074/jbc.275.5.3365; Chang R, 1998, BBA-BIOMEMBRANES, V1371, P254, DOI 10.1016/S0005-2736(98)00031-5; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; DEKRUIJFF B, 1994, FEBS LETT, V346, P78, DOI 10.1016/0014-5793(94)00404-8; Faro C, 1999, J BIOL CHEM, V274, P28724, DOI 10.1074/jbc.274.40.28724; Faro C, 1998, ADV EXP MED BIOL, V436, P423; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frazao C, 1999, J BIOL CHEM, V274, P27694, DOI 10.1074/jbc.274.39.27694; Gamen S, 1998, J IMMUNOL, V161, P1758; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HEELEE I, 1997, FEBS LETT, V400, P158; James MNG, 1998, ASPARTIC PROTEINASES; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Nir S, 1999, MOL MEMBR BIOL, V16, P95, DOI 10.1080/096876899294814; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; Runeberg-Roos P, 1998, PLANT J, V15, P139, DOI 10.1046/j.1365-313X.1998.00187.x; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685	37	50	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38190	38196		10.1074/jbc.M006093200	http://dx.doi.org/10.1074/jbc.M006093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982803	hybrid			2023-01-03	WOS:000165739800010
J	Feagan, BG; Wong, CJ; Kirkley, A; Johnston, DWC; Smith, FC; Whitsitt, P; Wheeler, SL; Lau, CY; Johnston, W; Beaupre, L; Schaump, L; Bohonis, D; Greaves, K; Rorabeck, C; Bourne, R; Murkin, J; McCalden, R; MacDonald, S; McCabe, C; Smith, F; Dale, NI; Reynolds, L; Whitsitt, P; Rochon, N; Taylor, D; O'Farrell, TA; Boyce, D; Pisesky, W; O'Connor, G; LeNoble, E; Mantle, M; Bond, D; Turner, K; Bond, P; Swilzer, K; Laflamme, GH; Pynn, B; Dow, G; Steeves, J; Clark, A; Pavlatos-Jones, G; MacLoughlin, C; Laliberte, P; Grenier, A; Chabot, J; Lortie, M; Godin, C; Pynn, B; Waddell, J; Morton, J; Sandler, A; Kaszas, Z; Warriner, B; Werry, D; Metcalfe, C; Tile, M; Dubrovskis, V; Garnett, R; Krepski, B; Cicutti, N; Huk, O; Pynn, B; Wilson, J; Johnston, N; Mulock, R; Sarazin, B; Liddiard, E; Bergman, B; Johnson, W				Feagan, BG; Wong, CJ; Kirkley, A; Johnston, DWC; Smith, FC; Whitsitt, P; Wheeler, SL; Lau, CY; Johnston, W; Beaupre, L; Schaump, L; Bohonis, D; Greaves, K; Rorabeck, C; Bourne, R; Murkin, J; McCalden, R; MacDonald, S; McCabe, C; Smith, F; Dale, NI; Reynolds, L; Whitsitt, P; Rochon, N; Taylor, D; O'Farrell, TA; Boyce, D; Pisesky, W; O'Connor, G; LeNoble, E; Mantle, M; Bond, D; Turner, K; Bond, P; Swilzer, K; Laflamme, GH; Pynn, B; Dow, G; Steeves, J; Clark, A; Pavlatos-Jones, G; MacLoughlin, C; Laliberte, P; Grenier, A; Chabot, J; Lortie, M; Godin, C; Pynn, B; Waddell, J; Morton, J; Sandler, A; Kaszas, Z; Warriner, B; Werry, D; Metcalfe, C; Tile, M; Dubrovskis, V; Garnett, R; Krepski, B; Cicutti, N; Huk, O; Pynn, B; Wilson, J; Johnston, N; Mulock, R; Sarazin, B; Liddiard, E; Bergman, B; Johnson, W		London Clin Trials Res Grp	Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AUTOLOGOUS BLOOD; VENOUS THROMBOSIS; ELECTIVE SURGERY; DONATION; KNEE; EFFICACY; RISK	Background: The optimum regimen of epoetin alfa for prevention of allogeneic blood transfusion is unknown. Objective: To determine whether a modified regimen of epoetin alfa reduces allogeneic blood transfusion in patients undergoing hip arthroplasty. Design: Randomized, double-blind, multicenter trial comparing two modified dose regimens of epoetin alfa with placebo. Setting: 13 teaching hospitals and 4 community hospitals in Canada. Patients: 201 patients undergoing primary hip arthroplasty who had a hemoglobin concentration of 98 to 137 g/L and did not predonate blood. Intervention: Patients were assigned in a 3:5:5 ratio to receive four weekly doses of epoetin alfa, 40 000 U (high-dose; n = 44) or 20 000 U (low-dose; n = 79), or placebo (n = 78), starting 4 weeks before surgery. All patients received oral iron supplementation, 450 mg/d, for 42 or more days before surgery. Measurements: The primary end point was allogeneic transfusion. Secondary end points were thromboembolic events and change in reticulocyte count and hemoglobin concentration. Results: Both modified epoetin alfa regimens significantly reduced the need for allogeneic transfusion: Five (11.4%) patients in the high-dose group (P = 0.001) and 18 (22.8%) patients in the low-dose group (P = 0.003) had transfusion, compared with 35 (44.9%) patients in the placebo group. The hematologic response was substantial in patients who received epoetin alfa. In the high-dose group, low-dose group, and placebo group, the preoperative increase in reticulocyte count was 58.8, 37.0 and 1.8 x 10(9) cells/L (P < 0.004), respectively, and the increase in hemoglobin concentration was 19.5, 17.2, and 1.2 g/L (P < 0.001). The incidence of thromboembolic events did not differ among groups. Conclusions: Both modified epoetin alfa regimens were effective compared with placebo in reducing allogeneic transfusion in patients undergoing hip arthroplasty. Patients who received high-dose epoetin alfa had the lowest transfusion rate.	John P Robarts Res Inst, London Clin Trials Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, London, ON N6A 3K7, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Sir William Osler Hlth Inst, Hamilton, ON, Canada; LakeRidge Hlth Oshawa, Oshawa, ON, Canada; Janssen Ortho Inc, Toronto, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; Johnson & Johnson	Feagan, BG (corresponding author), John P Robarts Res Inst, London Clin Trials Res Grp, Box 5015,100 Perth Dr, London, ON N6A 5K8, Canada.		Feagan, Brian G/M-4283-2015; Feagan, Brian/G-3292-2011; MacDonald, Steven J/B-6173-2015					[Anonymous], 1993, Lancet, V341, P1227; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; Bhandari S, 1998, J CLIN PHARM THER, V23, P73, DOI 10.1046/j.1365-2710.1998.00147.x; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; Cheung WK, 1998, CLIN PHARMACOL THER, V64, P412, DOI 10.1016/S0009-9236(98)90072-8; CHURCHILL DN, 1994, J AM SOC NEPHROL, V4, P1809; Churchill WH, 1998, TRANSFUSION, V38, P530, DOI 10.1046/j.1537-2995.1998.38698326332.x; de Andrade J R, 1996, Am J Orthop (Belle Mead NJ), V25, P533; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DUNN CJ, 1995, DRUG AGING, V7, P131, DOI 10.2165/00002512-199507020-00007; Dupuis JY, 1999, CAN MED ASSOC J, V160, P997; Forgie MA, 1998, ARCH INTERN MED, V158, P610, DOI 10.1001/archinte.158.6.610; Gandini G, 1999, TRANSFUSION, V39, P174, DOI 10.1046/j.1537-2995.1999.39299154732.x; Goldberg M A, 1996, Am J Orthop (Belle Mead NJ), V25, P544; Goldberg MA, 1995, AM J SURG, V170, pS37, DOI 10.1016/S0002-9610(99)80057-9; Goldman M, 1997, TRANSFUSION, V37, P523, DOI 10.1046/j.1537-2995.1997.37597293885.x; Goodnough LT, 1997, NEW ENGL J MED, V336, P933, DOI 10.1056/NEJM199703273361307; Goodnough LT, 1998, VOX SANG, V75, P128, DOI 10.1159/000030973; JOHNSON CA, 1992, ADV PERIT D, V8, P444; Klein HG, 1995, AM J SURG, V170, pS21, DOI 10.1016/S0002-9610(99)80054-3; LAINE LA, 1988, DIGEST DIS SCI, V33, P172, DOI 10.1007/BF01535729; Larocque BJ, 1998, TRANSFUSION, V38, P932, DOI 10.1046/j.1537-2995.1998.381098440857.x; Lee SJ, 1998, TRANSFUSION, V38, P757, DOI 10.1046/j.1537-2995.1998.38898375515.x; Leutz D W, 1994, J Arthroplasty, V9, P543, DOI 10.1016/0883-5403(94)90103-1; Linden JV, 1997, TRANSFUSION, V37, P455, DOI 10.1046/j.1537-2995.1997.37597293872.x; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; RHEIN R, 1992, BRIT MED J, V304, P465; RUTHERFORD CJ, 1994, AM J MED, V96, P139, DOI 10.1016/0002-9343(94)90134-1; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Stowell CP, 1999, ORTHOPEDICS, V22, pS105; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1995, TRANSFUSION, V35, P703; Woronoff-Lemsi MC, 1999, TRANSFUSION, V39, P933, DOI 10.1046/j.1537-2995.1999.39090933.x	35	116	125	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					845	854		10.7326/0003-4819-133-11-200012050-00008	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378LL	11103054				2023-01-03	WOS:000165585800003
J	Borst-Eilers, E				Borst-Eilers, E			Availability of pharmaceutical drugs	LANCET			English	Article									Minist Hlth Welf & Sports, The Hague, Netherlands	Ministry of Health, Welfare & Sport	Borst-Eilers, E (corresponding author), Minist Hlth Welf & Sports, The Hague, Netherlands.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S6	S6		10.1016/S0140-6736(00)91992-5	http://dx.doi.org/10.1016/S0140-6736(00)91992-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191519	Bronze			2023-01-03	WOS:000166074900008
J	Quill, TE				Quill, TE			Initiating end-of-life discussions with seriously ill patients - Addressing the "elephant in the room"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARDIOPULMONARY RESUSCITATION; PATIENTS PERSPECTIVES; PALLIATIVE CARE; DECISION-MAKING; FAMILY MEMBERS; DYING PATIENTS; DEATH; PHYSICIANS; DIFFERENCE; HOSPICE	Discussions about end-of-life issues are difficult for clinicians to initiate. Patients, their families, and clinicians frequently collude to avoid mentioning death or dying, even when the patient's suffering is severe and prognosis is poor. In addition to determining from observational research when and where communication problems exist, much can be learned from in-depth discussions with patients, family members, and physicians who are facing these issues together. Using segments of interviews with a patient with advanced pulmonary fibrosis, his son, and his primary cave physician, this article illustrates and explores some of these communication issues, including the who, what, when, why, and how of end-of-life discussions. Studies from the medical literature, the patient's and physician's particular experience together, and the author's clinical experience provide practical insights into how to address these issues. Initiating end-of-life discussions earlier and more systematically could allow patients to make more informed choices, achieve better palliation of symptoms, and have more opportunity to work on issues of life closure.	Univ Rochester, Dept Med, Rochester, NY USA; Genesee Hosp, Rochester, NY USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Genesee Hosp, Dept Med, 224 Alexander St, Rochester, NY 14607 USA.	timothy.quill@viahealth.org						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Ariu┐s P., 1991, HOUR OUR DEATH; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; BYOCK I, DYING WELL PROSPECT; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; FADEN R, 1994, CLIN GERIATR MED, V10, P541, DOI 10.1016/S0749-0690(18)30339-2; Field MJ, 1997, APPROACHING DEATH IM; FRANKEL R, 1997, ADV DIRECTIVES END L; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KOENIG BA, 1995, WESTERN J MED, V163, P244; Kuczewski MG, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528574; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LAZARE A, 1989, OUTPATIENT PSYCHIAT, P157; LENTZNER HR, 1992, AM J PUBLIC HEALTH, V82, P1093, DOI 10.2105/AJPH.82.8.1093; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; LYNN J, 1995, WESTERN J MED, V163, P250; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Quill T, 1996, MIDWIFE DYING PROCES; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; WAISEL DB, 1995, ANN INTERN MED, V122, P304, DOI 10.7326/0003-4819-122-4-199502150-00011; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	42	288	291	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2502	2507		10.1001/jama.284.19.2502	http://dx.doi.org/10.1001/jama.284.19.2502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074781	Green Published			2023-01-03	WOS:000165183800025
J	Sachs, GA				Sachs, GA			Sometimes dying still stings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2423	2423		10.1001/jama.284.19.2423	http://dx.doi.org/10.1001/jama.284.19.2423			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371MY	11074757				2023-01-03	WOS:000165183800001
J	Schlattner, U; Wallimann, T				Schlattner, U; Wallimann, T			Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; FORMS; RESIDUES; FLUORESCENCE; LOCALIZATION; EXPRESSION; INHIBITION; COMPLEXES; PROTEINS; KINETICS	Octamer stability and membrane binding of mitochondrial creatine kinase (MtCK) are important for proper functioning of the enzyme and were suggested as targets for regulatory mechanisms, A quantitative analysis of these properties, using fluorescence spectroscopy, gel filtration, and surface plasmon resonance, revealed substantial differences between the two types of MtCK isoenzymes, sarcomeric (sMtCK) and ubiquitous (uMtCK), As compared with human and chicken sMtCK, human uMtCK showed a 23-34 times slower octamer dissociation rate, a reduced reoctamerization rate and a superior octamer stability as deduced from the octamer/dimer ratios at thermodynamic equilibrium. Octamer stability of sMtCK increased with temperature up to 30 degrees C, indicating a substantial contribution of hydrophobic interactions, while it decreased in the case of uMtCK, indicating the presence of additional polar dimer/dimer interactions. These conclusions are consistent with the recently solved x-ray structure of the human uMtCK (Eder, IM., Fritz-Wolf, K., Kabsch, W., Wallimann, T., and Schlattner, U. (2000) Proteins 39, 216-225), When binding to 16% cardiolipin membranes, sMtCK showed slightly faster on-rates and higher affinities than uMtCK. However, human uMtCK was able to recruit the highest number of binding sites on the vesicle surface. The observed divergence of ubiquitous and sarcomeric MtCK is discussed with respect to their molecular structures and the possible physiological implications.	ETH Zurich, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schlattner, U (corresponding author), ETH Zurich, Inst Cell Biol, Swiss Fed Inst Technol, Honggerberg HPM F44, CH-8093 Zurich, Switzerland.		Wallimann, Theo/C-6047-2008; Schlattner, Uwe/D-1267-2009	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911				Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; CHIEN JY, 1948, J AM CHEM SOC, V70, P2256, DOI 10.1021/ja01186a078; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Forstner M, 1998, BIOPHYS J, V75, P1016, DOI 10.1016/S0006-3495(98)77590-3; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; GROSS M, 1995, BIOCHEMISTRY-US, V34, P6660, DOI 10.1021/bi00020a011; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KANEMITSU F, 1984, CLIN CHIM ACTA, V138, P175; Khuchua ZA, 1998, J BIOL CHEM, V273, P22990, DOI 10.1074/jbc.273.36.22990; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MARCILLAT O, 1987, BIOCHIM BIOPHYS ACTA, V890, P233, DOI 10.1016/0005-2728(87)90024-7; MATSUSHITA M, 1993, CLIN CHIM ACTA, V216, P103, DOI 10.1016/0009-8981(93)90143-R; Matthews RT, 1998, J NEUROSCI, V18, P156; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; PRATT R, 1987, PATHOLOGY, V19, P162, DOI 10.3109/00313028709077128; ROJO M, 1991, J BIOL CHEM, V266, P20290; Schlattner U, 2000, J BIOENERG BIOMEMBR, V32, P123, DOI 10.1023/A:1005576831968; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHLEGEL J, 1990, J BIOL CHEM, V265, P9221; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; Vacheron MJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P316, DOI 10.1006/abbi.1997.0181; VANDORSTEN F, 1995, BIOCHIM BIOPHYS ACTA, V1274, P59; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9	42	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17314	17320		10.1074/jbc.M001919200	http://dx.doi.org/10.1074/jbc.M001919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748055	hybrid			2023-01-03	WOS:000087485000016
J	Plant, PK; Owen, JL; Elliott, MW				Plant, PK; Owen, JL; Elliott, MW			Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial	LANCET			English	Article							POSITIVE PRESSURE VENTILATION; NASAL VENTILATION; FAILURE; RISK	Background Within the intensive-care unit, non-invasive ventilation (NIV) can prevent the need for intubation and the mortality associated with severe episodes of chronic. obstructive pulmonary disease (COPD). The aim of this study was to find whether the introduction of NIV, early after the admission on a general respiratory ward, was effective at reducing the need for intubation and the mortality associated with acute exacerbations of COPD. Methods We did a prospective multicentre randomised controlled study comparing NIV with standard therapy in patients with mild to moderate acidosis. NIV was administered on the ward with a simple non-invasive ventilator and a standardised predefined protocol. Patients were recruited from 14 UK hospitals over 22 months. Findings 236 patients were recruited, 118 received standard therapy alone and 118 additional NIV. The two groups had similar characteristics at enrolment. The use of NIV significantly reduced the need for intubation as defined by the failure criteria. 32/118 (27%) of the standard group failed compared with 18/118 (15%) of the NIV group (p=0.02). in-hospital mortality was also reduced by NIV, 24/118 (20%) died in the standard group compared with 12/118 (10%) in the NIV group (p=0.05). In both groups pH; PaCO2, and respiratory rate improved at 4 h (p<0.01). However, NIV led to a more rapid improvement in pH in the first hour (p=0.02) and a greater fall in respiratory rate at 4 h (p=0.035). The duration of breathlessness was also reduced by NIV (p=0.025). Interpretation The early use of NIV for mildly and moderately acidotic patients with COPD in the general ward setting leads to more rapid improvement of physiological variables, a reduction in the need for invasive mechanical ventilation (with objective criteria), and a reduction in in-hospital mortality.	St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Plant, PK (corresponding author), St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England.							Angus RM, 1996, THORAX, V51, P1048, DOI 10.1136/thx.51.10.1048; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; BERGSTROM N, 1987, NURS RES, V36, P205, DOI 10.1097/00006199-198707000-00002; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; FLENLEY DC, 1971, LANCET, V1, P961; HUDSON L D, 1989, American Review of Respiratory Disease, V140, pS19; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; SHNEERSON J, 1996, EUR RESPIR J, V19, P393; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339	14	773	848	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 3	2000	355	9219					1931	1935		10.1016/S0140-6736(00)02323-0	http://dx.doi.org/10.1016/S0140-6736(00)02323-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320BV	10859037				2023-01-03	WOS:000087381900008
J	Hutter, JC; Kuehnert, MJ; Wallis, RR; Lucas, DD; Sen, S; Jarvis, WR				Hutter, JC; Kuehnert, MJ; Wallis, RR; Lucas, DD; Sen, S; Jarvis, WR			Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS CENTER; CELLULOSE; INTOXICATION; OXIDATION; MEMBRANES	Context A recent event in which 7 patients at 1 hospital developed decreased vision and hearing, conjunctivitis, headache, and other severe neurologic symptoms 7 to 24 hours after hemodialysis drew attention to the issue of the long-term integrity of dialysis machines and materials. Objective To determine the cause of the adverse reactions that occurred during this event. Design, Patients, and Setting Retrospective cohort study of all 9 patients who received hemodialysis at hospital A on September 18, 1996, the day of the outbreak. A case-patient was defined as any hospital A patient with acute onset of decreased vision and hearing and conjunctivitis after dialysis on that day. Non-case-patients were all others who underwent dialysis at hospital A on that day but did not develop adverse reactions. in an attempt to reproduce the conditions of the event, cellulose acetate dialysis membranes of various ages were retrieved from other sources and tested for physical and chemical degradation, and degradation products were identified, characterized, and injected intravenously into rabbits. Main Outcome Measures Clinical signs and symptoms, time to resolution of symptoms, mortality, and dialyzer type and age, for case- vs non-case-patients. Results Seven of the 9 patients met the case definition. In addition to diminished vision and hearing, conjunctivitis, and headache, some case-patients had blood leak alarm activation (n=6), confusion/lethargy (n=5), corneal opacification (n=4), cardiac arrest (n=2), or other neurologic signs and symptoms. One case-patient died during hospitalization after the event; 5 of 7 case-patients died within 13 months. Resolution of signs and symptoms varied but persisted more than 3 years or until death in 3 of the 6 patients who survived hospitalization. All case-patients but no non-case-patients were exposed to 11.5-year-old cellulose acetate dialyzers (all of these dialyzers were discarded by the hospital before our investigation). Laboratory investigation of field-retrieved 0- to 13.6-year-old dialyzers of similar type indicated significant chemical degradation in the older membranes. In vivo injection of extracts of membrane degradation products produced iritis and hemorrhages in rabbits' eyes. Conclusions Severe patient injury was associated with exposure to aged cellulose acetate membranes of dialyzers, allowing cellulose acetate degradation products to enter the blood. Clinicians should be aware that aged cellulose acetate membranes may cause severe adverse reactions.	US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20852 USA; Ctr Dis Control & Prevent, Hosp Infect Program, Natl Ctr Infect Dis, Atlanta, GA USA	US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	Hutter, JC (corresponding author), US FDA, Ctr Devices & Radiol Hlth, 12725 Twinbrook Pkwy,HFZ 150, Rockville, MD 20852 USA.							ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASTM, 1983, STAND METH TEST CELL; Brandrup J., 1989, POLYM HDB, V3rd ed.; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CHURCHILL DN, 1988, NEPHRON, V50, P325, DOI 10.1159/000185197; DAKA JN, 1994, 20 ANN M SOC BIOM AP; DAUGIRDAS JT, 1988, KIDNEY INT S24, V33, pS37; DEAN AG, 1990, EPI INFO VERSION 6 W; Favero MS, 1996, HOSP EPIDEMIOLOGY IN, P693; FUJIWARA N, 1994, DESALINATION, V96, P431, DOI 10.1016/0011-9164(94)85192-1; GLATER J, 1983, DESALINATION, V46, P389, DOI 10.1016/0011-9164(83)87181-1; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HENDERSON LW, 1993, YB NEPHROLOGY, P210; KESSLER LG, 1996, NOTICE MANUFACTURERS; KROSCHWITZ J, 1985, ENCY POLYM SCI ENG; KUMANO A, 1994, DESALINATION, V96, P451, DOI 10.1016/0011-9164(94)85194-8; MCCRAY SB, 1991, J MEMBRANE SCI, V59, P305; MURPHY AP, 1991, DESALINATION, V85, P45, DOI 10.1016/0011-9164(91)85145-K; OBA T, 1984, ARTIF ORGANS, V8, P429, DOI 10.1111/j.1525-1594.1984.tb04319.x; PEGUES DA, 1992, KIDNEY INT, V42, P1232, DOI 10.1038/ki.1992.409; PEGUES DA, 1992, J AM SOC NEPHROL, V3, P1002; Perry RH., 1984, PERRYS CHEM ENG HDB; PHILIPP B, 1984, PURE APPL CHEM, V56, P391, DOI 10.1351/pac198456030391; RANBY RG, 1959, J POLYM SCI, V36, P561; VOS KD, 1966, J APPL POLYM SCI, V10, P825, DOI 10.1002/app.1966.070100515; YIN L, 1997, NOTICE MANUFACTURERS	27	32	32	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2128	2134		10.1001/jama.283.16.2128	http://dx.doi.org/10.1001/jama.283.16.2128			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791505				2023-01-03	WOS:000086542800029
J	Faber-Langendoen, K; Karlawish, JHT				Faber-Langendoen, K; Karlawish, JHT		Univ Pennsylvania	Should assisted suicide be only physician assisted?	ANNALS OF INTERNAL MEDICINE			English	Article							ATTITUDES; EUTHANASIA; DEATH; ONCOLOGISTS; RELIGION; CANCER	Discussions in the media, courts, legislatures, and professional societies generally assume assistance with suicide to be a-physician's task; in these venues it is commonly referred to as "physician-assisted suicide." This paper defines both the necessity and the limits of the physician's role in assisted suicide by asking the question: Should assisted suicide be only physician assisted? Although physician involvement is necessary, we argue that it is not sufficient to ensure that patients requesting assisted suicide receive the best care. Assisted suicide requires physician involvement, but physicians' limited competence in performing the full range of tasks, the competencies of other professions, and the possibility that other professions could expand their authority in this area suggest that physician-assisted suicide is a far too narrow construct of the task. The willingness of other professionals-including nurses, social workers, and clergy-to participate and even take the lead in assisting suicides is critical to meet society's interest that assisted suicide should be humane, effective, and confined to appropriate cases. As long as legislation and guidelines focus exclusively on the physician's role, our laws and regulations will fall short of meeting societal expectations.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Faber-Langendoen, K (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [K01AG000931] Funding Source: NIH RePORTER; NIA NIH HHS [1K01-AG00931] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Admiraal P V, 1995, Ned Tijdschr Geneeskd, V139, P265; *AM MED ASS COUNC, 1932, JAMA-J AM MED ASSOC, V270, P365; *AM NURS ASS, 1994, POS STAT ASS SUIC, P1; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1996, DRUG USE ASSISTED SU, P267; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BRODY H, 1997, PHYSICIAN ASSISTED S, P136; BYOCK I, 1997, PHYSICIAN ASSISTED S, P107; CALLAHAN D, 1997, PHYSICIAN ASSISTED S, P69; CAPLAN AL, 2000, ANN INTERN MED, V132, P482; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FIELD MJ, 1997, APPROACHING DEATH IM, P363; GILLESPIE M, 1999, KEVORKIAN FACE MURDE; Goldfarb LM, 1996, AM J DRUG ALCOHOL AB, V22, P549, DOI 10.3109/00952999609001680; Humphry, 1991, FINAL EXIT PRACTICAL; JAMISON S, 1995, FINAL ACTS LOVE FAMI; Koenig H G, 1991, J Pastoral Care, V45, P254; Loewy E H, 1992, J Clin Ethics, V3, P29; MAUGANS TA, 1991, J FAM PRACTICE, V32, P210; MILES SH, 1995, HASTINGS CENT REP, V25, P17, DOI 10.2307/3562108; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; *N CUMM FDN FETZ I, 1997, SPIR BEL DYING PROC; *NAT ASS BOARDS PH, 1997, 1997 98 SURV PHARM L, P65; *NAT ASS SOC WORK, 1994, CLIENT SELF DET END, P58; NEELEMAN J, 1993, ACTA PSYCHIAT SCAND, V88, P420, DOI 10.1111/j.1600-0447.1993.tb03484.x; *ONC NURS SOC, 1995, ONC NURS SOC END AM; RUPP MT, 1994, AM J HOSP PHARM, V51, P69, DOI 10.1093/ajhp/51.1.69; SuarezAlmazor ME, 1997, J CLIN ONCOL, V15, P418, DOI 10.1200/JCO.1997.15.2.418; Tulsky JA, 2000, ANN INTERN MED, V132, P494, DOI 10.7326/0003-4819-132-6-200003210-00012; van der Wal G, 1992, Ned Tijdschr Geneeskd, V136, P1299; 1997, OREG NURSE, V62, P5	36	22	22	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					482	487		10.7326/0003-4819-132-6-200003210-00010	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733449				2023-01-03	WOS:000085834700009
J	Pomeroy, VM; Tallis, RC				Pomeroy, VM; Tallis, RC			Need to focus research in stroke rehabilitation	LANCET			English	Editorial Material							CENTRALLY PARETIC HAND; MOTOR CORTEX; SUPPORT		Univ Manchester, Sch Med, Stroke Assoc Therapy Res Unit, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Med, Dept Geriatr Med, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Pomeroy, VM (corresponding author), Hope Hosp, Clin Sci Bldg,Eccles Old Rd, Salford M6 8HD, Lancs, England.	vpomeroy@fs1.ho.man.ac.uk		Pomeroy, Valerie/0000-0003-4487-823X				Ada L, 1998, J NEUROL NEUROSUR PS, V64, P628, DOI 10.1136/jnnp.64.5.628; Bonn D, 1998, LANCET, V352, P119, DOI 10.1016/S0140-6736(98)85026-5; Boult C, 1997, J AM GERIATR SOC, V45, P881, DOI 10.1111/j.1532-5415.1997.tb01519.x; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Hallett M, 1998, NEUROREHABILITATION, V10, P131, DOI 10.3233/NRE-1998-10205; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HUMMELSHEIM H, 1995, ELECTROMYOGR MOTOR C, V97, P18, DOI 10.1016/0924-980X(94)00279-G; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Langhorne P, 1996, Physiother Res Int, V1, P75; Nudo RJ, 1996, J NEUROSCI, V16, P785; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; POMEROY VM, IN PRESS CLIN REHABI; Tyson SF, 1998, CLIN REHABIL, V12, P395, DOI 10.1191/026921598669871795; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; Young J, 1996, BRIT MED J, V313, P677	20	34	34	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					836	837		10.1016/S0140-6736(99)08143-X	http://dx.doi.org/10.1016/S0140-6736(99)08143-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711941				2023-01-03	WOS:000085766900038
J	Henney, JE				Henney, JE			Parkinson treatment approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2023-01-03	WOS:000083908700006
J	Rodes, J; Bruguera, M				Rodes, J; Bruguera, M			The uses of error: latrogenic hepatitis	LANCET			English	Article									Hosp Clin & Prov Barcelona, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona	Rodes, J (corresponding author), Hosp Clin & Prov Barcelona, Villarroel 170, Barcelona 08036, Spain.								0	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 10	2001	357	9258					791	791		10.1016/S0140-6736(00)04184-2	http://dx.doi.org/10.1016/S0140-6736(00)04184-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	409TC	11253985				2023-01-03	WOS:000167400900040
J	Hilbert, G; Gruson, D; Vargas, F; Valentino, R; Gbikpi-Benissan, G; Dupon, M; Reiffers, J; Cardinaud, JP				Hilbert, G; Gruson, D; Vargas, F; Valentino, R; Gbikpi-Benissan, G; Dupon, M; Reiffers, J; Cardinaud, JP			Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE-PRESSURE VENTILATION; INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; NEUTROPENIC PATIENTS; SUPPORT VENTILATION; MALIGNANCIES; TRANSPLANTATION; COMPLICATIONS; MASK	Background: Avoiding intubation is a major goal in the management of respiratory failure, particularly in immunosuppressed patients. Nevertheless, there are only limited data on the efficacy of noninvasive ventilation in these high-risk patients. Methods: We conducted a prospective, randomized trial of intermittent noninvasive ventilation, as compared with standard treatment with supplemental oxygen and no ventilatory support, in 52 immunosuppressed patients with pulmonary infiltrates, fever, and an early stage of hypoxemic acute respiratory failure. Periods of noninvasive ventilation delivered through a face mask were alternated every three hours with periods of spontaneous breathing with supplemental oxygen. The ventilation periods lasted at least 45 minutes. Decisions to intubate were made according to standard, predetermined criteria. Results: The base-line characteristics of the two groups were similar; each group of 26 patients included 15 patients with hematologic cancer and neutropenia. Fewer patients in the noninvasive-ventilation group than in the standard-treatment group required endotracheal intubation (12 vs. 20, P=0.03), had serious complications (13 vs. 21, P=0.02), died in the intensive care unit (10 vs. 18, P=0.03), or died in the hospital (13 vs. 21, P=0.02). Conclusions: In selected immunosuppressed patients with pneumonitis and acute respiratory failure, early initiation of noninvasive ventilation is associated with significant reductions in the rates of endotracheal intubation and serious complications and an improved likelihood of survival to hospital discharge. (N Engl J Med 2001;344:481-7.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Hosp, Div Med Intens Care, Bordeaux, France; Univ Hosp, Dept Med & Infect Dis, Bordeaux, France; Univ Hosp, Dept Hematol, Bordeaux, France	CHU Bordeaux; CHU Bordeaux; CHU Bordeaux	Hilbert, G (corresponding author), Hop Pellegrin, F-33076 Bordeaux, France.	gilles.hilbert@chu-bordeaux.fr						Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Blot F, 1997, EUR J CANCER, V33, P1031, DOI 10.1016/S0959-8049(97)00042-7; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Conti G, 1998, INTENS CARE MED, V24, P1283, DOI 10.1007/s001340050763; CRAWFORD SW, 1988, AM REV RESPIR DIS, V137, P682, DOI 10.1164/ajrccm/137.3.682; ESTOPA R, 1984, CRIT CARE MED, V12, P26, DOI 10.1097/00003246-198401000-00007; Ewig S, 1998, EUR RESPIR J, V12, P116, DOI 10.1183/09031936.98.12010116; FANTA CH, 1989, RESPIRATORY INFECTIO, P221; Gruson D, 2000, CRIT CARE MED, V28, P2224, DOI 10.1097/00003246-200007000-00007; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; Hilbert G, 1997, INTENS CARE MED, V23, P955, DOI 10.1007/s001340050438; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; Hilbert G, 2000, CRIT CARE MED, V28, P3185, DOI 10.1097/00003246-200009000-00012; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MASUR H, 1985, JAMA-J AM MED ASSOC, V253, P1769, DOI 10.1001/jama.253.12.1769; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Meduri GU, 1998, LUNG BIOL HEALTH DIS, V118, P921; OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; Rubenfeld GD, 1996, ANN INTERN MED, V125, P625, DOI 10.7326/0003-4819-125-8-199610150-00001; Stauffer JL, 1994, PRINCIPLES PRACTICE, P711; TEASDALE G, 1974, LANCET, V2, P81; Tognet E, 1994, Clin Intensive Care, V5, P282	28	738	777	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					481	487		10.1056/NEJM200102153440703	http://dx.doi.org/10.1056/NEJM200102153440703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172189				2023-01-03	WOS:000166922100003
J	Schwetz, BA				Schwetz, BA			New anticoagulant approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2023-01-03	WOS:000166817200006
J	Hardy, J				Hardy, J			Sedation in terminally ill patients	LANCET			English	Editorial Material							HOSPICE		Royal Marsden, Dept Palliat Med, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	Hardy, J (corresponding author), Royal Marsden, Dept Palliat Med, Sutton SM2 5PT, Surrey, England.		Hardy, Janet/F-2501-2012	Hardy, Janet/0000-0003-1127-9951				Back Ian N., 1992, Palliative Medicine, V6, P293, DOI 10.1177/026921639200600404; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fainsinger RL, 1998, J PAIN SYMPTOM MANAG, V16, P145, DOI 10.1016/S0885-3924(98)00066-9; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; SYKES N, 2000, PAIN EUROPE, V3, P71	9	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1866	1867		10.1016/S0140-6736(00)03252-9	http://dx.doi.org/10.1016/S0140-6736(00)03252-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130377				2023-01-03	WOS:000165665400004
J	Robinson, D; Smith, AMJ; Johnston, GD				Robinson, D; Smith, AMJ; Johnston, GD			Severity of overdose after restriction of paracetamol availability: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Queens Univ Belfast, Dept Therapeut & Pharmacol, Belfast BT9 7BL, Antrim, North Ireland; Royal Victoria Hosp, Reg Med & Poisons Informat Unit, Belfast BT12 6BA, Antrim, North Ireland	Queens University Belfast	Johnston, GD (corresponding author), Queens Univ Belfast, Dept Therapeut & Pharmacol, Whitla Med Bldg, Belfast BT9 7BL, Antrim, North Ireland.							Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; Prince MI, 2000, LANCET, V355, P2047, DOI 10.1016/S0140-6736(00)02354-0; Routledge P, 1998, BRIT MED J, V317, P1609; *SECR STAT HLTH, 1999, SAV LIV OUR HLTH NAT; Turvill JL, 2000, LANCET, V355, P2048, DOI 10.1016/S0140-6736(00)02355-2	5	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	2000	321	7266					926	927		10.1136/bmj.321.7266.926	http://dx.doi.org/10.1136/bmj.321.7266.926			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	365XE	11030678	Bronze, Green Published			2023-01-03	WOS:000089975100020
J	Salazar, AM; Warden, DL; Schwab, K; Spector, J; Braverman, S; Walter, J; Cole, R; Rosner, MM; Martin, EM; Ecklund, J; Ellenbogen, RG				Salazar, AM; Warden, DL; Schwab, K; Spector, J; Braverman, S; Walter, J; Cole, R; Rosner, MM; Martin, EM; Ecklund, J; Ellenbogen, RG		Defense Vet Head Injury Program DV	Cognitive rehabilitation for traumatic brain injury - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILITARY MEDICAL SYSTEM; HEAD-INJURY; BENEFIT	Context Traumatic brain injury (TBI) is a principal cause of death and disability in young adults. Rehabilitation for TBI has not received the same level of scientific scrutiny for efficacy and cost-efficiency that is expected in other medical fields. Objective To evaluate the efficacy of inpatient cognitive rehabilitation for patients with TBI. Design and Setting Single-center, parallel-group, randomized trial conducted from January 1992 through February 1997 at a US military medical referral center. Patients One hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury, manifested by a Glasgow Coma Scale score of 13 or less, or posttraumatic amnesia lasting at least 24 hours, or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging. Interventions Patients were randomly assigned to an intensive, standardized, 8-week, in-hospital cognitive rehabilitation program (n=67) or a limited home rehabilitation program with weekly telephone support from a psychiatric nurse (n=53). Main Outcome Measures Return to gainful employment and fitness for military duty at 1-year follow-up, compared by intervention group. Results At 1-year follow-up, there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment (90% vs 94%, respectively; P=.51; difference, 4% [95% confidence interval {CI}, -5% to 14%]) or fitness for duty (73% vs 66%,respectively; P=.43; difference, 7% [95% CI, -10% to 24%]). There also were no significant differences in cognitive, behavioral, or quality-of-life measures. In a post-hoc subset analysis of patients who were unconscious for more than 1 hour (n=75) following TBI, the in-hospital group had a greater return-to-duty rate (80% vs 58%; P=.05). Conclusions In this study, the overall benefit of in-hospital cognitive rehabilitation for patients with moderate-to-severe TBI was similar to that of home rehabilitation. These findings emphasize the importance of conducting randomized trials to evaluate TBI rehabilitation interventions.	Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Henry M Jackson Fdn, Def & Vet Head Injury Program, Rockville, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA	Salazar, AM (corresponding author), Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Bldg 1,Room B210, Washington, DC 20307 USA.							ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Ben-Yishay Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Braverman SE, 1999, BRAIN INJURY, V13, P405; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CHESNUT R, 1998, EVIDENCE REPORT REHA, P11; CHESNUT R, 1999, EVIDENCE REPORT REHA, P1; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; Fichera, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI [https://doi.org/10.1300/J294v12n02_03, DOI 10.1300/1294V12N02_03]; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76, DOI DOI 10.1097/00001199-199106000-00010; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; *US ARM, 1995, STAND MED FITN ARM R, P14; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563	33	185	188	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	2000	283	23					3075	3081		10.1001/jama.283.23.3075	http://dx.doi.org/10.1001/jama.283.23.3075			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PV	10865301	Bronze			2023-01-03	WOS:000087574900031
J	Steinhauser, KE; Clipp, EC; McNeilly, M; Christakis, NA; McIntyre, LM; Tulsky, JA				Steinhauser, KE; Clipp, EC; McNeilly, M; Christakis, NA; McIntyre, LM; Tulsky, JA			In search of a good death: Observations of patients, families, and providers	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							QUALITY-OF-LIFE; PATIENTS PERSPECTIVES; ADVANCE DIRECTIVES; CARE; END; PERSONNEL; DISEASE	Despite a recent increase in the attention given to improving end-of-life care, our understanding of what constitutes a good death is surprisingly lacking. The purpose of this study was to gather descriptions of the components of a good death from patients, families, and providers through focus group discussions and in-depth interviews. Seventy-five participants-including physicians, nurses. social workers, chaplains, hospice volunteers, patients, and recently bereaved family members-were recruited from a university medical center, a Veterans Affairs medical center, and a community hospice. Participants identified six major components of a good death: pain and symptom management, clear decision making, preparation for death, completion, contributing to others, and affirmation of the whole person. The six themes are process-oriented attributes of a good death, and each has biomedical, psychological, social, and spiritual components. Physicians' discussions of a good death differed greatly from those of other groups. Physicians offered the most biomedical perspective, and patients, families, and other health care professionals defined a broad range of attributes integral to the quality of dying. Although there is no "right" way to die, these six themes may be used as a framework for understanding what participants tend to value at the end of life. Biomedical care is critical, but it is only a point of departure toward total end-of-life care. For patients and families, psychosocial and spiritual issues are as important as physiologic concerns.	Duke Univ, Duke Vet Affairs Med Ctr 152, Durham, NC 27705 USA; Inst Multiculturalism, Durham, NC USA; Univ Chicago, Chicago, IL 60637 USA	Duke University; University of Chicago	Steinhauser, KE (corresponding author), Duke Univ, Duke Vet Affairs Med Ctr 152, 508 Fulton St, Durham, NC 27705 USA.	karensteinhauser@mindspring.com	McIntyre, Lauren/J-8414-2012; Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	McIntyre, Lauren/0000-0002-0077-3359; 				Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ARIES P, 1980, HOUR OUR DEATH; Armstrong K, 1998, SOC WORK HEALTH CARE, V27, P33, DOI 10.1300/J010v27n01_03; BYOCK I, 1997, DYING WELL PEACE POS, P4311; Christakis NA, 1999, DEATH FORETOLD PROPH; CLIPP EC, 1992, CANCER, V69, P1074, DOI 10.1002/1097-0142(19920215)69:4<1074::AID-CNCR2820690440>3.0.CO;2-L; Cohen S R, 1992, J Palliat Care, V8, P40; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; CORBIN J, 1990, BASICS QUALITIVE RES; Cudmore J, 1996, Nurs Crit Care, V1, P120; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Erikson E.H., 1982, LIFE CYCLE COMPLETED; Field MJ, 1997, APPROACHING DEATH IM; FOUCAULT M, 1973, BIRHT CLIN ARCHEOLOG; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; FOWLIE M, 1989, PALLIATIVE MED, V3, P55; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Kaufman SR, 1998, GERONTOLOGIST, V38, P715, DOI 10.1093/geront/38.6.715; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krueger R.A., 1994, FOCUS GROUPS PRACTIC, V2nd; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; Rosebush PA, 1998, MIL MED, V163, P559, DOI 10.1093/milmed/163.8.559; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; Starr P., 1982, SOCIAL TRANSFORMATIO; STERN P, 1985, QUALITATIVE RES METH; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; *VET HLTH AD, POLICY IMPLEMENTATIO	34	689	699	1	110	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 16	2000	132	10					825	832		10.7326/0003-4819-132-10-200005160-00011	http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313XN	10819707				2023-01-03	WOS:000087025100009
J	Cavicchi, M; Beau, P; Crenn, P; Degott, C; Messing, B				Cavicchi, M; Beau, P; Crenn, P; Degott, C; Messing, B			Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure	ANNALS OF INTERNAL MEDICINE			English	Article							P-GLYCOPROTEIN GENE; URSODEOXYCHOLIC ACID; CHRONIC CHOLESTASIS; LIPID EMULSIONS; BOWEL RESECTION; FUNCTION TESTS; CHILDREN; RATS; TRANSPLANTATION; METRONIDAZOLE	Background: Liver cholestasis can be a life-threatening complication during home parenteral nutrition and may lead to combined liver-intestinal transplantation. Objective: To assess the prevalence of home parenteral nutrition-related liver disease and its contributing factors in patients with permanent intestinal failure. Design: Prospective cohort study. Setting: Two approved home parenteral nutrition centers, Patients: 90 patients with permanent intestinal failure who were receiving home parenteral nutrition were enrolled from 1985 to 1996. Intervention: Clinical, biological, endoscopic, and ultrasonographic follow-up. Histologic examination of the liver was done in 57 patients (112 liver biopsies). Measurements: The Kaplan-Meier method was used to determine the actuarial occurrence of chronic cholestasis and complicated home parenteral nutrition-related liver disease (bilirubin level greater than or equal to 60 mu mol/L [3.5 mg/dL], factor V level less than or equal to 50%, portal hypertension, encephalopathy, ascites, gastrointestinal bleeding, or histologically proven extensive fibrosis or cirrhosis). Contributing factors were assessed by using univariate and multivariate (Cox model) analysis. Results: 58 patients (65%) developed chronic cholestasis after a median of 6 months (range, 3 to 132 months), and 37 (41.5%)developed complicated home parenteral nutrition-related liver disease after a median of 17 months (range, 2 to 155 months). Of these patients, 17 showed extensive fibrosis after 26 months (range, 2 to 148 months) and 5 had cirrhosis after 37 months (range, 26 to 77 months). The prevalence of complicated home parenteral nutrition-related liver disease was 26% +/- 9% at 2 years and 50% +/- 13% at 6 years. Six patients died of liver disease (22% of all deaths). In multivariate analysis, chronic cholestasis was significantly associated with a parenteral nutrition-independent risk for liver disease, a bowel remnant shorter than 50 cm in length, and a parenteral lipid intake of 1 g/kg of body weight per day or more (omega-6-rich long-chain triglycerides), whereas complicated home parenteral nutrition-related liver disease was significantly associated with chronic cholestasis and lipid parenteral intake of 1 g/kg per day or more. Conclusion: The prevalence of complicated home parenteral nutrition-related liver disease increased with longer duration of parenteral nutrition. This condition was one of the main causes of death in patients with permanent intestinal failure. Parenteral intake of w-6-rich long-chain triglycerides lipid emulsion consisting of less than 1 g/kg per day is recommended in these patients.	Hop Lariboisiere, Serv Gastroenterol & Assistance Nutr, F-75475 Paris 10, France; Ctr Hosp La Miletrie, Poitiers, France; Hop Beaujon, Clichy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Messing, B (corresponding author), Hop Lariboisiere, Serv Gastroenterol & Assistance Nutr, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	bernard.messing@lrb.ap-hop-paris.fr	CRENN, Pascal/B-5850-2008	CRENN, Pascal/0000-0002-8213-2319				ALLARDYCE DB, 1982, SURG GYNECOL OBSTET, V154, P641; BEAU P, 1994, J HEPATOL, V20, P240, DOI 10.1016/S0168-8278(05)80064-9; BEAU P, 1994, GASTROEN CLIN BIOL, V18, P63; BELLI DC, 1987, JPEN-PARENTER ENTER, V11, P67, DOI 10.1177/014860718701100167; BENJAMIN DR, 1981, AM J CLIN PATHOL, V76, P276; BOWYER BA, 1985, JPEN-PARENTER ENTER, V9, P11, DOI 10.1177/014860718500900111; Brousse N, 1996, BRIT MED J, V312, P261; BURNES JU, 1992, JPEN-PARENTER ENTER, V16, P327, DOI 10.1177/0148607192016004327; CANO N, 1994, NUTR CLIN METAB, V8, P149; CAPRON JP, 1983, LANCET, V1, P446; CLARKE PJ, 1991, JPEN-PARENTER ENTER, V15, P54, DOI 10.1177/014860719101500154; CLAYTON PT, 1993, GASTROENTEROLOGY, V105, P1806, DOI 10.1016/0016-5085(93)91079-W; Cox DR., 1989, ANAL BINARY DATA, V2nd; CRAIG RM, 1980, GASTROENTEROLOGY, V79, P131; Crenn P, 1997, CLIN NUTR, V16, P133, DOI 10.1016/S0261-5614(97)80240-3; DAHMS BB, 1981, GASTROENTEROLOGY, V81, P136; DEGOTT C, 1988, GASTROENTEROLOGY, V95, P183, DOI 10.1016/0016-5085(88)90309-5; DRONGOWSKI RA, 1989, JPEN-PARENTER ENTER, V13, P586, DOI 10.1177/0148607189013006586; FISCHER GW, 1980, LANCET, V2, P819; Forbush B, 1998, GASTROENTEROLOGY, V114, pA1241, DOI 10.1016/S0016-5085(98)85034-8; FOUINFORTUNET H, 1982, GASTROENTEROLOGY, V82, P932; GERARDBONCOMPAIN M, 1992, JPEN-PARENTER ENTER, V16, P78, DOI 10.1177/014860719201600178; GOGOS CA, 1992, NUTRITION, V8, P26; Grant D, 1999, TRANSPLANTATION, V67, P1061, DOI 10.1097/00007890-199904150-00021; GUERTIN F, 1991, JPEN-PARENTER ENTER, V15, P247, DOI 10.1177/0148607191015003247; Harris JA., 1919, BIOMETRIC STUDY BASA; INNES GK, 1988, TRANSPLANTATION, V45, P749, DOI 10.1097/00007890-198804000-00017; ITO Y, 1991, JPEN-PARENTER ENTER, V15, P271, DOI 10.1177/0148607191015003271; KAMINSKI DL, 1980, SURGERY, V88, P93; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONO K, 1988, GASTROENTEROLOGY, V94, P787, DOI 10.1016/0016-5085(88)90255-7; LAMBERT JR, 1985, JPEN-PARENTER ENTER, V9, P501, DOI 10.1177/0148607185009004501; LEVECQ H, 1988, GASTROEN CLIN BIOL, V12, P691; MARTINEZ M, 1987, LIPIDS, V22, P133, DOI 10.1007/BF02537290; MESSING B, 1992, NUTRITION, V8, P30; Messing B, 1999, GASTROENTEROLOGY, V117, P1043, DOI 10.1016/S0016-5085(99)70388-4; MESSING B, 1995, GASTROENTEROLOGY, V108, P1005, DOI 10.1016/0016-5085(95)90196-5; MESSING B, 1990, AM J CLIN NUTR, V52, P1094, DOI 10.1093/ajcn/52.6.1094; MESSING B, 1994, TRANSPL P, V26, P1438; MESSING B, 1982, GASTROEN CLIN BIOL, V6, P740; MUGHAL M, 1986, LANCET, V2, P383; NANJI AA, 1985, JPEN-PARENTER ENTER, V9, P307, DOI 10.1177/0148607185009003307; PEDEN VH, 1971, J PEDIATR-US, V78, P180, DOI 10.1016/S0022-3476(71)80289-5; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Piquette-Miller M, 1998, PHARMACEUT RES, V15, P706, DOI 10.1023/A:1011962818051; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; Quigley EMM, 1996, GASTROENTEROLOGY, V110, P2009, DOI 10.1053/gast.1996.v110.agast962009; Roth B, 1996, INTENS CARE MED, V22, P1224, DOI 10.1007/s001340050242; SCOTTCONNER CEH, 1994, J SURG RES, V57, P316, DOI 10.1006/jsre.1994.1151; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Spagnuolo MI, 1996, GASTROENTEROLOGY, V111, P716, DOI 10.1053/gast.1996.v111.pm8780577; Stanko RT, 1987, GASTROENTEROLOGY, V92, P197, DOI 10.1016/0016-5085(87)90859-6; Tabachnik B.G., 1983, USING MULTIVARIATE S; TKOUB M, 1997, CLIN NUTR S1, V16, P32; Trauner M, 1997, GASTROENTEROLOGY, V113, P255, DOI 10.1016/S0016-5085(97)70103-3; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDEVENTER SJH, 1988, GASTROENTEROLOGY, V94, P825, DOI 10.1016/0016-5085(88)90261-2; vanNieuwkerk CMJ, 1996, GASTROENTEROLOGY, V111, P165, DOI 10.1053/gast.1996.v111.pm8698195; WOLFE BM, 1988, ARCH SURG-CHICAGO, V123, P1084	59	434	450	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					525	532		10.7326/0003-4819-132-7-200004040-00003	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744588				2023-01-03	WOS:000086129300002
J	Weiss, RB; Rifkin, RM; Stewart, FM; Theriault, RL; Williams, LA; Herman, AA; Beveridge, RA				Weiss, RB; Rifkin, RM; Stewart, FM; Theriault, RL; Williams, LA; Herman, AA; Beveridge, RA			High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study	LANCET			English	Article							BONE-MARROW SUPPORT; RANDOMIZED TRIAL; CELL SUPPORT	Background The efficacy of high-dose chemotherapy with progenitor-cell rescue for women with breast cancer is a controversial issue. Although historically controlled trials have suggested a survival advantage for high-dose chemotherapy, several randomised studies have yet to confirm this advantage. Two studies, however, by Bezwoda, of patients with high-risk and metastatic disease, seemed to show a significant survival advantage for high-dose compared with conventional-dose chemotherapy for metastatic and high-risk primary breast cancer. Methods To corroborate the study results before starting a large international confirmatory study, a US team did an onsite review of records for patients in the high-risk study. Limited numbers of records were made available for review, all of which were for patients who received the high-dose-chemotherapy regimen. Findings There was much disparity between the reviewed records and the data presented at two international meetings. In addition, the reviewers saw no signed informed consent, and the institutional review committee had no record of approval for the investigational therapy. After the site visit, Bezwoda admitted scientific misconduct by using a different control chemotherapy regimen from that described in presented data. Interpretation The Bezwoda study should not be used as the basis for further trials to test the efficacy of the cyclophosphamide, mitoxantrone, etoposide regimen for high-dose chemotherapy in women with high-risk primacy breast cancer. This review validates the essential nature of on-site audits, especially in single-institution studies.	US Oncol Inc, Houston, TX 77060 USA; Rockville, Washington, DC USA; Univ Massachusetts, Med Ctr, Dept Med, Worcester, MA USA; Univ Texas, MD Anderson Canc Ctr, Med Breast Canc Serv, Houston, TX 77030 USA; Med Univ Southern Africa, Natl Sch Publ Hlth, Pretoria, South Africa	University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; Sefako Makgatho Health Sciences University	Beveridge, RA (corresponding author), US Oncol Inc, 16825 Northchase Dr,Suite 1300, Houston, TX 77060 USA.	roy.beveridge@usoncology.com						Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; Bezwoda WR, 1999, EUR J CANCER, V35, pS230, DOI 10.1016/S0959-8049(99)81322-7; BEZWODA WR, 1999, P ASCO, V18, P2; BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, P115; Gianni AM, 1997, J CLIN ONCOL, V15, P2312, DOI 10.1200/JCO.1997.15.6.2312; Hortobagyi GN, 2000, JNCI-J NATL CANCER I, V92, P225, DOI 10.1093/jnci/92.3.225; Nylenna M, 1999, LANCET, V354, P57, DOI 10.1016/S0140-6736(98)07133-5; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 1999, P ASCO, V18, P1; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; Weiss R B, 1999, Oncologist, V4, P450; Weiss RB, 1998, CANCER CHEMOTH PHARM, V42, pS88, DOI 10.1007/s002800051087; WEISS RB, 1993, JAMA-J AM MED ASSOC, V270, P459, DOI 10.1001/jama.270.4.459; 2000, CANC LETT, V26, P1	17	99	101	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					999	1003		10.1016/S0140-6736(00)90024-2	http://dx.doi.org/10.1016/S0140-6736(00)90024-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768448				2023-01-03	WOS:000086054000039
J	Albers, GW; Bates, VE; Clark, WM; Bell, R; Verro, P; Hamilton, SA				Albers, GW; Bates, VE; Clark, WM; Bell, R; Verro, P; Hamilton, SA			Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC STROKE; THROMBOLYSIS; PA	Context Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. Objective To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. Design and Setting Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). Intervention Intravenous tPA (recombinant alteplase). Patients Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55% were men. Main Outcome Measures Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. Results Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13%. At 30 days after treatment, 35% of patients had very favorable outcomes (modified Rankin score, 0-1) and 43% were functionally independent (modified Ran kin score, 0-2). Thirteen patients (3.3%) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2%) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6%), and included treatment with tPA more than 3 hours after symptom onset in 13.4%, treatment with anticoagulants within 24 hours of tPA administration in 9.3%, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7%. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33% of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. Conclusions This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.	Stanford Univ, Med Ctr, Stanford Stroke Ctr, Palo Alto, CA 94304 USA; Millard Fillmore Hosp, Dent Neurol Inst, Buffalo, NY USA; Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Seton Hall Univ, Edison, NJ USA; Genentech Inc, San Francisco, CA 94080 USA	Stanford University; State University of New York (SUNY) System; Oregon Health & Science University; Jefferson University; Seton Hall University; Roche Holding; Genentech	Albers, GW (corresponding author), Stanford Univ, Med Ctr, Stanford Stroke Ctr, 701 Welch Rd,B325, Palo Alto, CA 94304 USA.	albers@leland.stanford.edu		Albers, Gregory/0000-0003-0263-4632				Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; Adams HP, 1996, NEUROLOGY, V47, P835; Albers GW, 1998, CHEST, V114, p683S, DOI 10.1378/chest.114.5_Supplement.683S; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Grond M, 1998, STROKE, V29, P1544, DOI 10.1161/01.STR.29.8.1544; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Katzan IL, 1999, STROKE, V30, P266; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Lopez-Yunez AM, 1999, STROKE, V30, P264, DOI 10.1161/01.STR.30.11.2495; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Marler JR, 1999, STROKE, V30, P244; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Villar-Cordova C, 1998, NEUROLOGY, V50, P1491, DOI 10.1212/WNL.50.5.1491; Wang DZ, 2000, STROKE, V31, P77, DOI 10.1161/01.STR.31.1.77; Zweifler RM, 1998, NEUROLOGY, V50, P501, DOI 10.1212/WNL.50.2.501	19	508	529	2	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	2000	283	9					1145	1150		10.1001/jama.283.9.1145	http://dx.doi.org/10.1001/jama.283.9.1145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286BQ	10703776	Bronze			2023-01-03	WOS:000085424100023
J	Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D				Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D			Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland; N Glasgow Hosp Univ NHS Trust, Univ Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Stallard, S (corresponding author), N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GAMBRELL RD, 1992, AM FAM PHYSICIAN S5, V46, P87; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X	5	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					348	349		10.1136/bmj.320.7231.348	http://dx.doi.org/10.1136/bmj.320.7231.348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657329	Green Submitted, Green Published, Green Accepted, Bronze			2023-01-03	WOS:000085211400025
J	Philipp, M; Kohnen, R; Hiller, KO				Philipp, M; Kohnen, R; Hiller, KO			Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks	BRITISH MEDICAL JOURNAL			English	Article							ANTIDEPRESSANT; TERM; WORT	Objectives To assess the efficacy and safety of hypericum extract (STEI 300, Steiner Arzneimittel, Berlin) compared with imipramine and placebo in patients in primary care with a current episode of moderate depression. Design Randomised, double blind, multicentre, parallel group trial for 8 weeks. Setting Trained panel of IS general practitioners from four German states: Bavaria Berlin, Rhineland Palatinate, and Saxony. Participants 263 patients (66 men, 197 women) with moderate depression according to ICD-10 (international classification of diseases, 10th revision) codes F32.1 and F33.1. Interventions 1050 mg hypericum extract (350 mg three times daily), 100 mg imipramine (50 mg, 25 mg, and 25 mg daily), or placebo three times daily Main outcome measures Change from baseline score on the It item version of the Hamilton depression scale, the Hamilton anxiety scale, the clinical global impressions scale, Zung's self rating depression scale, and SF-YB, and adverse events profile. Results Hypericum extract was more effective at reducing Hamilton depression scores than placebo and as effective as imipramine (mean - 15.4 (SD 8.1), -12.1 (7.4). and -14.2 (7.3) respectively). Comparable results were found for Hamilton anxiety and clinical global impressions scales and were most pronounced for the Zung self rating depression scale. Quality of life was more improved in the standardised mental component scale of the SF-36 with both active treatments than with placebo but in the physical component scale was improved only by hypericum extract compared with placebo. The rate of adverse events with hypericum extract was in the range of the placebo group but lower than that of the imipramine group (0.5, 0.6, and 1.2 events per patient respectively). Conclusions At an average dose of 350 mg three times daily hypericum extract was more effective than placebo and at least as effective as 100 mg imipramine daily in the treatment of moderate depression. Treatment with hypericum extract is safe and improves quality of life.	Steiner Arzneimittel, D-12207 Berlin, Germany; Bezirkskrankenhaus Landshut, D-84034 Landstuhl, Germany; Imerem Inst Med Res Management & Biometr, D-90478 Nurnberg, Germany		Hiller, KO (corresponding author), Steiner Arzneimittel, D-12207 Berlin, Germany.							Angst J, 1997, BMJ-BRIT MED J, V315, P1143; Bollini P, 1999, BRIT J PSYCHIAT, V174, P297, DOI 10.1192/bjp.174.4.297; DeSmet PAGM, 1996, BMJ-BRIT MED J, V313, P241, DOI 10.1136/bmj.313.7052.241; Ernst E, 1998, EUR J CLIN PHARMACOL, V54, P589, DOI 10.1007/s002280050519; *EUR COMM, 1998, CPMPICH36396 EUR COM; *EUR COMM, 1990, NOT GUID MED PROD TR; *EUR COMM, 1997, CPMPICH13595 EUR COM; *GERM COMM, 1992, BUNDESANZEIGER  0808; Heiligenstein J H, 1995, Int Psychogeriatr, V7 Suppl, P125, DOI 10.1017/S1041610295002407; LEHMACHER W, 1993, EUROPAISCHE PERSPEKT, P152; Lepine JP, 1997, INT CLIN PSYCHOPHARM, V12, P19, DOI 10.1097/00004850-199701000-00003; LINDE K, 1999, COCHRANE LIB; Linden M, 1996, NERVENARZT, V67, P205; Montgomery SA., 1994, EUROPEAN NEUROPSYCHO, V4, P283, DOI [DOI 10.1016/0924-977X(94)90093-0, 10.1016/0924-977X(94)90093-0]; PRESKORN SH, 1992, J CLIN PSYCHIAT, V53, P5; Rohmel J, 1998, STAT MED, V17, P1703; Volz HP, 1997, PHARMACOPSYCHIATRY, V30, P72, DOI 10.1055/s-2007-979522	17	156	158	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1534	1538		10.1136/bmj.319.7224.1534	http://dx.doi.org/10.1136/bmj.319.7224.1534			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591711	Green Published, Bronze			2023-01-03	WOS:000084245600021
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine and the doctor	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England		Zollman, C (corresponding author), Res Council Complementary Med, London, England.							LEWITH G, 1996, OXFORD GEN PRACTICE; *RES COUNC COMPL M, 1998, MED ATT COMPL MED RE; SHARMA U, 1995, COMPLEMENTARY MED TO; 1993, COMPLEMENTARY MED NE	4	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1558	1561		10.1136/bmj.319.7224.1558	http://dx.doi.org/10.1136/bmj.319.7224.1558			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591724	Green Published			2023-01-03	WOS:000084245600029
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Unconventional approaches to nutritional medicine	BRITISH MEDICAL JOURNAL			English	Review																		ANTHONY HM, 1997, ENV MED CLIN PRACTIC; BROSTOFF J, 1992, COMPLETE GUIDE FOOD; DAVIES S, 1987, NUTR MED; MURRAY M, 1999, ENCY NATURAL MED	4	7	8	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1419	1422		10.1136/bmj.319.7222.1419	http://dx.doi.org/10.1136/bmj.319.7222.1419			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574865	Green Published, Green Submitted			2023-01-03	WOS:000083995200033
J	Langhorne, P; Legg, L				Langhorne, P; Legg, L		Outpatient Therapy Trialists	Therapy for stroke patients living at home	LANCET			English	Letter									Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	Royal Infirmary of Edinburgh	Langhorne, P (corresponding author), Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.			BERNABEI, Roberto/0000-0002-9197-004X				LANGHORNE P, 1999, P 7 COCHR C ROM OCT; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	2	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1730	1731		10.1016/S0140-6736(05)76718-0	http://dx.doi.org/10.1016/S0140-6736(05)76718-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568599				2023-01-03	WOS:000083652800056
J	Collier, AC; Kalish, LA; Busch, MP; Gernsheimer, T; Assmann, SF; Lane, TA; Asmuth, DM; Lederman, MM; Murphy, EL; Kumar, P; Kelley, M; Flanigan, TP; McMahon, DK; Sacks, HS; Kennedy, MS; Holland, PV				Collier, AC; Kalish, LA; Busch, MP; Gernsheimer, T; Assmann, SF; Lane, TA; Asmuth, DM; Lederman, MM; Murphy, EL; Kumar, P; Kelley, M; Flanigan, TP; McMahon, DK; Sacks, HS; Kennedy, MS; Holland, PV		Viral Activation Transfusion Study	Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection - The viral activation transfusion study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIPLE CYTOMEGALOVIRUS STRAINS; RECOMBINANT-HUMAN-ERYTHROPOIETIN; WHOLE-BLOOD; HIV-INFECTION; COMPONENTS; REDUCTION; TYPE-1; ALLOIMMUNIZATION; IMMUNOMODULATION; QUANTITATION	Context Allogeneic blood transfusions have immunomodulatory effects and have been associated with activation of human immunodeficiency virus (HIV) and cytomegalovirus (CMV) in vitro and of HIV in small pilot studies. Retrospective studies suggest that transfusions adversely affect the clinical course of HIV. Data in selected non-HIV-infected patients requiring blood transfusion have suggested clinical benefit with leukocyte-reduced red blood cells (RBCs). Objective To compare the effects of leukoreduced and unmodified RBC transfusions on survival, complications of acquired immunodeficiency syndrome, and relevant laboratory markers in HIV-infected patients. Design and Setting Double-blind randomized controlled trial conducted in 11 US academic medical centers from July 1995 through June 1999, with a median follow-up of 12 months (24 months in survivors). Patients A total of 531 persons infected with HIV and CMV, aged 14 years or older, who required transfusions for anemia; 259 received leukoreduced transfusions and 262 received unmodified transfusions (10 did not receive the planned transfusion). Main Outcome Measures Survival and change in plasma HIV RNA level 7 days after transfusion, compared by type of transfusion. Results At entry, the groups were similar in demographic, clinical, and relevant laboratory characteristics. A total of 3864 RBC units were transfused. Two hundred eighty-nine deaths occurred (151 with leukoreduced transfusion; 138 with unmodified transfusion); median survival was 13.0 and 20.5 months, respectively (relative hazard [RH], 1.20; 95% confidence interval [CI], 0.95-1.51; log-rank P = .12). Analyses adjusted for prognostic factors suggested possible worse survival with leukoreduction (RH, 1.35; 95% CI, 1.06-1.72). There was no difference in time to new opportunistic event/death or frequency of transfusion reactions. No changes in plasma HIV RNA level were seen in either group at days 7, 14, 21, or 28, even in patients not taking antiretroviral drugs. There were no differences in trends between groups in CMV DNA, CD4 cell counts, activated (CD38% or human leukocyte antigen-DR) CD8 cell counts, or plasma cytokine levels. Conclusions We found no evidence of HIV, CMV, or cytokine activation following blood transfusion in patients with advanced HIV infection, Leukoreduction provided no clinical benefit in these patients. These data demonstrate the importance of conducting controlled studies of effects of leukoreduction in different patient populations, since smaller studies in other patient populations have suggested leukoreduction may be beneficial.	Univ Washington, Sch Med, Seattle, WA USA; New England Res Inst, Watertown, MA 02172 USA; Blood Ctr Pacific, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Puget Sound Blood Ctr, Seattle, WA 98104 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Texas, Sch Med, Galveston, TX 77555 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Georgetown Univ, Sch Med, Washington, DC USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Mt Sinai Sch Med, New York, NY USA; Ohio State Univ, Med Ctr, Columbus, OH 43210 USA; Sacramento Med Fdn Blood Ctr, Sacramento, CA USA	University of Washington; University of Washington Seattle; HealthCore, Inc; University of California System; University of California San Francisco; Puget Sound Blood Center; University of California System; University of California San Diego; University of Texas System; University of Texas Medical Branch Galveston; Case Western Reserve University; Georgetown University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at Mount Sinai; University System of Ohio; Ohio State University	Collier, AC (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359929, Seattle, WA 98104 USA.	acollier@u.washington.edu		Asmuth, David/0000-0003-0916-7950	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB057116, N01HB057115, N01HB057126, N01HB057117, N01HB057118, N01HB057123, N01HB057119, N01HB057124, N01HB057125, N01HB057120, N01HB057127, N01HB057121, N01HB057122] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [N01-HB-57127, N01-HB-57124, N01-HB-57118, N01-HB-57116, N01-HB-57115, N01-HB-57117, N01-HB-57122, N01-HB-57121, N01-HB-57125, N01-HB-57120, N01-HB-57119, N01-HB-57126, N01-HB-57123] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Association of Blood Banks, 1998, AABB NEWS BRIEFS, V20, P16; AuBuchon JP, 1997, ANN INTERN MED, V127, P904, DOI 10.7326/0003-4819-127-10-199711150-00009; Baldanti F, 1998, ARCH VIROL, V143, P1701, DOI 10.1007/s007050050410; BLAJCHMAN MA, 1993, BLOOD, V81, P1880; Blajchman MA, 1999, TRANSFUSION, V39, P665, DOI 10.1046/j.1537-2995.1999.39070665.x; BLATT SP, 1993, JAMA-J AM MED ASSOC, V269, P622, DOI 10.1001/jama.269.5.622; BLUMBERG N, 1983, VOX SANG, V44, P212, DOI 10.1111/j.1423-0410.1983.tb01886.x; Bordin JO, 1999, TRANSFUSION, V39, P718, DOI 10.1046/j.1537-2995.1999.39070718.x; BORDIN JO, 1994, BLOOD, V84, P1703; BOWDEN RA, 1995, BLOOD, V86, P3598, DOI 10.1182/blood.V86.9.3598.bloodjournal8693598; BRANTLEY SG, 1988, TRANSFUSION, V28, P463, DOI 10.1046/j.1537-2995.1988.28588337338.x; BUSCH MP, 1992, BLOOD, V80, P2128; Busch MP, 1996, TRANSFUSION, V36, P854, DOI 10.1046/j.1537-2995.1996.361097017169.x; Carpenter C, 1998, ANN INTERN MED, V128, P1057, DOI 10.7326/0003-4819-128-12_Part_2-199806151-00002; *CDCP, 1993, MMWR-MORBID MORTAL W, V417, P1; CHEUNG KS, 1977, J INFECT DIS, V135, P841, DOI 10.1093/infdis/135.5.841; Chin-Yee I, 1998, TRANSFUSION MED, V8, P49; Coyle TE, 1997, MED CLIN N AM, V81, P449, DOI 10.1016/S0025-7125(05)70526-5; DEGRAANHENTZEN YCE, 1989, TRANSFUSION, V29, P757; Dzik S, 2000, TRANSFUS MED REV, V14, P34, DOI 10.1016/S0887-7963(00)80114-5; DZIK WH, 1994, TRANSFUSION, V34, P1007, DOI 10.1046/j.1537-2995.1994.341195065024.x; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; EIZURU Y, 1990, INTERVIROLOGY, V31, P355, DOI 10.1159/000150172; Fiebig E, 2000, TRANSFUSION, V40, P761, DOI 10.1046/j.1537-2995.2000.40070761.x; Fiebig EW, 1997, CYTOMETRY, V29, P340, DOI 10.1002/(SICI)1097-0320(19971201)29:4<340::AID-CYTO11>3.0.CO;2-U; Frabetti F, 1998, TRANSFUSION, V38, P1082, DOI 10.1046/j.1537-2995.1998.38111299056320.x; GATENBY PA, 1993, AM J REPROD IMMUNOL, V29, P88, DOI 10.1111/j.1600-0897.1993.tb00571.x; GEORGE CD, 1986, AM J SURG, V152, P329, DOI 10.1016/0002-9610(86)90269-2; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; Groopman JE, 1997, SEMIN HEMATOL, V34, P27; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HENRY DH, 1992, ANN INTERN MED, V117, P739, DOI 10.7326/0003-4819-117-9-739; HILLYER CD, 1994, TRANSFUSION, V34, P929, DOI 10.1046/j.1537-2995.1994.341095026982.x; Hillyer CD, 1999, TRANSFUS MED REV, V13, P1, DOI 10.1016/S0887-7963(99)80084-4; Houbiers JG, 1997, TRANSFUSION, V37, P126, DOI 10.1046/j.1537-2995.1997.37297203513.x; Hyllner M, 1997, TRANSFUSION, V37, P264, DOI 10.1046/j.1537-2995.1997.37397240207.x; Jacobsen N, 1996, VOX SANG, V70, P185; Jensen L S, 1998, Curr Opin Hematol, V5, P376, DOI 10.1097/00062752-199811000-00004; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; KARNOFSK.DA, 1965, CANCER, V18, P1517, DOI 10.1002/1097-0142(196512)18:12<1517::AID-CNCR2820181202>3.0.CO;2-#; Kirkley SA, 1998, TRANSFUSION MED, V8, P195; KLEIN HG, 1996, CLIN PRACTICE TRANSF, P59; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Koval KJ, 1997, J ORTHOP TRAUMA, V11, P260, DOI 10.1097/00005131-199705000-00004; Kreuzer KA, 1997, ANN HEMATOL, V75, P179, DOI 10.1007/s002770050340; Kristiansson M, 1996, ACTA ANAESTH SCAND, V40, P496, DOI 10.1111/j.1399-6576.1996.tb04475.x; Larsson S, 1998, TRANSFUSION, V38, P271, DOI 10.1046/j.1537-2995.1998.38398222871.x; Lederman MM, 2000, AIDS, V14, P951, DOI 10.1097/00002030-200005260-00006; LEE TH, 1994, TRANSFUSION, V34, P986, DOI 10.1046/j.1537-2995.1994.341195065038.x; Lee TH, 1998, TRANSFUSION, V38, P262, DOI 10.1046/j.1537-2995.1998.38398222870.x; Long CM, 1998, J CLIN MICROBIOL, V36, P2434, DOI 10.1128/JCM.36.9.2434-2438.1998; McFarland J, 1997, NEW ENGL J MED, V337, P1861; MINCHEFF MS, 1993, VOX SANG, V65, P18, DOI 10.1111/j.1423-0410.1993.tb04519.x; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Moore RD, 1998, J ACQ IMMUN DEF SYND, V19, P29, DOI 10.1097/00042560-199809010-00004; Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178; Mudido PM, 1996, TRANSFUSION, V36, P860, DOI 10.1046/j.1537-2995.1996.361097017170.x; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Napier A, 1998, TRANSFUSION MED, V8, P59; OLDING LB, 1975, J EXP MED, V141, P561, DOI 10.1084/jem.141.3.561; OPELZ G, 1973, TRANSPLANT P, V5, P253; Opelz G, 1997, TRANSPLANTATION, V63, P964, DOI 10.1097/00007890-199704150-00010; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patton LL, 1999, ORAL SURG ORAL MED O, V88, P561, DOI 10.1016/S1079-2104(99)70086-7; Pellegrin I, 1999, J CLIN MICROBIOL, V37, P3124, DOI 10.1128/JCM.37.10.3124-3132.1999; PETERS WR, 1989, DIS COLON RECTUM, V32, P749, DOI 10.1007/BF02562122; PHAIR JP, 1993, ARCH INTERN MED, V153, P2669, DOI 10.1001/archinte.153.23.2669; POPOVSKY MA, 1995, TRANSFUSION, V35, P612, DOI 10.1046/j.1537-2995.1995.35795357887.x; PRINCE HE, 1986, TRANSPLANTATION, V41, P235, DOI 10.1097/00007890-198602000-00019; SCHECHTER GP, 1972, NEW ENGL J MED, V287, P1169, DOI 10.1056/NEJM197212072872303; SLOAND E, 1994, TRANSFUSION, V34, P48, DOI 10.1046/j.1537-2995.1994.34194098603.x; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; SPECTOR SA, 1984, J INFECT DIS, V150, P953, DOI 10.1093/infdis/150.6.953; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; VAMVAKAS E, 1993, TRANSFUSION, V33, P111, DOI 10.1046/j.1537-2995.1993.33293158041.x; Vamvakas EC, 1998, TRANSFUS MED REV, V12, P258, DOI 10.1016/S0887-7963(98)80002-3; Vamvakas EC, 1996, TRANSFUSION, V36, P175, DOI 10.1046/j.1537-2995.1996.36296181932.x; Vamvakas EC, 2000, TRANSFUS MED REV, V14, P137, DOI 10.1016/S0887-7963(00)80004-8; Wang YF, 1999, NAT MED, V5, P1004, DOI 10.1038/12440; Weisbach V, 1999, VOX SANG, V76, P100; WILLIAMS JG, 1989, LANCET, V2, P1524; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	83	71	72	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2001	285	12					1592	1601		10.1001/jama.285.12.1592	http://dx.doi.org/10.1001/jama.285.12.1592			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	413HH	11268267	Bronze			2023-01-03	WOS:000167606600026
J	Andrews, GR				Andrews, GR			Care of older people - Promoting health and function in an ageing population	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; LIFE-STYLE; RANDOMIZED TRIAL; COLLEGE ALUMNI; EXERCISE; MORBIDITY; MORTALITY; STRENGTH; DISEASE; MUSCLE		Flinders Univ S Australia, Ctr Aging Studies, Bedford Pk, SA 5042, Australia	Flinders University South Australia	Andrews, GR (corresponding author), Flinders Univ S Australia, Ctr Aging Studies, Sci Pk, Bedford Pk, SA 5042, Australia.							ABDELLAH FG, 1988, SURG GEN WORKSH HLTH; Andersen RE, 1999, JAMA-J AM MED ASSOC, V281, P335, DOI 10.1001/jama.281.4.335; BLAIR SN, 1985, PUBLIC HEALTH REP, V100, P172; *CAN MIN SUPPL SER, 1994, STRAT POP HLTH INV H; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRISCH RE, 1986, DIABETES, V35, P1101, DOI 10.2337/diabetes.35.10.1101; GINN J, 1997, RES OLDER PEOPLES HL; KOHL HW, 1988, SPORTS MED, V6, P222, DOI 10.2165/00007256-198806040-00004; Malbut-Shennan K, 1999, CORONARY ARTERY DIS, V10, P37; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCMURDO MET, 1993, AGE AGEING, V22, P11, DOI 10.1093/ageing/22.1.11; McMurdo MET, 1999, BRIT J SPORT MED, V33, P295, DOI 10.1136/bjsm.33.5.295; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Richmond DE, 1996, NEW ZEAL MED J, V109, P122; *ROYAL COMM LONG T, 1999, ESP OLD AG LONG TERM; RUUSKANEN JM, 1995, AGE AGEING, V24, P292, DOI 10.1093/ageing/24.4.292; Sayer AA, 1998, AGE AGEING, V27, P579, DOI 10.1093/ageing/27.5.579; SPSS Inc, 2006, HLTH ED J, DOI DOI 10.1177/001789699705600102; TAYLOR CB, 1985, PUBLIC HEALTH REP, V100, P195; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; *WHO, 1998, WORLD HLTH REP LIF 2	29	54	54	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 24	2001	322	7288					728	729		10.1136/bmj.322.7288.728	http://dx.doi.org/10.1136/bmj.322.7288.728			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	416GB	11264216	Green Published			2023-01-03	WOS:000167771000031
J	Kern, KB; Halperin, HR; Field, J				Kern, KB; Halperin, HR; Field, J			New guidelines for cardiopulmonary resuscitation and emergency cardiac care - Changes in the management of cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPRESSION-DECOMPRESSION RESUSCITATION; TRIAL		Amer Heart Assoc, Adv Cardiac Life Support Subcomm, Dallas, TX USA; Univ Arizona, Sarver Heart Ctr, Cardiol Sect, Coll Med, Tucson, AZ 85724 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Penn State Univ, Coll Med, Hershey, PA USA	University of Arizona; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kern, KB (corresponding author), Univ Arizona, Sarver Heart Ctr, Cardiol Sect, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	kernk@u.arizona.edu						[Anonymous], 1986, JAMA-J AM MED ASSOC, V255, P2905; [Anonymous], 1980, JAMA-J AM MED ASSOC, V244, P453; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; KERBER RE, 1992, JAMA-J AM MED ASSOC, V268, P2172; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Plaisance P, 1997, CIRCULATION, V95, P955; Plaisance P, 1999, NEW ENGL J MED, V341, P569, DOI 10.1056/NEJM199908193410804; Plaisance P, 2000, CIRCULATION, V101, P989, DOI 10.1161/01.CIR.101.9.989; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; Standards for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care (ECC), 1974, JAMA-J AM MED ASSOC, V227, P833; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Willerson JT, 2000, CIRCULATION, V102, P1	18	18	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2001	285	10					1267	1269		10.1001/jama.285.10.1267	http://dx.doi.org/10.1001/jama.285.10.1267			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	408QK	11255370				2023-01-03	WOS:000167339000002
J	Lynn, J				Lynn, J			Serving patients who may die soon and their families - The role of hospice and other services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; END; MANAGEMENT; HOUSE	case story of a 47-year-old man with advanced rectal carcinoma illustrates the professional services and care system strategies available to help clinicians serve patients coming to the end of life. For this patient, who understands his prognosis, primary care physician services include (1) prevention and relief of symptoms, (2) assessment of each treatment before and during implementation, (3) ensuring that the patient designates a surrogate decision-maker and makes advance plans, and (4) preparation of patient and family for the time near death. Good care may entail enduring unavoidably difficult times with patients and their families. Enrollment in a hospice program requires that decisionmakers confront the prognosis and their uncertainties about it, consider the desirability of other services, recognize variations among available hospice programs, address financial issues, and weigh the distress of patients and loved ones at being labeled as "dying." Hospice provides competent, continuous, and reasonably comprehensive care, but it has some constraints. Function and symptoms for those living with serious chronic illness at the end of life generally follow 1 of 3 trajectories: (a) a short period of obvious decline at the end, which is typical of cancer; (b) long-term disability, with periodic exacerbations, and unpredictable timing of death, which characterizes dying with chronic organ system failures; or (c) self-care deficits and a slowly dwindling course to death, which usually results from frailty or dementia. Effective and reliable care for persons coming to the end of life will require changes in the organization and financing of care to match these trajectories, as well as compassionate and skillful clinicians.	RAND Corp, Ctr Improve Care Dying, Arlington, VA 22202 USA	RAND Corporation	Lynn, J (corresponding author), RAND Corp, Ctr Improve Care Dying, 1200 S Hayes St, Arlington, VA 22202 USA.							BUCKMAN R, 1993, BREAK BAD NEWS GUIDE; Buckman R, 1998, BREAK BAD NEWS PATIE, P203; Corr C A, 1994, Crit Care Nurs Clin North Am, V6, P545; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; DEPARLE L, 2000, COMMUNICATION   0912; Du Pen SL, 1999, J CLIN ONCOL, V17, P361, DOI 10.1200/JCO.1999.17.1.361; Field MJ, 1997, APPROACHING DEATH IM; FWLER NM, 2000, J PALLIAT MED, V3, P165; Gage B., 2000, IMPORTANT QUESTIONS; GAGE B, 2000, MEDICARES HOSPICE BE; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; *HLTH CAR FIN ADM, 2000, OV MED PROGR; *HLTH CAR FIN ADM, 2000, MED HOSP BEN SPEC CA; *HLTH CAR FIN ADM, 2000, HOSP MAN, pCH4; HOGAN C, 2000, MEDICARE BENEFICIARI; HUSKAMP H, IN PRESS HLTH AFF MI; KIDDER D, 1992, HEALTH SERV RES, V27, P195; Lee W, 1998, GERIATRICS, V53, P62; LEWIN LS, 1995, ANAL COST SAVINGS ME; LORENZ K, 2000, 12 ANN ASS AM AC HOS; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633; Lynn J, 1998, J Palliat Med, V1, P337, DOI 10.1089/jpm.1998.1.337; Lynn J, 2000, Jt Comm J Qual Improv, V26, P254; Lynn J, 1999, J AM GERIATR SOC, V47, P1058, DOI 10.1111/j.1532-5415.1999.tb05227.x; LYNN J, 1999, HDB MORTALS GUIDANCE; LYNN J, 2000, IMPROVING CARE END L; *MED EC CO, 2000, 2000 DRUG TOP RED BO; *MISS DEM PROJ, 2000, MISS DEM PROJ QUAL L; *NAT CTR HLTH STAT, 2000, BIRTHS MARR DIV DEAT; *NAT ELD REF SYST, 2000, COST NURS HOM CAR; *NAT HOSP ORG, 2000, MED GUID DET PROGN S; *NAT HOSP PALL CAR, 2000, FACTS FIG HOSP CAR A; National Health and Medical Research Council and the Australian Research Council, 1999, NAT GAMBL IMP STUD C, P6; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Rich MW, 1999, J CARD FAIL, V5, P64, DOI 10.1016/S1071-9164(99)90026-X; Sachs GA, 2000, JAMA-J AM MED ASSOC, V284, P2423, DOI 10.1001/jama.284.19.2423; SAMUELSON RJ, 1995, DETROIT NEWS    0813; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; *US GEN ACC OFF, 2000, MED BEN US HOSP FEW; WILKINSON A, 1999, J HLTH CARE LAW POLI, V12, P501; WILKINSON AM, 2000, CRITICAL ISSUES AGIN	46	193	196	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					925	932		10.1001/jama.285.7.925	http://dx.doi.org/10.1001/jama.285.7.925			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	402BE	11180736				2023-01-03	WOS:000166965500030
J	Anderson, J; Baum, M; Bero, LA; Chalmers, I; Chapman, S; Deary, IJ; Ebrahim, S; Martyn, SOOLISS; Evans, M; Farrell, M; Greaves, D; Higginson, I; Hippisley-Cox, J; James, B; McKenzie, H; Macaulay, AC; Rabow, M; Smyth, RL; Stores, G; Wolpert, L				Anderson, J; Baum, M; Bero, LA; Chalmers, I; Chapman, S; Deary, IJ; Ebrahim, S; Martyn, SOOLISS; Evans, M; Farrell, M; Greaves, D; Higginson, I; Hippisley-Cox, J; James, B; McKenzie, H; Macaulay, AC; Rabow, M; Smyth, RL; Stores, G; Wolpert, L			Music to be born to, music to die to	BRITISH MEDICAL JOURNAL			English	Editorial Material									Monash Univ, So Healthcare Network, Ctr Clin Effectiveness, Melbourne, Vic, Australia; UCL, London WC1E 6BT, England; Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; UK Cochrane Ctr, Oxford, England; Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland; Univ Bristol, Dept Social Med, Bristol, Avon, England; Natl Addict Ctr, London, England; Kings Coll London, London WC2R 2LS, England; St Christophers Hospice, London, England; Univ Nottingham, Nottingham NG7 2RD, England; Inst Hlth Sector Dev, London, England; McGill Univ, Montreal, PQ H3A 2T5, Canada; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Liverpool, Royal Liverpool Childrens Hosp Alder Hey, Inst Child Hlth, Liverpool, Merseyside, England	Monash University; University of London; University College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cochrane Centre; University of Edinburgh; University of Bristol; University of London; King's College London; University of London; King's College London; University of Nottingham; McGill University; University of California System; University of California San Francisco; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool	Anderson, J (corresponding author), Monash Univ, So Healthcare Network, Ctr Clin Effectiveness, Melbourne, Vic, Australia.		Hippisley-Cox, Julia/AAY-2788-2020; Deary, Ian J/C-6297-2009; Higginson, Irene J/C-7309-2012	Hippisley-Cox, Julia/0000-0002-2479-7283; Deary, Ian J/0000-0002-1733-263X; Higginson, Irene J/0000-0002-3687-1313					0	1	1	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2000	321	7276					1577	1579		10.1136/bmj.321.7276.1577	http://dx.doi.org/10.1136/bmj.321.7276.1577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387RA	11124186	Green Published			2023-01-03	WOS:000166134500023
J	Lori, F; Lewis, MG; Xu, JQ; Varga, G; Zinn, DE; Crabbs, C; Wagner, W; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Tinelli, C; Lisziewicz, J				Lori, F; Lewis, MG; Xu, JQ; Varga, G; Zinn, DE; Crabbs, C; Wagner, W; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Tinelli, C; Lisziewicz, J			Control of SIV rebound through structured treatment interruptions during early infection	SCIENCE			English	Article							VIRAL LOAD; HIV-1; DISCONTINUATION; SUPPRESSION; RESPONSES; LYMPHOCYTES; INHIBITOR; VIREMIA; PLASMA	In a randomized controlled trial with acute simian immunodeficiency virus (SIV)-infected macaques, both highly active antiretroviral therapy (HAART) and HAART with fixed-schedule structured treatment interruption (STI-HAART; alternating 3 weeks on and 3 weeks off therapy) suppressed viral load. In the STI-HAART group, T cell virus-specific immune response (VIR) and control of viral rebound increased concurrently during subsequent interruptions. In contrast, VIR did not increase and SIV rebounded after permanent treatment withdrawal in all animals on continuous HAART. Fixed-schedule STI-HAART appears to be an effective alternative to continuous HAART for the early treatment of retroviral infection.	Res Inst Genet & Human therapy, Washington, DC 20007 USA; So Res Inst, Frederick, MD 21701 USA; IRCCS Policlin S Matteo, Pavia, Italy	IRCCS Fondazione San Matteo	Lisziewicz, J (corresponding author), Res Inst Genet & Human therapy, Med Dent Bldg SW307,3900 Reservoir Rd NW, Washington, DC 20007 USA.	right@gunet.georgetown.edu		Tinelli, Carmine/0000-0002-8749-1978; Lisziewicz, Julianna/0000-0002-3349-4495				CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; deJong MD, 1997, AIDS, V11, pF79, DOI 10.1097/00002030-199711000-00002; FAGARD C, 2000, 7 C RETR OPP INF SAN; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; Jubault V, 1998, AIDS, V12, P2358; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; MILLER V, 1999, ROM STAT ART C TREAT; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenwirth B, 2000, J VIROL, V74, P1704, DOI 10.1128/JVI.74.4.1704-1711.2000; Staszewski S, 1998, AIDS, V12, P2360; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197	21	145	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1591	1593		10.1126/science.290.5496.1591	http://dx.doi.org/10.1126/science.290.5496.1591			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090360				2023-01-03	WOS:000165446200055
J	Gemperli, MP				Gemperli, MP			Rethinking the role of the learned intermediary: The effect of direct-to-consumer advertising on litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Gemperli, MP (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							HUTTON MB, 1996, TRIAL, V32, P74; Terzian TV, 1999, AM J LAW MED, V25, P149	2	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2241	2241		10.1001/jama.284.17.2241	http://dx.doi.org/10.1001/jama.284.17.2241			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367GD	11056600	hybrid			2023-01-03	WOS:000090052600036
J	Keller, SM; Adak, S; Wagner, H; Herskovic, A; Komaki, R; Brooks, BJ; Perry, MC; Livingston, RB; Johnson, DH				Keller, SM; Adak, S; Wagner, H; Herskovic, A; Komaki, R; Brooks, BJ; Perry, MC; Livingston, RB; Johnson, DH		Eastern Cooperative Oncology Grp	A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEMOTHERAPY; RADIOTHERAPY; CARCINOMA; CISPLATIN; TABLES	Background: We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non-small-cell lung cancer. Methods: After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per square meter of body-surface area intravenously on day 1) and etoposide (120 mg per square meter intravenously on days 1, 2, and 3) administered concurrently with radiotherapy (a total of 50.4 Gy, given in 28 daily fractions) or radiotherapy alone (a total of 50.4 Gy, given in 28 daily fractions). Results: Of the 488 patients who were enrolled in the study, 242 were assigned to receive radiotherapy alone and 246 were assigned to receive chemotherapy and radiotherapy. The median duration of follow-up was 44 months. Treatment-associated mortality was 1.2 percent in the group given radiotherapy alone and 1.6 percent in the group given chemotherapy and radiotherapy. The median survival was 39 months in the group given radiotherapy and 38 months in the group given chemotherapy and radiotherapy (P= 0.56 by the log-rank test). The relative likelihood of survival among patients assigned to receive chemotherapy and radiotherapy, as compared with those assigned to receive radiotherapy alone, was 0.93 (95 percent confidence interval, 0.74 to 1.18). Intrathoracic disease recurred within the radiation field in 30 of 234 patients (13 percent) in the group given radiotherapy and in 28 of 236 patients (12 percent) in the group given chemotherapy and radiotherapy (P=0.84); data on recurrence were not available for 18 patients. Conclusions: As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.	Beth Israel Deaconess Med Ctr, Dept Surg, New York, NY 10003 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA; Oakwood Hosp, Dept Radiat Oncol, Detroit, MI USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Alton Ochsner Med Fdn & Ochsner Clin, Div Med Oncol, Baton Rouge, LA USA; Univ Missouri, Ellis Fischer Canc Ctr, Div Hematol & Med Oncol, Columbia, MO USA; Univ Washington, Div Med Oncol, Seattle, WA 98195 USA; Vanderbilt Univ, Div Med Oncol, Nashville, TN USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; H Lee Moffitt Cancer Center & Research Institute; Beaumont Health; University of Texas System; UTMD Anderson Cancer Center; Ochsner Health System; University of Missouri System; University of Missouri Columbia; University of Washington; University of Washington Seattle; Vanderbilt University	Keller, SM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, 1st Ave & 16th St, New York, NY 10003 USA.	skeller@bethisraelny.org	Johnson, David H./A-7437-2009		NATIONAL CANCER INSTITUTE [U10CA031946, U10CA023318] Funding Source: NIH RePORTER; NCI NIH HHS [CA31946, CA120046, CA23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI W, 1995, BRIT MED J, V311, P899; BELANI CP, 1998, P AN M AM SOC CLIN, V17, pA455; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; DAUTZENBERG B, 1995, CANCER, V76, P779, DOI 10.1002/1097-0142(19950901)76:5<779::AID-CNCR2820760511>3.0.CO;2-O; DHINGRA HM, 1985, J CLIN ONCOL, V3, P176, DOI 10.1200/JCO.1985.3.2.176; GANDARA DR, 1989, J NATL CANCER I, V81, P790, DOI 10.1093/jnci/81.10.790; HOLMES EC, 1986, J CLIN ONCOL, V4, P710, DOI 10.1200/JCO.1986.4.5.710; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLER SM, 1988, TECHNIQUE MEDIASTINA; LAD T, 1988, J CLIN ONCOL, V6, P9; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mayer, 1998, CHEST, V113, P564; Mayer R, 1997, CHEST, V112, P954, DOI 10.1378/chest.112.4.954; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; *STUD GROUP ADJ CH, 1995, EUR J SURG ONCOL, V21, P69; TISI GM, 1983, AM REV RESPIR DIS, V127, P659, DOI 10.1164/arrd.1983.127.5.659; Wada H, 1996, J CLIN ONCOL, V14, P1048, DOI 10.1200/JCO.1996.14.4.1048; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; XU GC, 1998, CHINESE J ONCOL, V20, P228	23	334	352	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1217	1222		10.1056/NEJM200010263431703	http://dx.doi.org/10.1056/NEJM200010263431703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071672				2023-01-03	WOS:000090014100003
J	Demakis, JG; Beauchamp, C; Cull, WL; Denwood, R; Eisen, SA; Lofgren, R; Nichol, K; Woolliscroft, J; Henderson, WG				Demakis, JG; Beauchamp, C; Cull, WL; Denwood, R; Eisen, SA; Lofgren, R; Nichol, K; Woolliscroft, J; Henderson, WG		Dept Vet Affairs Computer Rem	Improving residents' compliance with standards of ambulatory care - Results from the VA cooperative study on computerized reminders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTIVE CARE; CONTROLLED TRIAL; PHYSICIAN PERFORMANCE; INFLUENZA VACCINATION; PATIENT REMINDERS; BLOOD-PRESSURE; PROTOCOL; FEEDBACK; RESPOND; WORK	Context Computerized systems to remind physicians to provide appropriate care have not been widely evaluated in large numbers of patients in multiple clinical settings. Objective To examine whether a computerized reminder system operating in multiple Veterans Affairs (VA) ambulatory care clinics improves resident physician compliance with standards of ambulatory care. Design, Setting, and Participants A total of 275 resident physicians at 12 VA medical centers were randomly assigned in firms or half-day clinic blocks to either a reminder group (n=132) or a control group (n=143), During a 17-month study period (January 31, 1995-June 30, 1996), the residents cared for 12989 unique patients for whom at least 1 of the studied standards of care (SOC) was applicable. Main Outcome Measures Compliance with 13 SOC, tracked using hospital databases and encounter forms completed by residents, compared between residents in the reminder group vs those in the control group. Results Measuring compliance as the proportion of patients in compliance with all applicable SOC by their last visit during the study period, the reminder group had statistically significantly higher rates of compliance than the control group for all standards combined (58.8% vs 53.5%; odds ratio [OR], 1.24; 95% confidence interval [CI], 1.08-1.42; P=.002) and for 5 of the 13 standards examined individually. Measuring compliance as the proportion of all visits for which care was indicated in which residents provided proper care, the reminder group also had statistically significantly higher rates of compliance than the control group for all standards combined (17.9% vs 12.2%; OR, 1.57; 95% CI, 1.45-1.71; P<.001) and for 9 of the 13 standards examined individually. The benefit of reminders, however, declined throughout the course of the study, even though the reminders remained active. Conclusions Our data indicate that reminder systems installed at multiple sites can improve residents' compliance to multiple SOC. The benefits of such systems, however, appear to deteriorate over time. Future research needs to explore methods to better sustain the benefits of reminders.	VA Hlth Serv Res & Dev Serv, Washington, DC USA; Durham VAMC, Dept Ambulatory Care, Durham, NC USA; Hines VA Cooperat Studies Program Coordinating Ct, Hines, IL USA; St Louis VAMC, Dept Rheumatol, St Louis, MO USA; Med Coll Wisconsin, Dept Gen Internal Med, Milwaukee, WI 53226 USA; Minneapolis VAMC, Dept Internal Med, Minneapolis, MN USA; Univ Michigan, Dept Gen Med, Ann Arbor, MI 48109 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Michigan System; University of Michigan	Henderson, WG (corresponding author), Edward Hines Vet Adm Hosp, 151K,POB 5000, Hines, IL 60141 USA.			Eisen, Seth/0000-0001-7746-6624				BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BARNETT GO, 1978, MED CARE, V16, P1962; BECKER DM, 1989, AM J PREV MED, V5, P353, DOI 10.1016/S0749-3797(18)31056-0; Davis D, 1998, INT J PSYCHIAT MED, V28, P21, DOI 10.2190/UA3R-JX9W-MHR5-RC81; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; LANDIS S, 1992, NC MED J, V53, P578; LIPSITZ SR, 1994, BIOMETRICS, V50, P270, DOI 10.2307/2533218; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Sicotte C, 1996, J BEHAV MED, V19, P367, DOI 10.1007/BF01904763; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; Wensing M, 1994, Int J Qual Health Care, V6, P115	26	157	159	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1411	1416		10.1001/jama.284.11.1411	http://dx.doi.org/10.1001/jama.284.11.1411			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989404	Bronze			2023-01-03	WOS:000089242500036
J	Brott, T; Bogousslavsky, J				Brott, T; Bogousslavsky, J			Drug therapy - Treatment of acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; AMERICAN-HEART-ASSOCIATION; EARLY INTRAVENOUS THROMBOLYSIS; RANDOMIZED CONTROLLED TRIAL; HEALTH-CARE PROFESSIONALS; CAROTID TERRITORY STROKE; ACUTE HEMISPHERIC STROKE; PERFUSION-WEIGHTED MRI; SPECIAL WRITING GROUP		Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland	Mayo Clinic; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Brott, T (corresponding author), Mayo Clin, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	brott.thomas@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030678] Funding Source: NIH RePORTER; NINDS NIH HHS [2RO1 NS3067806 EDC-2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; Adams HP, 1999, NEUROLOGY, V53, P122, DOI 10.1212/WNL.53.1.122; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; ADAMS HP, 1998, CEREBROVASC DIS, P1430; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 1999, STROKE, V30, P1604, DOI 10.1161/01.STR.30.8.1604; *AM HEART ASS, 1997, HEART STROK STAT UPD; [Anonymous], 1998, JAMA, V279, P1265; Asplund K, 1996, CEREBROVASC DIS, V6, P3, DOI 10.1159/000107983; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; Atkinson RP, 1998, CEREBROVASC DIS, V8, P23, DOI 10.1159/000047500; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BARNWELL SL, 1994, AM J NEURORADIOL, V15, P1817; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; Becker KJ, 1996, AM J NEURORADIOL, V17, P255; Bednar MM, 1999, STROKE, V30, P887, DOI 10.1161/01.STR.30.4.887; Bendszus M, 1998, NEURORADIOLOGY, V40, P54, DOI 10.1007/s002340050540; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BOCK RW, 1996, SURG CEREBROVASCULAR, P48; Bogousslavsky J, 1997, CEREBROVASC DIS, V7, P113; Bogousslavsky J, 1998, CEREBROVASC DIS, V8, P59; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; BRATINA P, 1995, STROKE, V26, P409, DOI 10.1161/01.STR.26.3.409; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brott T, 1998, STROKE, V29, P1504, DOI 10.1161/01.STR.29.8.1504; Brott T, 1997, STROKE, V28, P1530, DOI 10.1161/01.STR.28.8.1530; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; BROTT T, 1991, THROMBOLYTIC THERAPY, P196; Buchan AM, 2000, NEUROLOGY, V54, P679, DOI 10.1212/WNL.54.3.679; CANDELISE L, 1995, LANCET, V346, P1509; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chamorro A, 1999, ARCH NEUROL-CHICAGO, V56, P1098, DOI 10.1001/archneur.56.9.1098; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Cross DT, 1997, AM J NEURORADIOL, V18, P1221; Culebras A, 1997, STROKE, V28, P1480, DOI 10.1161/01.STR.28.7.1480; Darby DG, 1999, STROKE, V30, P2043, DOI 10.1161/01.STR.30.10.2043; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; Devuyst G, 1999, CURR OPIN NEUROL, V12, P73, DOI 10.1097/00019052-199902000-00012; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; DUVUYST G, 1997, ACUTE STOKE TREATMEN, P65; EINHAUPL KM, 1991, LANCET, V338, P597, DOI 10.1016/0140-6736(91)90607-Q; Elmstahl S, 1999, DYSPHAGIA, V14, P61, DOI 10.1007/PL00009588; Endo S, 1998, AM J NEURORADIOL, V19, P1169; EZURA M, 1992, SURG NEUROL, V38, P353, DOI 10.1016/0090-3019(92)90021-E; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; Firlik AD, 1998, J NEUROSURG, V89, P243, DOI 10.3171/jns.1998.89.2.0243; Fisher M, 1998, JAMA-J AM MED ASSOC, V279, P1298, DOI 10.1001/jama.279.16.1298; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Grau AJ, 1999, ARCH NEUROL-CHICAGO, V56, P1159, DOI 10.1001/archneur.56.9.1159; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; GRESHAM GE, 1995, CLIN PRACTICE GUIDEL, V16; GRESHAM GE, 1998, STROKE PATHOPHYSIOLO, P1389; Grond M, 1998, STROKE, V29, P1544, DOI 10.1161/01.STR.29.8.1544; Grond M, 1998, ARCH NEUROL-CHICAGO, V55, P466, DOI 10.1001/archneur.55.4.466; Grotta J, 1997, NEW ENGL J MED, V337, P1310; Grotta JC, 1998, STROKE, V29, P429, DOI 10.1161/01.STR.29.2.429; GUBITZ G, 1999, COCHRANE REV, V2; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Heiss WD, 1999, STROKE, V30, P1486, DOI 10.1161/01.STR.30.7.1486; Higashida R T, 1994, J Endovasc Surg, V1, P4; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOMMEL M, 1998, CEREBROVASC DIS, V8, pA64; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Jahan R, 1999, AM J NEURORADIOL, V20, P1291; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.0.CO;2-Y; KOROGI Y, 1994, RADIOLOGY, V193, P187, DOI 10.1148/radiology.193.1.8090890; KOTHARI R, 1995, STROKE, V26, P937, DOI 10.1161/01.STR.26.6.937; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; KRIEGER D, 1992, J NEUROL, V239, P183, DOI 10.1007/BF00839136; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Lansberg MG, 1999, STROKE, V30, P678, DOI 10.1161/01.STR.30.3.678; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Mann G, 1999, STROKE, V30, P744, DOI 10.1161/01.STR.30.4.744; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; Marks MP, 1999, NEUROLOGY, V52, P1792, DOI 10.1212/WNL.52.9.1792; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; MCDOWELL FH, 1993, J STROKE CEREBROVASC, V3, P133; McNamara RL, 1997, ANN INTERN MED, V127, P775, DOI 10.7326/0003-4819-127-9-199711010-00001; Mitchell PJ, 1997, CEREBROVASC DIS, V7, P94, DOI 10.1159/000108174; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Pathansali R, 1998, J HUM HYPERTENS, V12, P73, DOI 10.1038/sj.jhh.1000569; PELZ DM, 1986, RADIOLOGY, V160, P369, DOI 10.1148/radiology.160.2.3726115; *PER CENTR NERV SY, 1996, PER CENTR NERV SYST; Pohjasvaara T, 1998, STROKE, V29, P75, DOI 10.1161/01.STR.29.1.75; Porteous G H, 1999, Prehosp Emerg Care, V3, P211; POWERS WJ, 1993, NEUROLOGY, V43, P461, DOI 10.1212/WNL.43.3_Part_1.461; Reith J, 1997, STROKE, V28, P1585, DOI 10.1161/01.STR.28.8.1585; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; ROPPER AH, 1988, NEUROLOGICAL NEUROSU, P23; Rosenblum WI, 1997, J NEUROTRAUM, V14, P313, DOI 10.1089/neu.1997.14.313; Sandercock P, 1997, LANCET, V349, P1569; SASAKI O, 1995, NEUROSURGERY, V36, P246, DOI 10.1227/00006123-199502000-00002; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; SHERMAN DG, 1996, SURG CEREBROVASCULAR, P43; Stegmayr B, 1999, STROKE, V30, P709, DOI 10.1161/01.STR.30.4.709; Strobel CJ, 1999, ENVIRON MONIT ASSESS, V56, P1, DOI 10.1023/A:1005911822444; Suarez JI, 1999, STROKE, V30, P2094, DOI 10.1161/01.STR.30.10.2094; *SUBC ADV CARD LIF, 1997, ADV CARDIAC LIFE SUP; Tanne D, 1999, NEUROLOGY, V53, P424, DOI 10.1212/WNL.53.2.424; Thorvaldsen P, 1997, STROKE, V28, P500, DOI 10.1161/01.STR.28.3.500; TOMSICK T, 1992, AM J NEURORADIOL, V13, P257; Toni D, 2000, NEUROLOGY, V54, P684, DOI 10.1212/WNL.54.3.684; Trouillas P, 1996, STROKE, V27, P882, DOI 10.1161/01.STR.27.5.882; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; Ueda T, 1999, STROKE, V30, P2360, DOI 10.1161/01.STR.30.11.2360; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; Wang DZ, 2000, STROKE, V31, P77, DOI 10.1161/01.STR.31.1.77; Wildermuth S, 1998, STROKE, V29, P935, DOI 10.1161/01.STR.29.5.935; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; Zivin JA, 1998, NEUROLOGY, V50, P599, DOI 10.1212/WNL.50.3.599	143	230	262	5	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					710	722		10.1056/NEJM200009073431007	http://dx.doi.org/10.1056/NEJM200009073431007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974136				2023-01-03	WOS:000089100500007
J	Glynn, SA; Kleinman, SH; Schreiber, GB; Busch, MP; Wright, DJ; Smith, JW; Nass, CC; Williams, AE				Glynn, SA; Kleinman, SH; Schreiber, GB; Busch, MP; Wright, DJ; Smith, JW; Nass, CC; Williams, AE		Retrovirus Epidemiology Donor Stud	Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; RISK; HEPATITIS	Context Evaluating trends in blood donor infectious disease rates is essential for monitoring blood supply safety and donor screening effectiveness. Objective To determine changes overtime in blood donor population infection rates of human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis C virus (HCV), and hepatitis B virus (HBV), Design Cross-sectional survey data from the National Heart, Lung, and Blood Institute-sponsored Retrovirus Epidemiology Donor Study. Setting Five blood centers in different regions of the United States. Participants A total of 1.9 million volunteer blood donors with 1 or more nonautologous donations from January 1991 to December 1996. Main Outcome Measures Changes in rates of HIV, HTLV, HCV, and HBV infections were evaluated by comparing yearly prevalence estimates (per 100 000 donations) for first-ti me allogeneic donors and period-specific incidence rates (IRs) (per 100 000 person-years) for repeat allogeneic donors between 1991 and 1996 (for HCV, from about March 1992 to June 1996). Results Prevalence of HIV decreased in first-time donors from 0.030% to 0.015% (P=.006) and HCV prevalence decreased from 0.63% to 0.40% (P<.001). Trends were not statistically significant for the proportion of first-time donors with hepatitis B surface antigen (HBsAg) or HTLV, For repeat donors, IRs did not change significantly, indicating a stable but low level of seroconversion. The overall IRs (95% confidence intervals) per 100 000 person-years were 2.92 (2.26-3.70) for HIV, 1.59 (1.12-2.19) for HTLV, 3.25 (2.36-4.36) for HCV, and an estimated 10.43 (7.99-13.37) for HBV (based on an HBsAg rate of 2.66 [2.04-3.41] with presumed false-positive results considered negative). The HBV IR estimate with presumed false-positive results considered positive (for comparability to previous analyses) was 17.83 (14.60-21.56). Conclusion The decrease in HIV and HCV prevalence rates, combined with the previously documented lower rates of infection in first-time donors compared with the general population, suggests the continued benefit of behavioral risk factor screening.	WESTAT Corp, Rockville, MD 20850 USA; Blood Ctr Pacific, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Blood Syst Inc, Scottsdale, AZ USA; Oklahoma Blood Inst, Oklahoma City, OK USA; Amer Red Cross, Blood Serv Greater Chesapeake & Potomac Reg, Baltimore, MD USA; Amer Red Cross, Holland Lab, Biomed Serv, Rockville, MD USA	Westat; University of California System; University of California San Francisco; Vitalant; American Red Cross; American Red Cross	Glynn, SA (corresponding author), WESTAT Corp, WB 280,1441 W Montgomery Ave, Rockville, MD 20850 USA.	GlynnS1@westat.com			DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097078, N01HB047114] Funding Source: NIH RePORTER	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BASTIAANS MJS, 1982, VOX SANG, V42, P203, DOI 10.1111/j.1423-0410.1982.tb01096.x; BUSCH MP, 1994, BLOOD, V83, P1143; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1992, BLOOD SAFETY CURRENT, P1; BUSCH MP, 1997, APPL MOL BIOL BLOOD, P123; Coleman PJ, 1998, J INFECT DIS, V178, P954, DOI 10.1086/515696; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD R, 1982, VIRAL HEPATITIS, P145; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; KAPLAN JE, 1989, AM FAM PHYSICIAN, V40, P189; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; Kleinman S, 1998, TRANSFUSION, V38, p92S; Kleinman S, 1998, TRANSFUS MED REV, V12, P288, DOI 10.1016/S0887-7963(98)80004-7; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; Kleinman S, 1996, CLIN PRACTICE TRANSF, P245; KLEINMAN SH, 1994, J CLIN MICROBIOL, V32, P603, DOI 10.1128/JCM.32.3.603-607.1994; Korelitz JJ, 1997, TRANSFUSION, V37, P634, DOI 10.1046/j.1537-2995.1997.37697335159.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; *SAS I INC, 1989, SAS STAT US GUID VER, P405; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SNEDECOR GW, 1980, STAT METHODS, P75; Ward J W, 1997, AIDS Clin Rev, P1; Williams AE, 1997, JAMA-J AM MED ASSOC, V277, P967, DOI 10.1001/jama.277.12.967; Wright DJ, 1999, TRANSFUSION, V39, p106S; ZUCK TF, 1988, NEW ENGL J MED, V318, P511, DOI 10.1056/NEJM198802253180809; 1990, MMWR MORB MORTAL WKL, V39, P915	33	194	207	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					229	235		10.1001/jama.284.2.229	http://dx.doi.org/10.1001/jama.284.2.229			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889598	Bronze			2023-01-03	WOS:000087933100029
J	Posas, F; Chambers, JR; Heyman, JA; Hoeffler, JP; de Nadal, E; Arino, J				Posas, F; Chambers, JR; Heyman, JA; Hoeffler, JP; de Nadal, E; Arino, J			The transcriptional response of yeast to saline stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; OSMOTIC-STRESS; PROTEIN PHOSPHATASE; GENE-EXPRESSION; GLYCOGEN-METABOLISM; PLASMA-MEMBRANE; TOLERANCE; PATHWAYS; ATPASE	Adaptation to changes in extracellular salinity is a critical event for cell survival. Genome-wide DNA chip analysis has been used to analyze the transcriptional response of yeast cells to saline stress. About 7% of the genes encoded in the yeast genome are induced more than 5-fold after a mild and brief saline shock (0.4 M NaCl, 10 min). Interestingly, most responsive genes showed a very transient expression pattern, as mRNA levels dramatically declined after 20 min in the presence of stress. A quite similar set of genes increased expression in cells subjected to higher saline concentrations (0.8 M NaCl), although in this case the response was delayed. Therefore, our data show that cells respond to saline stress by inducing the expression of a very large number of genes and suggest that stress adaptation requires regulation of many cellular aspects. The transcriptional induction of most genes that are strongly responsive to salt stress was highly or fully dependent on the presence of the stress-activated mitogen-activated protein kinase Hog1, indicating that the Hog1-mediated signaling pathway plays a key role in global gene regulation under saline stress conditions.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Pompeu Fabra, Dept Ciencies Expt Salut, Cell Signaling Unit, E-08003 Barcelona, Spain; Invitrogen Corp, Carlsbad, CA 92008 USA	Autonomous University of Barcelona; Pompeu Fabra University; Thermo Fisher Scientific	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed V, E-08193 Barcelona, Spain.	J.Arino@cc.uab.es	Arino, Joaquin/D-3756-2011; Posas, Francesc/K-1364-2013; de Nadal, Eulàlia/J-8178-2014	Arino, Joaquin/0000-0002-6774-2987; Posas, Francesc/0000-0002-4164-7076; de Nadal, Eulàlia/0000-0003-0039-5607; Arino Carmona, Joaquin/0000-0002-0390-4270				Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; [Anonymous], [No title captured]; BILSLANDMARCHES.E, 2000, IN PRESS MOL CELL BI; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CLOTET J, 1995, EUR J BIOCHEM, V229, P207, DOI 10.1111/j.1432-1033.1995.tb20457.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hounsa CG, 1998, MICROBIOL-UK, V144, P671, DOI 10.1099/00221287-144-3-671; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Lee JH, 1999, P NATL ACAD SCI USA, V96, P5873, DOI 10.1073/pnas.96.10.5873; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P544; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NARASIMHAN ML, 1991, PLANT PHYSIOL, V97, P562, DOI 10.1104/pp.97.2.562; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nevoigt E, 1997, FEMS MICROBIOL REV, V21, P231, DOI 10.1016/S0168-6445(97)00058-2; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramaswamy NT, 1998, GENETICS, V149, P57; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Winderickx J, 1996, MOL GEN GENET, V252, P470, DOI 10.1007/s004380050252; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; ZHAO S, 1994, GENE, V146, P215, DOI 10.1016/0378-1119(94)90295-X	47	317	336	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17249	17255		10.1074/jbc.M910016199	http://dx.doi.org/10.1074/jbc.M910016199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748181	hybrid			2023-01-03	WOS:000087485000007
J	Cox, PA				Cox, PA			Will tribal knowledge survive the millennium?	SCIENCE			English	Editorial Material									Natl Trop Bot Garden, Kauai, HI 96765 USA		Cox, PA (corresponding author), Natl Trop Bot Garden, POB 340, Kauai, HI 96765 USA.								0	153	168	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					44	45		10.1126/science.287.5450.44	http://dx.doi.org/10.1126/science.287.5450.44			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644221				2023-01-03	WOS:000084578400023
J	Smith, ER; Storch, J				Smith, ER; Storch, J			The adipocyte fatty acid-binding protein binds to membranes by electrostatic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MEMBRANES; COLLISIONAL TRANSFER; CYTOCHROME-C; CARDIOLIPIN; MECHANISM; REVERSIBILITY; PURIFICATION; LIVER; NMR	The adipocyte fatty acid-binding protein (AFABP) is believed to transfer unesterified fatty acids (FA) to phospholipid membranes via a collisional mechanism that involves ionic interactions between lysine residues on the protein surface and phospholipid headgroups, This hypothesis is derived largely from kinetic analysis of FA transfer from AFABP to membranes. In this study, we examined directly the binding of AFABP to large unilamellar vesicles (LUV) of differing phospholipid compositions, AFABP bound LW containing either cardiolipin or phosphatidic acid, and the amount of protein bound depended upon the mol % anionic phospholipid. The K-a for CL or PA in LUV containing 25 mol % of these anionic phospholipids was approximately 2 x 10(3) M-1 No detectable binding occurred when AFABP was mixed with zwitterionic membranes, nor when acetylated AFABP in which surface lysines had been chemically neutralized was mixed with anionic membranes. The binding of AFABP to acidic membranes depended upon the ionic strength of the incubation buffer: greater than or equal to 200 mM NaCl reduced protein-lipid complex formation in parallel with a decrease in the rate of FA transfer from AFABP to negatively charged membranes. It was further found that AFABP, but not acetylated AFABP, prevented cytochrome c, a well characterized peripheral membrane protein, from binding to membranes. These results directly demonstrate that AFABP binds to anionic phospholipid membranes and suggest that, although generally described as a cytosolic protein, AFABP may behave as a peripheral membrane protein to help target fatty acids to and/or from intracellular sites of utilization.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.			Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389, DK09303] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; BERCLAZ T, 1984, BIOCHEMISTRY-US, V23, P4033, DOI 10.1021/bi00313a004; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; FAUCON JF, 1976, BIOCHIM BIOPHYS ACTA, V435, P283; Gericke A, 1997, BIOCHEMISTRY-US, V36, P8311, DOI 10.1021/bi970679s; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang C, 1974, Methods Enzymol, V32, P485; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V269, P10517; Liou HL, 1998, FASEB J, V12, pA514; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NARAYANAN V, 1988, J BIOL CHEM, V263, P8332; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P4896, DOI 10.1021/bi00182a018; POWELL GL, 1985, BIOCHEMISTRY-US, V24, P2902, DOI 10.1021/bi00333a013; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; Sankaram M.B., 1993, NEW COMPREHENSIVE BI, VVolume 25, P127; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TRAPP BD, 1984, J NEUROCHEM, V43, P944, DOI 10.1111/j.1471-4159.1984.tb12828.x; UYEMURA K, 1977, J NEUROCHEM, V29, P61, DOI 10.1111/j.1471-4159.1977.tb03924.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; XU ZH, 1991, J BIOL CHEM, V266, P14367	36	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	1999	274	50					35325	35330		10.1074/jbc.274.50.35325	http://dx.doi.org/10.1074/jbc.274.50.35325			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	264NG	10585398	hybrid			2023-01-03	WOS:000084187900010
J	Grande, GE; Todd, CJ; Barclay, SIG; Farquhar, MC				Grande, GE; Todd, CJ; Barclay, SIG; Farquhar, MC			Does hospital at home for palliative care facilitate death at home? Randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ILL CANCER-PATIENTS; COST-EFFECTIVENESS; TERMINALLY ILL; CLINICAL-TRIAL; SERVICE; TIME	Objective To evaluate the impact on place of death of a hospital at home service for palliative care. Design Pragmatic randomised controlled trial. Setting Former Cambridge health district. Participants 229 patients referred to the hospital at home service; 43 randomised to control group (standard care), 186 randomised to hospital at home. Intervention Hospital at home versus standard care. Main outcome measures Place of death. Results Twenty five (58%,) control patients died at home compared with 124 (67%) patients allocated to hospital at home. This difference was not significant; intention to treat analysis did not show that hospital at home increased the number of deaths at home. Seventy three patients randomised to hospital at home were not admitted to the service. Patients admitted to hospital at home were significantly more likely to die at home (88/113; 78%) than control patients. It is not possible to determine whether this was due to hospital at home itself or other characteristics of the patients admitted to the service. The study attained less statistical power than initially planned. Conclusion In a locality with good provision of standard community care we could not show that hospital at home allowed more patients: to die at home, although neither does the study refute this. Problems relating to recruitment, attrition, and the vulnerability of the patient group make randomised controlled trials in palliative care difficult While these difficulties have to be recognised they are not insurmountable with the appropriate resourcing and setting.	Univ Cambridge, Inst Publ Hlth, Dept Community Med,Hlth Serv Res Grp, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England	University of Cambridge	Grande, GE (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Community Med,Hlth Serv Res Grp, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.		Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010; Farquhar, Morag C/C-5666-2015; Grande, Gunn/A-6163-2011	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Farquhar, Morag C/0000-0001-7991-7679; Grande, Gunn/0000-0003-2200-1680; Barclay, Stephen/0000-0002-4505-7743				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Boyd K. J., 1994, Annals Academy of Medicine Singapore, V23, P271; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; CARTWRIGHT A, 1991, BRIT J GEN PRACT, V41, P271; CHARLTON RC, 1991, FAM PRACT, V8, P356, DOI 10.1093/fampra/8.4.356; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; Hinton John, 1994, Palliative Medicine, V8, P197, DOI 10.1177/026921639400800303; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; MCQUAY H, 1994, BMJ-BRIT MED J, V309, P1315, DOI 10.1136/bmj.309.6965.1315; MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; Raftery JP, 1996, PALLIATIVE MED, V10, P151, DOI 10.1177/026921639601000210; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; WARD AWM, 1987, COMMUNITY MED, V9, P47; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	19	79	80	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1472	1475		10.1136/bmj.319.7223.1472	http://dx.doi.org/10.1136/bmj.319.7223.1472			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582932	Green Published, Bronze			2023-01-03	WOS:000084129200023
J	Herrington, DM				Herrington, DM			The HERS trial results: Paradigms lost?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; RISK; ESTROGEN; DISEASE; USERS; PREVENTION; PROGESTIN	The Heart and Estrogen/progestin Replacement Study (HERS) found no overall effect of 4.1 years of therapy with estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. However, within the overall null effect, a 50% increase in cardiovascular events was seen in the first year, followed by fewer events after 2 years of treatment in the hormone therapy group than in the placebo group. Understanding the cause of th is pattern of early increase and late reduction in risk is key to interpreting the HERS results and reconciling them with the large number of observational and other studies of the cardiovascular effects of estrogen. There are two possibilities. One is that the HERS regimen of estrogen plus progestin has no effect on risk for heart disease, and the pattern of changing risk over time is simply the result of chance or confounding. The other is that the pattern of early increase and late reduction in risk is due to real but opposing effects of this regimen. Several lines of evidence support each possibility. Attrition of a susceptible cohort of women uniquely at risk for a cardiovascular complication from hormone therapy coupled with a gradually progressive beneficial effect due to lipid lowering and other factors is a promising potential explanation. The HERS results remind us of the need for clinical trials to evaluate both the benefits and risks of new therapies. They also illustrate how much more we need to know about the cardiovascular effects of hormone replacement therapy.	Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA	Wake Forest University	Herrington, DM (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dherring@wfubmc.edu						Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grundy SM, 1997, CIRCULATION, V95, P2329, DOI 10.1161/01.CIR.95.9.2329; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SMITH SC, 1995, CIRCULATION, V92, P2; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	16	84	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					463	466		10.7326/0003-4819-131-6-199909210-00012	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498564				2023-01-03	WOS:000082641100010
J	Gilbert, D; Walley, T; New, B				Gilbert, D; Walley, T; New, B			Lifestyle medicines	BRITISH MEDICAL JOURNAL			English	Article							PROTON PUMP INHIBITORS; RESTRICTIONS; VIAGRA		Off Publ Management, London WC1X 8JT, England; Univ Liverpool, Dept Pharmacol, Liverpool L69 3GF, Merseyside, England	University of Liverpool	Gilbert, D (corresponding author), Off Publ Management, 252B Grays Inn Rd, London WC1X 8JT, England.							Bashford JNR, 1998, BRIT MED J, V317, P452; Beecham L, 1999, BRIT MED J, V318, P279, DOI 10.1136/bmj.318.7179.279; Dolan P, 1999, BRIT MED J, V318, P916, DOI 10.1136/bmj.318.7188.916; Ferriman A, 1999, BRIT MED J, V318, P1305, DOI 10.1136/bmj.318.7194.1305a; Freemantle N, 2000, BRIT MED J, V320, P1156, DOI 10.1136/bmj.320.7243.1156; GIBLERT D, 1999, LIFESTYLE DRUGS WHO; HADORN DC, 1997, RATIONING TALK ACTIO, P183; HALL C, 1998, DAILY TELEGRAPH 0708; Ham C, 1998, BRIT MED J, V316, P1965, DOI 10.1136/bmj.316.7149.1965; KLEIN R, 1997, RATIONING TALK ACTIO, P85; LABELLE R, 1994, J HEALTH ECON, V13, P347, DOI 10.1016/0167-6296(94)90036-1; LEUFKENS H, 1994, BRIT MED J, V309, P1137, DOI 10.1136/bmj.309.6962.1137; MCIVER S., 1998, HLTH DEBATE INDEPEND; McManus P, 1998, BRIT J CLIN PHARMACO, V46, P409, DOI 10.1046/j.1365-2125.1998.00791.x; *NAT I CLIN EXC, 1999, NICE GUID ZAN REL TR; NEW B, 1996, RATIONING NHS PRINCI, P31; *NHS EX, 1999, TREATM IMP; *NHS EX, 1999, TREATM IMP PAT SEV D; REISSMAN D, 1999, DIS MANAG HEALTH OUT, V6, P249; *ROYAL COLL PHYS L, 1999, CLIN MAN OV OB PAT P; Shakespeare J, 2000, BRIT MED J, V320, P291, DOI 10.1136/bmj.320.7230.291; Smith R, 1999, BRIT MED J, V318, P209; Swedish Parliamentary Priorities Commission, 1995, PRIOR HLTH CAR ETH E; Walley T, 1998, BRIT MED J, V317, P487; 2000, BMJ, V320, P204	25	45	45	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	2000	321	7272					1341	1344		10.1136/bmj.321.7272.1341	http://dx.doi.org/10.1136/bmj.321.7272.1341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	378BK	11090522	Green Published			2023-01-03	WOS:000165561600036
J	Valenzuela, TD; Roe, DJ; Nichol, G; Clark, LL; Spaite, DW; Hardman, RG				Valenzuela, TD; Roe, DJ; Nichol, G; Clark, LL; Spaite, DW; Hardman, RG			Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION REPORT; RESUSCITATION; POLICE	Background: The use of automated external defibrillators by persons other than paramedics and emergency medical technicians is advocated by the American Heart Association and other organizations. However, there are few data on the outcomes when the devices are used by nonmedical personnel for out-of-hospital cardiac arrest. Methods: We studied a prospective series of cases of sudden cardiac arrest in casinos. Casino security officers were instructed in the use of automated external defibrillators. The locations where the defibrillators were stored in the casinos were chosen to make possible a target interval of three minutes or less from collapse to the first defibrillation. Our protocol called for a defibrillation first (if feasible), followed by manual cardiopulmonary resuscitation. The primary outcome was survival to discharge from the hospital. Results: Automated external defibrillators were used in 105 patients whose initial cardiac rhythm was ventricular fibrillation. Fifty-six of the patients (53 percent) survived to discharge from the hospital. Among the 90 patients whose collapse was witnessed (86 percent), the clinically relevant time intervals were a mean (+/-SD) of 3.5+/-2.9 minutes from collapse to attachment of the defibrillator, 4.4+/-2.9 minutes from collapse to the delivery of the first defibrillation shock, and 9.8+/-4.3 minutes from collapse to the arrival of the paramedics. The survival rate was 74 percent for those who received their first defibrillation no later than three minutes after a witnessed collapse and 49 percent for those who received their first defibrillation after more than three minutes. Conclusions: Rapid defibrillation by nonmedical personnel using an automated external defibrillator can improve survival after out-of-hospital cardiac arrest due to ventricular fibrillation. Intervals of no more than three minutes from collapse to defibrillation are necessary to achieve the highest survival rates.	Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85724 USA; Univ Arizona, Coll Publ Hlth, Dept Epidemiol & Biostat, Tucson, AZ 85724 USA; Univ Ontario, Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON, Canada; Clark Cty Fire Dept, Las Vegas, NV USA	University of Arizona; University of Arizona; University of Ottawa; Ottawa Hospital Research Institute	Valenzuela, TD (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave,POB 245057, Tucson, AZ 85724 USA.		Nichol, Graham/Z-4996-2019	Spaite, Daniel/0000-0003-2601-6476				Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Becker L, 1996, CARDIAC ARREST SCI P, P28; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1995, SUDDEN CARDIAC DEATH, P1; ENGELSTEIN ED, 1998, HURSTS HEART ARTERIE, V1, P1081; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Myerburg R, 1997, HEART DIS TXB CARDIO; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 1998, CIRCULATION, V97, P1429; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Safar PBN, 1988, CARDIOPULMONARY CERE; Valenzuela TD, 1997, CIRCULATION, V96, P3308; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X	19	941	1003	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1206	1209		10.1056/NEJM200010263431701	http://dx.doi.org/10.1056/NEJM200010263431701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071670	Green Published			2023-01-03	WOS:000090014100001
J	Burstein, HJ; Winer, EP				Burstein, HJ; Winer, EP			Primary care - Primary care for survivors of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ESTROGEN REPLACEMENT THERAPY; QUALITY-OF-LIFE; SURGICAL-ADJUVANT-BREAST; BONE-MINERAL DENSITY; LYMPH-NODE DISSECTION; BOWEL-PROJECT P-1; FOLLOW-UP CARE; RADIATION-THERAPY; ENDOMETRIAL CANCER; CONTRALATERAL BREAST		Dana Farber Canc Inst, Breast Oncol Ctr, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Burstein, HJ (corresponding author), Dana Farber Canc Inst, Breast Oncol Ctr, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.							Armstrong K, 2000, NEW ENGL J MED, V342, P564, DOI 10.1056/NEJM200002243420807; Barakat RR, 1999, J CLIN ONCOL, V17, P1967, DOI 10.1200/JCO.1999.17.7.1967; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Bast RC, 1996, J CLIN ONCOL, V14, P2843; BERNSTEIN JL, 1992, AM J EPIDEMIOL, V136, P937, DOI 10.1093/oxfordjournals.aje.a116566; Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654; BERTELLI G, 1991, ANN ONCOL, V2, P575, DOI 10.1093/oxfordjournals.annonc.a058023; Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BRYCE CJ, 1998, BREAST CANC RES TREA, V50, P284; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; BYRNE J, 1992, AM J OBSTET GYNECOL, V166, P788, DOI 10.1016/0002-9378(92)91335-8; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; CARPENTER JS, 1997, CANCER, V82, P1682; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Chang J, 1998, BREAST CANCER RES TR, V48, P81, DOI 10.1023/A:1005999008736; Chlebowski RT, 1999, J CLIN ONCOL, V17, P130, DOI 10.1200/JCO.1999.17.1.130; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; COBLEIGH MA, 1995, JAMA-J AM MED ASSOC, V273, P378; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Collichio FA, 1998, ONCOLOGY-NY, V12, P759; COLLICHIO FA, 1998, ONCOLOGY HUNTINGT, V12, P769; COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737; Cummings SR, 1999, JAMA-J AM MED ASSOC, V282, P2124; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Dawson LA, 1998, EUR J CANCER, V34, P2000, DOI 10.1016/S0959-8049(98)00208-1; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; DHODAPKAR MV, 1995, CANCER-AM CANCER SOC, V75, P43, DOI 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#; Diamandidou E, 1996, J CLIN ONCOL, V14, P2722, DOI 10.1200/JCO.1996.14.10.2722; Dorval M, 1998, J CLIN ONCOL, V16, P487, DOI 10.1200/JCO.1998.16.2.487; Duckitt K, 1998, CURR OPIN OBSTET GYN, V10, P199, DOI 10.1097/00001703-199806000-00004; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; EVANS GRD, 1995, PLAST RECONSTR SURG, V96, P1111, DOI 10.1097/00006534-199510000-00016; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Ganz PA, 1996, BREAST CANCER RES TR, V38, P183, DOI 10.1007/BF01806673; Ganz PA, 1998, J CLIN ONCOL, V16, P501, DOI 10.1200/JCO.1998.16.2.501; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120; Goodwin PJ, 1999, J CLIN ONCOL, V17, P2365, DOI 10.1200/JCO.1999.17.8.2365; Grosse A, 1997, INT J RADIAT ONCOL, V38, P761, DOI 10.1016/S0360-3016(97)00062-X; Hack TF, 1999, J CLIN ONCOL, V17, P143, DOI 10.1200/JCO.1999.17.1.143; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Hewitt M, 1999, J NATL CANCER I, V91, P1480, DOI 10.1093/jnci/91.17.1480; HIGGINS S, 1994, CANCER-AM CANCER SOC, V73, P2175, DOI 10.1002/1097-0142(19940415)73:8<2175::AID-CNCR2820730823>3.0.CO;2-#; Hojris I, 1999, LANCET, V354, P1425, DOI 10.1016/S0140-6736(99)02245-X; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; Holmes MD, 1999, CANCER, V86, P2707; HORTOBAGYI G N, 1986, NCI (National Cancer Institute) Monographs, P105; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; JOHNSON CH, 1989, ARCH SURG-CHICAGO, V124, P819; Kavanagh AM, 2000, LANCET, V355, P270, DOI 10.1016/S0140-6736(99)07319-5; Kroman N, 1997, LANCET, V350, P319, DOI 10.1016/S0140-6736(97)03052-3; LARSON D, 1986, INT J RADIAT ONCOL, V12, P1575, DOI 10.1016/0360-3016(86)90280-4; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LINGOS TI, 1991, INT J RADIAT ONCOL, V21, P355, DOI 10.1016/0360-3016(91)90782-Y; Loprinzi C. L., 1999, Breast Cancer Research and Treatment, V57, P34; Loprinzi CL, 1997, J CLIN ONCOL, V15, P969, DOI 10.1200/JCO.1997.15.3.969; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; LOPRINZI CL, 2000, P AN M AM SOC CLIN, V19, pA2; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; MAUNSELL E, 1992, CANCER-AM CANCER SOC, V70, P120, DOI 10.1002/1097-0142(19920701)70:1<120::AID-CNCR2820700120>3.0.CO;2-U; MELLINK WAM, 1991, CANCER-AM CANCER SOC, V67, P1844, DOI 10.1002/1097-0142(19910401)67:7<1844::AID-CNCR2820670705>3.0.CO;2-W; Mortimer JE, 1999, J CLIN ONCOL, V17, P1488, DOI 10.1200/JCO.1999.17.5.1488; MULVIHILL JJ, 1987, CANCER, V60, P1143, DOI 10.1002/1097-0142(19870901)60:5<1143::AID-CNCR2820600537>3.0.CO;2-E; MUSS HB, 1991, AM J CLIN ONCOL-CANC, V14, P55, DOI 10.1097/00000421-199102000-00013; Nixon AJ, 1998, J CLIN ONCOL, V16, P1374, DOI 10.1200/JCO.1998.16.4.1374; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; PANDYA KJ, 1985, CANCER, V55, P202, DOI 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X; Paszat, 1999, J CLIN ONCOL, V17, P740; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; PETREK JA, 2000, DIS BREAST, P1033; PEZNER RD, 1986, INT J RADIAT ONCOL, V12, P2079, DOI 10.1016/0360-3016(86)90005-2; PIERCE SM, 1992, INT J RADIAT ONCOL, V23, P915, DOI 10.1016/0360-3016(92)90895-O; POWLES TJ, 1993, LANCET, V342, P60, DOI 10.1016/0140-6736(93)91931-B; Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704; Pritchard KI, 1996, J CLIN ONCOL, V14, P2731, DOI 10.1200/JCO.1996.14.10.2731; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Ragaz J, 1998, J CLIN ONCOL, V16, P2018, DOI 10.1200/JCO.1998.16.6.2018; RIES L, 1996, NIH PUBL; Rockson SG, 1998, CANCER, V83, P2814; Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SCHAG CAC, 1993, J CLIN ONCOL, V11, P783, DOI 10.1200/JCO.1993.11.4.783; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; Schrag D, 2000, JAMA-J AM MED ASSOC, V283, P617, DOI 10.1001/jama.283.5.617; SCHUSTER RH, 1992, PLAST RECONSTR SURG, V90, P445, DOI 10.1097/00006534-199209000-00013; Segar M L, 1998, Oncol Nurs Forum, V25, P107; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; Shapiro CL, 1998, J CLIN ONCOL, V16, P3493, DOI 10.1200/JCO.1998.16.11.3493; SLAVIN SA, 1994, PLAST RECONSTR SURG, V93, P1191, DOI 10.1097/00006534-199405000-00013; SMITH P, 1993, MATURITAS, V16, P145, DOI 10.1016/0378-5122(93)90059-Q; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Somerfield MR, 1997, J CLIN ONCOL, V15, P2149; STEARNS V, 1998, BREAST CANC RES TREA, V50, P308; STIERER M, 1989, CANCER, V64, P1128, DOI 10.1002/1097-0142(19890901)64:5<1128::AID-CNCR2820640527>3.0.CO;2-H; Suh-Burgmann EJ, 1999, ANN INTERN MED, V131, P127, DOI 10.7326/0003-4819-131-2-199907200-00009; Surbone A, 1997, CANCER, V79, P1271, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1271::AID-CNCR1>3.0.CO;2-K; SUTTON R, 1990, CANCER, V65, P847, DOI 10.1002/1097-0142(19900215)65:4<847::AID-CNCR2820650402>3.0.CO;2-A; Swain S, 1999, ONCOLOGY-NY, V13, P397; Swain S, 1999, ONCOLOGY-NY, V13, P551; Swain S, 1999, ONCOLOGY-NY, V13, P859; SWAIN S, 1999, ONCOLOGY, V13, P727; SWAIN S, 1999, ONCOLOGY, V13, P109; SWAIN S, 1999, ONCOLOGY, V13, P245; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; TRALINS AH, 1995, AM J CLIN ONCOL-CANC, V18, P40, DOI 10.1097/00000421-199502000-00008; VALAGUSSA P, 1994, ANN ONCOL, V5, P209, DOI 10.1093/oxfordjournals.annonc.a058795; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; Vassilopoulou-Sellin R, 1999, J CLIN ONCOL, V17, P1482, DOI 10.1200/JCO.1999.17.5.1482; VASSILOPOULOUSE.R, 1996, CANCER, V79, P867; VassilopoulouSellin R, 1996, CANCER-AM CANCER SOC, V78, P1043, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1043::AID-CNCR14>3.0.CO;2-2; Velentgas P, 1999, CANCER, V85, P2424, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2424::AID-CNCR17>3.0.CO;2-4; Venn A, 1999, LANCET, V354, P1586, DOI 10.1016/S0140-6736(99)05203-4; Warmuth MA, 1998, CANCER, V83, P1362, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1362::AID-CNCR13>3.0.CO;2-2; Weber B, 1998, EUR J CANCER, V34, pS42, DOI 10.1016/S0959-8049(98)80161-5; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; WOLF DM, 1992, GYNECOL ONCOL, V45, P118, DOI 10.1016/0090-8258(92)90273-L; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903	124	158	159	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	2000	343	15					1086	1094		10.1056/NEJM200010123431506	http://dx.doi.org/10.1056/NEJM200010123431506			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	362FA	11027744				2023-01-03	WOS:000089766900006
J	Mehta, SR; Eikelboom, JW; Yusuf, S				Mehta, SR; Eikelboom, JW; Yusuf, S			Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; FRONT-LOADED ALTEPLASE; DOUBLE-BLIND; RECOMBINANT STAPHYLOKINASE; CORONARY THROMBOLYSIS; INTRAVENOUS UROKINASE; PATENCY TRIAL; ANISTREPLASE; STREPTOKINASE	Background Although thrombolytic therapy given by bolus injection seems to be as effective as infusion over 60-90 min, no single trial has been adequately powered to detect clinically important safety differences between the two strategies. We did a meta-analysis to find out whether bolus administration of thrombolytics is associated with an increased frequency of intracranial haemorrhage, Methods We identified randomised trials comparing bolus with infusion thrombolytic therapy by a search of electronic databases, reference lists, and conference proceedings. Odds ratios for primary intracranial haemorrhage, non-haemorrhagic stroke, mortality, and reinfarction were calculated for each trial and were combined in a fixed-effects model. Findings Seven trials, involving a total of 103 972 patients, met our inclusion criteria. Bolus treatment was associated with an increased risk of intracranial haemorrhage compared with infusion (0.8 vs 0.6%; odds ratio 1.25 [95% CI 1.08-1.45]; p=0.003). The increased risk was most striking in trials comparing bolus with infusion administration of the same agent (1.75 [1.32-2.33], p=0.0001), but was also evident in trials comparing a newer-generation bolus agent with standard infusion therapy (1.25 [1.03-1.50]; p=0.02). The rates of non-haemorrhagic stroke (0.94 [0.81-1.09]), 30-day mortality (1.01 [0.97-1.06]), or reinfarction (1.04 [0.97-1.11]) did not differ between the two strategies. Interpretation The increased risk of bolus thrombolytic treatment seems to be primarily associated with the method of administration rather than properties of the agents. Although the increased risk of intracranial haemorrhage is small, physicians should balance this risk against the putative benefits of easier administration with no difference in mortality or reinfarction.	McMaster Univ, Hamilton Hlth Sci Corp, Div Cardiol, Hamilton, ON, Canada; McMaster Univ, Hamilton Hlth Sci Corp, Populat Hlth Inst, Hamilton, ON, Canada	McMaster University; McMaster University	Yusuf, S (corresponding author), Hamilton Gen Hosp, McMaster Clin, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.csu.mcmaster.ca	Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285				ANDERSON JL, 1992, J AM COLL CARDIOL, V20, P753, DOI 10.1016/0735-1097(92)90170-R; ANDERSON JL, 1991, CIRCULATION, V83, P126, DOI 10.1161/01.CIR.83.1.126; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antman EM, 1999, CIRCULATION, V100, P498; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Bar FW, 1998, CIRCULATION, V98, P505; Bar FW, 1998, J THROMB THROMBOLYS, V6, P147, DOI 10.1023/A:1008809907268; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BASSAND JP, 1991, CIRCULATION, V84, P1107, DOI 10.1161/01.CIR.84.3.1107; Bleich SD, 1998, AM HEART J, V136, P741, DOI 10.1016/S0002-8703(98)70024-9; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Califf RM, 2000, AM HEART J, V139, pS33, DOI 10.1067/mhj.2000.104090; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; CANNON CP, 1994, J AM COLL CARDIOL, V24, P1602, DOI 10.1016/0735-1097(94)90163-5; Cannon CP, 1997, CIRCULATION, V95, P351; den Heijer P, 1998, CIRCULATION, V98, P2117, DOI 10.1161/01.CIR.98.20.2117; GEMMILL JD, 1991, BRIT HEART J, V66, P134; HOGG KJ, 1990, LANCET, V335, P254, DOI 10.1016/0140-6736(90)90069-H; HUNT D, 1992, LANCET, V339, P753; *INT JOINT EFF COM, 1995, LANCET, V346, P329; Kawai C, 1997, J AM COLL CARDIOL, V29, P1447, DOI 10.1016/S0735-1097(97)00074-0; KAWAI C, 1992, CIRCULATION S, V86, P1; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; LOPEZSENDON J, 1988, CIRCULATION S2, V78, P277; MATHEY DG, 1985, AM J CARDIOL, V55, P878, DOI 10.1016/0002-9149(85)90710-6; MONNIER P, 1987, DRUGS, V33, P175, DOI 10.2165/00003495-198700333-00029; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; PACOURET G, 1991, EUR HEART J, V12, P179, DOI 10.1093/oxfordjournals.eurheartj.a059866; Park SJ, 1998, AM J CARDIOL, V82, P811, DOI 10.1016/S0002-9149(98)00444-5; PURVIS JA, 1994, J AM COLL CARDIOL, V23, P6, DOI 10.1016/0735-1097(94)90495-2; PURVIS JA, 1991, AM J CARDIOL, V68, P1570, DOI 10.1016/0002-9149(91)90311-8; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; RELIKVANWELY L, 1991, AM J CARDIOL, V68, P296; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; Tebbe U, 1998, J AM COLL CARDIOL, V31, P487, DOI 10.1016/S0735-1097(97)00553-6; TEBBE U, 1989, AM J CARDIOL, V64, P448, DOI 10.1016/0002-9149(89)90419-0; Topol E, 1997, NEW ENGL J MED, V337, P1118; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; Vanderschueren S, 1996, THROMB HAEMOSTASIS, V76, P541; VandeWerf F, 1997, NEW ENGL J MED, V337, P1124; VOGT P, 1993, AM J CARDIOL, V71, P274, DOI 10.1016/0002-9149(93)90790-J; Weitz JI, 1999, THROMB HAEMOSTASIS, V82, P974; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	47	52	53	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					449	454		10.1016/S0140-6736(00)02552-6	http://dx.doi.org/10.1016/S0140-6736(00)02552-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981887				2023-01-03	WOS:000088657700009
J	Ross, R; Dagnone, D; Jones, PJH; Smith, H; Paddags, A; Hudson, R; Janssen, I				Ross, R; Dagnone, D; Jones, PJH; Smith, H; Paddags, A; Hudson, R; Janssen, I			Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							VISCERAL ADIPOSE-TISSUE; ISCHEMIC-HEART-DISEASE; BODY-MASS INDEX; INSULIN SENSITIVITY; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; CARDIOVASCULAR-DISEASE; GLUCOSE-METABOLISM; FAT DISTRIBUTION; BLOOD-PRESSURE	Background: The independent effects of diet- or exercise-induced weight loss on the reduction of obesity and related comorbid conditions are not known. The effects of exercise without weight loss on fat distribution and other risk factors are also unclear. Objective: To determine the effects of equivalent diet- or exercise-induced weight loss and exercise without weight loss on subcutaneous fat, visceral fat, skeletal muscle mass, and insulin sensitivity in obese men. Design: Randomized, controlled trial. Setting: University research center. Participants: 52 obese men (mean body mass index [+/-SD], 31.3 +/- 2.0 kg/m(2)) with a mean waist circumference of 110.1 +/- 5.8 cm, Intervention: Participants were randomly assigned to one of four study groups (diet-induced weight loss, exercise-induced weight loss, exercise without weight loss, and control) and were observed for 3 months. Measurements: Change in total, subcutaneous, and visceral fat; skeletal muscle mass; cardiovascular fitness; glucose tolerance and insulin sensitivity. Results: Body weight decreased by 7.5 kg (8%) in both weight loss groups and did not change in the exercise without weight loss and control groups. Compared with controls, cardiovascular fitness (peak oxygen uptake) in the exercise groups improved by approximately 16% (P < 0.01). Although total fat decreased in both weight loss groups (P < 0.001), the average reduction was 1.3 kg (95% CI, 0.3 to 2.3 kg) greater in the exercise-induced weight loss group than in the diet-induced weight loss group (P = 0.03). Similar reductions in abdominal subcutaneous, visceral, and visceral fat-to-subcutaneous fat ratios were observed in the weight loss groups (P < 0.001), Abdominal and visceral fat also decreased in the exercise without weight loss group (P = 0.001). Plasma glucose and insulin values (fasting and oral glucose challenge) did not change in the treatment groups compared with controls (P = 0.10 for all comparisons). Average improvement in glucose disposal was similar in the diet-induced weight loss group (5.6 mg/kg skeletal muscle per minute) and in the exercise-induced weight loss group (7.2 mg/kg skeletal muscle per minute) (P > 0.2). However, these values were significantly greater than those in the control and exercise without weight loss groups (P < 0.001). Conclusions: Weight loss induced by increased daily physical activity without caloric restriction substantially reduces obesity (particularly abdominal obesity) and insulin resistance in men. Exercise without weight loss reduces abdominal fat and prevents further weight gain.	Queens Univ, Sch Phys & Hlth Educ, Kingston, ON K7L 3N6, Canada; McGill Univ, Montreal, PQ, Canada	Queens University - Canada; McGill University	Ross, R (corresponding author), Queens Univ, Sch Phys & Hlth Educ, Kingston, ON K7L 3N6, Canada.	rossr@post.queensu.ca	Janssen, Ian/B-7700-2009	Janssen, Ian/0000-0003-2159-3012; Jones, Peter/0000-0001-5887-2846				ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245; [Anonymous], 1996, JAMA, V276, P241; BALLOR DL, 1994, INT J OBESITY, V18, P35; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Dengel DR, 1996, J APPL PHYSIOL, V81, P318, DOI 10.1152/jappl.1996.81.1.318; Despres Jean-Pierre, 1993, Nutrition Research Reviews, V6, P137, DOI 10.1079/NRR19930010; DESPRES JP, 1995, INT J OBESITY, V19, pS76; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DYER AR, 1989, J HUM HYPERTENS, V3, P299; Fried S K, 1993, Obes Res, V1, P443; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; Goodpaster BH, 1999, DIABETES, V48, P839, DOI 10.2337/diabetes.48.4.839; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; Harris JA., 1919, BIOMETRIC STUDY BASA; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Henriksson J, 1995, J Cardiovasc Risk, V2, P303, DOI 10.1097/00043798-199508000-00004; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; JONES PJH, 1993, J APPL PHYSIOL, V75, P1790, DOI 10.1152/jappl.1993.75.4.1790; KAHN HA, 1971, J CHRON DIS, V23, P617, DOI 10.1016/0021-9681(71)90158-5; KAYMAN S, 1990, AM J CLIN NUTR, V52, P800, DOI 10.1093/ajcn/52.5.800; Kelley D.E., 1995, DIABETES REV, V3, P366; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; LARSSON B, 1981, INT J OBESITY, V5, P97; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; Meek SE, 1999, DIABETES, V48, P10, DOI 10.2337/diabetes.48.1.10; MIKINES KJ, 1988, AM J PHYSIOL, V254, pE248, DOI 10.1152/ajpendo.1988.254.3.E248; Miller WC, 1997, INT J OBESITY, V21, P941, DOI 10.1038/sj.ijo.0800499; Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115, DOI 10.1152/jappl.1998.85.1.115; MOTT DM, 1986, METABOLISM, V35, P160, DOI 10.1016/0026-0495(86)90118-6; Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385; Niskanen L, 1996, INT J OBESITY, V20, P154; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OLEFSKY J, 1975, METABOLISM, V24, P495, DOI 10.1016/0026-0495(75)90074-8; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rice B, 1999, DIABETES CARE, V22, P684, DOI 10.2337/diacare.22.5.684; Ross R, 1996, J APPL PHYSIOL, V81, P2445, DOI 10.1152/jappl.1996.81.6.2445; Ross R, 1997, SPORTS MED, V24, P55, DOI 10.2165/00007256-199724010-00005; Ross R, 1996, DIABETES CARE, V19, P1404, DOI 10.2337/diacare.19.12.1404; SCHULZ LO, 1994, AM J CLIN NUTR, V60, P676, DOI 10.1093/ajcn/60.5.676; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; Snyder WS, 1975, REPORT TASK GROUP RE; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; WIDEN EIM, 1992, DIABETES, V41, P354, DOI 10.2337/diabetes.41.3.354; Williams MJ, 1996, INT J OBESITY, V20, P613; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; World Health Organization, 1997, OB PREV MAN GLOB EP	54	938	961	1	134	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2000	133	2					92	103		10.7326/0003-4819-133-2-200007180-00008	http://dx.doi.org/10.7326/0003-4819-133-2-200007180-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335RL	10896648				2023-01-03	WOS:000088258500002
J	Brown, DA; London, E				Brown, DA; London, E			Structure and function of sphingolipid- and cholesterol-rich membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DETERGENT-RESISTANT MEMBRANES; T-CELL ACTIVATION; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; FC-EPSILON-RI; LIPID RAFTS; TYROSINE PHOSPHORYLATION; BIOLOGICAL-MEMBRANES; TRANSMEMBRANE DOMAIN; MASS-SPECTROMETRY; ANTIGEN RECEPTOR		SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	deborah.brown@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47897, GM 48596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chuang FYS, 2000, J IMMUNOL, V164, P350, DOI 10.4049/jimmunol.164.1.350; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Green JM, 1997, J CELL BIOL, V139, P1209, DOI 10.1083/jcb.139.5.1209; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lang ML, 1999, J IMMUNOL, V163, P5391; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Lou ZK, 2000, J EXP MED, V191, P347, DOI 10.1084/jem.191.2.347; MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Montanari GC, 1998, IEEE T DIELECT EL IN, V5, P148, DOI 10.1109/94.660821; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PERSCHL A, 1995, J CELL SCI, V108, P1033; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Puertollano R, 1998, J BIOL CHEM, V273, P12740, DOI 10.1074/jbc.273.21.12740; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	68	1968	2026	3	257	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17221	17224		10.1074/jbc.R000005200	http://dx.doi.org/10.1074/jbc.R000005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10770957	hybrid			2023-01-03	WOS:000087485000001
J	Kovacs, JA; Masur, H				Kovacs, JA; Masur, H			Drug therapy: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; ACTIVE ANTIRETROVIRAL THERAPY; PLACEBO-CONTROLLED TRIAL; RANDOMIZED TRIAL; TRIMETHOPRIM-SULFAMETHOXAZOLE; ACQUIRED-IMMUNODEFICIENCY; CYTOMEGALOVIRUS RETINITIS; MAINTENANCE THERAPY; TOXOPLASMIC ENCEPHALITIS		NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Masur, H (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr, Bethesda, MD 20892 USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				ABERG JA, 2000, P 7 C RETR OPP INF S, P123; AMPEL NM, 1999, AIDS THERAPY, P423; [Anonymous], 1995, CLIN INFECT DIS   S1, V21, pS32; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; [Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; BENSON CA, 1996, P 3 C RETR OPP INF W, P91; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Cohn DL, 1999, CLIN INFECT DIS, V29, P125, DOI 10.1086/520141; COSTAGLIOLA D, 1998, 12 INT C AIDS GEN JU, P82; CURRIER JS, 1999, 39 INT C ANT AG CHEM, P19; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; Dunne MW, 1999, LANCET, V354, P891, DOI 10.1016/S0140-6736(98)10328-8; DWORKIN M, 1999, P 6 C RETR OPP INF C, P198; El-Sadr WM, 1999, CLIN INFECT DIS, V29, P775, DOI 10.1086/520433; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; ELSADR WM, 2000, P 7 C RETR OPP INF S, P122; Engels EA, 1999, ANN INTERN MED, V131, P256, DOI 10.7326/0003-4819-131-4-199908170-00004; FLEMING C, 2000, P 7 C RETR OPP INF S, P123; FLEXNER C, 1999, AIDS THERAPY, P785; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; FURRER H, 2000, P 7 C RETR OPP INF S, P122; Giorgi JV, 1998, AIDS, V12, P1833, DOI 10.1097/00002030-199814000-00015; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; Gordin FM, 1999, CLIN INFECT DIS, V28, P1080, DOI 10.1086/514748; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Graham NMH, 1996, ARCH INTERN MED, V156, P889, DOI 10.1001/archinte.156.8.889; Grulich AE, 1999, J ACQ IMMUN DEF SYND, V21, pS27; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Havlir DV, 1998, CLIN INFECT DIS, V27, P1369, DOI 10.1086/515018; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; JOHNSON S, 2000, P 7 C RETR OPP INF S, P127; Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1; Kaplan JE, 1998, J INFECT DIS, V178, P1126, DOI 10.1086/515658; KAPLAN JE, 1999, 39 INT C ANT AG CHEM, P13; Katlama C, 1996, CLIN INFECT DIS, V22, P268, DOI 10.1093/clinids/22.2.268; KAZANJIAN P, 2000, P 7 C RETR OPP INF S, P119; Keely SP, 1997, J CLIN MICROBIOL, V35, P2745, DOI 10.1128/JCM.35.11.2745-2747.1997; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; KOLETAR SL, 2000, P 7 C RETR OPP INF S, P122; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; LEDERGERBER B, 2000, P 7 C RETR OPP INF S, P235; LEOUNG G, 1997, 37 INT C ANT AG CHEM; Lewis RA, 1997, ANN INTERN MED, V126, P264, DOI 10.7326/0003-4819-126-4-199702150-00002; Lewis RA, 1997, J INFECT DIS, V176, P50, DOI 10.1086/514039; LOPEZ JC, 1999, 39 INT C ANT AG CHEM, P19; LUNDGREN JD, 1995, CLIN INFECT DIS, V21, P106, DOI 10.1093/clinids/21.1.106; LUNDGREN JD, 1999, 39 INT C ANT AG CHEM, P91; Ma L, 1999, J INFECT DIS, V180, P1969, DOI 10.1086/315148; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MARTIN D, 2000, P 7 C RETR OPP INF S, P119; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; McKinsey DS, 1999, CLIN INFECT DIS, V28, P1049, DOI 10.1086/514744; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Miller V, 1999, LANCET, V353, P463, DOI 10.1016/S0140-6736(98)04954-X; MIRO JM, 2000, P 7 C RETR OPP INF S, P119; MOORE RD, 1998, P 5 C RETR OPP INF C, P113; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; Newell ML, 1997, AIDS, V11, P1859; Nielsen H, 1998, SCAND J INFECT DIS, V30, P597, DOI 10.1080/00365549850161160; OPRAVIL M, 1995, CLIN INFECT DIS, V20, P531, DOI 10.1093/clinids/20.3.531; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PARA MF, 1997, P 4 C RETR OPP INF W, P65; PEARSON RD, 1985, ANN INTERN MED, V103, P782, DOI 10.7326/0003-4819-103-5-782; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; PODZAMCZER D, 1995, ANN INTERN MED, V123, P175, DOI 10.7326/0003-4819-123-3-199508010-00003; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RICHARDS FO, 1995, CLIN INFECT DIS, V21, pS49, DOI 10.1093/clinids/21.Supplement_1.S49; Saag MS, 1999, CLIN INFECT DIS, V28, P291, DOI 10.1086/515110; SCHNEIDER MME, 1995, J INFECT DIS, V171, P1632, DOI 10.1093/infdis/171.6.1632; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; Schuman P, 1997, ANN INTERN MED, V126, P689, DOI 10.7326/0003-4819-126-9-199705010-00003; Shafran SD, 1996, NEW ENGL J MED, V335, P377, DOI 10.1056/NEJM199608083350602; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; STEWART JA, 1995, CLIN INFECT DIS, V21, pS114, DOI 10.1093/clinids/21.Supplement_1.S114; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006; Tsolaki AG, 1996, J INFECT DIS, V174, P141, DOI 10.1093/infdis/174.1.141; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; US Public Health Service and Infectious Diseases Society of America, 1999, MMWR-MORBID MORTAL W, V48, P1; *USPHS RIF TRIAL G, 1998, AM J RESP CRIT CAR S, V157, P7; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; WARD JW, 1996, 34 ANN M INF DIS SOC, P81; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; WHEAT J, 1999, AIDS THERAPY, P412; Whitcup SM, 1999, JAMA-J AM MED ASSOC, V282, P1633, DOI 10.1001/jama.282.17.1633; Yangco BG, 2000, ANN INTERN MED, V132, P201, DOI 10.7326/0003-4819-132-3-200002010-00005; ZURLO JJ, 1995, CLIN INFECT DIS, V20, P768, DOI 10.1093/clinids/20.4.768; 1989, MMWR MORB MORTAL S5, V38, P1; 1992, MMWR MORB MORTAL WKL, V41, P4; 1981, MMWR MORB MORTAL WKL, V30, P250	110	151	161	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1416	1429		10.1056/NEJM200005113421907	http://dx.doi.org/10.1056/NEJM200005113421907			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805828				2023-01-03	WOS:000086940600007
J	Ware, LB; Matthay, MA				Ware, LB; Matthay, MA			Medical progress - The acute respiratory distress syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; CRITICALLY ILL PATIENTS; EXTRACORPOREAL MEMBRANE-OXYGENATION; PERMEABILITY PULMONARY-EDEMA; RANDOMIZED CONTROLLED TRIAL; HIGH-DOSE CORTICOSTEROIDS; III PROCOLLAGEN PEPTIDE; INHALED NITRIC-OXIDE; QUALITY-OF-LIFE		Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Matthay, MA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.	mmatt@itsa.ucsf.edu	Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702	NHLBI NIH HHS [U01 HL108713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL108713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; ABERLE DR, 1988, RADIOLOGY, V168, P73, DOI 10.1148/radiology.168.1.3380985; Abraham E, 1999, CRIT CARE MED, V27, P1478, DOI 10.1097/00003246-199908000-00013; Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ANDERSON WR, 1992, ULTRASTRUCT PATHOL, V16, P615, DOI 10.3109/01913129209023751; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ASHBAUGH DG, 1967, LANCET, V2, P319; BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BARNARD JW, 1994, J APPL PHYSIOL, V77, P774, DOI 10.1152/jappl.1994.77.2.774; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150; BISHOP MJ, 1983, AM REV RESPIR DIS, V128, P998; BITTERMAN PB, 1992, AM J MED, V92, pS39, DOI 10.1016/0002-9343(92)90606-C; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Dobbs LG, 1998, P NATL ACAD SCI USA, V95, P2991, DOI 10.1073/pnas.95.6.2991; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; Folkesson HG, 1998, AM J PHYSIOL-LUNG C, V275, pL478, DOI 10.1152/ajplung.1998.275.3.L478; Folkesson HG, 1996, J APPL PHYSIOL, V80, P1431, DOI 10.1152/jappl.1996.80.5.1431; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; FUKUDA Y, 1987, AM J PATHOL, V126, P171; Fulkerson WJ, 1996, ARCH INTERN MED, V156, P29, DOI 10.1001/archinte.156.1.29; Garat C, 1997, CHEST, V111, P1381, DOI 10.1378/chest.111.5.1381; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GHIO AJ, 1989, AM REV RESPIR DIS, V140, P862; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; Gillis P, 1999, J CELL SCI, V112, P2049; Goodman LR, 1996, RADIOL CLIN N AM, V34, P33; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Gunther A, 2000, AM J RESP CRIT CARE, V161, P454; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HEFFNER JE, 1995, AM J RESP CRIT CARE, V152, P1518, DOI 10.1164/ajrccm.152.5.7582287; HEYLAND DK, 1993, INTENS CARE MED, V19, P435, DOI 10.1007/BF01711083; Hirschl RB, 1996, JAMA-J AM MED ASSOC, V275, P383, DOI 10.1001/jama.275.5.383; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; Ingbar DH, 1998, LUNG BIOL HEALTH DIS, V116, P477; Jiang XP, 1998, AM J PHYSIOL-CELL PH, V275, pC1610, DOI 10.1152/ajpcell.1998.275.6.C1610; KIRBY RR, 1975, CHEST, V67, P156, DOI 10.1378/chest.67.2.156; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; Lasnier JM, 1996, J APPL PHYSIOL, V81, P1723, DOI 10.1152/jappl.1996.81.4.1723; LAUFE MD, 1986, AM J MED, V80, P1022, DOI 10.1016/0002-9343(86)90659-5; LESSARD MR, 1994, ANESTHESIOLOGY, V80, P983, DOI 10.1097/00000542-199405000-00006; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LEWIS JF, 1993, AM REV RESPIR DIS, V147, pU1065; LINDROOS PM, 1995, AM J RESP CELL MOL, V13, P455, DOI 10.1165/ajrcmb.13.4.7546776; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MARTIN C, 1995, CHEST, V107, P196, DOI 10.1378/chest.107.1.196; Martinet Y, 1996, ARCH TOX S, V18, P127; Masclans JR, 1996, AM J RESP CRIT CARE, V154, P529, DOI 10.1164/ajrccm.154.2.8756833; Matalon S, 1996, AM J PHYSIOL-LUNG C, V271, pL1, DOI 10.1152/ajplung.1996.271.1.L1; Matthay M A, 1999, Chest, V116, p119S; MATTHAY MA, 1994, SEMIN RESP CRIT CARE, V15, P271, DOI 10.1055/s-2007-1006373; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; Meade MO, 2000, AM J RESP CRIT CARE, V161, P85, DOI 10.1164/ajrccm.161.1.9809003; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; Modelska K, 1999, AM J RESP CRIT CARE, V160, P1450, DOI 10.1164/ajrccm.160.5.9901096; Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MONTGOMERY AB, 1989, AM REV RESPIR DIS, V139, P1548, DOI 10.1164/ajrccm/139.6.1548; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; MURRAY JF, 1977, AM REV RESPIR DIS, V115, P1071; Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037; Nelson S, 1998, J INFECT DIS, V178, P1075, DOI 10.1086/515694; Newman V, 2000, AM J RESP CRIT CARE, V161, P990, DOI 10.1164/ajrccm.161.3.9901042; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809; PAYEN D, 1999, INTENS CARE MED S, V25, pS166; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; PRATT PC, 1979, AM J PATHOL, V95, P191; Prescott SM, 1999, J CLIN INVEST, V104, P1019, DOI 10.1172/JCI8506; PREWITT RM, 1981, J CLIN INVEST, V67, P409, DOI 10.1172/JCI110049; PREWITT RM, 1981, ANESTHESIOLOGY, V55, P537, DOI 10.1097/00000542-198111000-00010; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; RADERMACHER P, 1990, ANESTHESIOLOGY, V72, P238, DOI 10.1097/00000542-199002000-00005; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Saint S, 1998, AM J MED, V105, P515, DOI 10.1016/S0002-9343(98)00322-2; Saldias FJ, 1999, J APPL PHYSIOL, V87, P30, DOI 10.1152/jappl.1999.87.1.30; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; SCHNAPP LM, 1995, CRIT CARE MED, V23, P272, DOI 10.1097/00003246-199502000-00012; SIMMONS RS, 1987, AM REV RESPIR DIS, V135, P924, DOI 10.1164/arrd.1987.135.4.924; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; SUCHYTA MR, 1993, RESPIRATION, V60, P103; Sznajder JI, 1999, AM J RESP CRIT CARE, V160, P1441; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; Viget N, 1999, AM J RESP CRIT CARE, V159, pA600; VILLAR J, 1989, AM REV RESPIR DIS, V140, P814, DOI 10.1164/ajrccm/140.3.814; Wang YB, 1999, J APPL PHYSIOL, V87, P1852, DOI 10.1152/jappl.1999.87.5.1852; Ware LB, 1999, AM J RESP CRIT CARE, V159, P980, DOI 10.1164/ajrccm.159.3.9802105; WARE LB, 1999, AM J RESP CRIT SA694, V159; WARE LB, 2000, AM J RESP CRIT CARE, V161, pA380; Waters CM, 1997, AM J PHYSIOL-LUNG C, V272, pL681, DOI 10.1152/ajplung.1997.272.4.L681; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WEBSTER NR, 1988, ANAESTHESIA, V43, P923, DOI 10.1111/j.1365-2044.1988.tb05652.x; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Widdcombe JH, 2000, AM J PHYSIOL-LUNG C, V278, pL231, DOI 10.1152/ajplung.2000.278.2.L231; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388; WIENERKRONISH JP, 1988, CHEST, V93, P852, DOI 10.1378/chest.93.4.852; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009; ZAPOL WM, 1979, AM REV RESPIR DIS, V119, P547; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	149	3946	4199	8	196	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1334	1349		10.1056/NEJM200005043421806	http://dx.doi.org/10.1056/NEJM200005043421806			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793167				2023-01-03	WOS:000086782400006
J	Ferrand, E; Robert, R; Ingrand, P; Lemaire, F				Ferrand, E; Robert, R; Ingrand, P; Lemaire, F		French LATAREA Grp	Withholding and withdrawal of life support in intensive-care units in France: a prospective survey	LANCET			English	Article							SUSTAINING TREATMENT; DECISIONS; LIMIT	Background In France, there are no guidelines available on withholding and withdrawal of life-sustaining treatments, and information on the frequency of such decisions is scarce. Methods We undertook a prospective 2-month survey in 113, of a total of 220, intensive-care units (ICUs) in France to study the frequency of, and processes leading to, decisions to withhold and withdraw life-sustaining treatments. Findings Life-supporting therapies were withheld or withdrawn in 807 (11.0%) of 7309 patients (withholding in 336 [4.6%] and withdrawal in 471 [6.4%], preceded in 358 by withholding). Of 1175 deaths in ICU, 628 (53%) were preceded by a decision to limit life-supporting therapies. Futility and poor expected quality of life were the most frequently cited reasons. Decisions were strongly correlated with the simplified acute physiological score, but an independent centre effect persisted after adjustment for this score. Decisions were mostly taken by all the ICU medical staff, with (54%) or without (34%) the nursing staff; however, a single physician made decisions in 12% of cases. The patient's family was involved in the decision-making process in 44% of cases. The patient's willingness to limit his or her own care was known in only 8% of the cases; only 0.5% of the patients were involved in decisions. Interpretation Withholding and withdrawal of life-support therapies are widely practised in French ICUs, despite their prohibition by the French legislation. The lack of an official statement from French scientific bodies may explain several limitations on the various steps of the decision-making process.	Henri Mondor Univ Hosp, Surg Unit, Creteil, France; Henri Mondor Univ Hosp, Med Unit, Creteil, France; Henri Mondor Univ Hosp, Intens Care Unit, Creteil, France; Jean Bernard Univ Hosp, Dept Biostat, Poitiers, France; Jean Bernard Univ Hosp, Med Intens Care Unit, Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Poitiers; CHU Poitiers	Ferrand, E (corresponding author), Hop Henri Mondor, Unite Reanimat Chirurg & Traumatol, Serv Anesthesie Reanimat, 51 Rue M de Lattre de Tassigny, F-94010 Creteil, France.	eferrand@club-internet.fr						[Anonymous], 1990, CRIT CARE MED, V18, P1435; [Anonymous], 1991, Am Rev Respir Dis, V144, P726; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; *APPL INT C, 1992, J MED ETHICS S, V18, P1; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; *CCNE, 1998, CAH COM CONS NAT ETH, P3; COHEN LM, 1993, ARCH INTERN MED, V153, P2481, DOI 10.1001/archinte.153.21.2481; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Danis M, 1997, CRIT CARE MED, V25, P887; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FAVEREAU E, 1998, LIBERATION      0312, P1; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Peillon D, 1997, ANN FR ANESTH, V16, P25, DOI 10.1016/S0750-7658(97)84274-8; PEILLON D, 1995, REAN URG, V4, P3; Portes L., 1954, RECHERCHE ETHIQUE ME; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE, P121; Robert R, 1996, REAN URG, V5, P611; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; Turner JS, 1996, INTENS CARE MED, V22, P1020, DOI 10.1007/s001340050207; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WOOD GG, 1995, CAN J ANAESTH, V42, P186, DOI 10.1007/BF03010673	27	348	362	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	2001	357	9249					9	14		10.1016/S0140-6736(00)03564-9	http://dx.doi.org/10.1016/S0140-6736(00)03564-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197395				2023-01-03	WOS:000166341500008
J	Fromm, R; Guntupalli, K				Fromm, R; Guntupalli, K			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Review							MECHANICAL VENTILATION; UNIT		Methodist Hosp, Houston, TX 77030 USA; Ben Taub Gen Hosp, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston	Fromm, R (corresponding author), Methodist Hosp, 6565 Fannin St,Room 196, Houston, TX 77030 USA.							ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	6	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2000	133	12					974	980		10.7326/0003-4819-133-12-200012190-00013	http://dx.doi.org/10.7326/0003-4819-133-12-200012190-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384NT	11119399				2023-01-03	WOS:000165952300006
J	Deliens, L; Mortier, F; Bilsen, J; Cosyns, M; Vander Stichele, R; Vanoverloop, J; Ingels, K				Deliens, L; Mortier, F; Bilsen, J; Cosyns, M; Vander Stichele, R; Vanoverloop, J; Ingels, K			End-of-life decisions in medical practice in Flanders, Belgium: a nationwide survey	LANCET			English	Article							PHYSICIAN-ASSISTED SUICIDE; MAIL SURVEYS; EUTHANASIA; NETHERLANDS	Background Our study is a repeat of the Dutch death-certificate study on end-of-life decisions (ELDs). The main objective was to estimate the frequency of euthanasia (the administration of lethal drugs with the explicit intention of shortening the patient's life at the patient's explicit request), physician-assisted suicide (PAS), and other ELDs in medical practice in Flanders, Belgium. Methods A 20% random sample of 3999 deaths was selected from all deaths recorded between Jan 1 and April 30, 1998. The physicians who signed the corresponding death certificates received one questionnaire by post per death. Findings The physicians' response rate was 1355 (52%). 1925 deaths were described. The results were corrected for non-response bias, and extrapolated to estimated annual rates after seasonal adjustment for death causes, and we estimate that 705 (1.3%, 95% CI 1.0-1.6) deaths resulted from euthanasia or PAS. In 1796 (3.2%, 2.7-3.8) cases, lethal drugs were given without the explicit request of the patient. Alleviation of pain and symptoms with opioids in doses with a potential life-shortening effect preceded death in 10 416 (18.5%, 17.3-19.7) cases and non-treatment decisions in 9218 (16.4%, 15.3-17.5) cases, of which 3261 (5.8%, 5.1-6.5) with the explicit intention of ending the patient's life. Interpretation ELDs are prominent in medical practice in Flanders. The frequency of deaths preceded by an ELD is similar to that in the Netherlands, but lower than that in Australia. However, in Flanders the rate of administration of lethal drugs to patients without their explicit request is similar to Australia, and significantly higher than that in the Netherlands.	Free Univ Brussels, Dept Med Sociol & Hlth Sci, B-1090 Brussels, Belgium; State Univ Ghent, Ctr Environm Philosophy & Bioeth, B-9000 Ghent, Belgium; State Univ Ghent, Dept Gen Practice, B-9000 Ghent, Belgium; Flemish Inst Gen Practice, Antwerp, Belgium; Minist Flanders, Prevent & Social Hlth Care Div, Brussels, Belgium; Catholic Univ Nijmegen, Acad Hosp, Nijmegen, Netherlands	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University; Radboud University Nijmegen	Deliens, L (corresponding author), Free Univ Brussels, Dept Med Sociol & Hlth Sci, Laarbeeklaan 103, B-1090 Brussels, Belgium.		Stichele, Robert Vander/K-7203-2015; Ingels, K.J.A.O./L-4404-2015	Stichele, Robert Vander/0000-0001-9118-9651; Mortier, Freddy/0000-0002-5390-3508; Deliens, Luc/0000-0002-8158-2422				Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BERNARD HR, 1984, ANNU REV ANTHROPOL, V13, P495, DOI 10.1146/annurev.an.13.100184.002431; DELIENS L, 1991, NUISARTS NU, V20, P113; DILLMAN DA, 1991, ANNU REV SOCIOL, V17, P225, DOI 10.1146/annurev.so.17.080191.001301; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Jochemsen H, 1999, J MED ETHICS, V25, P16, DOI 10.1136/jme.25.1.16; Kaner EF, 1998, BRIT J GEN PRACT, V48, P1067; KEOWN J, 1995, EUTHANASIA EXAMINED, P261; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; LEMESHOW S, 1992, ADEQUACY SAMPLE SIZE, P1; MCCULLAGH P, 1994, GEN LINEAR MODELS, P72; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Mortier F, 2000, BIOETHICS, V14, P254, DOI 10.1111/1467-8519.00195; *NAT RAAD ORD GEN, 1997, TIJDSCHR NAT RAAD OR, V7, P27; *RAADG COM BIOETH, 1998, BIOETHIC BELG    MAY, P2; SIBBALD B, 1998, BR J GE PRACT, V48, P1067; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; [No title captured]	19	225	227	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1806	1811		10.1016/S0140-6736(00)03233-5	http://dx.doi.org/10.1016/S0140-6736(00)03233-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	377UY	11117913				2023-01-03	WOS:000165545700012
J	Parmanum, J; Field, D; Rennie, J; Steer, P				Parmanum, J; Field, D; Rennie, J; Steer, P		Brit Assoc Perinatal Med	National census of availability of neonatal intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COTS	Objective To determine whether availability of neonatal intensive care cots is a problem in any or all parts of the United Kingdom. Design Three month census fi-om 1 April to 30 June 1999 comprising simple data sheets on transfers out of tertiary units. Setting The 37 largest high risk perinatal centres in the United Kingdom. Participants One obstetric specialist and one neonatal specialist in each centre. Main outcome measures Suboptimal care resulting directly from pressure on service-that is, transfers out of tertiary units (either in utero or after delivery) because the unit was "full" and not because the hospital was incapable of providing the care needed. Results All units provided data. The number of intensive care cots in each unit was between five and 16. During the three months 309 transfers occurred (equivalent to 1236 per year), of which 264 were in utero and 45 postnatal. Sixty five in utero transfers involved multiple births, hence the census related to 382 babies (1528 per year). There was considerable regional variation. The reason for transfer in most cases was "lack of neonatal beds". Conclusions Currently most major perinatal centres in the United Kingdom are regularly unable to meet in-house demand; this has implications for the service as a whole. The NHS has set no standards to help health authorities and primary care groups develop services relating to this specialty; such a step may well be an appropriate lever for change.	Univ Leicester, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Kings Coll Hosp London, London SE5 9RS, England; Imperial Coll Sch Med, London W2 1PG, England	University of Leicester; King's College Hospital NHS Foundation Trust; King's College Hospital; Imperial College London	Field, D (corresponding author), Univ Leicester, Dept Child Hlth, Robert Kilpatrick Clin Sci Bldg, Leicester LE2 7LX, Leics, England.	dfield@lri.org.uk						BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; *CLIN STAND ADV GR, 1993, ACC AV NEON INT CAR; *DEP EP PUBL HLTH, 1999, TRENT NEON SURV 1998; Field D, 1999, ARCH DIS CHILD-FETAL, V80, pF111, DOI 10.1136/fn.80.2.F111; FIELD DJ, 1989, BRIT MED J, V299, P1305, DOI 10.1136/bmj.299.6711.1305; MCINTOSH N, 1989, BRIT MED J, V298, P169; MCLOUGHLIN A, 1993, ARCH DIS CHILD-FETAL, V68, P597, DOI 10.1136/adc.68.5_Spec_No.597; Milligan DWA, 1997, ARCH DIS CHILD-FETAL, V76, pF197, DOI 10.1136/fn.76.3.F197; MORRIS D, 1993, ARCH DIS CHILD-FETAL, V68, P544; National Association of Health Authorities, 1993, REINV HLTH CAR NEW M; *ROYAL COLL PHYS, 1988, MED CAR NEWB ENGL WA; SIMPSON H, 1981, ARCH DIS CHILD, V56, P90, DOI 10.1136/adc.56.2.90; 1999, TIMES           0803	13	39	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2000	321	7263					727	729		10.1136/bmj.321.7263.727	http://dx.doi.org/10.1136/bmj.321.7263.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999901	Green Published, Bronze			2023-01-03	WOS:000089546600018
J	Astin, JA; Harkness, E; Ernst, E				Astin, JA; Harkness, E; Ernst, E			The efficacy of "distant healing": A systematic review of randomized trials	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-CARE UNIT; THERAPEUTIC TOUCH; ALTERNATIVE MEDICINE; INTERCESSORY PRAYER; HEALTH-CARE; OUTCOMES; RELIGION; REMOTE; PAIN	Purpose: To conduct a systematic review of the available data on the efficacy of any form of "distant healing" (prayer, mental healing, Therapeutic Touch, or spiritual healing) as treatment for any medical condition. Data Sources: Studies were identified by an electronic search of the MEDLINE, PsychLIT, EMBASE, CISCOM, and Cochrane Library databases from their inception to the end of 1999 and by contact with researchers in the field. Study Selection: Studies with the following features were included: random assignment, placebo or other adequate control, publication in peer-reviewed journals, clinical (rather than experimental) investigations, and use of human participants. Data Extraction: Two investigators independently extracted data on study design, sample size, type of intervention, type of control, direction of effect (supporting or refuting the hypothesis), and nature of the outcomes. Data Synthesis: A total of 23 trials involving 2774 patients met the inclusion criteria and were analyzed. Heterogeneity of the studies precluded a formal meta-analysis. Of the trials, 5 examined prayer as the distant healing intervention, 11 assessed noncontact Therapeutic Touch, and 7 examined other forms of distant healing. Of the 23 studies, 13 (57%) yielded statistically significant treatment effects, 9 showed no effect over control interventions, and 1 showed a negative effect. Conclusions: The methodologic limitations of several studies make it difficult to draw definitive conclusions about the efficacy of distant healing. However, given that approximately 57% of trials showed a positive treatment effect, the evidence thus far merits further study.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Exeter, Exeter, Devon, England	University System of Maryland; University of Maryland Baltimore; University of Exeter	Astin, JA (corresponding author), Kernan Hosp Mans, Complementary Med Program, 2200 Kernan Dr, Baltimore, MD 21207 USA.	jastin@compmed.ummc.umaryland.edu		Harkness, Elaine/0000-0001-6625-7739				Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BENOR DJ, 1990, COMPLEMENT MED RES, V4, P9; BEUTLER JJ, 1988, BRIT MED J, V296, P1491, DOI 10.1136/bmj.296.6635.1491; BRAUD W, 1983, J PARAPSYCHOL, V47, P95; BROWN CK, 1995, COMPLEMENT THER MED, V3, P230; BYRD RC, 1988, SOUTHERN MED J, V81, P826, DOI 10.1097/00007611-198807000-00005; Cohen J., 2013, STAT POWER ANAL BEHA; Collipp P J, 1969, Med Times, V97, P201; Daley B, 1997, J ADV NURS, V25, P1123, DOI 10.1046/j.1365-2648.1997.19970251123.x; Dossey L, 1997, Altern Ther Health Med, V3, P10; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Gordon A, 1998, J FAM PRACTICE, V47, P271; GREYSON B, 1996, J SCI EXPLORATION, V10, P447; HARKNESS EF, IN PRESS AM J MED; Harris WS, 1999, ARCH INTERN MED, V159, P2273, DOI 10.1001/archinte.159.19.2273; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOYCE CRB, 1965, J CHRON DIS, V18, P367, DOI 10.1016/0021-9681(65)90040-8; KASS JD, 1991, J SCI STUD RELIG, V30, P203, DOI 10.2307/1387214; KELLER E, 1986, NURS RES, V35, P101; Krucoff MW, 1998, CIRCULATION, V98, P280; LEVIN JS, 1994, SOC SCI MED, V38, P1475, DOI 10.1016/0277-9536(94)90109-0; Luskin F, 2000, J Cardiopulm Rehabil, V20, P8, DOI 10.1097/00008483-200001000-00002; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Matthews DA, 1998, ARCH FAM MED, V7, P118, DOI 10.1001/archfami.7.2.118; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MILLER RN, 1982, MED HYPOTHESES, V8, P481, DOI 10.1016/0306-9877(82)90009-3; OMATHUNA D, 1999, COCHRANE DATABASE SY, V2; OMATHUNA DP, 1998, SCI REV ALTERNATE ME, V2, P56; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; ROBERTS L, 1999, COCHRANE DATABASE SY, V2; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; Sicher F, 1998, WESTERN J MED, V169, P356; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Targ E, 1997, Altern Ther Health Med, V3, P92; Targ E, 1997, Altern Ther Health Med, V3, P74; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; Turner JG, 1998, J ADV NURS, V28, P10, DOI 10.1046/j.1365-2648.1998.00770.x; Walker S R, 1997, Altern Ther Health Med, V3, P79; Wallis C., 1996, TIME, P58; WARBER SL, IN PRESS FOCUS ALTER; Winstead-Fry P, 1999, ALTERN THER HEALTH M, V5, P58; WIRTH DP, 1995, SOC SCI MED, V41, P249, DOI 10.1016/0277-9536(94)00312-H; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; WIRTH DP, 1994, COMPLEMENTARY THERAP, V2, P187; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WIRTH DP, 1996, COMPLEMENTARY THERAP, V4, P237; WIRTH DP, 1993, COMPLEMENT THER MED, V1, P133; Wiseman R, 1997, J PARAPSYCHOL, V61, P197	52	202	205	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					903	910		10.7326/0003-4819-132-11-200006060-00009	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	319HF	10836918				2023-01-03	WOS:000087334900008
J	Peipert, JF				Peipert, JF			Ambulatory gynecology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTERIAL VAGINOSIS; COST-EFFECTIVENESS; PRETERM BIRTH; HIV-INFECTION; VAGINAL FLORA; METRONIDAZOLE; TECHNOLOGIES; DISTURBANCES; PREGNANCY; WOMEN		Brown Univ, Sch Med, Women & Infants Hosp,Div Res Womens Hlth, Dept Obstet Gynecol & Community Hlth, Providence, RI 02912 USA	Brown University; Women & Infants Hospital Rhode Island	Peipert, JF (corresponding author), Women & Infants Hosp, Dept Obstet & Gynecol, 101 Dudley St, Providence, RI 02905 USA.							*AG HLTH CAR POL R, 1999, 5 AG HLTH CAR POL RE; Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Diaz-Rosario LA, 1999, ARCH PATHOL LAB MED, V123, P817; Grimes D, 1998, LANCET, V352, P428; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILLIER S, 1999, SEXUALLY TRANSMITTED, P563; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; Oleen-Burkey M A, 1995, Infect Dis Obstet Gynecol, V3, P149, DOI 10.1155/S1064744995000500; Raab SS, 1999, AM J CLIN PATHOL, V111, P259; Royce RA, 1999, J ACQ IMMUN DEF SYND, V20, P382, DOI 10.1097/00042560-199904010-00009; Sawaya GF, 1999, CLIN OBSTET GYNECOL, V42, P922, DOI 10.1097/00003081-199912000-00020; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Taha TE, 1999, J ACQ IMMUN DEF SYND, V20, P52, DOI 10.1097/00042560-199901010-00008; Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019; Trussell J, 2000, OBSTET GYNECOL, V95, P267, DOI 10.1016/S0029-7844(99)00518-9; *US PREV SERV TASK, 1995, GUID CLIN PREV SERV	18	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	2000	283	20					2630	2632		10.1001/jama.283.20.2630	http://dx.doi.org/10.1001/jama.283.20.2630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314FP	10819923				2023-01-03	WOS:000087046000002
J	Miller, FG; Fins, JJ; Snyder, L				Miller, FG; Fins, JJ; Snyder, L			Assisted suicide compared with refusal of treatment: A valid distinction?	ANNALS OF INTERNAL MEDICINE			English	Article							VOLUNTARY ACTIVE EUTHANASIA; TERMINALLY ILL PATIENTS; DEATH; HYDRATION; NUTRITION	The continuing debate over the deeply controversial issue of physician-assisted suicide has been complicated by confusion about how this practice resembles or differs from refusal of life-sustaining treatment. Perspectives on ethics and policy hinge on the contested issue of whether a valid distinction can be made between assisted suicide and withdrawal of treatment. This paper uses three illustrative cases to examine leading arguments for and against the recognition of a fundamental distinction between these practices. The first case involves assisted suicide by ingestion of prescribed barbiturates, the second involves withdrawal of artificial nutrition and hydration, and the third involves a decision to stop eating and drinking. On theoretical and practical grounds, this paper defends the position that there is a valid distinction between assisted suicide and refusal of treatment.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Virginia, Charlottesville, VA USA	University of Pennsylvania; Pennsylvania Medicine; University of Virginia	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org		Fins, Joseph/0000-0002-7221-0053				Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P238; BEAUCHAMP TL, 1995, ETHICAL ISSUES DEATH, P112; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BROCK DW, 1993, LIFE DEATH, P208; BROCK DW, 1993, LIFE DEATH, P165; BRODY H, 1993, J CLIN ETHIC, V4, P112; CALLAHAN D, 1993, TROUBLED DREAM LIFE, P76; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Field MJ, 1997, APPROACHING DEATH IM; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1996, BIOLAW LEGAL ETHICAL, pS136; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS, P146; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PENCE GE, 1995, CLASSIC CASES MED ET, P51; Powell T, 1996, J LAW MED ETHICS, V24, P54, DOI 10.1111/j.1748-720X.1996.tb01833.x; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; Snyder L, 1996, Pa Med, V99, P10; Ubel PA, 1997, J CLIN ETHIC, V8, P242; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13	27	27	28	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					470	475		10.7326/0003-4819-132-6-200003210-00008	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733447				2023-01-03	WOS:000085834700007
J	Rhymes, JA; McCullough, LB; Luchi, RJ; Teasdale, TA; Wilson, N				Rhymes, JA; McCullough, LB; Luchi, RJ; Teasdale, TA; Wilson, N			Withdrawing very low-burden interventions in chronically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rhymes, JA (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza,M310, Houston, TX 77030 USA.							Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; Brock D. W., 1995, ENCY BIOETHICS, P563; Garcia J. L. A., 1995, ENCY BIOETHICS, P636; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; WALTER JL, 1995, ENCY BIOETHICS, P1353	5	39	39	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1061	1063		10.1001/jama.283.8.1061	http://dx.doi.org/10.1001/jama.283.8.1061			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697070				2023-01-03	WOS:000085308600039
J	St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D				St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D			Changes in the scope of care provided by primary care physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES; MANAGED-CARE; CONSULTATION	Background: Strategies to control medical costs and improve the quality of care often translate into decisions affecting the range of services primary care physicians provide to patients, which patients are referred for specialty care, and the points in disease processes at which referrals are made. This study focused on physicians' assessments of changes in the scope of care provided by primary care physicians and their assessments of the appropriateness of the scope of the care that primary care physicians are expected to provide. Methods: We analyzed data from the 1996-1997 Community Tracking Study Physician Survey. Telephone interviews were conducted with 12,385 physicians (reflecting a response rate of 65 percent) who were drawn from a representative random sample of physicians providing direct patient care in the continental United States and not employed by the federal government. The analysis was based on responses from the 7015 primary care physicians and 5092 specialists who had been in practice for at least two years. Results: Thirty percent of the primary care physicians and 50 percent of the specialists reported that the scope of care provided by primary care physicians had increased during the previous two years. Twenty-four percent of the primary care physicians and 38 percent of the specialists reported that the scope of care expected to be provided by primary care physicians was greater than it should be. According to multivariate analysis, primary care physicians other than general or family practitioners (i.e., pediatricians and general internists), those who were in one- or two-physician practices, those who received revenues from capitation, and those who served as gatekeepers for their patients' care were significantly more likely to report that the scope of care they were expected to provide was greater than it should be. Conclusions: The finding that nearly one in four primary care physicians reported that the scope of care they were expected to provide was greater than it should be arouses concern about the potential impact of changes in the delivery of health care. The associations we found between financial and administrative aspects of managed care and physicians' concern about the scope of care they provide to their patients deserve careful consideration. (N Engl J Med 1999;341:1980-5.) (C)1999, Massachusetts Medical Society.	Kansas Hlth Inst, Topeka, KS 66612 USA; Ctr Study Hlth Syst Change, Washington, DC USA; Massachusetts Gen Hosp, Partners Healthcare Syst, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	St Peter, RF (corresponding author), Kansas Hlth Inst, 100 SE 9th St,3rd Fl, Topeka, KS 66612 USA.							EISENBERG J, 1986, DOCTORS DECISIONS CO; Grembowski DE, 1998, MED CARE RES REV, V55, P3, DOI 10.1177/107755879805500101; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; Hirth RA, 1996, MED CARE, V34, P1199, DOI 10.1097/00005650-199612000-00005; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1535; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; KEIL L, 1998, TECHNICAL PUBLICATIO, V9; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuo D, 1998, JAMA-J AM MED ASSOC, V280, P905, DOI 10.1001/jama.280.10.905; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; METCALF CE, 1996, TECHNICAL PUBLICATIO, V1; RESCHOVSKY JD, 1998, TECHNICAL PUBLICATIO, V10; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Rosser WW, 1996, J FAM PRACTICE, V42, P139; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136	20	92	94	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1980	1985		10.1056/NEJM199912233412606	http://dx.doi.org/10.1056/NEJM199912233412606			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607816				2023-01-03	WOS:000084399400006
J	van Weel, C				van Weel, C			Examination of context of medicine	LANCET			English	Editorial Material							BREAST-CANCER		Univ Med Ctr St Radboud, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Med Ctr St Radboud, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				FREDRIKSON M, 1993, BRAIN BEHAV IMMUN, V7, P79, DOI 10.1006/brbi.1993.1008; FREEMAN GK, 1984, FAM PRACT, V1, P124; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; Kirsch I., 1997, PLACEBO EFFECT INTER; PETTINGALE KW, 1981, J PSYCHOSOM RES, V25, P453, DOI 10.1016/0022-3999(81)90071-4; PINKUS T, 1997, J MIND BODY HLTH, V13, P3; Starfield B, 1994, LANCET, V344, P129; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; van Weel C, 1999, LANCET, V353, P916, DOI 10.1016/S0140-6736(98)08024-6; van Weel C, 2000, J FAM PRACTICE, V49, P938; VANDULMEN AM, 2000, CONTEXTWERKING GENEE; vanWeel C, 1996, LANCET, V348, P1431, DOI 10.1016/S0140-6736(96)08116-0	12	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 10	2001	357	9258					733	734		10.1016/S0140-6736(00)04176-3	http://dx.doi.org/10.1016/S0140-6736(00)04176-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	409TC	11253959				2023-01-03	WOS:000167400900003
J	Henderson, L; Kitzinger, J; Green, J				Henderson, L; Kitzinger, J; Green, J			Representing infant feeding: content analysis of British media portrayals of bottle feeding and breast feeding	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective To examine how breast feeding and bottle feeding are represented by the British media. Design Content analysis. Subjects Television programmes and newspaper articles that made reference to infant feeding during March 1999. Setting UK mass media Main outcome measures Visual and verbal references to breast or bottle feeding in newspapers and television programmes. Results Overall, 235 references to infant feeding were identified in the television sample and 38 in the newspaper sample. Bottle feeding was shown more often than breast feeding and was presented as less problematic. Bottle feeding was associated with "ordinary" families whereas breast feeding was associated with middle class or celebrity women. The health risks of formula milk and ale health benefits of breast feeding were rarely mentioned. Conclusions The media rarely present positive information on breast feeding, even though this feeding practice is associated with the most health benefits. Health professionals and policy makers should be aware of patterns in media cover-age and the cultural background within which women make decisions about infant feeding.	Brunel Univ, Dept Human Sci, Ctr Media & Commun Res, Uxbridge UB8 3PH, Middx, England; Univ Leeds, Mother & Infant Res Unit, Leeds LS2 9LN, W Yorkshire, England	Brunel University; University of Leeds	Henderson, L (corresponding author), Brunel Univ, Dept Human Sci, Ctr Media & Commun Res, Uxbridge UB8 3PH, Middx, England.			Kitzinger, Jenny/0000-0002-2593-8033				AMOS A, 1992, BRIT MED J, V304, P99, DOI 10.1136/bmj.304.6819.99; ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; BEGG N, 1999, BRIT MED J, V318, P30; Chapman S. L. D., 1994, FIGHT PUBLIC HLTH; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; GRILLI R, 1999, COCHRANE LIB; Henderson L, 1999, SOCIOL HEALTH ILL, V21, P560, DOI 10.1111/1467-9566.00173; Hoddinott P, 1999, BRIT MED J, V318, P30, DOI 10.1136/bmj.318.7175.30; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; MACLEAN HM, 1989, HLTH PROMOTION, V3, P355; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MILLER D, 1997, CIRCUIT MASS COMMUNI; Philo G., 1996, MEDIA MENTAL DISTRES; PISACANE A, 1990, LANCET, V336, P336	14	84	84	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1196	+		10.1136/bmj.321.7270.1196	http://dx.doi.org/10.1136/bmj.321.7270.1196			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073512	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000165357100029
J	Broyles, RS; Tyson, JE; Heyne, ET; Heyne, RJ; Hickman, JF; Swint, M; Adams, SS; West, LA; Pomeroy, N; Hicks, PJ; Ahn, C				Broyles, RS; Tyson, JE; Heyne, ET; Heyne, RJ; Hickman, JF; Swint, M; Adams, SS; West, LA; Pomeroy, N; Hicks, PJ; Ahn, C			Comprehensive follow-up cave and life-threatening illnesses among high-risk infants - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; COST-EFFECTIVENESS; PRIMARY-CARE; HEALTH; CHILDREN; MORTALITY; OUTCOMES; NEWBORNS; MEDICINE; AGE	Context Inner-city high-risk infants often receive limited and fragmented care, a problem that may increase serious illness. Objective To assess whether access to comprehensive care in a follow-up clinic is cost-effective in reducing life-threatening illnesses among high-risk, inner-city infants. Design Randomized controlled trial. Setting and Participants A total of 887 very-low-birth-weight infants born in a Texas county hospital between January 1988 and March 1996 and followed up in a children's hospital clinic. One hundred four infants who became ineligible or died after randomization but before nursery discharge were excluded from the analysis. Interventions Infants were randomly assigned to receive routine follow-up care (well-baby care and care for chronic illnesses; n=441) or comprehensive care (which included the components of routine care plus care for acute illnesses, with 24-hour access to a primary caregiver; n=446). Main Outcome Measures Life-threatening illnesses (ie, causing death or hospital admission for pediatric intensive care) occurring between nursery discharge and age 1 year, assessed by blinded evaluators from inpatient charts and state Medicaid and vital statistics records; and hospital costs (estimated from department-specific cost-to-charge ratios). Results Comprehensive care resulted in a mean of 3.1 more clinic visits and 6.7 more telephone conversations with clinic staff (P<.001 for both). One-year outcomes were unknown for fewer comprehensive-care infants than routine-care infants (9 vs 28; P=.001). Identified deaths were similar (11 in comprehensive care vs 13 in routine care; P=.68). The comprehensive-care group had 48% fewer life-threatening illnesses (33 vs 63; P<.001), 57% fewer intensive care admissions (23 vs 53; P=.003), and 42% fewer intensive care days (254 vs 440; P=.003). Comprehensive care did not increase the mean estimated cost per infant for all care ($6265 with comprehensive care and $9913 with routine care). Conclusion Comprehensive follow-up care by experienced caregivers can be highly effective in reducing life-threatening illness without increasing costs among high-risk inner-city infants.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Univ Texas, Houston Sch Publ Hlth, Houston, TX USA; Childrens Med Ctr Dallas, Dallas, TX USA	University of Texas System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System	Tyson, JE (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin St,MSB 3-228, Houston, TX 77030 USA.			Hicks, Patricia/0000-0003-3781-780X	AHRQ HHS [HS06837] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006837] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; AYLWARD GP, 1985, J DEV BEHAV PEDIATR, V6, P3; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; Broyles RS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.3.e8; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Hannan EL, 1999, NEW ENGL J MED, V340, P1677, DOI 10.1056/NEJM199905273402112; Hoffmann C, 1997, AM J MED SCI, V313, P99, DOI 10.1097/00000441-199702000-00005; LASKY RE, 1987, AM J DIS CHILD, V141, P100, DOI 10.1001/archpedi.1987.04460010100037; LAVE JR, 1994, MED CARE, V32, pJS77; LEUTWYLER K, 1995, SCI AM, V272, P124, DOI 10.1038/scientificamerican0495-124; LEWIT EM, 1995, FUTURE CHILD, V5, P35, DOI 10.2307/1602506; LITTLE BB, 1988, AM J PERINAT, V5, P206, DOI 10.1055/s-2007-999686; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; ORNSTEIN M, 1991, ACTA PAEDIATR SCAND, V80, P741, DOI 10.1111/j.1651-2227.1991.tb11943.x; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rogowski J, 1998, PEDIATRICS, V102, P35, DOI 10.1542/peds.102.1.35; SACKETT DL, 2000, EVIDENCE BASED MED, V5, P112; Scholer SJ, 1999, PEDIATRICS, V103, P1183, DOI 10.1542/peds.103.6.1183; SCOTT DT, 1999, OSKIS PEDIAT PRINCIP, P209; SHWARTZ M, 1995, INQUIRY, V32, P4765; SMITH DR, 1991, AM J MED SCI, V302, P313, DOI 10.1097/00000441-199111000-00010; SOLL RF, 1992, EFFECTIVE CARE NEWBO, P329; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83; TYSON JE, 1988, EARLY HUM DEV, V16, P13, DOI 10.1016/0378-3782(88)90083-7; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WOLKE D, 1995, LANCET, V345, P447, DOI 10.1016/S0140-6736(95)90425-5	34	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2000	284	16					2070	2076		10.1001/jama.284.16.2070	http://dx.doi.org/10.1001/jama.284.16.2070			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	364QA	11042755	Bronze			2023-01-03	WOS:000089902100027
J	Guyatt, GH; Haynes, RB; Jaeschke, RZ; Cook, DJ; Green, L; Naylor, CD; Wilson, MC; Richardson, WS				Guyatt, GH; Haynes, RB; Jaeschke, RZ; Cook, DJ; Green, L; Naylor, CD; Wilson, MC; Richardson, WS		Evidence-Based Med Working Grp	Users' Guides to The Medical Literature - XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIAL; NARRATIVE BASED MEDICINE; HELP ME; DECISION-ANALYSIS; HEART-FAILURE; ARTICLE; WILL; THERAPY; RECOMMENDATIONS	This series provides clinicians with strategies and tools to interpret and integrate evidence from published research in their care of patients. The 2 key principles for applying all the articles in this series to patient care relate to the value-laden nature of clinical decisions and to the hierarchy of evidence postulated by evidence-based medicine. Clinicians need to be able to distinguish high from low quality in primary studies, systematic reviews, practice guidelines, and other integrative research focused on management recommendations. An evidence-based practitioner must also understand the patient's circumstances or predicament; identify knowledge gaps and frame questions to fill those gaps; conduct an efficient literature search; critically appraise the research evidence; and apply that evidence to patient care. However, treatment judgments often reflect clinician or societal values concerning whether intervention benefits are worth the cost. Many unanswered questions concerning how to elicit preferences and how to incorporate them in clinical encounters constitute an enormously challenging frontier for evidence-based medicine. Time limitation remains the biggest obstacle to evidence-based practice but clinicians should seek evidence from as high in the appropriate hierarchy of evidence as possible, and every clinical decision should be geared toward the particular circumstances of the patient.	McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Fac Med, Dept Med, Toronto, ON, Canada; Univ Toronto, Fac Med, Off Dean, Toronto, ON, Canada; Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC USA; Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst & Med, Dept Ambulatory Care, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst & Med, Dept Res, San Antonio, TX USA	McMaster University; McMaster University; University of Toronto; University of Toronto; University of Michigan System; University of Michigan; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Guyatt, GH (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Haynes, Robert Brian/0000-0002-1453-3196				Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Greenhalgh T, 1999, BRIT MED J, V318, P48; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; GUYATT GH, 2000, BRIT MED J, V320, P945; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Haynes R B, 1996, ACP J Club, V125, pA14; Haynes R B, 1997, ACP J Club, V126, pA14; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunt DL, 2000, JAMA-J AM MED ASSOC, V283, P1875, DOI 10.1001/jama.283.14.1875; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LARSON EB, 1993, JAMA-J AM MED ASSOC, V270, P2708, DOI 10.1001/jama.270.22.2708; Lechat P, 1999, LANCET, V353, P9; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Mahon J, 1996, BRIT MED J, V312, P1069; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Nisbett R., 1980, HUMAN INFERENCE; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	42	489	508	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1290	1296		10.1001/jama.284.10.1290	http://dx.doi.org/10.1001/jama.284.10.1290			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979117				2023-01-03	WOS:000089124600037
J	Jordhoy, MS; Fayers, P; Saltnes, T; Ahlner-Elmqvist, M; Jannert, M; Kaasa, S				Jordhoy, MS; Fayers, P; Saltnes, T; Ahlner-Elmqvist, M; Jannert, M; Kaasa, S			A palliative-care intervention and death at home: a cluster randomised trial	LANCET			English	Article							CANCER-PATIENTS; COST-EFFECTIVENESS; TERMINALLY ILL; PLACE; CHALLENGES; PROGRAMS; HOSPICE; ISSUES	Background The Palliative Medicine Unit at University Hospital of Trondheim, Norway, started an intervention programme that aims to enable patients to spend more time at home and die there if they prefer. Close cooperation was needed with the community health-care professionals, who acted as the principal formal caregivers, and a multidisciplinary consultant team coordinated the care. We did a cluster randomised trial to assess the intervention's effectiveness compared with conventional care Methods Community health-care districts in and around Trondheim, Norway, were defined as the clusters to be randomised. We enrolled 434 patients (235 assigned intervention and 199 conventional care [controls]) in these districts who had incurable malignant disease and an expected survival of 2-9 months. Main outcomes were place of death and time spent in institutions in the last month of life. Findings 395 patients died. Of these, more intervention patients than controls died at home (54 [25%] vs 26 [15%], p<0.05). The time spent at home was not significantly increased, although intervention patients spent a smaller proportion of time in nursing homes in the last month of life than did controls (7.2 vs 14.6%, p<0.05). Hospital use was similar in the two groups. Interpretation The palliative-care intervention enabled more patients to die at home. More resources for care in the home (palliative care training and staff) and an increased focus on use of nursing homes would be necessary, however, to increase time at home and reduce hospital admissions.	Univ Trondheim Hosp, Kreftbygget Univ Hosp Trondheim, Norwegian Univ Sci & Technol, Unit Appl Clin Res, N-7006 Trondheim, Norway; Malmo Univ Hosp, Dept Otorhinolaryngol, Malmo, Sweden; Univ Trondheim Hosp, Dept Radiotherapy & Oncol, Palliat Med Unit, N-7006 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Lund University; Skane University Hospital; Norwegian University of Science & Technology (NTNU)	Jordhoy, MS (corresponding author), Univ Trondheim Hosp, Kreftbygget Univ Hosp Trondheim, Norwegian Univ Sci & Technol, Unit Appl Clin Res, N-7006 Trondheim, Norway.		Fayers, Peter M/A-5999-2010	Fayers, Peter/0000-0003-4778-1513; Slaaen, Marit/0000-0002-1038-8032				Ashby M, 1993, Palliat Med, V7, P273, DOI 10.1177/026921639300700403; DeConno F, 1996, EUR J CANCER, V32A, P1142, DOI 10.1016/0959-8049(96)00036-6; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; EFFRAN B, 1993, INTRO BOOTSTRAP, P88; Grande GE, 1998, SOC SCI MED, V47, P565, DOI 10.1016/S0277-9536(98)00115-4; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Higginson IJ, 1999, BRIT MED J, V319, P462, DOI 10.1136/bmj.319.7208.462; Higginson IJ, 1998, PALLIATIVE MED, V12, P353, DOI 10.1191/026921698672530176; Hinton John, 1994, Palliative Medicine, V8, P197, DOI 10.1177/026921639400800303; Hughes SL, 1997, HEALTH SERV RES, V32, P415; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; Jordhoy MS, 1999, PALLIATIVE MED, V13, P299, DOI 10.1191/026921699668963873; KANE RL, 1984, LANCET, V1, P890; KOEPSELL TD, 1992, ANNU REV PUBL HEALTH, V13, P31, DOI 10.1146/annurev.pu.13.050192.000335; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; *NORG OFF UTR, 1997, OMS KUNNSK NORSK KRE; Porta M, 1997, PALLIATIVE MED, V11, P116, DOI 10.1177/026921639701100205; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Raftery JP, 1996, PALLIATIVE MED, V10, P151, DOI 10.1177/026921639601000210; Rinck GC, 1997, J CLIN ONCOL, V15, P1697, DOI 10.1200/JCO.1997.15.4.1697; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; *SOS HELS I SAM ME, 1998, STYR INF HELS SOS I; Stajduhar KI, 1998, J PALLIAT CARE, V14, P8, DOI 10.1177/082585979801400304; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; VINCIGUERRA V, 1986, J CLIN ONCOL, V4, P1521, DOI 10.1200/JCO.1986.4.10.1521; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	28	222	226	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 9	2000	356	9233					888	893		10.1016/S0140-6736(00)02678-7	http://dx.doi.org/10.1016/S0140-6736(00)02678-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	353DP	11036893				2023-01-03	WOS:000089259800010
J	van Basten, JPA; van Driel, MF; Hoekstra, HJH; Sleijfer, DT				van Basten, JPA; van Driel, MF; Hoekstra, HJH; Sleijfer, DT			Erectile dysfunction with chemotherapy	LANCET			English	Letter							TESTICULAR CANCER		Isala Clin, Dept Urol, Zwolle, Netherlands; Univ Groningen Hosp, Dept Urol, Groningen, Netherlands; Univ Groningen Hosp, Dept Surg Oncol, Groningen, Netherlands; Univ Groningen Hosp, Dept Clin Oncol, Groningen, Netherlands	Isala Clinics; University of Groningen; University of Groningen; University of Groningen	van Basten, JPA (corresponding author), Isala Clin, Dept Urol, Zwolle, Netherlands.		hoekstra, harald/AAR-3263-2021					Chatterjee R, 2000, LANCET, V355, P1335, DOI 10.1016/S0140-6736(00)02121-8; Van Basten JPA, 1999, BJU INT, V84, P671; vanBasten JPA, 1997, J CLIN ONCOL, V15, P2442, DOI 10.1200/JCO.1997.15.6.2442	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 8	2000	356	9224					169	169		10.1016/S0140-6736(05)73187-1	http://dx.doi.org/10.1016/S0140-6736(05)73187-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331UG	10963279				2023-01-03	WOS:000088036600058
J	Caplan, AL; Snyder, L; Faber-Langendoen, K				Caplan, AL; Snyder, L; Faber-Langendoen, K		Univ Pennsylvania	The role of guidelines in the practice of physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							DEATH; NETHERLANDS; EUTHANASIA; MODEL; CARE	Oregon has legalized and implemented physician-assisted suicide, while observers argue about the moral import of attempting to formulate guidelines; the utility any set of guidelines can have for physician practice, health care providers, patients, or families; and whether guidelines can really protect against harm or abuse. What were once theoretical questions have taken on new urgency. The debate over the value and power of guidelines includes the following questions: What has been the experience of efforts to implement physician-assisted suicide using consensus guidelines? What goals are guidelines intended to serve? Who should formulate guidelines? What features should be reflected in any proposed guidelines to make them practical and to permit achievement of their goals? Are there any fundamental obstacles to the creation or implementation of guidelines', Is dying a process that is amenable to direction under guidelines, be they issued by physicians, departments of health, blue ribbon panels, or other regulatory bodies? This paper explores these questions as physician-assisted suicide becomes legal.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org						Albom M., 1997, TUESDAYS MORRIE OLD; Anderson P, 1996, ALL US AM TALK MEANI; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Battin Margaret, 1994, LEAST WORST DEATH ES; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Byock I., 1997, DYING WELL; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Coleman CH, 1996, J LAW MED ETHICS, V24, P217, DOI 10.1111/j.1748-720X.1996.tb01855.x; *COMM STUD MED PRA, 1991, MED DEC END LIF; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; *DUTCH SOC ADV PHA, 1994, ADM PREP EUTH; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Faber-Langendoen K, 2000, ANN INTERN MED, V132, P482, DOI 10.7326/0003-4819-132-6-200003210-00010; Field MJ, 1997, APPROACHING DEATH IM; Fins, 1996, Cancer Control, V3, P272; Gomez Carlos F., 1991, REGULATING DEATH EUT; Heilig S, 1997, WESTERN J MED, V166, P370; Hendin H., 1998, SEDUCED DEATH DOCTOR; Humphrey D., 1991, FINAL EXIT PRACTICAL; HUMPHREY D, 1993, LAWFUL EXIT LIMITS F; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kubler-Ross Elisabeth, 1997, WHEEL LIFE MEMOIR LI; LARUE GA, 1996, PLAYING GOD 50 RELIG; MCNEES P, 1998, DYING BOOK COMFORT; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Miller FG, 1997, CAMB Q HEALTHC ETHIC, V6, P78, DOI 10.1017/S0963180100007635; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS; Nuland S.B., 1994, HOW WE DIE; PECK MS, 1997, DENIAL SOUL; PIJNENBORG P, 1995, END LIFE DECISIONS D; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Rabe David, 1998, QUESTION MERCY; ROLLIN B, 1985, LAST WISH; SHAVELSON L, 1995, CHOSEN DEATH DYING C; SIMONS M, 1995, NY TIMES        0909; Smith W.J., 1997, FORCED EXIT SLIPPERY; SNEIDERMAN B, 1992, HUM MED, V8, P104; Snyder L, 1996, Pa Med, V99, P10; TILDEN VP, 1997, J FAMILY NURSING, V3, P120; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VITEZ M, 1998, FINAL CHOICES SEEKIN; Webb M, 1997, GOOD DEATH NEW AM SE; Young EWD, 1997, WESTERN J MED, V166, P381	47	24	24	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					476	481		10.7326/0003-4819-132-6-200003210-00009	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733448				2023-01-03	WOS:000085834700008
J	Quill, TE; Lee, BC; Nunn, S				Quill, TE; Lee, BC; Nunn, S		Univ Pennslyvania	Palliative treatments of last resort: Choosing the least harmful alternative	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN-ASSISTED SUICIDE; VOLUNTARY ACTIVE EUTHANASIA; LIFE-SUSTAINING TREATMENT; CRITICALLY ILL PATIENTS; TERMINAL DEHYDRATION; DECISION-MAKING; HOPELESSLY ILL; UNITED-STATES; CARE; DEATH	Comprehensive palliative care, as exemplified by many state-of-the-art hospice programs, is the standard of care for the dying. Although palliative care is very effective, physicians, nurses, patients, families, and loved ones regularly face clinically, ethically, legally, and morally challenging decisions throughout the dying process. This is especially true when terminally ill patients are ready to die in the face of complex, difficult-to-treat suffering and request assistance from their health care providers. Although physician-assisted suicide has received the most attention as a potential last-resort response, this practice remains illegal in the United States except in Oregon, and even there it is relatively infrequent. More commonly, decisions are made about accelerating opioid therapy for pain, forgoing life-sustaining therapy, voluntarily stopping eating and drinking, and administering terminal sedation in response to unacceptable suffering. The moral distinctions between these practices are critical to some but relatively inconsequential to others. This paper illustrates, through summaries of real clinical cases, how each of these practices might be used in response to patients in particular clinical circumstances, keeping in focus the patient's values as well as those of families, other loved ones, and health care providers. The challenge is to find the least harmful solution to the patient's problem without abandoning patients and their loved ones to unacceptable suffering or to acting in a more deleterious way on their own.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Rochester, Sch Med, Genesee Hosp, Rochester, NY USA; Compass Dying Federat, Portland, OR USA	University of Pennsylvania; Pennsylvania Medicine; University of Rochester	Quill, TE (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.							ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Byock I R, 1993, J Palliat Care, V9, P25; Cherny N I, 1994, J Palliat Care, V10, P31; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; Glantz L H, 1987, Law Med Health Care, V15, P231; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T E, 1998, J Palliat Med, V1, P333, DOI 10.1089/jpm.1998.1.333; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Quill TE, 1993, DEATH DIGNITY MAKING; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	38	89	90	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					488	493		10.7326/0003-4819-132-6-200003210-00011	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733450				2023-01-03	WOS:000085834700010
J	Ramakrishna, BS; Venkataraman, S; Srinivasan, P; Dash, P; Young, GP; Binder, HJ				Ramakrishna, BS; Venkataraman, S; Srinivasan, P; Dash, P; Young, GP; Binder, HJ			Amylase-resistant starch plus oral rehydration solution for cholera.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHAIN FATTY-ACIDS; RAT DISTAL COLON; DIARRHEA; ABSORPTION; DYSFUNCTION; EFFICACY; THERAPY; IMPACT; SODIUM	Background: Although standard glucose-based oral rehydration therapy corrects the dehydration caused by cholera, it does not reduce the diarrhea. Short-chain fatty acids, which are produced in the colon from nonabsorbed carbohydrates, enhance sodium absorption. We conducted a study to determine the effects of an orally administered, nonabsorbed starch (i.e., one resistant to digestion by amylase) on fecal fluid loss and the duration of diarrhea in patients with cholera. Methods: We randomly assigned 48 adolescents and adults with cholera to treatment with standard oral rehydration therapy (16 patients), standard therapy and 50 g of rice flour per liter of oral rehydration solution (16 patients), or standard therapy and 50 g of high-amylose maize starch, an amylase-resistant starch, per liter of oral rehydration solution (16 patients). The primary end points were fecal weight (for every 12-hour period during the first 48 hours after enrollment) and the length of time to the first formed stool. Results: The mean (+/-SD) fecal weights in the periods 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours after enrollment were significantly lower in the resistant-starch group (2206+/-1158 g, 1810+/-1018 g, and 985+/-668 g) than in the standard-therapy group (3251+/-766 g, 2621+/-1149 g, and 2498+/-1080 g; P=0.01, P=0.04, and P=0.001, respectively). From 36 to 48 hours after enrollment, fecal weight was also significantly lower with the resistant-starch therapy than with the rice-flour therapy (985+/-668 g vs. 1790+/-866 g, P=0.01). The mean duration of diarrhea was significantly shorter with the resistant-starch therapy (56.7+/-18.6 hours) than with standard therapy alone (90.9+/-29.8 hours, P=0.001) or the rice-flour therapy (70.8+/-20.2 hours, P=0.05). Fecal excretion of starch was higher with the resistant-starch therapy (32.6+/-30.4) than with the standard therapy (11.7+/-4.1 g, P=0.002) or the rice-flour therapy (15.1+/-8.4 g, P=0.01). Conclusions: The addition of a resistant starch to oral rehydration solution reduces fecal fluid loss and shortens the duration of diarrhea in adolescents and adults with cholera. (N Engl J Med 2000;342:308-13.) (C) 2000, Massachusetts Medical Society.	Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore 632004, Tamil Nadu, India; Flinders Univ S Australia, Adelaide, SA 5001, Australia; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Christian Medical College & Hospital (CMCH) Vellore; Flinders University South Australia; Yale University	Ramakrishna, BS (corresponding author), Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore 632004, Tamil Nadu, India.		Ramakrishna, Balakrishnan/D-6808-2015; Subramanian, Venkataraman/B-8274-2011	Ramakrishna, Balakrishnan/0000-0001-5090-9501; Young, Graeme/0000-0001-9458-8383; Subramanian, Venkataraman/0000-0003-3603-0861				[Anonymous], 1978, LANCET, V2, P300; BABANIYI OA, 1991, J TROP PEDIATRICS, V37, P57, DOI 10.1093/tropej/37.2.57; BEHRENS RH, 1993, T R SOC TROP MED S3, V87; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BINDER HJ, 1990, PFLUG ARCH EUR J PHY, V417, P365, DOI 10.1007/BF00370654; Binder HJ, 1998, GASTROENTEROLOGY, V115, P512, DOI 10.1016/S0016-5085(98)70237-9; Binder HJ, 1991, LARGE INTESTINE PHYS, P141; Brown I, 1996, NUTR REV, V54, pS115, DOI 10.1111/j.1753-4887.1996.tb03830.x; CARPENTER CCJ, 1992, J INFECT DIS, V166, P2, DOI 10.1093/infdis/166.1.2; CUMMINGS JH, 1987, AM J CLIN NUTR, V45, P1243, DOI 10.1093/ajcn/45.5.1243; Desjeux JF, 1997, BAILLIERE CLIN GASTR, V11, P509, DOI 10.1016/S0950-3528(97)90029-4; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; GREENOUGH WB, 1993, J DIARRHOEAL DIS RES, V11, P1; HYDEN SA, 1955, LANTBRUKSHOGSK ANN, V22, P139; Krishnan S, 1999, DIGEST DIS SCI, V44, P1924, DOI 10.1023/A:1018871412748; MEEUWISSE GW, 1983, ACTA PAEDIATR SCAND, V72, P161, DOI 10.1111/j.1651-2227.1983.tb09689.x; MUIR JG, 1995, AM J CLIN NUTR, V61, P792, DOI 10.1093/ajcn/61.4.792; NATH SK, 1989, AM J PHYSIOL, V256, pG335, DOI 10.1152/ajpgi.1989.256.2.G335; PHILLIPS J, 1995, AM J CLIN NUTR, V61, P1; PIERRELOUIS JN, 1991, AM J PUBLIC HEALTH, V81, P1205, DOI 10.2105/AJPH.81.9.1205; PIZARRO D, 1992, NEW ENGL J MED, V326, P488; PIZARRO D, 1991, NEW ENGL J MED, V324, P517, DOI 10.1056/NEJM199102213240802; RAMAKRISHNA BS, 1990, DIGESTION, V45, P93, DOI 10.1159/000200229; RAMAKRISHNA BS, 1993, GUT, V34, P1215, DOI 10.1136/gut.34.9.1215; READ NW, 1982, LANCET, V2, P481; REIS EC, 1994, PEDIATRICS, V93, P708; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SCHEPPACH W, 1988, SCAND J GASTROENTERO, V23, P755, DOI 10.3109/00365528809093945; SPEELMAN P, 1986, GASTROENTEROLOGY, V91, P1164, DOI 10.1016/S0016-5085(86)80012-9; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X	31	157	176	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					308	313		10.1056/NEJM200002033420502	http://dx.doi.org/10.1056/NEJM200002033420502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10655529				2023-01-03	WOS:000085070300002
J	Linde, K; Berner, M				Linde, K; Berner, M			Commentary: Has hypericum found its place in antidepressant treatment?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, D-8000 Munich, Germany; Univ Freiburg, Dept Psychiat & Psychotherapy, D-79104 Freiburg, Germany	Technical University of Munich; University of Freiburg	Linde, K (corresponding author), Tech Univ Munich, Dept Internal Med 2, Ctr Complementary Med Res, Ismaninger Str 22, D-8000 Munich, Germany.							Harrer G, 1999, ARZNEIMITTELFORSCH, V49, P289; Laakmann G, 1998, PHYTOMEDICINE, V5, P435, DOI 10.1016/S0944-7113(98)80039-1; LINDE K, 1999, COCHRANE LIB; Schrader E, 1998, HUM PSYCHOPHARM CLIN, V13, P163, DOI 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.3.CO;2-9	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1539	1539						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10651472				2023-01-03	WOS:000084245600022
J	Clark, WM; Wissman, S; Albers, GW; Jhamandas, JH; Madden, KP; Hamilton, S				Clark, WM; Wissman, S; Albers, GW; Jhamandas, JH; Madden, KP; Hamilton, S		ATLANTIS Study Investigators	Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECASS	Context Recombinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limited to within 3 hours of symptom onset. This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset. Objective To test the efficacy and safety of rt-PA in patients with acute ischemic stroke when administered between 3 and 5 hours after symptom onset. Design The Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study is a phase 3, placebo-controlled, double-blind randomized study conducted between December 1993 and July 1998, with up to 90 days of follow-up. Setting One hundred forty university and community hospitals in North America. Patients An intent-to-treat population of 613 acute ischemic stroke patients was enrolled, with 547 of these treated as assigned within 3 to 5 hours of symptom onset. A total of 39 others were treated within 3 hours of symptom onset, 24 were treated more than 5 hours after symptom onset, and 3 never received any study drug. Intervention Administration of 0.9 mg/kg of rt-PA (n = 272) or placebo (n = 275) intravenously over 1 hour. Main Outcome Measures Primary efficacy was an excellent neurologic recovery at day 90 (National Institutes of Health Stroke Scale [NIHSS] score of less than or equal to 1); secondary end points included excellent recovery on functional outcome measures (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90. Serious adverse events were also assessed. Results In the target population, 32% of the placebo and 34% of rt-PA patients had an excellent recovery at 90 days (P = .65). There were no differences on any of the secondary functional outcome measures. In the first 10 days treatment with rt-PA significantly increased the rate of symptomatic intracerebral hemorrhage (ICH) (1.1% vs 7.0% [P<.001]), a symptomatic ICH (4.7% vs 11.4% [P = .004]), and fatal ICH (0.3% vs 3.0% [P<.001]). Mortality at 90 days was 6.9% with placebo and 11.0% with rt-PA (P = .09). Results in the intent-to-treat population were similar. Conclusions This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.	Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Stucky Res Ctr, Ft Wayne, IN USA; Stanford Univ, Stanford Stroke Ctr, Palo Alto, CA 94304 USA; Univ Alberta, Dept Neurol, Edmonton, AB, Canada; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA; Genentech Inc, San Francisco, CA 94080 USA	Oregon Health & Science University; Stanford University; University of Alberta; Marshfield Clinic; Roche Holding; Genentech	Clark, WM (corresponding author), Oregon Hlth & Sci Univ, Oregon Stroke Ctr, UHS 44,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	clarkw@ohsu.edu	Buchan, Alastair M/B-9095-2009	Buchan, Alastair M/0000-0002-2918-5200; Albers, Gregory/0000-0003-0263-4632				Albers GW, 1999, STROKE, V30, P244; ALBERTS MJ, 1993, STROKE, V24, P1817, DOI 10.1161/01.STR.24.12.1817; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; CLARK W, IN PRESS STROKE; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JENNETT B, 1975, LANCET, V1, P480; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Tanner CM, 1998, NEUROLOGY, V50, pA373; VANSWIETEN JC, 1998, STROKE, V14, P61	13	841	882	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2019	2026		10.1001/jama.282.21.2019	http://dx.doi.org/10.1001/jama.282.21.2019			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591384				2023-01-03	WOS:000083908700021
J	Mangus, RS; Dipiero, A; Hawkins, CE				Mangus, RS; Dipiero, A; Hawkins, CE			Medical students' attitudes toward physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUTHANASIA	Context In November 1994, Oregon became the first US state to legalize physician-assisted suicide (PAS) as an option for end-of-life care. Objective This study compares the attitudes and experiences of medical students in Oregon regarding PAS to those of fourth-year medical students in the United States outside Oregon. Design A survey of all students at the Oregon Health Sciences University and fourth-year medical students at 3 non-Oregonian US medical schools. Participants Oregon medical students returned 227 questionnaires (58%), and 113 were returned from control schools (33%). Results A similar percentage of both study groups favored the legalization of PAS (64% vs 66%; P=.74). If the practice were legal, 55% of the total surveyed reported they "might be willing to write a lethal prescription," (50% Oregon students vs 60% control; P=.13 and 44% fourth-year Oregon students vs 60% control; P=.04). Among fourth-year students, 20% reported a request by a patient to the student or a preceptor for a lethal prescription in the past year (26% vs 16%; P=.09). Conclusions This study demonstrates support for and willingness by many medical students to participate in PAS. Some medical students reported observation of PAS during their training experience. Fourth-year Oregon students reported significantly less willingness than other students to provide a patient with a lethal prescription, perhaps indicating hesitancy to include PAS in clinical practice.	Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Mangus, RS (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.		Mangus, Richard S/M-1446-2018	Mangus, Richard S/0000-0003-4300-2594				Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Muller MT, 1996, MED EDUC, V30, P428, DOI 10.1111/j.1365-2923.1996.tb00863.x; *MULTN COUNT EL DI, 1994, OR VOT PAMPHL BALL M, V16; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P967, DOI 10.1001/jama.278.12.967; Steinberg MA, 1997, MED J AUSTRALIA, V166, P131, DOI 10.5694/j.1326-5377.1997.tb140042.x; Verhoef MJ, 1996, CAN MED ASSOC J, V155, P885	10	20	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2080	2081		10.1001/jama.282.21.2080	http://dx.doi.org/10.1001/jama.282.21.2080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591396	hybrid			2023-01-03	WOS:000083908700033
J	Drakulovic, MB; Torres, A; Bauer, TT; Nicolas, JM; Nogue, S; Ferrer, N				Drakulovic, MB; Torres, A; Bauer, TT; Nicolas, JM; Nogue, S; Ferrer, N			Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial	LANCET			English	Article							INTENSIVE-CARE UNITS; GASTROESOPHAGEAL REFLUX; TRACHEAL COLONIZATION; MULTIVARIATE-ANALYSIS; PULMONARY ASPIRATION; RESPIRATORY-TRACT; ENTERAL NUTRITION; INFECTION; SUCRALFATE; RANITIDINE	Background Risk factors for nosocomial pneumonia, such as gastro-oesophageal reflux and subsequent aspiration, can be reduced by semirecumbent body position in intensive-care patients. The objective of this study was to assess whether the incidence of nosocomial pneumonia can also be reduced by this measure. Methods This trial was stopped after the planned interim analysis, 86 intubated and mechanically ventilated patients of one medical and one respiratory intensive-care unit at a tertiary-care university hospital were randomly assigned to semirecumbent (n=39) or supine (n=47) body position. The frequency of clinically suspected and microbiologically confirmed nosocomial pneumonia (clinical plus quantitative bacteriological criteria) was assessed in both groups. Body position was analysed together with known risk factors for nosocomial pneumonia. Findings The frequency of clinically suspected nosocomial pneumonia was lower in the semirecumbent group than in the supine group (three of 39 [8%] vs 16 of 47 [34%]; 95% CI for difference 10.0-42.0, p=0.003). This was also true for microbiologically confirmed pneumonia (semirecumbent 2/39 [5%] vs supine 11/47 [23%]; 4.2-31.8, p=0.018). Supine body position (odds ratio 6.8 [1.7-26.7], p=0.006) and enteral nutrition (5.7 [1.5-22.8], p=0.013) were independent risk factors for nosocomial pneumonia and the frequency was highest for patients receiving enteral nutrition in the supine body position (14/28, 50%). Mechanical ventilation for 7 days or more (10.9 [3.0-40.4], p=0.001) and a Glasgow coma scale score of less than 9 were additional risk factors. Interpretation The semirecumbent body position reduces frequency and risk of nosocomial pneumonia, especially in patients who receive enteral nutrition. The risk of nosocomial pneumonia is increased by long-duration mechanical ventilation and decreased consciousness.	Univ Barcelona, Hosp Clin, Serv Pneumol & Allergia Resp, Resp Intens Care Unit, Barcelona, Spain; Univ Barcelona, Hosp Clin, Area Vigilancia Intens, Inst Invest Biomed August Pi & Sunyer,Dept Med, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Torres, A (corresponding author), Hosp Clin Barcelona, Serv Pneumol & Allergia Resp, Villarroel 170, E-08036 Barcelona, Spain.	atorres@medicina.ub.es	Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ferrer, Miguel/0000-0001-8171-6673				Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BONTEN MJM, 1994, CHEST, V105, P878, DOI 10.1378/chest.105.3.878; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; DELATORRE FJ, 1995, AM J RESP CRIT CARE, V152, P1028, DOI 10.1164/ajrccm.152.3.7663779; DUMOULIN GC, 1982, LANCET, V1, P242; ELEBIARY M, 1993, AM J RESP CRIT CARE, V147, P1552; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; FABREGAS N, IN PRESS THORAX; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; Fernandez-Crehuet R, 1997, INFECT CONT HOSP EP, V18, P825; GEORGE DL, 1993, INFECT CONT HOSP EP, V14, P163, DOI 10.1086/646705; HARDY JF, 1988, CAN J ANAESTH, V35, P162, DOI 10.1007/BF03010658; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PRODHOM G, 1994, ANN INTERN MED, V120, P653, DOI 10.7326/0003-4819-120-8-199404150-00005; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; Stoutenbeek C P, 1997, Semin Respir Infect, V12, P294; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	30	724	778	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1851	1858		10.1016/S0140-6736(98)12251-1	http://dx.doi.org/10.1016/S0140-6736(98)12251-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584721				2023-01-03	WOS:000083909100010
J	Stewart, S; Marley, JE; Horowitz, JD				Stewart, S; Marley, JE; Horowitz, JD			Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study	LANCET			English	Article							ELDERLY PATIENTS; HOSPITALIZATION; MORBIDITY; OUTCOMES; CARE	Background Hospital admissions among patients with congestive heart failure (CHF) are a major contributor to health-care costs. Previous investigations suggest that the therapeutic efficacy of pharmacotherapy in CHF may be improved by strategies incorporating home visits to identify and address factors precipitating deterioration and resultant readmission. Methods Chronic CHF patients discharged home after acute hospital admission were randomly assigned usual care (n=100) or a multidisciplinary, home-based intervention (n=100), consisting of a home visit by a cardiac nurse 7-14 days after discharge. The primary endpoint of the study was frequency of unplanned readmission plus out-of-hospital death within 6 months. Findings During 6 months' follow-up there were 129 primary endpoint events in the usual-care group and 77 in the intervention group (p=0.02). More intervention-group than usual-care patients remained event-free (38 vs 51; p=0.04). Overall, there were fewer unplanned readmissions (68 vs 118; p=0.03) and associated days in hospital (460 vs 1173; p=0.02) among intervention-group patients. Hospital-based costs were Australian $490 300 for the intervention group and A$922 600 for the usual-care group (p=0.16); the mean cost of the intervention was A$350 per patient, and other community-based costs were similar for both groups. Interpretation A home-based intervention has the potential to decrease the rate of unplanned readmissions and associated health-care costs, prolong event-free and total survival, and improve quality of life among patients with chronic CHF.	Univ Adelaide, Dept Gen Practice, Adelaide, SA 5005, Australia; Univ Adelaide, Queen Elizabeth Hosp, Dept Cardiol, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Horowitz, JD (corresponding author), Queen Elizabeth Hosp, Dept Cardiol, 28 Woodville Rd, Woodville, SA 5011, Australia.		Stewart, Simon/M-3316-2016; Marley, John/F-1239-2010	Stewart, Simon/0000-0001-9032-8998; Horowitz, John/0000-0001-6883-0703				Burns RB, 1997, J AM GERIATR SOC, V45, P276, DOI 10.1111/j.1532-5415.1997.tb00940.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Jaagosild P, 1998, ARCH INTERN MED, V158, P1081, DOI 10.1001/archinte.158.10.1081; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Luzier AB, 1998, AM J CARDIOL, V82, P465, DOI 10.1016/S0002-9149(98)00361-0; MCMURRAY J, 1993, BR J MED EC, V6, P99; Michalsen A, 1998, HEART, V80, P437, DOI 10.1136/hrt.80.5.437; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rich MW, 1996, AM J MED, V101, P270, DOI 10.1016/S0002-9343(96)00172-6; Stewart S, 1999, AUST NZ J MED, V29, P220, DOI 10.1111/j.1445-5994.1999.tb00687.x; Stewart S, 1999, ARCH INTERN MED, V159, P257, DOI 10.1001/archinte.159.3.257; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WILLIAMS JF, 1995, J AM COLL CARDIOL, V26, P1376	26	430	452	0	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1077	1083		10.1016/S0140-6736(99)03428-5	http://dx.doi.org/10.1016/S0140-6736(99)03428-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	239PA	10509499				2023-01-03	WOS:000082777500013
J	Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M				Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M			Use of complementary therapies for arthritis among patients of rheumatologists	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE USE; UNCONVENTIONAL MEDICINE; RHEUMATOID-ARTHRITIS; UNITED-STATES; HEALTH-CARE; PREVALENCE; REMEDIES; OSTEOARTHRITIS; COMMUNITY; PRACTITIONERS	Background: Use of complementary and alternative medicine (CAM) is common among persons with chronic conditions. Objective: To identify correlates of and describe patients' perspective on use of CAM for rheumatologic conditions. Design: Telephone survey. Setting: Three university practices and three private rheumatology practices. Patients: 232 of 428 eligible consecutive patients (54%) with scheduled appointments. Measurements: Patients answered questions on CAM use, functional status, pain, provider satisfaction, and health services utilization. Chart reviews provided demographic information and rheumatologic diagnoses. Bivariate analyses identified correlates of four CAM outcomes (history, magnitude, and frequency of CAM use and communication about CAM use with a physician), and multiple logistic regression identified independent correlates of regular CAM use. Results: Approximately two thirds of the respondents (n = 146) had used CAM. Of these 146 respondents, 82 (56%) currently used CAM and 132 (90%) regularly used CAM or had done so in the past. Fifty-five respondents (24%) had used three or more types of CAM. In multivariate analyses, persons who used CAM regularly were more likely to have osteoarthritis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a college degree (odds ratio, 2.6 [CI, 1.3 to 5.4]) than patients who had never used CAM. Nearly half of the respondents discussed CAM use with their physicians. The most common reasons for not disclosing CAM use were that the physician had not asked about it and that the patient forgot to tell the physician; fear of disapproval was rarely cited. Discussions about CAM use between patient and physician occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used several types of CAM. Conclusions: Patients with rheumatologic conditions frequently use CAM. Severe pain and osteoarthritis predict regular use of CAM but do not predict a greater likelihood of discussing CAM use with physicians. Routine inquiry by physicians will probably detect CAM use.	Indiana Univ, Richard L Roudebush Vet Affairs Med Ctr, Sch Med, Indianapolis, IN 46202 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Rao, JK (corresponding author), Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, MHS, 508 Fulton St, Durham, NC 27705 USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Arcury TA, 1996, ARTHRIT CARE RES, V9, P384, DOI 10.1002/1529-0131(199610)9:5<384::AID-ANR1790090507>3.0.CO;2-Y; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BOISSET M, 1994, J RHEUMATOL, V21, P148; CAMPION EW, 1993, NEW ENGL J MED, V328, P282, DOI 10.1056/NEJM199301283280413; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; CORNELISSEN PGJ, 1988, ANN RHEUM DIS, V47, P150, DOI 10.1136/ard.47.2.150; Cronan T A, 1993, Arthritis Care Res, V6, P149, DOI 10.1002/art.1790060307; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Dalen JE, 1998, ARCH INTERN MED, V158, P2179, DOI 10.1001/archinte.158.20.2179; Davidoff F, 1998, ANN INTERN MED, V129, P1068, DOI 10.7326/0003-4819-129-12-199812150-00014; DEVELLIS RF, 1993, J RHEUMATOL, V20, P866; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fairfield KM, 1998, ARCH INTERN MED, V158, P2257, DOI 10.1001/archinte.158.20.2257; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P2111, DOI 10.1001/jama.1997.03550230087045; GRAY D, 1985, SOC SCI MED, V21, P507, DOI 10.1016/0277-9536(85)90034-6; GRAY D, 1983, MED ANTHROPOL, V7, P29; HIGHAM C, 1983, PRACTITIONER, V227, P1201; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KESTIN M, 1985, MED J AUSTRALIA, V143, P516, DOI 10.5694/j.1326-5377.1985.tb119916.x; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MILLER IW, 1979, PSYCHOL BULL, V86, P93, DOI 10.1037/0033-2909.86.1.93; Nicassio PM, 1997, J RHEUMATOL, V24, P2008; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Rao JK, 1998, ARTHRIT CARE RES, V11, P253, DOI 10.1002/art.1790110406; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; STRUTHERS GR, 1983, RHEUMATOL INT, V3, P151, DOI 10.1007/BF00541593; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; VECCHIO PC, 1994, J RHEUMATOL, V21, P145; VISSER GJ, 1992, BRIT J RHEUMATOL, V31, P485; WASNER CK, 1991, RHEUM DIS CLIN N AM, V17, P197; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; WIENER CL, 1975, SOC SCI MED, V9, P97, DOI 10.1016/0037-7856(75)90101-8; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1124	46	283	287	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					409	416		10.7326/0003-4819-131-6-199909210-00003	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498556				2023-01-03	WOS:000082641100002
J	Rustamadji				Rustamadji			Family medicine between west and east	LANCET			English	Article											Rustamadji (corresponding author), Rancho Indah Estate,JI Tanjung 10,Blok B-2, Jakarta 12530, Indonesia.	Rufo@CBN.net.id							0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC	2000	356			S			S29	S29		10.1016/S0140-6736(00)92015-4	http://dx.doi.org/10.1016/S0140-6736(00)92015-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191485				2023-01-03	WOS:000166074900031
J	Crawley, L; Payne, R; Bolden, J; Payne, T; Washington, P; Williams, S				Crawley, L; Payne, R; Bolden, J; Payne, T; Washington, P; Williams, S		Initiative Improve Palliative End	Palliative and end-of-life care in the African American community	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; ADVANCE DIRECTIVES; MEASURING QUALITY; RACIAL VARIATION; PAIN MANAGEMENT; DECISION-MAKING; RACE; ETHNICITY; BLACK; ATTITUDES		Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Balm Gilead End Life Initiat Cooper Green Hosp, Birmingham, AL USA; Harlem Palliat Care Network, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Dept Pain & Symptom Res, Houston, TX 77030 USA; Tuskegee Univ, Natl Ctr Bioeth Res & Hlth Care, Tuskegee, AL 36088 USA	Stanford University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tuskegee University	Crawley, L (corresponding author), Stanford Univ, Ctr Biomed Eth, 701 Welch Rd,Bldg A,Suite 1105, Palo Alto, CA 94304 USA.	lcrawley@stanford.edu						Al-Jeilani M, 1987, Acta Neurochir Suppl (Wien), V38, P132; ANGELOU M, 1997, NORTON ANTHOLOGY AFR, P2039; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; Burrs F A, 1995, Hosp J, V10, P15; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Clayton L A, 1993, J Health Care Poor Underserved, V4, P83; CRAWLEY L, 2000, CTR LIT MED HLTH PRO, V12, P5; CRAWLEY L, 1999, ANN M NAT MED ASS AU; DULA A, 1994, CLIN GERIATR MED, V10, P419, DOI 10.1016/S0749-0690(18)30330-6; DULA A, 1994, CAMB Q HEALTHC ETHIC, V3, P347, DOI 10.1017/S0963180100005168; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; Freeman HP, 2000, NEW ENGL J MED, V342, P1045, DOI 10.1056/NEJM200004063421411; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; Gordon A K, 1996, Hosp J, V11, P49, DOI 10.1300/J011v11n01_04; Gordon A K, 1995, Hosp J, V10, P65; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Hauser JM, 1997, CAMB Q HEALTHC ETHIC, V6, P58, DOI 10.1017/S0963180100007611; Hoffman-Goetz L, 1999, PSYCHO-ONCOL, V8, P36, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<36::AID-PON330>3.0.CO;2-8; HOOKS B, 2000, OTHER SIDE, V36, P43; Horner RD, 1998, CANC TREAT, P99; JOHNSON JW, 1992, TRIALS TRIBULATIONS, P171; Jones MR, 2000, STROKE, V31, P563, DOI 10.1161/01.STR.31.3.563; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; Kumasaka L, 1996, AM J NURS, V96, P45, DOI 10.1097/00000446-199606000-00044; Low JF, 1997, AM J OCCUP THER, V51, P215, DOI 10.5014/ajot.51.3.215; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MARABLE M, 1994, MEDIA STUD J, V8, P11; MBITI JS, 1991, INTRO AFRICAN RELIG, P116; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; MESSNER SF, 1992, CRIMINOLOGY, V30, P421, DOI 10.1111/j.1745-9125.1992.tb01111.x; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; NHPCO, FACTS FIG HOSP CAR A; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; Reese DJ, 1999, SOC WORK, V44, P549, DOI 10.1093/sw/44.6.549; Rossler D, 1987, Acta Neurochir Suppl (Wien), V38, P127; Signorielli N., 1993, MASS MEDIA IMAGES IM, P37; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Todd KH, 2000, ANN EMERG MED, V35, P11, DOI 10.1016/S0196-0644(00)70099-0; TROPH S, 1999, ST LOUIS J REV, V29, P1; *US DEP HHS, HLTH PEOPL 2010	48	219	219	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2518	2521		10.1001/jama.284.19.2518	http://dx.doi.org/10.1001/jama.284.19.2518			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074786				2023-01-03	WOS:000165183800029
J	Meisel, A; Snyder, L; Quill, T				Meisel, A; Snyder, L; Quill, T			Seven legal barriers to end-of-life care - Myths, realities, and grains of truth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; PALLIATIVE CARE; TERMINAL SEDATION; ADVANCE DIRECTIVES; MALPRACTICE CLAIMS; SLOW EUTHANASIA; DECISION-MAKING; SUPREME-COURT; MANAGEMENT; DIALOGUE	Objective The American College of Physicians-American Society of Internal Medicine (ACP-ASIM) End-of-Life Care Consensus Panel was convened in 1997 to identify clinical, ethical, and policy problems in end-of-life care, to analyze critically the available evidence and guidelines, and to offer consensus recommendations on how to improve care of the dying. Topic selection and content presentation were carefully debated to maximize the project's focus on providing practical clinical and other guidance to clinicians who are not specialists in palliative care. This statement examines current legal myths, realities, and grains of truth in end-of-life care. Participants The Consensus Panel comprises 13 medical and bioethics experts, clinicians, and educators in care at the end of life selected by the Ethics and Human Rights Committee, College leadership, and the Center for Ethics and Professionalism at the ACP-ASIM. Evidence A literature review including a MEDLINE search of articles from 1970-1998 and review of end-of-life care literature and organizational bibliographies was conducted. Unpublished sources were also identified by participants, as was anecdotal clinical experience. Consensus Process The draft statement was debated by panel members over a series of 3 to 4 meetings. For this statement, the initial draft and subsequent revised drafts were discussed in 1998-1999. The statement then underwent external peer review and revision before panel approval and the journal peer review process. Conclusions Legal myths about end-of-life care can undermine good care and ethical medical practice. In addition, at times ethics, clinical judgment, and the law conflict, Patients (or families) and physicians can find themselves considering clinical actions that are ethically appropriate, but raise legal concerns. The 7 major legal myths regarding end-of-life care are: (1) forgoing life-sustaining treatment for patients without decision-making capacity requires evidence that this was the patient's actual wish; (2) withholding or withdrawing of artificial fluids and nutrition from terminally ill or permanently unconscious patients is illegal; (3) risk management personnel must be consulted before life-sustaining medical treatment may be terminated; (4) advance directives must comply with specific forms, are not transferable between states, and govern all future treatment decisions; oral advance directives are unenforceable; (5) if a physician prescribes or administers high doses of medication to relieve pain or other discomfort in a terminally ill patient, resulting in death, he/she will be criminally prosecuted; (6) when a terminally ill patient's suffering is overwhelming despite palliative care, and he/she requests a hastened death, there are no legally permissible options to ease suffering; and (7) the 1997 Supreme Court decisions outlawed physician-assisted suicide. Many legal barriers to end-of-life care are more mythical than real, but sometimes there is a grain of truth. Physicians must know the law of the state in which they practice.	Amer Coll Physicians, Ctr Eth & Professionalism, Amer Soc Internal Med, Philadelphia, PA 19106 USA; Univ Pittsburgh, Sch Law, Ctr Med Eth, Pittsburgh, PA 15260 USA; Genesee Hosp, Dept Med, Rochester, NY 14607 USA	American College of Physicians; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Snyder, L (corresponding author), Amer Coll Physicians, Ctr Eth & Professionalism, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@mail.acponline.org						Alpers A, 1998, J LAW MED ETHICS, V26, P308, DOI 10.1111/j.1748-720X.1998.tb01678.x; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BREITBART W, 1997, OXFORD TXB PALLIATIV, P437; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Duffy FD, 1998, ANN INTERN MED, V128, P139, DOI 10.7326/0003-4819-128-2-199801150-00011; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Field MJ, 1997, APPROACHING DEATH IM; Garcia J. L. A., 1995, ENCY BIOETHICS, P636; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Jacobson JA, 1997, J CLIN ETHIC, V8, P359; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; KAPP MB, 1996, J HLTH CARE RISK MAN, V16, P411; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Marco CA, 1997, ACAD EMERG MED, V4, P898, DOI 10.1111/j.1553-2712.1997.tb03816.x; Meisel A, 1995, AM J LAW MED, V21, P335; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MEISEL A, 1995, RIGHT DIE; MEISEL A, 1999, U MD J HLTH CARE LAW, V2, P201; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; Miller FG, 2000, ANN INTERN MED, V132, P470, DOI 10.7326/0003-4819-132-6-200003210-00008; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher David, 1994, MD Law Rev, V53, P1255; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Shapiro RS, 1996, J LAW MED ETHICS, V24, P360, DOI 10.1111/j.1748-720X.1996.tb01879.x; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003	37	116	117	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2495	2501		10.1001/jama.284.19.2495	http://dx.doi.org/10.1001/jama.284.19.2495			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074780				2023-01-03	WOS:000165183800024
J	Guthrie, B; Wyke, S				Guthrie, B; Wyke, S			Controversy in primary care - Does continuity in general practice really matter?	BRITISH MEDICAL JOURNAL			English	Article							PATIENT SATISFACTION; RANDOMIZED TRIAL; PRACTITIONERS; CONSULTATIONS	Continuity is an official core value of general practice in the United Kingdom,(1) but there are at least two potentially conflicting definitions of it Both definitions are powerfully expressed in a recent report from the BMA, entitled Shaping Tomorrow.(2) For general practitioners, continuity of care has traditionally meant that a patient visits the same doctor(3 4) What matters is personal continuity, in which an ongoing doctor-patient relationship ensures that care takes account of the patient's personal and social context By contrast, recent statements from the NHS Executive emphasise the importance of consistency and coordination of care.(5) From this perspective, continuity can be enhanced by appropriate organisation, guidelines, and electronic medical records, irrespective of which doctor is seen.	Univ Edinburgh, Dept Community Hlth Sci, Div Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland; Royal Coll Gen Practitioners, Scottish Sch Primary Care, Edinburgh EH2 1JX, Midlothian, Scotland	University of Edinburgh	Guthrie, B (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Div Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland.		Guthrie, Bruce/HHM-9696-2022	Guthrie, Bruce/0000-0003-4191-4880				BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; *BMA GEN PRACT COM, 2000, PRIM CAR TRUSTS IMPL; *BMA GEN PRACT COM, 2000, SHAP TOM ISS FAC GEN; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; Flint C, 1989, Midwifery, V5, P11, DOI 10.1016/S0266-6138(89)80059-2; FREEMAN G, 1985, J ROY COLL GEN PRACT, V35, P423; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; FREEMAN GK, 1994, BRIT J GEN PRACT, V44, P395; GORDIS L, 1971, PEDIATRICS, V48, P766; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; NAZARETH I, 1993, BRIT MED J, V306, P1103, DOI 10.1136/bmj.306.6885.1103; *NHS EX, 2000, PRIM COMM CAR; ROWLEY MJ, 1995, MED J AUSTRALIA, V163, P289, DOI 10.5694/j.1326-5377.1995.tb124592.x; Royal College of General Practitioners, 1972, FUT GEN PRACT; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413	18	44	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					734	735		10.1136/bmj.321.7263.734	http://dx.doi.org/10.1136/bmj.321.7263.734			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999906	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000089546600025
J	Buyse, M; Thirion, P; Carlson, RW; Burzykowski, T; Molenberghs, G; Piedbois, P				Buyse, M; Thirion, P; Carlson, RW; Burzykowski, T; Molenberghs, G; Piedbois, P		Meta-Analysis Grp Canc	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis	LANCET			English	Article							POSTOPERATIVE ADJUVANT THERAPY; CLINICAL-TRIALS; COLON-CANCER; END-POINTS; FLUOROURACIL; LEUCOVORIN; SURROGATE; APPROVAL; DRUGS	Background Treatment of advanced colorectal cancer has progressed substantially. However, improvements in response rates have not always translated into significant survival benefits. Doubts have therefore been raised about the usefulness of tumour response as a clinical endpoint. Methods This meta-analysis was done on individual data from 3791 patients enrolled in 25 randomised trials of first-line treatment with standard bolus intravenous fluoropyrimidines versus experimental treatments (fluorouracil plus leucovorin, fluorouracil plus methotrexate, fluorouracil continuous infusion, or hepatic-arterial infusion of floxuridine), Analyses were by intention to treat. Findings Compared with bolus fluoropyrimidines, experimental fluoropyrimidines led to significantly higher tumour response rates (454 responses among 2031 patients vs 209 among 1760; odds ratio 0.48 [95% CI 0.40-0.57], p<0.0001) and better survival (1808 deaths among 2031 vs 1580 among 1760; hazard ratio 0.90 [0.84-0.97], p=0.003). The survival benefits could be explained by the higher tumour response rates. However, a treatment that lowered the odds of failure to respond by 50% would be expected to decrease the odds of death by only 6%. In addition, less than half of the variability of the survival benefits in the 25 trials could be explained by the variability of the response benefits in these trials. Interpretation These analyses confirm that an increase in tumour response rate translates into an increase in overall survival for patients with advanced colorectal cancer. However, in the context of individual trials, knowledge that a treatment has benefits on tumour response does not allow accurate prediction of the ultimate benefit on survival.	Int Inst Drug Dev, B-1050 Brussels, Belgium; Limburgs Univ Ctr, Diepenbeek, Belgium; Hop Henri Mondor, Dept Oncol, F-94010 Creteil, France; Stanford Univ, Med Ctr, Div Med Oncol, Stanford, CA 94305 USA; Inst Oncol, Warsaw, Poland	International Drug Development Institute; Hasselt University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Stanford University; Maria Sklodowska-Curie National Research Institute of Oncology	Buyse, M (corresponding author), Int Inst Drug Dev, 430 Ave Louise B14, B-1050 Brussels, Belgium.	mbuyse@id2.be	Carlson, Robert/AAQ-8098-2020; Burzykowski, Tomasz/T-2222-2018	Burzykowski, Tomasz/0000-0003-3378-975X; Buyse, Marc/0000-0002-4559-0994				ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BURZYKOWSKI T, 1999, P BIOPH SECT AM STAT, P40; Buyse M, 1996, J NATL CANCER I, V88, P252; Buyse M, 1996, STAT MED, V15, P2797, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V; Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853; Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49; Cocchetto DM, 1998, DRUG INF J, V32, P27, DOI 10.1177/009286159803200105; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; Food and Drug Administration, 1996, REINV REG CANC DRUGS; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GRAF W, 1994, BRIT J CANCER, V70, P559, DOI 10.1038/bjc.1994.345; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; LABIANCA R, 1995, LANCET, V345, P939; LAVIN P, 1980, CANCER, V46, P1536, DOI 10.1002/1097-0142(19801001)46:7<1536::AID-CNCR2820460707>3.0.CO;2-K; Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1; MOLENBERGHS G, IN PRESS STAT MED; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; OYE RK, 1984, JAMA-J AM MED ASSOC, V252, P2722, DOI 10.1001/jama.252.19.2722; PIEDBOIS P, 1994, J CLIN ONCOL, V12, P960; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; WEISS GB, 1983, CONTROL CLIN TRIALS, V4, P43, DOI 10.1016/S0197-2456(83)80011-7; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Wolmark N, 1998, J CLIN ONCOL, V16, P301; World Health Organization, 1979, WHO HDB REP RES CANC	27	330	338	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					373	378		10.1016/S0140-6736(00)02528-9	http://dx.doi.org/10.1016/S0140-6736(00)02528-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972369				2023-01-03	WOS:000088486000009
J	Toner, GC; Stockler, MR; Boyer, MJ; Jones, M; Thomson, DB; Harvey, VJ; Olver, IN; Dhillon, H; McMullen, A; Gebski, VJ; Levi, JA; Simes, RJ				Toner, GC; Stockler, MR; Boyer, MJ; Jones, M; Thomson, DB; Harvey, VJ; Olver, IN; Dhillon, H; McMullen, A; Gebski, VJ; Levi, JA; Simes, RJ		Australian New Zealand Germ Cell T	Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial	LANCET			English	Article							TESTICULAR CANCER; COMBINATION CHEMOTHERAPY; CLINICAL-TRIALS; POOR RISK; BLEOMYCIN; TUMORS; ETOPOSIDE; CISPLATIN; THERAPY; CARCINOMA	Background Most patients with metastatic germ-cell tumours are cured with chemotherapy. However, the optimum chemotherapy regimen is uncertain, and there is variation in international practice. We did a multicentre randomised trial to compare two standard chemotherapy regimens for men with good-prognosis germ-cell tumours. Methods Good prognosis was defined by modified Memorial Sloan-Kettering criteria. The first regimen (regimen A) was based on treatment recommendations from Indiana University and comprised three cycles of 20 mg/m(2) cisplatin on days 1-5, 100 mg/m(2) etoposide on days 1-5, and 30 kU bleomycin on days 1, 8, and 15, repeated every 21 days. The second regimen (regimen B) was based on the control regimen of a published randomised clinical trial and comprised four cycles of 100 mg/m(2) cisplatin on day 1, 120 mg/m(2) etoposide on days 1-3, and 30 kU bleomycin on day 1, repeated every 21 days. The primary outcome measure was overall survival. Analysis was by intention to treat. Findings 166 patients were randomised, 83 to each regimen. The trial was stopped when the second planned interim analysis met predefined stopping rules. The median follow-up was 33 months, Overall survival was substantially better with regimen A (three vs 13 deaths, hazard ratio 0.22 [95% CI 0.06-0.77], p=0.008). This difference was due to deaths from cancer tone vs nine), and not deaths from treatment (two vs two) and remained significant after adjustment for other prognostic factors (0.25 [0.07-0.88], p=0.03). Interpretation In men with good-prognosis germ-cell tumours, the regimen developed at Indiana University is superior to the alternative regimen studied in this trial. The lower total dose and dose-intensity of bleomycin and the lower dose-intensity of etoposide in regimen B could be responsible for the worse outcome.	Peter MacCallum Canc Inst, Med Oncol Unit, E Melbourne, Vic 3002, Australia; Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; Princess Alexandra Hosp, Med Oncol Unit, Brisbane, Qld 4102, Australia; Sydney Canc Ctr, Med Oncol Unit, Sydney, NSW, Australia; Auckland Hosp, Clin Oncol Unit, Auckland, New Zealand; Royal Adelaide Hosp, Med Oncol Unit, Adelaide, SA 5000, Australia; Royal N Shore Hosp, Med Oncol Unit, Sydney, NSW, Australia	Peter Maccallum Cancer Center; University of Sydney; University of Sydney; Auckland City Hospital; Royal Adelaide Hospital; Royal North Shore Hospital; University of Sydney	Toner, GC (corresponding author), Peter MacCallum Canc Inst, Med Oncol Unit, St Andrews Pl, E Melbourne, Vic 3002, Australia.		Dhillon, Haryana M/G-8503-2011; Thomson, Damien B/F-9076-2013; Stockler, Martin R/N-3859-2016; Olver, Ian/I-1518-2015; Toner, Guy C/G-1738-2011	Dhillon, Haryana M/0000-0003-4039-5169; Stockler, Martin R/0000-0003-3793-8724; Olver, Ian/0000-0001-5478-1576; Toner, Guy/0000-0001-9873-3592; Boyer, Michael/0000-0002-0452-2987				BAJORIN D, 1988, J CLIN ONCOL, V6, P786, DOI 10.1200/JCO.1988.6.5.786; BAJORIN DF, 1991, CANCER, V67, P28, DOI 10.1002/1097-0142(19910101)67:1<28::AID-CNCR2820670106>3.0.CO;2-3; BAJORIN DF, 1991, UROL INT, V46, P298, DOI 10.1159/000282155; Bajorin DF, 1997, J CLIN ONCOL, V15, P1717, DOI 10.1200/JCO.1997.15.5.1717; BOSL GJ, 1988, J CLIN ONCOL, V6, P1231, DOI 10.1200/JCO.1988.6.8.1231; CULINE S, 1999, P AM SOC CLIN ONCOL, V18, pA1188; deWit R, 1997, J CLIN ONCOL, V15, P1837, DOI 10.1200/JCO.1997.15.5.1837; DEWIT R, 2000, P AM SOC CLIN ONCOL, V19, pA1281; DEWIT R, 1999, P AM SOC CLIN ONCOL, V18, pA1187; EINHORN LH, 1989, J CLIN ONCOL, V7, P387, DOI 10.1200/JCO.1989.7.3.387; EINHORN LH, 1981, CANCER RES, V41, P3275; EINHORN LH, 1981, NEW ENGL J MED, V305, P727, DOI 10.1056/NEJM198109243051303; Horwich A, 1997, J CLIN ONCOL, V15, P1844, DOI 10.1200/JCO.1997.15.5.1844; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; LEVI JA, 1993, J CLIN ONCOL, V11, P1300, DOI 10.1200/JCO.1993.11.7.1300; McKiernan JM, 1999, J UROLOGY, V162, P361, DOI 10.1016/S0022-5347(05)68560-6; Mead GM, 1997, J CLIN ONCOL, V15, P594; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; PECKHAM MJ, 1981, BRIT J UROL, V53, P162, DOI 10.1111/j.1464-410X.1981.tb03160.x; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; Saxman SB, 1998, J CLIN ONCOL, V16, P702, DOI 10.1200/JCO.1998.16.2.702; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; Silva ID, 1999, INT J CANCER, V83, P630; SLEVIN ML, 1989, J CLIN ONCOL, V7, P1333, DOI 10.1200/JCO.1989.7.9.1333; TONER GC, 1991, CANCER-AM CANCER SOC, V67, P2049, DOI 10.1002/1097-0142(19910415)67:8<2049::AID-CNCR2820670807>3.0.CO;2-H; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302	26	75	76	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 10	2001	357	9258					739	745		10.1016/S0140-6736(00)04165-9	http://dx.doi.org/10.1016/S0140-6736(00)04165-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	409TC	11253966				2023-01-03	WOS:000167400900010
J	Tamblyn, R; Laprise, R; Hanley, JA; Abrahamowicz, M; Scott, S; Mayo, N; Hurley, J; Grad, R; Latimer, E; Perreault, R; McLeod, P; Huang, A; Larochelle, P; Mallet, L				Tamblyn, R; Laprise, R; Hanley, JA; Abrahamowicz, M; Scott, S; Mayo, N; Hurley, J; Grad, R; Latimer, E; Perreault, R; McLeod, P; Huang, A; Larochelle, P; Mallet, L			Adverse events associated with prescription drug cost-sharing among poor and elderly persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; LONGITUDINAL DATA-ANALYSIS; ATTRIBUTABLE FRACTION; PRIMARY-CARE; MEDICAID; THERAPY; PAYMENT; IMPACT; VALIDATION; POPULATION	Context Rising costs of medications and inequities in access have sparked calls for drug policy reform in the United States and Canada. Control of drug expenditures by prescription cost-sharing for elderly persons and poor persons is a contentious issue because little is known about the health impact in these subgroups. Objectives To determine (1) the impact of introducing prescription drug cost-sharing on use of essential and less essential drugs among elderly persons and welfare recipients and (2) rates of emergency department (ED) visits and serious adverse events associated with reductions in drug use before and after policy implementation. Design and Setting Interrupted time-series analysis of data from 32 months before and 17 months after introduction of a prescription coinsurance and deductible cost-sharing policy in Quebec in 1996, Separate 10-month prepolicy control and post-policy cohort studies were conducted to estimate the impact of the drug reform on adverse events. Participants A random sample of 93 950 elderly persons and 55 333 adult welfare medication recipients. Main Outcome Measures Mean daily number of essential and less essential drugs used per month, ED visits, and serious adverse events (hospitalization, nursing home admission, and mortality) before and after policy introduction. Results After cost-sharing was introduced, use of essential drugs decreased by 9.12% (95% confidence interval [CI], 8.7%-9.6%) in elderly persons and by 14.42% (95% CI, 13.3%-15.6%) in welfare recipients; use of less essential drugs decreased by 15.14% (95% CI, 14.4%-15.9%) and 22.39% (95% CI, 20.9%-23.9%), respectively. The rate (per 10000 person-months) of serious adverse events associated with reductions in use of essential drugs increased from 5.8 in the prepolicy control cohort to 12.6 in the postpolicy cohort in elderly persons (a net increase of 6.8 [95% CI, 5.6-8.0]) and from 14.7 to 27.6 in welfare recipients (a net increase of 12.9 [95% CI, 10.2-15.5]). Emergency department visit rates related to reductions in the use of essential drugs also increased by 14.2 (95% CI, 8.5-19.9) per 10000 person-months in elderly persons (prepolicy control cohort, 32.9; postpolicy cohort, 47.1) and by 54.2 (95% CI, 33.5-74.8) among welfare recipients (prepolicy control cohort, 69.6; postpolicy cohort, 123.8). These increases were primarily due to an increase in the proportion of recipients who reduced their use of essential drugs. Reductions in the use of less essential drugs were not associated with an increase in risk of adverse events or ED visits. Conclusions In our study, increased cost-sharing for prescription drugs in elderly persons and welfare recipients was followed by reductions in use of essential drugs and a higher rate of serious adverse events and ED visits associated with these reductions.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	McGill University; McGill University	Tamblyn, R (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Royal Victoria Hosp Site,Ross Pavil,Room 4-12,687, Montreal, PQ H3A 1A1, Canada.		mallet, louise/AAA-4088-2020; Tamblyn, Robyn/L-6010-2016	mallet, louise/0000-0002-3151-8991; Latimer, Eric/0000-0002-4485-1056; Abrahamowicz, Michal/0000-0002-3172-3952				BACOVSKY RA, 1998, C NAT APPR PHARM JAN; BLOOM BS, 1985, MED CARE, V23, P872, DOI 10.1097/00005650-198507000-00004; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEMERS M, 1994, COUT SERVICES MED DU, P39; DEYO RA, 1993, J CLIN EPIDEMIOL, V46, P1081, DOI 10.1016/0895-4356(93)90104-9; Efron B., 1993, INTRO BOOTSTRAP; Goetghebeur E, 1998, STAT MED, V17, P341, DOI 10.1002/(SICI)1097-0258(19980215)17:3<341::AID-SIM766>3.0.CO;2-X; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Grymonpre RE, 1998, ANN PHARMACOTHER, V32, P749, DOI 10.1345/aph.17423; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; HURLEY J, 1991, CAN PUBLIC POL, V17, P473, DOI 10.2307/3551708; HUTTIN C, 1994, HEALTH POLICY, V27, P53, DOI 10.1016/0168-8510(94)90157-0; INUI TS, 1980, MED CARE, V18, P986, DOI 10.1097/00005650-198010000-00002; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Levy R A, 1992, Pharmacoeconomics, V2, P219, DOI 10.2165/00019053-199202030-00005; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lohr KathleenN., 1986, USE MED CARE RAND HL; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; Martin BC, 1996, MED CARE, V34, P686, DOI 10.1097/00005650-199607000-00003; Martin M, 1996, CAN MED ASSOC J, V154, P1264; *MIN PUBL WORKS GO, 1997, CAN HLTH ACT BUILD L; MORGENSTERN H, 1998, MODERN EPIDEMIOLOGY, P459; NELSON AA, 1984, MED CARE, V22, P724, DOI 10.1097/00005650-198408000-00004; Newhouse JP, 1993, FREE ALL LESSONS RAN; OBRIEN B, 1989, J HEALTH ECON, V8, P109, DOI 10.1016/0167-6296(89)90011-8; Reeder C E, 1993, Pharmacoeconomics, V4, P92, DOI 10.2165/00019053-199304020-00004; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Rockhill B, 1998, AM J EPIDEMIOL, V147, P826, DOI 10.1093/oxfordjournals.aje.a009535; RYAN M, 1991, SOC SCI MED, V33, P681, DOI 10.1016/0277-9536(91)90022-5; Simon GE, 1996, AM J PSYCHIAT, V153, P331; SIMON GE, 1994, AM J PSYCHIAT, V151, P908; SMITH DG, 1993, INQUIRY-J HEALTH CAR, V30, P189; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Tamblyn R, 2000, J CLIN EPIDEMIOL, V53, P183, DOI 10.1016/S0895-4356(99)00136-5; Tamblyn R, 1998, ENCY BIOSTATISTICS, P1235; WARD MM, 1993, J CLIN EPIDEMIOL, V46, P645, DOI 10.1016/0895-4356(93)90038-3; *WHO, 1999, WHO DRUG INFORMATION, V13, P249; Wilkins R, 1993, Health Rep, V5, P157; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; [No title captured]	49	600	607	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2001	285	4					421	429		10.1001/jama.285.4.421	http://dx.doi.org/10.1001/jama.285.4.421			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	394CG	11242426	Green Published, Bronze			2023-01-03	WOS:000166506000029
J	Treloar, A; Philpot, M; Beats, B				Treloar, A; Philpot, M; Beats, B			Concealing medication in patients' food	LANCET			English	Editorial Material							ETHICAL DILEMMA; NURSE		Mem Hosp, Oxleas NHS Trust, London SE18 3RZ, England; Mem Hosp, Guys Med Sch, London SE18 3RZ, England; Mem Hosp, Kings Med Sch, London SE18 3RZ, England; Mem Hosp, St Thomas Med Sch, London SE18 3RZ, England; Inst Psychiat, London, England; S London & Maudsley NHS Trust, London, England; St Martins Hosp, London, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust	Treloar, A (corresponding author), Mem Hosp, Oxleas NHS Trust, Shooters Hill, London SE18 3RZ, England.							*BMA LAW SOC, 1995, ASS MENT CAP GUID DO; Colenda CC, 1999, AM J GERIAT PSYCHIAT, V7, P12; DEDEYN P, 1999, INT J GERIATR PSYCH, V14, P459; Dyer C, 1998, BRIT MED J, V317, P1339, DOI 10.1136/bmj.317.7169.1339; Gormley N, 1999, INT J GERIATR PSYCH, V14, P509, DOI 10.1002/(SICI)1099-1166(199907)14:7<509::AID-GPS979>3.0.CO;2-H; Griffith D, 1996, BRIT MED J, V313, P1250, DOI 10.1136/bmj.313.7067.1250; Jones R., 1999, MENTAL HLTH ACT MANU; Kellett JM, 1996, BRIT MED J, V313, P1249, DOI 10.1136/bmj.313.7067.1249; *LORD HIGH CHANC, 1999, MAK DEC GOV PROP MAK; *N LAK HEALTHC N C, 2000, N LAK HEALTHC NHS TR; Pereira S., 1999, PSYCHIATR BULL, V23, P342, DOI DOI 10.1192/PB.23.6.342; Re C, 1994, WLR, V1, P290; Re MB, 1997, FLR, V2; *SCOTT EX, 1999, MAK RIGHT MOV RIGHTS; TRELOAR A, 1990, J ROY SOC MED, V93, P408; Treloar AJ, 1999, INT J GERIATR PSYCH, V14, P1039, DOI 10.1002/(SICI)1099-1166(199912)14:12<1039::AID-GPS60>3.0.CO;2-C; *UK CENTR COUNC NU, 1992, STAND ADM MED; Valmana A, 1997, BRIT MED J, V314, P300	18	23	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 6	2001	357	9249					62	64		10.1016/S0140-6736(00)03578-9	http://dx.doi.org/10.1016/S0140-6736(00)03578-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EQ	11197375				2023-01-03	WOS:000166341500036
J	Dahl, JL				Dahl, JL			Improving the practice of pain management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EDUCATION; OUTCOMES; BARRIERS		Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahl, JL (corresponding author), Univ Wisconsin, Sch Med, Madison, WI 53706 USA.							[Anonymous], [No title captured]; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Drayer RA, 1999, J PAIN SYMPTOM MANAG, V17, P434, DOI 10.1016/S0885-3924(99)00022-6; Jacox A, 1994, AHCPR PUBLICATION; Joranson D E, 1998, Semin Oncol Nurs, V14, P158, DOI 10.1016/S0749-2081(98)80022-3; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; *PAIN POL STUD GRO, 2000, GUID EV ACH BAL FED; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Stross JK, 1999, ANN INTERN MED, V131, P304, DOI 10.7326/0003-4819-131-4-199908170-00009; Weissman DE, 1996, J PAIN SYMPTOM MANAG, V12, P364, DOI 10.1016/S0885-3924(96)00185-6	10	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2785	2785		10.1001/jama.284.21.2785	http://dx.doi.org/10.1001/jama.284.21.2785			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105189	hybrid			2023-01-03	WOS:000165509500036
J	Page, RL; Joglar, JA; Kowal, RC; Zagrodzky, JD; Nelson, LL; Ramaswamy, K; Barbera, SJ; Hamdan, MH; McKenas, DK				Page, RL; Joglar, JA; Kowal, RC; Zagrodzky, JD; Nelson, LL; Ramaswamy, K; Barbera, SJ; Hamdan, MH; McKenas, DK			Use of automated external defibrillators by a US airline.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; TRANSTHORACIC VENTRICULAR DEFIBRILLATION; PUBLIC-ACCESS DEFIBRILLATION; CARDIAC LIFE-SUPPORT; BIPHASIC WAVE-FORM; ARREST; PROFESSIONALS; STATEMENT; COMMITTEE; SURVIVAL	Background: Passengers who have ventricular fibrillation aboard commercial aircraft rarely survive, owing to the delay in obtaining emergency care and defibrillation. Methods: In 1997, a major U.S. airline began equipping its aircraft with automated external defibrillators. Flight attendants were trained in the use of the defibrillator and applied the device when passengers had a lack of consciousness, pulse, or respiration. The automated external defibrillator was also used as a monitor for other medical emergencies, generally at the direction of a passenger who was a physician. The electrocardiogram that was obtained during each use of the device was analyzed by two arrhythmia specialists for appropriateness of use. We analyzed data on all 200 instances in which the defibrillators were used between June 1, 1997, and July 15, 1999. Results: Automated external defibrillators were used for 200 patients (191 on the aircraft and 9 in the terminal), including 99 with documented loss of consciousness. Electrocardiographic data were available for 185 patients. The administration of shock was advised in all 14 patients who had electrocardiographically documented ventricular fibrillation, and no shock was advised in the remaining patients (sensitivity and specificity of the defibrillator in identifying ventricular fibrillation, 100 percent). The first shock successfully defibrillated the heart in 13 patients (defibrillation was withheld in 1 case at the family's request). The rate of survival to discharge from the hospital after shock with the automated external defibrillator was 40 percent. A total of 36 patients either died or were resuscitated after cardiac arrest. No complications arose from use of the automated external defibrillator as a monitor in conscious passengers. Conclusions: The use of the automated external defibrillator aboard commercial aircraft is effective, with an excellent rate of survival to discharge from the hospital after conversion of ventricular fibrillation. There are not likely to be complications when the device is used as a monitor in the absence of ventricular fibrillation.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol,Sect Clin Cardiac Electrophysiol, Dallas, TX 75390 USA; Amer Airlines, Ft Worth, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Page, RL (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol,Sect Clin Cardiac Electrophysiol, Rm CS7-102,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Page, Richard L./L-5501-2014	Page, Richard L./0000-0001-5603-1330				ALDRETE JA, 1983, SOUTHERN MED J, V76, P12; ANDERSON RN, 1997, MONTHLY VITAL STAT R, V45, P2; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; CHEN PS, 1986, CIRCULATION, V73, P1022, DOI 10.1161/01.CIR.73.5.1022; CUMMINS RO, 1988, JAMA-J AM MED ASSOC, V259, P1983, DOI 10.1001/jama.259.13.1983; Cummins RO, 1998, CIRCULATION, V97, P1654, DOI 10.1161/01.CIR.97.16.1654; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Donaldson E, 1996, AUST NZ J SURG, V66, P431, DOI 10.1111/j.1445-2197.1996.tb00777.x; GRUNDY JW, 2000, CIRCULATION, V100, P1703; Mittal S, 1999, J AM COLL CARDIOL, V34, P1595, DOI 10.1016/S0735-1097(99)00363-0; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; ORourke RA, 1997, CIRCULATION, V96, P2775, DOI 10.1161/01.CIR.96.9.2775; Page RL, 1998, CIRCULATION, V97, P1429; Ruckman RF, 1999, J AIR LAW COMMER, V65, P77; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; WADE B, 1999, NY TIMES        0706, P24; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; 2000, J AM COLL CARDIOL, V35, P825; 2000, FED REG         0524, V65, P33702	23	430	435	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1210	1216		10.1056/NEJM200010263431702	http://dx.doi.org/10.1056/NEJM200010263431702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071671				2023-01-03	WOS:000090014100002
J	Cuttini, M; Nadai, M; Kaminski, M; Hansen, G; de Leeuw, R; Lenoir, S; Persson, J; Rebagliato, M; Reid, M; de Vonderweid, U; Lenard, HG; Orzalesi, M; Saracci, R				Cuttini, M; Nadai, M; Kaminski, M; Hansen, G; de Leeuw, R; Lenoir, S; Persson, J; Rebagliato, M; Reid, M; de Vonderweid, U; Lenard, HG; Orzalesi, M; Saracci, R		EURONIC Study Grp	End-of-life decisions in neonatal intensive care: physicians' self-reported practices in seven European countries	LANCET			English	Article							ETHICAL DECISIONS; INFANTS; UNIT; SUPPORT; DEATH; NETHERLANDS; DILEMMAS; NURSERY	Background The ethical issue of foregoing life-sustaining treatment for newborn infants at high risk of death or severe disability is extensively debated, but there is little information on how physicians in different countries actually confront this issue to reach end-of-life decisions. The EURONIC project aimed to investigate practices as reported by physicians themselves. Methods The study recruited a large, representative sample of 122 neonatal intensive-care units (NICUs) by census tin Luxembourg, the Netherlands, and Sweden) or stratified random sampling (in France, Germany, the UK, Italy, and Spain) with an overall response rate of 86%. Physicians' practices of end-of-life decision-making were investigated through an anonymous, self-administered questionnaire. 1235 completed questionnaires were returned (response rate 89%). Findings In all countries, most physicians reported having been involved at least once in setting limits to intensive care because of incurable conditions (61-96%); smaller proportions reported such involvement because of a baby's poor neurological prognosis (46-90%). Practices such as continuation of current treatment without intensification and withholding of emergency manoeuvres were widespread, but withdrawal of mechanical ventilation was reported by variable proportions (28-90%). Only in France (73%) and the Netherlands (47%) was the administration of drugs with the aim of ending life reported with substantial frequency. Age, length of professional experience, and the importance of religion in the physician's life affected the likelihood of reporting of non-treatment decisions. Interpretation A vast majority of neonatologists in European NICUs have been involved in end-of-life limitation of treatments, but type of decision-making varies among countries, Cultur-related and other country-specific factors are more relevant than characteristics of individual physicians or units in explaining such variability.	Burlo Garofolo Childrens Hosp, Epidemiol Unit, I-34137 Trieste, Italy; Burlo Garofolo Childrens Hosp, Neonatal Intens Care Unit, I-34137 Trieste, Italy; INSERM, U149, Epidemiol Unit Womens & Childrens Hlth, Villejuif, France; Univ Halle Wittenberg, Dept Pediat, Halle, Germany; Univ Amsterdam, Dept Neonatol, Amsterdam, Netherlands; Fac Med Toulouse, INSERM, CJF 8908, Unit Res Reprod, F-31073 Toulouse, France; Ctr Med Technol Assessment, Linkoping, Sweden; Miguel Hernandez Univ, Dept Publ Hlth, Alicante, Spain; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8QQ, Lanark, Scotland; Univ Dusseldorf, Dept Pediat, D-4000 Dusseldorf, Germany; Bambino Gesu Childrens Hosp, Neonatal Intens Care Unit, Rome, Italy; Natl Res Council, IFC, Div Epidemiol, Pisa, Italy	IRCCS Burlo Garofolo; IRCCS Burlo Garofolo; Institut National de la Sante et de la Recherche Medicale (Inserm); Martin Luther University Halle Wittenberg; University of Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidad Miguel Hernandez de Elche; University of Glasgow; Heinrich Heine University Dusseldorf; IRCCS Bambino Gesu; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Cuttini, M (corresponding author), Burlo Garofolo Childrens Hosp, Epidemiol Unit, Via Istria 65-1, I-34137 Trieste, Italy.		Cuttini, Marina/AAI-1987-2019; Rebagliato, Marisa/L-6116-2018	Cuttini, Marina/0000-0002-3284-6874; Rebagliato, Marisa/0000-0001-5825-0190				Avery GB, 1998, SEMIN PERINATOL, V22, P216, DOI 10.1016/S0146-0005(98)80037-2; Cuttini M, 1999, ARCH DIS CHILD-FETAL, V81, pF84, DOI 10.1136/fn.81.2.F84; Cuttini M, 1997, PAEDIATR PERINAT EP, V11, P461, DOI 10.1046/j.1365-3016.1997.d01-29.x; DEHAN M, 1993, M S-MED SCI, V9, P260, DOI 10.4267/10608/2907; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; Garel M, 1997, ARCH PEDIATRIE, V4, P662, DOI 10.1016/S0929-693X(97)83370-2; Guillemin J, 1986, MIXED BLESSINGS INTE; KELLY NP, 1994, J PAEDIATR CHILD H, V30, P419, DOI 10.1111/j.1440-1754.1994.tb00692.x; Lemeshow S, 1998, AM J EPIDEMIOL, V148, P298; LEVIN BW, 1990, SOC SCI MED, V30, P901, DOI 10.1016/0277-9536(90)90218-H; Mason JK, 1996, LANCET, V347, P810, DOI 10.1016/S0140-6736(96)90875-2; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; MCHAFFIE HE, 1996, LIFE DEATH DECISIONS; MULLER JH, 1992, SOC SCI MED, V34, P885, DOI 10.1016/0277-9536(92)90257-Q; Nederlandse Vereniging voor Kindergeneeskunde, 1992, DOEN LAT GRENZ MED H; Partridge JC, 1997, PEDIATRICS, V99, P76, DOI 10.1542/peds.99.1.76; Payer L., 1988, MED CULTURE VARIETIE; RAGATZ SC, 1983, CLIN PEDIATR, V22, P729, DOI 10.1177/000992288302201101; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; RHODEN NK, 1986, HASTINGS CENT REP, V16, P34, DOI 10.2307/3563115; *ROYAL COLL PAED C, 1997, WITHH WITHDR LIF SAV; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; Stevenson DK, 1998, SEMIN PERINATOL, V22, P198, DOI 10.1016/S0146-0005(98)80035-9; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64; WHITELAW A, 1986, LANCET, V2, P328; YOUNG EWD, 1990, AM J DIS CHILD, V144, P549, DOI 10.1001/archpedi.1990.02150290043023; YOUNG EWD, 1984, MONOGRAPH WORLD REHA, V25; 1999, CORRIERE SERA   0316; 2000, LANCET, V355, P79	31	270	273	0	30	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 17	2000	355	9221					2112	2118		10.1016/S0140-6736(00)02378-3	http://dx.doi.org/10.1016/S0140-6736(00)02378-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	325QD	10902625				2023-01-03	WOS:000087687100011
J	Inwald, D; Jakobovits, I; Petros, A				Inwald, D; Jakobovits, I; Petros, A			Ethical debate - Brain stem death: managing care when accepted medical guidelines and religious beliefs are in conflict - Consideration and compromise are possible	BRITISH MEDICAL JOURNAL			English	Article									Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, London WC1N 1EH, England; Great Ormond St Hosp Children, Paediat Intens Care Unit, London WC1N 3JH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Inwald, D (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, 30 Guilford St, London WC1N 1EH, England.			Inwald, David/0000-0001-9518-7821				BLEICH JD, 1991, TIME DEATH JEWISH LA; PALLIS C, 1983, BRIT MED J, V286, P123, DOI 10.1136/bmj.286.6359.123; *ROYAL COLL PAED C, 1997, WITHH WITHDR LIF SAV; TENDLER M, 1991, JEWISH OBSERVER, V24, P11; *WORD GROUP C MED, 1976, LANCET, V2, P1069; WOSNER SH, 1995, PATHWAYS MED	6	16	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1266	1267		10.1136/bmj.320.7244.1266	http://dx.doi.org/10.1136/bmj.320.7244.1266			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797044	Green Published			2023-01-03	WOS:000086981400027
J	Rector, TS				Rector, TS			Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK	Context Many Medicare beneficiaries enroll in managed care health plans to obtain outpatient drug benefits. Increasing pharmaceutical utilization and costs and decreasing drug benefits increase the likelihood that medication use by such enrollees will exceed drug benefits, which may lead to health plan disenrollment. Objective To test the hypothesis that exhaustion of managed care drug benefits by Medicare beneficiaries is associated with disenrollment from the health plan. Design Retrospective cohort study followed up for 1 year (1998) using an enrollment/claims database. Setting Four geographically diverse network-model health plans that had annual drug benefits of $300, $500, $600, or $1000. Participants A total of 61 412 elderly Medicare beneficiaries. Main Outcome Measure Voluntary disenrollment from health plans by members who did or did not exhaust their drug benefits. Results The likelihood of exhausting 1998 drug benefits ranged from 17% to 25% across health plans (P<.001). The relative hazards of disenrollment from the 4 plans when drug benefits had been exhausted were 2.5 (95% confidence interval [CI], 2.3-2.8), 1.9 (95% CI, 1.7-2.1), 2.7 (95% CI, 2.0-3.6), and 2.1 (95% CI, 1.9-2.4). Statistical adjustments for age, sex, prior enrollment, hospital admissions, physician visits, and county of residence did not alter these estimates. Conclusions Exhaustion of drug benefits was associated with a significant increase in the likelihood of disenrollment of Medicare beneficiaries, this finding arouses concern that Medicare beneficiaries must change plans to have financial access to medications, which can lead to discontinuity in care and diversion of resources from care to administrative matters. Policymakers should strive to avoid fragmented systems of providing drug benefits.	Unitedhlth Grp, Ctr Hlth Care Policy & Evaluat, Minneapolis, MN 55440 USA		Rector, TS (corresponding author), Unitedhlth Grp, Ctr Hlth Care Policy & Evaluat, POB 1459, Minneapolis, MN 55440 USA.							ALLISON PD, 1995, SURVIVAL ANAL USING, P111; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; Greenwald LM, 1998, INQUIRY-J HEALTH CAR, V35, P193; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; JERNIGAN CL, 1999, J MANAGED CARE PHARM, V5, P44; Mueller C, 1997, AM J PUBLIC HEALTH, V87, P1626, DOI 10.2105/AJPH.87.10.1626; Newcomer R, 1996, INQUIRY-J HEALTH CAR, V33, P144; PORELL FW, 1992, FACTORS ASS DISENROL; Riley GF, 1997, HEALTH AFFAIR, V16, P117, DOI 10.1377/hlthaff.16.5.117; Schlesinger M, 1999, HEALTH SERV RES, V34, P547; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Wilson J, 1998, CLIN THER, V20, P1263, DOI 10.1016/S0149-2918(98)80121-5	12	34	34	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2163	2167		10.1001/jama.283.16.2163	http://dx.doi.org/10.1001/jama.283.16.2163			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791512				2023-01-03	WOS:000086542800036
J	van der Zee, J; Gonzalez, DG; van Rhoon, GC; van Dijk, JDP; van Putten, WLJ; Hart, AAM				van der Zee, J; Gonzalez, DG; van Rhoon, GC; van Dijk, JDP; van Putten, WLJ; Hart, AAM		Dutch Deep Hyperthermia Grp	Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial	LANCET			English	Article							TRANSITIONAL-CELL-CARCINOMA; RADIATION-THERAPY; UTERINE CERVIX; RECTAL-CANCER; SIZE; ONCOLOGY; BLADDER; FAILURE	Background Local-control rates after radiotherapy for locally advanced tumours of the bladder, cervix, and rectum are disappointing. We investigated the effect of adding hyperthermia to standard radiotherapy. Methods The study was a prospective, randomised, multicentre trial. 358 patients were enrolled from 1990 to 1996, in cancer centres in the Netherlands, who had bladder cancer stages T2, T3, or T4, N0, M0, cervical cancer stages IIB, IIIB, or IV, or rectal cancer stage M0-1 were assessed. Patients were randomly assigned radiotherapy (median total dose 65 Gy) alone (n=176) or radiotherapy plus hyperthermia (n=182). Our primary endpoints were complete response and duration of local control. We did the analysis by intention to treat. Findings Complete-response rates were 39% after radiotherapy and 55% after radiotherapy plus hyperthermia (p<0.001). The duration of local control was significantly longer with radiotherapy plus hyperthermia than with radiotherapy alone (p=0.04). Treatment effect did not differ significantly by tumour site, but the addition of hyperthermia seemed to be most important for cervical cancer, for which the complete-response rate with radiotherapy plus hyperthermia was 83% compared with 57% after radiotherapy alone (p=0.003). 3-year overall survival was 27% in the radiotherapy group and 51% in the radiotherapy plus hyperthermia group. For bladder cancer, an initial difference in local control disappeared during follow-up. Interpretation Hyperthermia in addition to standard radiotherapy may be especially useful in locally advanced cervical tumours. Studies of larger numbers of patients are needed for other pelvic tumour sites before practical recommendations can be made.	Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Stat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Zee, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	zee@hyph.azr.nl	van Rhoon, Gerard/AAK-8286-2020	van Rhoon, Gerard/0000-0002-7365-5783				Barillot I, 1997, INT J RADIAT ONCOL, V38, P969, DOI 10.1016/S0360-3016(97)00145-4; BENTZEN SM, 1992, BRIT J CANCER, V65, P102, DOI 10.1038/bjc.1992.19; BENTZEN SM, 1984, RADIOTHER ONCOL, V2, P255, DOI 10.1016/S0167-8140(84)80066-3; BRADY LW, 1990, CANCER, V65, P610, DOI 10.1002/1097-0142(19900201)65:3+<610::AID-CNCR2820651304>3.0.CO;2-G; BRIERLEY JD, 1995, INT J RADIAT ONCOL, V31, P255, DOI 10.1016/0360-3016(94)E0102-P; BRIZEL DM, 1995, INT J RADIAT ONCOL, V32, P1121, DOI 10.1016/0360-3016(95)00106-9; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Datta N, 1987, INDIAN MED GAZETTE, V121, P68; de Wit R, 1999, BRIT J CANCER, V80, P1387, DOI 10.1038/sj.bjc.6690533; DUNCAN W, 1986, RADIOTHER ONCOL, V7, P299, DOI 10.1016/S0167-8140(86)80059-7; *EARL BREAST CANC, 1988, N ENGL J MED, V319; GIBBS FA, 1996, THERMORADIOTHERAPY T, V2, P121; GONZALEZ DG, 1996, THERMORADIOTHERAPY T, V2, P105; Gospodarowicz M K, 1991, Clin Oncol (R Coll Radiol), V3, P155, DOI 10.1016/S0936-6555(05)81190-2; Hermanek P, 1987, UICC TNM CLASSIFICAT; Hockel M, 1996, CANCER RES, V56, P4509; International Commission on Radiation Units and Measurements, 1993, PRESCR REC REP PHOT; ITO H, 1994, RADIOTHER ONCOL, V31, P240, DOI 10.1016/0167-8140(94)90429-4; Kapp KS, 1998, INT J RADIAT ONCOL, V42, P531, DOI 10.1016/S0360-3016(98)00255-7; MAGEE BJ, 1991, BRIT J RADIOL, V64, P812, DOI 10.1259/0007-1285-64-765-812; MAMEGHAN H, 1995, INT J RADIAT ONCOL, V31, P247, DOI 10.1016/0360-3016(94)E0135-7; Perez CA, 1998, INT J RADIAT ONCOL, V41, P307, DOI 10.1016/S0360-3016(98)00067-4; Raaphorst GP, 1990, INTRO PRACTICAL ASPE, P10; Rau B, 1998, ANN SURG, V227, P380, DOI 10.1097/00000658-199803000-00010; SCHNEIDER CJ, 1994, INT J HYPERTHER, V10, P733, DOI 10.3109/02656739409022451; Sharma S., 1989, ENDOCURIETHERAPY HYP, V5, P151; Thomas GM, 1999, NEW ENGL J MED, V340, P1198, DOI 10.1056/NEJM199904153401509; TREURNIETDONKER AD, 1991, CANCER-AM CANCER SOC, V67, P2042, DOI 10.1002/1097-0142(19910415)67:8<2042::AID-CNCR2820670806>3.0.CO;2-4; Van der Zee J, 1998, INT J RADIAT ONCOL, V40, P1205, DOI 10.1016/S0360-3016(98)00008-X; Van der Zee J, 1998, PROGRESS IN RADIO-ONCOLOGY VI, P137; WATSON ER, 1978, BRIT J RADIOL, V51, P879, DOI 10.1259/0007-1285-51-611-879	31	715	728	0	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1119	1125		10.1016/S0140-6736(00)02059-6	http://dx.doi.org/10.1016/S0140-6736(00)02059-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791373				2023-01-03	WOS:000086380900008
J	Douillard, JY; Cunningham, D; Roth, AD; Navarro, M; James, RD; Karasek, P; Jandik, P; Iveson, T; Carmichael, J; Alakl, M; Gruia, G; Awad, L; Rougier, P				Douillard, JY; Cunningham, D; Roth, AD; Navarro, M; James, RD; Karasek, P; Jandik, P; Iveson, T; Carmichael, J; Alakl, M; Gruia, G; Awad, L; Rougier, P			Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; 24-HOUR INFUSION; CLINICAL-TRIALS; TOPOISOMERASE-I; 5-FLUOROURACIL; ONCOLOGY; FAILURE	Background Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer. Methods 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients. Findings The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0.001 for evaluable patients, 35 vs 22%, p<0.005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6.7 vs 4.4 months, p<0. 001), and overall survival was higher (median 17.4 vs 14.1 months, p=0.031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable. Interpretation Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.	Ctr Rene Gauducheau, F-44805 St Herblain, France; Royal Marsden Hosp, London SW3 6JJ, England; Hosp Cantonal, Geneva, Switzerland; Hosp Duran & Reynals, Barcelona, Spain; Masaryk Mem Canc Inst, Brno, Czech Republic; Univ Hosp, Hradec Kralove, Czech Republic; Royal S Hants Hosp, Southampton SO9 4PE, Hants, England; City Hosp, Nottingham NG5 1PB, England; Rhone Poulenc, Rorer, France; Hosp A Pare, Boulogne, France	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Royal Marsden NHS Foundation Trust; University of Geneva; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Masaryk Memorial Cancer Institute; University Hospital Hradec Kralove; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Nottingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Douillard, JY (corresponding author), Ctr Rene Gauducheau, F-44805 St Herblain, France.			Cunningham, David/0000-0001-5158-1069				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; CREEMERS GJ, 1994, CANCER TREAT REV, V20, P73, DOI 10.1016/0305-7372(94)90011-6; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; De Gramont A, 1998, P AN M AM SOC CLIN, V17, P985; Ducreux M, 1999, J CLIN ONCOL, V17, P2901, DOI 10.1200/JCO.1999.17.9.2901; FAGES B, 1997, P ASCO, V16; FINDLAY M, 1994, ANN ONCOL, V5, P239, DOI 10.1093/oxfordjournals.annonc.a058800; GIACCHETTI S, 1997, P AN M AM SOC CLIN, V16, P229; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IZZO J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P217; JAGER E, 1995, EUR J CANC A, V31; JAXEL C, 1989, CANCER RES, V49, P1465; Kohne CH, 1998, J CLIN ONCOL, V16, P418; MARSONI S, 1987, CANC TREAT REP, V71, P7180; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; SALTZ LB, 1999, P AN M AM SOC CLIN, V18, P233; SCHMOLL HJ, 1996, IS THERE 2 LINE THER; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Vanhoefer U, 1999, J CLIN ONCOL, V17, P907, DOI 10.1200/JCO.1999.17.3.907; WEH HJ, 1994, ANN ONCOL, V5, P233, DOI 10.1093/oxfordjournals.annonc.a058799	24	2612	2728	1	99	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1041	1047		10.1016/S0140-6736(00)02034-1	http://dx.doi.org/10.1016/S0140-6736(00)02034-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744089				2023-01-03	WOS:000086380800010
J	Nolan, TW				Nolan, TW			System changes to improve patient safety	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; TASK COMPLEXITY; MEDICINE		Associates Proc Improvement, Silver Spring, MD 20910 USA		Nolan, TW (corresponding author), Associates Proc Improvement, 1110 Bonifant St, Silver Spring, MD 20910 USA.	TNolan@apiweb.org						BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Cook RI, 1994, HUMAN ERROR MED, P255; Fraass BA, 1998, INT J RADIAT ONCOL, V42, P651, DOI 10.1016/S0360-3016(98)00244-2; HINCKLEY CM, 1995, J QUAL TECHNOL, V27, P242, DOI 10.1080/00224065.1995.11979596; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEVENSON MD, 1993, SOLID STATE TECHNOL, V36, P18; LEVESON NG, 1993, SAFEWARE SYSTEMS SAF; MAYLOR EA, 1992, Q J EXP PSYCHOL-A, V44, P119, DOI 10.1080/14640749208401286; Murray SA, 1996, HUM FACTORS, V38, P323, DOI 10.1518/001872096779048011; Norman D.A., 1988, PSYCHOL EVERYDAY THI; Norman D. A., 1993, THINGS MAKE US SMART; Park K, 1997, HDB HUMAN FACTORS ER, P150; Reason J., 1990, HUMAN ERROR; Salvendy G., 2021, HDB HUMAN FACTORS ER, DOI [10.1002/9781119636113, DOI 10.1002/9781119636113]; SARTER NB, 1992, INT J AVIAT PSYCHOL, V4, P1; Strong MJ, 1999, NEUROLOGY, V53, pS31; Ushakov IA, 1994, HDB RELIABILITY ENG; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; WICHMAN H, 1983, HUM FACTORS, V25, P583, DOI 10.1177/001872088302500512	22	202	217	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					771	773		10.1136/bmj.320.7237.771	http://dx.doi.org/10.1136/bmj.320.7237.771			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720364	Green Published			2023-01-03	WOS:000086054700029
J	Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C				Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C			Critical role of micelles in pancreatic lipase activation revealed by small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-SALT; TAURODEOXYCHOLATE MICELLES; CRYSTAL-STRUCTURE; HORSE COLIPASE; CO-LIPASE; PORCINE; COMPLEX; DETERGENTS; ADSORPTION; VESICLES	In the duodenum, pancreatic lipase (PL) develops its activity on triglycerides by binding to the bile-emulsified oil droplets in the presence of its protein cofactor pancreatic colipase (PC), The neutron crystal structure of a PC-PL-micelle complex (Hermoso, J,, Pignol, D,, Penel, S,, Roth, M,, Chapus, C,, and Fontecilla-Camps, J, C, (1997) EMBO J, 16, 5531-5536) has suggested that the stabilization of the enzyme in its active conformation and its adsorption to the emulsified oil droplets are mediated by a preformed lipase-colipase-micelle complex. Here, we correlate the ability of different amphypathic compounds to activate FL, with their association with PC-FL in solution, The method of small angle neutron scattering with D2O/H2O contrast variation was used to characterize a solution containing PC-FL complex and taurodeoxycholate micelles, The resulting radius of gyration (56 Angstrom) and the match point of the solution indicate the formation of a ternary complex that is similar to the one observed in the neutron crystal structure. In addition, we show that either bile salts, lysophospholipids, or nonionic detergents that form micelles with radii of gyration ranging from 13 to 26 Angstrom are able to bind to the PC-FL complex, whereas smaller micelles or nonmicellar compounds are not. This further supports the notion of a micelle size-dependent affinity process for lipase activation in vivo.	CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; UPR 9036 CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille, France; Inst Max Von Laue Paul Langevin, Large Scale Struct Grp, F-38042 Grenoble, France; CSIC, Inst Rocasolano, Grp Cristalog Macromol & Biol Estruct, E-28006 Madrid, Spain	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut Laue-Langevin (ILL); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Fontecilla-Camps, JC (corresponding author), CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				BORGSTRO.B, 1973, EUR J BIOCHEM, V37, P60, DOI 10.1111/j.1432-1033.1973.tb02957.x; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; CANIONI P, 1981, BIOCHIM BIOPHYS ACTA, V670, P305, DOI 10.1016/0005-2795(81)90101-X; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CHAPUS C, 1975, FEBS LETT, V58, P155, DOI 10.1016/0014-5793(75)80247-X; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; CHARLES M, 1975, EUR J BIOCHEM, V58, P555, DOI 10.1111/j.1432-1033.1975.tb02405.x; CHARLES M, 1980, J MOL BIOL, V139, P297, DOI 10.1016/0022-2836(80)90132-1; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; EGELHAAF SU, 1994, J PHYS CHEM-US, V98, P8560, DOI 10.1021/j100085a041; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2571; GHOSH R, 1981, 81GH29T ILL; GRANON S, 1986, BIOCHIM BIOPHYS ACTA, V671, P54; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; HOFMANN AF, 1967, ANNU REV MED, V18, P333, DOI 10.1146/annurev.me.18.020167.002001; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; MCINTYRE JC, 1990, BIOCHEMISTRY-US, V29, P2092, DOI 10.1021/bi00460a019; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PEDERSEN JS, 1995, J PHYS CHEM-US, V99, P1299, DOI 10.1021/j100004a033; SARI H, 1978, FEBS LETT, V95, P229, DOI 10.1016/0014-5793(78)81000-X; SARI H, 1975, BIOCHIMIE, V57, P1045, DOI 10.1016/S0300-9084(75)80360-9; SMALL DM, 1968, J AM OIL CHEM SOC, V45, P108, DOI 10.1007/BF02915334; TIMMINS P, 1994, BIOPHYS CHEM, V53, P27, DOI 10.1016/0301-4622(94)00073-5; VANDERMEERS A, 1975, FEBS LETT, V49, P334, DOI 10.1016/0014-5793(75)80779-4; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, NATURE, V362, P812; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	32	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4220	4224		10.1074/jbc.275.6.4220	http://dx.doi.org/10.1074/jbc.275.6.4220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660587	Green Published, hybrid			2023-01-03	WOS:000085288800071
J	Auerbach, AD; Hamel, MB; Davis, RB; Connors, AF; Regueiro, C; Desbiens, N; Goldman, L; Califf, RM; Dawson, NV; Wenger, N; Vidaillet, H; Phillips, RS				Auerbach, AD; Hamel, MB; Davis, RB; Connors, AF; Regueiro, C; Desbiens, N; Goldman, L; Califf, RM; Dawson, NV; Wenger, N; Vidaillet, H; Phillips, RS		SUPPORT Investigators	Resource use and survival of patients hospitalized with congestive heart failure: Differences in care by specialty of the attending physician	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			ACUTE MYOCARDIAL-INFARCTION; MEDICAL OUTCOMES; PROPENSITY SCORE; MORTALITY; CARDIOLOGISTS; MANAGEMENT; PROGNOSIS; SUPPORT; DISEASE; DYSFUNCTION	Background: Previous studies suggest that specialty care is more costly but may produce improved outcomes for patients with acute cardiac illnesses. Objective: To determine whether patients with congestive heart failure who are cared for by cardiologists experienced differences in costs, care patterns, and survival compared with patients of generalists. Design: Prospective cohort study. Setting: 5 U.S. teaching hospitals between 1989 and 1994, Patients: 1298 patients hospitalized with an exacerbation of congestive heart failure. Measurements: Hospital costs; average daily Therapeutic Intervention Scoring System (TISS) score; and survival censored at 30, 180, and 365 days and 31 December 1994. Results: Compared with patients of generalists, patients of cardiologists were younger (mean age, 63.3 and 71.4 years; P < 0.001) and had lower Acute Physiology Scores at the time of admission (35.1 and 36.7; P < 0.001) but were more likely to have a history of ventricular arrhythmias (21.0% and 10.2%; P < 0.001). At 6 months, 201 (27%) patients of cardiologists and 149 (27%) patients of generalists had died. After adjustment for sociodemographic characteristics and severity of illness, patients of cardiologists incurred costs that were 42.9% (95% CI, 27.8% to 59.8%) higher and average daily TISS scores that were 2.83 points (CI, 1.96 to 3.68 points) higher than those of patients of generalists. Patients of cardiologists were more likely,to undergo right-heart catheterization (adjusted odds ratio, 2.9 [CI, 1.7 to 4.9]) or cardiac catheterization (adjusted:odds ratio, 3.9 [CI, 2.4 to 6.2]) and had higher odds for transfer to an intensive care unit and electrocardiographic monitoring. Adjusted survival did not differ significantly between groups at 30 days; however, there was a trend toward improved survival among patients of cardiologists at 1 year (adjusted relative hazard, 0.82 [Cl, 0.65 to 1.04])and at maximum follow-up (adjusted relative hazard, 0.80 [CI, 0.66 to 0.96]). Conclusions: In this observational study of patients hospitalized with congestive heart failure, cardiologist care was associated with greater costs and resource use and no difference in survival at 30 days of follow-up. Whether the trend toward better survival at longer follow-up represents differences in care or unadjusted illness severity is uncertain.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Univ Tennessee, Coll Med, Chattanooga, TN USA; Duke Univ, Med Ctr, Durham, NC USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA; Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	University of California System; University of California San Francisco; University of Virginia; University of Tennessee System; University of Tennessee Health Science Center; Duke University; Case Western Reserve University; MetroHealth System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Marshfield Clinic; Allegheny General Hospital	Auerbach, AD (corresponding author), Univ Calif San Francisco, Dept Med, Box 0120, San Francisco, CA 94143 USA.			Connors, Alfred F./0000-0001-7123-3360				Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1528, DOI 10.1001/jama.272.19.1528; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Doval HC, 1996, CIRCULATION, V94, P3198, DOI 10.1161/01.CIR.94.12.3198; EDWARDS BS, 1992, MAYO CLIN PROC, V67, P485, DOI 10.1016/S0025-6196(12)60400-5; Goldman L, 1996, NEW ENGL J MED, V335, P1918, DOI 10.1056/NEJM199612193352510; GOLDMAN S, 1993, CIRCULATION, V87, P24; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Harjai KJ, 1998, AM J CARDIOL, V82, P82, DOI 10.1016/S0002-9149(98)00234-3; HUGHES CV, 1993, CIRCULATION, V87, P111; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KARLSON BW, 1992, CARDIOLOGY, V81, P134, DOI 10.1159/000175788; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRELLING B, 1990, J CLIN EPIDEMIOL, V43, P55; LEE TH, 1988, ANN INTERN MED, V108, P887, DOI 10.7326/0003-4819-108-6-887; LEIER CV, 1994, AM HEART J, V128, P564, DOI 10.1016/0002-8703(94)90633-5; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PARAMESHWAR J, 1992, AM HEART J, V123, P421, DOI 10.1016/0002-8703(92)90656-G; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Regueiro CR, 1998, AM J MED, V105, P366, DOI 10.1016/S0002-9343(98)00290-3; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3; Rickenbacher PR, 1996, J AM COLL CARDIOL, V27, P1192, DOI 10.1016/0735-1097(95)00587-0; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; STRAUSS MJ, 1986, MED CARE, V24, P915, DOI 10.1097/00005650-198610000-00005; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VanDenBerg MP, 1997, HEART, V77, P309, DOI 10.1136/hrt.77.4.309; VANDENBROEK SAJ, 1992, AM J CARDIOL, V70, P359, DOI 10.1016/0002-9149(92)90619-A; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; Willison DJ, 1998, ARCH INTERN MED, V158, P1778, DOI 10.1001/archinte.158.16.1778	45	105	106	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					191	200		10.7326/0003-4819-132-3-200002010-00004	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	276XE	10651599				2023-01-03	WOS:000084903000003
J	Loitman, JE				Loitman, JE			Pain management: Beyond pharmacology to acupuncture and hypnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Brown Univ, Sch Med, Providence, RI 02912 USA	Brown University	Loitman, JE (corresponding author), Brown Univ, Sch Med, Providence, RI 02912 USA.							Blumberg D L, 1995, Altern Ther Health Med, V1, P31; BROSE W, 1992, AM PSYCHIAT PRESS TX; Crock RD, 1999, ALTERN THER HEALTH M, V5, P61; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Freeman J W, 1997, S D J Med, V50, P65; KELLERMAN J, 1983, J ADOLESC HLTH CARE, V4, P35; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X; Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005; MORGAN AH, 1973, INT J CLIN EXP HYP, V21, P78, DOI 10.1080/00207147308409308; National Institutes of Health, 1995, INT BEH REL APPR TRE, P1; *NIH, 1997, NIH CONS DEV C AC; Pomeranz B, 1996, J Altern Complement Med, V2, P53, DOI 10.1089/acm.1996.2.53; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; Reston, 1971, NY TIMES, P1; Reston J, 1971, NY TIMES, V1, P6; Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004	17	3	4	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					118	119		10.1001/jama.283.1.118	http://dx.doi.org/10.1001/jama.283.1.118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632295				2023-01-03	WOS:000084514400040
J	Leibovici, L				Leibovici, L			Alternative (complementary) medicine: a cuckoo in the nest of empiricist reed warblers	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Rabin Med Ctr, Dept Internal Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Internal Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	leibovic@post.tau.ac.il						Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Mock DW, 1999, NATURE, V397, P647, DOI 10.1038/17679; Rigas B, 1999, LANCET, V354, P1634, DOI 10.1016/S0140-6736(99)06034-1; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P836, DOI 10.1136/bmj.319.7213.836; Zollman C, 1999, BRIT MED J, V319, P1558, DOI 10.1136/bmj.319.7224.1558; ZOLLMAN C, 1999, BRIT MED J, V319, P1254; ZOLLMAN C, 1999, BRIT MED J, V319, P1176; ZOLLMAN C, 1999, BRIT MED J, V319, P973; ZOLLMAN C, 1999, BRIT MED J, V319, P1419; ZOLLMAN C, 1999, BRIT MED J, V319, P1115	16	15	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1629	1631		10.1136/bmj.319.7225.1629	http://dx.doi.org/10.1136/bmj.319.7225.1629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600974	Green Published			2023-01-03	WOS:000084562600025
J	Ernst, E				Ernst, E			Second thoughts about safety of St John's wort	LANCET			English	Editorial Material									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							AJOHNE A, 1999, JAHR KLIN PHARM BERL; BON S, 1999, SCHWEITZER APOTHEKER, V16, P535; Brevoort P., 1998, HerbalGram, P33; ERESHEFSKY B, 1999, P 39 ANN M NEW CLIN; GEWERTZ N, P 39 ANN M NEW CLIN; Harrison P, 1998, CAN MED ASSOC J, V158, P637; Lantz MS, 1999, J GERIATR PSYCH NEUR, V12, P7, DOI 10.1177/089198879901200103; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Martin TG, 1996, ANN EMERG MED, V28, P520, DOI 10.1016/S0196-0644(96)70116-6; MAURER A, 1999, EUR J CLIN PHARMACOL, V55, pA22; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Rey JM, 1998, MED J AUSTRALIA, V169, P583, DOI 10.5694/j.1326-5377.1998.tb123424.x; ROBY CA, 1999, P 39 ANN M NEW CLIN; Stevinson C, 1999, CNS DRUGS, V11, P125, DOI 10.2165/00023210-199911020-00004	15	221	229	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2014	2016		10.1016/S0140-6736(99)00418-3	http://dx.doi.org/10.1016/S0140-6736(99)00418-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636361				2023-01-03	WOS:000084183300004
J	Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ				Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ			Bronchiolitis-associated hospitalizations among US children, 1980-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; GROUP-A; GROUP-B; UNITED-STATES; INFECTION; EPIDEMIOLOGY; CARE; WASHINGTON; EMERGENCY; ILLNESS	Context Respiratory syncytial virus (RSV) causes more lower respiratory tract infections, often manifested as bronchiolitis, among young children than any other pathogen. Few national estimates exist of the hospitalizations attributable to RSV, and recent advances in prophylaxis warrant an update of these estimates. Objectives To describe rates of bronchiolitis-associated hospitalizations and to estimate current hospitalizations associated with RSV infection. Design and Setting Descriptive analysis of US National Hospital Discharge Survey data from 1980 through 1996. Participants Children younger than 5 years who were hospitalized in short-stay, nonfederal hospitals for bronchiolitis. Main Outcome Measure Bronchiolitis-associated hospitalization rates by age and year. Results During the 17-year study period, an estimated 1.65 million hospitalizations for bronchiolitis occurred among children younger than 5 years, accounting for 7.0 million inpatient days. Fifty-seven percent of these hospitalizations occurred among children younger than 6 months and 81 % among those younger than 1 year. Among children younger than 1 year, annual bronchiolitis hospitalization rates increased 2.4-fold, from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996. During 1988-1995, infant hospitalization rates for bronchiolitis increased significantly (P for trend <.001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did not vary significantly (P for trend = .20). The proportion of hospitalizations for lower respiratory tract illnesses among children younger than 1 year associated with bronchiolitis increased from 2.2% in 1980 to 47.4% in 1996; among total hospitalizations, this proportion increased from 5.4% to 16.4%, Averaging bronchiolitis hospitalizations during 1994-1996 and assuming that RSV was the etiologic agent in 50% to 80% of November through April hospitalizations, an estimated 51 240 to 81 985 annual bronchiolitis hospitalizations among children younger than 1 year were related to RSV infection. Conclusions During 1980-1996, rates of hospitalization of infants with bronchiolitis increased substantially, as did the proportion of total and lower respiratory tract hospitalizations associated with bronchiolitis. Annual bronchiolitis hospitalizations associated with RSV infection among infants may be greater than previous estimates for RSV bronchiolitis and pneumonia hospitalizations combined.	Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Off Director, Atlanta, GA USA; Univ Washington, Sch Med, Dept Pediat, Div Gen Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shay, DK (corresponding author), Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.	dks4@cdc.gov		Shay, David/0000-0001-9619-4820				ANDERSON LJ, 1988, PEDIATRICS, V82, P300; ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; ANDERSON LJ, 1991, J INFECT DIS, V163, P687, DOI 10.1093/infdis/163.4.687; [Anonymous], 1998, Pediatrics, V102, P1211; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; BREESE C, 1975, NEW ENGL J MED, V293, P1343, DOI 10.1056/NEJM197512252932604; CAUL EO, 1976, J HYG-CAMBRIDGE, V77, P383, DOI 10.1017/S0022172400055765; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1163; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893, DOI 10.1001/archpedi.1995.02170210067012; DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006; FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492; GARDNER PS, 1973, BMJ-BRIT MED J, V2, P571, DOI 10.1136/bmj.2.5866.571; GILCHRIST S, 1994, J INFECT DIS, V170, P986, DOI 10.1093/infdis/170.4.986; Gillum B S, 1996, Vital Health Stat 13, P1; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1987, PEDIAT VIROL, V2, P1; GRAVES EJ, 1999, VITAL HLTH STAT, V13, P1; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1994, SCIENCE, V265, P1393, DOI 10.1126/science.7915433; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HALL CB, 1998, TXB PEDIAT INFECT DI, P2087; HAUPT BJ, 1992, VITAL HLTH STAT, V13, P1; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Hofferth SL, 1996, FUTURE CHILD, V6, P41, DOI 10.2307/1602418; *I MED, 1986, NEW VACC DEV EST PRI, V2, P299; Institute of Medicine, 1986, NEW VACC DEV EST PRI, V1, P397; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; Kozak L J, 1995, Adv Data, P1; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; MANEKER AJ, 1995, ANN EMERG MED, V25, P36, DOI 10.1016/S0196-0644(95)70352-7; MCCONNOCHLE KM, 1990, J PEDIAT, V162, P1283; MCINTOSH EDG, 1993, PEDIATR INFECT DIS J, V12, P815, DOI 10.1097/00006454-199310000-00004; MONTO AS, 1971, AM J EPIDEMIOL, V94, P290, DOI 10.1093/oxfordjournals.aje.a121322; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; *NAT CTR HLTH STAT, 1998, NAT HOSP DISCH SURV; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; *RES COUNC SUBC RE, 1978, BRIT MED J, V2, P796; Saijo Masayuki, 1993, Acta Paediatrica Japonica, V35, P233; Shah BV, 1996, SUDAAN USERS MANUAL; SIMS DG, 1976, BRIT MED J, V2, P1095, DOI 10.1136/bmj.2.6044.1095; SINGLETON RJ, 1995, PEDIATR INFECT DIS J, V14, P26, DOI 10.1097/00006454-199501000-00005; SIRKEN MG, 1992, MANUAL STANDARDS PRO; *US BUR CENS, 1998, INT EST POP AG SEX R; *US DHHS, 1998, DET DAT 1979 96 PUBL; *US PHS HLTH CAR F, 1998, INT CLASS DIS; Walsh EE, 1997, J INFECT DIS, V175, P814, DOI 10.1086/513976; YAMAMOTO LG, 1993, AM J EMERG MED, V11, P109, DOI 10.1016/0735-6757(93)90101-G; Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005	53	1029	1106	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1440	1446		10.1001/jama.282.15.1440	http://dx.doi.org/10.1001/jama.282.15.1440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535434	Bronze			2023-01-03	WOS:000083111000029
J	Druss, BG; Rosenheck, RA				Druss, BG; Rosenheck, RA			Association between use of unconventional therapies and conventional medical services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; ALTERNATIVE MEDICINE; UNITED-STATES; COSTS; DEPRESSION; CARE; PATTERNS	Context The terms alternative and complementary medicine suggest 2 contradictory possibilities. Whether individuals use unconventional therapies as a substitute for or as an "add on" to conventional medical treatments is uncertain. Objective To determine the association between use of unconventional therapies and conventional medical care in a national sample. Design, Setting, and Participants The 1996 Medical Expenditure Panel Survey was distributed to a probability sample of the noninstitutionalized civilian US population. Of 24 676 individuals responding (77.7% response rate), 16 068 adults 18 years or older were included in the analysis. Main Outcome Measures Visits to practitioners for unconventional therapies and conventional medical services, including number of inpatient, outpatient, and emergency department visits and use of 8 types of preventive medical services (blood pressure, cholesterol level, physical examination, influenza vaccination, prostate examination, breast examination, mammography, and Papanicolaou test). Results During 1996, an estimated 6.5% of the US population had visits for both unconventional therapies and conventional medical care; 1.8% used only unconventional services; 59.5% used only conventional care; and 32.2% used neither. Compared with those with only conventional visits, those who used both types of care had significantly more outpatient physician visits (7.9 vs 5.4; P<.001), and used more of all types of preventive services except mammography. These groups did not differ significantly in inpatient care, prescription drug use, or number of emergency department visits. Individuals in the top quartile of number of physician visits were more than twice as likely as those in the bottom quartile to have used unconventional therapies in the past year (14.5% vs 6.4%; P<.001). The association between unconventional treatments and physician visits remained after adjusting for potential confounders and across different types of unconventional treatment. Conclusions In this sample, use of unconventional therapies was substantially lower than has been reported in previous national surveys, but was associated with increased use of physician services. From a health services perspective, practitioner-based unconventional therapies appear to serve more as a complement than an alternative to conventional medicine.	Yale Univ, Dept Psychiat, West Haven, CT USA; Yale Univ, Dept Publ Hlth, West Haven, CT USA	Yale University; Yale University	Druss, BG (corresponding author), 950 Campbell Ave,116A, West Haven, CT 06516 USA.	benjamin.druss@yale.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; CAIRNS J, 1995, BRIT MED J, V311, P1520, DOI 10.1136/bmj.311.7019.1520; COHEN J, 1997, AHCPR PUBL; COHEN S, 1997, AHCPR PUBL; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P263; DADY PJ, 1987, NEW ZEAL MED J, V100, P110; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eskinazi DP, 1998, JAMA-J AM MED ASSOC, V280, P1621, DOI 10.1001/jama.280.18.1621; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Gundling KE, 1998, ARCH INTERN MED, V158, P2185, DOI 10.1001/archinte.158.20.2185; HASKELL W, 1998, STANF CTR RES DIS PR; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Jonas W, 1998, JAMA, V279, P708; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; KOLATA G, 1998, N Y TIMES       0604, P4; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P1553, DOI 10.1001/jama.280.18.1553; MCFARLAND BH, 1985, MED CARE, V23, P1221, DOI 10.1097/00005650-198511000-00001; *MED EXP PAN SURV, 1997, AHCPR PUBL; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; SPIGELBLATT L, 1994, PEDIATRICS, V94, P811; Von Korff M, 1998, PSYCHOSOM MED, V60, P143, DOI 10.1097/00006842-199803000-00005; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	25	292	292	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					651	656		10.1001/jama.282.7.651	http://dx.doi.org/10.1001/jama.282.7.651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517718	Bronze			2023-01-03	WOS:000082033700024
J	Clifton, GL; Miller, ER; Choi, SC; Levin, HS; McCauley, S; Smith, KR; Muizelaar, JP; Wagner, FC; Marion, DW; Luerssen, TG; Chesnut, RM; Schwartz, M				Clifton, GL; Miller, ER; Choi, SC; Levin, HS; McCauley, S; Smith, KR; Muizelaar, JP; Wagner, FC; Marion, DW; Luerssen, TG; Chesnut, RM; Schwartz, M			Lack of effect of induction of hypothermia after acute brain injury.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; PRESSURE	Background: Induction of hypothermia in patients with brain injury was shown to improve outcomes in small clinical studies, but the results were not definitive. To study this issue, we conducted a multicenter trial comparing the effects of hypothermia with those of normothermia in patients with acute brain injury. Methods: The study subjects were 392 patients 16 to 65 years of age with coma after sustaining closed head injuries who were randomly assigned to be treated with hypothermia (body temperature, 33 degreesC), which was initiated within 6 hours after injury and maintained for 48 hours by means of surface cooling, or normothermia. All patients otherwise received standard treatment. The primary outcome measure was functional status six months after the injury. Results: The mean age of the patients and the type and severity of injury in the two treatment groups were similar. The mean (+/-SD) time from injury to randomization was 4.3+/-1.1 hours in the hypothermia group and 4.1+/-1.2 hours in the normothermia group, and the mean time from injury to the achievement of the target temperature of 33 degreesC in the hypothermia group was 8.4+/-3.0 hours. The outcome was poor (defined as severe disability, a vegetative state, or death) in 57 percent of the patients in both groups. Mortality was 28 percent in the hypothermia group and 27 percent in the normothermia group (P=0.79). The patients in the hypothermia group had more hospital days with complications than the patients in the normothermia group. Fewer patients in the hypothermia group had high intracranial pressure than in the normothermia group. Conclusions: Treatment with hypothermia, with the body temperature reaching 33 degreesC within eight hours after injury, is not effective in improving outcomes in patients with severe brain injury. (N Engl J Med 2001;344:556-63.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Neurosurg,Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; St Louis Univ, Dept Neurosurg, St Louis, MO 63103 USA; Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA USA; Indiana Univ, Div Neurosurg, Indianapolis, IN 46204 USA; Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA; Univ Toronto, Sunnybrook Med Ctr, Dept Neurosurg, Toronto, ON M4N 3M5, Canada	University of Texas System; University of Texas Health Science Center Houston; Virginia Commonwealth University; Virginia Commonwealth University; Baylor College of Medicine; Saint Louis University; University of California System; University of California Davis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indiana University System; Indiana University-Purdue University Indianapolis; Oregon Health & Science University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Clifton, GL (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Neurosurg,Vivian L Smith Ctr Neurol Res, 6431 Fannin,Suite 7-148, Houston, TX 77030 USA.	guy.l.clifton@uth.tmc.edu	Marion, Donald/AAR-5749-2021	Chesnut, Randall/0000-0001-6377-3666	NINDS NIH HHS [R01 NS32786-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Department of Health and Human Services (DHHS), 1996, FED REGISTER, V61, P51531; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JENNETT B, 1975, LANCET, V1, P480; LASKOWSKI EJ, 1960, NEUROLOGY, V10, P499, DOI 10.1212/WNL.10.5.499; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Myles G L, 1995, J Neurosci Nurs, V27, P35; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1955, AM J PHYSIOL, V183, P19, DOI 10.1152/ajplegacy.1955.183.1.19; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; 1995, FED REG, V60, P38353	28	911	965	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	2001	344	8					556	563		10.1056/NEJM200102223440803	http://dx.doi.org/10.1056/NEJM200102223440803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403LU	11207351	Green Published			2023-01-03	WOS:000167044600003
J	Zerzan, J; Stearns, S; Hanson, L				Zerzan, J; Stearns, S; Hanson, L			Access to palliative care and hospice in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENT ASSESSMENT INSTRUMENT; OF-LIFE CARE; ALZHEIMERS-DISEASE; PAIN; QUALITY; MANAGEMENT; SURVIVAL; CRITERIA; DEMENTIA; PATIENT	Nursing homes are the site of death for many elderly patients with incurable chronic illness, yet dying nursing home residents have limited access to palliative care and hospice. The probability that a nursing home will be the site of death increased from 18.7% in 1986 to 20.0% by 1993. Dying residents experience high rates of untreated pain and other symptoms. They and their family members are isolated from social and spiritual support. Hospice improves end-of-life care for dying nursing home residents by improving pain control, reducing hospitalization, and reducing use of tube feeding, but it is rarely used. For example, in 1997 only 13% of hospice enrollees were in nursing homes while 87% were in private homes, and 70% of nursing homes had no hospice patients. Hospice use varies by region, and rates of use are associated with nursing home administrators' attitudes toward hospice and contractual obligations. Current health policy discourages use of palliative care and hospice for dying nursing home residents. Quality standards and reimbursement rules provide incentives for restorative care and technologically intensive treatments rather than labor-intensive palliative care, Reimbursement incentives, contractual requirements, and concerns about health care fraud also limit its use. Changes in health policy, quality standards, and reimbursement incentives are essential to improve access to palliative care and hospice for dying nursing home residents.	Univ N Carolina, Div Gen Med, Dept Hlth Policy & Adm, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ N Carolina, Ctr Hlth Eth & Policy, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; Oregon Health & Science University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hanson, L (corresponding author), Univ N Carolina, Div Gen Med, Dept Hlth Policy & Adm, Sch Publ Hlth, CB 7110,5035 Old Clin Bldg, Chapel Hill, NC 27599 USA.			Hanson, Laura/0000-0001-5120-6058				Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; BRODER M, 1996, MED ETHICS POLICIES; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COLLOPY B, 1991, HASTINGS CENT REP  S, V21, P1; DEGNER LF, 1991, CANCER NURS, V14, P246, DOI 10.1097/00002820-199114050-00004; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Hanson L. C., 1999, JGIM, V14, P101; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HAUPT BJ, 1998, ADV DATA, V299, P1; Hayley DC, 1996, ARCH INTERN MED, V156, P249, DOI 10.1001/archinte.156.3.249; *HLTH CAR FIN ADM, 1997, MED PROGR MAN STAT M; HOLTZMAN J, 1994, J AM GERIATR SOC, V42, P275, DOI 10.1111/j.1532-5415.1994.tb01751.x; Institute of Medicine, 1986, IMPR QUAL CAR NURS H; Jones B, 1997, Hosp J, V12, P41; KEAY TJ, 1994, J AM GERIATR SOC, V42, P853, DOI 10.1111/j.1532-5415.1994.tb06557.x; Keay TJ, 1998, AM FAM PHYSICIAN, V57, P491; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LELAND J, 1996, NURSE HOME EC, V3, P8; LINN MW, 1989, INT J AGING HUM DEV, V28, P305, DOI 10.2190/JA0E-9T0Y-H2K8-QBV6; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; McMillan A, 1990, Health Care Financ Rev, V12, P1; Miller S C, 1998, J Palliat Med, V1, P367, DOI 10.1089/jpm.1998.1.367; Miller SC, 2000, OUTCOMES UTILIZATION; Mor V, 1997, J AM GERIATR SOC, V45, P1002, DOI 10.1111/j.1532-5415.1997.tb02973.x; Murphy K, 1997, J AM GERIATR SOC, V45, P1104, DOI 10.1111/j.1532-5415.1997.tb05974.x; *N CAR DIV FAC SER, 1997, ANN HOSP LIC DAT S 1; *NAT HOSP ORG, 1999, HOSP FACT SHEET; *NAT HOSP ORG MED, 1996, MED GUID DET PROGN S; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; Petrisek AC, 1999, GERONTOLOGIST, V39, P279, DOI 10.1093/geront/39.3.279; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; *US DEP HHS OFF IN, 1993, OEI129200550 US DEP; *US DEP HHS OFF IN, 1997, OEI059500250 US DEP; *US DEP HHS OFF IN, 1997, OEI059500251 US DEP; *US GEN ACC OFF, 1996, GAOHEHS96145; Vladeck BC, 1996, JAMA-J AM MED ASSOC, V275, P425; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; von Gunten C F, 1996, Oncology (Williston Park), V10, P1070; Watt C K, 1997, Am J Hosp Palliat Care, V14, P63, DOI 10.1177/104990919701400204; Watt K, 1996, Am J Hosp Palliat Care, V13, P47, DOI 10.1177/104990919601300616; WEINER J, 1994, JAMA-J AM MED ASSOC, V271, P1525, DOI 10.1001/jama.271.19.1525; WEISSMAN DE, 1995, J PAIN SYMPTOM MANAG, V10, P292, DOI 10.1016/0885-3924(95)00006-K; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x; WON A, 1999, ANN LONG TERM CARE, V7, P92; 1987, FED REG, V56, P48865	54	110	109	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2489	2494		10.1001/jama.284.19.2489	http://dx.doi.org/10.1001/jama.284.19.2489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074779				2023-01-03	WOS:000165183800023
J	Delclaux, C; L'Her, E; Alberti, C; Mancebo, J; Abroug, F; Conti, G; Guerin, C; Schortgen, F; Lefort, Y; Antonelli, M; Lepage, E; Lemaire, F; Brochard, L				Delclaux, C; L'Her, E; Alberti, C; Mancebo, J; Abroug, F; Conti, G; Guerin, C; Schortgen, F; Lefort, Y; Antonelli, M; Lepage, E; Lemaire, F; Brochard, L			Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOGENIC PULMONARY-EDEMA; PNEUMOCYSTIS-CARINII PNEUMONIA; MECHANICAL VENTILATION; DISTRESS SYNDROME; NONINVASIVE VENTILATION; FAILURE; THERAPY; CPAP; SUPPORT	Context Continuous positive airway pressure (CPAP) is widely used in the belief that it may reduce the need for intubation and mechanical ventilation in patients with acute hypoxemic respiratory insufficiency. Objective To compare the physiologic effects and the clinical efficacy of CPAP vs standard oxygen therapy in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency. Design, Setting, and Patients Randomized, concealed, and unblinded trial of 123 consecutive adult patients who were admitted to 6 intensive care units between September 1997 and January 1999 with a PaO2/FIO2 ratio of 300 mm Hg or less due to bilateral pulmonary edema (n=102 with acute lung injury and n=21 with cardiac disease). Interventions Patients were randomly assigned to receive oxygen therapy alone (n=61) or oxygen therapy plus CPAP (n=62). Main Outcome Measures Improvement in PaO2/FIO2 ratio, rate of endotracheal intubation at any time during the study, adverse events, length of hospital stay, mortality, and duration of ventilatory assistance, compared between the CPAP and standard treatment groups. Results Among the CPAP vs standard therapy groups, respectively, causes of respiratory failure (pneumonia, 54% and 55%), presence of cardiac disease (33% and 35%), severity at admission, and hypoxemia (median [5th-95th percentile] PaO2/FIO2 ratio, 140 [59-288] mm Hg vs 148 [62-283] mm Hg; P=.43) were similarly distributed. After 1 hour of treatment, subjective responses to treatment (P<.001) and median (5th-95th percentile) PaO2/FIO2 ratios were greater with CPAP (203 [45-431] mm Hg vs 151 [73-482] mm Hg; P=.02), No further difference in respiratory indices was observed between the groups. Treatment with CPAP failed to reduce the endotracheal intubation rate (21 [34%] vs 24 [39%] in the standard therapy group; P=.53), hospital mortality (19 [31%] vs 18 [30%]; P=.89), or median (5th-95th percentile) intensive care unit length of stay (6.5 [1-57] days vs 6.0 [1-36] days; P=.43), A higher number of adverse events occurred with CPAP treatment (18 vs 6; P=.01), Conclusion In this study, despite early physiologic improvement, CPAP neither reduced the need for intubation nor improved outcomes in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency primarily due to acute lung injury.	Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, Med Intens Care Unit, F-94010 Creteil, France; Univ Paris, INSERM, U492, Creteil, France; Cavalle Blanche Hosp, Med Intens Care Unit, Brest, France; St Pau Hosp, Intens Care Unit, Barcelona, Spain; La Sapienza Univ Hosp, Intens Care Unit, Rome, Italy; Croix Rousse Hosp, Med Intens Care Unit, Lyon, France; St Louis Hosp, Dept Biostat, Paris, France; Henri Mondor Hosp, Dept Biostat, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Sapienza University Rome; University Hospital Sapienza Rome; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Brochard, L (corresponding author), Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, Med Intens Care Unit, F-94010 Creteil, France.		Antonelli, Massimo/F-9848-2010; Abroug, Fekri/ABI-6564-2022; Antonelli, Massimo/K-9915-2016; Abroug, Fekri/ADJ-0934-2022; guerin, claude/H-5692-2014	Antonelli, Massimo/0000-0003-3007-1670; Abroug, Fekri/0000-0002-5626-5329; guerin, claude/0000-0003-4700-6672; Schortgen, Frederique/0000-0003-1756-7508				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRANSON RD, 1995, RESP CARE EQUIPMENT, P470; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; CARLSSON C, 1981, INTENS CARE MED, V7, P225, DOI 10.1007/BF01702624; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GREGG RW, 1990, CRIT CARE MED, V18, P21, DOI 10.1097/00003246-199001000-00006; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; HURST JM, 1985, J TRAUMA, V25, P1065; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; Kelly AM, 1997, AUST NZ J MED, V27, P319, DOI 10.1111/j.1445-5994.1997.tb01985.x; L'HerE, 1998, Eur J Emerg Med, V5, P313; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; ROUBY JJ, 1992, INTENS CARE MED, V18, P69, DOI 10.1007/BF01705035; Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983; URETZKY G, 1980, CRIT CARE MED, V8, P486, DOI 10.1097/00003246-198009000-00002; VENUS B, 1979, CHEST, V76, P257, DOI 10.1378/chest.76.3.257; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	29	307	321	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2352	2360		10.1001/jama.284.18.2352	http://dx.doi.org/10.1001/jama.284.18.2352			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066186	Bronze			2023-01-03	WOS:000165074500030
J	Vickers, A				Vickers, A			Recent advances - Complementary medicine	BRITISH MEDICAL JOURNAL			English	Review							CONTROLLED TRIALS; ACUPUNCTURE; ABC; HEALTH; BACK		Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Vickers, A (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.			Vickers, Andrew/0000-0003-1525-6503				[Anonymous], 1998, COMPLEMENT THER MED, V6, P211; Bhattacharya B, 2000, J Altern Complement Med, V6, P77, DOI 10.1089/acm.2000.6.77; *BRIT MED ASS BOAR, 2000, AC EFF SAF PRACT; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654; FRASER J, 1993, J ADV NURS, V18, P238, DOI 10.1046/j.1365-2648.1993.18020238.x; Grossman SA, 1999, ONCOLOGY-NY, V13, P33; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Haynes RB, 1999, BRIT MED J, V319, P1632; Inglis B., 1965, FRINGE MED; Koch ME, 1998, ANESTHESIOLOGY, V89, P300, DOI 10.1097/00000542-199808000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; LINDE K, 2000, COCHRANE LIB; Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x; Moerman D E, 2000, Adv Mind Body Med, V16, P33; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richards K C, 1998, Am J Crit Care, V7, P288; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; SMITH WP, 1995, J CLIN PSYCHOL, V51, P269; Vickers A, 1999, BRIT MED J, V319, P1176, DOI 10.1136/bmj.319.7218.1176; Vickers A, 1999, Complement Ther Med, V7, P3, DOI 10.1016/S0965-2299(99)80053-3; Vickers A. J., 1998, Complementary Therapies in Medicine, V6, P185, DOI 10.1016/S0965-2299(98)80026-5; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; WHITE AR, 2000, COCHRANE LIB; WILT T, 2000, COCHRANE LIB; Winter M J, 1994, J Post Anesth Nurs, V9, P340; WOOD C, 1993, J ROY SOC MED, V86, P254; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P901, DOI 10.1136/bmj.319.7214.901; 1980, BMJ, V280, P1; 1999, BMJ, V319, pR2	36	69	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					683	686		10.1136/bmj.321.7262.683	http://dx.doi.org/10.1136/bmj.321.7262.683			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987776	Green Published			2023-01-03	WOS:000089444100031
J	Jones, RL; Young, LS; Adams, DH				Jones, RL; Young, LS; Adams, DH			Immunotherapy in hepatocellular carcinoma	LANCET			English	Editorial Material							TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; PEPTIDE		Univ Birmingham, Inst Clin Sci, Liver Res Labs, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Inst Clin Sci, CRC Inst Canc Studies, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham	Adams, DH (corresponding author), Univ Birmingham, Inst Clin Sci, Liver Res Labs, Birmingham B15 2TH, W Midlands, England.		Young, Lawrence S/B-7213-2009; Adams, David H/C-9092-2009	Young, Lawrence S/0000-0003-3919-4298; Adams, David H/0000-0001-6776-0336				BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Brinckerhoff LH, 2000, CURR OPIN ONCOL, V12, P163, DOI 10.1097/00001622-200003000-00012; Butterfield LH, 1999, CANCER RES, V59, P3134; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Fong YM, 1999, ANN SURG, V229, P790, DOI 10.1097/00000658-199906000-00005; LAFRENIERE R, 1986, J IMMUNOL METHODS, V94, P37, DOI 10.1016/0022-1759(86)90213-9; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Yoong KF, 1998, J IMMUNOL, V160, P3978	10	5	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 2	2000	356	9232					784	785		10.1016/S0140-6736(00)02648-9	http://dx.doi.org/10.1016/S0140-6736(00)02648-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350LF	11022921				2023-01-03	WOS:000089101800004
J	Woelk, H				Woelk, H		Remotiv Imipramine Study Grp	Comparison of St John's wort and imipramine for treating depression: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODERATE DEPRESSION; CLINICAL-TRIALS; EXTRACT; MULTICENTER; PLACEBO; LI-160	Objectives To compare the efficacy and tolerability of Hypericum perforatum (St John's wort extract) with imipramine in patients with mild to moderate depression. Design Randomised, multicentre, double blind, parallel group trial. Setting 40 outpatient clinics in Germany. Participants 324 outpatients with mild to moderate depression. Intervention 75 mg imipramine twice daily or 250 mg hypericum extract ZE 117 twice daily for 6 weeks. Main outcome measures Hamilton depression rating scale, clinical global impression scale, and patient's global impression scale. Results Among the 157 participants taking hypericum mean scores on the Hamilton depression scale decreased from 22.4 at baseline to 12.00 at end point; among the 167 participants taking imipramine they fell from 22.1 to 12.75. Mean clinical global impression scores at end point were 2.22 out of 7 for the hypericum group and 2.42 for the imipramine group. On the 7 point self assessments of global improvement completed by participants (score of 1 indicating "very much improved" and 7 indicating "very much deteriorated") mean scores were 2.44 in the hypericum group and 2.60 in the imipramine group. None of the differences between treatment groups were significant However, the mean score on the anxiety-somatisation subscale of the Hamilton scale (3.79 in the hypericum group and 4.26 in the imipramine group) indicated a significant advantage for hypericum relative to imipramine. Mean scores on the 5 point scale used by participants to assess tolerability (score of 1 indicating excellent tolerability and 5 indicating very poor tolerability) were better for hypericum (1.67) than imipramine (2.35). Adverse events occurred in 62/157 (39%) participants taking hypericum and in 105/167 (63%) taking imipramine. 4 (3%) participants taking hypericum withdraw because of adverse events compared with 26 (16%) taking imipramine. Conclusions This Hypericum perforatum extract is therapeutically equivalent to imipramine in treating mild to moderate depression, but patients tolerate hypericum better.	Univ Giessen, Akad Lehrkrankenhaus, Klin Psychiat & Psychotherapie, D-35394 Giessen, Germany	Justus Liebig University Giessen	Woelk, H (corresponding author), Univ Giessen, Akad Lehrkrankenhaus, Klin Psychiat & Psychotherapie, Licher Str 106, D-35394 Giessen, Germany.							ANGST J, 1989, PHARMACOPSYCHIATRY, V22, P3, DOI 10.1055/s-2007-1014568; *COMM PROP MED PRO, 1997, NOT GUID GOOD CLIN P; Commission Nationale de Pharmacopee France [French Pharmacopoeia Commission], 1982, PHARM FRANC; DeSmet PAGM, 1996, BMJ-BRIT MED J, V313, P241, DOI 10.1136/bmj.313.7052.241; Ernst E, 1995, Fortschr Med, V113, P354; *EUR UN, 1996, GOOD CLIN PRACT CLIN, V3, P115; FERNIE WT, 1997, HERBAL SIMPLES; Guy W, 1976, ECDEU ASSESSMENT MAN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HANSGEN KD, 1998, J GERIAT PSYCHIAT S1, V7; HARRER G, 1994, J GERIAT PSYCHIAT S1, V7; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; *KOMM DTSCH ARZN C, 1986, JOH HYP HERB; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; PICKERING C, 1979, CHRONOLOGICAL HIST P; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; PRATT A, 1953, WILD FLOWERS; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Schrader E, 1998, HUM PSYCHOPHARM CLIN, V13, P163, DOI 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.3.CO;2-9; Vorbach E U, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS19, DOI 10.1177/089198879400700107; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Witte B, 1995, Fortschr Med, V113, P404	27	182	189	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					536	539		10.1136/bmj.321.7260.536	http://dx.doi.org/10.1136/bmj.321.7260.536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968813	Bronze, Green Published			2023-01-03	WOS:000089174100017
J	Hallett, M				Hallett, M			Transcranial magnetic stimulation and the human brain	NATURE			English	Article							MOTOR CORTEX EXCITABILITY; VISUAL-CORTEX; PARKINSONS-DISEASE; CORTICAL OUTPUTS; CEREBRAL-CORTEX; READING HAND; REORGANIZATION; DEPRESSION; MODULATION; ORGANIZATION	Transcranial magnetic stimulation (TMS) is rapidly developing as a powerful, non-invasive tool for studying the human brain. A pulsed magnetic field creates current flow in the brain and can temporarily excite or inhibit specific areas. TMS of motor cortex can produce a muscle twitch or block movement; TMS of occipital cortex can produce visual phosphenes or scotomas. TMS can also alter the functioning of the brain beyond the time of stimulation, offering potential for therapy.	NINDS, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Hallett, M (corresponding author), NINDS, Human Motor Control Sect, NIH, Bldg 10,Room 5N226,10 Ctr Dr,MSC 1428, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002669, Z01NS002669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; BARKER AT, 1985, LANCET, V1, P1106; BECKERS G, 1995, BRAIN, V118, P49, DOI 10.1093/brain/118.1.49; BRUNHOLZL C, 1994, ARCH NEUROL-CHICAGO, V51, P245, DOI 10.1001/archneur.1994.00540150039013; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Corthout E, 1999, NEUROPSYCHOLOGIA, V37, P137; DAY BL, 1989, BRAIN, V112, P649, DOI 10.1093/brain/112.3.649; Di Lazzaro V, 1998, ELECTROMYOGR MOTOR C, V109, P397, DOI 10.1016/S0924-980X(98)00038-1; Epstein CM, 1996, NEUROLOGY, V47, P1590, DOI 10.1212/WNL.47.6.1590; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; Gerloff C, 1997, BRAIN, V120, P1587, DOI 10.1093/brain/120.9.1587; Ghabra MB, 1999, NEUROLOGY, V52, P768, DOI 10.1212/WNL.52.4.768; Hallett M, 1998, ARCH NEUROL-CHICAGO, V55, P601, DOI 10.1001/archneur.55.5.601; Hallett M, 1999, EEG CL N SU, P183; HALLETT M, 1993, SPASTICITY MECH MANA, P67; KEW JJM, 1994, J NEUROPHYSIOL, V72, P2517, DOI 10.1152/jn.1994.72.5.2517; Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315; Liepert J, 1995, ELECTROMYOGR MOTOR C, V97, P382, DOI 10.1016/0924-980X(95)00194-P; MANO Y, 1995, ANN NEUROL, V38, P15, DOI 10.1002/ana.410380106; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; PascualLeone A, 1995, ANN NEUROL, V38, P910, DOI 10.1002/ana.410380611; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; PASCUALLEONE A, 1994, NEUROLOGY, V44, P892, DOI 10.1212/WNL.44.5.892; Paus T, 1997, J NEUROSCI, V17, P3178; REUTENS DC, 1993, ANN NEUROL, V34, P351, DOI 10.1002/ana.410340308; RIDDING MC, 1995, J NEUROL NEUROSUR PS, V59, P493, DOI 10.1136/jnnp.59.5.493; Rijntjes M, 1997, ANN NEUROL, V41, P621, DOI 10.1002/ana.410410511; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SANES JN, 1990, EXP BRAIN RES, V79, P479; Siebner HR, 1999, NEUROREPORT, V10, P589, DOI 10.1097/00001756-199902250-00027; Siebner HR, 1999, NEUROLOGY, V52, P529, DOI 10.1212/WNL.52.3.529; Triggs WJ, 1999, BIOL PSYCHIAT, V45, P1440, DOI 10.1016/S0006-3223(99)00031-1; Valzania F, 1999, CLIN NEUROPHYSIOL, V110, P152, DOI 10.1016/S0013-4694(98)00115-1; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Zangaladze A, 1999, NATURE, V401, P587, DOI 10.1038/44139; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	41	1035	1090	4	191	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 13	2000	406	6792					147	150		10.1038/35018000	http://dx.doi.org/10.1038/35018000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	335BA	10910346				2023-01-03	WOS:000088221100036
J	Nortier, JL; Martinez, MM; Schmeiser, HH; Arlt, VM; Bieler, CA; Petein, M; Depierreux, MF; De Pauw, L; Abramowicz, D; Vereerstraeten, P; Vanherweghem, JL				Nortier, JL; Martinez, MM; Schmeiser, HH; Arlt, VM; Bieler, CA; Petein, M; Depierreux, MF; De Pauw, L; Abramowicz, D; Vereerstraeten, P; Vanherweghem, JL			Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERSTITIAL RENAL FIBROSIS; DNA-ADDUCTS; ANALGESIC NEPHROPATHY; SLIMMING REGIMEN; ACID; RATS; IDENTIFICATION; DISEASE; TUMORS	Background: Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of the herbs in these pills (Stephania tetrandra) was inadvertently replaced by Aristolochia fangchi, which is nephrotoxic and carcinogenic. Methods: The diagnosis of a neoplastic lesion in the native urinary tract of a renal-transplant recipient who had Chinese-herb nephropathy prompted us to propose regular cystoscopic examinations and the prophylactic removal of the native kidneys and ureters in all our patients with end-stage Chinese-herb nephropathy who were being treated with either transplantation or dialysis. Surgical specimens were examined histologically and analyzed for the presence of DNA adducts formed by aristolochic acid. All prescriptions written for weight-reducing compounds during the period of exposure (1990 to 1992) in these patients were obtained, and the cumulative doses were calculated. Results: Among 39 patients who agreed to undergo prophylactic surgery, there were 18 cases of urothelial carcinoma (prevalence, 46 percent; 95 percent confidence interval, 29 to 62 percent): 17 cases of carcinoma of the ureter, renal pelvis, or both and 1 papillary bladder tumor. Nineteen of the remaining patients had mild-to-moderate urothelial dysplasia, and two had normal urothelium. All tissue samples analyzed contained aristolochic acid-related DNA adducts. The cumulative dose of aristolochia was a significant risk factor for urothelial carcinoma, with total doses of more than 200 g associated with a higher risk of urothelial carcinoma. Conclusions: The prevalence of urothelial carcinoma among patients with end-stage Chinese-herb nephropathy (caused by aristolochia species) is high. (N Engl J Med 2000;342:1686-92.) (C) 2000, Massachusetts Medical Society.	Free Univ Brussels, Hop Erasme, Dept Nephrol, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Dept Pathol, B-1070 Brussels, Belgium; German Canc Res Ctr, Div Mol Toxicol, D-6900 Heidelberg, Germany	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Helmholtz Association; German Cancer Research Center (DKFZ)	Nortier, JL (corresponding author), Free Univ Brussels, Hop Erasme, Dept Nephrol, 808 Route Lennik, B-1070 Brussels, Belgium.	jnortier@ulb.ac.be	Abramowicz, Daniel/F-7578-2017	Abramowicz, Daniel/0000-0002-6556-9199; Nortier, Joelle/0000-0003-3609-8217; Arlt, Volker Manfred/0000-0003-4314-9318				Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; [Anonymous], 1997, J CLIN PATHOL; Bieler CA, 1997, CARCINOGENESIS, V18, P1063, DOI 10.1093/carcin/18.5.1063; BOSTWICK DG, 1997, UROLOGIC SURG PATHOL, P246; CABANNE F, 1992, PATHOLOGIE GENITALE, P354; Castegnaro M, 1998, INT J CANCER, V77, P70, DOI 10.1002/(SICI)1097-0215(19980703)77:1&lt;70::AID-IJC12&gt;3.0.CO;2-D; COSYNS JP, 1994, LANCET, V344, P188, DOI 10.1016/S0140-6736(94)92786-3; COSYNS JP, 1994, KIDNEY INT, V45, P1680, DOI 10.1038/ki.1994.220; Cosyns JP, 1999, AM J KIDNEY DIS, V33, P1011, DOI 10.1016/S0272-6386(99)70136-8; De Broe ME, 1999, AM J KIDNEY DIS, V33, P1171, DOI 10.1016/S0272-6386(99)70159-9; De Broe ME, 1998, NEW ENGL J MED, V338, P446, DOI 10.1056/NEJM199802123380707; DEPIERREUX M, 1994, AM J KIDNEY DIS, V24, P172, DOI 10.1016/S0272-6386(12)80178-8; EVERSON RB, 1986, SCIENCE, V231, P54, DOI 10.1126/science.3941892; INT AGCY RES CANC, 1993, IARC MONOG EVAL CARC, V56, P489; JACKSON L, 1964, CANCER CHEMOTH REP, P35; Kliem V, 1996, TRANSPLANT INT, V9, P231, DOI 10.1111/j.1432-2277.1996.tb00885.x; Lord GM, 1999, LANCET, V354, P481, DOI 10.1016/S0140-6736(99)03380-2; Malak J, 1998, J ALTERN COMPLEM MED, V4, P131, DOI 10.1089/acm.1998.4.131; McIntyre M, 1998, J ALTERN COMPLEM MED, V4, P15, DOI 10.1089/acm.1998.4.1-15; MENGS U, 1993, ARCH TOXICOL, V67, P307, DOI 10.1007/BF01973700; MENGS U, 1982, ARCH TOXICOL, V51, P107, DOI 10.1007/BF00302751; MURPHY WM, 1982, J UROLOGY, V127, P849, DOI 10.1016/S0022-5347(17)54105-1; Nortier J., 1998, Journal of the American Society of Nephrology, V9, p164A; Pena JM, 1996, NEPHROL DIAL TRANSPL, V11, P1359, DOI 10.1093/ndt/11.7.1359; PEZZUTO JM, 1988, MUTAT RES, V206, P447, DOI 10.1016/0165-1218(88)90052-3; Pfohl-Leszkowicz A, 1993, IARC Sci Publ, P141; POURRAT J, 1994, PRESSE MED, V23, P1669; RICHARDS B, 1991, BRIT J UROL, V67, P369, DOI 10.1111/j.1464-410X.1991.tb15164.x; SCHMEISER HH, 1985, BIOCHEM PHARMACOL, V34, P455, DOI 10.1016/0006-2952(85)90085-1; SCHMEISER HH, 1986, CARCINOGENESIS, V7, P59, DOI 10.1093/carcin/7.1.59; SCHMEISER HH, 1990, CANCER RES, V50, P5464; Schmeiser HH, 1996, CANCER RES, V56, P2025; STEFANOVIC V, 1991, AM J NEPHROL, V11, P1, DOI 10.1159/000168264; TANAKA A, 1997, JPN J NEPHROL, V39, P794; TANAKA A, 1997, JPN J NEPHROL, V39, P438; VANHAELEN M, 1994, LANCET, V343, P174, DOI 10.1016/S0140-6736(94)90964-4; VANHERWEGHEM JL, 1995, NEPHROL DIAL TRANSPL, V10, P270; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Yang CS, 2000, AM J KIDNEY DIS, V35, P313, DOI 10.1016/S0272-6386(00)70343-X	39	744	805	4	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	2000	342	23					1686	1692		10.1056/NEJM200006083422301	http://dx.doi.org/10.1056/NEJM200006083422301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321HD	10841870				2023-01-03	WOS:000087449300001
J	Verdier, RI; Fitzgerald, DW; Johnson, WD; Pape, JW				Verdier, RI; Fitzgerald, DW; Johnson, WD; Pape, JW			Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL MANIFESTATIONS; HAITI	Background: In developing countries, Isospora belli and Cyclospora cayetanensis frequently cause chronic diarrhea in HIV-infected patients. Objective: To compare 1 week of trimethoprim-sulfamethoxazole treatment and 1 week of ciprofloxacin treatment in HIV-infected patients with chronic diarrhea caused by I. belli and C. cayetanensis. Design: Randomized, controlled trial. Setting: HIV clinic in Port-au-Prince, Haiti. Patients: 42 HIV-infected patients with chronic diarrhea due to I. belli (n = 22) or C. cayetanensis (n = 20). Interventions: Patients were randomly assigned to receive oral trimethoprim-sulfamethoxazole (160 mg or 800 mg) or ciprofloxacin (500 mg) twice daily for 7 days. Patients who responded clinically and microbiologically received prophylaxis for 10 weeks (1 tablet orally, three times per week). Measurements: Treatment success was measured by cessation of diarrhea and negative stool examination at day 7. Prophylaxis success was measured by recurrent disease rate. Results: Diarrhea ceased in all 19 patients treated with trimethoprim-sulfamethoxazole. Eighteen of 19 patients had negative results on stool examination at day 7 (95%). Among the 23 patients who received ciprofloxacin, diarrhea ceased in 20 (87% [Cl, 66% to 97%]) and 16 had negative results on stool examination at day 7 (70%). By survival analysis, diarrhea from isosporiasis and cyclosporiasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin. All patients receiving secondary prophylaxis with trimethoprim-sulfamethoxatole remained disease-free, and 15 of 16 patients receiving secondary prophylaxis with ciprofloxacin remained disease-free. Conclusions: A 1-week course of trimethoprim-sulfamethoxazole is effective in HIV-infected patients with cyclosporiasis or isosporiasis. Although ciprofloxacin is not as effective, it is acceptable for patients who cannot tolerate trimethoprim-suifamethoxazole.	Cornell Univ, Div Int Med & Infect Dis, Coll Med, New York, NY 10021 USA; Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti	Cornell University	Johnson, WD (corresponding author), Cornell Univ, Div Int Med & Infect Dis, Coll Med, Room A-421,1300 York Ave, New York, NY 10021 USA.				FIC NIH HHS [TW 00018] Funding Source: Medline; NIAID NIH HHS [T32 AI07613, R37 AI22624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022624, T32AI007613] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYARD PJ, 1992, J ACQ IMMUN DEF SYND, V5, P1237; DEHOVITZ JA, 1985, ANN INTERN MED, V103, P479, DOI 10.7326/0003-4819-103-3-479_2; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DIVO AA, 1988, ANTIMICROB AGENTS CH, V32, P1182, DOI 10.1128/AAC.32.8.1182; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; MALEBRANCHE R, 1983, LANCET, V2, P873; PAPE J, 1993, CLIN INFECT DIS, V17, pS341, DOI 10.1093/clinids/17.Supplement_2.S341; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603; PAPE JW, 1988, AIDS, V2, pS161, DOI 10.1097/00002030-198800001-00024; SALMON D, 1990, ANTIMICROB AGENTS CH, V34, P2327, DOI 10.1128/AAC.34.12.2327	14	101	108	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 6	2000	132	11					885	888		10.7326/0003-4819-132-11-200006060-00006	http://dx.doi.org/10.7326/0003-4819-132-11-200006060-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319HF	10836915				2023-01-03	WOS:000087334900005
J	Hallstrom, A; Cobb, L; Johnson, E; Copass, M				Hallstrom, A; Cobb, L; Johnson, E; Copass, M			Cardiopulmonary resuscitation by chest compression alone or with mouth-to-mouth ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY CPR INSTRUCTION; VENTRICULAR-FIBRILLATION; CARDIAC-ARREST; TELEPHONE	Background: Despite extensive training of citizens of Seattle in cardiopulmonary resuscitation (CPR), bystanders do not perform CPR in almost half of witnessed cardiac arrests. Instructions in chest compression plus mouth-to-mouth ventilation given by dispatchers over the telephone can require 2.4 minutes. In experimental studies, chest compression alone is associated with survival rates similar to those with chest compression plus mouth-to-mouth ventilation. We conducted a randomized study to compare CPR by chest compression alone with CPR by chest compression plus mouth-to-mouth ventilation. Methods: The setting of the trial was an urban, fire-department-based, emergency-medical-care system with central dispatching. In a randomized manner, telephone dispatchers gave bystanders at the scene of apparent cardiac arrest instructions in either chest compression alone or chest compression plus mouth-to-mouth ventilation. The primary end point was survival to hospital discharge. Results: Data were analyzed for 241 patients randomly assigned to receive chest compression alone and 279 assigned to chest compression plus mouth-to-mouth ventilation. Complete instructions were delivered in 62 percent of episodes for the group receiving chest compression plus mouth-to-mouth ventilation and 81 percent of episodes for the group receiving chest compression alone (P=0.005). Instructions for compression required 1.4 minutes less to complete than instructions for compression plus mouth-to-mouth ventilation. Survival to hospital discharge was better among patients assigned to chest compression alone than among those assigned to chest compression plus mouth-to-mouth ventilation (14.6 percent vs. 10.4 percent), but the difference was not statistically significant (P=0.18). Conclusions: The outcome after CPR with chest compression alone is similar to that after chest compression with mouth-to-mouth ventilation, and chest compression alone may be the preferred approach for bystanders inexperienced in CPR. (N Engl J Med 2000;342:1546-53.) (C) 2000, Massachusetts Medical Society.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Medic I, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hallstrom, A (corresponding author), 1107 NE 45th St,Suite 505, Seattle, WA 98105 USA.		Ferreira, Daniel/E-9005-2010	Ferreira, Daniel/0000-0002-4683-0179	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008197] Funding Source: NIH RePORTER; AHRQ HHS [5 R01 HS08197-04] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Becker LB, 1997, CIRCULATION, V96, P2102, DOI 10.1161/01.CIR.96.6.2102; Berg RA, 1997, CIRCULATION, V96, P4364; CARTER WB, 1984, ANN EMERG MED, V13, P695, DOI 10.1016/S0196-0644(84)80730-1; COWIE MR, 1993, AM J PUBLIC HEALTH, V83, P955, DOI 10.2105/AJPH.83.7.955; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EISENBERG MS, 1985, AM J PUBLIC HEALTH, V75, P47, DOI 10.2105/AJPH.75.1.47; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; MEURSING BTJ, 1983, J AM COLL CARDIOL, V1, P610; THIES W, 1989, JAMA-J AM MED ASSOC, V262, P2714; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737	12	386	412	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1546	1553		10.1056/NEJM200005253422101	http://dx.doi.org/10.1056/NEJM200005253422101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824072	Bronze			2023-01-03	WOS:000087193100001
J	Wade, DT; de Jong, BA				Wade, DT; de Jong, BA			Recent advances - Recent advances in rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; PROGRESSIVE MULTIPLE-SCLEROSIS; QUALITY-OF-LIFE; PHYSICAL THERAPY; BOTULINUM TOXIN; STROKE PATIENTS; DOUBLE-BLIND; IMPACT; INTERVENTIONS; RELIABILITY		Rivermead Rehabil Ctr, Oxford OX1 4XD, England; Univ Amsterdam, Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Wade, DT (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.	derick.wade@dial.pipex.com		Wade, Derick/0000-0002-1188-8442				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Badley E M, 1993, Disabil Rehabil, V15, P161; BADLEY EM, 1997, REHABILITATION PHYSI; Bowling A., 1995, MEASURING DIS; BROWN RJ, 1993, BEHAV SOCIAL REHABIL; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; Cardol M, 1999, DISABIL REHABIL, V21, P97, DOI 10.1080/096382899297819; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Di Fabio RP, 1998, ARCH PHYS MED REHAB, V79, P141, DOI 10.1016/S0003-9993(98)90290-8; EKDAWI MY, 1994, PSYCHIATR REHABIL J, P16; Forlander DA, 1999, CLIN REHABIL, V13, P97, DOI 10.1191/026921599675502264; Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Indredavik B, 1998, STROKE, V29, P895, DOI 10.1161/01.STR.29.5.895; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Lew MF, 1997, NEUROLOGY, V49, P701, DOI 10.1212/WNL.49.3.701; Lin KC, 1997, OCCUP THER J RES, V17, P25, DOI 10.1177/153944929701700102; Lindroth Y, 1997, ARTHRIT CARE RES, V10, P325, DOI 10.1002/art.1790100507; Mann WC, 1999, ARCH FAM MED, V8, P210, DOI 10.1001/archfami.8.3.210; Mant J, 1998, CLIN REHABIL, V12, P465, DOI 10.1191/026921598668972226; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OLIVE RM, 1983, SOCIAL WORK DISABLED; Post MWM, 1999, CLIN REHABIL, V13, P5, DOI 10.1191/026921599701532072; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; Rudd AG, 1999, J ROY COLL PHYS LOND, V33, P460; VANTULDER MW, 1999, COCHRANE LIB; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wade DT, 1996, J NEUROL NEUROSUR PS, V61, P242, DOI 10.1136/jnnp.61.3.242; Wade DT, 1998, CLIN REHABIL, V12, P183, DOI 10.1191/026921598677470232; Wade DT, 1999, CLIN REHABIL, V13, P164, DOI 10.1191/026921599673848768; Wade DT, 1998, CLIN REHABIL, V12, P363, DOI 10.1191/026921598666679396; WADE DT, 2000, NATL CLIN GUIDELINES; Wade DT., 1992, MEASUREMENT NEUROLOG; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Wood P., 1980, INT CLASSIFICATION I	39	189	190	3	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2000	320	7246					1385	1388		10.1136/bmj.320.7246.1385	http://dx.doi.org/10.1136/bmj.320.7246.1385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	317NY	10818031	Green Published			2023-01-03	WOS:000087232500025
J	Finestone, HM				Finestone, HM			Safe feeding methods in stroke patients	LANCET			English	Editorial Material							MALNUTRITION		London Hlth Sci Ctr, Dept Phys Med & Rehabil, London, ON N6A 5A5, Canada	London Health Sciences Centre	Finestone, HM (corresponding author), London Hlth Sci Ctr, Dept Phys Med & Rehabil, Univ Campus, London, ON N6A 5A5, Canada.							APTAKER RL, 1994, ARCH PHYS MED REHAB, V75, P80; AXELSSON K, 1989, J AM DIET ASSOC, V89, P1092; Buelow J M, 1990, Rehabil Nurs, V15, P260; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; FINEGOLD SM, 1991, REV INFECT DIS, V13, pS737; FINESTONE HM, 1995, ARCH PHYS MED REHAB, V76, P310, DOI 10.1016/S0003-9993(95)80655-5; FINESTONE HM, 1996, ARCH PHYS MED REHAB, V77, P430; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; HICKS ME, 1990, AM J ROENTGENOL, V154, P725, DOI 10.2214/ajr.154.4.2107665; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; Nakajoh K, 2000, J INTERN MED, V247, P39, DOI 10.1046/j.1365-2796.2000.00565.x; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; WEINBERG AD, 1995, JAMA-J AM MED ASSOC, V274, P1552, DOI 10.1001/jama.274.19.1552	13	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 13	2000	355	9216					1662	1663		10.1016/S0140-6736(00)02234-0	http://dx.doi.org/10.1016/S0140-6736(00)02234-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CY	10905238				2023-01-03	WOS:000086983800005
J	Spillman, BC; Lubitz, J				Spillman, BC; Lubitz, J			The effect of longevity on spending for acute and long-term care.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NURSING-HOME CARE; EXPENDITURES; PERSPECTIVE; TRENDS; AGE	Background: The proportion of the population made up of elderly persons in the United States is projected to increase from 13 percent of the population in 2000 to 20 percent by 2030. The implications for health care expenditures may be profound, because elderly persons use health care services at a greater rate than younger persons. We estimated total expenditures for acute and long-term care from the age of 65 years until death and in the last two years of life. Methods: We combined data from Medicare, the National Mortality Followback Survey, and the National Medical Expenditure Survey to estimate total national expenditures for health care according to the age at death. We also simulated expenditures with the use of projected demographic characteristics of two cohorts: people turning 65 in 2000 and those turning 65 in 2015. Results: Total expenditures (in 1996 dollars) from the age of 65 years until death increase substantially with longevity, from $31,181 for persons who die at the age of 65 years to more than $200,000 for those who die at the age of 90, in part because of steep increases in nursing home expenditures for very old persons. Spending in the last two years of life also increases with longevity, but a reduction in Medicare expenditures ($37,000 for persons who die at the age of 75 years and $21,000 for those who die at the age of 95) moderates the effect of the increase in nursing home expenditures ($6,000 for those who die at the age of 75 years and $32,000 for those who die at the age of 95). Health care spending for women is consistently higher than that for men, after adjustment for the increased longevity of women. Simulations show that increased longevity after the age of 65 years has a relatively small effect on the anticipated increase in spending, especially for services covered by Medicare, from 2000 to 2015. The effects of the larger number of people born in 1950 than in 1935 and the larger number of people surviving to the age of 65 years are much more important. Conclusions: In the United States, the effect of longevity on expenditures for acute care differs from its effect on expenditures for long-term care. Acute care expenditures, principally for hospital care and physicians' services, increase at a reduced rate as the age at death increases, whereas expenditures for long-term care increase at an accelerated rate. Increases in longevity after the age of 65 years may result in greater spending for long-term care, but the increase in the number of elderly persons has a more important effect on total spending. (N Engl J Med 2000;342:1409-15.) (C)2000, Massachusetts Medical Society.	Urban Inst, Ctr Hlth Policy, Washington, DC 20037 USA; Natl Ctr Hlth Stat, Off Anal Epidemiol & Hlth Promot, Hyattsville, MD USA; US Hlth Care Financing Adm, Off Strateg Planning, Baltimore, MD 21207 USA	Urban Institute; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Spillman, BC (corresponding author), Urban Inst, Ctr Hlth Policy, 2100 M St NW, Washington, DC 20037 USA.							Braden BR, 1998, HEALTH CARE FINANC R, V20, P83; *C BUDG OFF, 1997, LONG TERM BUDG PRESS; CARLSON BL, 1995, J ECON SOC MEAS, V21, P187; *CTR COST FIN STUD, 1998, DATA NAT MED EXP SUR; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; GORNICK M, 1993, HEALTH AFFAIR, V12, P140, DOI 10.1377/hlthaff.12.2.140; Gruenberg L, 1996, HEALTH CARE FINANC R, V17, P59; Guralnik J M, 1997, J Am Med Womens Assoc (1972), V52, P113; HELDING C, 1992, HLTH CARE FINANCE S, P23; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KEMPER P, 1991, INQUIRY-J HEALTH CAR, V28, P333; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; *OFF ACT, 1999, US LIF TABL FUNCT AC; *OFF ACT, 1999, SOC SEC AR POP 1999; Riley G F, 1989, Health Care Financ Rev, V11, P1; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; *SOC SEC ADM, 2000, 2000 ANN REP BOARD T; TEMKINGREENER H, 1992, MILBANK Q, V70, P679, DOI 10.2307/3350216; VERBRUGGE LM, 1990, WOMEN HLTH MED AM HI, P41; WAIDMANN TA, 1998, INTER EVIDENCE TREND; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WEISSERT WG, 1994, J AM GERIATR SOC, V42, P348, DOI 10.1111/j.1532-5415.1994.tb01763.x	25	254	258	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1409	1415		10.1056/NEJM200005113421906	http://dx.doi.org/10.1056/NEJM200005113421906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312JR	10805827				2023-01-03	WOS:000086940600006
J	Fagon, JY; Chastre, J; Wolff, M; Gervais, C; Parer-Aubas, S; Stephan, F; Similowski, T; Mercat, A; Diehl, JL; Sollet, JP; Tenaillon, A				Fagon, JY; Chastre, J; Wolff, M; Gervais, C; Parer-Aubas, S; Stephan, F; Similowski, T; Mercat, A; Diehl, JL; Sollet, JP; Tenaillon, A		VAP Trial Grp	Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article						ventilators, mechanical; pneumonia; cross infection; bronchoalveolar lavage; diagnosis	RESPIRATORY-DISTRESS SYNDROME; INTENSIVE-CARE UNIT; NOSOCOMIAL PNEUMONIA; BRONCHOSCOPIC TECHNIQUES; CLINICAL JUDGMENT; ORGAN FAILURE; DIAGNOSIS; IMPACT; SEPSIS; INFECTION	Background: Optimal management of patients who are clinically suspected of having ventilator-associated pneumonia remains open to debate. Objective: To evaluate the effect on clinical outcome and antibiotic use of two strategies to diagnose ventilator-associated pneumonia and select initial treatment for this condition. Design: Multicenter, randomized, uncontrolled trial. Setting: 31 intensive care units in France. Patients: 413 patients suspected of having ventilator-associated pneumonia. Intervention: The invasive management strategy was based on direct examination of bronchoscopic protected specimen brush samples or bronchoalveolar lavage samples and their quantitative cultures. The noninvasive ("clinical") management strategy was based on clinical criteria, isolation of microorganisms by nonquantitative analysis of endotracheal aspirates, and clinical practice guidelines. Measurements: Death from any cause, quantification of organ failure, and antibiotic use at 14 and 28 days. Results: Compared with patients who received clinical management, patients who received invasive management had reduced mortality at day 14(16.2% and 25.8%; difference, -9.6 percentage points [95% CI, -17.4 to -1.8 percentage points]; P = 0.022), decreased mean Sepsis-related Organ Failure Assessment scores at day 3 (6.1 +/- 4.0 and 7.0 +/- 4.3; P = 0.033) and day 7 (4.9 +/- 4.0 and 5.8 +/- 4.4; P = 0.043), and decreased antibiotic use (mean number of antibiotic-free days, 5.0 +/- 5.1 and 2.2 +/- 3.5; P < 0.001). At 28 days, the invasive management group had significantly more antibiotic-free days (11.5 +/- 9.0 compared with 7.5 +/- 7.6; P < 0.001), and only multivariate analysis showed a significant difference in mortality (hazard ratio, 1.54 [CI, 1.10 to 2.16]; P = 0.01). Conclusions: Compared with a noninvasive management strategy, an invasive management strategy was significantly associated with fewer deaths at 14 days, earlier attenuation of organ dysfunction, and less antibiotic use in patients suspected of having ventilator-associated pneumonia.	Hop Broussais, Serv Reanimat Med, F-75674 Paris 14, France; Hop Bichat Claude Bernard, F-75877 Paris 18, France; Hop Tenon, F-75970 Paris, France; Hop La Pitie Salpetriere, Paris, France; Hop Boucicault, Paris, France; Ctr Hosp Univ Nimes, Nimes, France; CHU Montpellier, Montpellier, France; Hop Bicetre, Le Kremlin Bicetre, France; Ctr Hosp Victor Dupouy, Argenteuil, France; Ctr Hosp Louise Michel, Evry, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Fagon, JY (corresponding author), Hop Broussais, Serv Reanimat Med, 96 Rue Didot, F-75674 Paris 14, France.		Mercat, Alain/AFU-4426-2022					AlvarezLerma F, 1996, INTENS CARE MED, V22, P387, DOI 10.1007/BF01712153; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bonten MJM, 1997, AM J RESP CRIT CARE, V156, P1820, DOI 10.1164/ajrccm.156.6.9610117; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; Chastre J, 1995, CLIN INFECT DIS, V21, pS226, DOI 10.1093/clind/21.Supplement_3.S226; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; CHASTRE J, 1988, AM J MED, V85, P499; Chastre J, 1998, AM J RESP CRIT CARE, V157, P1165, DOI 10.1164/ajrccm.157.4.9708057; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CROCE MA, 1994, J TRAUMA, V37, P721, DOI 10.1097/00005373-199411000-00005; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Helling TS, 1996, AM J SURG, V171, P570, DOI 10.1016/S0002-9610(96)00040-2; Heyland DK, 1999, CHEST, V115, P1076, DOI 10.1378/chest.115.4.1076; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; Pittet D, 1998, LANCET, V352, P83, DOI 10.1016/S0140-6736(98)85005-8; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Sterling TR, 1996, CHEST, V110, P1025, DOI 10.1378/chest.110.4.1025; Tenover FC, 1996, JAMA-J AM MED ASSOC, V275, P300, DOI 10.1001/jama.275.4.300; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9; 1996, AM J RESP CIRT CARE, V153, P1711	37	545	571	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					621	+		10.7326/0003-4819-132-8-200004180-00004	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766680				2023-01-03	WOS:000086497500003
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Emanuel, LL			Understanding economic and other burdens of terminal illness: The experience of patients and their caregivers	ANNALS OF INTERNAL MEDICINE			English	Article						terminally ill; terminal care; cost of illness; caregivers; physician role	PHYSICIAN-ASSISTED SUICIDE; MENTAL-HEALTH; UNITED-STATES; CARE; EUTHANASIA; CANCER; ATTITUDES; FAMILIES; ADULTS; NEEDS	Background: Terminal illness imposes substantial burdens-economic and otherwise-on patients and caregivers. The cause of these burdens is not understood. Objective: To determine the mechanism for economic and noneconomic burdens of terminal illness and to identify potential ameliorating interventions. Design: In-person interviews of terminally ill patients and their caregivers. Setting: Six randomly selected U.S. sites: Worcester, Massachusetts; St. Louis, Missouri; Tucson, Arizona; Birmingham, Alabama; Brooklyn, New York; and Mesa County, Colorado. Participants: 988 terminally ill patients and 893 caregivers. Measurements: Needs for transportation, nursing care, homemaking, and personal care; subjective perception of economic burden; expenditure of more than 10% of household income on health care costs; caregiver depression and sense of interference with his or her life; and patient consideration of euthanasia or physician-assisted suicide. Results: Of all patients, 34.7% had substantial care needs. Patients who had substantial care needs were more likely to report that they had a subjective sense of economic burden (44.9% compared with 35.3%; difference, 9.6 percentage points [95% CI, 3.1 to 16.1]; P = 0.005); that 10% of their household income was spent on health care (28.0% compared with 17.0%; difference, 11.0 percentage points [CI, 4.8 to 17.1]; P less than or equal to 0.001); and that they or their families had to take out a loan or mortgage, spend their savings, or obtain an additional job (16.3% compared with 10.2%; difference, 6.1 percentage points [CI, 1.4 to 10.6]; P = 0.004). Patients with substantial care needs were more likely to consider euthanasia or physician-assisted suicide (P = 0.001). Caregivers of these patients were more likely to have depressive symptoms (31.4% compared with 24.8%; difference, 6.6 percentage points [CI, 0.4 to 12.8]; P = 0.01) and to report that caring for the patients interfered with their lives (35.6% compared with 24.3%; difference, 11.3 percentage points [CI, 5.0 to 17.7]; P = 0.001). Caregivers of patients whose physicians listened to patients' and caregivers' needs had fewer burdens. Conclusions: Substantial care needs are an important cause of the economic and other burdens imposed by terminal illness. Through empathy, physicians may be able to ameliorate some of these burdens.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; AMC Canc Res Ctr, Denver, CO USA; Johns Hopkins Univ, Baltimore, MD USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; AMC Cancer Research Center; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							BERKMAN BJ, 1993, CANCER-AM CANCER SOC, V72, P2846, DOI 10.1002/1097-0142(19931101)72:9+<2846::AID-CNCR2820721515>3.0.CO;2-3; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; *BUR CENS, 1998, STAT ABSTR US 1998; CANTOR MH, 1983, GERONTOLOGIST, V23, P597, DOI 10.1093/geront/23.6.597; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EPSTEIN AM, 1995, INQUIRY-J HEALTH CAR, V32, P211; Field MJ, 1997, APPROACHING DEATH IM; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; *GROUP HLTH ASS AM, 1992, NAT DIR HMOS; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Zubrod C.G., 1960, J CHRON DIS, V11, P7	30	294	299	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					451	+		10.7326/0003-4819-132-6-200003210-00005	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733444				2023-01-03	WOS:000085834700004
J	Horne, MK; Chang, R				Horne, MK; Chang, R			Thrombolytic therapy for deep venous thrombosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL ANTICOAGULANT-THERAPY; VEIN THROMBOSIS; STREPTOKINASE; HEPARIN; THROMBOEMBOLISM; EPISODE; LYSIS	We present the case of a man bedridden by deep venous thrombosis who was given intraclot instillations of recombinant tissue plasminogen activator with remarkable improvement. Although such aggressive treatment may be justified in severe cases, the role for thrombolytic agents for less symptomatic deep venous thrombosis is undefined. We discuss the question of when thrombolytic therapy should be considered. However, proper clinical trials are needed before firm recommendations can be made.	NIH, Hematol Serv, Dept Clin Pathol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NIH, Special Procedures Unit, Dept Radiol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Horne, MK (corresponding author), NIH, Hematol Serv, Dept Clin Pathol, Warren G Magnuson Clin Ctr, Bldg 10,Room 2C306,9000 Rockville Pike, Bethesda, MD 20892 USA.	mhorne@nih.gov						Akesson H, 1990, Eur J Vasc Surg, V4, P43, DOI 10.1016/S0950-821X(05)80037-4; AMESEN H, 1982, ACTA MED SCAND, V211, P65; BROWN W D, 1989, Chest, V95, p276S, DOI 10.1378/chest.95.5.276S; Centeno RF, 1999, AM SURGEON, V65, P229; COLLEN D, 1986, HAEMOSTASIS, V16, P25; COMEROTA AJ, 1995, THROMBOLYTIC THERAPY, P175; ELLIOT MS, 1979, BRIT J SURG, V66, P838, DOI 10.1002/bjs.1800661203; Holmstrom M, 1997, THROMB HAEMOSTASIS, V78, P803; KILLEWICH LA, 1985, ARCH SURG-CHICAGO, V120, P424; KILLEWICH LA, 1989, J VASC SURG, V9, P89, DOI 10.1067/mva.1989.vs0090089; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MARKEL A, 1992, ARCH INTERN MED, V152, P1265, DOI 10.1001/archinte.152.6.1265; *MED EC BOOKS, 1998, 1998 DRUG TOP RED BO; MEISSNER MH, 1993, J VASC SURG, V18, P596, DOI 10.1016/0741-5214(93)90069-X; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; OMEARA JJ, 1994, NEW ENGL J MED, V330, P1864, DOI 10.1056/NEJM199406303302605; Patel NH, 1998, ANN VASC SURG, V12, P471, DOI 10.1007/s100169900187; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; Schafer AI, 1999, NEW ENGL J MED, V340, P955, DOI 10.1056/NEJM199903253401209; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SHERRY S, 1980, ANN INTERN MED, V93, P141, DOI 10.7326/0003-4819-93-1-141; SUDLOW MF, 1992, LANCET, V340, P873; Tarry W C, 1994, Ann Vasc Surg, V8, P583, DOI 10.1007/BF02017416; WATZ R, 1979, ACTA MED SCAND, V205, P293	26	5	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2164	2166		10.1001/jama.282.22.2164	http://dx.doi.org/10.1001/jama.282.22.2164			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591339				2023-01-03	WOS:000083971400036
J	Pillai, S; Catellani, C				Pillai, S; Catellani, C			A woman experiencing difficulty with breastfeeding	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Miro Ctr Integrat Med, Evanston, IL USA		Pillai, S (corresponding author), Miro Ctr Integrat Med, Evanston, IL USA.							Lawrence RA, 2001, JAMA-J AM MED ASSOC, V285, P73, DOI 10.1001/jama.285.1.73; LOCKIE A, 1989, FAMILY GUIDE HOMEOPA, P430; LOCKIE A, 1995, COMPLETE GUIDE HOMEO, P140	3	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2001	285	12					1576	1576						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	413HH	11268259				2023-01-03	WOS:000167606600018
J	Shen, JN; Wenger, N; Glaspy, J; Hays, RD; Albert, PS; Choi, C; Shekelle, PG				Shen, JN; Wenger, N; Glaspy, J; Hays, RD; Albert, PS; Choi, C; Shekelle, PG			Electroacupuncture for control of myeloablative chemotherapy-induced emesis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER-CHEMOTHERAPY; ACUPUNCTURE; CYCLOPHOSPHAMIDE; ONDANSETRON; ENKEPHALIN; CISPLATIN; NAUSEA	Context High-dose chemotherapy poses considerable challenges to emesis management. Although prior studies suggest that acupuncture may reduce nausea and emesis, it is unclear whether such benefit comes from the nonspecific effects of attention and clinician-patient interaction. Objective To compare the effectiveness of electroacupuncture vs minimal needling and mock electrical stimulation or antiemetic medications alone in controlling emesis among patients undergoing a highly emetogenic chemotherapy regimen. Design Three-arm, parallel-group, randomized controlled trial conducted from March 1996 to December 1997, with a 5-day study period and a 9-day follow-up. Setting Oncology center at a university medical center. Patients One hundred four women (mean age, 46 years) with high-risk breast cancer. Interventions Patients were randomly assigned to receive low-frequency electroacupuncture at classic antiemetic acupuncture points once daily for 5 days (n=37), minimal needling at control points with mock electrostimulation on the same schedule (n=33); or no adjunct needling (n=34). All patients received concurrent triple antiemetic pharmacotherapy and high-dose chemotherapy (cyclophosphamide, cisplatin, and carmustine). Main Outcome Measures Total number of emesis episodes occurring during the 5-day study period and the proportion of emesis-free days, compared among the 3 groups. Results The number of emesis episodes occurring during the 5 days was lower for patients receiving electroacupuncture compared with those receiving minimal needling or pharmacotherapy alone (median number of episodes, 5, 10, and 15, respectively; P<.001). The electroacupuncture group had fewer episodes of emesis than the minimal needling group (P<.001), whereas the minimal needling group had fewer episodes of emesis than the antiemetic pharmacotherapy alone group (P=.01), The differences among groups were not significant during the 9-day follow-up period (P=.18), Conclusions in this study of patients with breast cancer receiving high-dose chemotherapy, adjunct electroacupuncture was more effective in controlling emesis than minimal needling or antiemetic pharmacotherapy alone, although the observed effect had limited duration.	NIAAA, Clin Studies Lab, Brain Electrophysiol & Imaging Sect, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90024 USA; RAND Corp, Santa Monica, CA USA; NCI, Biometr Res Branch, NIH, Bethesda, MD 20892 USA; W Los Angeles Vet Affairs Med Ctr, Dept Med, Vet Affairs Hlth Serv REs & Dev Serv, Los Angeles, CA 90073 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shen, JN (corresponding author), NIAAA, Clin Studies Lab, Brain Electrophysiol & Imaging Sect, NIH, Room 6 S-240,Mail Stop 1610,10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X	BHP HRSA HHS [PE19001-09] Funding Source: Medline	BHP HRSA HHS		AGLIETTI L, 1990, CANCER CHEMOTH PHARM, V26, P239, DOI 10.1007/BF02897209; BUCINSKAITE V, 1994, BRAIN RES, V666, P128, DOI 10.1016/0006-8993(94)90294-1; Cagnoni PJ, 1999, BONE MARROW TRANSPL, V24, P1, DOI 10.1038/sj.bmt.1701832; CHENG RSS, 1989, SCI BASES ACUPUNCTUR, P119; DUNDEE JW, 1987, LANCET, V1, P1083; DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508; EPSTEIN BS, 1993, HDB NAUSEA VOMITING, P93; Frigerio C, 1996, LANCET, V347, P1484, DOI 10.1016/S0140-6736(96)91720-1; Gilbert CJ, 1998, CANCER CHEMOTH PHARM, V42, P497, DOI 10.1007/s002800050851; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; GRALLA RJ, 1991, EUR J CANCER, V27, pS5; GRUNBERG SM, 1993, NEW ENGL J MED, V329, P1790; HAN JS, 1984, NEUROPHARMACOLOGY, V23, P1; HARRIS AL, 1982, LANCET, V1, P714; JENKINS M, 1980, ACUPUNCT MED, V7, P21; KOBRINSKY NL, 1988, AM J PEDIAT HEMATOL, V10, P209; LAO L, 1997, P DEP DEF BREAST CAN, V3, P861; Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031; LESLIE RA, 1992, COLLOQ INSE, V223, P19; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McCullagh P., 1989, GEN LINEAR MODELS; MORROW G, 1992, BR J CANC S19, V66, pS60; MORROW GR, 1992, BRIT J CANCER, V66, pS54; Navari RM, 1999, NEW ENGL J MED, V340, P190, DOI 10.1056/NEJM199901213400304; OCONNOR J, 1981, ACUPUNCTURE COMPREHE, P557; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Rudd JA, 1999, EUR J PHARMACOL, V374, P77, DOI 10.1016/S0014-2999(99)00285-X; Tonato M, 1996, SUPPORT CARE CANCER, V4, P281, DOI 10.1007/BF01358880; VACCAGALLOWAY LL, 1985, PEPTIDES, V6, P177, DOI 10.1016/0196-9781(85)90029-4; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602	31	206	222	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	2000	284	21					2755	2761		10.1001/jama.284.21.2755	http://dx.doi.org/10.1001/jama.284.21.2755			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377JB	11105182	Bronze			2023-01-03	WOS:000165509500030
J	Kubba, A; Guillebaud, J; Anderson, RA; MacGregor, EA				Kubba, A; Guillebaud, J; Anderson, RA; MacGregor, EA			Contraception	LANCET			English	Review							ORAL-CONTRACEPTIVES; MYOCARDIAL-INFARCTION; ETHINYL ESTRADIOL; BONE-DENSITY; MEDROXYPROGESTERONE ACETATE; INTRAUTERINE SYSTEM; MU-G; LEVONORGESTREL; WOMEN; RISK	The supremacy of combined oral contraceptives (OCs) is being challenged. For too long combined OCs have been seen as synonymous with contraception, helping to maintain ignorance of alternative methods. Further, the efficacy of these OCs and condoms is often compromised by incorrect or inconsistent use. We particularly welcome developments in male systemic methods, that allow men to share not only in conception but also in contraception, and methods that are completely forgettable once instituted, especially if usable by adolescents.	UCL, Margaret Pyke Ctr, Dept Obstet & Gynaecol, London W1P 1LB, England; Guys St Thomas Hosp, Dept Obstet & Gynaecol, GKT Sch Med, London, England; Univ Edinburgh, Ctr Reprod Biol, MRC, Reprod Biol Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Margaret Pyke Mem Trust, London, England	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Edinburgh	Guillebaud, J (corresponding author), UCL, Margaret Pyke Ctr, Dept Obstet & Gynaecol, London W1P 1LB, England.	j.guillebaud@lineone.net		MacGregor, E Anne/0000-0002-4116-9828				Adachi JD, 1997, BRIT J OBSTET GYNAEC, V104, P64, DOI 10.1111/j.1471-0528.1997.tb10651.x; Anderson RA, 1999, J CLIN ENDOCR METAB, V84, P3556, DOI 10.1210/jc.84.10.3556; ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0; Aribarg A, 1996, FERTIL STERIL, V65, P821; Backman T, 2000, BRIT J OBSTET GYNAEC, V107, P335, DOI 10.1111/j.1471-0528.2000.tb13228.x; BAGSHAW SN, 1988, AUST NZ J OBSTET GYN, V28, P137, DOI 10.1111/j.1479-828X.1988.tb01643.x; BAIRD DT, 1993, CLIN APPL MIFEPRISTO, P148; Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; BOUNDS W, 1993, EUR J OBSTET GYN R B, V48, P123, DOI 10.1016/0028-2243(93)90252-8; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; *COLL STUD CARD DI, 1998, CONTRACEPTION, V57, P315; CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; DIAZ S, 1999, INT PLANNED PARENTHO, V33, P3; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; EDWARDS J, 1999, BR J FARM PLANN, V24, pS1; GARDNER R, 1999, POPULATION REPORTS H, P1; Gbolade B, 1998, BRIT J OBSTET GYNAEC, V105, P790, DOI 10.1111/j.1471-0528.1998.tb10211.x; Glasier AF, 2000, HUM REPROD, V15, P646, DOI 10.1093/humrep/15.3.646; Grimes D, 1998, LANCET, V352, P428; GUILLEBAUD J, 1995, BRIT MED J, V311, P1111, DOI 10.1136/bmj.311.7013.1111; Heinemann L A, 1999, Eur J Contracept Reprod Health Care, V4, P67, DOI 10.3109/13625189909064007; Jernstrom H, 1999, LANCET, V354, P1846, DOI 10.1016/S0140-6736(99)04336-6; JUNGHOFFMANN C, 1990, AM J OBSTET GYNECOL, V163, P2183, DOI 10.1016/0002-9378(90)90560-T; Kasprzak L, 1999, BMJ-BRIT MED J, V318, P786, DOI 10.1136/bmj.318.7186.786; KAUPPINENMAKELIN R, 1992, CLIN ENDOCRINOL, V36, P203, DOI 10.1111/j.1365-2265.1992.tb00959.x; KINNIBURGH D, 2000, INT J OBSTET GYNAECO, V70; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; LANDE R, 1995, POP REP SER K, P1; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Martin CW, 2000, HUM REPROD, V15, P637, DOI 10.1093/humrep/15.3.637; Meriggiola MC, 1997, J ANDROL, V18, P240; Michaelsson K, 1999, LANCET, V353, P1481, DOI 10.1016/S0140-6736(98)09044-8; MUHN P, 1995, CONTRACEPTION, V51, P99, DOI 10.1016/0010-7824(94)00015-O; MULLER N, 1998, INT PLANNED PARENTHO, V32, P1; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; NIESCHLAG E, 1998, TESTOSTERONE ACTION, P513; O'Brien P, 1999, BRIT MED J, V319, P1199, DOI 10.1136/bmj.319.7218.1199; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Petitti DB, 2000, OBSTET GYNECOL, V95, P736, DOI 10.1016/S0029-7844(00)00782-1; Piaggio G, 1999, LANCET, V353, P721, DOI 10.1016/S0140-6736(98)05718-3; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Rice CF, 1999, HUM REPROD, V14, P982, DOI 10.1093/humrep/14.4.982; Rowe PJ, 1997, CONTRACEPTION, V56, P341; Royal College of Obstetricians and Gynaecologists, 1999, MAL FEM STER EV BAS, V4; SCHWARTZ JL, 1999, CONTRACEPTION OFFICE, P113; Sturridge F, 1997, BRIT J OBSTET GYNAEC, V104, P285, DOI 10.1111/j.1471-0528.1997.tb11455.x; Sullivan H, 1999, FERTIL STERIL, V72, P115, DOI 10.1016/S0015-0282(99)00205-8; Thomas SL, 2000, LANCET, V355, P922, DOI 10.1016/S0140-6736(99)11159-0; Trussell J, 1999, CONTRACEPTION, V59, P147, DOI 10.1016/S0010-7824(99)00018-9; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P779; UN International Conference on Population and Development, 1994, PROGR ACT; Van Look PFA, 1999, FERTIL STERIL, V72, P431; Walker AM, 1998, CONTRACEPTION, V57, P169, DOI 10.1016/S0010-7824(98)00014-6; Wildemeersch D, 1999, BRIT J FAM PLAN, V24, P149; YUZPE AA, 1982, FERTIL STERIL, V37, P508; Zimmermann T, 1999, EUR J CONTRACEP REPR, V4, P155, DOI 10.3109/13625189909040810	56	19	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1913	1919		10.1016/S0140-6736(00)03269-4	http://dx.doi.org/10.1016/S0140-6736(00)03269-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130398				2023-01-03	WOS:000165665400037
J	Lamping, DL; Constantinovici, N; Roderick, P; Normand, C; Henderson, L; Harris, S; Brown, E; Gruen, R; Victor, C				Lamping, DL; Constantinovici, N; Roderick, P; Normand, C; Henderson, L; Harris, S; Brown, E; Gruen, R; Victor, C			Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study	LANCET			English	Article							SF-36 HEALTH SURVEY; RENAL-REPLACEMENT THERAPY; SURVEY QUESTIONNAIRE; RATIONING DEBATE; SURVIVAL; DISEASE; BRITAIN; ENGLAND; CARE; AGE	Background Evidence-based health policy is urgently needed to meet the increasing demand for health services among elderly people, particularly for expensive technologies such as renal-replacement therapy. Age has been used to ration dialysis, although not always explicitly, despite the lack of rigorous empirical evidence about how elderly people fare on dialysis. We undertook a comprehensive assessment of outcomes in patients 70 years or over. Methods We did a 12-month prospective cohort study of outcomes in 221 patients with end-stage renal failure aged 70 years or over recruited from four hospital-based renal units, We assessed 1-year survival in 125 incident patients (70-86 years) and disease burden (hospital admissions, quality of life, costs) in 174 prevalent patients (70-93 years). Findings 1-year survival rates were: 71% overall; 80%, 69%, and 54% in patients 70-74 years, 75-79 years, and 80 years and older, respectively (p=0008); and 88%, 71%, and 64% in patients with no, one, or two or more comorbid conditions, respectively (p=0056), Cox regression analyses showed that mortality was significantly associated with age 80 years and older (relative risk 2.79 [95% CI 1.28-6.93]) and peripheral vascular disease (2.83 [1.29-6.17]), but not with diabetes, ischaemic heart disease, cerebrovascular disease, chronic obstructive airways disease, sex, or treatment method. In terms of disease burden, hospital admissions represent a low proportion of costs and was not required by a third of patients, mental quality of life in elderly dialysis patients was similar to that of elderly people in the general population, and the average annual cost per patient of pound 20 802 (US$31 200) (68% dialysis treatment, 1% transport, 19% inpatient hospital admissions, 12% medications) was within the range of other life-extending interventions. Interpretation Our results suggest that age alone should not be used as a barrier to referral and treatment and emphasise the need to consider the benefits of dialysis in elderly people. Indicators of the ability to benefit from treatment, rather than chronological age, should be used to develop policies that ensure equal access to care for all.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England; Kensington & Chelsea & Westminster Hlth Author, Dept Publ Hlth, London, England; Royal Free & UCL, Dept Primary Care & Populat Sci, London, England; Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton, Hants, England; Charing Cross Hosp, Dept Renal Med, London, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of Southampton; Imperial College London; St Georges University London	Lamping, DL (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England.	donna.lamping@lshtm.ac.uk		Victor, Christina/0000-0002-4213-3974; Normand, Charles/0000-0002-0885-5754				ANSELL D, 1999, 2 UK REN REG; Barrett BJ, 1997, AM J KIDNEY DIS, V29, P214, DOI 10.1016/S0272-6386(97)90032-9; Bosanquet N, 1993, Health Trends, V25, P146; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Chandna SM, 1999, BRIT MED J, V318, P217; *CIPFA, 1997, PERS SOC SERV STAT H; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; Davies R, 1997, NEPHROL DIAL TRANSPL, V12, P2512, DOI 10.1093/ndt/12.12.2512; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; *DEP HLTH, 1994, REP HLTH CAR STRAT U; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Graham B, 1997, BRIT J GEN PRACT, V47, P170; Haycox A, 1996, J Manag Med, V10, P6, DOI 10.1108/02689239610113487; HAYES V, 1995, AGE AGEING, V24, P120, DOI 10.1093/ageing/24.2.120; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; KHAN IH, 1996, QJM, V89, P397; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Mallick N, 1999, NEPHROL DIAL TRANSPL, V14, P37, DOI 10.1093/ndt/14.1.37; Mallick NP, 1997, NEPHROL DIAL TRANSPL, V12, P25; *REN ASS ROYAL COL, 1997, TREATM AD PAT REN FA; Roderick PJ, 1998, QJM-MON J ASSOC PHYS, V91, P581, DOI 10.1093/qjmed/91.8.581; Stanton J, 1999, SOC SCI MED, V49, P1169, DOI 10.1016/S0277-9536(99)00158-6; *US REN DAT SYST, 1991, AM J KIDNEY DIS S, V18, P17; Varekamp I, 1998, SOC SCI MED, V47, P113, DOI 10.1016/S0277-9536(98)00012-4; WARE JE, 1994, SF36 PHYSICAL MENTAL; WATKINS PJ, 1989, BRIT MED J, V299, P1135; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274	32	260	277	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1543	1550		10.1016/S0140-6736(00)03123-8	http://dx.doi.org/10.1016/S0140-6736(00)03123-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	370QV	11075766				2023-01-03	WOS:000165134500008
J	Autran, B; Carcelain, G				Autran, B; Carcelain, G			AIDS - Boosting immunity to HIV - Can the virus help?	SCIENCE			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; RESPONSES; DISCONTINUATION; INFECTION; VIREMIA; TYPE-1		Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France.	brigitte.autran@psl.ap-hop-paris.fr						CARCELAIN G, IN PRESS J VIROL; Dalod M, 1998, J INFECT DIS, V178, P61, DOI 10.1086/515587; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Mollet L, 2000, J IMMUNOL, V165, P1692, DOI 10.4049/jimmunol.165.3.1692; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013	12	43	44	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					946	+		10.1126/science.290.5493.946	http://dx.doi.org/10.1126/science.290.5493.946			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11184735				2023-01-03	WOS:000165103200036
J	Majeed, A; Bardsley, M; Morgan, D; O'Sullivan, C; Bindman, AB				Majeed, A; Bardsley, M; Morgan, D; O'Sullivan, C; Bindman, AB			Cross sectional study of primary care groups in London: association of measures of socioeconomic and health status with hospital admission rates	BRITISH MEDICAL JOURNAL			English	Article							SMALL-AREA ANALYSIS; ALLOCATING RESOURCES; CLINICAL GOVERNANCE; INPATIENT SERVICES; GENERAL PRACTICES; NEW-ZEALAND; AUTHORITIES; MODEL	Objectives To calculate socioeconomic and health status measures for the primary care groups in London and to examine the association between these measures and hospital admission rates. Design Cross sectional study. Setting 66 primary care groups in London, total list size 8.0 million people. Main outcome measures Elective and emergency standardised hospital admission ratios; standardised admission rates for diabetes and asthma. Results Standardised hospital admission ratios varied from 74 to 116 for total admissions and from 50 to 124 for emergency admissions. Directly standardised admission rates for asthma varied from 152 to 801 per 100 000 (mean 364) and for diabetes from 235 to 1034 per 100 000 (mean 538). There were large differences in the mortality, socioeconomic, and general practice characteristics of the primary care groups. Hospital admission rates were significantly correlated with many of the measures of chronic illness and deprivation. The strongest correlations were with disability living allowance (R = 0.64 for total admissions and R = 0.62 for emergency admissions, P <0.0001). Practice characteristics were less strongly associated with hospital admission rates. Conclusions It is feasible to produce a range of socioeconomic, health status, and practice measures for primary care groups for use in needs assessment and in planning and monitoring health services. These measures show that primary care groups have highly variable patient and practice characteristics and that hospital admission rates are associated with chronic illness and deprivation. These variations will need to be taken into account when assessing performance.	UCL, Sch Publ Policy, London WC1H 9EZ, England; E & City London Hlth Author, Hlth Londoners Project, London E1 1RD, England; UCL Hosp NHS Trust, Res & Dev Directorate, London NW1 2LT, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Majeed, A (corresponding author), UCL, Sch Publ Policy, London WC1H 9EZ, England.	a.majeed@ucl.ac.uk	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Bardsley, Martin/0000-0002-9853-6019; Majeed, Azeem/0000-0002-2357-9858	FIC NIH HHS [F06 TW002336] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002336] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Aveyard P, 1997, J Eval Clin Pract, V3, P275, DOI 10.1046/j.1365-2753.1997.t01-1-00004.x; Baker R, 1999, BRIT MED J, V318, P779, DOI 10.1136/bmj.318.7186.779; BARDSLEY M, 2000, MAPING HLTH PRIMARY; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; Dixon J, 1998, BRIT MED J, V317, P125, DOI 10.1136/bmj.317.7151.125; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Majeed A, 1999, BRIT MED J, V318, P772, DOI 10.1136/bmj.318.7186.772; MAJEED A, 1999, PUBLIC HLTH MED, V1, P4; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; Malcolm L, 1997, BRIT MED J, V314, P1890, DOI 10.1136/bmj.314.7098.1890; Malcolm L, 1999, BRIT MED J, V319, P1340, DOI 10.1136/bmj.319.7221.1340; *NHS EX, 1999, QUAL PERF NHS HIGH L; *NHS EX, 1988, EX ATTR DAT SET; Reid FDA, 1999, BRIT MED J, V319, P98, DOI 10.1136/bmj.319.7202.98; SCALLY G, 1998, BRIT MED J, V316, P39; *SECR STAT HLTH, 1997, NEW NHS; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050	19	63	63	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 28	2000	321	7268					1057	1060		10.1136/bmj.321.7268.1057	http://dx.doi.org/10.1136/bmj.321.7268.1057			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PU	11053180	Bronze, Green Published			2023-01-03	WOS:000165076800027
J	Hettiaratehy, S; Clarke, J; Taubel, J				Hettiaratehy, S; Clarke, J; Taubel, J			Burns after photodynamic therapy	BRITISH MEDICAL JOURNAL			English	Article							HEAD; NECK		Chelsea & Westminster Hosp, Reg Burns Ctr, London SW10 9NH, England; Charterhouse Clin Res Unit, London W6 0TN, England	Imperial College London	Hettiaratehy, S (corresponding author), Chelsea & Westminster Hosp, Reg Burns Ctr, London SW10 9NH, England.		Taubel, Jorg/I-1286-2019	Taubel, Jorg/0000-0002-0010-207X				DILKES MG, 1995, J LARYNGOL OTOL, V109, P1072, DOI 10.1017/S0022215100132050; Farber NE, 1996, ANESTHESIOLOGY, V84, P983, DOI 10.1097/00000542-199604000-00028; Kubler AC, 1999, LASER SURG MED, V25, P60, DOI 10.1002/(SICI)1096-9101(1999)25:1<60::AID-LSM8>3.0.CO;2-X; McCaughan JS, 1997, J THORAC CARDIOV SUR, V114, P940, DOI 10.1016/S0022-5223(97)70008-4	4	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1245	1245		10.1136/bmj.320.7244.1245	http://dx.doi.org/10.1136/bmj.320.7244.1245			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797034	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000086981400020
J	Vella, K; Goldfrad, C; Rowan, K; Bion, J; Black, N				Vella, K; Goldfrad, C; Rowan, K; Bion, J; Black, N			Use of consensus development to establish national research priorities in critical care	BRITISH MEDICAL JOURNAL			English	Article							DELPHI	Objectives To test the Feasibility of using a nominal group technique to establish clinical and health services research priorities in critical care and to test the representativeness of the group's views. Design Generation of topics by means of a national survey a nominal group technique to establish the level of consensus: a survey to test the representativeness of the results. Setting United Kingdom and Republic of Ireland. Subjects Nominal group composed of 10 doctors (8 consultants, 2 trainees) and 2 nurses. Main outcome measure Level of support (median) and level of agreement (mean absolute deviation from the median) derived from a 9 point Likert scale. Results Of the 325 intensive care units approached. 187 (58%) responded, providing about 1000 suggestions for research Of the 106 most frequently suggested topics considered by the nominal group. 37 attracted strong support. 48 moderate support and 21 weak support. There was more agreement after the group had met-overall mean of the mean absolute deviations from the median fell from 1.41 to 1.26. The group's views represented the views of the wider community of critical care staff (r = 0.73, P < 0.01). There was no significant difference in the views of staff from teaching or from non-teaching hospitals. Of the 37 topics that attracted the strongest support, 24 were concerned with organisational aspects of critical care and only 13 with technology assessment or clinical research. Conclusions A nominal group technique is feasible and reliable for determining research priorities among clinicians. This approach is more democratic and transparent than the traditional methods used by research funding bodies. The results suggest that clinicians perceive research into the best ways of delivering and organising services as a high priority.	London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; Intens Care & Natl Audit & Res Ctr, London WC1H 9HR, England; Univ Birmingham, Dept Anaesthesia & Intens Care, Birmingham B15 2TH, W Midlands, England	University of London; London School of Hygiene & Tropical Medicine; Intensive Care National Audit & Research Centre; University of Birmingham	Black, N (corresponding author), London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.			Bion, Julian/0000-0003-0344-5403				Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608; Black N, 1999, J Health Serv Res Policy, V4, P236; BOND S, 1982, J ADV NURS, V7, P565, DOI 10.1111/j.1365-2648.1982.tb00277.x; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; Harrington JM, 1996, OCCUP ENVIRON MED, V53, P642, DOI 10.1136/oem.53.9.642; LINDEMAN CA, 1975, NURS RES, V24, P434, DOI 10.1097/00006199-197511000-00006; Mootz RD, 1997, J MANIP PHYSIOL THER, V20, P201; Rudy S F, 1996, ORL Head Neck Nurs, V14, P16; Schmidt K, 1997, J Pediatr Nurs, V12, P201, DOI 10.1016/S0882-5963(97)80002-4; Sedlak C, 1998, Orthop Nurs, V17, P51; THOMAS B, 1983, J NURS EDUC, V22, P335; vanderBeek AJ, 1997, OCCUP ENVIRON MED, V54, P504, DOI 10.1136/oem.54.7.504	12	123	124	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					976	980		10.1136/bmj.320.7240.976	http://dx.doi.org/10.1136/bmj.320.7240.976			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303XP	10753149	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000086453100022
J	Cook, RI; Render, M; Woods, DD				Cook, RI; Render, M; Woods, DD			Gaps in the continuity of care and progress on patient safety	BRITISH MEDICAL JOURNAL			English	Article									Univ Chicago, VA Patient Safety Ctr Inquiry GAPS, Chicago, IL 60637 USA; Cincinnati VAMC, VA Patient Safety Ctr Inquiry GAPS, Cincinnati, OH 45220 USA; Ohio State Univ, VA Patient Safety Ctr Inquiry GAPS, Columbus, OH 43210 USA	University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; Ohio State University	Cook, RI (corresponding author), Univ Chicago, VA Patient Safety Ctr Inquiry GAPS, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.							BARLEY SR, 1997, CRAFT SCI TECHNICAL, P16; Cook R., 1998, TALE 2 STORIES CONTR; Cook RI, 1994, HUMAN ERROR MED, P255; COOK RI, 1999, ENHANCING PATIENT SA, P61; Klein Gary., 1998, SOURCES POWER PEOPLE; Kohn LTCJ., BUILDING SAFER HLTH; *NAT PAT SAF FDN, 1999, AG RES DEV PAT SAF; RASMUSSEN J, 1994, COGNITIVE SYSTEMS EN, P135; SENDERS JW, 1999, ENHANCING PATIENT SA, P65; Woods D. D., 1999, HDB APPL COGNITIVE P, P141; Woods D.D., 1988, TASKS ERRORS MENTAL, P128	11	323	327	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					791	794		10.1136/bmj.320.7237.791	http://dx.doi.org/10.1136/bmj.320.7237.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720370	Green Published			2023-01-03	WOS:000086054700035
J	Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC				Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC			Symptoms and suffering at the end of life in children with cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALLIATIVE CARE; FAMILY MEMBERS; PAIN	Background: Cancer is the second leading cause of death in children, after accidents. Little is known, however, about the symptoms and suffering at the end of life in children with cancer. Methods: In 1997 and 1998, we interviewed the parents of children who had died of cancer between 1990 and 1997 and who were cared for at Children's Hospital in Boston, the Dana-Farber Cancer Institute, or both. Additional data were obtained by reviewing medical records. Results: Of 165 eligible parents, we interviewed 103 (62 percent), 98 by telephone and 5 in person. The interviews were conducted a mean (+/-SD) of 3.1+/-1.6 years after the death of the child. Almost 80 percent died of progressive disease, and the rest died of treatment-related complications. Forty-nine percent of the children died in the hospital; nearly half of these deaths occurred in the intensive care unit. According to the parents, 89 percent of the children suffered "a lot'' or "a great deal'' from at least one symptom in their last month of life, most commonly pain, fatigue, or dyspnea. Of the children who were treated for specific symptoms, treatment was successful in 27 percent of those with pain and 16 percent of those with dyspnea. On the basis of a review of the medical records, parents were significantly more likely than physicians to report that their child had fatigue, poor appetite, constipation, and diarrhea. Suffering from pain was more likely in children whose parents reported that the physician was not actively involved in providing end-of-life care (odds ratio, 2.6; 95 percent confidence interval, 1.0 to 6.7). Conclusions: Children who die of cancer receive aggressive treatment at the end of life. Many have substantial suffering in the last month of life, and attempts to control their symptoms are often unsuccessful. Greater attention must be paid to palliative care for children who are dying of cancer. (N Engl J Med 2000;342:326-33.) (C) 2000, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu	Harding, Richard/G-9729-2012		AHRQ HHS [5 T32 HS00063] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fainsinger R, 1991, J Palliat Care, V7, P5; FIELD MJ, 1997, APPROACHING DEATH IM, V17, P437; Frager G, 1996, J PALLIATIVE CARE, V12, P9; Goldman A, 1998, BRIT MED J, V316, P49, DOI 10.1136/bmj.316.7124.49; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; KANE RL, 1984, LANCET, V1, P890; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MAUER AM, 1987, AM J PEDIAT HEMATOL, V9, P58; Monti M, 1996, J PAIN SYMPTOM MANAG, V12, P18, DOI 10.1016/0885-3924(96)00044-9; Power David, 1993, Palliative Medicine, V7, P213, DOI 10.1177/026921639300700308; Robinson WM, 1997, PEDIATRICS, V100, P205, DOI 10.1542/peds.100.2.205; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Sanders J, 1997, PEDIATRICS, V99, P139; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; Streiner DL, 1995, HLTH MEASUREMENT SCA, V2nd; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; 1991, JAMA, V275, P1232	28	758	770	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					326	333		10.1056/NEJM200002033420506	http://dx.doi.org/10.1056/NEJM200002033420506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10655532				2023-01-03	WOS:000085070300006
J	Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Jones, J; Parker, G				Wilson, A; Parker, H; Wynn, A; Jagger, C; Spiers, N; Jones, J; Parker, G			Randomised controlled trial of effectiveness of Leicester hospital at home scheme compared with hospital care	BRITISH MEDICAL JOURNAL			English	Article							SICKNESS IMPACT PROFILE; SHORT GENERIC VERSION; EARLY DISCHARGE; STATE	Objective To compare effectiveness of patient care in hospital at home scheme with hospital care. Design Pragmatic randomised controlled trial. Setting Leicester hospital at home scheme and the city's three acute hospitals Participants 199 consecutive patients referred to hospital at home bu their general practitioner and assessed as being suitable for admission. Six of 102 patients randomised to hospital at home refused admission, as did 23 of 97 allocated to hospital. Intervention Hospital at home or hospital inpatient care. Main outcome measures Mortality and change in health status (Barthel index, sickness impact profile 68, EuroQol, Philadelphia geriatric morale scale) assessed at 2 weeks and 3 months after randomisation. The main process measures were service inputs, discharge destination, readmission rates, length of initial stay, and total days of care. Results Hospital at home group and hospital group showed no significant differences in health status (median scores on sickness impact profile 68 were 29 and 30 respectively at 2 weeks. and 24 and 26 at 3 months) or in dependency; (Barthel scores 15 and 14 at 2 weeks and 16 for both groups at 3 months). At 3 months' follow up. 26 (25%) of hospital at home group had died compared with 30 (31%) of hospital group (relative risk 0.82 (95% confidence interval 0.52 to 1.28)). Hospital at home group required fewer days of treatment than hospital group, both in terms of initial stay (median 8 days v 14.5 days, P = 0.026) and total days of care at 3 months (median 9 days v 16 days, P = 0.031). Conclusions Hospital at home scheme delivered care as effectively as hospital, with no clinically important differences in health status. Hospital at home resulted in significantly shorter lengths of stay, which did not lead to a higher rate of subsequent admission. Objective To compare effectiveness of patient care in hospital at home scheme with hospital care. Design Pragmatic randomised controlled trial. Setting Leicester hospital at home scheme and the city's three acute hospitals.	Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Nuffield Community Care Studies Unit, Leicester LE1 6TP, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester	Wilson, A (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England.			Jagger, Carol/0000-0002-6377-9926; Parker, Gillian Mary/0000-0002-2221-6748				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1998, BRIT MED J, V316, P1761, DOI 10.1136/bmj.316.7147.1761; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; MAHONEY F I, 1965, Md State Med J, V14, P61; MORRIS JN, 1975, J GERONTOL, V30, P77, DOI 10.1093/geronj/30.1.77; PATTIE AH, 1976, BRIT J PSYCHIAT, V129, P68, DOI 10.1192/bjp.129.1.68; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; SHEPPERD S, 1998, COCHRANE LIB; WILSON A, 1997, BR J COMMUNITY HLTH, V2, P234	15	75	75	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1542	1546		10.1136/bmj.319.7224.1542	http://dx.doi.org/10.1136/bmj.319.7224.1542			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	265LK	10591717	Bronze, Green Published			2023-01-03	WOS:000084245600025
J	Andersson, GBJ; Lucente, T; Davis, AM; Kappler, RE; Lipton, JA; Leurgans, S				Andersson, GBJ; Lucente, T; Davis, AM; Kappler, RE; Lipton, JA; Leurgans, S			A comparison of osteopathic spinal manipulation with standard care for patients with low back pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CLINICAL-TRIALS; COSTS; VALIDITY; THERAPY	Background The effect of osteopathic manual therapy (i.e., spinal manipulation) in patients with chronic and subchronic back pain is largely unknown, and its use in such patients is controversial. Nevertheless, manual therapy is a frequently used method of treatment in this group of patients. Methods We performed a randomized, controlled trial that involved patients who had had back pain for at least three weeks but less than six months. We screened 1193 patients; 178 were found to be eligible and were randomly assigned to treatment groups; 23 of these patients subsequently dropped out of the study. The patients were treated either with one or more standard medical therapies (72 patients) or with osteopathic manual therapy (83 patients). We used a variety of outcome measures, including scores on the Roland-Morris and Oswestry questionnaires, a visual-analogue pain scale, and measurements of range of motion and straight-leg raising, to assess the results of treatment over a 12-week period. Results Patients in both groups improved during the 12 weeks. There was no statistically significant difference between the two groups in any of the primary outcome measures. The osteopathic-treatment group required significantly less medication (analgesics, antiinflammatory agents, and muscle relaxants) (P<0.001) and used less physical therapy (0.2 percent vs. 2.6 percent, P<0.05). More than 90 percent of the patients in both groups were satisfied with their care. Conclusions Osteopathic manual care and standard medical care have similar clinical results in patients with subacute low back pain. However, the use of medication is greater with standard care. (N Engl J Med 1999;341:1426-31.) (C)1999, Massachusetts Medical Society.	Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Chicago Coll Osteopath Med, Downers Grove, IL USA	Rush University; Rush University; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine	Andersson, GBJ (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, 1653 W Congress Pkwy,1471 Jelke, Chicago, IL 60612 USA.	ganderss@rush.edu						ANDERSSON GBJ, 1983, SPINE, V8, P880, DOI 10.1097/00007632-198311000-00011; Armitage P., 1994, STAT METHODS MED RES; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; BLOCH R, 1987, SPINE, V12, P430, DOI 10.1097/00007632-198706000-00002; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CONRAD DA, 1994, SPINE, V19, pS2101; Daltroy LH, 1996, SPINE, V21, P741, DOI 10.1097/00007632-199603150-00017; Deyo RA, 1996, SPINE, V21, P2840, DOI 10.1097/00007632-199612150-00007; Deyo RA, 1996, SPINE, V21, P2826, DOI 10.1097/00007632-199612150-00003; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; Fairbank J C, 1980, Physiotherapy, V66, P271; Gabriel SE, 1997, ARTHRIT CARE RES, V10, P56, DOI 10.1002/art.1790100109; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; HRUBY RJ, 1995, OSTEOPATHIC MED PAST, P49; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1995, SPINE, V20, P228, DOI 10.1097/00007632-199501150-00021; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; MACDONALD RS, 1991, SPINE, V16, P104; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Palmer BF, 1996, ADV INTERNAL MED, V41, P605; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSEN M, 1994, REPORT CSAG COMMITTE; ROSSLEE B, 1995, OSTEOPATHIC MED PAST, P89; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; SHEKELLE PG, 1994, SPINE, V19, P858, DOI 10.1097/00007632-199404000-00026; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHEKELLE PG, 1995, SPINE, V20, P221, DOI 10.1097/00007632-199501150-00018; Smalley WE, 1996, J GEN INTERN MED, V11, P461, DOI 10.1007/BF02599040; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005; VonKorff M, 1996, SPINE, V21, P2833, DOI 10.1097/00007632-199612150-00004; Ward RC, 1997, FDN OSTEOPATHIC MED; *WORKC CORP, 1993, GUID MAN BACK INJ EM, P1	34	200	203	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1426	1431		10.1056/NEJM199911043411903	http://dx.doi.org/10.1056/NEJM199911043411903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547405				2023-01-03	WOS:000083472100003
J	Cazeau, S; Leclercq, C; Lavergne, T; Walker, S; Varma, C; Linde, C; Garrigue, S; Kappenberger, L; Haywood, GA; Santini, M; Bailleul, C; Daubert, JC				Cazeau, S; Leclercq, C; Lavergne, T; Walker, S; Varma, C; Linde, C; Garrigue, S; Kappenberger, L; Haywood, GA; Santini, M; Bailleul, C; Daubert, JC		Multisite Stimulation Cardiomyopat	Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; BUNDLE-BRANCH-BLOCK; 6-MINUTE WALK TEST; PEAK OXYGEN-UPTAKE; DILATED CARDIOMYOPATHY; ATRIOVENTRICULAR DELAY; AMBULATORY PATIENTS; EXERCISE CAPACITY; SURVIVAL; CHAMBER	Background: One third of patients with chronic heart failure have electrocardiographic evidence of a major intraventricular conduction delay, which may worsen left ventricular systolic dysfunction through asynchronous ventricular contraction. Uncontrolled studies suggest that multisite biventricular pacing improves hemodynamics and well-being by reducing ventricular asynchrony. We assessed the clinical efficacy and safety of this new therapy. Methods: Sixty-seven patients with severe heart failure (New York Heart Association class III) due to chronic left ventricular systolic dysfunction, with normal sinus rhythm and a duration of the QRS interval of more than 150 msec, received transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle). This single-blind, randomized, controlled crossover study compared the responses of the patients during two periods: a three-month period of inactive pacing (ventricular inhibited pacing at a basic rate of 40 bpm) and a three-month period of active (atriobiventricular) pacing. The primary end point was the distance walked in six minutes; the secondary end points were the quality of life as measured by questionnaire, peak oxygen consumption, hospitalizations related to heart failure, the patients' treatment preference (active vs. inactive pacing), and the mortality rate. Results: Nine patients were withdrawn from the study before randomization, and 10 failed to complete both study periods. Thus, 48 patients completed both phases of the study. The mean (+/-SD) distance walked in six minutes was 23 percent greater with active pacing (399+/-100 m vs. 326+/-134 m, P<0.001), the quality-of-life score improved by 32 percent (P<0.001), peak oxygen uptake increased by 8 percent (P<0.03), hospitalizations were decreased by two thirds (P<0.05), and active pacing was preferred by 85 percent of the patients (P<0.001). Conclusions: Although it is technically complex, atriobiventricular pacing significantly improves exercise tolerance and quality of life in patients with chronic heart failure and intraventricular conduction delay. (N Engl J Med 2001;344:873-80.) Copyright (C) 2001 Massachusetts Medical Society.	CHU, Hop Pontchaillou, Ctr Cardiopneumol, Dept Cardiol & Malad Vasc, F-35033 Rennes, France; InParys, St Cloud, France; Hop Broussais, F-75674 Paris, France; Harefield Hosp, Harefield UB9 6JH, Middx, England; Univ London St Georges Hosp, London, England; Karolinska Hosp, S-10401 Stockholm, Sweden; Hop Cardiol Haut Leveque, Bordeaux, France; CHU Vaudois, CH-1011 Lausanne, Switzerland; Derriford Hosp, Plymouth PL6 8DH, Devon, England; Osped San Filippo Neri, Rome, Italy; ELA Rech, Le Plessis Robinson, France	CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; St Georges University London; Karolinska Institutet; Karolinska University Hospital; CHU Bordeaux; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Derriford Hospital; San Filippo Neri Hospital	Daubert, JC (corresponding author), CHU, Hop Pontchaillou, Ctr Cardiopneumol, Dept Cardiol & Malad Vasc, F-35033 Rennes, France.	jean-claude.daubert@CHU-rennes.fr		LInde, Cecilia/0000-0002-9039-6023				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Alonso C, 1999, AM J CARDIOL, V84, P1417, DOI 10.1016/S0002-9149(99)00588-3; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Auricchio A, 1999, AM J CARDIOL, V83, p136D; Blanc JJ, 1997, CIRCULATION, V96, P3273; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; CAZEAU S, 1994, PACE, V17, P1974, DOI 10.1111/j.1540-8159.1994.tb03783.x; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cleland JGF, 1998, LANCET, V352, P19; Daubert JC, 1999, EUR J HEART FAIL, V1, P281, DOI 10.1016/S1388-9842(99)00042-2; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; FOSTER AH, 1995, ANN THORAC SURG, V59, P294, DOI 10.1016/0003-4975(94)00878-B; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; Goldstein DJ, 1998, NEW ENGL J MED, V339, P1522, DOI 10.1056/NEJM199811193392107; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Kindermann M, 1997, PACE, V20, P2453, DOI 10.1111/j.1540-8159.1997.tb06085.x; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; Narang R, 1996, EUR HEART J, V17, P120; Nelson GS, 2000, CIRCULATION, V101, P2703, DOI 10.1161/01.CIR.101.23.2703; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; Opasich C, 1998, AM J CARDIOL, V81, P1497, DOI 10.1016/S0002-9149(98)00218-5; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; Rector TS, 1987, HEART FAIL, V3, P198, DOI DOI 10.1177/1474515111435605; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WEBER KT, 1982, CIRCULATION, V65, P1213, DOI 10.1161/01.CIR.65.6.1213; WILENSKY RL, 1988, AM J CARDIOL, V62, P276, DOI 10.1016/0002-9149(88)90225-1; XIAO HB, 1991, BRIT HEART J, V66, P443; XIAO HB, 1992, BRIT HEART J, V68, P403; Zugck C, 2000, EUR HEART J, V21, P540, DOI 10.1053/euhj.1999.1861	43	2010	2123	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2001	344	12					873	880		10.1056/NEJM200103223441202	http://dx.doi.org/10.1056/NEJM200103223441202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	412PN	11259720				2023-01-03	WOS:000167563700002
J	Marenco, JP; Wang, PJ; Link, MS; Homoud, MK; Estes, NAM				Marenco, JP; Wang, PJ; Link, MS; Homoud, MK; Estes, NAM			Improving survival from sudden cardiac arrest - The role of the automated external defibrillator	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-ACCESS DEFIBRILLATION; BIPHASIC WAVE-FORMS; EMERGENCY MEDICAL TECHNICIANS; HEALTH-CARE PROFESSIONALS; ASSOCIATION TASK-FORCE; BASIC LIFE-SUPPORT; IN-HOSPITAL CHAIN; VENTRICULAR-FIBRILLATION; RAPID DEFIBRILLATION; PREHOSPITAL DEFIBRILLATION	Context Sudden cardiac death is a major public health problem in the United States, and improving survival after out-of-hospital cardiac arrest has been the subject of intense study. Early defibrillation has been shown to be critical to improving survival. Use of automated external defibrillators (AEDs) has become an important component of emergency medical systems, and recent advances in AED technology have allowed expansion of AED use to nontraditional first responders and the lay public. Objectives To examine advancements in AED technology, review the impact of AEDs on time to defibrillation and survival, and explore the future role of AEDs in the effort to improve survival following sudden cardiac arrest. Data Sources MEDLINE was searched for articles from 1966 through December 2000 (Medical Subject Headings: electric countershock, heart arrest, resuscitation, emergency medical services; keywords: automatic external defibrillator, automated external defibrillator, public access defibrillation). Reference lists of relevant articles, news releases, and product information from manufacturers were also reviewed. Study Selection Initial MEDLINE search produced 4816 articles, from which 101 articles were selected for referencing based on having been published in a peer-reviewed journal and on relevance to the subject of the manuscript as determined by all 5 authors. Data Extraction All studies were critically reviewed for relevance, accuracy, and quality of data and study design by all authors. Data Synthesis Recent advances in AED technology and design have resulted in marked simplification of AED operation, improvements in accuracy and effectiveness, and reductions in cost. Use of AEDs by first responders and laypersons has reduced time to defibrillation and improved survival from sudden cardiac arrest in several communities. Initial studies of the cost-effectiveness of AED use in comparison with other commonly used treatments are favorable. Conclusion The AED represents an efficient method of delivering defibrillation to persons experiencing out-of-hospital cardiac arrest and its use by both traditional and nontraditional first responders appears to be safe and effective. The rapidly expanding role of AEDs in traditional emergency medical systems is supported by the literature, and initial studies of public access to defibrillation offer hope that further improvements in survival after sudden cardiac death can be achieved.	Tufts Univ New England Med Ctr, New England Cardiac Arrhythmia Ctr, Div Cardiol, Dept Med, Boston, MA 02111 USA	Tufts Medical Center	Estes, NAM (corresponding author), Tufts Univ New England Med Ctr, New England Cardiac Arrhythmia Ctr, Div Cardiol, Dept Med, 750 Washington St, Boston, MA 02111 USA.	nestes@lifespan.org						AKHTAR M, 1992, CIRCULATION, V85, P1; American Heart Association in collaboration with International Liaison Committee On Resuscitation, 2000, CIRCULATION, V102, P160; Asplin BR, 1999, JAMA-J AM MED ASSOC, V282, P1033, DOI 10.1001/jama.282.11.1033-a; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BARDY GH, 1995, CIRCULATION, V91, P1768, DOI 10.1161/01.CIR.91.6.1768; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; BARDY GH, 1997, CIRCULATION S, V96, P560; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BRISON RJ, 1992, CAN MED ASSOC J, V147, P191; CARLSON MD, 1988, AM J CARDIOL, V61, P787, DOI 10.1016/0002-9149(88)91067-3; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1984, LANCET, V2, P318; Cummins RO, 1998, CIRCULATION, V97, P1654, DOI 10.1161/01.CIR.97.16.1654; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DALZELL GWN, 1991, BRIT HEART J, V65, P311; DALZELL GWN, 1989, AM J CARDIOL, V64, P741, DOI 10.1016/0002-9149(89)90757-1; Davis E A, 1998, Prehosp Emerg Care, V2, P101, DOI 10.1080/10903129808958851; Destro A, 1996, RESUSCITATION, V31, P39, DOI 10.1016/0300-9572(95)00914-0; DIACK AW, 1979, MED INSTRUM, V13, P78; DICKEY W, 1992, BRIT HEART J, V67, P334; EISENBERG M, 1981, JAMA-J AM MED ASSOC, V246, P50, DOI 10.1001/jama.246.1.50; EISENBERG MS, 1986, SCI AM, V254, P37, DOI 10.1038/scientificamerican0586-37; EISENBERG MS, 1989, AM J CARDIOL, V63, P443, DOI 10.1016/0002-9149(89)90316-0; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; Gliner Bradford E., 1998, Biomedical Instrumentation and Technology, V32, P631; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; GREENE HL, 1995, AM J CARDIOL, V75, P1135, DOI 10.1016/S0002-9149(99)80745-0; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; HASKELL WL, 1978, CIRCULATION, V57, P920, DOI 10.1161/01.CIR.57.5.920; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; HOYT R, 1981, CIRCULATION, V64, P818, DOI 10.1161/01.CIR.64.4.818; IDEKER RE, 1997, 2 AM HEART ASS PUBL; JAKOBSSON J, 1987, EUR HEART J, V8, P1189, DOI 10.1093/oxfordjournals.eurheartj.a062191; Jermyn B D, 2000, Prehosp Emerg Care, V4, P43, DOI 10.1080/10903120090941632; Jones FD, 1999, J CLIN ANESTH, V11, P336, DOI 10.1016/S0952-8180(99)00042-2; KAYE W, 1995, ANN EMERG MED, V25, P163, DOI 10.1016/S0196-0644(95)70318-7; KAYE W, 1995, RESUSCITATION, V30, P151, DOI 10.1016/0300-9572(95)00881-S; Kaye W, 1996, RESUSCITATION, V31, P181, DOI 10.1016/0300-9572(95)00941-8; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kerber RE, 1997, CIRCULATION, V95, P1677; KERBER RE, 1988, CIRCULATION, V77, P1038, DOI 10.1161/01.CIR.77.5.1038; KERBER RE, 1993, ANN EMERG MED, V22, P296, DOI 10.1016/S0196-0644(05)80459-7; KERBER RE, 1994, CIRCULATION, V89, P2369, DOI 10.1161/01.CIR.89.5.2369; KOUWENHOVEN WB, 1969, ANN INTERN MED, V71, P449, DOI 10.7326/0003-4819-71-3-449; LAZZAM C, 1991, CAN J CARDIOL, V7, P113; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Mancini M E, 1998, Am J Crit Care, V7, P314; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MCDANIEL CM, 1988, PACING CLIN ELECTROP, V11, P155; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; *NAT CTR HLTH STAT, 1997, MONTHLY VITAL STAT R, V45, pS2; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; PELESKA B, 1966, CIRC RES, V18, P10, DOI 10.1161/01.RES.18.1.10; Poole JE, 1997, J CARDIOVASC ELECTR, V8, P1373, DOI 10.1111/j.1540-8167.1997.tb01034.x; Robertson RM, 2000, NEW ENGL J MED, V343, P1259, DOI 10.1056/NEJM200010263431709; SHUSTER M, 1993, ANN EMERG MED, V22, P721, DOI 10.1016/S0196-0644(05)81856-6; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; SoRelle R, 1999, CIRCULATION, V99, P2606, DOI 10.1161/01.CIR.99.20.2606; Spearpoint KG, 2000, RESUSCITATION, V44, P165, DOI 10.1016/S0300-9572(00)00158-1; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; STULTS KR, 1987, ANN EMERG MED, V16, P872, DOI 10.1016/S0196-0644(87)80525-5; SWARTZ JF, 1993, CIRCULATION, V88, P2646, DOI 10.1161/01.CIR.88.6.2646; Sweeney TA, 1998, ANN EMERG MED, V31, P234, DOI 10.1016/S0196-0644(98)70313-0; Tang WC, 1999, J AM COLL CARDIOL, V34, P815, DOI 10.1016/S0735-1097(99)00270-3; Tang WC, 2000, CRIT CARE MED, V28, pN222, DOI 10.1097/00003246-200011001-00014; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; Walcott GP, 1998, CIRCULATION, V98, P2210, DOI 10.1161/01.CIR.98.20.2210; WATTS DD, 1995, ANN EMERG MED, V26, P635, DOI 10.1016/S0196-0644(95)70017-X; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEISFELDT ML, 1995, CIRCULATION, V92, P2763, DOI 10.1161/01.CIR.92.9.2763; WHITE RD, 1994, ANN EMERG MED, V23, P1009, DOI 10.1016/S0196-0644(94)70095-8; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; Whittaker RJ, 1996, GLOBAL ECOL BIOGEOGR, V5, P1; WILSON CM, 1989, J ELECTROCARDIOL, V22, P241, DOI 10.1016/0022-0736(89)90035-6; Yamanouchi Y, 1999, CIRCULATION, V100, P826, DOI 10.1161/01.CIR.100.8.826; Yamanouchi Y, 1998, CIRCULATION, V98, P2487, DOI 10.1161/01.CIR.98.22.2487; Zimmermann P G, 1997, J Emerg Nurs, V23, P340, DOI 10.1016/S0099-1767(97)90224-5; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	98	184	187	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2001	285	9					1193	1200		10.1001/jama.285.9.1193	http://dx.doi.org/10.1001/jama.285.9.1193			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	406BH	11231750	Bronze			2023-01-03	WOS:000167194700024
J	Pervaiz, S				Pervaiz, S			Reactive oxygen-dependent production of novel photochemotherapeutic agents	FASEB JOURNAL			English	Article						PDT; photodynamic reaction; photosensitizer; mitochondrial permeability	SINGLET MOLECULAR-OXYGEN; CYTOCHROME-C RELEASE; PHOTODYNAMIC THERAPY; TUMOR-CELLS; HEMATOPOIETIC-CELLS; FLASH-PHOTOLYSIS; MEROCYANINE 540; LYMPHOMA-CELLS; PROTEIN DAMAGE; HUMAN LEUKEMIA	The reactive nature of species derived from oxygen, such as singlet oxygen and hydrogen peroxide, has been exploited in the clinical setting for targeting bacteria, viruses, and tumor cells by photodynamic excitation of a variety of chromophores, This modality, termed photodynamic therapy (PDT), is currently being used to treat some forms of cancer. However, the applicability of conventional PDT is limited due to the absolute dependence on simultaneous exposure of the target to the photoactive com pound and light, In 1990, we demonstrated that the need for simultaneous exposure of the biological target to light and photosensitizer could be circumvented by prior exposure (activation) of the sensitizer molecule to light and its subsequent use as any other anti-cancer or and-viral drug. By dint of the nature of the protocol, this process was termed preactivation. Since then, the generation of biologically active molecules in vitro by preactivation has been validated using a variety of chromophores, such as merocyanine 540, Photofrin II, and naphthalimide. Here we briefly review the role of reactive oxygen species in the photodynamic effect, and provide an explanation for the mechanism of preactivation. We propose that photo-oxidation not only provides a novel means for the generation of biologically active molecules, but could also explain, at least in part the mechanism of conventional PDT, It is Likely that the light-dependent breakdown of the chromophore to generate novel active compounds, in addition to reactive oxygen species, also contributes to the photodynamic damage observed on simultaneous exposure of the chromophore and target tissue to light during PDT.-Pervaiz, S. Reactive oxygen-dependent production of novel photochemotherapeutic agents.	Natl Univ Singapore, Dept Physiol, Singapore 117597, Singapore	National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015					AGARWAL ML, 1991, CANCER RES, V51, P5993; Anderson C, 1997, PHOTOCHEM PHOTOBIOL, V65, P895, DOI 10.1111/j.1751-1097.1997.tb01940.x; BARRETT AJ, 1990, J PHOTOCH PHOTOBIO B, V6, P309, DOI 10.1016/1011-1344(90)85101-2; Blum H.F., 1941, PHOTODYNAMIC ACTION; CHAN PJ, 1991, ARCH ANDROLOGY, V27, P103, DOI 10.3109/01485019108987660; CHANH TC, 1992, J ACQ IMMUN DEF SYND, V5, P188; CHANH TC, 1994, ANTIVIR RES, V25, P133, DOI 10.1016/0166-3542(94)90102-3; Dahle J, 1999, PHOTOCHEM PHOTOBIOL, V70, P363, DOI 10.1111/j.1751-1097.1999.tb08150.x; DAS M, 1985, CANCER RES, V45, P6328; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVILA J, 1991, PHOTOCHEM PHOTOBIOL, V53, P1, DOI 10.1111/j.1751-1097.1991.tb08460.x; Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X; DIWU ZJ, 1994, PHARMACOL THERAPEUT, V63, P1, DOI 10.1016/0163-7258(94)90054-X; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; DOUGHERTY TJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P879, DOI 10.1111/j.1751-1097.1987.tb07898.x; FRANCK B, 1992, PHOTOCHEM PHOTOBIOL, V56, P271, DOI 10.1111/j.1751-1097.1992.tb02157.x; FREEMAN BA, 1984, FREE RADICALS MOL BI; FREITAS I, 1990, J PHOTOCH PHOTOBIO B, V7, P359, DOI 10.1016/1011-1344(90)85169-W; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Garbo GM, 1996, J PHOTOCH PHOTOBIO B, V34, P109, DOI 10.1016/1011-1344(96)07343-5; GOMER CJ, 1989, RADIAT RES, V120, P1, DOI 10.2307/3577632; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GULLIYA KS, 1990, EUR J CANCER, V26, P551, DOI 10.1016/0277-5379(90)90072-2; GULLIYA KS, 1990, PHOTOCHEM PHOTOBIOL, V52, P831, DOI 10.1111/j.1751-1097.1990.tb08689.x; GULLIYA KS, 1989, BLOOD, V73, P1059; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hsi RA, 1999, DRUGS, V57, P725, DOI 10.2165/00003495-199957050-00005; HUANG SK, 1992, CANCER RES, V52, P6774; ITOH T, 1993, BONE MARROW TRANSPL, V12, P191; JESIONEK A, 1903, MUENCH MED WOCHSCHS, V47, P20420; Jodlbauer A., 1904, DEUT ARCH KLIN MED, V80, P427; Jori G, 1996, J PHOTOCH PHOTOBIO B, V36, P87, DOI 10.1016/S1011-1344(96)07352-6; KALYANARAMAN B, 1987, P NATL ACAD SCI USA, V84, P2999, DOI 10.1073/pnas.84.9.2999; KANG Q, 1992, PHOTOCHEM PHOTOBIOL, V56, P489, DOI 10.1111/j.1751-1097.1992.tb02192.x; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; KESSEL D, 1995, PHOTOCHEM PHOTOBIOL, V62, P875; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; KESSEL D, 1992, ONCOL RES, V4, P219; KESSEL D, 1995, J PHOTOCH PHOTOBIO B, V28, P13, DOI 10.1016/1011-1344(94)07085-3; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LIPSON RL, 1961, J NATL CANCER I, V26, P1; Mayer LD, 1997, J PHARMACOL EXP THER, V280, P1406; Mayer LD, 1998, CANCER METAST REV, V17, P211, DOI 10.1023/A:1006070906949; MEAGHER RC, 1989, CANCER RES, V49, P3637; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; MULRONEY CM, 1994, SEMIN ONCOL, V21, P24; Nauta JM, 1996, EUR J ORAL SCI, V104, P69, DOI 10.1111/j.1600-0722.1996.tb00049.x; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; PANDEY RK, 1991, PHOTOCHEM PHOTOBIOL, V53, P65, DOI 10.1111/j.1751-1097.1991.tb08468.x; PATHAK MA, 1982, JNCI-J NATL CANCER I, V69, P163, DOI 10.1093/jnci/69.1.163; Peng Q, 1996, ULTRASTRUCT PATHOL, V20, P109, DOI 10.3109/01913129609016306; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; PERVAIZ S, 1992, FREE RADICAL BIO MED, V12, P389, DOI 10.1016/0891-5849(92)90088-X; PERVAIZ S, 1993, CANCER CHEMOTH PHARM, V31, P467, DOI 10.1007/BF00685037; Raab O, 1900, Z BIOL-MUNICH, V39, P524; RICCHELLI F, 1993, PHOTOCHEM PHOTOBIOL, V58, P53, DOI 10.1111/j.1751-1097.1993.tb04903.x; SCHLEGEL RA, 1980, CELL, V20, P321, DOI 10.1016/0092-8674(80)90618-2; SCHWARTZ S, 1955, U MINNESOTA MED B, V7, P7; SIEBER F, 1987, LEUKEMIA RES, V11, P43, DOI 10.1016/0145-2126(87)90104-4; SIEBER F, 1987, PHOTOCHEM PHOTOBIOL, V46, P1035, DOI 10.1111/j.1751-1097.1987.tb04890.x; SINGH RJ, 1992, PHOTOCHEM PHOTOBIOL, V55, P483, DOI 10.1111/j.1751-1097.1992.tb04268.x; SINGH RJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P493, DOI 10.1111/j.1751-1097.1991.tb03661.x; SMITH OM, 1991, EXP HEMATOL, V19, P785; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VALINSKY JE, 1978, CELL, V13, P487, DOI 10.1016/0092-8674(78)90322-7; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; VERMEERSCH G, 1991, PHOTOCHEM PHOTOBIOL, V54, P661, DOI 10.1111/j.1751-1097.1991.tb02072.x; Villanueva A, 1999, ONCOL RES, V11, P447; VOGELMANN E, 1976, PHOTOCHEM PHOTOBIOL, V24, P595, DOI 10.1111/j.1751-1097.1976.tb06878.x	74	53	61	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					612	617		10.1096/fj.00-0555rev	http://dx.doi.org/10.1096/fj.00-0555rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259379				2023-01-03	WOS:000167419500018
J	MacKie, RM; Stewart, B; Brown, SM				MacKie, RM; Stewart, B; Brown, SM			Intralesional injection of herpes simplex virus 1716 in metastatic melanoma	LANCET			English	Article							TYPE-1	We have previously shown that avirulent but replication-competent herpes simplex virus (HSV) 1716 causes cell death in human melanoma cell lines in vitro and selectively replicates in melanoma tissue in nude mice. We now present a pilot study of intratumoral Injection of HSV1716 Into subcutaneous nodules of metastatic melanoma in five patients with stage 4 melanoma. Two patients each received one Injection, two received two Injections, and one received four injections of 10(3) plaque-forming units HSV1716. In one patient, Rattening of previously palpable tumour nodules was seen 21 days after two direct injections of HSV1716, and in injected nodules from all three patients who received two or more injections there was microscopic evidence of tumour necrosis. Immunohistochemical staining of injected nodules revealed evidence of virus replication confined to tumour cells. These findings suggest that HSV1716 is non-toxic and could be of therapeutic benefit in patients with metastatic melanoma.	Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Neurovirol Res Labs, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	MacKie, RM (corresponding author), Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland.							BROWN SM, 1994, J GEN VIROL, V75, P2367, DOI 10.1099/0022-1317-75-9-2367; KESARI S, 1995, LAB INVEST, V73, P636; MACLEAN AR, 1991, J GEN VIROL, V72, P631, DOI 10.1099/0022-1317-72-3-631; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Randazzo BP, 1997, J INVEST DERMATOL, V108, P933, DOI 10.1111/1523-1747.ep12295238	5	129	144	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 17	2001	357	9255					525	526		10.1016/S0140-6736(00)04048-4	http://dx.doi.org/10.1016/S0140-6736(00)04048-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402WT	11229673				2023-01-03	WOS:000167011700014
J	Scheer, S; Chu, PL; Klausner, JD; Katz, MH; Schwarcz, SK				Scheer, S; Chu, PL; Klausner, JD; Katz, MH; Schwarcz, SK			Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS	LANCET			English	Article							VIRAL LOAD; COMBINATION THERAPIES; EPIDEMIOLOGIC SYNERGY; ANTIVIRAL TREATMENT; HIV; TRANSMISSION; RISK; PREVENTION; PROTEASE; SEMEN	Background There has been an increase in high-risk sexual behaviour and sexually transmitted diseases (STD) during the time period when highly active antiretroviral therapy (HAART) became widely available. We examined whether taking HAART increased the risk of acquiring an STD-an epidemiological marker of unsafe sex-in people with AIDS. Methods We did a computerised match of people in the San Francisco STD and AIDS registries. People with AIDS who were diagnosed before 1999 and alive in November, 1995, or later, were classified as having had an STD after AIDS diagnosis or not having had an STD after AIDS diagnosis. We used a Cox proportional hazards model to see whether use of antiretroviral therapy was associated with acquiring an STD after AIDS, after adjustment for sex, age, race, HIV-1 risk category, and CD4 count at AIDS diagnosis. Findings People with AIDS who had had HAART showed an independent increase in the risk of developing an STD (hazard ratio 4.10; 95% CI 2.84-5.94). Americans of African origin, younger age, and higher CD4 count at AIDS diagnosis were also associated with acquiring an STD after AIDS. The number of people living with AIDS who acquired an STD increased over time from 60 (0.66%) in 1995 to 113 (1.32%) in 1998 (p<0.001). Interpretation We have shown that people on HAART are more likely to develop an STD, an epidemiological marker of unsafe sex. More intensive risk-reduction counselling and STD screening for people with AIDS is needed.	San Francisco Dept Publ Hlth, Seroepidemiol & Surveillance Sect, San Francisco, CA 94102 USA; San Francisco Dept Publ Hlth, Sexually Transmitted Dis Prevent & Control Serv, San Francisco, CA 94102 USA	San Francisco Department of Public Health; San Francisco Department of Public Health	Scheer, S (corresponding author), San Francisco Dept Publ Hlth, Seroepidemiol & Surveillance Sect, San Francisco, CA 94102 USA.	susan_scheer@dph.sf.ca.us						BOYER CB, 1991, SOC SCI MED, V33, P11, DOI 10.1016/0277-9536(91)90446-J; BUCHBINDER S, 1998, 12 INT AIDS C GEN SW; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P45; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; DETELS R, 1998, JAMA-J AM MED ASSOC, V28, P1497; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Ekstrand ML, 1999, AIDS, V13, P1525, DOI 10.1097/00002030-199908200-00013; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Haase AT, 1998, NEW ENGL J MED, V339, P1846, DOI 10.1056/NEJM199812173392510; Hamm HE, 1996, FASEB J, V10, P3; Kelly JA, 1998, AIDS, V12, pF91, DOI 10.1097/00002030-199810000-00001; Klausner JD, 2000, JAMA-J AM MED ASSOC, V284, P447, DOI 10.1001/jama.284.4.447; Kravcik S, 1998, J ACQ IMMUN DEF SYND, V19, P124, DOI 10.1097/00042560-199810010-00004; LEHMAN J, 2000, 7 C RETR OPP INF SAN; Miller M, 2000, AIDS, V14, pF33, DOI 10.1097/00002030-200003100-00001; MURPHY S, 1998, 12 INT C AIDS GEN SW; NABULSI A, 1996, 11 INT C AIDS VANC C; Nieuwkerk PT, 2000, AIDS, V14, P181, DOI 10.1097/00002030-200001280-00014; OSMOND D, 1998, 12 INT AIDS C GEN SW; OTTEN RA, 1996, 12 INT AIDS C VANC C; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PIENIAZEK D, 1996, 3 C RETR OPP INF WAS; Ping LH, 2000, J VIROL, V74, P8946, DOI 10.1128/JVI.74.19.8946-8952.2000; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Remien RH, 1998, AIDS, V12, P1560, DOI 10.1097/00002030-199812000-00025; REMIEN RH, 1998, 12 INT AIDS C GEN SW; *SAN FRANC DEP PUB, 1999, SEX TRANSM DIS PREV; Schwarcz SK, 1999, AIDS, V13, P1109, DOI 10.1097/00002030-199906180-00015; van der Straten A, 2000, AIDS, V14, pF47, DOI 10.1097/00002030-200003100-00003; Vanable PA, 2000, HEALTH PSYCHOL, V19, P134, DOI 10.1037//0278-6133.19.2.134; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vernazza PL, 1999, AIDS, V13, P155, DOI 10.1097/00002030-199902040-00003; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	37	138	144	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	2001	357	9254					432	435		10.1016/S0140-6736(00)04007-1	http://dx.doi.org/10.1016/S0140-6736(00)04007-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	400HF	11273063				2023-01-03	WOS:000166865600012
J	DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE				DeFeo-Jones, D; Garsky, VM; Wong, BK; Feng, DM; Bolyar, T; Haskell, K; Kiefer, DM; Leander, K; McAvoy, E; Lumma, P; Wai, J; Senderak, ET; Motzel, SL; Keenan, K; Van Zwieten, M; Lin, JH; Freidinger, R; Huff, J; Oliff, A; Jones, RE			A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo	NATURE MEDICINE			English	Article							COMPLEX-FORMATION; PROTEIN; INHIBITORS	We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202, was hydrolyzed, resulting in the release of leucine-doxorubicin and doxorubicin, which are both very cytotoxic to cancer cells. However, L-377,202 was much less cytotoxic than conventional doxorubicin to cells in culture that do not secrete prostate-specific antigen. L-377,202 was approximately 15 times more effective than was conventional doxorubicin at inhibiting the growth of human prostate cancer tumors in nude mice when both drugs were used at their maximally tolerated doses. Nude mice inoculated with human prostate tumor cells secreting prostate-specific antigen showed considerable reductions in tumor burden with minimal total body weight loss when treated with L-377,202. This improvement in therapeutic index correlated with the selective localization of leucine-doxorubicin and free doxorubicin in tissues secreting prostate-specific antigen after exposure to L-377,202.	Merck Res Labs, Canc Res, W Point, PA 19486 USA; Merck Res Labs, Med Chem, W Point, PA 19486 USA; Merck Res Labs, Lab Anim Resources, W Point, PA 19486 USA; Merck Res Labs, Drug Metab, W Point, PA 19486 USA; Merck Res Labs, Safety Assessment, W Point, PA 19486 USA; Merck Res Labs, Vaccine Biometr Res, W Point, PA 19486 USA; Dupont Pharmaceut, Expt Stn, Wilmington, DE 19880 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; DuPont	Jones, RE (corresponding author), Merck Res Labs, Canc Res, W Point, PA 19486 USA.							AKIYAMA K, 1987, FEBS LETT, V225, P168, DOI 10.1016/0014-5793(87)81151-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432-1033.1994.tb18597.x; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; Denmeade SR, 1998, CANCER RES, V58, P2537; DIAMANDIS EP, 1995, SCAND J CLIN LAB INV, V55, P105, DOI 10.3109/00365519509090573; DIAMANDIS EP, 1994, BREAST CANCER RES TR, V32, P301, DOI 10.1007/BF00666007; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; HUSAIN MH, 1996, SEMIN ONCOL, V23, P24; JOHANSEN PB, 1981, CANCER CHEMOTH PHARM, V5, P267, DOI 10.1007/BF00434396; Leinonen J, 1996, J UROLOGY, V155, P1099, DOI 10.1016/S0022-5347(01)66399-7; LEVESQUE M, 1995, J CLIN LAB ANAL, V9, P123, DOI 10.1002/jcla.1860090209; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MACREZ C, 1967, PATHOL BIOL, V15, P949; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; *SAS I, 1990, SAS STAT US GUID VER, P897; SAS Institute, 1996, SAS STAT SOFTW CHANG; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WESTFALL PH, 1993, RESAMPLING BASED MUL, P112; YU H, 1994, J CLIN LAB ANAL, V8, P251, DOI 10.1002/jcla.1860080412; YU H, 1994, CLIN BIOCHEM, V27, P75, DOI 10.1016/0009-9120(94)90015-9	22	134	154	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2000	6	11					1248	1252		10.1038/81351	http://dx.doi.org/10.1038/81351			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GH	11062536				2023-01-03	WOS:000165114800032
J	Maclean, N; Pound, P; Wolfe, C; Rudd, A				Maclean, N; Pound, P; Wolfe, C; Rudd, A			Qualitative analysis of stroke patients' motivation for rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ILLNESS	Objective To explore the attitudes and beliefs of stroke patients identified by professionals as having either "high" or "low" motivation for rehabilitation. Design Qualitative study with semistructured interviews. Setting The stroke unit of an inner city teaching hospital. Participants 22 patients with stroke who were undergoing rehabilitation; 14 with high motivation for rehabilitation and eight with low motivation. Results All patients thought rehabilitation was important for recovery. High motivation patients were more likely to view rehabilitation as the most important means of recovery and to accord themselves an active role in rehabilitation. These patients were also more likely to understand rehabilitation and in particular to understand the specialist role of the nursing staff, Many patients reported independence at home as a personal goal, though few low motivation patients related this goal to success in rehabilitation. Information from professionals about rehabilitation, favourable comparisons with Other stroke patients, and the desire to leave hospital had a positive effect on motivation. Conversely overprotection from family members and professionals, lack of information or the receipt of "mixed messages" from professionals, and unfavourable comparisons with other patients had a negative effect. Conclusions There are some differences in beliefs between stroke patients identified as having low or high motivation for rehabilitation. These beliefs seem to be influenced by the environment in which the patient is rehabilitated. Professionals and carers should be made a aware of the ways in which their behaviour can positively and negatively affect motivation.	Kings Coll London, Guys Sch Med & Dent, Dept Publ Hlth Sci, London SE1 3QD, England; Kings Coll London, St Thomass Hosp Sch Med & Dent, Dept Publ Hlth Sci, London SE1 3QD, England; Kings Coll London, Kins Coll Sch Med & Dent, Dept Publ Hlth Sci, London SE1 3QD, England; St Thomas Hosp, Elderly Care Unit, London SE1 7EH, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Maclean, N (corresponding author), Kings Coll London, Guys Sch Med & Dent, Dept Publ Hlth Sci, London SE1 3QD, England.	macleanniall@hotmail.com						ANDERSON R, 1992, AFTERMATH STROKE; BECKER G, 1995, MED ANTHROPOL Q, V9, P165, DOI 10.1525/maq.1995.9.2.02a00040; Clark MS, 1997, CLIN REHABIL, V11, P162, DOI 10.1177/026921559701100210; Fitzpatrick R, 1994, Qual Health Care, V3, P107; Gold S, 1983, QUAL SOCIOL, V6, P238, DOI [10.1007/BF00987448, DOI 10.1007/BF00987448]; GRIFFITHS L, 1993, SOCIOL REV, V41, P415, DOI 10.1111/j.1467-954X.1993.tb00072.x; GUBRIUM J, 1982, DESCRIBING CARE IMAG; HOFFMAN JE, 1981, HLTH CANADIAN SOC; IBBOTSON J, 1978, PHYSIOTHERAPY, V61, P189; KAUFMAN S, 1986, SOC SCI MED, V22, P983, DOI 10.1016/0277-9536(86)90171-1; KAUFMAN S, 1988, J AGING STUD, V2, P217, DOI 10.1016/0890-4065(88)90002-3; KAUFMAN S R, 1988, Medical Anthropology Quarterly, V2, P338, DOI 10.1525/maq.1988.2.4.02a00040; KING P, 1939, CLIN REHABIL, V3, P289; Maclean N, 2000, SOC SCI MED, V50, P495; NIGEL G, 1993, RES SOCIAL LIFE; O'Gorman G, 1975, Physiotherapy, V61, P176; Patton M.Q., 1987, USE QUALITATIVE METH; Strauss A., 1990, BASICS GROUNDED THEO; TUPPER A, 1987, International Journal of Rehabilitation Research, V10, P119, DOI 10.1097/00004356-198700105-00024; WADE DT, 1987, BRIT J HOSP MED, V37, P200; Weber RP, 1990, BASIC CONTENT ANAL, P117; WOLFE B B, 1969, Pennsylvania Medicine, V72, P68	22	253	254	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2000	321	7268					1051	1054		10.1136/bmj.321.7268.1051	http://dx.doi.org/10.1136/bmj.321.7268.1051			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369PU	11053175	Bronze, Green Published			2023-01-03	WOS:000165076800024
J	Relling, MV; Pui, CH; Sandlund, JT; Rivera, GK; Hancock, ML; Boyett, JM; Schuetz, EG; Evans, WE				Relling, MV; Pui, CH; Sandlund, JT; Rivera, GK; Hancock, ML; Boyett, JM; Schuetz, EG; Evans, WE			Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; DOSE METHOTREXATE; CHILDREN; THERAPY; PHARMACODYNAMICS; PHARMACOKINETICS; 6-MERCAPTOPURINE; TRANSPLANTATION; IDENTIFICATION; INHIBITION	Background Many antileukaemic agents or their metabolites are inactivated by liver enzymes. Most anticonvulsant drugs induce drug-metabolising enzymes and thereby increase the clearance of anticancer agents. We investigated whether anticonvulsants compromise the efficacy of cancer chemotherapy. Methods We identified whom of 716 children treated consecutively for acute lymphoblastic leukaemia at a single academic hospital in the USA between 1984 and 1994 received treatment for 30 days or longer with anticonvulsants (phenytoin, phenobarbital, carbamazepine, or a combination) at the same time as antileukaemic therapy. Cox's proportional-hazards models were used to assess the prognostic significance of anticonvulsants on event-free survival and risk of haematological and central-nervous-system (CNS) relapse, with stratification for treatment protocol. Findings 40 (5.6%) of 716 patients received anticonvulsants. Use of these drugs was associated with age over 10 years (p=0.003), non-hyperdiploid leukaemia (p=0.031), and T-cell immunophenotype (p=0.022), After adjustment for age and ploidy, anticonvulsant therapy was significantly related to worse event-free survival (hazard ratio 2.67 [95% CI 1.50-4.76]; p=0.0009), haematological relapse (3.40 [1.69-6.88]; p=0.0006), and CNS relapse (2.90 [1.01-8.28]; p=0.047) among the 566 patients with B-lineage leukaemia, No such associations were seen among the 114 patients with T-cell leukaemia (p=0.61, 0.35, and 0.53, respectively). Faster clearance of teniposide (p=0.0001) and methotrexate (p=0.051), but not cytarabine (p=0.26) was found among patients receiving anticonvulsants. Interpretation Long-term anticonvulsant therapy increases the systemic clearance of several antileukaemic agents and is associated with lower efficacy of chemotherapy. Alternatives to enzyme;inducing anticonvulsants should be prescribed for patients receiving chemotherapy for acute lymphoblastic leukaemia.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Pharm, Memphis, TN 38163 USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Relling, MV (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Pui, Ching-Hon/N-8076-2018; Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012	Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322	NCI NIH HHS [CA20180, CA36401, CA51001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036401, R01CA051001, P01CA020180, R37CA036401, R29CA051001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER DK, 1992, J CLIN ONCOL, V10, P311, DOI 10.1200/JCO.1992.10.2.311; CAMITTA B, 1994, J CLIN ONCOL, V12, P1383, DOI 10.1200/JCO.1994.12.7.1383; Chessells JM, 2000, BRIT J HAEMATOL, V108, P204; CONNEY AH, 1967, PHARMACOL REV, V19, P317; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; EVANS WE, 1983, CLIN PHARMACOL THER, V33, P301, DOI 10.1038/clpt.1983.37; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; FREY BM, 1984, EUR J CLIN INVEST, V14, P1, DOI 10.1111/j.1365-2362.1984.tb00695.x; Gentile DM, 1996, J PHARMACOL EXP THER, V277, P105; KATKI AG, 1987, CHEM-BIOL INTERACT, V62, P237, DOI 10.1016/0009-2797(87)90025-1; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; MURPHY JA, 1995, LANCET, V346, P443, DOI 10.1016/S0140-6736(95)92816-2; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; OCHS JJ, 1984, LANCET, V2, P1422; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; REICH SD, 1976, CANCER RES, V36, P3803; Relling MV, 1999, BLOOD, V93, P2817; RELLING MV, 1994, MOL PHARMACOL, V45, P352; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RODMAN JH, 1994, J CLIN ONCOL, V12, P2390, DOI 10.1200/JCO.1994.12.11.2390; SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Steinherz PG, 1996, J CLIN ONCOL, V14, P389, DOI 10.1200/JCO.1996.14.2.389; Stram DO, 1996, BIOMETRICS, V52, P1079, DOI 10.2307/2533069; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911; Villikka K, 1999, CLIN PHARMACOL THER, V66, P589, DOI 10.1016/S0009-9236(99)90067-X; WASSNER SJ, 1976, J PEDIATR-US, V88, P134, DOI 10.1016/S0022-3476(76)80745-7; WINICK NJ, 1992, J NATL CANCER I, V84, P252, DOI 10.1093/jnci/84.4.252	31	130	134	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					285	290		10.1016/S0140-6736(00)02503-4	http://dx.doi.org/10.1016/S0140-6736(00)02503-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071183				2023-01-03	WOS:000088305900009
J	Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M				Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M			Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release	ONCOGENE			English	Article						CD95; hyperthermia; cytochrome c; glioma; mitochondria	HUMAN-MALIGNANT GLIOMA; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CD95L-INDUCED APOPTOSIS; GENE-TRANSFER; FUNCTIONS DOWNSTREAM; CASPASE ACTIVATION; DEATH RECEPTORS; LETHAL WEAPON; MITOCHONDRIA	CD95L-induced apoptosis involves caspase activation and is facilitated when RNA and protein synthesis are inhibited. Here, we report that hyperthermia sensitizes malignant glioma cells to CD95L- and APO2L-induced apoptosis in the absence, but not in the presence, of inhibitors of RNA and protein synthesis. Hyperthermia does not alter CD95 expression at the cell surface and does not modulate the morphology of CD95-mediated cell death on electron microscopy, Bcl-2 gene transfer inhibits apoptosis and abrogates the sensitization mediated by hyperthermia, Hyperthermia does not overcome resistance to apoptosis conferred by the viral caspase inhibitor, crm-A, indicating the absolute requirement for the activation of crm-A-sensitive caspases, probably caspase 8, for apoptosis, CD95L-evoked DEVD-amc-cleaving caspase activity is enhanced by hyperthermia, suggesting that hyperthermia operates up-stream of caspase processing to promote apoptosis, There is no uniformly enhanced processing of three caspase 3 substrate, poly-ADP ribose polymerase (PARP), protein kinase C (PKC) delta and DNA fragmentation factor (DFF) 45, Yet, hyperthermia promotes CD95L-evoked DNA fragmentation, Interestingly, hyperthermia enhances the CD95L-evoked release of cytochrome c in the absence, but not in the presence, of CHX. In contrast, the reduction of the mitochondrial membrane potential is enhanced by hyperthermia both in the absence and presence of CHX, and enhanced cytochrome c release is not associated with significantly enhanced caspase 9 processing. The potentiation of cytochrome c release at hyperthermic conditions in the absence of CHX is abrogated by Bcl-2, Thus, either hyperthermia or inhibition of protein synthesis by CHX potentiate cytotoxic cytokine-induced apoptosis, These pathways show no synergy, but rather redundance, indicating that CHX may function to promote apoptosis in response to cytotoxic cytokines by inhibiting the synthesis of specific proteins whose synthesis, function or degradation is temperature-sensitive.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KLOSTERGAARD J, 1992, CANCER RES, V52, P5271; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; WATANABE N, 1988, CANCER RES, V48, P650; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yount GL, 1998, CANCER RES, V58, P3819	37	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2338	2345		10.1038/sj.onc.1203554	http://dx.doi.org/10.1038/sj.onc.1203554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822385				2023-01-03	WOS:000086974300009
J	Goldman, LE; Eisenberg, MJ				Goldman, LE; Eisenberg, MJ			Identification and management of patients with failed thrombolysis after acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSLUMINAL CORONARY ANGIOPLASTY; TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; ARTERY BYPASS-SURGERY; ST SEGMENT ELEVATION; RESCUE ANGIOPLASTY; RANDOMIZED TRIAL; ELECTROCARDIOGRAPHIC EVIDENCE; REPERFUSION THERAPY; ADJUNCTIVE THERAPY	Clinical outcome after thrombolytic therapy for acute myocardial infarction is closely related to restoration of flow in the infarct-related artery. Because thrombolytic therapy does not achieve coronary artery patency in 15% to 50% of patients, the early identification and treatment of patients with failed thrombolysis may lead to improved clinical outcomes. Unfortunately, the noninvasive identification of patients with failed thrombolysis continues to be problematic. Reduction in chest pain, decrease in ST-segment elevation, and presence of arrhythmias, although suggestive of reperfusion, are not diagnostic. Biochemical markers may hold promise for improved early identification of failed thrombolysis. In the setting of failed thrombolysis, clinical outcome may be improved by "rescue" percutaneous transluminal coronary angioplasty (PTCA) of the infarct-related artery. Several studies suggest that successful rescue PTCA is associated with high technical success rates and improved clinical outcomes. However, these same studies also suggest that patients with failed rescue PTCA may have higher mortality rates than patients who are treated conservatively. On the basis of current data, if failed thrombolysis is suspected, rescue PTCA should be considered, particularly in patients with anterior myocardial infarction and early presentation. Further investigations are needed to study the role of adjunctive methods such as stenting, glycoprotein IIb/IIIa inhibition, and intraaortic balloon counterpulsation in the setting of rescue PTCA. Because of the relative lack of prospective data in this area, additional studies are urgently needed to help improve the ability to identify and manage patients with failed thrombolysis after acute myocardial infarction.	McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada	McGill University	Eisenberg, MJ (corresponding author), McGill Univ, Jewish Gen Hosp, Div Cardiol, 3755 Cote St Catherine Rd,Suite A-118, Montreal, PQ H3T 1E2, Canada.	marke@epid.jgh.mcgill.ca						ABBOTTSMITH CW, 1990, J AM COLL CARDIOL, V16, P770, DOI 10.1016/S0735-1097(10)80320-1; ABE S, 1994, J AM COLL CARDIOL, V23, P1382, DOI 10.1016/0735-1097(94)90381-6; ANDERSON JL, 1993, CIRCULATION, V87, P1829, DOI 10.1161/01.CIR.87.6.1829; [Anonymous], 1985, NEW ENGL J MED, V312, P932; Antoniucci D, 1998, J AM COLL CARDIOL, V31, P1234, DOI 10.1016/S0735-1097(98)00097-7; BELENKIE I, 1992, CAN J CARDIOL, V8, P357; BRENER SJ, 1997, AM J CARDIOL 4, P24; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CALIFF RM, 1988, CIRCULATION, V77, P1090, DOI 10.1161/01.CIR.77.5.1090; CANNON CP, 1995, J INTERV CARDIOL, V8, P117, DOI 10.1111/j.1540-8183.1995.tb00526.x; Davies CH, 1998, LANCET, V351, P1191, DOI 10.1016/S0140-6736(97)11198-9; DEWOOD MA, 1983, CIRCULATION, V68, P8; DOEVENDANS PA, 1995, AM J CARDIOL, V75, P1206, DOI 10.1016/S0002-9149(99)80763-2; Drenth JPH, 1998, BRIT MED J, V317, P147, DOI 10.1136/bmj.317.7151.147; ELLIS AK, 1988, CIRCULATION, V78, P1352, DOI 10.1161/01.CIR.78.6.1352; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; ELLIS SG, 1992, J AM COLL CARDIOL, V19, P681, DOI 10.1016/S0735-1097(10)80292-X; Garot P, 1998, AM J CARDIOL, V82, P554, DOI 10.1016/S0002-9149(98)00409-3; Gibson CM, 1997, AM J CARDIOL, V80, P21, DOI 10.1016/S0002-9149(97)00277-4; Gruberg L, 1998, CARDIOLOGY, V90, P48, DOI 10.1159/000006816; Himbert D, 1998, CATHETER CARDIO DIAG, V44, P371, DOI 10.1002/(SICI)1097-0304(199808)44:4<371::AID-CCD1>3.0.CO;2-1; HOHNLOSER SH, 1991, J AM COLL CARDIOL, V18, P44, DOI 10.1016/S0735-1097(10)80215-3; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; ISHIHARA M, 1991, AM HEART J, V122, P385, DOI 10.1016/0002-8703(91)90990-Y; ISHIHARA M, 1995, AM J CARDIOL, V76, P73, DOI 10.1016/S0002-9149(99)80805-4; Juliard JM, 1999, AM J CARDIOL, V83, P305, DOI 10.1016/S0002-9149(98)00858-3; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KEREIAKES DJ, 1988, J AM COLL CARDIOL, V11, P899, DOI 10.1016/S0735-1097(98)90043-2; LANGER A, 1995, J AM COLL CARDIOL, V25, P1552, DOI 10.1016/0735-1097(95)00110-P; LAPERCHE T, 1995, CIRCULATION, V92, P2079, DOI 10.1161/01.CIR.92.8.2079; LEE KF, 1988, J THORAC CARDIOV SUR, V95, P216; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; LINCOFF AM, 1995, AM J CARDIOL, V75, P871, DOI 10.1016/S0002-9149(99)80678-X; MCKENDALL GR, 1995, AM J CARDIOL, V76, P1108, DOI 10.1016/S0002-9149(99)80315-4; MIYATA M, 1994, J AM COLL CARDIOL, V23, P1009, DOI 10.1016/0735-1097(94)90583-5; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; OHMAN EM, 1991, AM HEART J, V121, P895, DOI 10.1016/0002-8703(91)90205-V; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; PIRWITZ MJ, 1994, CORONARY ARTERY DIS, V5, P385, DOI 10.1097/00019501-199405000-00004; Rodriguez A, 1998, AM J CARDIOL, V81, P1286, DOI 10.1016/S0002-9149(98)00154-4; Rodriguez AE, 1996, AM J CARDIOL, V77, P685, DOI 10.1016/S0002-9149(97)89200-4; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; Ross AM, 1998, J AM COLL CARDIOL, V31, P1511, DOI 10.1016/S0735-1097(98)00141-7; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Saito S., 1997, Journal of the American College of Cardiology, V29, p390A; SARAN RK, 1990, BRIT HEART J, V64, P113; SHECHTER M, 1992, J AM COLL CARDIOL, V20, P1460, DOI 10.1016/0735-1097(92)90437-R; SIMOONS ML, 1988, LANCET, V1, P199; STEG PG, 1994, AM J CARDIOL, V74, P172; Steinhubl SR, 1997, LANCET, V350, P532, DOI 10.1016/S0140-6736(05)63135-2; Stewart JT, 1998, J AM COLL CARDIOL, V31, P1499, DOI 10.1016/S0735-1097(98)00139-9; Stone GW, 1997, J AM COLL CARDIOL, V29, P1459, DOI 10.1016/S0735-1097(97)00088-0; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; Wong CK, 1999, AM J CARDIOL, V83, P164, DOI 10.1016/S0002-9149(98)00818-2	60	21	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					556	565		10.7326/0003-4819-132-7-200004040-00008	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744593				2023-01-03	WOS:000086129300007
J	Murray, BE				Murray, BE			Drug therapy: Vancomycin-resistant enterococcal infections.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GASTROINTESTINAL-TRACT COLONIZATION; RP-59500 QUINUPRISTIN-DALFOPRISTIN; UNIVERSITY MEDICAL-CENTER; BLOOD-STREAM INFECTIONS; FAECIUM SHUNT INFECTION; INTENSIVE-CARE UNIT; IN-VITRO ACTIVITIES; EXPERIMENTAL ENDOCARDITIS; GLYCOPEPTIDE RESISTANCE; ANTIMICROBIAL AGENTS		Univ Texas, Sch Med, Dept Med, Div Infect Dis, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Div Infect Dis, Houston, TX 77030 USA; Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Murray, BE (corresponding author), Univ Texas, Sch Med, Dept Med, Div Infect Dis, 6431 Fannin,JFB 1-728, Houston, TX 77030 USA.	infdis@heart.med.uth.tmc.edu						Aarestrup FM, 1996, ANTIMICROB AGENTS CH, V40, P1938, DOI 10.1128/AAC.40.8.1938; Aeschlimann JR, 1998, ANTIMICROB AGENTS CH, V42, P2710, DOI 10.1128/AAC.42.10.2710; Allerberger F, 1999, J ANTIMICROB CHEMOTH, V43, P211, DOI 10.1093/jac/43.2.211; Anglim AM, 1997, ARCH INTERN MED, V157, P1132, DOI 10.1001/archinte.157.10.1132; [Anonymous], 1995, INFECT CONT HOSP EP, V16, P105; Arthur M, 1997, J BACTERIOL, V179, P97, DOI 10.1128/jb.179.1.97-106.1997; Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; Arthur M, 1996, J INFECTION, V32, P11, DOI 10.1016/S0163-4453(96)80003-X; Aslangul E, 1997, J INFECT DIS, V175, P598, DOI 10.1093/infdis/175.3.598; Beezhold DW, 1997, CLIN INFECT DIS, V24, P704, DOI 10.1093/clind/24.4.704; BINGEN EH, 1991, J CLIN MICROBIOL, V29, P1888, DOI 10.1128/JCM.29.9.1888-1892.1991; Bonten MJM, 1998, ARCH INTERN MED, V158, P1127, DOI 10.1001/archinte.158.10.1127; BOYCE JM, 1995, INFECT CONT HOSP EP, V16, P634; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; Boyce JM, 1996, INFECT CONT HOSP EP, V17, P211; BOYLE JF, 1993, J CLIN MICROBIOL, V31, P1280, DOI 10.1128/JCM.31.5.1280-1285.1993; Bradley SJ, 1999, J ANTIMICROB CHEMOTH, V43, P261, DOI 10.1093/jac/43.2.261; Brandt CM, 1996, J INFECT DIS, V173, P909, DOI 10.1093/infdis/173.4.909; Brennen C, 1998, J AM GERIATR SOC, V46, P157, DOI 10.1111/j.1532-5415.1998.tb02532.x; Brooks S, 1998, INFECT CONT HOSP EP, V19, P333; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; Byers KE, 1998, INFECT CONT HOSP EP, V19, P261; Carias LL, 1998, J BACTERIOL, V180, P4426, DOI 10.1128/JB.180.17.4426-4434.1998; CARON F, 1995, J INFECT DIS, V171, P106, DOI 10.1093/infdis/171.1.106; Caron F, 1997, ANTIMICROB AGENTS CH, V41, P2749, DOI 10.1128/AAC.41.12.2749; CERCENADO E, 1992, ANTIMICROB AGENTS CH, V36, P2201, DOI 10.1128/AAC.36.10.2201; Chia JKS, 1995, CLIN INFECT DIS, V21, P1520, DOI 10.1093/clinids/21.6.1520; CLARK NC, 1993, ANTIMICROB AGENTS CH, V37, P2311, DOI 10.1128/AAC.37.11.2311; COHEN MA, 1995, ANTIMICROB AGENTS CH, V39, P2123, DOI 10.1128/AAC.39.9.2123; COLLINS LA, 1993, ANTIMICROB AGENTS CH, V37, P1364, DOI 10.1128/AAC.37.6.1364; Coque TM, 1996, ANTIMICROB AGENTS CH, V40, P2605, DOI 10.1128/AAC.40.11.2605; Dever LL, 1998, AM J INFECT CONTROL, V26, P40, DOI 10.1016/S0196-6553(98)70060-4; Dever LL, 1996, MICROB DRUG RESIST, V2, P415, DOI 10.1089/mdr.1996.2.415; Dodge RA, 1997, CLIN INFECT DIS, V25, P1269, DOI 10.1086/516977; Edmond MB, 1996, CLIN INFECT DIS, V23, P1234, DOI 10.1093/clinids/23.6.1234; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; ELIOPOULOS GM, 1993, INFECT DIS CLIN N AM, V7, P117; Eliopoulos GM, 1996, ANTIMICROB AGENTS CH, V40, P1745, DOI 10.1128/AAC.40.7.1745; Evans ME, 1996, INFECT CONT HOSP EP, V17, P356; Evers S, 1996, MICROB DRUG RESIST, V2, P219, DOI 10.1089/mdr.1996.2.219; Facklam Richard R., 1995, P308; Fantin B, 1997, ANTIMICROB AGENTS CH, V41, P931, DOI 10.1128/AAC.41.5.931; Fines M, 1999, ANTIMICROB AGENTS CH, V43, P2161, DOI 10.1128/AAC.43.9.2161; Fontana R, 1996, MICROB DRUG RESIST, V2, P209, DOI 10.1089/mdr.1996.2.209; Furlong WB, 1997, CLIN INFECT DIS, V25, P163, DOI 10.1086/516895; GRAYSON ML, 1990, ANTIMICROB AGENTS CH, V34, P1792, DOI 10.1128/AAC.34.9.1792; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HAYDEN MK, 1993, J INFECT DIS, V167, P1224, DOI 10.1093/infdis/167.5.1224; Heaton MP, 1996, GENE, V171, P9, DOI 10.1016/0378-1119(96)00022-4; Henning KJ, 1996, PEDIATR INFECT DIS J, V15, P848, DOI 10.1097/00006454-199610000-00004; HODGES TL, 1992, ANTIMICROB AGENTS CH, V36, P121, DOI 10.1128/AAC.36.1.121; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; *HOSP INF CONTR PR, 1995, INFECT CONT HOSP EP, V16, P498; Howe RA, 1997, J ANTIMICROB CHEMOTH, V40, P144, DOI 10.1093/jac/40.1.144; INGERMAN M, 1987, J INFECT DIS, V155, P1226, DOI 10.1093/infdis/155.6.1226; Iwen PC, 1997, ANTIMICROB AGENTS CH, V41, P494, DOI 10.1128/AAC.41.2.494; Jensen LB, 1998, J CLIN MICROBIOL, V36, P437, DOI 10.1128/JCM.36.2.437-442.1998; JONES RN, 1995, DIAGN MICR INFEC DIS, V21, P85, DOI 10.1016/0732-8893(94)00147-O; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; Kim WJ, 1999, J INFECT DIS, V179, P163, DOI 10.1086/314564; Kirst HA, 1998, ANTIMICROB AGENTS CH, V42, P1303, DOI 10.1128/AAC.42.5.1303; KLARE I, 1995, FEMS MICROBIOL LETT, V125, P165, DOI 10.1111/j.1574-6968.1995.tb07353.x; KLARE I, 1995, FEMS MICROBIOL LETT, V127, P273; KORTEN V, 1994, ANTIMICROB AGENTS CH, V38, P611, DOI 10.1128/AAC.38.3.611; LANDMAN D, 1995, J ANTIMICROB CHEMOTH, V36, P253, DOI 10.1093/jac/36.1.253; LANDRY SL, 1989, AM J INFECT CONTROL, V17, P323, DOI 10.1016/0196-6553(89)90001-1; Lautenbach E, 1998, CLIN INFECT DIS, V27, P1259, DOI 10.1086/515002; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P92, DOI 10.1128/AAC.35.1.92; Leclercq R, 1997, CLIN INFECT DIS, V24, P545, DOI 10.1093/clind/24.4.545; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; Linden PK, 1997, J ANTIMICROB CHEMOTH, V39, P145, DOI 10.1093/jac/39.suppl_1.145; Linden PK, 1996, CLIN INFECT DIS, V22, P663, DOI 10.1093/clinids/22.4.663; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; LOSONSKY GA, 1994, CLIN INFECT DIS, V19, P163, DOI 10.1093/clinids/19.1.163; Lucas GM, 1998, CLIN INFECT DIS, V26, P1127, DOI 10.1086/520311; LYNN WA, 1994, LANCET, V344, P1025, DOI 10.1016/S0140-6736(94)91687-X; MAKI DG, 1988, MEDICINE, V67, P248, DOI 10.1097/00005792-198807000-00005; Mato R, 1996, MICROB DRUG RESIST, V2, P309, DOI 10.1089/mdr.1996.2.309; Mato SP, 1999, PEDIATR INFECT DIS J, V18, P483, DOI 10.1097/00006454-199905000-00023; Matsumura S, 1998, CLIN INFECT DIS, V27, P1554, DOI 10.1086/517755; MCGEER A, 1995, 35 INT C ANT AG CHEM, P283; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; Mekonen ET, 1995, MICROB DRUG RESIST, V1, P249, DOI 10.1089/mdr.1995.1.249; Mevius D, 1998, J ANTIMICROB CHEMOTH, V42, P275, DOI 10.1093/jac/42.2.275; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P251, DOI 10.1093/jac/44.2.251; Montecalvo MA, 1997, CLIN INFECT DIS, V25, P929, DOI 10.1086/597643; MONTECALVO MA, 1995, ANTIMICROB AGENTS CH, V39, P794, DOI 10.1128/AAC.39.3.794; Montecalvo MA, 1996, ARCH INTERN MED, V156, P1458, DOI 10.1001/archinte.156.13.1458; Montecalvo MA, 1995, INFECT CONT HOSP EP, V16, P680; MONTECALVO MA, 1997, 37 INT C ANT AG CHEM, P303; MORENO F, 1995, CLIN INFECT DIS, V21, P1234, DOI 10.1093/clinids/21.5.1234; MORENO F, 1994, DIAGN MICR INFEC DIS, V20, P41, DOI 10.1016/0732-8893(94)90017-5; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MORRISON AJ, 1986, ARCH INTERN MED, V146, P1549, DOI 10.1001/archinte.146.8.1549; MURRAY BE, 1992, ANTIMICROB AGENTS CH, V36, P2355, DOI 10.1128/AAC.36.11.2355; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nachman SA, 1995, MICROB DRUG RESIST, V1, P95, DOI 10.1089/mdr.1995.1.95; *NAT COMM CLIN LAB, 1997, PERF STAND ANT DISK, P1; NAVARRO F, 1994, ANTIMICROB AGENTS CH, V38, P1788, DOI 10.1128/AAC.38.8.1788; Newell KA, 1998, TRANSPLANTATION, V65, P439, DOI 10.1097/00007890-199802150-00027; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NORRIS AH, 1995, CLIN INFECT DIS, V20, P1137, DOI 10.1093/clinids/20.5.1137; NOSKIN GA, 1995, CLIN INFECT DIS, V20, P296, DOI 10.1093/clinids/20.2.296; Noskin GA, 1999, CLIN INFECT DIS, V28, P689, DOI 10.1086/517221; ODONOVAN CA, 1994, DIAGN MICR INFEC DIS, V18, P105, DOI 10.1016/0732-8893(94)90074-4; ORR KE, 1994, LANCET, V344, P65, DOI 10.1016/S0140-6736(94)91092-8; Papanicolaou GA, 1996, CLIN INFECT DIS, V23, P760, DOI 10.1093/clinids/23.4.760; Pegues DA, 1997, J CLIN MICROBIOL, V35, P1565, DOI 10.1128/JCM.35.6.1565-1570.1997; Perichon B, 1997, ANTIMICROB AGENTS CH, V41, P2016, DOI 10.1128/AAC.41.9.2016; PESTEL M, 1995, ANTIMICROB AGENTS CH, V39, P2341, DOI 10.1128/AAC.39.10.2341; Poyart C, 1997, ANTIMICROB AGENTS CH, V41, P24, DOI 10.1128/AAC.41.1.24; Quale J, 1996, CLIN INFECT DIS, V23, P1020, DOI 10.1093/clinids/23.5.1020; QUINTILIANI R, 1994, FEMS MICROBIOL LETT, V119, P359; Quintiliani R, 1996, GENE, V172, P1, DOI 10.1016/0378-1119(96)00110-2; RENDEFOURNIER R, 1993, ANTIMICROB AGENTS CH, V37, P2119, DOI 10.1128/AAC.37.10.2119; Rippere K, 1998, J INFECT DIS, V178, P584, DOI 10.1086/517480; Roghmann MC, 1997, CLIN INFECT DIS, V24, P514, DOI 10.1093/clinids/24.3.514; RUBIN LG, 1992, INFECT CONT HOSP EP, V13, P700; Rybkine T, 1998, J INFECT DIS, V178, P159, DOI 10.1086/515605; SACHER HL, 1991, J CLIN PHARMACOL, V31, P719, DOI 10.1002/j.1552-4604.1991.tb03766.x; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; Satake S, 1997, J CLIN MICROBIOL, V35, P2325, DOI 10.1128/JCM.35.9.2325-2330.1997; Schaberg DR, 1991, AM J MED S3B, V16, P72; Schoonmaker DJ, 1998, J CLIN MICROBIOL, V36, P2105, DOI 10.1128/JCM.36.7.2105-2108.1998; Schwalbe RS, 1999, LANCET, V353, P722, DOI 10.1016/S0140-6736(98)05441-5; SHAY DK, 1995, PEDIATR CLIN N AM, V42, P703; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; Taylor SE, 1998, EUR J CLIN MICROBIOL, V17, P798, DOI 10.1007/s100960050190; Tornieporth NG, 1996, CLIN INFECT DIS, V23, P767, DOI 10.1093/clinids/23.4.767; Tripodi MF, 1998, EUR J CLIN MICROBIOL, V17, P734, DOI 10.1007/s100960050171; Tsai SF, 1998, ANTIMICROB AGENTS CH, V42, P1229, DOI 10.1128/AAC.42.5.1229; Tush GM, 1998, CLIN INFECT DIS, V26, P1460, DOI 10.1086/517663; UTTLEY AHC, 1988, LANCET, V1, P57; vandenBogaard AE, 1997, NEW ENGL J MED, V337, P1558, DOI 10.1056/NEJM199711203372117; VanderAuwera P, 1996, J INFECT DIS, V173, P1129, DOI 10.1093/infdis/173.5.1129; Wade JJ, 1995, MICROB DRUG RESIST, V1, P241, DOI 10.1089/mdr.1995.1.241; Weinstein JT, 1996, INFECT CONT HOSP EP, V17, P36; Weinstein MR, 1999, CLIN INFECT DIS, V29, P361, DOI 10.1086/520216; WELLS CL, 1995, CLIN INFECT DIS, V21, P45, DOI 10.1093/clinids/21.1.45; WHITMAN MS, 1993, ANTIMICROB AGENTS CH, V37, P2069, DOI 10.1128/AAC.37.10.2069; Whitman MS, 1996, ANTIMICROB AGENTS CH, V40, P1526, DOI 10.1128/AAC.40.6.1526; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259; Woodford N, 1998, ANTIMICROB AGENTS CH, V42, P502, DOI 10.1128/AAC.42.3.502; Zaman MM, 1996, J ANTIMICROB CHEMOTH, V37, P127, DOI 10.1093/jac/37.1.127; Zhanel GG, 1998, DIAGN MICR INFEC DIS, V31, P343, DOI 10.1016/S0732-8893(98)00019-4	149	615	647	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	2000	342	10					710	721		10.1056/NEJM200003093421007	http://dx.doi.org/10.1056/NEJM200003093421007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290ZW	10706902				2023-01-03	WOS:000085708800007
J	Henney, JE				Henney, JE			Alternative supply of penicillin G	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2023-01-03	WOS:000084956500005
J	Deyle, GD; Henderson, NE; Matekel, RL; Ryder, MG; Garber, MB; Allison, SC				Deyle, GD; Henderson, NE; Matekel, RL; Ryder, MG; Garber, MB; Allison, SC			Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							OSTEO-ARTHRITIS; PROGRAM; CAPACITY; MUSCLE; REHABILITATION; FLEXIBILITY; CRITERIA; PATIENT; WOMAC; HIP	Background: Few investigations include both subjective and objective measurements of the effectiveness of treatments for osteoarthritis of the knee. Beneficial interventions may decrease the disability associated with osteoarthritis and the need for more invasive treatments. Objective: To evaluate the effectiveness of physical therapy for osteoarthritis of the knee, applied by experienced physical therapists with formal training in manual therapy. Design: Randomized, controlled clinical trial. Setting: Outpatient physical therapy department of a large military medical center. Patients: 83 patients with osteoarthritis of the knee who were randomly assigned to receive treatment (n = 42; 15 men and 27 women [mean age, 60 +/- 11 years]) or placebo (n = 41; 19 men and 22 women [mean age, 62 +/- 10 years]). Intervention: The treatment group received manual therapy, applied to the knee as well as to the lumbar spine, hip, and ankle as required, and performed a standardized knee exercise program in the clinic and at home. The placebo group had subtherapeutic ultrasound to the knee at an intensity of 0.1 W/cm(2) with a 10% pulsed mode. Both groups were treated at the clinic twice weekly for 4 weeks. Measurements: Distance walked in 6 minutes and sum of the function, pain, and stiffness subscores of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). A tester who was blinded to group assignment made group comparisons at the initial visit (before initiation of treatment), 4 weeks, 8 weeks, and 1 year. Results: Clinically and statistically significant improvements in 6-minute walk distance and WOMAC score at 4 weeks and 8 weeks were seen in the treatment group but not the placebo group. By 8 weeks, average 6-minute walk distances had improved by 13.1% and WOMAC scores had improved by 55.8% over baseline values in the treatment group (P < 0.05). After controlling for potential confounding variables, the average distance walked in 6 minutes at 8 weeks among patients in the treatment group was 170 m (95% CI, 71 to 270 m) more than that in the placebo group and the average WOMAC scores were 599 mm higher (95% CI, 197 to 1002 mm). At 1 year, patients in the treatment group had clinically and statistically significant gains over baseline WOMAC scores and walking distance; 20% of patients in the placebo group and 5% of patients in the treatment group had undergone knee arthroplasty. Conclusions: A combination of manual physical therapy and supervised exercise yields functional benefits for patients with osteoarthritis of the knee and may delay or prevent the need for surgical intervention.	Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; Baylor Univ, USA, Ft Sam Houston, TX 78234 USA; Madigan Army Med Ctr, Tacoma, WA 98431 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; Baylor University; Madigan Army Medical Center	Deyle, GD (corresponding author), Brooke Army Med Ctr, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	gail.deyle@amedd.army.mil						ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ALTMAN RD, 1991, J RHEUMATOL, V18, P10; ALTMAN RD, 1987, J RHEUMATOL, V14, P3; BANDY WD, 1994, PHYS THER, V74, P845, DOI 10.1093/ptj/74.9.845; BANG MD, 2000, IN PRESS J ORTHOP SP; BARR S, 1994, J RHEUMATOL, V21, P2106; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bellamy N, 1995, WOMAC OSTEOARTHRITIS; DALY MP, 1993, CLIN GERIATR MED, V9, P783, DOI 10.1016/S0749-0690(18)30377-X; DINUBILE NA, 1991, CLIN SPORT MED, V10, P33; ETTINGER WH, 1994, MED SCI SPORT EXER, V26, P1435; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; EVJENTH O, 1988, MUSCLE STRETCHING MA, V1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, AM J PHYS MED REHAB, V73, P413, DOI 10.1097/00002060-199411000-00006; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P1319, DOI 10.1016/0003-9993(93)90087-Q; FISHER NM, 1994, ARCH PHYS MED REHAB, V75, P792; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; Greenman P., 1996, PRINCIPLES MANUAL ME; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HICKS JE, 1989, J MUSCULOSKEL MED, V6, P40; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LANE NE, 1993, RHEUM DIS CLIN N AM, V19, P617; Maitland G., 1991, PERIPHERAL MANIPULAT; MAITLAND GD, 1985, VERTEBRAL MANIPULATI; Mangione KK, 1996, PHYS THER, V76, P387; MCNEIL JM, 1994, JAMA-J AM MED ASSOC, V272, P1735; NESHER G, 1994, CLIN GERIATR MED, V10, P659, DOI 10.1016/S0749-0690(18)30322-7; PANUSH RS, 1994, BAILLIERE CLIN RHEUM, V8, P79, DOI 10.1016/S0950-3579(05)80226-2; PANUSH RS, 1994, SOUTH MED J, V87, pS74; PINALS RS, 1992, CLIN THER, V14, P336; PRENTICE WE, 1992, J SPORT REHABIL, V1, P249; PUETT DW, 1994, ANN INTERN MED, V121, P133, DOI 10.7326/0003-4819-121-2-199407150-00010; TICHENOR CI, 1998, ORTHOPAEDIC MANUAL P; WALLIN D, 1985, AM J SPORT MED, V13, P263, DOI 10.1177/036354658501300409; YTTERBERG SR, 1994, BAILLIERE CLIN RHEUM, V8, P161, DOI 10.1016/S0950-3579(05)80230-4; Zachazewski J. E., 1996, ATHLETIC INJURIES RE	40	439	451	1	75	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					173	181		10.7326/0003-4819-132-3-200002010-00002	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276XE	10651597				2023-01-03	WOS:000084903000001
J	Carter, AJ				Carter, AJ			Dwale: an anaesthetic from old England	BRITISH MEDICAL JOURNAL			English	Article									N Staffordshire Hosp, Dept Anaesthet, Stoke On Trent ST4 6QG, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Carter, AJ (corresponding author), N Staffordshire Hosp, Dept Anaesthet, Stoke On Trent ST4 6QG, Staffs, England.							BOWMAN WC, 1963, J PHARM PHARMACOL, V15, pI25; CAMERON ML, 1993, ANGLOSAXON MED, P12; Carter AJ, 1996, BRIT MED J, V313, P1630, DOI 10.1136/bmj.313.7072.1630; CONNOR RD, 1987, WEIGHTS MEASURES ENG, P125; DREISBACH RH, 1987, HDB POISONING, P499; DRUMMER OH, 1995, MED J AUSTRALIA, V162, P592, DOI 10.5694/j.1326-5377.1995.tb138553.x; ELLIS ES, 1946, ANCIENT ANODYNES, P82; GRIEVE M, 1931, MODERN HERBAL, V2, P476; HUSON P, 1970, MASTERING WITCHCRAFT, P146; KEYS TE, 1945, HIST SURG ANAESTHESI, P104; MANN J, 1992, MURDER MAGIC MED, P76; MURRAY JAH, 1897, NEW ENGLISH DICT, P488; RAWCLIFFE C, 1997, MED SOC LATER MEDIEV, P184; VICARY R, 1995, DIST PLANT LORE, P393; VOIGTS LE, 1992, HEALTH, DISEASE AND HEALING IN MEDIEVAL CULTURE, P34; 1981, READERS DIGEST, P157	16	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1623	1626		10.1136/bmj.319.7225.1623	http://dx.doi.org/10.1136/bmj.319.7225.1623			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600971	Green Published			2023-01-03	WOS:000084562600023
J	Haynes, RB				Haynes, RB			Commentary: A warning to complementary medicine practitioners: get empirical or else	BRITISH MEDICAL JOURNAL			English	Editorial Material									McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Haynes, RB (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada.			Haynes, Robert Brian/0000-0002-1453-3196				HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802	2	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1632	1632						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10660326				2023-01-03	WOS:000084562600026
J	Kraft, GH				Kraft, GH			Rehabilitation still the only way to improve function in multiple sclerosis	LANCET			English	Editorial Material							COGNITIVE DYSFUNCTION; IMPACT		Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kraft, GH (corresponding author), Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA.							Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; Heide AC, 1998, AM J NEURORADIOL, V19, P1047; Kraft G H, 1998, J Spinal Cord Med, V21, P117; KRAFT GH, 1996, VETERANS AFFAIRS REH, V33, P329; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Rumrill Jr P. D., 1996, EMPLOYMENT ISSUES MU; Schwartz L, 1999, AM J PHYS MED REHAB, V78, P525, DOI 10.1097/00002060-199911000-00006; Solari A, 1999, NEUROLOGY, V52, P57, DOI 10.1212/WNL.52.1.57; Stolz W, 1994, CHRONIC DIS DISABILI, P3; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502	15	61	61	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2016	2017		10.1016/S0140-6736(99)90035-1	http://dx.doi.org/10.1016/S0140-6736(99)90035-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636362				2023-01-03	WOS:000084183300005
J	Henney, JE				Henney, JE			Review of generic bioequivalence studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2023-01-03	WOS:000083908700005
J	Brodison, A; Chauhan, A				Brodison, A; Chauhan, A			Spinal-cord stimulation in management of angina	LANCET			English	Editorial Material							ELECTRICAL-STIMULATION; PAIN RELIEF; PECTORIS; ABSTRACTS		Victoria Hosp, Dept Cardiol, Blackpool FY3 8N, England		Chauhan, A (corresponding author), Victoria Hosp, Dept Cardiol, Blackpool FY3 8N, England.							ANDERSON C, 1994, BRIT HEART J, V71, P419; DEJONGSTE MJL, 1994, BRIT HEART J, V71, P413; DEJONGSTE MJL, 1994, J AM COLL CARDIOL, V23, P1592, DOI 10.1016/0735-1097(94)90661-0; Hautvast RWM, 1996, AM J CARDIOL, V77, P462, DOI 10.1016/S0002-9149(97)89338-1; Mannheimer C, 1998, CIRCULATION, V97, P1157, DOI 10.1161/01.CIR.97.12.1157; MANNHEIMER C, 1988, BRIT HEART J, V59, P56; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MURPHY DF, 1987, PAIN, V28, P365, DOI 10.1016/0304-3959(87)90070-4; Murray S, 1999, HEART, V82, P89, DOI 10.1136/hrt.82.1.89; TenVaarwerk IAM, 1999, HEART, V82, P82, DOI 10.1136/hrt.82.1.82	10	11	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1748	1749		10.1016/S0140-6736(99)00296-2	http://dx.doi.org/10.1016/S0140-6736(99)00296-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577633				2023-01-03	WOS:000083853000006
J	Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G				Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G			Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis	ANNALS OF INTERNAL MEDICINE			English	Article							SYDNEY SYSTEM; INFECTION; CLASSIFICATION; FERRITIN	Background: Iron deficiency anemia is the most common form of anemia worldwide. Recent studies have suggested an association between Helicobacter pylori infection and iron deficiency. Objective: To investigate the effects of eradicating H. pylori with combination antibiotic therapy on iron deficiency anemia in patients with H. pylori-associated gastritis. Design: Case series. Setting: University hospital. Patients: 30 patients with a long history of iron deficiency anemia in whom H. pylori-associated gastritis was the only pathologic gastrointestinal finding detected. Intervention: Eradication therapy with two antibiotics and discontinuation of iron replacement therapy. Measurements: Complete blood count ferritin levels, and gastroscopy with biopsy to evaluate H. pylori status. Results: At 6 months, 75% of patients had recovered from anemia (P < 0.001), ferritin values increased from 5.7 +/- 0.7 mu g/L to 24.5 +/- 5.2 mu g/L (95% CI, 8.85 to 29.97). After 12 months, 91.7% of patients had recovered from anemia. Conclusions: Cure of H, pylori infection is associated with reversal of iron dependence and recovery from iron deficiency anemia.	Univ Roma La Sapienza, Rome, Italy	Sapienza University Rome	Annibale, B (corresponding author), Univ Rome, Policlin Umberto I, Dept Clin Med 2, I-00161 Rome, Italy.		Annibale, Bruno/A-5372-2008	Annibale, Bruno/0000-0001-9120-5957; Marignani, Massimo/0000-0002-8912-9972				BAIRD IM, 1959, Q J MED, V28, P21; BANERJEE S, 1994, GUT, V35, P317, DOI 10.1136/gut.35.3.317; BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; Carnicer J, 1997, J PEDIATR GASTR NUTR, V25, P441, DOI 10.1097/00005176-199710000-00017; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOIG P, 1993, J BACTERIOL, V175, P557, DOI 10.1128/JB.175.2.557-560.1993; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUFOUR C, 1993, J PEDIATR GASTR NUTR, V17, P225, DOI 10.1097/00005176-199308000-00018; HALLEBERG L, 1993, DAVIDSON PASSMORE HU, P174; HUSSON MO, 1993, INFECT IMMUN, V61, P2694, DOI 10.1128/IAI.61.6.2694-2697.1993; LAINE L, 1998, SLEISENGER FORDTRANS, P198; Marignani M, 1996, CURR THER RES CLIN E, V57, P544, DOI 10.1016/S0011-393X(96)80064-6; Marignani M, 1999, AM J GASTROENTEROL, V94, P766; Marignani M, 1997, SCAND J GASTROENTERO, V32, P617, DOI 10.3109/00365529709025109; Meining A, 1997, VIRCHOWS ARCH, V431, P11, DOI 10.1007/s004280050063; Milman N, 1998, GASTROENTEROLOGY, V115, P268, DOI 10.1016/S0016-5085(98)70192-1; Peach HG, 1998, MED J AUSTRALIA, V169, P188, DOI 10.5694/j.1326-5377.1998.tb140218.x; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; ZAITOUN AM, 1994, J CLIN PATHOL, V47, P810, DOI 10.1136/jcp.47.9.810; Zhang ZW, 1998, GUT, V43, P322, DOI 10.1136/gut.43.3.322	20	172	178	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					668	672		10.7326/0003-4819-131-9-199911020-00006	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577329				2023-01-03	WOS:000083446200005
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Acupuncture	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									FILSHIE J, 1997, MED ACUPUNCTURE; KAPTCHUK T, 1983, CHINESE MED WEB HAS; Maciocia G., 1989, FDN CHINESE MED	3	89	92	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					973	976		10.1136/bmj.319.7215.973	http://dx.doi.org/10.1136/bmj.319.7215.973			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10514163	Green Published			2023-01-03	WOS:000083111700030
J	van Weel, C; van Grunsven, P				van Weel, C; van Grunsven, P			Resistance to prescribing and to antibiotics	LANCET			English	Editorial Material							DOXYCYCLINE; TRIAL		Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Graham A, 1999, BRIT MED J, V319, P173, DOI 10.1136/bmj.319.7203.173; HAYNES RB, COMPLIANCE HLTH CARE; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Spach DH, 1998, ANN ALLERG ASTHMA IM, V81, P293, DOI 10.1016/S1081-1206(10)63121-3; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; ZWART S, 1999, THESIS U UTRECHT UTR; 1990, LANCET, V335, P262	9	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1052	1052		10.1016/S0140-6736(99)90107-1	http://dx.doi.org/10.1016/S0140-6736(99)90107-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509494				2023-01-03	WOS:000082777500008
J	Hanly, PJ; Pierratos, A				Hanly, PJ; Pierratos, A			Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; TRANSPLANTATION; EXPERIENCE; KIDNEY	Background: Sleep apnea is common in patients with chronic renal failure and is not improved by either conventional hemodialysis or peritoneal dialysis. With nocturnal hemodialysis, patients undergo hemodialysis seven nights per week at home, while sleeping. We hypothesized that nocturnal hemodialysis would correct sleep apnea in patients with chronic renal failure because of its greater effectiveness. Methods: Fourteen patients who were undergoing conventional hemodialysis for four hours on each of three days per week underwent overnight polysomnography. The patients were then switched to nocturnal hemodialysis for eight hours during each of six or seven nights a week. They underwent polysomnography again 6 to 15 months later on one night when they were undergoing nocturnal hemodialysis and on another night when they were not. Results: The mean (+/-SD) serum creatinine concentration was significantly lower during the period when the patients were undergoing nocturnal hemodialysis than during the period when they were undergoing conventional hemodialysis (3.9+/-1.1 vs. 12.8+/-3.2 mg per deciliter [342+/-101 vs. 1131+/-287 micromol per liter], P<0.001). The conversion from conventional hemodialysis to nocturnal hemodialysis was associated with a reduction in the frequency of apnea and hypopnea from 25+/-25 to 8+/-8 episodes per hour of sleep (P=0.03). This reduction occurred predominantly in seven patients with sleep apnea, in whom the frequency of episodes fell from 46+/-19 to 9+/-9 per hour (P=0.006), accompanied by increases in the minimal oxygen saturation (from 89.2+/-1.8 to 94.1+/-1.6 percent, P=0.005), transcutaneous partial pressure of carbon dioxide (from 38.5+/-4.3 to 48.3+/-4.9 mm Hg, P=0.006), and serum bicarbonate concentration (from 23.2+/-1.8 to 27.8+/-0.8 mmol per liter, P<0.001). During the period when these seven patients were undergoing nocturnal hemodialysis, the apnea-hypopnea index measured on nights when they were not undergoing nocturnal hemodialysis was greater than that on nights when they were undergoing nocturnal hemodialysis, but it still remained lower than it had been during the period when they were undergoing conventional hemodialysis (P=0.05). Conclusions: Nocturnal hemodialysis corrects sleep apnea associated with chronic renal failure. (N Engl J Med 2001;344:102-7.) Copyright (C) 2001 Massachusetts Medical Society.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Humber River Reg Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Pierratos, A (corresponding author), St Michaels Hosp, Dept Med, Rm 3049,Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.		Pierratos, Andreas/AAZ-1834-2020	Pierratos, Andreas/0000-0003-2810-0698				*AM SLEEP DIS ASS, 1990, DIAGN CLASS COMM INT, P65; Auckley DH, 1999, AM J KIDNEY DIS, V34, P739, DOI 10.1016/S0272-6386(99)70401-4; Brissenden J. E., 1998, Journal of the American Society of Nephrology, V9, p168A; FLETCHER EC, 1993, J AM SOC NEPHROL, V4, P1111; HAMILTON RW, 1976, J APPL PHYSIOL, V41, P216, DOI 10.1152/jappl.1976.41.2.216; HUDGEL DW, 1987, AM REV RESPIR DIS, V135, P899, DOI 10.1164/arrd.1987.135.4.899; KIMMEL PL, 1989, J NEPHROL, V1, P59; Kraus MA, 1997, ADV PERIT D, V13, P88; LANGEVIN B, 1993, CHEST, V103, P1330, DOI 10.1378/chest.103.5.1330; MENDELSON WB, 1990, CLIN NEPHROL, V33, P247; MILLMAN RP, 1985, NEPHRON, V40, P407, DOI 10.1159/000183509; Mucsi I, 1998, KIDNEY INT, V53, P1399, DOI 10.1046/j.1523-1755.1998.00875.x; O'Sullivan DA, 1998, MAYO CLIN PROC, V73, P1035, DOI 10.4065/73.11.1035; ONAL E, 1986, J APPL PHYSIOL, V61, P1438, DOI 10.1152/jappl.1986.61.4.1438; Onal E., 1993, KIDNEY, V2, P309; Pierratos A, 1999, NEPHROL DIAL TRANSPL, V14, P2835, DOI 10.1093/ndt/14.12.2835; Pierratos A, 1998, J AM SOC NEPHROL, V9, P859; Raj DSC, 2000, NEPHROL DIAL TRANSPL, V15, P58, DOI 10.1093/ndt/15.1.58; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; SOREIDE E, 1991, KIDNEY INT, V40, P539, DOI 10.1038/ki.1991.243; STEPANSKI E, 1995, J AM SOC NEPHROL, V6, P192; Wilcox I, 1998, EUR RESPIR J, V11, P7, DOI 10.1183/09031936.98.11010007	22	387	395	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					102	107		10.1056/NEJM200101113440204	http://dx.doi.org/10.1056/NEJM200101113440204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150360	Bronze			2023-01-03	WOS:000166281100004
J	Iwu, MM; Gbodossou, E				Iwu, MM; Gbodossou, E			The role of traditional medicine	LANCET			English	Article									PROMETRA, Dakar, Senegal; BDPC Int Off, Silver Spring, MD 20902 USA		Iwu, MM (corresponding author), BDPC Int Off, 11303 Amherst Ave 2, Silver Spring, MD 20902 USA.								0	10	10	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC	2000	356			S			S3	S3		10.1016/S0140-6736(00)91989-5	http://dx.doi.org/10.1016/S0140-6736(00)91989-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386RG	11191486	Bronze			2023-01-03	WOS:000166074900005
J	Morice, AH				Morice, AH			Helium/oxygen and severe COPD	LANCET			English	Editorial Material							PRESSURE		Castle Hill Hosp, Acad Dept Med, Cottingham HU16 5JQ, East Yorkshire, England	University of Hull	Morice, AH (corresponding author), Castle Hill Hosp, Acad Dept Med, Cottingham HU16 5JQ, East Yorkshire, England.							PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; SASSOON CSH, 1991, AM REV RESPIR DIS, V143, P469, DOI 10.1164/ajrccm/143.3.469; Tassaux D, 2000, CRIT CARE MED, V28, P2721, DOI 10.1097/00003246-200008000-00006	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2000	356	9244					1785	1786		10.1016/S0140-6736(00)03226-8	http://dx.doi.org/10.1016/S0140-6736(00)03226-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377UY	11117906				2023-01-03	WOS:000165545700005
J	Chen, DX; Endres, RL; Erickson, CA; Weis, KF; McGregor, MW; Kawaoka, Y; Payne, LG				Chen, DX; Endres, RL; Erickson, CA; Weis, KF; McGregor, MW; Kawaoka, Y; Payne, LG			Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice	NATURE MEDICINE			English	Article							TRANSCUTANEOUS IMMUNIZATION; CHOLERA-TOXIN; MURINE MODEL; VIRUS; INFECTION; CELLS; CHALLENGE; EFFICACY; IMMUNITY; MUCOSAL		PowderJect Vaccines, Madison, WI 53719 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chen, DX (corresponding author), PowderJect Vaccines, 585 Sci Dr, Madison, WI 53719 USA.							Becker Y, 1996, Adv Exp Med Biol, V397, P97; BERNARD KW, 1987, JAMA-J AM MED ASSOC, V257, P1059, DOI 10.1001/jama.257.8.1059; BOS JD, 1997, SKIN IMMUNE SYSTEM S, P9; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; Chen DX, 1996, INFECT IMMUN, V64, P1900, DOI 10.1128/IAI.64.6.1900-1905.1996; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; FADDA G, 1987, EUR J EPIDEMIOL, V3, P176; FENNER F, 1982, REV INFECT DIS, V4, P916; Flohe SB, 1998, EUR J IMMUNOL, V28, P3800, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3800::AID-IMMU3800&gt;3.0.CO;2-0; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Glenn GM, 1999, INFECT IMMUN, V67, P1100, DOI 10.1128/IAI.67.3.1100-1106.1999; Glenn GM, 1998, J IMMUNOL, V161, P3211; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y; Paul A, 1998, VACCINE, V16, P188, DOI 10.1016/S0264-410X(97)00185-0; Rimmelzwaan GF, 1999, VACCINE, V17, P2512, DOI 10.1016/S0264-410X(99)00063-8; Saelens X, 1999, EUR J BIOCHEM, V260, P166, DOI 10.1046/j.1432-1327.1999.00150.x; Sarphie DF, 1997, J CONTROL RELEASE, V47, P61, DOI 10.1016/S0168-3659(96)01616-1; SARPHIE DF, 1995, DIABETES, V44, P129; SHEERAR MG, 1989, J GEN VIROL, V70, P3297, DOI 10.1099/0022-1317-70-12-3297; Swain W E, 2000, Dev Biol (Basel), V104, P115; Teunissen M. B., 1997, SKIN IMMUNE SYSTEM S, P59; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515; WRAITH DC, 1987, J GEN VIROL, V68, P433, DOI 10.1099/0022-1317-68-2-433	26	95	104	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2000	6	10					1187	1190		10.1038/80538	http://dx.doi.org/10.1038/80538			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017153				2023-01-03	WOS:000089674700046
J	Strachan, DP; Moran, SE; McInneny, K; Smalls, M				Strachan, DP; Moran, SE; McInneny, K; Smalls, M			Reduced risk of hospital admission for childhood asthma among Scottish twins: record linkage study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	A recent study of Swedish army conscripts found a reduced prevalence of asthma and allergic rhinitis among twins.' We analysed routine data on hospital admissions in Scotland to compare risks of asthma and other respiratory complaints among twins and singletons.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland	St Georges University London; NHS National Services Scotland	Strachan, DP (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Braback L, 1998, CLIN EXP ALLERGY, V28, P936; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235	5	18	19	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					732	733		10.1136/bmj.321.7263.732	http://dx.doi.org/10.1136/bmj.321.7263.732			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999904	Green Published, Bronze			2023-01-03	WOS:000089546600021
J	Adrogue, HJ; Madias, NE				Adrogue, HJ; Madias, NE			Primary care: Hyponatremia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CENTRAL PONTINE MYELINOLYSIS; SEVERE SYMPTOMATIC HYPONATREMIA; ANTI-DIURETIC HORMONE; RAPID CORRECTION; INAPPROPRIATE SECRETION; MAGNETIC-RESONANCE; NEUROLOGIC COMPLICATIONS; ORGANIC OSMOLYTES; MANAGEMENT; VASOPRESSIN		Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Renal Sect, Houston, TX USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Tufts University; Tufts Medical Center	Madias, NE (corresponding author), Tufts Univ New England Med Ctr, Div Nephrol, Box 172,750 Washington St, Boston, MA 02111 USA.	nmadias@infonet.tufts.edu						ADELMAN RD, 1996, NELSON TXB PEDIAT, P189; Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; AGARWAL R, 1994, AM J KIDNEY DIS, V24, P108, DOI 10.1016/S0272-6386(12)80169-7; ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ANDROGUE HJ, 1994, SALT WATER, P205; ARIEFF AI, 1976, KIDNEY INT, V10, P104, DOI 10.1038/ki.1976.82; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; BERL T, 1990, KIDNEY INT, V37, P1006, DOI 10.1038/ki.1990.78; BRUNNER JE, 1990, ANN NEUROL, V27, P61, DOI 10.1002/ana.410270110; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; CHENG JC, 1990, AM J MED, V88, P561, DOI 10.1016/0002-9343(90)90518-I; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; DEWITT LD, 1984, NEUROLOGY, V34, P570, DOI 10.1212/WNL.34.5.570; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; FICHMAN MP, 1971, ANN INTERN MED, V75, P853, DOI 10.7326/0003-4819-75-6-853; Fraser CL, 1997, AM J MED, V102, P67, DOI 10.1016/S0002-9343(96)00274-4; FRIZZELL RT, 1986, JAMA-J AM MED ASSOC, V255, P772, DOI 10.1001/jama.255.6.772; Gennari F.J., 1998, OXFORD TXB CLIN NEPH, V1, P175; GENNARI FJ, 1984, NEW ENGL J MED, V310, P102, DOI 10.1056/NEJM198401123100207; GENNARI FJ, 1974, NEW ENGL J MED, V291, P714, DOI 10.1056/NEJM197410032911408; GOLDMAN MB, 1988, NEW ENGL J MED, V318, P397, DOI 10.1056/NEJM198802183180702; GONZALES R, 1994, AM J KIDNEY DIS, V23, P735, DOI 10.1016/S0272-6386(12)70286-X; Gross P, 1998, KIDNEY INT, pS6; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; KARP BI, 1993, MEDICINE, V72, P359, DOI 10.1097/00005792-199311000-00001; KLEINSCHMIDTDEMASTERS BK, 1981, SCIENCE, V211, P1068, DOI 10.1126/science.7466381; KRAMER DS, 1983, AM J MED, V75, P712, DOI 10.1016/0002-9343(83)90462-X; KUMAR S, 1999, DISORDERS WATER EL 1, V1; LARAGH JH, 1954, J CLIN INVEST, V33, P807, DOI 10.1172/JCI102952; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; Lauriat SM, 1997, J AM SOC NEPHROL, V8, P1599; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; MAAS AHJ, 1985, CLIN CHEM, V31, P482; OH MS, 1995, NEPHRON, V70, P143, DOI 10.1159/000188576; OH MS, 1989, AM J MED SCI, V298, P41, DOI 10.1097/00000441-198907000-00008; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; ROSE BD, 1994, CLIN PHYSL ACID BASE, P651; Saito T, 1997, J CLIN ENDOCR METAB, V82, P1054, DOI 10.1210/jc.82.4.1054; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; SONNENBLICK M, 1993, CHEST, V103, P601, DOI 10.1378/chest.103.2.601; Soupart A, 1996, CLIN NEPHROL, V46, P149; Sterns R, 1996, FLUIDS ELECTROLYTES, P63; STERNS RH, 1987, ANN INTERN MED, V107, P656, DOI 10.7326/0003-4819-107-5-656; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; STERNS RH, 1990, AM J MED, V88, P557, DOI 10.1016/0002-9343(90)90517-H; STERNS RH, 1994, J AM SOC NEPHROL, V4, P1522; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; STERNS RH, 1991, CONT MANAGEMENT CRIT, V1, P161; TANNEAU RS, 1994, J CLIN PSYCHIAT, V55, P349; Verbalis J G, 1993, Curr Opin Nephrol Hypertens, V2, P636, DOI 10.1097/00041552-199307000-00015; VERBALIS JG, 1991, BRAIN RES, V567, P274, DOI 10.1016/0006-8993(91)90806-7; Verbalis JG, 1998, PRIMER KIDNEY DIS, p57 ~63; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168	60	1082	1131	0	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	2000	342	21					1581	1589		10.1056/NEJM200005253422107	http://dx.doi.org/10.1056/NEJM200005253422107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316XJ	10824078				2023-01-03	WOS:000087193100007
J	Schatzkin, A; Lanza, E; Corle, D; Lance, P; Iber, F; Caan, B; Shike, M; Weissfeld, J; Burt, R; Cooper, MR; Kikendall, JW; Cahill, J; Freedman, L; Marshall, J; Schoen, RE; Slattery, M				Schatzkin, A; Lanza, E; Corle, D; Lance, P; Iber, F; Caan, B; Shike, M; Weissfeld, J; Burt, R; Cooper, MR; Kikendall, JW; Cahill, J; Freedman, L; Marshall, J; Schoen, RE; Slattery, M		Polyp Prevention Trial Study Grp	Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; COLON-CANCER; ANTIOXIDANT VITAMINS; CLINICAL-TRIAL; NURSES HEALTH; LARGE-BOWEL; PREVENTION; RISK; WOMEN; EPIDEMIOLOGY	Background: We tested the hypothesis that dietary intervention can inhibit the development of recurrent colorectal adenomas, which are precursors of most large-bowel cancers. Methods: We randomly assigned 2079 men and women who were 35 years of age or older and who had had one or more histologically confirmed colorectal adenomas removed within six months before randomization to one of two groups: an intervention group given intensive counseling and assigned to follow a diet that was low in fat (20 percent of total calories) and high in fiber (18 g of dietary fiber per 1000 kcal) and fruits and vegetables (3.5 servings per 1000 kcal), and a control group given a standard brochure on healthy eating and assigned to follow their usual diet. Subjects entered the study after undergoing complete colonoscopy and removal of adenomatous polyps; they remained in the study for approximately four years, undergoing colonoscopy one and four years after randomization. Results: A total of 1905 of the randomized subjects (91.6 percent) completed the study. Of the 958 subjects in the intervention group and the 947 in the control group who completed the study, 39.7 percent and 39.5 percent, respectively, had at least one recurrent adenoma; the unadjusted risk ratio was 1.00 (95 percent confidence interval, 0.90 to 1.12). Among subjects with recurrent adenomas, the mean (+/-SE) number of such lesions was 1.85+/-0.08 in the intervention group and 1.84+/-0.07 in the control group. The rate of recurrence of large adenomas (with a maximal diameter of at least 1 cm) and advanced adenomas (defined as lesions that had a maximal diameter of at least 1 cm or at least 25 percent villous elements or evidence of high-grade dysplasia, including carcinoma) did not differ significantly between the two groups. Conclusions: Adopting a diet that is low in fat and high in fiber, fruits, and vegetables does not influence the risk of recurrence of colorectal adenomas. (N Engl J Med 2000;342:1149-55.) (C) 2000, Massachusetts Medical Society.	NCI, Bethesda, MD 20892 USA; SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA; Vet Affairs Edward Hines Jr Hosp, Vet Affairs Med Ctr, Hines, IL USA; Kaiser Fdn Res Inst, Oakland, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Utah, Salt Lake City, UT USA; Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; WESTAT Corp, Rockville, MD 20850 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Arizona, Tucson, AZ USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; Wake Forest University; Wake Forest Baptist Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Westat; Memorial Sloan Kettering Cancer Center; University of Arizona	Schatzkin, A (corresponding author), NCI, Bethesda, MD 20892 USA.			Caan, Bette/0000-0002-5803-310X				Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; Friedman LM., 1981, FUNDAMENTALS CLIN TR; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; Ji BT, 1998, CANCER EPIDEM BIOMAR, V7, P661; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; Kleinbaum DG., 1982, EPIDEMIOLOGIC RES PR; Kritchevsky David, 1999, American Journal of Medicine, V106, p28S, DOI 10.1016/S0002-9343(98)00344-1; Lanza E, 1996, CANCER EPIDEM BIOMAR, V5, P584; Little R. J. A., 1987, STAT ANAL MISSING DA; Liu SM, 1999, AM J CLIN NUTR, V70, P412; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; MARESPERLMAN JA, 1993, J NUTR, V123, P489, DOI 10.1093/jn/123.3.489; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCKEOWNEYSSEN GE, 1995, J CLIN EPIDEMIOL, V48, pR1; MCMICHAEL AJ, 1988, CANCER RES, V48, P751; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502; SCHATZKIN A, 1994, JNCI-J NATL CANCER I, V86, P1053, DOI 10.1093/jnci/86.14.1053; Schatzkin A, 1996, CANCER EPIDEM BIOMAR, V5, P375; TOMINAGA S, 1994, CANC MORTALITY MORBI; WAKABAYASHI K, 1992, CANCER RES, V52, pS2092; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; ZHAO LP, 1991, NUTR CANCER, V15, P169, DOI 10.1080/01635589109514124; [No title captured]	37	683	704	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1149	1155		10.1056/NEJM200004203421601	http://dx.doi.org/10.1056/NEJM200004203421601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770979				2023-01-03	WOS:000086523700001
J	Mulnard, RI; Cotman, CW; Kawas, C; van Dyck, CH; Sano, H; Doody, R; Koss, E; Pfeiffer, E; Jin, S; Gamst, A; Grundman, M; Thomas, R; Thal, LJ				Mulnard, RI; Cotman, CW; Kawas, C; van Dyck, CH; Sano, H; Doody, R; Koss, E; Pfeiffer, E; Jin, S; Gamst, A; Grundman, M; Thomas, R; Thal, LJ		Alzheimers Dis Cooperative St	Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GONADAL-STEROIDS; APOLIPOPROTEIN-E; DEMENTIA; RISK; BRAIN; DECLINE; WOMEN; RATS; AGE	Context Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women. Objective To determine whether estrogen replacement therapy affects global, cognitive, or functional decline in women with mild to moderate AD. Design The Alzheimer's Disease Cooperative Study, a randomized, double-blind, placebo-controlled clinical trial conducted between October 1995 and January 1999. Setting Thirty-two study sites in the United States. Participants A total of 120 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 28 who had had a hysterectomy. Interventions Participants were randomized to estrogen, 0.625 mg/d (n = 42), or 1.25 mg/d (n = 39), or to identically appearing placebo (n = 39). One subject withdrew after randomization but before receiving medication; 97 subjects completed the trial. Main Outcome Measures The primary outcome measure was change on the Clinical Global Impression of Change (CGIC) 7-point scale, analyzed by intent to treat; secondary outcome measures included other global measures as well as measures of mood, specific cognitive domains (memory, attention, and language), motor function, and activities of daily living; compared by the combined estrogen groups vs the placebo group at 2, 6, 12, and 15 months of follow-up. Results The CGIC score for estrogen vs placebo was 5.1 vs 5.0 (P = .43); 80% of participants taking estrogen vs 74% of participants taking placebo worsened (P = .48). Secondary outcome measures also showed no significant differences, with the exception of the Clinical Dementia Rating Scale, which suggested worsening among patients taking estrogen (mean posttreatment change in score for estrogen, 0.5 vs 0.2 for placebo; P = .01). Conclusions Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. The study does not support the role of estrogen for the treatment of this disease. The potential role of estrogen in the prevention of AD, however, requires further research.	Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA; Johns Hopkins Univ, Baltimore, MD USA; Yale Univ, New Haven, CT USA; Columbia Univ, New York, NY USA; Baylor Coll Med, Houston, TX 77030 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ S Florida, Tampa, FL USA; Univ Calif San Diego, San Diego, CA 92103 USA	University of California System; University of California Irvine; Johns Hopkins University; Yale University; Columbia University; Baylor College of Medicine; Case Western Reserve University; State University System of Florida; University of South Florida; University of California System; University of California San Diego	Mulnard, RI (corresponding author), Univ Calif Irvine, Inst Brain Aging & Dementia, 1113 Gillespie Neurosci Res Facil, Irvine, CA 92697 USA.		Gamst, Anthony/AAH-9440-2019	Kawas, Claudia/0000-0001-9577-230X	NIA NIH HHS [U19 AG010483, U01-AG10483] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U19AG010483, U01AG010483] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Army Individual Test Battery, 1944, ARM COMB FITN TEST; Asthana S, 1999, PSYCHONEUROENDOCRINO, V24, P657, DOI 10.1016/S0306-4530(99)00020-7; Benton A, 1978, PSYCHOL ASSESSMENT R; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; Craft S, 1998, NEUROLOGY, V51, P149, DOI 10.1212/WNL.51.1.149; DalForno G, 1996, ARCH NEUROL-CHICAGO, V53, P345; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Dubal DB, 1999, J NEUROSCI, V19, P6385; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANKFURT M, 1994, NEUROENDOCRINOLOGY, V59, P245, DOI 10.1159/000126665; GOULD E, 1990, J NEUROSCI, V10, P1286; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HIDALGO A, 1995, J NEUROBIOL, V27, P470, DOI 10.1002/neu.480270404; HONJO H, 1989, J STEROID BIOCHEM, V34, P521; Johnson JK, 1998, BRAIN RES, V798, P18, DOI 10.1016/S0006-8993(98)00363-1; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; JOSEPH JA, 1989, BRAIN RES, V505, P195, DOI 10.1016/0006-8993(89)91442-X; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kritzer MF, 1999, J COMP NEUROL, V409, P438, DOI 10.1002/(SICI)1096-9861(19990705)409:3<438::AID-CNE8>3.0.CO;2-5; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; MATHEWS CG, 1964, INSTRUCTION MANUAL A; MCDERMOTT JL, 1994, HORM BEHAV, V28, P16, DOI 10.1006/hbeh.1994.1002; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mohs RC, 1997, ALZ DIS ASSOC DIS, V11, pS13; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REITAN RM, 1990, HALSTEAD REITAN NEUR; Rodriguez MM, 1998, CLIN GERIATR MED, V14, P177; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Simpkins JW, 1997, AM J MED, V103, P195; Sloane PD, 1998, AM FAM PHYSICIAN, V58, P1577; STERN Y, 1994, J GERONTOL, V49, pM216, DOI 10.1093/geronj/49.5.M216; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wechsler D, 2008, WECHSLER ADULT INTEL; ZUCKERMAN M, 1965, J CONSULT PSYCHOL, V29, P594, DOI 10.1037/h0022750	49	708	727	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1007	1015		10.1001/jama.283.8.1007	http://dx.doi.org/10.1001/jama.283.8.1007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697060	Bronze			2023-01-03	WOS:000085308600029
J	Ernst, MO; Banks, MS; Bulthoff, HH				Ernst, MO; Banks, MS; Bulthoff, HH			Touch can change visual slant perception	NATURE NEUROSCIENCE			English	Article							IDEAL OBSERVERS; TEXTURE; PSYCHOPHYSICS; SHAPE; CUES	The visual system uses several signals to deduce the three-dimensional structure of the environment, including binocular disparity, texture gradients, shading and motion parallax. Although each of these sources of information is independently insufficient to yield reliable three-dimensional structure from everyday scenes, the visual system combines them by weighting the available information; altering the weights would therefore change the perceived structure. We report that haptic feedback (active touch) increases the weight of a consistent surface-slant signal relative to inconsistent signals. Thus, appearance of a subsequently viewed surface is changed: the surface appears slanted in the direction specified by the haptically reinforced signal.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Univ Calif Berkeley, Vis Sci Program, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA	Max Planck Society; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Ernst, MO (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.		Bülthoff, Heinrich H/J-6579-2012; Bülthoff, Heinrich/AAC-8818-2019	Bülthoff, Heinrich H/0000-0003-2568-0607; Ernst, Marc/0000-0003-4197-8569				Backus BT, 1999, PERCEPTION, V28, P217, DOI 10.1068/p2753; Backus BT, 1999, VISION RES, V39, P1143, DOI 10.1016/S0042-6989(98)00139-4; BLAKE A, 1993, VISION RES, V33, P1723, DOI 10.1016/0042-6989(93)90037-W; Bradshaw MF, 1996, VISION RES, V36, P1255, DOI 10.1016/0042-6989(95)00190-5; BUCKLEY D, 1993, VISION RES, V33, P919, DOI 10.1016/0042-6989(93)90075-8; BULTHOFF HH, 1996, ATTENTION PERFORM, V16, P49; Clark J.J., 1990, DATA FUSION SENSORY; FESTINGER L, 1967, J EXPT PSYCHOL MONOG, V74; Gibson JJ, 1933, J EXP PSYCHOL, V16, P1, DOI 10.1037/h0074626; GILLAM B, 1993, PERCEPTION, V22, P1025, DOI 10.1068/p221025; HARRIS CS, 1965, PSYCHOL REV, V72, P419, DOI 10.1037/h0022616; JOHNSTON EB, 1993, VISION RES, V33, P813, DOI 10.1016/0042-6989(93)90200-G; Knill DC, 1998, VISION RES, V38, P1683, DOI 10.1016/S0042-6989(97)00325-8; LANDY MS, 1995, VISION RES, V35, P389, DOI 10.1016/0042-6989(94)00176-M; LEDERMAN SJ, 1981, J EXP PSYCHOL HUMAN, V7, P902, DOI 10.1037/0096-1523.7.4.902; Massie TH, 1994, PHANTOM HAPTIC INTER, P295; Rock I., 1966, NATURE PERCEPTUAL AD; ROCK I, 1964, SCIENCE, V143, P595; ROGERS BJ, 1995, PERCEPTION, V24, P155, DOI 10.1068/p240155; Stratton G. M., 1897, PSYCHOL REV, V4, P463, DOI [10.1037/h0075482, DOI 10.1037/H0071173]; Stratton G.M., 1897, PSYCHOL REV, V4, P341, DOI [DOI 10.1037/H0075482, 10.1037/h0075482]; van Ee R, 1999, PERCEPTION, V28, P1121; VONHELMHOLTZ H, 1867, HDB PHYSIL OPTIK, V3; Walk R. D., 1981, INTERSENSORY PERCEPT; Welch R. B., 1978, PERCEPTUAL MODIFICAT; WELCH RB, 1986, HDB PERCEPTION HUMAN	26	151	153	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	JAN	2000	3	1					69	73		10.1038/71140	http://dx.doi.org/10.1038/71140			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	292TB	10607397				2023-01-03	WOS:000085810200014
J	Coulehan, J				Coulehan, J			An alternative view: listening to patients	LANCET			English	Article									SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Coulehan, J (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, L3-086, Stony Brook, NY 11794 USA.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1467	1468		10.1016/S0140-6736(05)77604-2	http://dx.doi.org/10.1016/S0140-6736(05)77604-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543688				2023-01-03	WOS:000083277400042
J	Jorres, A; Gahl, GM; Dobis, C; Polenakovic, MH; Cakalaroski, K; Rutkowski, B; Kisielnicka, E; Krieter, DH; Rumpf, KW; Guenther, C; Gaus, W; Hoegel, J				Jorres, A; Gahl, GM; Dobis, C; Polenakovic, MH; Cakalaroski, K; Rutkowski, B; Kisielnicka, E; Krieter, DH; Rumpf, KW; Guenther, C; Gaus, W; Hoegel, J		Int Multicentre Study Grp	Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial	LANCET			English	Article							FACTORS INFLUENCING SURVIVAL; APACHE-II; HEMODIALYSIS	Background There is controversy as to whether haemodialysis-membrane biocompatibility tie, the potential to activate complement and neutrophils) influences mortality of patients with acute renal failure. We did a prospective randomised multicentre trial in patients with dialysis-dependent acute renal failure treated with two different types of low-flux membrane. Methods 180 patients with acute renal failure were randomly assigned bioincompatible Cuprophan (n=90) or polymethylmethacrylate (n=90) membranes. The main outcome was survival 14 days after the end of therapy (treatment success). Odds ratios for survival were calculated and the two groups were compared by Fisher's exact test. Analyses were based on patients treated according to protocol (76 Cuprophan, 84 polymethyl methacrylate). Findings At the start of dialysis, the groups did not differ significantly in age, sex, severity of illness las calculated by APACHE II scores), prevalence of oliguria, or biochemical measures of acute renal failure. 44 patients (58% [95% CI 46-69]) assigned Cuprophan membranes and 50 patients (60% [48-70]) assigned polymethyl-methacrylate membranes survived. The odds ratio for treatment failure on Cuprophan compared with polymethyl-methacrylate membranes was 1.07 (054-2.11; p=0.87). No difference between Cuprophan and polymethyl-methacrylate membranes was detected when the analysis was adjusted for age and APACHE II score, 18 patients in the Cuprophan group and 20 in the polymethyl-methacrylate group had clinical complications of therapy (mainly hypotension). Interpretation There were no differences in outcome for patients with dialysis-dependent acute renal failure between those treated with Cuprophan membranes and those treated with polymethyl-methacrylate membranes.	Humboldt Univ, Fak Med, Univ Klinikum Charite, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany; Univ St Cyril & Methudius, Dept Nephrol, Skopje 91000, Macedonia; Med Univ Gdansk, Dept Nephrol, Gdansk, Poland; Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany; Membrana GmbH, Wuppertal, Germany; Univ Ulm, Dept Biometry & Med Documentat, Ulm, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saints Cyril & Methodius University of Skopje; Fahrenheit Universities; Medical University Gdansk; University of Gottingen; Ulm University	Jorres, A (corresponding author), Humboldt Univ, Fak Med, Univ Klinikum Charite, Dept Nephrol & Med Intens Care, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.		Cakalaroski, Koco/L-4251-2019					BRADY HR, 1995, LANCET, V346, P1533, DOI 10.1016/S0140-6736(95)92057-9; CHEW SL, 1993, NEPHROL DIAL TRANSPL, V8, P101; COSENTINO F, 1994, NEPHROL DIAL TRANSPL, V9, P179; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; Jacobs C, 1997, NEPHROL DIAL TRANSPL, V12, P38, DOI 10.1093/ndt/12.1.38; KAPLAN AA, 1995, NEW ENGL J MED, V332, P961; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KURTAL H, 1995, ARTIF ORGANS, V19, P391, DOI 10.1111/j.1525-1594.1995.tb02347.x; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; MAHER ER, 1989, Q J MED, V72, P857; MUJAIS S, 1994, LANCET, V344, P1362, DOI 10.1016/S0140-6736(94)90720-X; Mujais S K, 1995, ASAIO J, V41, P137; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; Shaldon S, 1996, LANCET, V347, P205, DOI 10.1016/S0140-6736(96)90392-X; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Ward RA, 1997, NEPHROL DIAL TRANSPL, V12, P965, DOI 10.1093/ndt/12.5.965; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111	21	102	103	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1337	1341		10.1016/S0140-6736(99)01213-1	http://dx.doi.org/10.1016/S0140-6736(99)01213-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533862				2023-01-03	WOS:000083149900011
J	Schwetz, BA				Schwetz, BA			First drug for cervical dystonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Off Commissioner Food & Drugs, Rockville, MD 20857 USA		Schwetz, BA (corresponding author), Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	2001	285	6					724	724		10.1001/jama.285.6.724-a	http://dx.doi.org/10.1001/jama.285.6.724-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399MP	11176890				2023-01-03	WOS:000166817200007
J	Daaleman, TP; VandeCreek, L				Daaleman, TP; VandeCreek, L			Placing religion and spirituality in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; BREAST-CANCER; PHYSICIANS; ATTITUDES; BELIEFS; ADULTS; DEATH; OLDER		Univ Kansas, Med Ctr, Dept Family Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Hist & Philosophy Med, Ctr Aging, Kansas City, KS 66160 USA; Healthcare Chaplaincy, New York, NY USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Daaleman, TP (corresponding author), Univ Kansas, Med Ctr, Dept Family Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	tdaalema@kumc.edu		Daaleman, Timothy/0000-0002-1649-4266				Antonovsky, 1987, UNRAVELING MYSTERY H; Bradshaw A, 1996, SOC SCI MED, V43, P409, DOI 10.1016/0277-9536(95)00406-8; Brady MJ, 1999, PSYCHO-ONCOLOGY, V8, P417, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<417::AID-PON398>3.3.CO;2-W; BRODY H, 1992, HEALERS POWER; BYOCK R, 1997, DYING WELL PROSPECT; CASSEL CK, 1999, PRINCIPLES CARE PATI; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Coward D. D, 1989, NURS SCI QUART, V3, P162; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; Daaleman TP, 1998, ARCH FAM MED, V7, P548, DOI 10.1001/archfami.7.6.548; DAALEMAN TP, 1997, BIOETHICS FORUM, V13, P49; Dorff Elliot N, 1991, Conserv Jud, V43, P3; Dow KH, 1996, BREAST CANCER RES TR, V39, P261, DOI 10.1007/BF01806154; DOYLE D., 1999, OXFORD TXB PALLIATIV; DUBOSE ER, 1999, PHYSICIAN ASSISTED S; ELLISON CG, 1991, J HEALTH SOC BEHAV, V32, P80, DOI 10.2307/2136801; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; FITCHETT G, 1998, PSYCHO-ONCOLOGY, P790; Folkman S., 1984, STRESS APPRAISAL COP; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; *GEN ASS UN UN, 1988, RIGHT DIE DIGN P GEN; Holland JC, 1998, PSYCHO-ONCOL, V7, P460, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R; *I MED, 1997, APPR DEATH IMPR CAR; JENKINS RA, 1988, SOC SCI MED, V26, P625, DOI 10.1016/0277-9536(88)90027-5; Kaczorowski J M, 1989, Hosp J, V5, P105; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KRAUSE N, 1989, J GERONTOL, V44, pS4, DOI 10.1093/geronj/44.1.S4; Larson DB, 1998, SCI RES SPIRITUALITY; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Mathew L M, 1986, Clin Geriatr Med, V2, P617; MEIER DE, 1998, NEW ENGL J MED, V338, P967; *NAT C CATH BISH, 1994, ETH REL DIR CATH HLT; Neimeyer R. A., 1994, DEATH ANXIETY HDB RE; OCONNELL LJ, 1995, WESTERN J MED, V163, P231; Pargament K.I., 1997, PSYCHOL RELIG COPING; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; POST SG, 1995, J LAW MED ETHICS, V23, P20, DOI 10.1111/j.1748-720X.1995.tb01326.x; REED PG, 1987, RES NURS HEALTH, V10, P335, DOI 10.1002/nur.4770100507; Seale C, 1998, CONSTRUCTING DEATH S; SEIDLITZ L, 1995, J AM GERIATR SOC, V43, P993, DOI 10.1111/j.1532-5415.1995.tb05563.x; Smith Elizabeth D., 1993, Journal of Psychosocial Oncology, V11, P89; SPIEGEL D, 1989, LANCET, V2, P888; Sullivan M, 1998, J AM GERIATR SOC, V46, P1251, DOI 10.1111/j.1532-5415.1998.tb04541.x; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; THOMPSON SC, 1988, J SOC CLIN PSYCHOL, V7, P260, DOI 10.1521/jscp.1988.7.2-3.260; Van Ness Peter, 1996, SPIRITUALITY SECULAR; *WHO, 1990, TECHN REP SER WHO, V804; Wulff David M., 1997, PSYCHOL RELIG CLASSI; Wuthnow Robert, 1998, HEAVEN SPIRITUALITY	51	109	110	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2514	2517		10.1001/jama.284.19.2514	http://dx.doi.org/10.1001/jama.284.19.2514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074785				2023-01-03	WOS:000165183800028
J	Harthorne, JW				Harthorne, JW			Effects of physiologic pacing versus ventricular pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Harthorne, JW (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; Gesell RA, 1911, AM J PHYSIOL, V29, P32; Mines GR, 1913, J PHYSIOL-LONDON, V46, P349; Nielsen JC, 1998, CIRCULATION, V97, P987; STEWART WJ, 1984, AM J CARDIOL, V54, P308, DOI 10.1016/0002-9149(84)90188-7	5	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1417	1418						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11183885				2023-01-03	WOS:000165152800023
J	Lazar, MA				Lazar, MA			Gene regulation - One man's food	NATURE			English	Article							ALPHA		Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019					BARTLETT J, 2001, BARTLETTS FAMILIAR Q; BOELSTERLI UA, 1991, ARCH TOXICOL, V65, P351, DOI 10.1007/BF02284256; Holden PR, 1999, J MOL ENDOCRINOL, V22, P1, DOI 10.1677/jme.0.0220001; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Okino S T, 2000, Vitam Horm, V59, P241, DOI 10.1016/S0083-6729(00)59009-8; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	12	3	4	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 19	2000	407	6806					852	853		10.1038/35038199	http://dx.doi.org/10.1038/35038199			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	364PZ	11057652				2023-01-03	WOS:000089901900034
J	Feudtner, C				Feudtner, C			Dare we go gently	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434					0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2000	284	13					1621	1622		10.1001/jama.284.13.1621	http://dx.doi.org/10.1001/jama.284.13.1621			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	357KY	11015775				2023-01-03	WOS:000089501900001
J	Hill, WG; Zeidel, ML				Hill, WG; Zeidel, ML			Reconstituting the barrier properties of a water-tight epithelial membrane by design of leaflet-specific liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN URINARY-BLADDER; CANINE KIDNEY-CELLS; APICAL MEMBRANE; NONELECTROLYTE PERMEABILITIES; BIOLOGICAL-MEMBRANES; PROTON; ASYMMETRY; VESICLES; CHOLESTEROL; CONDUCTANCE	To define aspects of lipid composition and bilayer asymmetry critical to barrier function, we examined the permeabilities of liposomes that model individual leaflets of the apical membrane of a barrier epithelium, Madin-Darby canine kidney type 1 cells. Using published Lipid compositions we prepared exofacial liposomes containing phosphatidylcholine, sphingomyelin, glycosphingolipids, and cholesterol; and cytoplasmic liposomes containing phosphatidylethanolamine, phosphatidylserine, and cholesterol. The osmotic permeability of cytoplasmic liposomes to water (P-f), solutes, and NH3 was 18-90-fold higher than for the exofacial liposomes (P-f(ex) = 2.4 +/- 0.4 x 10(-4) cm/s, P-f(cy) = 4.4 +/- 0.3 x 10(-3) cm/s; P-glycerol(ex) = 2.5 +/- 0.3 x 10(-8) cm/s, P-glycerol(cy) = 2.2 +/- 0.02 x 10(-6) cm/s; P-NH3(ex) = 0.13 +/- 0.4 x 10(-4) cm/s, P-NH3(cy) = 7.9 +/- 1.0 x 10(-3) cm/s). By contrast, the apparent proton permeability of exofacial liposomes was 4-fold higher than cytoplasmic liposomes (PH+(ex) = 1.1 +/- 0.1 x 10(-2) cm/s, PH+(cy) = 2.7 +/- 0.6 x 10(-3) cm/s). By adding single leaflet permeabilities, we calculated a theoretical P-f for a Madin-Darby canine kidney apical membrane of 4.6 x 10(-4) cm/s, which compares favorably with experimentally determined values. In exofacial liposomes lacking glycosphingolipids or sphingomyelin, permeabilities were 2-7-fold higher, indicating that both species play a role in barrier function. Removal of cholesterol resulted in 40-280-fold increases in permeability. Fire conclude: 1) that we have reconstituted the biophysical properties of a barrier membrane, 2) that the barrier resides in the exofacial leaflet, 3) that both sphingomyelin and glycosphingolipids play a role in reducing membrane permeability but that there is an ab solute requirement for cholesterol to mediate this effect, 4) that these results further validate the hypothesis that each leaflet offers an independent resistance to permeation, and 5) that proton permeation was enhanced by sphingolipid/cholesterol interactions.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zeidel, ML (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Dept Med, 1218 Scaifie Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	zeidel@msx.dept-med.pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43955] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSUKOV LI, 1986, BIOCHIM BIOPHYS ACTA, V862, P87, DOI 10.1016/0005-2736(86)90472-4; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Brookes PS, 1997, BBA-BIOMEMBRANES, V1330, P157, DOI 10.1016/S0005-2736(97)00160-0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1995, PERMEABILITY STABILI, P161; Farinas J, 1996, BIOPHYS J, V71, P3511, DOI 10.1016/S0006-3495(96)79546-2; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Lavelle JP, 1998, AM J PHYSIOL-RENAL, V274, pF205, DOI 10.1152/ajprenal.1998.274.1.F205; Lavelle JP, 2000, AM J PHYSIOL-RENAL, V278, pF540, DOI 10.1152/ajprenal.2000.278.4.F540; LEWIS SA, 1977, AM J PHYSIOL, V232, pF187, DOI 10.1152/ajprenal.1977.232.3.F187; LEWIS SA, 1984, J MEMBRANE BIOL, V82, P123, DOI 10.1007/BF01868937; LEWIS SA, 1990, METHOD ENZYMOL, V192, P632; LEWIS SA, 1977, J GEN PHYSIOL, V70, P427, DOI 10.1085/jgp.70.4.427; LICHTENBERGER LM, 1987, CLIN INVEST MED, V10, P181; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Rivers R, 1998, AM J PHYSIOL-RENAL, V274, pF453, DOI 10.1152/ajprenal.1998.274.3.F453; Rivers RL, 1996, AM J PHYSIOL-CELL PH, V271, pC226, DOI 10.1152/ajpcell.1996.271.1.C226; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; Timbs MM, 1996, J MEMBRANE BIOL, V153, P1, DOI 10.1007/s002329900104; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; Zeidel ML, 1996, AM J PHYSIOL-RENAL, V271, pF243, DOI 10.1152/ajprenal.1996.271.2.F243	45	76	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30176	30185		10.1074/jbc.M003494200	http://dx.doi.org/10.1074/jbc.M003494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10903312	hybrid			2023-01-03	WOS:000089577900038
J	Brown, J; Kellermann, AL				Brown, J; Kellermann, AL			The shocking truth about automated external defibrillators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; EMERGENCY MEDICAL TECHNICIANS; VENTRICULAR-FIBRILLATION; RAPID DEFIBRILLATION; FOLLOW-UP; SURVIVAL; RESUSCITATION; SERVICES; SYSTEM; POLICE		Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA	Emory University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kellermann, AL (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.	AKELL01@sph.emory.edu						AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BECK CS, 1947, JAMA-J AM MED ASSOC, V135, P985, DOI 10.1001/jama.1947.62890150005007a; COBB LA, 1975, CIRCULATION, V52, P223; CUMMINS O, 1997, ADV CARDIAC LIFE SUP, P1; CUMMINS RO, 1984, LANCET, V2, P318; EISENBERG MS, 1989, AM J CARDIOL, V63, P443, DOI 10.1016/0002-9149(89)90316-0; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; Gentile D, 1988, J Tenn Med Assoc, V81, P144; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; HALLSTROM AP, 2000, CRISP CURRENT AWARD; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kloeck W, 1997, CIRCULATION, V95, P2183, DOI 10.1161/01.CIR.95.8.2183; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Lui JCZ, 1999, RESUSCITATION, V41, P113, DOI 10.1016/S0300-9572(99)00058-1; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; *OFF INF PUBL AFF, 1997, CPSC WARNS SMOK DET; ORNATO JP, 1984, ANN EMERG MED, V13, P1096, DOI 10.1016/S0196-0644(84)80331-5; Riegel B, 1998, Am J Crit Care, V7, P402; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Sweeney TA, 1998, ANN EMERG MED, V31, P234, DOI 10.1016/S0196-0644(98)70313-0; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; 1998, NY TIMES        1126, pA22; 2000, EM TODAY        0614, P1	31	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1438	1441		10.1001/jama.284.11.1438	http://dx.doi.org/10.1001/jama.284.11.1438			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989410				2023-01-03	WOS:000089242500042
J	Takayama, T; Sekine, T; Makuuchi, M; Yamasaki, S; Kosuge, T; Yamamoto, J; Shimada, K; Sakamoto, M; Hirohashi, S; Ohashi, Y; Kakizoe, T				Takayama, T; Sekine, T; Makuuchi, M; Yamasaki, S; Kosuge, T; Yamamoto, J; Shimada, K; Sakamoto, M; Hirohashi, S; Ohashi, Y; Kakizoe, T			Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial	LANCET			English	Article							ACTIVATED KILLER CELLS; T-CELLS; RECOMBINANT INTERLEUKIN-2; CANCER; LIVER; RESECTION; LYMPHOCYTES; ANTIGENS; PROGRESS; SURGERY	Background Postsurgical recurrence of hepatocellular carcinoma (HCC) is frequent and fatal. Adoptive immunotherapy is active against HCC. We assessed whether postoperative immunotherapy could lower the frequency of recurrence. Methods Between 1992 and 1995, we did a randomised trial in which 150 patients who had undergone curative resection for HCC were assigned adoptive immunotherapy (n=76) or no adjuvant treatment (n=74). Autologous lymphocytes activated vitro with recombinant interleukin-2 and antibody to CD3 were infused five times during the first 6 months. Primary endpoints were time to first recurrence and recurrence-free survival and analyses were by intention to treat. Findings 76 patients received 370 (97%) of 380 scheduled lymphocyte infusions (mean cell number per patient 7.1x10(10) [SD 2.1]; CD3 and HLA-DR ceils 78% [16]), and none had grade 3 or 4 adverse events. After a median follow-up of 4.4 years (range 0.2-6.7), adoptive immunotherapy decreased the frequency of recurrence by 18% compared with controls (45% [59] vs 57% [77]) and reduced the risk of recurrence by 41% (95% CI 12-60, p=0.01). Time to first recurrence in the immunotherapy group was significantly longer than that in the control group (48% [37-59] vs 33% [22-43] at 3 years, 38% [22-54] vs 22% [11-34] at 5 years; p=0.008). The immunotherapy group had significantly longer recurrence-free survival (p=0.01) and disease-specific survival (p=0.04) than the control group. Overall survival did not differ significantly between groups (p=0.09). Interpretation Adoptive immunotherapy is a safe, feasible treatment that can lower recurrence and improve recurrence-free outcomes after surgery for HCC.	Univ Tokyo, Fac Med,Dept Surg, Div Hepatobiliary Pancreat & Transplantat Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Natl Canc Ctr Hosp, Tokyo 1130033, Japan; Univ Tokyo, Div Expt Med, Tokyo 1130033, Japan; Univ Tokyo, Div Pathol, Tokyo 1130033, Japan; Univ Tokyo, Natl Canc Ctr, Res Inst, Tokyo 1130033, Japan; Univ Tokyo, Sch Hlth Sci & Nursing, Dept Biostat, Tokyo 1130033, Japan	University of Tokyo; National Cancer Center - Japan; University of Tokyo; University of Tokyo; University of Tokyo; National Cancer Center - Japan; University of Tokyo; University of Tokyo	Takayama, T (corresponding author), Univ Tokyo, Fac Med,Dept Surg, Div Hepatobiliary Pancreat & Transplantat Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Sakamoto, Michiie/N-2917-2015; 幕内, 雅敏 m/A-2140-2012					ARUGA A, 1991, INT J CANCER, V49, P19, DOI 10.1002/ijc.2910490105; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Bruix J, 1997, HEPATOLOGY, V25, P259; Chang AE, 1996, CRIT REV ONCOL HEMAT, V22, P213, DOI 10.1016/1040-8428(96)00194-1; Fong YM, 1999, ANN SURG, V229, P790, DOI 10.1097/00000658-199906000-00005; Funaki NO, 1997, HEPATOLOGY, V25, P564, DOI 10.1002/hep.510250312; KONOMI Y, 1995, JPN J CANCER RES, V86, P854, DOI 10.1111/j.1349-7006.1995.tb03096.x; LAFRENIERE R, 1985, CANCER RES, V45, P3735; LAI ECS, 1995, ANN SURG, V221, P291, DOI 10.1097/00000658-199503000-00012; Lau WY, 1999, LANCET, V353, P797, DOI 10.1016/S0140-6736(98)06475-7; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; MAKUUCHI M, 1993, SEMIN SURG ONCOL, V9, P298, DOI 10.1002/ssu.2980090404; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; ONISHI S, 1989, HEPATOLOGY, V10, P349, DOI 10.1002/hep.1840100318; OSBAND ME, 1990, LANCET, V335, P994, DOI 10.1016/0140-6736(90)91064-H; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; SAWCZUK IS, 1997, P AN M AM SOC CLIN, V16, pA326; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Scott Andrew M., 1997, Lancet (North American Edition), V349, P19; SEKINE T, 1993, BIOMED PHARMACOTHER, V47, P73, DOI 10.1016/0753-3322(93)90294-U; SUNG CH, 1989, J CLIN INVEST, V83, P421, DOI 10.1172/JCI113900; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; TAKAYAMA T, 1991, CANCER, V68, P2391, DOI 10.1002/1097-0142(19911201)68:11<2391::AID-CNCR2820681110>3.0.CO;2-7; Takayama T, 1998, HEPATOLOGY, V28, P1436, DOI 10.1002/hep.510280539; TAKAYAMA T, 1990, LANCET, V336, P1150, DOI 10.1016/0140-6736(90)92768-D; Yamamoto J, 1996, BRIT J SURG, V83, P1219	28	697	768	1	44	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 2	2000	356	9232					802	807		10.1016/S0140-6736(00)02654-4	http://dx.doi.org/10.1016/S0140-6736(00)02654-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350LF	11022927				2023-01-03	WOS:000089101800010
J	Vincent, JL				Vincent, JL			Need for intensivists in intensive-care units	LANCET			English	Editorial Material							RESOURCE UTILIZATION; OUTCOMES		Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Erasme Hosp, Dept Intens Care, 808 Route Lennik, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951				Bach PB, 1998, AM J RESP CRIT CARE, V158, P1410, DOI 10.1164/ajrccm.158.5.9804042; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; LI TC, 1984, JAMA-J AM MED ASSOC, V252, P2027; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Rosen BS, 1999, AUST NZ J OPHTHALMOL, V27, P153, DOI 10.1046/j.1440-1606.1999.00174.x; TAN IKS, 2000, CRIT CARE SHOCK, V1, P1; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Trunkey DD, 1999, ANN SURG, V229, P172, DOI 10.1097/00000658-199902000-00002; Vincent JL, 1997, INTENS CARE MED, V23, P1181, DOI 10.1007/s001340050479	13	47	47	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					695	696		10.1016/S0140-6736(00)02622-2	http://dx.doi.org/10.1016/S0140-6736(00)02622-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085683				2023-01-03	WOS:000088948200003
J	Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P				Smith, AJ; van Helvoort, A; van Meer, G; Szabo, K; Welker, E; Szakacs, G; Varadi, A; Sarkadi, B; Borst, P			MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; RESISTANCE-ASSOCIATED PROTEIN; HUMAN MULTIDRUG TRANSPORTER; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; HOMOZYGOUS DISRUPTION; CYCLOSPORINE-A; INSECT CELLS; GENE FAMILY	The human MDR3 gene is a member of the multidrug resistance (MDR) gene family. The MDR3 P-glycoprotein is a transmembrane protein that translocates phosphatidylcholine. The MDR1 P-glycoprotein related transports cytotoxic drugs. Its overexpression can make cells resistant to a variety of drugs. Attempts to show that MDR3 P-glycoprotein can cause MDR have been unsuccessful thus far. Here, we report an increased directional transport of several MDR1 P-glycoprotein substrates, such as digoxin, paclitaxel, and vinblastine, through polarized monolayers of MDR3-transfected cells. Transport of other good MDR1 P-glycoprotein substrates, including cyclosporin A and dexamethasone, was not detectably increased. MDR3 P-glycoprotein-dependent transport of a short-chain phosphatidylcholine analog and drugs was inhibited by several MDR reversal agents and other drugs, indicating an interaction between these compounds and MDR3 P-gp, Insect cell membranes from Sf9 cells overexpressing MDR3 showed specific MgATP binding and a vanadate-dependent, N-ethylmaleimide-sensitive nucleotide trapping activity, visualized by covalent binding with [alpha-P-32]8 azido-ATP. Nucleotide trapping was (nearly) abolished by paclitaxel, vinblastine, and the MDR reversal agents verapamil, cyclosporin A, and PSC 833. We conclude that MDR3 P-glycoprotein can bind and transport a subset of MDR1 P-glycoprotein substrates. The rate of MDR3 P-wglycoprotein-mediated transport is low for most drugs, explaining why this protein is not detectably involved in multidrug resistance. It remains possible, however, that drug binding to MDR3 P-glycoprotein could adversely affect phospholipid or toxin secretion under conditions of stress (e.g. in pregnant heterozygotes with one MDR3 null allele).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Cell Biol & Histol Lab, NL-1105 AZ Amsterdam, Netherlands; Hungarian Acad Sci, Membrane Res Grp, Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Univ Utrecht, Fac Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Hungarian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Utrecht University; Utrecht University	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Welker, Ervin/AAC-6493-2022; van Meer, Gerrit/AAH-1560-2021; Smith, Alexander/A-5142-2009; Szakacs, Gergely/A-2580-2009; van Helvoort, Ardy/U-7549-2019; Sarkadi, Balazs/I-5024-2013; Varadi, Andras/A-2055-2012	Szakacs, Gergely/0000-0002-9311-7827; van Helvoort, Ardy/0000-0002-3585-0676; van Meer, Gerrit/0000-0002-5976-6436				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSCHMAN E, 1994, CANCER RES, V54, P4892; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; Crawford AR, 1997, J CLIN INVEST, V100, P2562, DOI 10.1172/JCI119799; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Groen AK, 1996, J THEOR BIOL, V182, P427, DOI 10.1006/jtbi.1996.0183; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; Jacquemin E, 1999, LANCET, V353, P210, DOI 10.1016/S0140-6736(05)77221-4; Kino K, 1996, FEBS LETT, V399, P29, DOI 10.1016/S0014-5793(96)01265-3; LINCKE CR, 1991, J BIOL CHEM, V266, P5303; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; NOOTER K, 1990, INT J CANCER, V45, P626, DOI 10.1002/ijc.2910450409; Raggers RJ, 1999, J CELL SCI, V112, P415; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RUETZ S, 1994, TRENDS PHARMACOL SCI, V15, P260, DOI 10.1016/0165-6147(94)90322-0; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Scheffer G. L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P667; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith AJ, 1998, J NATL CANCER I, V90, P1161, DOI 10.1093/jnci/90.15.1161; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1996, MULTIDRUG RESISTANCE, P95	51	209	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23530	23539		10.1074/jbc.M909002199	http://dx.doi.org/10.1074/jbc.M909002199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10918072	hybrid, Green Published			2023-01-03	WOS:000088564200019
J	El-Sadr, WM; Burman, WJ; Grant, LB; Matts, JP; Hafner, R; Crane, L; Zeh, D; Gallagher, B; Mannheimer, SB; Martinez, A; Gordin, F				El-Sadr, WM; Burman, WJ; Grant, LB; Matts, JP; Hafner, R; Crane, L; Zeh, D; Gallagher, B; Mannheimer, SB; Martinez, A; Gordin, F		Terry Beirn Community Programs Cli	Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; CYTOMEGALOVIRUS DISEASE; WEEKLY AZITHROMYCIN; ORAL GANCICLOVIR; CONTROLLED TRIAL; PREVENTION; AIDS; BACTEREMIA; ILLNESSES	Background: Several agents are effective in preventing Mycobacterium avium complex disease in patients with advanced human immunodeficiency virus (HIV) infection. However, there is uncertainty about whether prophylaxis should be continued in patients whose CD4+ cell counts have increased substantially with antiviral therapy. Methods: We conducted a multicenter, double-blind, randomized trial of treatment with azithromycin (1200 mg weekly) as compared with placebo in HIV-infected patients whose CD4+ cell counts had increased from less than 50 to more than 100 per cubic millimeter in response to antiretroviral therapy. The primary end point was M. avium complex disease or bacterial pneumonia. Results: A total of 520 patients entered the study; the median CD4+ cell count at entry was 230 per cubic millimeter. In 48 percent of the patients, the HIV RNA value was below the level of quantification. The median prior nadir CD4+ cell count was 23 per cubic millimeter, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness. During follow-up over a median period of 12 months, there were no episodes of confirmed M. avium complex disease in either group (95 percent confidence interval for the rate of disease in each group, 0 to 1.5 episodes per 100 person-years). Three patients in the azithromycin group (1.2 percent) and five in the placebo group (1.9 percent) had bacterial pneumonia (relative risk in the azithromycin group, 0.60; 95 percent confidence interval, 0.14 to 2.50; P=0.48). Neither the rate of progression of HIV disease nor the mortality rate differed significantly between the two groups. Adverse effects led to discontinuation of the study drug in 19 patients assigned to receive azithromycin (7.4 percent) and in 3 assigned to receive placebo (1.1 percent; relative risk, 6.6; P=0.002). Conclusions: Azithromycin prophylaxis can safely be withheld in HIV-infected patients whose CD4+ cell counts have increased to more than 100 cells per cubic millimeter in response to antiretroviral therapy. (N Engl J Med 2000;342:1085-92.) (C) 2000, Massachusetts Medical Society.	Harlem Hosp Med Ctr, Div Infect Dis, New York, NY 10037 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; NIAID, Div Aids, Bethesda, MD 20892 USA; Wayne State Univ, Detroit, MI USA; Res & Educ Grp, Portland, OR USA; Philadelphia FIGHT, Philadelphia, PA USA; Dept Vet Affairs Med Ctr, Washington, DC USA	Columbia University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Wayne State University	El-Sadr, WM (corresponding author), Harlem Hosp Med Ctr, Div Infect Dis, 506 Lenox Ave,Rm 3107, New York, NY 10037 USA.	wne1@columbia.edu			NCRR NIH HHS [RR00032] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABERG JA, 1999, 39 INT C ANT AG CHEM, P1164; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Benson C. A., 1996, P91; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CreweBrown HH, 1997, CLIN INFECT DIS, V25, P1165, DOI 10.1086/516104; Dunne MW, 1999, LANCET, V354, P891, DOI 10.1016/S0140-6736(98)10328-8; DWORKIN M, 1999, 6 C RETR OPP INF CHI, P198; El-Sadr WM, 1999, CLIN INFECT DIS, V29, P775, DOI 10.1086/520433; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; KEDREE MA, 1996, 11 INT C AIDS VANC B, P232; LOPEZ JC, 1999, 6 C RETR OPP INF CHI, P206; Meynard JL, 1996, CLIN INFECT DIS, V22, P437, DOI 10.1093/clinids/22.3.437; Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; Oldfield EC, 1998, CLIN INFECT DIS, V26, P611, DOI 10.1086/514566; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	32	106	109	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1085	1092		10.1056/NEJM200004133421503	http://dx.doi.org/10.1056/NEJM200004133421503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10766581	Green Published			2023-01-03	WOS:000086406700003
J	Newby, LK; Eisenstein, EL; Califf, RM; Thompson, TD; Nelson, CL; Peterson, ED; Armstrong, PW; Van de Werf, F; White, HD; Topol, EJ; Mark, DB				Newby, LK; Eisenstein, EL; Califf, RM; Thompson, TD; Nelson, CL; Peterson, ED; Armstrong, PW; Van de Werf, F; White, HD; Topol, EJ; Mark, DB			Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; HOSPITAL DISCHARGE; MEDICARE PATIENTS; TRIAL; ANGIOPLASTY; QUALITY; CARE; ERA	Background: Reducing the length of hospitalizations can reduce short-term costs, but there are few data on the long-term clinical and economic consequences of early discharge after uncomplicated myocardial infarction. Methods: Using data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial, we identified 22,361 patients with acute myocardial infarction who had an uncomplicated course for 72 hours after thrombolysis. Then, using a decision-analytic model, we examined the cost effectiveness of an additional day of hospitalization in this group. We defined incremental survival attributable to another day of monitored hospitalization, on the basis of the rate of resuscitation after cardiac arrest between 72 and 96 hours. Lifetime survival curves for each group in the decision-analytic model were estimated from one-year survival data from GUSTO-1. Results: Of the patients with an uncomplicated course within 72 hours after thrombolysis, 16 had ventricular arrhythmias during the next 24 hours; 13 of these patients (81 percent) survived for at least 24 hours. On average, another 0.006 year of life per patient could be saved by keeping patients with an uncomplicated course in the hospital another day. At a cost of $624 for hospital and physicians' services, extending the hospital stay by another day would cost $105,629 per year of life saved. In sensitivity analyses, it was found that a fourth day of hospitalization would be economically attractive only if its cost could be reduced by more than 50 percent or if a high-risk subgroup could be identified in which the estimated survival benefit would be doubled. Conclusions: Hospitalization of patients with uncomplicated myocardial infarction beyond three days after thrombolysis is economically unattractive by conventional standards. (N Engl J Med 2000;342:749-55.) (C)2000, Massachusetts Medical Society.	Duke Clin Res Inst, Durham, NC 27715 USA; Univ Ziekenhuizen Leuven, Louvain, Belgium; Univ Alberta, Edmonton, AB, Canada; Green Lane Hosp, Auckland 3, New Zealand; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Duke University; KU Leuven; University Hospital Leuven; University of Alberta; Cleveland Clinic Foundation	Newby, LK (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	newby001@mc.duke.edu	Peterson, Eric David/ABF-5033-2021	Armstrong, Paul/0000-0002-0460-3445; Mark, Daniel/0000-0001-6340-8087; Topol, Eric/0000-0002-1478-4729				EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; JAIN A, 1993, J AM COLL CARDIOL, V22, P1816, DOI 10.1016/0735-1097(93)90763-Q; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Krumholz HM, 1997, AM J CARDIOL, V79, P581, DOI 10.1016/S0002-9149(96)00819-3; Krumholz HM, 1999, JAMA-J AM MED ASSOC, V281, P37; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MADSEN EB, 1983, CIRCULATION, V68, P9, DOI 10.1161/01.CIR.68.1.9; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Mark DB, 2000, CIRCULATION, V101, P366, DOI 10.1161/01.CIR.101.4.366; Mark DB, 1998, CIRCULATION, V97, P1702, DOI 10.1161/01.CIR.97.17.1702; MARK DB, 1995, NEW ENGL J MED, V333, P267; MARK DB, 1997, TXB CARDIOVASCULAR M, P1033; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Pierard LA, 1999, AM HEART J, V137, P500, DOI 10.1016/S0002-8703(99)70499-0; SANZ G, 1993, J AM COLL CARDIOL, V22, P1795, DOI 10.1016/0735-1097(93)90759-T; Stratmann HG, 1998, AM HEART J, V136, P87, DOI 10.1016/S0002-8703(98)70186-3; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOPOL EJ, 1987, AM J CARDIOL, V60, P958, DOI 10.1016/0002-9149(87)90332-8; *TREEAG SOFTW, 1996, DATA 3 0 US MAN; Weinstein MC., 1996, COST EFFECTIVENESS H	27	98	99	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					749	755		10.1056/NEJM200003163421101	http://dx.doi.org/10.1056/NEJM200003163421101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717009				2023-01-03	WOS:000085846900001
J	Johanson, R				Johanson, R			Perineal massage for prevention of perineal trauma in childbirth	LANCET			English	Editorial Material							EPISIOTOMY; LACERATION		N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Johanson, R (corresponding author), N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.							AVERY MD, 1987, J NURSE-MIDWIFERY, V32, P181, DOI 10.1016/0091-2182(87)90095-4; AVERY MD, 1986, J NURSE-MIDWIFERY, V31, P128, DOI 10.1016/0091-2182(86)90148-5; CARROLI G, 1999, COCHRANE LIB; Graham I. D., 1997, EPISIOTOMY CHALLENGI; KETTLE C, 1999, PERINEAL TEARS; KETTLE C, 1999, CLIN EVID, V2, P522; Klein MC, 1997, AM J OBSTET GYNECOL, V176, P403, DOI 10.1016/S0002-9378(97)70506-4; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; LABRECQUE M, 1994, BIRTH-ISS PERINAT C, V21, P20, DOI 10.1111/j.1523-536X.1994.tb00911.x; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x	13	25	27	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					250	251		10.1016/S0140-6736(00)00020-9	http://dx.doi.org/10.1016/S0140-6736(00)00020-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675069				2023-01-03	WOS:000085045600005
J	Abrahm, JL				Abrahm, JL			The role of the clinician in palliative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrahm, JL (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; Buckman R., 1992, BREAK BAD NEWS GUIDE; *WHO, 1990, WHO TECHN REP SER, V804	3	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					116	116		10.1001/jama.283.1.116	http://dx.doi.org/10.1001/jama.283.1.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632293	Bronze			2023-01-03	WOS:000084514400038
J	Francis, LP				Francis, LP			Legal eights to health care at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Francis, LP (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							*US DEP HHS, 1988, HLTH US 1998	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2079	2079		10.1001/jama.282.21.2079	http://dx.doi.org/10.1001/jama.282.21.2079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591395				2023-01-03	WOS:000083908700032
J	Furlan, A; Higashida, R; Wechsler, L; Gent, M; Rowley, H; Kase, C; Pessin, M; Ahuja, A; Callahan, F; Clark, WM; Silver, F; Rivera, F				Furlan, A; Higashida, R; Wechsler, L; Gent, M; Rowley, H; Kase, C; Pessin, M; Ahuja, A; Callahan, F; Clark, WM; Silver, F; Rivera, F		PROACT Investigators	Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	24th American-Heart-Association International Conference on Stroke and Cerebral Circulation	FEB 04-06, 1999	NASHVILLE, TN	Amer Heart Assoc			TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; THROMBOLYTIC THERAPY; INTRAARTERIAL FIBRINOLYSIS; CAROTID TERRITORY; INFARCTION; UROKINASE; OCCLUSION; TIME; HANDICAP	Context Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed. Objective To determine the clinical efficacy and safety of intra-arterial (IA) recombinant prourokinase (r-proUK) in patients with acute stroke of less than 6 hours' duration caused by middle cerebral artery (MCA) occlusion. Design PROACT II (Prolyse in Acute Cerebral Thromboembolism II), a randomized, controlled, multicenter, open-label clinical trial with blinded follow-up conducted between February 1996 and August 1998. Setting Fifty-four centers in the United States and Canada. Patients A total of 180 patients with acute ischemic stroke of less than 6 hours' duration caused by angiographically proven occlusion of the MCA and without hemorrhage or major early infarction signs on computed tomographic scan. Intervention Patients were randomized to receive 9 mg of IA r-proUK plus heparin (n = 121)or heparin only (n = 59), Main Outcome Measures The primary outcome, analyzed by intention-to-treat, was based on the proportion of patients with slight or no neurological disability at 90 days as defined by a modified Rankin score of 2 or less. Secondary outcomes included MCA recanalization, the frequency of intracranial hemorrhage with neurological deterioration, and mortality. Results For the primary analysis, 40% of r-proUK patients and 25% of control patients had a modified Rankin score of 2 or less (P=.04). Mortality was 25% for the r-proUK group and 27% for the control group. The recanalization rate was 66% for the r-proUK group and 18% for the control group (P<.001). Intracranial hemorrhage with neurological deterioration within 24 hours occurred in 10% of r-proUK patients and 2% of control patients (P=.06). Conclusion Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical outcome at 90 days.	Cleveland Clin Fdn, Dept Neurol, Cerebrovasc Ctr, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Neuroradiol, San Francisco, CA 94143 USA; Univ Pittsburgh, Stroke Inst, Pittsburgh, PA USA; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Hamilton Civ Hosp, Res Ctr, Clin Trials Methodol Grp, Hamilton, ON, Canada; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Tufts Univ New England Med Ctr, Dept Neurol, Boston, MA 02111 USA; St Lukes Med Ctr, Dept Neurosurg, Milwaukee, WI USA; Centennial Med Ctr, Neurol Consultants PC, Nashville, TN USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Toronto Hosp, Western Div, Dept Neurol, Toronto, ON M5T 2S8, Canada; Baylor Univ, Med Ctr, Dept Vasc & Intervent Radiol, Dallas, TX USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McMaster University; McMaster University; Boston University; Tufts Medical Center; Oregon Health & Science University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Baylor University; Baylor University Medical Center	Furlan, A (corresponding author), Cleveland Clin Fdn, Dept Neurol, Cerebrovasc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	furlana@ccf.org		Silver, Frank/0000-0002-7569-8429; Kase, Carlos/0000-0002-3047-5010				BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; CANDELISE L, 1995, LANCET, V346, P1509; Clark WM, 1999, STROKE, V30, P234; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1994, AM J NEURORADIOL, V15, P1217; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; *EM MAN STROK INV, 1997, STROKE, V28, P273; FERGUSON RDG, 1994, AM J NEURORADIOL, V15, P1201; FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908; Fisher M, 1996, NEUROLOGY, V47, P884, DOI 10.1212/WNL.47.4.884; FURLAN AJ, 1991, THROMBOLYTIC THERAPY, P71; *GEN APPL, PLA960350 GEN APPL; Gonner F, 1998, STROKE, V29, P1894, DOI 10.1161/01.STR.29.9.1894; Gurewich V, 1998, STROKE, V29, P1255, DOI 10.1161/01.STR.29.6.1255; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; KASAI S, 1985, J BIOL CHEM, V260, P2382; LODDER J, 1986, STROKE, V17, P626, DOI 10.1161/01.STR.17.4.626; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARLER JR, 1997, RAPID IDENTIFICATION; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Muir KW, 1999, STROKE, V30, P180, DOI 10.1161/01.STR.30.1.180; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PANNELL R, 1986, BLOOD, V44, P217; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SANDERCOCK P, 1999, CURRENT REV CEREBROV, P217; Staroselskaya IA, 1999, NEUROLOGY, V52, pA455; TEBBE U, 1995, J AM COLL CARDIOL, V26, P365, DOI 10.1016/0735-1097(95)80008-5; THERON J, 1989, AM J NEURORADIOL, V10, P753; Tomsick T, 1996, AM J NEURORADIOL, V17, P79; TONI D, 1994, J NEUROL SCI, V123, P129, DOI 10.1016/0022-510X(94)90214-3; Ueda T, 1998, STROKE, V29, P2568, DOI 10.1161/01.STR.29.12.2568; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; WOLFE CDA, 1991, STROKE, V22, P1242, DOI 10.1161/01.STR.22.10.1242; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977	47	2227	2356	0	67	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2003	2011		10.1001/jama.282.21.2003	http://dx.doi.org/10.1001/jama.282.21.2003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	259TB	10591382				2023-01-03	WOS:000083908700019
J	Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C				Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C			Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; LIPOPROTEINS; MENOPAUSE; MORTALITY; HEALTH	Objective To assess whether risk factor profiles for cardiovascular disease differed, before starting treatment, between women who would subsequently use hormone replacement therapy and those who would remain untreated. Design Prospective population study, initiated in 1968-9, with follow ups in 1974, 1980, and 1992. Setting Gothenburg, Sweden. Participants 1201 women born in 1918, 1922, and 1930, representative of women of the same age in the general population. Main outcome measures Hormone replacement therapy as a function of initial systolic and diastolic blood pressure, waist and hip circumference, waist to hip ratio, body mass index, serum concentrations of cholesterol and triglycerides, smoking status, education, leisure time activity, and socioeconomic group. Results 179 of the 1201 women (14.9%) used hormone replacement therapy sometime during the 24 year follow up period. Multivariate models indicated that these women had significantly lower blood pressure, had less obesity, and belonged to a higher social group before the start of treatment than women who would remain untreated. Conclusion Women who would subsequently use hormone replacement therapy were already at lower cardiovascular risk before the start of treatment than women who would remain untreated. Some of the claimed beneficial effects of treatment may thus be explained by women who would use hormone replacement therapy representing a healthier cohort than women who would remain untreated.	Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, SE-41345 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Rodstrom, K (corresponding author), Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden.	Kerstin.Rodstrom@allmed.gu.se						BarrettConnor E, 1996, MATURITAS, V23, P227, DOI 10.1016/0378-5122(95)00975-2; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; Bengtsson C, 1997, SCAND J PRIM HEALTH, V15, P214, DOI 10.3109/02813439709035031; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND S, V549; Carlsson G., 1958, SOCIAL MOBILITY CLAS; CHRISTIANSEN C, 1991, AM J MED, V90, P107; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HALLING A, 1984, SWED DENT J, V8, P183; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VANDERMAAREL SM, 1995, EUR J HUM GENET, V3, P207; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816	22	51	52	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	1999	319	7214					890	893		10.1136/bmj.319.7214.890	http://dx.doi.org/10.1136/bmj.319.7214.890			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506047	Green Published, Bronze			2023-01-03	WOS:000082975600026
J	LeBlanc, ES; Janowsky, J; Chan, BKS; Nelson, HD				LeBlanc, ES; Janowsky, J; Chan, BKS; Nelson, HD			Hormone replacement therapy and cognition - Systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ESTROGEN-RECEPTOR-ALPHA; POSTMENOPAUSAL ESTROGEN; ALZHEIMERS-DISEASE; RISK-FACTORS; OLDER WOMEN; MEMORY; DECLINE; HIPPOCAMPUS; TRIAL; MOTOR	Context Some observational data suggest that hormone replacement therapy (HRT) may reduce the risk of cognitive decline and dementia but results have been conflicting. Objective To review and evaluate studies of HRT for preventing cognitive decline and dementia in healthy postmenopausal women. Data Sources Studies with English-language abstracts identified in MEDLINE (1966-August 2000), HealthSTAR (1975-August 2000, PsychINFO (1984-August 2000); Cochrane Library databases; and articles listed in reference lists of key articles, Study Selection Randomized controlled trials and cohort studies were reviewed for the effects of HRT on cognitive decline; cohort and case-control studies were reviewed for dementia risk. No randomized controlled trials regarding dementia risk were identified. Data Extraction Twenty-nine studies met inclusion criteria and were rated, Two reviewers rated study quality independently and 100% agreement was reached on Jadad scores and 80% agreement was reached on US Preventive Services Task Force quality scores. A final score was reached th rough consensus if reviewers disagreed. Data Synthesis Studies of cognition were not combined quantitatively because of heterogeneous study design. Women symptomatic from menopause had improvements in verbal memory, vigilance, reasoning, and motor speed, but no enhancement of other cognitive functions. Generally, no benefits were observed in asymptomatic women. A meta-analysis of observational studies suggested that HRT was associated with a decreased risk of dementia (summary odds ratio, 0.66; 95% confidence interval, 0.53-0.82). However, possible biases and lack of control for potential confounders limit interpretation of these studies. Studies did not contain enough information to assess adequately the effects of progestin use, various estrogen preparations or doses, or duration of therapy. Conclusions in women with menopausal symptoms, HRT may have specific cognitive effects, and future studies should target these effects, The meta-analysis found a decreased risk of dementia in HRT users but most studies had important methodological limitations.	Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Med Serv, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	LeBlanc, ES (corresponding author), Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA.	leblance@ohsu.edu			NATIONAL INSTITUTE ON AGING [R01AG012611] Funding Source: NIH RePORTER; NIA NIH HHS [AG12611] Funding Source: Medline; PHS HHS [290-97-0018] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Carlson LE, 1999, NEUROBIOL AGING, V20, P315, DOI 10.1016/S0197-4580(99)00052-4; CHIARELLO C, 1989, BRAIN COGNITION, V11, P18, DOI 10.1016/0278-2626(89)90002-X; DERBY CA, 1993, AM J EPIDEMIOL, V137, P1125, DOI 10.1093/oxfordjournals.aje.a116616; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Duka T, 2000, PSYCHOPHARMACOLOGY, V149, P129, DOI 10.1007/s002139900324; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; FRISK V, 1990, NEUROPSYCHOLOGIA, V28, P349, DOI 10.1016/0028-3932(90)90061-R; Funk JL, 1991, DEMENTIA, V2, P268; Gordis L., 1996, EPIDEMIOLOGY, P183; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Hackman B W, 1976, Curr Med Res Opin, V4, P303, DOI 10.1185/03007997609109322; HAMPSON E, 1988, BEHAV NEUROSCI, V102, P456, DOI 10.1037/0735-7044.102.3.456; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; HARRIS R, IN PRESS AM J PREV M; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Henderson Victor W., 1997, American Journal of Medicine, V103, p11S, DOI 10.1016/S0002-9343(97)00261-1; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Janowsky JS, 2000, J COGNITIVE NEUROSCI, V12, P407, DOI 10.1162/089892900562228; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kawas, 1998, NEUROLOGY, V51, P654; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Keefover RW, 1996, NEUROL CLIN, V14, P337, DOI 10.1016/S0733-8619(05)70260-7; KIMURA D, 1995, HORM BEHAV, V29, P312, DOI 10.1006/hbeh.1995.1022; LAZAK M, 1995, NEUROPSYCHOLOGICAL A; Matthews K, 1999, J AM GERIATR SOC, V47, P518, DOI 10.1111/j.1532-5415.1999.tb02563.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MORTEL KF, 1995, J NEUROPSYCH CLIN N, V7, P334; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Register TC, 1998, BRAIN RES, V788, P320, DOI 10.1016/S0006-8993(98)00036-5; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; Shaywitz SE, 1999, JAMA-J AM MED ASSOC, V281, P1197, DOI 10.1001/jama.281.13.1197; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Slavin RE, 1986, EDUC RESEARCHER, V15, P5, DOI DOI 10.3102/0013189X015009005; Smith CA, 1999, BRAIN COGNITION, V39, P203, DOI 10.1006/brcg.1999.1078; Spiegelhalter DJ, 1999, WINBUGS VERSION 1 2; Szklo M, 1996, AM J EPIDEMIOL, V144, P1048; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TERI L, 1997, W J MED, V4, P269; VANHULLE G, CONCENSUS MENOPAUSE; Wang PN, 2000, NEUROLOGY, V54, P2061, DOI 10.1212/WNL.54.11.2061; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; WATKINS R, IN PRESS J GERONTOL; Weiland NG, 1997, J COMP NEUROL, V388, P603, DOI 10.1002/(SICI)1096-9861(19971201)388:4<603::AID-CNE8>3.0.CO;2-6; Wren BG, 1998, DRUG AGING, V12, P343, DOI 10.2165/00002512-199812050-00001; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yaffe K, 1999, J AM GERIATR SOC, V47, P1176, DOI 10.1111/j.1532-5415.1999.tb05196.x; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	68	457	465	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2001	285	11					1489	1499		10.1001/jama.285.11.1489	http://dx.doi.org/10.1001/jama.285.11.1489			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	410VQ	11255426				2023-01-03	WOS:000167462100032
J	Johnson, AP; Warner, M; Broughton, K; James, D; Efsratiou, A; George, RC; Livermore, DM				Johnson, AP; Warner, M; Broughton, K; James, D; Efsratiou, A; George, RC; Livermore, DM			Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIVE ENDOCARDITIS; ENTEROCOCCI		Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England; Cent Publ Hlth Lab, Streptococcus & Diphtheria Reference Unit, Resp & Systemat Infect Lab, London NW9 5HT, England	Public Health England; Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England.	Ajohnson@phls.nhs.uk	Johnson, Alan P/F-4420-2014					COX RA, 1991, J ANTIMICROB CHEMOTH, V27, P1, DOI 10.1093/jac/27.1.1; Dyson C, 1999, J INFECTION, V38, P87, DOI 10.1016/S0163-4453(99)90074-9; Johnson AP, 1998, BMJ-BRIT MED J, V317, P629, DOI 10.1136/bmj.317.7159.629; Simmons NA, 1998, HEART, V79, P207; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2001	322	7283					395	396		10.1136/bmj.322.7283.395	http://dx.doi.org/10.1136/bmj.322.7283.395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	404JH	11179156	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000167093600024
J	Crowther, RE; Marshall, M; Bond, GR; Huxley, P				Crowther, RE; Marshall, M; Bond, GR; Huxley, P			Helping people with severe mental illness to obtain work: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUPPORTED EMPLOYMENT; PSYCHIATRIC REHABILITATION; OUTCOMES	Objective To determine the most effective way of helping people with severe mental illness to obtain competitive employment-that is, a job paid at the market rate, and for which any one can apply. Design Systematic review: Participants Eligible studies were randomised controlled trials comparing prevocational training or supported employment (for people with severe mental illness) with each other or with standard community care. Outcome measures The primary outcome was number of subjects in competitive employment outcomes, clinical outcomes, and costs. Results Eleven trials met the inclusion criteria. Five (1204 subjects) compared prevocational training with standard community care, one (256 subjects) compared supported employment with standard community care, and five (484 subjects) compared supported employment wit prevocational training. Subjects in supported employment were more likely to be in competitive employment than those who received prevocational training at 4, 6, 9, 12, 15, and 18 months (for example, 34% v 12% at 12 months; number needed to treat 4.45, 95% confidence interval 3.37 to 6.59). This effect was still present, although at a reduced level, after a sensitivity analysis that retained only the highest quality trials (31% v 12%; 5.3, 3.6 to 10.4). People in supported employment earned more and worked more hours per month than those who had had prevocational training. Conclusion Supported employment is more effective than prevocational training at helping people with severe mental illness obtain competitive employment.	Univ Manchester, Sch Psychiat & Behav Sci, Manchester PR2 9HT, Lancs, England; Indiana Univ Purdue Univ, Dept Psychol, Indianapolis, IN 46202 USA; Kings Coll London, Inst Psychiat, Hlth Serv Res, London SE5 8AF, England	University of Manchester; Indiana University System; Indiana University-Purdue University Indianapolis; University of London; King's College London	Marshall, M (corresponding author), Royal Preston Hosp, Acad Unit, Preston PR2 9HT, Lancs, England.	mmarshall@man.ac.uk	Crowther, Ruth/K-8461-2014; Young, Alexander/A-1523-2009; Huxley, Peter/AAE-7007-2019	Crowther, Ruth/0000-0002-7628-5618; Young, Alexander/0000-0002-9367-9213; 				BEARD JH, 1963, AM J ORTHOPSYCHIAT, V33, P701, DOI 10.1111/j.1939-0025.1963.tb01018.x; BECKER DR, 1994, COMMUNITY MENT HLT J, V30, P193, DOI 10.1007/BF02188630; Bond G.R., 1992, HDB PSYCHIAT REHABIL, P244; BOND GR, 1995, REHABIL PSYCHOL, V40, P75; Bond GR, 1997, PSYCHIATR SERV, V48, P335; Bond GR, 1999, J DISABIL POLICY STU, V10, P18, DOI [10.1177/104420739901000104, DOI 10.1177/104420739901000104]; Chandler D, 1996, PSYCHIATR SERV, V47, P1337; CLARK M, 1999, COCHR COLL REV HDB V; Cook JA, 2000, SCHIZOPHRENIA BULL, V26, P87, DOI 10.1093/oxfordjournals.schbul.a033448; Department of Health, 1998, MOD MENT HLTH SERV; DINCIN J, 1982, HOSP COMMUNITY PSYCH, V33, P645; Drake RE, 1999, ARCH GEN PSYCHIAT, V56, P627, DOI 10.1001/archpsyc.56.7.627; Drake RE, 1996, J CONSULT CLIN PSYCH, V64, P391, DOI 10.1037/0022-006X.64.2.391; *EUR EC INT GROUP, 1998, ERMIS DAT DORK; GERVEY R, 1994, PSYCHOL ASSESSMENT T; GRIFFITHS RD, 1974, PSYCHOL MED, V4, P316, DOI 10.1017/S0033291700043002; HATFIELD B, 1992, BRIT J SOC WORK, V22, P61; Lehman AF, 1995, SCHIZOPHRENIA BULL, V21, P645, DOI 10.1093/schbul/21.4.645; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; MCCREADIE RG, 1992, SOC PSYCH PSYCH EPID, V27, P40, DOI 10.1007/BF00788955; McFarlane WR, 2000, AM J ORTHOPSYCHIAT, V70, P203, DOI 10.1037/h0087819; MELTZER H, 1995, 2 OFF POP CENS SURV; Okpaku SO, 1997, PSYCHIATR REHABIL J, V20, P34, DOI 10.1037/h0095366; RIDGEWAY P, 1998, ACTIVE INGREDIENTS A; Shepherd G., 1994, RELATIVE VALUES DIFF; WEHMAN P, 1997, SUPPORTED EMPLOYMENT, P1; WOLKON GH, 1971, COMMUNITY MENT HLT J, V7, P312, DOI 10.1007/BF01434441	27	301	315	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2001	322	7280					204	208		10.1136/bmj.322.7280.204	http://dx.doi.org/10.1136/bmj.322.7280.204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	398BF	11159616	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000166733700026
J	Haller, CA; Benowitz, NL				Haller, CA; Benowitz, NL			Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAFFEINE; PHENYLPROPANOLAMINE; VASCULITIS; HEMORRHAGE; INGESTION; TOXICITY	Background: Dietary supplements that contain ephedra alkaloids (sometimes called ma huang) are widely promoted and used in the United States as a means of losing weight and increasing energy. In the light of recently reported adverse events related to use of these products, the Food and Drug Administration (FDA) has proposed limits on the dose and duration of use of such supplements. The FDA requested an independent review of reports of adverse events related to the use of supplements that contained ephedra alkaloids to assess causation and to estimate the level of risk the use of these supplements poses to consumers. Methods: We reviewed 140 reports of adverse events related to the use of dietary supplements containing ephedra alkaloids that were submitted to the FDA between June 1, 1997, and March 31, 1999. A standardized rating system for assessing causation was applied to each adverse event. Results: Thirty-one percent of cases were considered to be definitely or probably related to the use of supplements containing ephedra alkaloids, and 31 percent were deemed to be possibly related. Among the adverse events that were deemed definitely, probably, or possibly related to the use of supplements containing ephedra alkaloids, 47 percent involved cardiovascular symptoms and 18 percent involved the central nervous system. Hypertension was the single most frequent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); and seizures (7). Ten events resulted in death, and 13 events produced permanent disability, representing 26 percent of the definite, probable, and possible cases. Conclusions: The use of dietary supplements that contain ephedra alkaloids may pose a health risk to some persons. These findings indicate the need for a better understanding of individual susceptibility to the adverse effects of such dietary supplements. (N Engl J Med 2000;343:1833-8.) (C) 2000, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, Div Clin Pharmacol & Expt Therapeut, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Calif Poison Control Syst, San Francisco Div, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Benowitz, NL (corresponding author), Univ Calif San Francisco, Dept Med, Div Clin Pharmacol & Expt Therapeut, Box 1220, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA012393, R01DA002277, R37DA002277] Funding Source: NIH RePORTER; NIDA NIH HHS [DA12393, DA02277] Funding Source: Medline; NIGMS NIH HHS [T32GM07546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; BENOWITZ NL, 1990, ANNU REV MED, V41, P277, DOI 10.1146/annurev.me.41.020190.001425; BLANC S, 1979, CLIN PHARMACOL THER, V25, P493; BROWN NJ, 1991, CLIN PHARMACOL THER, V50, P363, DOI 10.1038/clpt.1991.152; BRUNO A, 1993, NEUROLOGY, V43, P1313, DOI 10.1212/WNL.43.7.1313; Chyka PA, 2000, DRUG SAFETY, V23, P87, DOI 10.2165/00002018-200023010-00006; COSTELLO JF, 1975, BR J CLIN PHARM, V2, P180; DREW CDM, 1978, BRIT J CLIN PHARMACO, V6, P221, DOI 10.1111/j.1365-2125.1978.tb04588.x; FALLIS RJ, 1985, NEUROLOGY, V35, P405, DOI 10.1212/WNL.35.3.405; *FDC, 2000, FDC REP; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Josefson D, 1996, BRIT MED J, V312, P1378, DOI 10.1136/bmj.312.7043.1378c; Perrotta DM, 1996, JAMA-J AM MED ASSOC, V276, P1711; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; Theoharides TC, 1997, J CLIN PSYCHOPHARM, V17, P437, DOI 10.1097/00004714-199710000-00025; TO LB, 1980, MED J AUSTRALIA, V2, P35, DOI 10.5694/j.1326-5377.1980.tb131811.x; Vahedi K, 2000, J NEUROL NEUROSUR PS, V68, P112, DOI 10.1136/jnnp.68.1.112; White LM, 1997, J CLIN PHARMACOL, V37, P116, DOI 10.1002/j.1552-4604.1997.tb04769.x; WIENER I, 1990, CATHETER CARDIO DIAG, V20, P51, DOI 10.1002/ccd.1810200113; WOOTEN MR, 1983, ANN NEUROL, V13, P337, DOI 10.1002/ana.410130321; Zaacks SM, 1999, J TOXICOL-CLIN TOXIC, V37, P485, DOI 10.1081/CLT-100102440; Zahn KA, 1999, J EMERG MED, V17, P289, DOI 10.1016/S0736-4679(98)00194-2	22	607	636	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2000	343	25					1833	1838		10.1056/NEJM200012213432502	http://dx.doi.org/10.1056/NEJM200012213432502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384KB	11117974	Bronze			2023-01-03	WOS:000165940400002
J	Katz, SJ; Kabeto, M; Langa, KM				Katz, SJ; Kabeto, M; Langa, KM			Gender disparities in the receipt of home care for elderly people with disability in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-General-Internal-Medicine	MAY 05-06, 2000	BOSTON, MASSACHUSETTS	Soc Gen Internal Med			INFORMAL CARE; PREDICTORS; PATTERNS; PARENTS; HELP	Context Projected demographic shifts in the US population over the next 50 years will cause families, health care practitioners, and policymakers to confront a marked increase in the number of people with disabilities living in the community. Concerns about the adequacy of community support are particularly salient to women, who make up a disproportionate number of disabled elderly people and who may be particularly vulnerable because they are more likely to live alone with limited financial resources. Objective To address gender differences in receipt of informal and formal home care. Design, Setting, and Participants Nationally representative survey conducted in 1993 among 7443 noninstitutionalized people (4538 women and 2905 men) aged 70 years or older. Main Outcome Measure Number of hours per week of informal (generally unpaid) and formal (generally paid) home care received by survey participants who reported any activity of daily living (ADL) or instrumental activity of daily living (IADL) impairment (n = 3109) com pared by gender and living arrangement and controlling for other factors. Results Compared with disabled men, disabled women were much more likely to be living alone (45.4% vs 16.8%, P<.001) and much less likely to be living with a spouse (27.8% vs 73.6%, P<.001). Overall, women received fewer hours of informal care per week than men (15.7 hours; 95% confidence interval [CI], 14.5-16.9 vs 21.2 hours; 95% CI, 19.7-22.8). Married disabled women received many fewer hours per week of informal home care than married disabled men (14.8 hours; 95% CI, 13.7-15.8 vs 26.2 hours; 95% CI, 24.6-27.9). Children (>80% women) were the dominant caregivers for disabled women while wives were the dominant caregivers of disabled men. Gender differences in formal home care were small (2.8 hours for women; 95% CI, 2.5-3.1 vs 2.1 hours for men; 95% CI, 1.7-2.4). Conclusion Large gender disparities appear to exist in the receipt of informal home care for disabled elderly people in the United States, even within married households, Programs providing home care support for disabled elderly people need to consider these large gender disparities and the burden they impose on families when developing intervention strategies in the community.	Univ Michigan, Dept Med, Div Gen Med, Ann Arbor, MI 48109 USA; Univ Michigan, Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI 48109 USA; Univ Michigan, CHOICES, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Katz, SJ (corresponding author), Univ Michigan, Dept Med, Div Gen Med, 300 N Ingalls,Suite 7E12,Box 0429, Ann Arbor, MI 48109 USA.		KATZ, STEVEN/ABH-8886-2020	Langa, Kenneth/0000-0002-2798-1836	NATIONAL INSTITUTE ON AGING [U01AG009740] Funding Source: NIH RePORTER; NIA NIH HHS [U01 AG009740] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson GF, 2000, HEALTH AFFAIR, V19, P191, DOI 10.1377/hlthaff.19.3.191; BARER BM, 1994, INT J AGING HUM DEV, V38, P29, DOI 10.2190/MCH0-VTER-DL6G-LECR; Boaz RF, 1997, J GERONTOL B-PSYCHOL, V52, pS317, DOI 10.1093/geronb/52B.6.S317; BURTON L, 1995, GERONTOLOGIST, V35, P744, DOI 10.1093/geront/35.6.744; *COLL STAT, 1999, STATA REF MAN; Duan N., 1983, J BUSINESS EC STAT, V1, P115, DOI [DOI 10.1080/07350015.1983.10509330, DOI 10.2307/1391852]; *HLTH CAR FIN ADM, 1998, NAT HLTH CAR EXP PRO; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Hopp FP, 1999, GERONTOLOGIST, V39, P167, DOI 10.1093/geront/39.2.167; IngersollDayton B, 1996, GERONTOLOGIST, V36, P483, DOI 10.1093/geront/36.4.483; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Langa KM, 2000, J GEN INTERN MED, V15, P79; LANGA KM, IN PRESS MED CARE; LEE GR, 1993, J GERONTOL, V48, pS9, DOI 10.1093/geronj/48.1.S9; Merlis M, 2000, HEALTH AFFAIR, V19, P141, DOI 10.1377/hlthaff.19.3.141; MILLER B, 1992, GERONTOLOGIST, V32, P498, DOI 10.1093/geront/32.4.498; Norgard TM, 1997, J GERONTOL B-PSYCHOL, V52, P93, DOI 10.1093/geronb/52B.Special_Issue.93; PENNING MJ, 1994, J GERONTOL, V49, P5202; Soldo BJ, 1997, J GERONTOL B-PSYCHOL, V52, P1, DOI 10.1093/geronb/52B.Special_Issue.1; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; STOLLER EP, 1993, GERONTOLOGIST, V33, P31, DOI 10.1093/geront/33.1.31; Stump TE, 1997, J GERONTOL B-PSYCHOL, V52, P49, DOI 10.1093/geronb/52B.Special_Issue.49; Wolf DA, 1997, J GERONTOL B-PSYCHOL, V52, P102, DOI 10.1093/geronb/52B.Special_Issue.102	24	126	127	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2000	284	23					3022	3027		10.1001/jama.284.23.3022	http://dx.doi.org/10.1001/jama.284.23.3022			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	382VC	11122589	Bronze			2023-01-03	WOS:000165847200027
J	Faber-Langendoen, K; Lanken, PN; Lo, B; Abrahm, J; Block, S; Breitbart, W; Byock, IR; Faber-Langendoen, K; Kitchens, LW; Lanken, P; Lynn, J; Meier, D; Quill, TE; Thibault, G; Tulsky, JA; Snyder, L; Karlawish, J				Faber-Langendoen, K; Lanken, PN; Lo, B; Abrahm, J; Block, S; Breitbart, W; Byock, IR; Faber-Langendoen, K; Kitchens, LW; Lanken, P; Lynn, J; Meier, D; Quill, TE; Thibault, G; Tulsky, JA; Snyder, L; Karlawish, J		ACP ASIM End Life Care Consensus	Dying patients in the intensive care unit: Forgoing treatment, maintaining care	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; ADVANCE DIRECTIVES; END; EXPERIENCE; WITHDRAWAL; DIALYSIS; SUPPORT; PREFERENCES; PREDICTION; MANAGEMENT	End-of-life care of patients in the intensive care unit (ICU) often requires dramatic shifts in attitudes and interventions, from traditional intensive rescue care to intensive palliative care. The care of patients dying in ICUs raises both clinical and ethical difficulties, Because fewer ICU patients are able to make decisions about withdrawing treatment, careful attention must be paid to previously expressed preferences and surrogate input Cultural and spiritual values of patients and families may differ markedly from those of clinicians. Although prognostic models are increasingly able to predict mortality rates for groups of ICU patients, their usefulness in guiding specific decisions to forgo treatment has not been established. When a decision to forgo treatment is made, the focus should be on specifying the patient's goals of care and assessing all treatments in light of these goals; interventions that do not contribute to the patient's goals should be discontinued. Symptoms accompanying withdrawal of life support can almost always be controlled with appropriate palliative measures. After ICU interventions are forgone, patient comfort must be the paramount objective. Whether in the ICU or elsewhere, hospitals have an ethical obligation to provide settings that offer dignified, compassionate, and skilled care.	SUNY Upstate Med Univ, Ctr Bioeth & Humanities, Syracuse, NY USA; Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Snyder, L (corresponding author), Amer Soc Internal Med, Amer Coll Phys, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@mail.acponline.org						American Thoracic Society, 1991, Ann Intern Med, V115, P478; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Burns JP, 2000, CRIT CARE MED, V28, P3060, DOI 10.1097/00003246-200008000-00064; Byock I, 1997, DYING WELL PROSPECT; Campbell ML, 1997, CRIT CARE MED, V25, P197, DOI 10.1097/00003246-199701000-00034; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Carlson RW, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852-b; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; Doyle D, 1998, OXFORD TXB PALLIATIV; Eidelman LA, 1998, INTENS CARE MED, V24, P162, DOI 10.1007/s001340050539; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1996, AM J RESP CRIT CARE, V153, pS4; Field MJ, 1997, APPROACHING DEATH IM; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; Gilligan T, 1996, CRIT CARE MED, V24, P352, DOI 10.1097/00003246-199602000-00028; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; King P A, 1991, Law Med Health Care, V19, P76; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOCH KA, 1994, CRIT CARE MED, V22, P233, DOI 10.1097/00003246-199402000-00013; Lanken PN, 1997, AM J RESP CRIT CARE, V156, P1282; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; Leggat JE, 1997, J AM SOC NEPHROL, V8, P1755; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; LUCE JM, 1992, CHEST, V101, P1185, DOI 10.1378/chest.101.5.1185; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; Miles S H, 1987, Theor Med, V8, P293, DOI 10.1007/BF00489465; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; QUILL TE, 1994, AM J CARDIOL, V74, P205, DOI 10.1016/0002-9149(94)90107-4; Reitemeier PJ, 1997, HASTINGS CENT REP, V27, P24, DOI 10.2307/3528022; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; TERES D, 1987, CRIT CARE MED, V15, P208, DOI 10.1097/00003246-198703000-00005; THIBAULT GE, 1997, APPROACHING DEATH IM, P363; TRUOG RD, 1994, J CLIN ETHIC, V5, P39	48	72	74	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2000	133	11					886	893		10.7326/0003-4819-133-11-200012050-00013	http://dx.doi.org/10.7326/0003-4819-133-11-200012050-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	378LL	11103059				2023-01-03	WOS:000165585800008
J	Routledge, EJ; White, R; Parker, MG; Sumpter, JP				Routledge, EJ; White, R; Parker, MG; Sumpter, JP			Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION FUNCTIONS; NUCLEAR HORMONE-RECEPTOR; RAT PITUITARY; MESSENGER-RNA; BINDING; LIGAND; PHYTOESTROGENS; IDENTIFICATION; ANTIESTROGENS; HETERODIMERS	It has been proposed that tissue-specific estrogenic and/or antiestrogenic actions of certain xenoestrogens may be associated with alterations in the tertiary structure of estrogen receptor (ER) alpha and/or ER beta following ligand binding; changes which are sensed by cellular factors (coactivators) required for normal gene expression. However, it is still unclear whether xenoestrogens affect the normal behavior of ER alpha and/or ER beta subsequent to receptor binding. In view of the wide range of structural forms now recognized to mimic the actions of the natural estrogens, we have assessed the ability of ER alpha and ER beta to recruit TIF2 and SRC-1a in the presence of 17 beta -estradiol, genistein, diethylstilbestrol, 4-tert-oc-tylphenol, 2',3',4',5' -tetrachlorobiphenyl-1, and bisphenol A. We show that ligand-dependent differences exist in the ability of ER alpha and ER beta to bind coactivator proteins in vitro, despite the similarity in binding affinity of the various ligands for both ER subtypes, The enhanced ability of ER beta (over ER alpha) to recruit coactivators in the presence of xenoestrogens was consistent with a greater ability of ERP to potentiate reporter gene activity in transiently transfected HeLa cells expressing SRC-1e and TIFS. We conclude that ligand-dependent differences in the ability of ER alpha and ER beta to recruit coactivator proteins may contribute to the complex tissue-dependent agonistic/antagonistic responses observed with certain xenoestrogens.	Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England; Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Brunel University; Cancer Research UK; University of London; Queen Mary University London	Routledge, EJ (corresponding author), Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England.	edwin.routledge@brunel.ac.uk	sumpter, john/HGB-7584-2022; Routledge, Edwin John/V-2336-2019; Routledge, Edwin/AGI-0283-2022	Routledge, Edwin/0000-0001-7695-364X				ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; Connor K, 1997, TOXICOL APPL PHARM, V145, P111, DOI 10.1006/taap.1997.8169; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; JANSEN HT, 1993, REPROD TOXICOL, V7, P237, DOI 10.1016/0890-6238(93)90230-5; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klinge CM, 1996, STEROIDS, V61, P278, DOI 10.1016/0039-128X(95)00219-G; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Le Bail JC, 1998, CANCER LETT, V130, P209, DOI 10.1016/S0304-3835(98)00141-4; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MADHABANANDA S, 1999, ENDOCRINOLOGY, V140, P963; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; RUH MF, 1995, BIOCHEM PHARMACOL, V50, P1485, DOI 10.1016/0006-2952(95)02061-6; SEIELSTAD DA, 1995, BIOCHEMISTRY-US, V34, P12605, DOI 10.1021/bi00039a016; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONBAUR E, 1996, EMBO J, V15, P110	49	271	278	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35986	35993		10.1074/jbc.M006777200	http://dx.doi.org/10.1074/jbc.M006777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964929	hybrid			2023-01-03	WOS:000165382000049
J	Lincoln, T				Lincoln, T			Medicine - Cardiac arrest can be less of a gamble	NATURE			English	Editorial Material																		Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	2000	408	6810					302	302		10.1038/35042660	http://dx.doi.org/10.1038/35042660			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	373NR	11185494				2023-01-03	WOS:000165296000028
J	Henney, JE				Henney, JE			New drug for HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2000	284	17					2178	2178		10.1001/jama.284.17.2178	http://dx.doi.org/10.1001/jama.284.17.2178			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367GD	11056574				2023-01-03	WOS:000090052600006
J	Ito, S				Ito, S			Drug therapy: Drug therapy for breast-feeding women.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-MILK; FED INFANTS; COTININE CONCENTRATIONS; N-DESMETHYLSERTRALINE; LACTATION PERIOD; PASSIVE SMOKING; NURSING MOTHER; TOPICAL IODINE; IN-VIVO; EXCRETION		Hosp Sick Children, Res Inst, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Ito, S (corresponding author), Hosp Sick Children, Res Inst, Div Clin Pharmacol & Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ito@sickkids.on.ca						ALTSHULER LL, 1995, J CLIN PSYCHIAT, V56, P243; ANDERSON PO, 1991, CLIN PHARMACY, V10, P594; ANDERSON PO, 1989, DICP ANN PHARMAC, V23, P614, DOI 10.1177/1060028089023007-822; ARNADA JV, 1992, PEDIAT PHARM, P193; ASTLEY SJ, 1990, NEUROTOXICOL TERATOL, V12, P161, DOI 10.1016/0892-0362(90)90129-Z; BAUER JH, 1979, AM J CARDIOL, V43, P860, DOI 10.1016/0002-9149(79)90090-0; BEGG EJ, 1992, BRIT J CLIN PHARMACO, V33, P501, DOI 10.1111/j.1365-2125.1992.tb04077.x; BENNETT PN, 1990, BRIT J CLIN PHARMACO, V29, P777, DOI 10.1111/j.1365-2125.1990.tb03703.x; BERLIN CM, 1980, PEDIATR PHARMACOL, V1, P135; BINKIEWICZ A, 1978, J PEDIATR-US, V93, P965, DOI 10.1016/S0022-3476(78)81220-7; BISDOM CJW, 1937, JAMA-J AM MED ASSOC, V109, P178; BLINICK G, 1975, AM J OBSTET GYNECOL, V121, P617, DOI 10.1016/0002-9378(75)90461-5; BONA G, 1992, EUR J RADIOL, V14, P22, DOI 10.1016/0720-048X(92)90056-F; BONATI M, 1992, INT J GYNECOL OBSTET, V39, P185; BOUTROY MJ, 1986, EUR J CLIN PHARMACOL, V30, P737, DOI 10.1007/BF00608227; Brent NB, 1998, CLIN PEDIATR, V37, P41, DOI 10.1177/000992289803700107; BRIGGS GG, 1998, DRUGS PREGNANCY LACT; BUCHANAN RA, 1968, CURR THER RES CLIN E, V10, P592; BURCH KJ, 1992, PEDIATRICS, V89, P676; CAZENEUVE C, 1994, BRIT J CLIN PHARMACO, V37, P405, DOI 10.1111/j.1365-2125.1994.tb05706.x; Chambers CD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e61; CHASNOFF IJ, 1987, PEDIATRICS, V80, P836; CLARK JH, 1981, CLIN PEDIATR, V20, P53, DOI 10.1177/000992288102000107; COBO E, 1973, AM J OBSTET GYNECOL, V115, P817, DOI 10.1016/0002-9378(73)90526-7; COULAM CB, 1982, TRANSPLANT P, V14, P605; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Cushing AH, 1998, AM J EPIDEMIOL, V147, P863, DOI 10.1093/oxfordjournals.aje.a009540; DAHLSTROM A, 1990, ACTA PAEDIATR SCAND, V79, P142, DOI 10.1111/j.1651-2227.1990.tb11430.x; DANZIGER Y, 1987, ARCH DIS CHILD, V62, P295, DOI 10.1136/adc.62.3.295; DELANGE F, 1988, ARCH DIS CHILD, V63, P106, DOI 10.1136/adc.63.1.106-a; DELGADOESCUETA AV, 1992, NEUROLOGY, V42, P149; DESWIET M, 1977, NEW ENGL J MED, V297, P1471; Epperson CN, 1997, NEW ENGL J MED, V336, P1189, DOI 10.1056/NEJM199704173361615; FAZIO G, 1990, NUCL PHYS A, V506, P158; FINCH E, 1954, J OBSTET GYN BRIT EM, V61, P833; FITZJOHN TP, 1982, BRIT J RADIOL, V55, P603, DOI 10.1259/0007-1285-55-656-603; FLECHNER SM, 1985, AM J KIDNEY DIS, V5, P60, DOI 10.1016/S0272-6386(85)80138-4; FREY B, 1990, EUR J PEDIATR, V150, P136, DOI 10.1007/BF02072057; Gale CR, 1996, LANCET, V347, P1072, DOI 10.1016/S0140-6736(96)90278-0; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; GREENBERGER PA, 1993, CLIN PHARMACOL THER, V53, P324, DOI 10.1038/clpt.1993.28; GREKAS DM, 1984, NEPHRON, V37, P68, DOI 10.1159/000183213; HACKETT LP, 1990, BRIT J CLIN PHARMACO, V29, P277, DOI 10.1111/j.1365-2125.1990.tb03635.x; HILBERT J, 1988, J CLIN PHARMACOL, V28, P234, DOI 10.1002/j.1552-4604.1988.tb03138.x; HILL R M, 1977, Clinical Obstetrics and Gynecology, V20, P381, DOI 10.1097/00003081-197706000-00018; HOLMDAHL KH, 1956, ACTA RADIOL, V45, P303; Howard CR, 1998, OBSTET GYN CLIN N AM, V25, P195, DOI 10.1016/S0889-8545(05)70365-X; ILETT KF, 1981, BRIT J RADIOL, V54, P537, DOI 10.1259/0007-1285-54-642-537; ISENBERG KE, 1990, J CLIN PSYCHIAT, V51, P169; ITO S, 1993, AM J OBSTET GYNECOL, V168, P1393, DOI 10.1016/S0002-9378(11)90771-6; ITO S, 1994, BRIT J CLIN PHARMACO, V38, P99, DOI 10.1111/j.1365-2125.1994.tb04331.x; ITO S, 1999, AMBULATORY PEDIAT CA, P1036; Jensen A.A., 1996, DRUGS HUMAN LACTATIO; KACEW S, 1993, J CLIN PHARMACOL, V33, P213, DOI 10.1002/j.1552-4604.1993.tb03946.x; KANEKO S, 1979, BRIT J CLIN PHARMACO, V7, P624, DOI 10.1111/j.1365-2125.1979.tb04654.x; KAUFFMAN RE, 1994, PEDIATRICS, V93, P137; KEMP J, 1985, BRIT J CLIN PHARMACO, V20, P497, DOI 10.1111/j.1365-2125.1985.tb05106.x; KOLETZKO S, 1989, BRIT MED J, V298, P1617, DOI 10.1136/bmj.298.6688.1617; Kristensen JH, 1998, BRIT J CLIN PHARMACO, V45, P453, DOI 10.1046/j.1365-2125.1998.00705.x; KUHNZ W, 1988, DEV PHARMACOL THERAP, V11, P147, DOI 10.1159/000457682; LESTER BM, 1993, J AM ACAD CHILD PSY, V32, P1253, DOI 10.1097/00004583-199311000-00020; LEWIS GJ, 1983, BRIT MED J, V286, P603, DOI 10.1136/bmj.286.6365.603; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCK W, 1987, EUR J PEDIATR, V146, P21, DOI 10.1007/BF00647276; LUNELL NO, 1985, EUR J CLIN PHARMACOL, V28, P597, DOI 10.1007/BF00544073; Mammen OK, 1997, J CLIN PSYCHIAT, V58, P100, DOI 10.4088/JCP.v58n0302; Marquet P, 1997, CLIN PHARMACOL THER, V62, P569, DOI 10.1016/S0009-9236(97)90053-9; MATHESON I, 1985, LANCET, V2, P1124; MATHESON I, 1985, PEDIATRICS, V76, P651; MATHESON I, 1985, BRIT MED J, V290, P1588, DOI 10.1136/bmj.290.6481.1588-a; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MCKENNA R, 1983, J PEDIATR-US, V103, P325, DOI 10.1016/S0022-3476(83)80378-3; MCKENNA WJ, 1983, AM J CARDIOL, V51, P1231, DOI 10.1016/0002-9149(83)90377-6; Mennella JA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e2; MENNELLA JA, 1993, JAMA-J AM MED ASSOC, V269, P1637, DOI 10.1001/jama.269.13.1637; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MOMOTANI N, 1989, CLIN ENDOCRINOL, V31, P591, DOI 10.1111/j.1365-2265.1989.tb01283.x; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; NAU H, 1982, CLIN PHARMACOKINET, V7, P508, DOI 10.2165/00003088-198207060-00003; NIELSEN ST, 1987, ACTA RADIOL, V28, P523; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; Nyberg G, 1998, TRANSPLANTATION, V65, P253; OHARE MF, 1980, BRIT J OBSTET GYNAEC, V87, P814, DOI 10.1111/j.1471-0528.1980.tb04618.x; OHMAN I, 1998, EPILEPSIA S2, V39; OO CY, 1995, CLIN PHARMACOL THER, V58, P548, DOI 10.1016/0009-9236(95)90175-2; ORME ML, 1977, BRIT MED J, V1, P1564, DOI 10.1136/bmj.1.6076.1564; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; PATRICK MJ, 1972, LANCET, V1, P542; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; PLOMP TA, 1992, EUR J OBSTET GYN R B, V43, P201, DOI 10.1016/0028-2243(92)90174-W; POLLOCK JI, 1994, DEV MED CHILD NEUROL, V36, P429, DOI 10.1111/j.1469-8749.1994.tb11869.x; PONS G, 1994, CLIN PHARMACOKINET, V27, P270, DOI 10.2165/00003088-199427040-00003; POSTELLON DC, 1982, JAMA-J AM MED ASSOC, V247, P463, DOI 10.1001/jama.1982.03320290013017; Rambeck B, 1997, EUR J CLIN PHARMACOL, V51, P481, DOI 10.1007/s002280050234; RAMBECK B, 1993, CLIN PHARMACOKINET, V25, P433, DOI 10.2165/00003088-199325060-00003; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; Ryan AS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.4.e12; RYU JE, 1985, DEV PHARMACOL THERAP, V8, P329, DOI 10.1159/000457057; RYU JE, 1985, DEV PHARMACOL THERAP, V8, P355, DOI 10.1159/000457060; SCHMIMMEL MS, 1989, J PEDIATR-US, V114, P476, DOI 10.1016/S0022-3476(89)80578-5; SCHOU M, 1973, BRIT MED J, V2, P138, DOI 10.1136/bmj.2.5859.138; SCHULTEHOBEIN B, 1992, ACTA PAEDIATR, V81, P550, DOI 10.1111/j.1651-2227.1992.tb12293.x; SCHWARTZBICKENBACH D, 1987, TOXICOL LETT, V35, P73, DOI 10.1016/0378-4274(87)90088-9; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516; SMITH IJ, 1989, J CLIN PHARMACOL, V29, P174, DOI 10.1002/j.1552-4604.1989.tb03309.x; Sprouse J, 1996, NEUROPSYCHOPHARMACOL, V14, P225, DOI 10.1016/0893-133X(95)00112-Q; Stahl MMS, 1997, J PEDIATR-US, V130, P1001, DOI 10.1016/S0022-3476(97)70292-0; Stowe ZN, 1997, AM J PSYCHIAT, V154, P1255; STRUNGE P, 1988, EUR HEART J, V9, P106; SYKES PA, 1976, BRIT MED J, V2, P1299, DOI 10.1136/bmj.2.6047.1299; Taddio A, 1996, J CLIN PHARMACOL, V36, P42, DOI 10.1002/j.1552-4604.1996.tb04150.x; TANAKA PA, 1987, CAN MED ASSOC J, V136, P940; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005; Thiru Y, 1997, BRIT MED J, V315, P463, DOI 10.1136/bmj.315.7106.463; Tomson T, 1997, EPILEPSIA, V38, P1039, DOI 10.1111/j.1528-1157.1997.tb01489.x; TOWNSEND RJ, 1984, AM J OBSTET GYNECOL, V149, P184, DOI 10.1016/0002-9378(84)90195-9; Tran A, 1998, BRIT J CLIN PHARMACO, V45, P409, DOI 10.1046/j.1365-2125.1998.t01-1-00693.x; TUNNESSEN WW, 1972, J PEDIATR-US, V81, P804, DOI 10.1016/S0022-3476(72)80111-2; VIO F, 1991, AM J CLIN NUTR, V54, P1011, DOI 10.1093/ajcn/54.6.1011; WEINSTEIN MR, 1969, DIS NERV SYST, V30, P828; Weyrauch U, 1977, Rofo, V127, P275; WILSON JT, 1980, CLIN PHARMACOKINET, V5, P1, DOI 10.2165/00003088-198005010-00001; WISCHNIK A, 1989, EUR J CLIN PHARMACOL, V36, P521, DOI 10.1007/BF00558080; Wisner KL, 1998, AM J PSYCHIAT, V155, P690, DOI 10.1176/ajp.155.5.690; WITTELS B, 1990, ANESTHESIOLOGY, V73, P864, DOI 10.1097/00000542-199011000-00012; Wojnar-Horton RE, 1997, BRIT J CLIN PHARMACO, V44, P543, DOI 10.1046/j.1365-2125.1997.t01-1-00624.x; WojnarHorton RE, 1996, BRIT J CLIN PHARMACO, V41, P217, DOI 10.1111/j.1365-2125.1996.tb00185.x; Yoshida K, 1998, BRIT J PSYCHIAT, V172, P175, DOI 10.1192/bjp.172.2.175	129	176	184	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					118	126		10.1056/NEJM200007133430208	http://dx.doi.org/10.1056/NEJM200007133430208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891521				2023-01-03	WOS:000088116500008
J	McAlister, FA; Straus, SE; Guyatt, GH; Haynes, RB				McAlister, FA; Straus, SE; Guyatt, GH; Haynes, RB		Evidence-Based Med Working Grp	Users' guides to the medical literature - XX. Integrating research evidence with the care of the individual patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL DECISION-MAKING; CORONARY HEART-DISEASE; CAROTID ENDARTERECTOMY; PATIENTS PREFERENCES; COST-EFFECTIVENESS; RANDOMIZED TRIALS; BREAST-CANCER; HELP ME; RISK; STROKE	Clinicians can use research results to determine optimal care for an individual patient by using a patient's baseline risk estimate, clinical prediction guidelines that quantitate an individual patient's potential for benefit, and published articles. We propose that when clinicians are determining the likelihood that treatment will prevent the target event (at the expense of adverse events) in a patient that they also incorporate the patient's values. The 3 main elements to joint clinical decision making are disclosure of information about the risks and benefits of therapeutic alternatives, exploration of the patient's values about both the therapy and potential outcomes, and the actual decision. In addressing the patient's risk of adverse events without treatment and risk of harm with therapy, clinicians must recognize that patients are rarely identical to the average study patient. Differences between study participants and patients in real-world practice tend to be quantitative (differences in degree of risk of the outcome or responsiveness to therapy) rather than qualitative (no risk or adverse response to therapy). The number needed to treat and number needed to harm can be used to generate patient-specific estimates relative to the risk of the outcome event, Clinicians must consider a patient's risk of adverse events from any intervention and incorporate the patient's values in clinical decision making by using information about the risks and benefits of therapeutic alternatives.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Mt Sinai Hosp Univ Hlth Network, Div Gen Internal Med, Toronto, ON, Canada; Univ Alberta Hosp, Div Gen Internal Med, Edmonton, AB T6G 2B7, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Alberta	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	sstraus@mtsinai.on.ca	McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341; Haynes, Robert Brian/0000-0002-1453-3196				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Bain DJ, 1998, BRIT J SURG, V85, P768; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Chassin MR, 1998, NEW ENGL J MED, V339, P1468, DOI 10.1056/NEJM199811123392010; Chatellier G, 1996, BRIT MED J, V312, P426; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; ELIASZIW M, 1995, STROKE, V26, P1747, DOI 10.1161/01.STR.26.10.1747; Elneihoum AM, 1998, STROKE, V29, P2114, DOI 10.1161/01.STR.29.10.2114; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Franzosi MG, 1998, CIRCULATION, V97, P2202, DOI 10.1161/01.CIR.97.22.2202; Gage BF, 1998, STROKE, V29, P1083, DOI 10.1161/01.STR.29.6.1083; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Glasziou P, 1998, ACP J Club, V129, pA15; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Ioannidis JPA, 1998, AM J EPIDEMIOL, V148, P1117; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Lilford RJ, 1998, BMJ-BRIT MED J, V317, P405; Llewellyn-Thomas H A, 1997, Can J Nurs Res, V29, P45; LLEWELLYNTHOMAS HA, 1991, SOC SCI MED, V32, P35, DOI 10.1016/0277-9536(91)90124-U; Margalith I, 1997, SOC SCI MED, V45, P419, DOI 10.1016/S0277-9536(96)00357-7; Mazur DJ, 1997, J GEN INTERN MED, V12, P114, DOI 10.1046/j.1525-1497.1997.00016.x; McAlister FA, 1999, J AM GERIATR SOC, V47, P811, DOI 10.1111/j.1532-5415.1999.tb03837.x; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; O'Connor A M, 1997, Can J Nurs Res, V29, P7; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PEDERSEN TR, 1995, LANCET, V345, P1274; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RIEGELMAN R, 1993, MED DECIS MAKING, V13, P247, DOI 10.1177/0272989X9301300312; Rothenbacher D, 1997, EUR J CANCER, V33, P1184, DOI 10.1016/S0959-8049(97)00034-8; Rothwell PM, 1997, BMJ-BRIT MED J, V315, P1571, DOI 10.1136/bmj.315.7122.1571; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; Sackett D L, 1997, ACP J Club, V127, pA15; Sackett DL, 2000, EVIDENCE BASED MED P; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5; SAUVE JS, 1993, JAMA-J AM MED ASSOC, V270, P2843, DOI 10.1001/jama.270.23.2843; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; SCHULMAN BA, 1979, MED CARE, V17, P267, DOI 10.1097/00005650-197903000-00004; Sculpher M, 1998, HEALTH ECON, V7, P129; Sharp SJ, 1996, BRIT MED J, V313, P735; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Stiggelbout AM, 1997, CAN MED ASSOC J, V157, P383; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Szabo E, 1997, ARCH INTERN MED, V157, P1352, DOI 10.1001/archinte.157.12.1352; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; VICKERY DM, 1988, MED CARE, V26, P580, DOI 10.1097/00005650-198806000-00006; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	76	165	168	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	2000	283	21					2829	2836		10.1001/jama.283.21.2829	http://dx.doi.org/10.1001/jama.283.21.2829			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	320BQ	10838653				2023-01-03	WOS:000087381500039
J	Moore, LB; Parks, DJ; Jones, SA; Bledsoe, RK; Consler, TG; Stimmel, JB; Goodwin, B; Liddle, C; Blanchard, SG; Willson, TM; Collins, JL; Kliewer, SA				Moore, LB; Parks, DJ; Jones, SA; Bledsoe, RK; Consler, TG; Stimmel, JB; Goodwin, B; Liddle, C; Blanchard, SG; Willson, TM; Collins, JL; Kliewer, SA			Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450 GENE INDUCTION; SIGNALING PATHWAY; HUMAN HEPATOCYTES; ENHANCER MODULE; CYP2B GENE; CAR; DEFINES; CYP3A4; PXR	Xenobiotics induce the transcription of cytochromes P450 (CYPs) 2B and 3A through the constitutive androstane receptor (CAR; NR1I3) and pregnane X receptor (PXR; NR1I2), respectively, In this report, we have systematically compared a series of xenobiotics and natural steroids for their effects on mouse and human CAR and PXR, Our results demonstrate dual regulation of PXR and CAR by a subset of compounds that affect CYP expression, Moreover, there are marked pharmacological differences between the mouse (m) and human (h) orthologs of both CAR and PXR, For example, the planar hydrocarbon 1,4-bis[2-(3,5-dichloropyridyl-oxy)]benzene activates mCAR and hPXR but has little or no activity on hCAR and mPXR, In contrast, the CAR deactivator androstanol activates both mouse and human PXR, Similarly, the PXR activator clotrimazole is a potent deactivator of hCAR, Using radioligand binding and fluorescence resonance energy transfer assays, we demonstrate that several of the compounds that regulate mouse and human CAR, including natural steroids, bind directly to the receptors, Our results suggest that CAR, like PXR, is a steroid receptor that is capable of recognizing structurally diverse compounds, Moreover, our findings underscore the complexity in the physiologic response to xenobiotics.	Glaxo Wellcome Inc, Res & Dev, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Sydney, Dept Clin Pharmacol, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Storr Liver Unit, Westmead Hosp, Westmead, NSW 2145, Australia	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Sydney; University of Sydney	Kliewer, SA (corresponding author), Glaxo Wellcome Inc, Res & Dev, Dept Mol Endocrinol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	sak15922@glaxowellcome.com	feinstein, doug/M-9414-2019					BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KOCAREK TA, 1995, DRUG METAB DISPOS, V23, P415; KOCAREK TA, 1993, BIOCHEM PHARMACOL, V48, P1815; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Nichols JS, 1998, ANAL BIOCHEM, V257, P112, DOI 10.1006/abio.1997.2557; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	20	701	731	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15122	15127		10.1074/jbc.M001215200	http://dx.doi.org/10.1074/jbc.M001215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748001	hybrid			2023-01-03	WOS:000087128300049
J	Goldfrad, C; Rowan, K				Goldfrad, C; Rowan, K			Consequences of discharges from intensive care at night	LANCET			English	Article							HIGH-DEPENDENCY UNIT; SOCIETY APACHE-II; CASE-MIX; SET-UP; BRITAIN; IMPACT; SHORTAGES; ADMISSION; PROVISION; REGISTER	Background It is generally believed that pressure for beds on intensive-care units (ICUs) has increased in the UK. This study used discharge at night as a proxy measure to investigate pressure. Methods Night was defined in two ways: "out of office hours' from 2200 to 0659 h and "the early hours of the morning" from 0000 to 0459 h. The rate of discharge at night was compared for 21 295 adult admissions to 62 ICUs covering the period 1995-98 with 10 806 admissions to 26 ICUs covering the period 1988-90. With data solely from 1995-98, the consequences of discharge at night and premature discharge were investigated. Findings Overall, 2269 (21.0%) admissions did not survive the ICU in 1988-90 compared with 4487 (21.1%) in 1995-98. Of ICU survivors, 2.7% were discharged at night (2200-0659 h) in 1988-90 compared with 6.0% in 1995-98. In 1995-98, night discharges (2200-0659 h) had a higher crude (odds ratio 1.46, 95% CI 1.18-1.80) and case-mix adjusted (1.33, 1.06-1.65) ultimate hospital mortality. Higher odds ratios were observed when the definition of night was 0000-0459 h. Premature discharge was commoner at night, 42.6% vs 5.0% and its importance was apparent when incorporated into the logistic-regression model (premature discharge 1.35, 1.10-1.65; night discharge 1.17, 0.92-1.49). Interpretation Night discharges from ICU are increasing in the UK. This practice is of concern because patients discharged at night fare significantly worse than those discharged during the day. Night discharges are more likely to be "premature" in the view of the clinicians involved. The implication of these results is that many hospitals have insufficient intensive-care beds. In deciding whether or not to invest more resources in intensive care we must, however, consider the cost-utility of this particular service compared with other ways that additional resources could be used.	Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England	Intensive Care National Audit & Research Centre	Rowan, K (corresponding author), Intens Care Natl Audit & Res Ctr, Tavistock House,Tavistock Sq, London WC1H 9HR, England.							BION J, 1995, BMJ-BRIT MED J, V310, P682, DOI 10.1136/bmj.310.6981.682; Black N, 1996, HEART, V76, P1, DOI 10.1136/hrt.76.4_Suppl_4.1; BULL AR, 1995, BRIT MED J, V310, P1010, DOI 10.1136/bmj.310.6985.1010b; CHADDA D, 1995, HLTH SERV J     0720, P4; DYER O, 1995, BRIT MED J, V310, P688, DOI 10.1136/bmj.310.6981.688a; Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241; KILPATRICK A, 1994, ANAESTHESIA, V49, P666, DOI 10.1111/j.1365-2044.1994.tb04393.x; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; METCALFE A, 1995, STUDY PROVISION INTE; Metcalfe MA, 1997, LANCET, V350, P7, DOI 10.1016/S0140-6736(96)10018-0; MITCHELL I, 1995, LANCET, V345, P652, DOI 10.1016/S0140-6736(95)90554-5; PEACOCK JE, 1995, BRIT MED J, V310, P1413, DOI 10.1136/bmj.310.6991.1413; Rowan K, 1996, BRIT MED J, V313, P1007; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; Rowan KM., 1992, THESIS U OXFORD; RYAN DW, 1995, BRIT MED J, V310, P1010, DOI 10.1136/bmj.310.6985.1010c; Ryan DW, 1997, ANAESTHESIA, V52, P265, DOI 10.1111/j.1365-2044.1997.068-az0055.x; SMITH GB, 1995, BRIT MED J, V310, P1412, DOI 10.1136/bmj.310.6991.1412b; Wallace PGM, 1997, BRIT MED J, V314, P369, DOI 10.1136/bmj.314.7077.369; Warden J, 1996, BRIT MED J, V313, P575; *WORK PART, 1994, REV INT CAR SERV W M; 1995, HLTH SERV J     0126, P6; [No title captured]	24	220	222	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1138	1142		10.1016/S0140-6736(00)02062-6	http://dx.doi.org/10.1016/S0140-6736(00)02062-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791376				2023-01-03	WOS:000086380900011
J	Messer, CJ; Eisch, AJ; Carlezon, WA; Whisler, K; Shen, L; Wolf, DH; Westphal, H; Collins, F; Russell, DS; Nestler, EJ				Messer, CJ; Eisch, AJ; Carlezon, WA; Whisler, K; Shen, L; Wolf, DH; Westphal, H; Collins, F; Russell, DS; Nestler, EJ			Role for GDNF in biochemical and behavioral adaptations to drugs of abuse	NEURON			English	Article							MESOLIMBIC DOPAMINE SYSTEM; VENTRAL TEGMENTAL AREA; MICE LACKING GDNF; CHOLERA-TOXIN INFUSION; MESSENGER-RNA LEVELS; C-RET PROTOONCOGENE; NERVE GROWTH-FACTOR; CYCLIC-AMP SYSTEM; NEUROTROPHIC FACTOR; NUCLEUS-ACCUMBENS	The present study examined a role for GDNF in adaptations to drugs of abuse. Infusion of GDNF into the ventral tegmental area (VTA), a dopaminergic brain region important for addiction, blocks certain biochemical adaptations to chronic cocaine or morphine as well as the rewarding effects of cocaine. Conversely, responses to cocaine are enhanced in rats by intra-VTA infusion of an anti-GDNF antibody and in mice heterozygous for a null mutation in the GDNF gene. Chronic morphine or cocaine exposure decreases levels of phosphoRet, the protein kinase that mediates GDNF signaling, in the VTA. Together, these results suggest a feedback loop, whereby drugs of abuse decrease signaling through endogenous GDNF pathways in the VTA, which then increases the behavioral sensitivity to subsequent drug exposure.	Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA; Yale Univ, Sch Med, Yale Ctr Genes & Behav, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; NIH, Lab Mammalian Genes & Dev, Bethesda, MD 20892 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Yale University; Yale University; National Institutes of Health (NIH) - USA; Amgen	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA.		; Wolf, Daniel/H-2581-2013	Eisch, Amelia/0000-0001-6476-5385; Wolf, Daniel/0000-0002-9731-8781; /0000-0002-4162-3947	NIDA NIH HHS [K08 DA000302-05] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K08DA000302] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akerud P, 1999, J NEUROCHEM, V73, P70, DOI 10.1046/j.1471-4159.1999.0730070.x; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BEITNERJOHNSON D, 1992, J NEUROSCI, V12, P2165; BEITNERJOHNSON D, 1991, J NEUROCHEM, V57, P344, DOI 10.1111/j.1471-4159.1991.tb02133.x; BEITNERJOHNSON D, 1993, J NEUROCHEM, V61, P1766, DOI 10.1111/j.1471-4159.1993.tb09814.x; Berhow MT, 1996, J NEUROSCI, V16, P4707; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; Boundy VA, 1998, J NEUROSCI, V18, P9989; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; CHEAH TB, 1973, J NEUROBIOL, V4, P443, DOI 10.1002/neu.480040505; CUNNINGHAM ST, 1993, J NEUROSCI, V13, P2342, DOI 10.1523/JNEUROSCI.13-06-02342.1993; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Gash D M, 1998, Adv Pharmacol, V42, P911; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GRAFSTEIN B, 1975, EXP NEUROL, V48, P32, DOI 10.1016/0014-4886(75)90170-3; Griesbeck O, 1996, COLD SPRING HARB SYM, V61, P77; Hebert MA, 1997, J PHARMACOL EXP THER, V282, P760; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Horger BA, 1999, J NEUROSCI, V19, P4110; HURD YL, 1992, BRAIN RES, V578, P317, DOI 10.1016/0006-8993(92)90264-A; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Kelley AE, 1997, SYNAPSE, V26, P46, DOI 10.1002/(SICI)1098-2396(199705)26:1<46::AID-SYN5>3.0.CO;2-E; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lu X, 1997, J COMP NEUROL, V388, P484; MISERENDINO MJD, 1995, BRAIN RES, V674, P299, DOI 10.1016/0006-8993(95)00030-T; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Nestler EJ, 1996, MOL PSYCHIATR, V1, P190; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Numan S, 1998, J NEUROSCI, V18, P10700; Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671; Nye HE, 1996, MOL PHARMACOL, V49, P636; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pich EM, 1997, SCIENCE, V275, P83; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pilotte NS, 1997, CURR OPIN NEUROL, V10, P534, DOI 10.1097/00019052-199712000-00017; Robinson TE, 1997, J NEUROSCI, V17, P8491; Robinson TE, 1999, SYNAPSE, V33, P160; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Self DW, 1998, J NEUROSCI, V18, P1848; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; SORG BA, 1993, J PHARMACOL EXP THER, V266, P424; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Vaidya VA, 1999, NEUROSCIENCE, V89, P157, DOI 10.1016/S0306-4522(98)00289-9; VRANA SL, 1993, J NEUROCHEM, V61, P2262, DOI 10.1111/j.1471-4159.1993.tb07468.x; Winkler C, 1996, J NEUROSCI, V16, P7206; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5; Wolf DH, 1999, J NEUROCHEM, V73, P1520, DOI 10.1046/j.1471-4159.1999.0731520.x; Xu RY, 1998, J NEUROCHEM, V70, P1383, DOI 10.1046/j.1471-4159.1998.70041383.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	64	133	163	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0896-6273			NEURON	Neuron	APR	2000	26	1					247	257		10.1016/S0896-6273(00)81154-X	http://dx.doi.org/10.1016/S0896-6273(00)81154-X			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	309MA	10798408	Bronze, Green Accepted			2023-01-03	WOS:000086770500024
J	Talan, DA; Stamm, WE; Hooton, TM; Moran, GJ; Burke, T; Iravani, A; Reuning-Scherer, J; Church, DA				Talan, DA; Stamm, WE; Hooton, TM; Moran, GJ; Burke, T; Iravani, A; Reuning-Scherer, J; Church, DA			Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; THERAPY; SUSCEPTIBILITY; AMPICILLIN	Context The optimal antimicrobial regimen and treatment duration for acute uncomplicated pyelonephritis are unknown. Objective To compare the efficacy and safety of a 7-day ciprofloxacin regimen and a 14-day trimethoprim-sulfamethoxazole regimen for the treatment of acute pyelonephritis in women. Design Randomized, double-blind comparative trial conducted from October 1994 through January 1997. Setting Twenty-five outpatient centers in the United States. Patients Of 378 enrolled premenopausal women aged at least 18 years with clinical diagnosis of acute uncomplicated pyelonephritis, 255 were included in the analysis. Other individuals were excluded for no baseline causative organism, inadequate receipt of study drug, loss to follow-up, no appropriate cultures, and other reasons. Interventions Patients were randomized to oral ciprofloxacin, 500 mg twice per day for 7 days (with or without an initial 400-mg intravenous dose) followed by placebo for 7 days (n = 128 included in analysis) vs trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (with or without intravenous ceftriaxone, 1 g) (n = 127 included in the analysis). Main Outcome Measure Continued bacteriologic and clinical cure, such that alternative antimicrobial drugs were not required, among evaluable patients through the 4- to 11-day posttherapy visit, compared by treatment group. Results At 4 to 11 days posttherapy, bacteriologic cure rates were 99% (112 of 113) for the ciprofloxacin regimen and 89% (90 of 101) for the trimethoprimsulfamethoxazole regimen (95% confidence interval [CI] for difference, 0.04-0.16; P =.004). Clinical cure rates were 96% (109 of 113) for the ciprofloxacin regimen and 83% (92 of 111) for the trimethoprim-sulfamethoxazole regimen (95% CI, 0.06-0.22; P =.002), Escherichia coli, which caused more than 90% of infections, was more frequently resistant to trimethoprim-sulfamethoxazole (18%) than to ciprofloxacin (0%; P<.001). Among trimethoprim-sulfamethoxazole-treated patients, drug resistance was associated with greater bacteriologic and clinical failure rates (P<.001 for both). Drug-related adverse events occurred in 24% of 191 ciprofloxacin-treated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respectively (95% CI, -0.001 to 0.2). Conclusions In our study of outpatient treatment of acute uncomplicated pyelonephritis in women, a 7-day ciprofloxacin regimen was associated with greater bacteriologic and clinical cure rates than a 14-day trimethoprim-sulfamethoxazole regimen, especially in patients infected with trimethoprim-sulfamethoxazole-resistant strains.	Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Med, Div Emergency Med, Los Angeles, CA USA; Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Med, Div Infect Dis, Los Angeles, CA USA; Univ Washington, Harborview Med Ctr, Dept Med, Div Infect Dis, Seattle, WA 98104 USA; Providence St Peters Hosp, Olympia, WA USA; Cent Florida Med Res Ctr, Orlando, FL USA; Bayer Corp, Div Pharmaceut, W Haven, CT USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harborview Medical Center; University of Washington; University of Washington Seattle; Bayer AG	Talan, DA (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.							ALON U, 1987, ANTIMICROB AGENTS CH, V31, P126, DOI 10.1128/AAC.31.1.126; *AM HOSP ASS, 1995, HOSP STAT; *AM MED ASS, 1997, PHYS CURR PROC TERM; BAILEY RR, 1992, NEW ZEAL MED J, V105, P102; BEUNDERS AJ, 1994, J ANTIMICROB CHEMOTH, V33, P17, DOI 10.1093/jac/33.suppl_A.17; BRAHAM E, 1982, CURR THER RES, V31, P536; *BUR LAB STAT, 1997, CONS PRIC IND MED CA; GLECKMAN R, 1985, J UROLOGY, V133, P176, DOI 10.1016/S0022-5347(17)48870-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; JERNELIUS H, 1988, ACTA MED SCAND, V223, P469; JOHNSON JR, 1991, J INFECT DIS, V163, P325, DOI 10.1093/infdis/163.2.325; MCCARTHY E, 1989, DHHS PUBLICATION; *MED EC CO INC, 1997, 1997 DRUG TOP REDB; *NAT COMM CLIN LAB, 1993, APPR STAND METH DIL; *NAT COMM CLIN LAB, 1993, APPR STAND PERF STAN; NORRBY SR, 1990, REV INFECT DIS, V12, P458; ODE B, 1980, ACTA MED SCAND, V207, P305; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; SAFRIN S, 1988, AM J MED, V85, P793; SEGAL MJ, 1995, MED RBRVS PHYSICIANS; STAMM WE, 1989, J INFECT DIS, V159, P400, DOI 10.1093/infdis/159.3.400; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STAMM WE, 1987, ANN INTERN MED, V106, P341, DOI 10.7326/0003-4819-106-3-341; *STAT MAR HLTH SER, 1998, CUR RAT REP; *STAT MAR HLTH SER, 1996, ACC BUDG MAN FISC OP; *US FOOD DRUG ADM, 1992, POINTS CONS, P20; WARD G, 1991, ANN EMERG MED, V20, P258, DOI 10.1016/S0196-0644(05)80935-7; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Winstanley TG, 1997, J ANTIMICROB CHEMOTH, V40, P591, DOI 10.1093/jac/40.4.591	31	303	319	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1583	1590		10.1001/jama.283.12.1583	http://dx.doi.org/10.1001/jama.283.12.1583			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735395	Bronze			2023-01-03	WOS:000085857300035
J	Nightingale, PG; Adu, D; Richards, NT; Peters, M				Nightingale, PG; Adu, D; Richards, NT; Peters, M			Implementation of rules based computerised bedside prescribing and administration: intervention study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; DECISION-SUPPORT; MEDICATION ERRORS; PREVENTION; SYSTEMS	Obectives: To Implement and assess a rules based computerised prescribing system with the aim of improving the safety of prescriptions and the administration of drugs. Design: Analysis of performance of computerised system plus questionnaire survey of users. Setting: 64 bed renal unit in a teaching hospital. Intervention: Introduction of the system into routine clinical use. Main outcome measures: Number of attempted prescriptions cancelled by the system; proportion of warning messages overridden; users' comparisons of the system with conventional procedures. Results: Between October 1998 and August 1999 die system cancelled 58 (0.07%) out of 87 789 prescriptions on the grounds of clinical safety. In addition, 427 (57%) attempted prescriptions generating high level warnings and 1257 (8%) generating low level warnings were not completed. In a user survey 82% (31/38) of doctors and nurses considered the system to be an improvement on conventional procedures. Conclusions: The system has contributed to safety and patient care. All prescriptions are complete and legible, and transcription errors have been eliminated. The system assists clinicians when they are writing a prescription by making available information on patients. The system supports clinical decision making and has been well received by doctors, nurses, and pharmacists.	Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Comp Lab, Birmingham B15 2TH, W Midlands, England; Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Dept Nephrol, Renal Serv, Birmingham B15 2TH, W Midlands, England; Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Dept Nephrol, Urol Serv, Birmingham B15 2TH, W Midlands, England	Birmingham City University; University of Birmingham; University of Birmingham; University of Birmingham	Nightingale, PG (corresponding author), Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Comp Lab, Birmingham B15 2TH, W Midlands, England.	P.G.Nightingale@bham.ac.uk						Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; FERNER RE, 1992, J MED DEFENCE UNION, V8, P60; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Purves IN, 1998, BRIT J GEN PRACT, V48, P1552; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181	18	127	128	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					750	753		10.1136/bmj.320.7237.750	http://dx.doi.org/10.1136/bmj.320.7237.750			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720357	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000086054700022
J	Lincoln, NB; Husbands, S; Trescoli, C; Drummond, AER; Gladman, JRF; Berman, P				Lincoln, NB; Husbands, S; Trescoli, C; Drummond, AER; Gladman, JRF; Berman, P			Five year follow up of a randomised controlled trial of a stroke rehabilitation unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England; Univ Nottingham, Ageing & Disabil Res Unit, Nottingham NG7 2UH, England; Nottingham City Hosp NHS Trust, Dept Med, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Lincoln, NB (corresponding author), Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England.	nbl@psychology.nottingham.ac.uk	Trescolí, Carlos/GLQ-7462-2022; Lincoln, Nadina B/B-9149-2009; Gladman, John/M-7429-2015	Gladman, John/0000-0002-8506-7786; Drummond, Avril/0000-0003-1220-8354				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Collin C, 1988, Int Disabil Stud, V10, P61; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005	4	31	31	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2000	320	7234					549	549		10.1136/bmj.320.7234.549	http://dx.doi.org/10.1136/bmj.320.7234.549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289LV	10688561	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000085624000023
J	Pellegrino, ED				Pellegrino, ED			Decisions to withdraw life-sustaining treatment - A moral algorithm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservoir Rd NW,D-238, Washington, DC 20007 USA.								0	90	96	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1065	1067		10.1001/jama.283.8.1065	http://dx.doi.org/10.1001/jama.283.8.1065			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284AM	10697071				2023-01-03	WOS:000085308600040
J	Zito, JM; Safer, DJ; dosReis, S; Gardner, JF; Boles, M; Lynch, F				Zito, JM; Safer, DJ; dosReis, S; Gardner, JF; Boles, M; Lynch, F			Trends in the prescribing of psychotropic medications to preschoolers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Psychiatric-Association	MAY 15-19, 1999	WASHINGTON, D.C.	Amer Psychiat Assoc			DEFICIT HYPERACTIVITY DISORDER; STIMULANT MEDICATION; CLONIDINE; CHILDREN; PSYCHOPHARMACOLOGY; METHYLPHENIDATE; ADOLESCENTS; PREVALENCE; QUESTIONS; EFFICACY	Context Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates. Objectives To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span. Design Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population - based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). Setting and Participants From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146 369 to 158 060; in a mid-Atlantic state Medicaid (MAM) program, from 34 842 to 54 237; and in an HMO setting in the Northwest, from 19 107 to 19 322. Main Outcome Measures Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites. Results The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); anti depressants (3.2); clonidine (2,3); and neuroleptics (0.9), A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7), Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents. Conclusions In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.	Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Kaiser Permanente, Ctr Hlth Res, Portland, OR USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Kaiser Permanente	Zito, JM (corresponding author), Univ Maryland, Sch Pharm, 100 Greene St,Room 5-13, Baltimore, MD 21201 USA.				NIMH NIH HHS [R01 MH55259] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055259] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHMANN PA, 1993, PEDIATRICS, V91, P1101; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P539, DOI 10.1097/00004583-199704000-00017; DAVILLA RR, 1991, CLARIFICATION POLICY; Erickson SJ, 1998, J PAEDIATR CHILD H, V34, P280, DOI 10.1046/j.1440-1754.1998.t01-1-00217.x; Firestone P, 1998, J CHILD ADOL PSYCHOP, V8, P13, DOI 10.1089/cap.1998.8.13; FOXMAN B, 1986, PEDIATRICS, V77, P482; Geller B, 1999, J AM ACAD CHILD PSY, V38, P513, DOI 10.1097/00004583-199905000-00012; Greenhill LL, 1998, CAN J PSYCHIAT, V43, P576, DOI 10.1177/070674379804300604; GRINFELD MJ, 1998, PSYCHIAT TIMES, V15, P69; Hoagwood K, 1996, J AM ACAD CHILD PSY, V35, P1055, DOI 10.1097/00004583-199608000-00017; JENSEN PS, 1994, PSYCHOPHARMACOL BULL, V30, P3; Kappagoda C, 1998, J PAEDIATR CHILD H, V34, P508, DOI 10.1046/j.1440-1754.1998.00301.x; Minde K, 1998, CAN J PSYCHIAT, V43, P571, DOI 10.1177/070674379804300603; PATHIYAL A, 1998, AM SOC CLIN PHARM TH; Perrin JM, 1999, ARCH PEDIAT ADOL MED, V153, P80; Pincus HA, 1998, JAMA-J AM MED ASSOC, V279, P526, DOI 10.1001/jama.279.7.526; POPPER CW, 1995, J CHILD ADOL PSYCHOP, V5, P157, DOI 10.1089/cap.1995.5.157; Prince JB, 1996, J AM ACAD CHILD PSY, V35, P599, DOI 10.1097/00004583-199605000-00014; RAPPLEY MD, 1998, PED AC SOC M JOINT S; Safer D.J., 2000, RITALIN THEORY PRACT, P7; Safer DJ, 1996, PEDIATRICS, V98, P1084; Swanson JM, 1995, J CHILD ADOL PSYCHOP, V5, P301, DOI 10.1089/cap.1995.5.301; Traversa G, 1998, J CHILD ADOL PSYCHOP, V8, P175, DOI 10.1089/cap.1998.8.175; Valentine J, 1996, J PAEDIATR CHILD H, V32, P223, DOI 10.1111/j.1440-1754.1996.tb01558.x; Vitiello B, 1997, ARCH GEN PSYCHIAT, V54, P871; Vitiello B, 1998, CAN J PSYCHIAT, V43, P582, DOI 10.1177/070674379804300605; Wilens TE, 1999, J AM ACAD CHILD PSY, V38, P614, DOI 10.1097/00004583-199905000-00025; Zito JM, 1998, J CHILD ADOL PSYCHOP, V8, P99, DOI 10.1089/cap.1998.8.99; ZITO JM, 1998, TRENDS PSYCHOTROPIC	29	634	641	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2000	283	8					1025	1030		10.1001/jama.283.8.1025	http://dx.doi.org/10.1001/jama.283.8.1025			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	284AM	10697062	Bronze			2023-01-03	WOS:000085308600031
J	Callahan, D				Callahan, D			Aging, death, and population health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hastings Ctr, Garrison, NY 10524 USA		Callahan, D (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.							CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Larson E B, 1999, Jt Comm J Qual Improv, V25, P480	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2077	2077		10.1001/jama.282.21.2077	http://dx.doi.org/10.1001/jama.282.21.2077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591393	hybrid			2023-01-03	WOS:000083908700030
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Hypnosis and relaxation therapies	BRITISH MEDICAL JOURNAL			English	Review																		KARLE H, 1996, HYPNOTHERAPY PRACTIC; SIEGEL B, 1989, LOVE MED MIRACLES; WAXMAN D, 1988, MED DENTAL HYPNOSIS	3	31	31	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1346	1349		10.1136/bmj.319.7221.1346	http://dx.doi.org/10.1136/bmj.319.7221.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567143	Green Published			2023-01-03	WOS:000083930200028
J	Hensher, M; Fulop, N; Coast, J; Jefferys, E				Hensher, M; Fulop, N; Coast, J; Jefferys, E			The hospital of the future - Better out than in? Alternatives to acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							COST MINIMIZATION ANALYSIS; HOME CARE; AT-HOME; ADMISSIONS; APPROPRIATENESS		Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Hensher, M (corresponding author), Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, Keppel St, London WC1E 7HT, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827; Fulop, Naomi/0000-0001-5306-6140; Coast, Joanna/0000-0002-3537-5166				ABELSMITH B, 1994, HEALTH POLICY, V28, P89, DOI 10.1016/0168-8510(94)90030-2; Apolone G, 1997, EUR J PUBLIC HEALTH, V7, P34, DOI 10.1093/eurpub/7.1.34; BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; Coast J, 1996, BRIT MED J, V312, P162; HAYES CB, 1995, IRISH MED J, V88, P124; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1997, J ROY SOC MED, V90, P181, DOI 10.1177/014107689709000401; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; Raftery J, 1998, J Health Serv Res Policy, V3, P149; READ S, 1994, PATIENTS MINOR INJUR; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERD S, 1998, COCHRANE LIB; Smith HE, 1997, J ROY COLL PHYS LOND, V31, P527; Steiner A, 1997, INTERMEDIATE CARE CO; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; Wilson A., 1997, J EPIDEMIOL COMMUNIT, V51, P593	21	37	37	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1127	1130		10.1136/bmj.319.7217.1127	http://dx.doi.org/10.1136/bmj.319.7217.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531112	Green Published			2023-01-03	WOS:000083419500035
J	Allen, C; Glasziou, P; Del Mar, C				Allen, C; Glasziou, P; Del Mar, C			Bed rest: a potentially harmful treatment needing more careful evaluation	LANCET			English	Article							LOW-BACK-PAIN; PROSPECTIVE RANDOMIZED TRIAL; LUMBAR-PUNCTURE HEADACHE; EARLY AMBULATION; MYOCARDIAL-INFARCTION; PATIENT COMFORT; CLINICAL-TRIAL; CATHETERIZATION; MOBILIZATION; ANGIOGRAPHY	Background Bed rest is not only used in the management of patients who are not able to mobilise, but is also prescribed as a treatment for a large number of medical conditions, a procedure that has been challenged. We searched the literature for evidence of benefit or harm of bed rest for any condition. Methods We systematically searched MEDLINE and the Cochrane library, and retrieved reports on randomised controlled trials of bed rest versus early mobilisation for any medical condition, including medical procedures. Findings 39 trials of bed rest for 15 different conditions (total patients 5777) were found. In 24 trials investigating bed rest following a medical procedure, no outcomes improved significantly and eight worsened significantly in some procedures (lumbar puncture, spinal anaesthesia, radiculography, and cardiac catheterisation). In 15 trials investigating bed rest as a primary treatment, no outcomes improved significantly and nine worsened significantly for some conditions (acute low back pain, labour, proteinuric hypertension during pregnancy, myocardial infarction, and acute infectious hepatitis). Interpretation We should not assume any efficacy for bed rest. Further studies need to be done to establish evidence for the benefit or harm of bed rest as a treatment.	Univ Queensland, Grad Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia	University of Queensland	Glasziou, P (corresponding author), Univ Queensland, Grad Sch Med, Ctr Gen Practice, Herston, Qld 4006, Australia.		Del Mar, Chris B/B-1136-2008; Glasziou, Paul/A-7832-2008	Del Mar, Chris B/0000-0003-3821-8163; Glasziou, Paul/0000-0001-7564-073X				ANDERSEN A P D, 1986, Regional-Anaesthesie, V9, P15; Antman EM, 1998, HARRISONS PRINCIPLES; BARKMAN A, 1994, HEART LUNG, V23, P112; Baum RA, 1996, CATHETER CARDIO DIAG, V39, P230, DOI 10.1002/(SICI)1097-0304(199611)39:3<230::AID-CCD4>3.0.CO;2-F; CARBAAT PAT, 1981, LANCET, V2, P1133; CHAKRAVARTY K, 1994, BRIT J RHEUMATOL, V33, P464; CHALMERS TC, 1955, J CLIN INVEST, V34, P1163, DOI 10.1172/JCI103164; COCHRANE AL, 1981, HERZ, V6, P112; COOK PT, 1989, ANAESTHESIA, V44, P389, DOI 10.1111/j.1365-2044.1989.tb11334.x; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Dock W, 1944, J AMER MED ASSOC, V125, P1083, DOI 10.1001/jama.1944.02850340009004; Elam Kenneth C., 1995, Journal of Emergency Medicine, V13, P143, DOI 10.1016/0736-4679(94)00134-0; EVANS C, 1987, Physiotherapy Canada, V39, P96; Fassoulaki A, 1991, Anaesthesiol Reanim, V16, P375; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; FOWLOW B, 1995, HEART LUNG, V24, P28, DOI 10.1016/S0147-9563(05)80092-5; Ghormley RK, 1944, J AMER MED ASSOC, V125, P1085, DOI 10.1001/jama.1944.02850340011005; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; Graham J, 1968, J Bone Joint Surg Br, V50, P562; HARRISON RF, 1993, INT J FERTIL, V38, P160; Harrison TR, 1944, J AMER MED ASSOC, V125, P1075, DOI 10.1001/jama.1944.02850340001001; Hilton J., 1863, INFLUENCE MECH PHYSL; Hippocrates, 1849, GENUINE WORKS HIPPOC; IRVIN CW, 1950, NEW ENGL J MED, V243, P486, DOI 10.1056/NEJM195009282431304; Isik FF, 1997, PLAST RECONSTR SURG, V100, P350, DOI 10.1097/00006534-199708000-00011; Juran N B, 1996, Am J Crit Care, V5, P442; Keeling A, 1996, Am J Crit Care, V5, P277; KEELING AW, 1994, APPL NURS RES, V7, P14, DOI 10.1016/0897-1897(94)90015-9; LAMERS HJ, 1973, BMJ-BRIT MED J, V1, P257, DOI 10.1136/bmj.1.5848.257; LAU KW, 1993, CATHETER CARDIO DIAG, V28, P34, DOI 10.1002/ccd.1810280107; Levine SA, 1944, J AMER MED ASSOC, V126, P80, DOI 10.1001/jama.1944.02850370018004; Lim R, 1997, AM J CARDIOL, V80, P222, DOI 10.1016/S0002-9149(97)00326-3; MACPHERSON P, 1983, CLIN RADIOL, V34, P325, DOI 10.1016/S0009-9260(83)80350-X; MACPHERSON P, 1985, NEURORADIOLOGY, V27, P214, DOI 10.1007/BF00344490; MACPHERSON P, 1984, CLIN RADIOL, V35, P287, DOI 10.1016/S0009-9260(84)80095-1; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MATHEWS DD, 1982, BRIT J OBSTET GYNAEC, V89, P128, DOI 10.1111/j.1471-0528.1982.tb04678.x; MATHEWS DD, 1980, BRIT J OBSTET GYNAEC, V87, P1095, DOI 10.1111/j.1471-0528.1980.tb04479.x; Menninger K, 1944, J AMER MED ASSOC, V125, P1087, DOI 10.1001/jama.1944.02850340013006; MILLER RR, 1976, ANN INTERN MED, V84, P700, DOI 10.7326/0003-4819-84-6-700; MILLS JA, 1971, NEW ENGL J MED, V284, P453, DOI 10.1056/NEJM197103042840901; MINUK GY, 1987, GASTROENTEROLOGY, V92, P290, DOI 10.1016/0016-5085(87)90119-3; PoolerLunse C, 1996, HEART LUNG, V25, P117, DOI 10.1016/S0147-9563(96)80113-0; PRATT JH, 1920, SOUTH MED J, V13, P481; Riegel B, 1996, Am J Crit Care, V5, P91; *ROYAL INF MED DIV, 1973, LANCET, V2, P346; SCHMITT M A, 1991, Journal of Burn Care and Rehabilitation, V12, P33, DOI 10.1097/00004630-199101000-00008; Serpell MG, 1998, BRIT MED J, V316, P1709, DOI 10.1136/bmj.316.7146.1709; SPRIGGS DA, 1992, POSTGRAD MED J, V68, P581, DOI 10.1136/pgmj.68.801.581; TEASDALE E, 1983, NEURORADIOLOGY, V25, P85, DOI 10.1007/BF00333297; THORNBERRY EA, 1988, BRIT J ANAESTH, V60, P195, DOI 10.1093/bja/60.2.195; VILMING ST, 1988, CEPHALALGIA, V8, P75, DOI 10.1046/j.1468-2982.1988.0802075.x; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; WALDHAUSEN JHT, 1990, ANN SURG, V212, P671, DOI 10.1097/00000658-199012000-00004; WEST RR, 1979, BRIT HEART J, V42, P381; WEST RR, 1985, BRIT HEART J, V53, P243; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; WILKINSON MJB, 1995, BRIT J GEN PRACT, V45, P481; Williams RH, 1938, AM HEART J, V15, P385, DOI 10.1016/S0002-8703(38)90292-3; Wood RA, 1997, CATHETER CARDIO DIAG, V42, P8, DOI 10.1002/(SICI)1097-0304(199709)42:1<8::AID-CCD3>3.0.CO;2-8; WYNN-WILLIAMS N, 1960, Tubercle, V41, P352, DOI 10.1016/S0041-3879(60)80037-2	61	297	306	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1229	1233		10.1016/S0140-6736(98)10063-6	http://dx.doi.org/10.1016/S0140-6736(98)10063-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520630				2023-01-03	WOS:000083010400007
J	Detmar, SB; Muller, MJ; Wever, LDV; Schornagel, JH; Aaronson, NK				Detmar, SB; Muller, MJ; Wever, LDV; Schornagel, JH; Aaronson, NK			Patient-physician communication during outpatient palliative treatment visits - An observational study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; CANCER-PATIENTS; CLINICAL-PRACTICE; CONSULTATION; CARE; SATISFACTION; PARTICIPATION; IMPACT; SKILLS	Context Improving health-related quality of life (HRQL) is an important goal of palliative treatment, but little is known about actual patient-physician communication regarding HRQL topics during palliative treatment. Objectives To investigate the content of routine communication regarding 4 specific HRQL issues between oncologists and their patients and to identify patient-, physician-, and visit-specific factors significantly associated with discussion of such issues. Design Observational study conducted between lune 1996 and January 1998, Setting Outpatient palliative chemotherapy clinic of a cancer hospital in the Netherlands, Participants Ten oncologists and 240 of their patients (72% female; mean age, 55 years) who had incurable cancer and were receiving outpatient palliative chemotherapy. Main outcome Measures Patient and physician questionnaires and audiotape analysis of communication regarding daily activities, emotional functioning, pain, and fatigue during an outpatient consultation using the Roter Interaction Analysis System. Results Physicians devoted 64% of their conversation to medical/technical issues and 23% to HRQL issues. Patients' communication behavior was divided more equally between medical/technical issues (41%) and HRQL topics (48%). Of the independent variables investigated, patients' self-reported HRQL was the most powerful predictor of discussing HRQL issues. Nevertheless, in 20% to 54% of the consultations in which patients were experiencing serious HRQL problems, no time was devoted to discussion of those problems. In particular, these patients' emotional functioning and fatigue were unaddressed 54% and 48% of the time, respectively. Discussion of HRQL issues was not more frequent in consultations in which tumor response was evaluated. Conclusion Despite increasing recognition of the importance of maintaining patients' HRQL as a goal of palliative treatment, the amount of patient-physician communication devoted to such issues remains limited and appears to make only a modest contribution, at least in an explicit sense, to the evaluation of treatment efficacy in daily clinical practice.	Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, NL-1066 CX Amsterdam, Netherlands; Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Aaronson, NK (corresponding author), Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	naaron@nki.nl	Aaronson, Neil K/AAV-8194-2021					AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; [Anonymous], 1996, J Clin Oncol, V14, P671; Baile W F, 1997, J Cancer Educ, V12, P166; Boon H, 1998, PATIENT EDUC COUNS, V35, P161, DOI 10.1016/S0738-3991(98)00063-9; BUTOW PN, 1994, ANN ONCOL, V5, P199, DOI 10.1093/oxfordjournals.annonc.a058793; Byrne P.S., 1976, DOCTORS TALKING PATI; Cella D F, 1990, Oncology (Williston Park), V4, P29; Coulter A, 1997, J Health Serv Res Policy, V2, P112; CULL A, 1995, BRIT J CANCER, V72, P229, DOI 10.1038/bjc.1995.308; Curt GA, 2000, ONCOLOGIST S, V5, P9, DOI DOI 10.1634/THEONCOLOGIST.5-SUPPL_2-9; Davidoff F, 1997, ANN INTERN MED, V127, P483, DOI 10.7326/0003-4819-127-6-199709150-00011; Detmar SB, 2000, J CLIN ONCOL, V18, P3295, DOI 10.1200/JCO.2000.18.18.3295; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; Ford S, 1996, SOC SCI MED, V42, P1511, DOI 10.1016/0277-9536(95)00265-0; FUNCH DP, 1988, MED CARE, V26, P1000, DOI 10.1097/00005650-198810000-00008; GANZ PA, 1994, CANCER, V74, P1445, DOI 10.1002/1097-0142(19940815)74:4+<1445::AID-CNCR2820741608>3.0.CO;2-#; Goldberg R, 1990, J Cancer Educ, V5, P193; Goldstein M., 1987, MULTILEVEL MODELS ED; GOUGH IR, 1991, CANCER, V68, P220, DOI 10.1002/1097-0142(19910701)68:1<220::AID-CNCR2820680140>3.0.CO;2-H; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HALL JA, 1994, HEALTH PSYCHOL, V13, P384, DOI 10.1037/0278-6133.13.5.384; Hancock Barry W., 1993, Current Opinion in Oncology, V5, P655, DOI 10.1097/00001622-199307000-00006; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; LEVINSON W, 1995, J GEN INTERN MED, V10, P375, DOI 10.1007/BF02599834; MAGUIRE P, 1988, BRIT MED J, V297, P847, DOI 10.1136/bmj.297.6652.847; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; Marvel MK, 1998, J FAM PRACTICE, V47, P343; McCann S, 1996, PSYCHOL HEALTH, V11, P857, DOI 10.1080/08870449608400281; Montazeri A, 1996, EUR J CANCER, V32A, P2284, DOI 10.1016/S0959-8049(96)00288-2; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Ong LML, 1998, PSYCHO-ONCOL, V7, P387, DOI 10.1002/(SICI)1099-1611(1998090)7:5<387::AID-PON316>3.0.CO;2-G; Ong LML, 2000, J CLIN ONCOL, V18, P3052, DOI 10.1200/JCO.2000.18.16.3052; Ong LML, 1999, PSYCHO-ONCOLOGY, V8, P155; Osoba D, 1996, CANCER TREAT REV, V22, P69, DOI 10.1016/S0305-7372(96)90066-3; PAYNE SA, 1992, SOC SCI MED, V35, P1505, DOI 10.1016/0277-9536(92)90053-S; PORZSOLT F, 1993, J CLIN ONCOL, V11, P378, DOI 10.1200/JCO.1993.11.2.378; Razavi D, 1997, EUR J CANCER, V33, pS15, DOI 10.1016/S0959-8049(97)00195-0; ROLAND MO, 1986, BRIT MED J, V292, P874, DOI 10.1136/bmj.292.6524.874; Roter D.L., 1992, DOCTORS TALKING PATI; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; ROTER DL, 1991, HUISARTS WET, V34, P295; SUTHERLAND HJ, 1990, J CLIN EPIDEMIOL, V43, P661, DOI 10.1016/0895-4356(90)90036-O; Taenzer P, 2000, PSYCHO-ONCOLOGY, V9, P203, DOI 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-P; Taylor KM, 1996, QUAL LIFE RES, V5, P5, DOI 10.1007/BF00435963; Till J E, 1994, Can J Oncol, V4, P243; van Dulmen AM, 2000, EUR J PEDIATR, V159, P489, DOI 10.1007/s004310051316; VANWIJK CMTG, 1991, WOMEN HEALTH, V17, P91; Wagner AK, 1997, QUAL LIFE RES, V6, P329, DOI 10.1023/A:1018479209369; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WAITZKIN H, 1985, J HEALTH SOC BEHAV, V26, P81, DOI 10.2307/2136599	51	131	132	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2001	285	10					1351	1357		10.1001/jama.285.10.1351	http://dx.doi.org/10.1001/jama.285.10.1351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	408QK	11255393	Bronze			2023-01-03	WOS:000167339000030
J	Luce, JM; Luce, JA				Luce, JM; Luce, JA			Management of dyspnea in patients with far-advanced lung disease - "Once I lose it, it's kind of hard to catch it..."	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIR-FLOW LIMITATION; OBSTRUCTIVE PULMONARY-DISEASE; EXERTIONAL BREATHLESSNESS; PRESSURE VENTILATION; EXERCISE TOLERANCE; REDUCES DYSPNEA; OUTCOMES; RELIEF; HYPOVENTILATION; REHABILITATION	Dyspnea is a common problem among patients with interstitial fibrosis, lung cancer, cystic fibrosis, and chronic obstructive pulmonary disease. The slow but steady progression of such diseases, often punctuated by acute exacerbations or secondary illnesses, can lead to decisionmaking dilemmas among patients and their caregivers, such as when to accept mechanical ventilation, when to forgo aggressive therapies, and when to make formal end-of-life care plans. Two cases, a 74-year-old woman with dyspnea secondary to emphysema and a 65-year-old woman with recurrent lung cancer and severe exertional fatigue and dyspnea, illustrate how dyspneic patients approaching the end of life can be evaluated and treated. Four management strategies for dyspnea are discussed: reducing ventilatory impedance, reducing ventilatory demand, improving respiratory muscle function, and altering central perception. Physicians should encourage endstage lung disease patients and their families to discuss issues such as hospitalization and mechanical ventilation, to prepare advance directives, and to participate in a plan to manage their dyspnea.	San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Luce, JM (corresponding author), San Francisco Gen Hosp, Div Pulm & Crit Care Med, 1001 Potrero Ave,Room 5K1, San Francisco, CA 94110 USA.	john_luce@sfgh.org						AHMEDZAI S, 1998, OXFORD TXB PALLIATIV, P583; Altose MD, 2000, NEW ENGL J MED, V343, P1902; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P577; [Anonymous], 1980, Ann Intern Med, V93, P391; Antony VB, 2000, AM J RESP CRIT CARE, V162, P1987, DOI 10.1164/ajrccm.162.5.ats8-00; AUBIER M, 1980, AM REV RESPIR DIS, V122, P747, DOI 10.1164/arrd.1980.122.5.747; BANZETT RB, 1987, J APPL PHYSIOL, V62, P567, DOI 10.1152/jappl.1987.62.2.567; BELMAN MJ, 1991, CHEST, V99, P566, DOI 10.1378/chest.99.3.566; Booth S, 1996, AM J RESP CRIT CARE, V153, P1515, DOI 10.1164/ajrccm.153.5.8630595; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Cristiano LM, 1997, AM J RESP CRIT CARE, V155, P1552, DOI 10.1164/ajrccm.155.5.9154856; DALES RE, 1989, AM REV RESPIR DIS, V139, P1459, DOI 10.1164/ajrccm/139.6.1459; DEWAN NA, 1994, CHEST, V105, P1061, DOI 10.1378/chest.105.4.1061; EFTHIMIOU J, 1988, AM REV RESPIR DIS, V137, P1075, DOI 10.1164/ajrccm/137.5.1075; Garrod R, 2000, AM J RESP CRIT CARE, V162, P1335, DOI 10.1164/ajrccm.162.4.9912029; HARVER A, 1989, ANN INTERN MED, V111, P117, DOI 10.7326/0003-4819-111-2-117; Heffner JE, 1997, AM J RESP CRIT CARE, V155, P1055, DOI 10.1164/ajrccm.155.3.9116986; *HLTH CAR FIN ADM, 2001, HOM OX THER REQ MED; Jacox A, 1994, AHCPR PUBLICATION; Keller CA, 1997, AM J RESP CRIT CARE, V156, P60, DOI 10.1164/ajrccm.156.1.9609101; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Lee RB, 2000, SEMIN SURG ONCOL, V18, P173; LIGHT RW, 1989, AM REV RESPIR DIS, V139, P126, DOI 10.1164/ajrccm/139.1.126; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; MAN GCW, 1986, CHEST, V90, P832, DOI 10.1378/chest.90.6.832; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Mejia R, 1999, AM J RESP CRIT CARE, V159, P1485, DOI 10.1164/ajrccm.159.5.9810039; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; MOUNTAIN R, 1978, NEW ENGL J MED, V298, P521, DOI 10.1056/NEJM197803092981001; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nishino T, 2000, AM J RESP CRIT CARE, V161, P1963, DOI 10.1164/ajrccm.161.6.9910009; ODonnell DE, 1997, AM J RESP CRIT CARE, V155, P530, DOI 10.1164/ajrccm.155.2.9032190; ODONNELL DE, 1993, AM REV RESPIR DIS, V148, P1351, DOI 10.1164/ajrccm/148.5.1351; ODonnell DE, 1997, AM J RESP CRIT CARE, V155, P109, DOI 10.1164/ajrccm.155.1.9001298; ODONNELL DE, 1995, AM J RESP CRIT CARE, V152, P2005, DOI 10.1164/ajrccm.152.6.8520769; Poole PJ, 1998, AM J RESP CRIT CARE, V157, P1877, DOI 10.1164/ajrccm.157.6.9711061; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Robinson TD, 2000, AM J RESP CRIT CARE, V161, P1524, DOI 10.1164/ajrccm.161.5.9904119; SCHWARTZSTEIN RM, 1987, AM REV RESPIR DIS, V136, P58, DOI 10.1164/ajrccm/136.1.58; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SHARP JT, 1980, AM REV RESPIR DIS, V122, P201; SILVERMAN M, 1988, AM REV RESPIR DIS, V137, P206, DOI 10.1164/ajrccm/137.1.206; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009, DOI 10.1164/ajrccm/142.5.1009; SMITH K, 1992, AM REV RESPIR DIS, V145, P533, DOI 10.1164/ajrccm/145.3.533; Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700; Smoller JW, 1998, PSYCHOSOMATICS, V39, P24, DOI 10.1016/S0033-3182(98)71377-5; STULBARG MS, 1989, CHEST, V95, P1123, DOI 10.1378/chest.95.5.1123; STULBARG MS, 2000, TXB RESP MED, P541; WOODCOCK AA, 1981, BRIT MED J, V283, P343, DOI 10.1136/bmj.283.6287.343	52	38	39	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2001	285	10					1331	1337		10.1001/jama.285.10.1331	http://dx.doi.org/10.1001/jama.285.10.1331			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	408QK	11255389				2023-01-03	WOS:000167339000026
J	Powell, P; Bentall, RP; Nye, FJ; Edwards, KHT				Powell, P; Bentall, RP; Nye, FJ; Edwards, KHT			Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE-BEHAVIOR THERAPY; SCALE; SF-36	Objective To assess the efficacy of an educational intervention explaining symptoms to encourage graded exercise in patients with chronic fatigue syndrome Design Randomised controlled trial. Setting Chromic fatigue clinic and infectious diseases outpatient clinic. Subjects 148 consecutively referred patients fulfilling Oxford criteria for chronic fatigue syndrome. Interventions Patients randomised to the control group received standardised medical care. Patients randomised to intervention received two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack, describing the role of disrupted physiological regulation in fatigue symptoms and encouraging home based graded exercise. The minimum intervention group had no further treatment, but the telephone intervention group received am additional seven follow up calls and the maximum intervention group an additional seven face to face sessions over four months. Main outcome measure A score of greater than or equal to 25 or an increase of greater than or equal to 10 on the SF-36 physical functioning subscale (range 10 to 30) 12 months after randomisation. Results 21 patients dropped out, mainly from the intervention groups. Intention to treat analysis showed 79 (69%) of patients in the intervention groups achieved a satisfactory outcome in physical functioning compared with two (6%) of controls, who received standardised medical care (P < 0.0001). Similar improvements were observed in fatigue, sleep, disability, and mood. No significant differences were found between the three intervention groups. Conclusions Treatment incorporating evidence based physiological explanations for symptoms was effective in encouraging self managed graded exercise. This resulted in substantial improvement compared with standardised medical care.	Univ Manchester, Dept Psychol, Manchester M13 9PL, Lancs, England; Aintree Univ Hosp NHS Fdn Trust, Reg Infect Dis Unit, Liverpool L9 7AL, Merseyside, England; Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England	University of Manchester; Aintree University Hospitals NHS Foundation Trust; University of Liverpool	Bentall, RP (corresponding author), Univ Manchester, Dept Psychol, Coupland 1, Manchester M13 9PL, Lancs, England.	bentall@psy.man.ac.uk	Winwood, Peter/A-6363-2008					CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CLEARE A, 1995, J AFFECT DISORDERS, V35, P293; De Lorenzo F, 1998, QJM-INT J MED, V91, P475, DOI 10.1093/qjmed/91.7.475; Deale A, 1997, AM J PSYCHIAT, V154, P408; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; EDWARDS R, 1994, CHRONIC FATIGUE SYND, P241; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Guy W., 1976, ASSESSMENT MANUAL PS, P217; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Morriss RK, 1997, J PSYCHOSOM RES, V42, P597, DOI 10.1016/S0022-3999(97)89895-9; POWELL P, 1999, BEHAV COGN PSYCHOTH, V27, P249; Reid S, 2000, BMJ-BRIT MED J, V320, P292, DOI 10.1136/bmj.320.7230.292; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; WESSELY S, 1993, NEUROLOGICAL REHABIL, P311; Wessely S, 1998, CHRONIC FATIGUE ITS; Williams G, 1996, CLIN PHYSIOL, V16, P327, DOI 10.1111/j.1475-097X.1996.tb00722.x; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	23	132	134	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2001	322	7283					387	390		10.1136/bmj.322.7283.387	http://dx.doi.org/10.1136/bmj.322.7283.387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	404JH	11179154	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000167093600022
J	Singhal, A; Cole, TJ; Lucas, A				Singhal, A; Cole, TJ; Lucas, A			Early nutrition in preterm infants and later blood pressure: two cohorts after randomised trials	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BIRTH-WEIGHT; CARDIOVASCULAR-DISEASE; ADULT LIFE; CHILDHOOD; CHILDREN; DIET; GROWTH; DEATH; INTRAUTERINE	Background Despite data relating body size in early life to later cardiovascular outcomes, the hypothesis that nutrition affects such outcomes has not been established. Breastfeeding has been associated with lower blood pressure in later life, but previous studies have not controlled for possible confounding factors by using a randomised design with prospective follow-up. We undertook such a study to test the hypothesis that early diet programmes blood pressure in later life in children randomly assigned different diets at birth. Methods Blood pressure was measured at age 13-16 years in 216 (23%) of a cohort of 926 children who were born prematurely and had participated at birth in two parallel randomised trials in five neonatal units in the UK. Dietary interventions were: donated banked breastmilk versus preterm formula and standard term formula versus preterm formula. Findings Children followed up at age 13-16 years were similar to those not followed up in terms of social class and anthropometry at birth. Mean arterial blood pressure at age 13-16 years was lower in the 66 children assigned banked breastmilk (alone or in addition to mother's milk) than in the 64 assigned preterm formula (mean 81.9 [SD 7.8] vs 86.1 [6.5] mm Hg; 95% Cl for difference -6.6 to -1.6; p=0.001). In non-randomised analyses, the proportion of enteral intake as human milk in the neonatal period was inversely related to later mean arterial pressure (beta=-0.3 mm Hg per 10% increase [95% CI -05 to -0.1]; p=0.006). No differences were found in the term formula (n=44) versus preterm formula (n=42) comparison. Interpretation Breastmilk consumption was associated with lower later blood pressure in children born prematurely. Our data provide experimental evidence of programming of a cardiovascular risk factor by early diet and further support the long-term beneficial effects of breastmilk.	Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Singhal, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.	a.singhal@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821, G9827821(62595)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anwar, 1997, Blood Press Monit, V2, P105; BARANOWSKI T, 1992, J CLIN EPIDEMIOL, V45, P513, DOI 10.1016/0895-4356(92)90100-2; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Ebrahim S, 1998, J PUBLIC HEALTH MED, V20, P441, DOI 10.1093/oxfordjournals.pubmed.a024800; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913; Gore SM, 1999, LIPIDS, V34, P185, DOI 10.1007/s11745-999-0353-0; Laor A, 1997, BRIT MED J, V315, P449, DOI 10.1136/bmj.315.7106.449; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leeson CPM, 1997, CIRCULATION, V96, P2233; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; LEWIS DS, 1986, J CLIN INVEST, V78, P899, DOI 10.1172/JCI112678; LEWIS DS, 1988, ARTERIOSCLEROSIS, V8, P274, DOI 10.1161/01.ATV.8.3.274; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1988, ARCH DIS CHILD, V63, P656, DOI 10.1136/adc.63.6.656; LUCAS A, 1994, BRIT MED J, V309, P304, DOI 10.1136/bmj.309.6950.304; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WHITTEN CF, 1980, ACTA PAEDIATR SCAND, P1; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21	30	400	411	2	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	2001	357	9254					413	419		10.1016/S0140-6736(00)04004-6	http://dx.doi.org/10.1016/S0140-6736(00)04004-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	400HF	11273059				2023-01-03	WOS:000166865600008
J	Hartley, D				Hartley, D			From the foot of the gurney	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		American Heart Association in collaboration with the International Liaison Committee on Resuscitation, 2000, CIRCULATION S8, V102, pI12; BELENGER M, 1997, J EMERG NURS, V23, P238; Rattrie E, 2000, Nurs Stand, V14, P32; Robinson SM, 1998, LANCET, V352, P614, DOI 10.1016/S0140-6736(97)12179-1	4	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	2001	285	4					380	380		10.1001/jama.285.4.380	http://dx.doi.org/10.1001/jama.285.4.380			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394CG	11242401				2023-01-03	WOS:000166506000001
J	Midgley, RSJ; Kerr, DJ				Midgley, RSJ; Kerr, DJ			ABC of colorectal cancer - Adjuvant therapy	BRITISH MEDICAL JOURNAL			English	Review									Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Midgley, RSJ (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.			Kerr, Rachel/0000-0002-7240-3269				GRAY R, 1997, GUIDANCE COMMISSIONI; Gray RG, 2000, LANCET, V355, P1588; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Midgley RS, 1997, CANCER TREAT REV, V23, P135, DOI 10.1016/S0305-7372(97)90035-9	4	20	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1208	+		10.1136/bmj.321.7270.1208	http://dx.doi.org/10.1136/bmj.321.7270.1208			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073515	Green Published			2023-01-03	WOS:000165357100032
J	Glogowska, M; Roulstone, S; Enderby, P; Peters, TJ				Glogowska, M; Roulstone, S; Enderby, P; Peters, TJ			Randomised controlled trial of community based speech and language therapy in preschool children	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; YOUNG-CHILDREN; INTERVENTION; TODDLERS; SKILLS	Objective To compare routine speech and language therapy in preschool children with delayed speech and language against 12 months of "watchful waiting. Design Pragmatic randomised controlled trial. Setting 16 community clinics in Bristol. Participants 159 preschool children with appreciable speech or language difficulties who fulfilled criteria for admission to speech and language therapy. Main outcome measures Four quantitative measures of speech and language, assessed at 6 and 12 months; a binary variable indicating improvement by 12 months, on the trial entry criterion. Results Improvement in auditory comprehension was significant in favour of therapy (adjusted difference in means 4.1, 95% confidence interval 0.5 to 7.6; P = 0.025). No significant differences were observed for expressive language (1.4, - 2.1 to 4.8; P = 0.44); phonology error rate (- 4.4, - 12.0 to 3.3; P = 0.26); language development (0.1, - 0.4 to 0.6; P = 0.73); or improvement on entry criterion (odds ratio 1.3, 0.67 to 2.4; P = 0.46). At the end of the trial, 70% of all children still had substantial speech and language deficits. Conclusions This study provides little evidence for the effectiveness of speech and language therapy compared with watchful waiting over 12 months. Providers of speech and language therapy should reconsider the appropriateness, timing, nature, and intensity of such therapy in preschool children. Continued research into more specific provision to subgroups of children is also needed to identify better treatment methods. The lack of resolution of difficulties for most of the children suggests that further research is needed to identify effective ways of helping this population of children.	Frenchay Hosp, Speech & Language Therapy Res Unit, Bristol BS16 1LE, Avon, England; Univ Sheffield, No Gen Hosp, Sch Hlth & Related Studies, Ctr Ageing & Rehabil Studies, Sheffield S5 7AU, S Yorkshire, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	Northern General Hospital; University of Sheffield; University of Bristol	Roulstone, S (corresponding author), Frenchay Hosp, Speech & Language Therapy Res Unit, Bristol BS16 1LE, Avon, England.			Peters, Tim/0000-0003-2881-4180; Enderby, Pamela/0000-0002-4371-9053				Almost D, 1998, DEV MED CHILD NEUROL, V40, P319; COOPER J, 1978, HELPING LANGUAGE DEV; Enderby P., 2009, THERAPY OUTCOME MEAS; ENDERBY PM, 1997, THRAPY OUTCOME MEASU; FELSENFELD S, 1992, J SPEECH HEAR RES, V35, P1114, DOI 10.1044/jshr.3505.1114; FEY ME, 1993, J SPEECH HEAR RES, V36, P141, DOI 10.1044/jshr.3601.141; GIBBARD D, 1994, EUR J DISORDER COMM, V29, P131; GLOGOWSKA M, 1999, THESIS U BRISTOL BRI; GLOGOWSKA M, IN PRESS INT J LANG; Gutfreund M., 1989, BRISTOL LANGUAGE DEV; HALL DMB, 1996, HLTH ALL CHILDREN RE; Johnson CJ, 1999, J SPEECH LANG HEAR R, V42, P744, DOI 10.1044/jslhr.4203.744; Law J, 1998, Health Technol Assess, V2, P1; LAW J, 1992, EARLY IDENTIFICATION; McConkey R, 1979, Spec Educ Forward Trends, V6, P13; PADEN EP, 1987, J SPEECH HEAR DISORD, V52, P232, DOI 10.1044/jshd.5203.232; PAUL R, 1991, J SPEECH HEAR RES, V34, P858, DOI 10.1044/jshr.3404.858; RESCORLA L, 1990, APPL PSYCHOLINGUIST, V11, P393, DOI 10.1017/S0142716400009644; Robertson SB, 1999, J SPEECH LANG HEAR R, V42, P1234, DOI 10.1044/jslhr.4205.1234; Roulstone S, 1999, CHILD CARE HLTH DEV, V25, P141, DOI 10.1046/j.1365-2214.1999.25220119.x; Sparrow SS, 2016, VINELAND 2 ADAPTIVE, V3rd; Steiner V. G., 1992, PRESCHOOL LANGUAGE S; Stothard SE, 1998, J SPEECH LANG HEAR R, V41, P407, DOI 10.1044/jslhr.4102.407	23	91	91	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	2000	321	7266					923	926		10.1136/bmj.321.7266.923	http://dx.doi.org/10.1136/bmj.321.7266.923			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	365XE	11030677	Green Published, Bronze			2023-01-03	WOS:000089975100019
J	Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B				Xu, Q; Li, YH; Cyras, C; Sanan, DA; Cordell, B			Isolation and characterization of apolipoproteins from murine microglia - Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PEPTIDE; ISOFORM-SPECIFIC BINDING; DIFFERENT PLAQUE TYPES; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; IN-VITRO; MESSENGER-RNA; CELL-DEATH; EXPRESSION; PROTEIN	Amyloid A beta deposition is a neuropathologic hallmark of Alzheimer's disease. Activated microglia are intimately associated with plaques and appear to facilitate A beta deposition, an event believed to contribute to pathogenesis. It is unclear if microglia can modulate pathogenesis of Alzheimer's disease by secreting lipoprotein particles. Here we show that cultured BV2 murine microglial cells, like astrocytes, secrete apolipoprotein E (apoE) and apolipoprotein J (apoJ) in a time-dependent manner. To isolate and identify BV2 microglial particles, gel filtration chromatography was employed to fractionate BV2-conditioned medium. Analyses by Western blot, lipid determination, electron microscopy, and native gel electrophoresis demonstrate that BV2 microglial cells release spherical low density lipoprotein (LDL)-like lipid-containing particles rich in apoJ but poor in apoE, These microglial particles are dissimilar in size, shape, and lipoprotein composition to astrocyte-derived particles. The microglial-derived particles were tested for functional activity. Under conditions of suppressed de novo cholesterol synthesis, the LDL-like particles effectively rescued primary rat cortical neurons from mevastatin-induced neurotoxicity, The particles were also shown to bind A beta, We speculate that the LDL-like apoJ-rich apoE-poor microglial lipoproteins preferentially bind the lipoprotein receptor, recognizing apoJ, which is abundant in the choroid plexus, facilitating A beta clearance from the brain. BV2 cells also secrete an apoE-rich lipid-poor species that binds A beta. Consistent with the role of apoE in A beta fibril formation and deposition, this microglial species may promote plaque formation.	Scios Inc, Sunnyvale, CA 94085 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	Scios; University of California System; University of California San Francisco; The J David Gladstone Institutes	Cordell, B (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94085 USA.							ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BURKEY BF, 1992, J LIPID RES, V33, P1517; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Cole GM, 1999, J NEUROSCI RES, V57, P504, DOI 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MessmerJoudrier S, 1996, EUR J NEUROSCI, V8, P2652, DOI 10.1111/j.1460-9568.1996.tb01560.x; Michel D, 1997, J CELL SCI, V110, P1635; Michikawa M, 1998, J NEUROSCI RES, V54, P58, DOI 10.1002/(SICI)1097-4547(19981001)54:1<58::AID-JNR7>3.0.CO;2-G; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Overmyer M, 1999, ACTA NEUROPATHOL, V97, P383, DOI 10.1007/s004010051002; Reardon CA, 1998, J LIPID RES, V39, P1372; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng JG, 1996, NEUROPATH APPL NEURO, V22, P334, DOI 10.1111/j.1365-2990.1996.tb01112.x; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WOOD PL, 1994, NEUROREPORT, V5, P977, DOI 10.1097/00001756-199404000-00031; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	56	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31770	31777		10.1074/jbc.M002796200	http://dx.doi.org/10.1074/jbc.M002796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10918055	hybrid			2023-01-03	WOS:000089858900033
J	Alter, HJ; Houghton, M				Alter, HJ; Houghton, M			Hepatitis C virus and eliminating post-transfusion hepatitis	NATURE MEDICINE			English	Editorial Material							NON-B-HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; ANTIBODY; BLOOD; CHIMPANZEES; INFECTION; ANTIGEN; AGENTS; TRANSMISSION		NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Immunol Sect, Bethesda, MD 20892 USA; Chiron Corp, Emeryville, CA 94608 USA	National Institutes of Health (NIH) - USA; Novartis	Alter, HJ (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Transfus Med, Immunol Sect, NIH Bldg 10,Room 1C711,9000 Rockville Pike, Bethesda, MD 20892 USA.			Houghton, Michael/0000-0003-3762-6771				Alter Harvey, 1999, American Journal of Medicine, V107, p16S; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; ALTER HJ, 1978, LANCET, V1, P459; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BRADLEY DW, 1985, J VIROL METHODS, V10, P307, DOI 10.1016/0166-0934(85)90047-3; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; De Francesco R, 2000, SEMIN LIVER DIS, V20, P69, DOI 10.1055/s-2000-9504; EZZELL C, 1988, NATURE, V333, P195; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FEINSTONE SM, 1973, SCIENCE, V182, P1026, DOI 10.1126/science.182.4116.1026; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FEINSTONE SM, 1983, INFECT IMMUN, V41, P816, DOI 10.1128/IAI.41.2.816-821.1983; HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636; HOLLINGER FB, 1978, INTERVIROLOGY, V10, P60, DOI 10.1159/000148969; Houghton M, 2000, CURR TOP MICROBIOL, V242, P327; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHIH JWK, 1986, PROG LIVER DIS, V8, P433; SHIMIZU YK, 1979, SCIENCE, V205, P197, DOI 10.1126/science.451589; Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4; STEVENS CE, 1984, ANN INTERN MED, V104, P488; TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	39	67	68	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2000	6	10					1082	1086		10.1038/80394	http://dx.doi.org/10.1038/80394			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	360NT	11017126				2023-01-03	WOS:000089674700017
J	Frader, JE				Frader, JE			Baby Doe blinders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Northwestern University	Frader, JE (corresponding author), Northwestern Univ, Sch Med, Chicago, IL 60611 USA.		Frader, Joel/A-8610-2010	Frader, Joel/0000-0001-5620-2400				PLESS JE, 1983, NEW ENGL J MED, V309, P664; 2000, EXPENDITURES PERINAT; 2000, PRETERM BIRTHS US 19; 2000, INT COMP INF MORT RA; 2000, HLTH EXPENDITURES; 2000, ADEQUACY PRENATAL CA	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1143	1143		10.1001/jama.284.9.1143	http://dx.doi.org/10.1001/jama.284.9.1143			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974698				2023-01-03	WOS:000089037200019
J	Sanders, J; Milne, S; Brown, P; Bell, AJ				Sanders, J; Milne, S; Brown, P; Bell, AJ			Assessment of aggression in psychiatric admissions: semistructured interview and case note survey	BRITISH MEDICAL JOURNAL			English	Article							RISK		St Lukes Hosp, Middlesbrough TS4 3AF, Cleveland, England		Milne, S (corresponding author), St Lukes Hosp, Middlesbrough TS4 3AF, Cleveland, England.							APPLEBY L, 1988, MED SCI LAW, V28, P291, DOI 10.1177/002580248802800405; Ferris LE, 1997, CAN J PSYCHIAT, V42, P1051, DOI 10.1177/070674379704201006; Reed J, 1997, BRIT J PSYCHIAT, V170, P4, DOI 10.1192/S0007125000298644; YRNE P, 1998, PSYCHIAT B, V22, P174	4	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1112	1112		10.1136/bmj.320.7242.1112	http://dx.doi.org/10.1136/bmj.320.7242.1112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	309RJ	10775220	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000086782800017
J	Shlipak, MG; Simon, JA; Vittinghoff, E; Lin, F; Barrett-Connor, E; Knopp, RH; Levy, RI; Hulley, SB				Shlipak, MG; Simon, JA; Vittinghoff, E; Lin, F; Barrett-Connor, E; Knopp, RH; Levy, RI; Hulley, SB			Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRE-BETA LIPOPROTEIN; POSTMENOPAUSAL WOMEN; LP(A) LIPOPROTEIN; ELEVATED LIPOPROTEIN(A); PLASMA LIPOPROTEIN(A); MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; LDL CHOLESTEROL; ARTERIAL-WALL; MEN	Context Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for coronary heart disease (CHD) events. However, few data exist on the clinical importance of Lp(a) lowering for CHD prevention. Hormone therapy with estrogen has been found to lower Lp(a) levels in women. Objective To determine the relationships among treatment with estrogen and progestin, serum Lp(a) levels, and subsequent CHD events in postmenopausal women. Design and Setting The Heart and Estrogen/progestin Replacement Study (HERS), a randomized, blinded, placebo-controlled secondary prevention trial conducted from January 1993 through July 1998 with a mean follow-up of 4.1 years at 20 centers. Participants A total of 2763 postmenopausal women younger than 80 years with coronary artery disease and an intact uterus. Mean age was 66.7 years. Intervention Participants were randomly assigned to receive either conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (n = 1380), or identical placebo (n = 1383). Main Outcome Measures Lipoprotein(a) levels and CHD events (nonfatal myocardial infarction and CHD death). Results Increased baseline Lp(a) levels were associated with subsequent CHD events among women in the placebo arm. After multivariate adjustment, women in the second, third, and fourth quartiles of baseline Lp(a) level had relative hazards (RHs) (compared with the first quartile) of 1.01 (95% confidence interval [CI], 0.64-1.59), 1.31 (95% CI, 0.85-2.04), and 1.54 (95% CI, 0.99-2.39), respectively, compared with women in the lowest quartile (P for trend =.03). Treatment with estrogen and progestin reduced mean (SD) Lp(a) levels significantly (-5.8 [15] mg/dL) (-0.20 [0.53] mu mol/L) compared with placebo (0.3 [17] mg/dL) (0.01 [0.60] mu mol/L) (P<.001). In a randomized subgroup comparison, women with low baseline Lp(a) levels had less benefit from estrogen and progestin than women with high Lp(a) levels; the RH for women assigned to estrogen and progestin compared with placebo were 1.49 (95% CI, 0.97-2.26) in the lowest quartile and 1.05 (95% CI, 0.67-1.65), 0.78 (0.52-1.18), and 0.85 (0.58-1.25) in the second, third, and fourth quartiles, respectively (P for interaction trend =.03). Conclusions Our data suggest that Lp(a) is an independent risk factor for recurrent CHD in postmenopausal women and that treatment with estrogen and progestin lowers Lp(a) levels. Estrogen and progestin therapy appears to have a more favorable effect (relative to placebo) in women with high initial Lp(a) levels than in women with low levels. This apparent interaction needs confirmation in other trials.	Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; Univ Washington, Seattle, WA 98195 USA; NW Lipid Res Clin, Seattle, WA USA; Amer Home Prod, Madison, NJ USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu						ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; Berg K, 1997, CLIN GENET, V52, P254; BERG K, 1974, CLIN GENET, V6, P230; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BROWN RL, 1989, APPL PSYCH MEAS, V13, P151, DOI 10.1177/014662168901300205; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; COLEMAN MP, 1992, ATHEROSCLEROSIS, V92, P177, DOI 10.1016/0021-9150(92)90276-M; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN G, 1972, ACTA MED SCAND, P1; Darling GM, 1997, NEW ENGL J MED, V337, P595, DOI 10.1056/NEJM199708283370903; Espeland MA, 1998, CIRCULATION, V97, P979; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Haines C, 1996, ARCH INTERN MED, V156, P866, DOI 10.1001/archinte.156.8.866; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; Kim CJ, 1996, ARCH INTERN MED, V156, P1693, DOI 10.1001/archinte.156.15.1693; Knopp RH, 1998, AM J CARDIOL, V82, p24U, DOI 10.1016/S0002-9149(98)00847-9; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; Marcovina SM, 1998, AM J CARDIOL, V82, p57U, DOI 10.1016/S0002-9149(98)00954-0; NOMA A, 1990, ATHEROSCLEROSIS, V84, P213, DOI 10.1016/0021-9150(90)90093-X; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REBLIN T, 1995, ATHEROSCLEROSIS, V113, P179, DOI 10.1016/0021-9150(94)05445-O; RHOADS GG, 1978, AM J EPIDEMIOL, V108, P350, DOI 10.1093/oxfordjournals.aje.a112631; RIDER AK, 1970, CIRCULATION, V42, pII10; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SACKS FM, 1994, ARCH INTERN MED, V154, P1106, DOI 10.1001/archinte.154.10.1106; *SAS I, 1996, SAS COMP PROGR; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SOMA MR, 1993, ARCH INTERN MED, V153, P1462, DOI 10.1001/archinte.153.12.1462; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	41	239	256	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1845	1852		10.1001/jama.283.14.1845	http://dx.doi.org/10.1001/jama.283.14.1845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770146				2023-01-03	WOS:000086248600030
J	Krauss, B; Green, SM				Krauss, B; Green, SM			Primary care: Sedation and analgesia for procedures in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSMUCOSAL FENTANYL CITRATE; CHLORAL HYDRATE SEDATION; NITROUS-OXIDE ANALGESIA; LACERATION REPAIR; PEDIATRIC SEDATION; ORAL MIDAZOLAM; PRESCHOOL-CHILDREN; KETAMINE SEDATION; INTRAVENOUS KETAMINE; CONSCIOUS SEDATION		Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA; Loma Linda Univ, Sch Med, Loma Linda, CA USA; Childrens Hosp, Loma Linda, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Loma Linda University; Loma Linda University; Children's Hospital Los Angeles	Krauss, B (corresponding author), Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	krauss@al.tch.harvard.edu	Krauss, Baruch/U-6182-2019					*AC PAIN MAN GUID, 1992, AHCPR PUBL; *AM NURS ASS, 1996, COMP ANA POS STAT, P148; [Anonymous], 1985, PEDIATRICS, V76, P317; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Beekman RP, 1996, EUR J PEDIATR, V155, P820; BELL GD, 1991, GUT, V32, P823, DOI 10.1136/gut.32.7.823; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P1073; BILLMIRE DA, 1985, J TRAUMA, V25, P1079; BONADIO WA, 1988, AM J DIS CHILD, V142, P203, DOI 10.1001/archpedi.1988.02150020105040; Burton JH, 1998, ACAD EMERG MED, V5, P112, DOI 10.1111/j.1553-2712.1998.tb02594.x; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; Dachs RJ, 1997, ANN EMERG MED, V29, P146, DOI 10.1016/S0196-0644(97)70321-4; DANIELS AL, 1992, CAN J ANAESTH, V39, P27, DOI 10.1007/BF03008668; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; *EM NURS ASS, 1992, CONS SED; Epstein RH, 1996, ANESTH ANALG, V83, P1200, DOI 10.1097/00000539-199612000-00012; FELD LH, 1990, ANESTHESIOLOGY, V73, P831, DOI 10.1097/00000542-199011000-00006; GAMIS AS, 1989, ANN EMERG MED, V18, P177, DOI 10.1016/S0196-0644(89)80110-6; GLASIER CM, 1995, AM J NEURORADIOL, V16, P111; Green SM, 1999, ACAD EMERG MED, V6, P975, DOI 10.1111/j.1553-2712.1999.tb01176.x; GREEN SM, 1990, ANN EMERG MED, V19, P1024, DOI 10.1016/S0196-0644(05)82568-5; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; HALLEN B, 1982, ANESTHESIOLOGY, V57, P340, DOI 10.1097/00000542-198210000-00024; HALPERIN DL, 1989, PEDIATRICS, V84, P281; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; HAWK W, 1990, Pediatric Emergency Care, V6, P84, DOI 10.1097/00006565-199006000-00003; HENNES HM, 1990, ANN EMERG MED, V19, P1006, DOI 10.1016/S0196-0644(05)82564-8; HENNRIKUS WL, 1994, J PEDIATR ORTHOPED, V14, P538, DOI 10.1097/01241398-199407000-00023; HUBBARD AM, 1992, J COMPUT ASSIST TOMO, V16, P3, DOI 10.1097/00004728-199201000-00002; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kim MK, 1999, ANN EMERG MED, V33, P395, DOI 10.1016/S0196-0644(99)70302-1; KOREN G, 1993, J PEDIATR-US, V122, pS30, DOI 10.1016/S0022-3476(11)80007-7; Krauss B, 1998, PEDIATR EMERG CARE, V14, P99, DOI 10.1097/00006565-199804000-00003; KRAUSS B, 1998, GUIDELINES PEDIAT PR; KRAUSS B, 1999, PEDIAT PROCEDURAL SE; LIU LMP, 1980, ANESTHESIOLOGY, V53, P343, DOI 10.1097/00000542-198010000-00014; LONGNECKER DE, 1973, ANESTH ANALG, V52, P447, DOI 10.1213/00000539-197352030-00033; MALINOVSKY JM, 1995, ANAESTHESIA, V50, P351, DOI 10.1111/j.1365-2044.1995.tb04616.x; MANULI MA, 1993, AM J ROENTGENOL, V160, P577, DOI 10.2214/ajr.160.3.8430557; OBRIEN JF, 1991, ANN EMERG MED, V20, P644, DOI 10.1016/S0196-0644(05)82384-4; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SACCHETTI A, 1937, ANN EMERG MED, V24, P540; SCHILLING CG, 1995, ANN EMERG MED, V25, P203, DOI 10.1016/S0196-0644(95)70325-X; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; SHANE SA, 1994, ANN EMERG MED, V24, P1065, DOI 10.1016/S0196-0644(94)70235-7; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; SIEVERS TD, 1991, PEDIATRICS, V88, P1172; SLOVIS TL, 1993, PEDIATR RADIOL, V23, P345, DOI 10.1007/BF02011953; Smith GA, 1997, PEDIATRICS, V100, P825, DOI 10.1542/peds.100.5.825; STRAIN JD, 1988, AM J ROENTGENOL, V151, P975, DOI 10.2214/ajr.151.5.975; THEROUX MC, 1993, PEDIATRICS, V91, P624; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; WELDON BC, 1992, ANESTH ANALG, V75, P51; Wilson Stephen, 1996, Pediatric Dentistry, V18, P287; YASTER M, 1990, PEDIATRICS, V86, P463; ZELTZER L, 1991, PAIN, V44, P73, DOI 10.1016/0304-3959(91)90150-V; Zempsky WT, 1998, J PEDIATR-US, V132, P1061, DOI 10.1016/S0022-3476(98)70413-5; 1993, PEDIAT DENT, V15, P297	68	274	277	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					938	945		10.1056/NEJM200003303421306	http://dx.doi.org/10.1056/NEJM200003303421306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738053				2023-01-03	WOS:000086179700006
J	Bates, DW				Bates, DW			Using information technology to reduce rates of medication errors in hospitals	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; SYSTEM; PREVENTION		Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.		Bates, David/AAE-7283-2019					Allan E L, 1995, Am Pharm, VNS35, P25; BARKER KN, 1984, AM J HOSP PHARM, V41, P1352, DOI 10.1093/ajhp/41.7.1352; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P2445, DOI 10.1093/ajhp/52.21.2445; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BOREL JM, 1995, AM J HEALTH-SYST PH, V52, P1875, DOI 10.1093/ajhp/52.17.1875; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CHESTER MIS, 1989, AM J HOSP PHARM, V46, P1380, DOI 10.1093/ajhp/46.7.1380; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; *MA HOSP ASS B, 1999, MASS HOSP ASS B 0303; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Sheridan T.B., 2018, HUMAN ERROR MED, P141	21	243	255	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					788	791		10.1136/bmj.320.7237.788	http://dx.doi.org/10.1136/bmj.320.7237.788			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720369	Green Published			2023-01-03	WOS:000086054700034
J	Sullivan, AD; Hedberg, K; Fleming, DW				Sullivan, AD; Hedberg, K; Fleming, DW			Legalized physician-assisted suicide in Oregon - The second year.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIEWS	Background and Methods: In 1997, Oregon legalized physician-assisted suicide. We have previously reported data on terminally ill Oregon residents who received prescriptions for lethal medications under the Oregon Death with Dignity Act and who died in 1998. We now report similar data for 1999, obtained from physicians' reports, death certificates, and interviews with physicians. We also report data from interviews with family members. Results: Information on 33 persons who received prescriptions for lethal medications in 1999 was reported to the Oregon Health Division; 26 died after taking the lethal medications, 5 died from their underlying illnesses, and 2 were alive as of January 1, 2000. One additional patient, who received a prescription in 1998, died after taking the medication in 1999. Thus, 27 patients died after ingesting lethal medications in 1999 (9 per 10,000 deaths in Oregon), as compared with 16 patients in 1998 (6 per 10,000). Results: The median age of the 27 patients who died in 1999 after taking lethal medications was 71 years. The most frequent underlying illnesses were cancer (in 17 patients), amyotrophic lateral sclerosis (in 4), and chronic obstructive pulmonary disease (in 4). All 27 patients had health insurance, 21 were receiving hospice care, and 13 were college graduates. According to both physicians and family members, patients requested assistance with suicide for several reasons, including loss of autonomy, loss of control of bodily functions, an inability to participate in activities that make life enjoyable, and a determination to control the manner of death. Conclusions: In the second as compared with the first year of legalized physician-assisted suicide in Oregon, the number of patients who died after ingesting lethal medications increased, but it remained small in relation to the total number of persons in Oregon who died. Patients who request assistance with suicide appear to be motivated by several factors, including loss of autonomy and a determination to control the way in which they die. (N Engl J Med 2000;342:598-604.) (C)2000, Massachusetts Medical Society.	Oregon Hlth Div, Portland, OR 97232 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), Oregon Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.	katrina.hedberg@state.or.us		Sullivan, Amy/0000-0003-3036-6719				Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Foley K, 1999, HASTINGS CENT REP, V29, P37, DOI 10.2307/3528194; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; GIANELLI D, 1999, AM MED NEWS     0308; HALEY K, 1998, OREGON DEATH DIGNITY; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Mangus RS, 1999, JAMA-J AM MED ASSOC, V282, P2080, DOI 10.1001/jama.282.21.2080; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; *SAS I, 1995, SAS SYST VERS 6 12; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009	13	166	166	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2000	342	8					598	604		10.1056/NEJM200002243420822	http://dx.doi.org/10.1056/NEJM200002243420822			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	286AX	10684921				2023-01-03	WOS:000085422400031
J	Mauz-Korholz, C; Harms, D; Calaminus, G; Gobel, U				Mauz-Korholz, C; Harms, D; Calaminus, G; Gobel, U		Maligne Keimzelltumoren Study Grp	Primary chemotherapy and conservative surgery for vaginal yolk-sac tumour	LANCET			English	Article								Vaginal yolk-sac tumours are usually incurable unless radical surgery is done. We have shown, however, that, neoadjuvant cisplatin-based chemotherapy with conservative surgery is effective in the management of these tumours, and results in a good survival rate, unlike germ-cell tumours of other origin.	Univ Dusseldorf, Med Ctr, D-40225 Dusseldorf, Germany; Univ Kiel, Med Ctr, Inst Paidopathol, Kiel, Germany	Heinrich Heine University Dusseldorf; University of Kiel	Gobel, U (corresponding author), Univ Dusseldorf, Med Ctr, Moorenstr 5, D-40225 Dusseldorf, Germany.		Mauz-Koerholz, Christine/AAX-4349-2020					GOBEL U, 1990, CRIT REV ONCOL HEMAT, V10, P89; Gobel U, 1998, MED PEDIATR ONCOL, V31, P8; LEVERGER G, 1983, ARCH FR PEDIATR, V40, P85; YOUNG RH, 1984, GYNECOL ONCOL, V18, P380, DOI 10.1016/0090-8258(84)90050-7	4	23	23	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2000	355	9204					625	625		10.1016/S0140-6736(99)05215-0	http://dx.doi.org/10.1016/S0140-6736(99)05215-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289HX	10696987				2023-01-03	WOS:000085615400018
J	Mullen, PE; Burgess, P; Wallace, C; Palmer, S; Ruschena, D				Mullen, PE; Burgess, P; Wallace, C; Palmer, S; Ruschena, D			Community care and criminal offending in schizophrenia	LANCET			English	Article							MENTAL DISORDER; VIOLENCE	Background The introduction of community care in psychiatry is widely thought to have resulted in more offending among the seriously mentally ill. This view affects public policy towards and public perceptions of such people. We investigated the association between the introduction of community care and the pattern of offending in patients with schizophrenia in Victoria, Australia. Methods We established patterns of offending from criminal records in two groups of patients with schizophrenia over their lifetime to date and in the 10 years after their first hospital admission. One group was first admitted in 1975 before major deinstitutionalisation in Victoria, the second group in 1985 when community care was becoming the norm. Each patient was matched to a control, by age, sex, and place of residence to allow for changing patterns of offending over time in the wider community. Findings Compared with controls, significantly more of those with schizophrenia were convicted at least once for ail categories of criminal offending except sexual offences (relative risk of offending in 1975=3.5 [95% CI 2.0-5.5), p=0.001, in 1985=3.0 [1.9-4.9], p=0.001). Among men, more offences were committed in the 1985 group than the 1975 group, but this was matched by a similar increase in convictions among the community controls. Those with schizophrenia who had also received treatment for substance abuse accounted for a disproportionate amount of offending. Analysis of admission data for the patients and the total population of admissions with schizophrenia showed that although there had been an increase of 74 days per annum spent in the community for each of the study population as a whole, first admissions spent only 1 more day in the community in 1985 compared with 1975. Interpretation Increased rates in criminal conviction for those with schizophrenia over the last 20 years are consistent with change in the pattern of offending in the general community. Deinstitutionalisation does not adequately explain such change. Mental-health services should aim to reduce the raised rates of criminal offending associated with schizophrenia, but turning the clock back on community care is unlikely to contribute towards any positive outcome.	Victorian Inst Forens Mental Hlth, Fairfield, Vic 3084, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic, Australia; Monash Univ, Dept Psychol Med, Clayton, Vic 3168, Australia	Monash University	Mullen, PE (corresponding author), Victorian Inst Forens Mental Hlth, Locked Bag 10, Fairfield, Vic 3084, Australia.	pmullen@vicnet.net.au	Burgess, Philip/ABD-3040-2020	Burgess, Philip/0000-0001-7184-0363				BURGESS PM, 1992, SOC PSYCH PSYCH EPID, V27, P83, DOI 10.1007/BF00788511; EATON WW, 1992, SCHIZOPHRENIA BULL, V18, P217, DOI 10.1093/schbul/18.2.217; HALL C, 1998, DAILY TELEGRAPH  FEB; *HLTH COMM SERV, 1993, VICT HLTH REF PSYCH; *HLTH COMM SERV, 1996, VICT MENT HLTH SERV; Krupinski J, 1982, SPECIAL PUBLICATION, V12; LINDQVIST P, 1990, BRIT J PSYCHIAT, V157, P345, DOI 10.1192/bjp.157.3.345; Modestin J, 1996, SCHIZOPHRENIA BULL, V22, P69, DOI 10.1093/schbul/22.1.69; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TAYLOR PJ, 1984, BRIT MED J, V288, P1945, DOI 10.1136/bmj.288.6435.1945; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; TAYLOR PJ, 1993, CRIME MENTAL DISORDE, P63; Torrey EF, 1995, AM J PUBLIC HEALTH, V85, P1611, DOI 10.2105/AJPH.85.12.1611; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458	16	141	143	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2000	355	9204					614	617		10.1016/S0140-6736(99)05082-5	http://dx.doi.org/10.1016/S0140-6736(99)05082-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	289HX	10696982				2023-01-03	WOS:000085615400013
J	Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A				Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A		China-US Collaborative Project Neu	Prevention of neural-tube defects with folic acid in China	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; DIETARY-FOLATE; PREVALENCE; RISK	Background Periconceptional use of multivitamins containing folic acid can reduce a woman's risk of having a baby with a neural-tube defect. Methods As part of a public health campaign conducted from 1993 to 1995 in an area of China with high rates of neural-tube defects (the northern region) and one with low rates (the southern region), we evaluated the outcomes of pregnancy in women who were asked to take a pill containing 400 mu g of folic acid alone daily from the time of their premarital examination until the end of their first trimester of pregnancy. Results Among the fetuses or infants of 130,142 women who took folic acid at any time before or during pregnancy and 117,689 women who had not taken folic acid, we identified 102 and 173, respectively, with neural-tube defects. Among the fetuses or infants of women who registered before their last menstrual period and who did not take any folic acid, the rates of neural-tube defects were 4.8 per 1000 pregnancies of at least 20 weeks' gestation in the northern region and 1.0 per 1000 in the southern region. Among the fetuses or infants of the women with periconceptional use of folic acid, the rates were 1.0 per 1000 in the northern region and 0.6 per 1000 in the southern region. The greatest reduction in risk occurred among the fetuses or infants of a subgroup of women in the northern region with periconceptional use who took folic acid pills more than 80 percent of the time. In the southern region the reduction in risk among the fetuses or infants of women with periconceptional use of folic acid was also significant (reduction in risk, 41 percent; 95 percent confidence interval, 3 to 64 percent). Conclusions Periconceptional intake of 400 mg of folic acid daily can reduce the risk of neural-tube defects in areas with high rates of these defects and in areas with low rates. (N Engl J Med 1999;341:1485-90.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Beijing Med Univ, Natl Ctr Maternal & Infant Hlth, Beijing 100083, Peoples R China; Beijing Med Univ, Dept Hlth Care Epidemiol, Beijing 100083, Peoples R China	Centers for Disease Control & Prevention - USA; Peking University; Peking University	Berry, RJ (corresponding author), Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-45, Atlanta, GA 30341 USA.			Berry, Robert/0000-0002-7162-5046				[Anonymous], 1991, MMWR MORB MORTAL WKL, V40, P513; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Cornel MC, 1997, TERATOLOGY, V55, P134; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Moore CA, 1997, AM J MED GENET, V73, P113; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; MURRAY CJL, 1996, GLOBAL BURDEN DIS IN, V10; Olney R, 1998, MENT RETARD DEV D R, V4, P241, DOI 10.1002/(SICI)1098-2779(1998)4:4<241::AID-MRDD2>3.3.CO;2-P; SAS Institute, 1997, SAS STAT SOFTW CHANG; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1980, LANCET, V1, P339; SMITHELLS RW, 1983, LANCET, V1, P1027; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; XIAO KZ, 1990, INT J EPIDEMIOL, V19, P978	18	1035	1100	4	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1485	1490		10.1056/NEJM199911113412001	http://dx.doi.org/10.1056/NEJM199911113412001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559448				2023-01-03	WOS:000083625800001
J	McNagny, SE				McNagny, SE			Prescribing hormone replacement therapy for menopausal symptoms	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; FIBROCYSTIC BREAST DISEASE; POSTMENOPAUSAL ESTROGEN THERAPY; MYOCARDIAL-INFARCTION; HOT FLASHES; CARDIOVASCULAR-DISEASE; ANDROGEN REPLACEMENT; VENOUS THROMBOEMBOLISM; TRANSDERMAL ESTROGEN; ENDOMETRIAL CANCER	This paper addresses the clinical presentation of menopause, pretreatment assessment for hormone replacement therapy, benefits and risks of this treatment, common hormone replacement regimens and their side effects, and patient management. The case-based discussion focuses on the clinical management of a patient who is considering hormone replacement therapy for menopausal symptoms.	Emory Univ, Sch Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, 69 Butler St, Atlanta, GA 30303 USA.	bhudson@mail.acponline.org			WHI NIH HHS [N01-WH-3211] Funding Source: Medline	WHI NIH HHS		Abraham D, 1997, MAYO CLIN PROC, V72, P1051, DOI 10.4065/72.11.1051; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Barrett-Connor E, 1998, J WOMENS HEALTH, V7, P839, DOI 10.1089/jwh.1998.7.839; Barrett-Connor E, 1998, J AM GERIATR SOC, V46, P918, DOI 10.1111/j.1532-5415.1998.tb02732.x; Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BERKOWITZ GS, 1984, INT J CANCER, V34, P443, DOI 10.1002/ijc.2910340403; BERKOWITZ GS, 1985, AM J EPIDEMIOL, V121, P238, DOI 10.1093/oxfordjournals.aje.a113994; Berman RS, 1997, J WOMENS HEALTH, V6, P219, DOI 10.1089/jwh.1997.6.219; Calle EE, 1997, CANCER CAUSE CONTROL, V8, P127, DOI 10.1023/A:1018403826168; Casson PR, 1996, INT J FERTIL MENOP S, V41, P412; Chae CU, 1997, THROMB HAEMOSTASIS, V78, P770; Chung TKH, 1996, MATURITAS, V25, P115, DOI 10.1016/0378-5122(96)01050-X; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; CORSON SL, 1993, INT J FERTIL, V38, P79; CROOK D, 1992, AM J OBSTET GYNECOL, V166, P950, DOI 10.1016/0002-9378(92)91370-P; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; EDEN JA, 1995, MENOPAUSE, V2, P67; ETTINGER B, 1993, CLIN THER, V15, P950; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; EVANS MP, 1995, MAYO CLIN PROC, V70, P800, DOI 10.4065/70.8.800; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; Fanchin R, 1997, OBSTET GYNECOL, V90, P396, DOI 10.1016/S0029-7844(97)00270-6; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gelfand MM, 1997, CLIN THER, V19, P383, DOI 10.1016/S0149-2918(97)80125-7; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Greendale GA, 1997, ENDOCRIN METAB CLIN, V26, P261, DOI 10.1016/S0889-8529(05)70246-2; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAAS S, 1988, OBSTET GYNECOL, V71, P671; HARGROVE JT, 1995, MED CLIN N AM, V79, P1337, DOI 10.1016/S0025-7125(16)30005-0; Hasler CM, 1998, J WOMENS HEALTH, V7, P519, DOI 10.1089/jwh.1998.7.519; Hebert-Croteau N, 1998, CANCER EPIDEM BIOMAR, V7, P653; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; HEMMINKI E, 1993, J CLIN EPIDEMIOL, V46, P211, DOI 10.1016/0895-4356(93)90068-C; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HEMMINKI E, 1993, OBSTET GYNECOL, V82, P1021; Hendrix SL, 1997, ENDOCRIN METAB CLIN, V26, P379, DOI 10.1016/S0889-8529(05)70253-X; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JICK SS, 1986, AM J EPIDEMIOL, V124, P746, DOI 10.1093/oxfordjournals.aje.a114450; Johnson SR, 1998, MED CLIN N AM, V82, P297, DOI 10.1016/S0025-7125(05)70608-8; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; Kaunitz AM, 1997, ENDOCRIN METAB CLIN, V26, P391, DOI 10.1016/S0889-8529(05)70254-1; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; Lindsay R, 1998, ENDOCRIN METAB CLIN, V27, P399, DOI 10.1016/S0889-8529(05)70012-8; LIP GYH, 1994, J HUM HYPERTENS, V8, P491; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; LUFKIN EG, 1994, MAYO CLIN PROC, V69, P131, DOI 10.1016/S0025-6196(12)61038-6; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MacGregor EA, 1997, NEUROL CLIN, V15, P125, DOI 10.1016/S0733-8619(05)70299-1; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MARCHESONI D, 1991, Clinical and Experimental Obstetrics and Gynecology, V18, P281; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McBee WL, 1997, ENDOCRIN METAB CLIN, V26, P329, DOI 10.1016/S0889-8529(05)70250-4; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; MILLER VT, 1994, OBSTET GYNECOL, V83, P173; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; NACHTIGALL LE, 1990, OBSTET GYNECOL, V75, pS77; NAGAMANI M, 1987, AM J OBSTET GYNECOL, V156, P561, DOI 10.1016/0002-9378(87)90050-0; Nagata C, 1998, MATURITAS, V29, P105, DOI 10.1016/S0378-5122(98)00012-7; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Sarrel P, 1998, J REPROD MED, V43, P847; Seidl MM, 1998, CAN FAM PHYSICIAN, V44, P1271; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SILBERSTEIN SD, 1991, NEUROLOGY, V41, P786, DOI 10.1212/WNL.41.6.786; Sotelo MM, 1997, ENDOCRIN METAB CLIN, V26, P313, DOI 10.1016/S0889-8529(05)70249-8; Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; SPORRONG T, 1989, OBSTET GYNECOL, V73, P754; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Staropoli CA, 1998, J WOMENS HEALTH, V7, P1149, DOI 10.1089/jwh.1998.7.1149; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Stevenson J C, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P30; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; STUMPF PG, 1994, OBSTET GYN CLIN N AM, V21, P219; Sulak PJ, 1997, ENDOCRIN METAB CLIN, V26, P399, DOI 10.1016/S0889-8529(05)70255-3; TAITEL HF, 1995, INT J FERTIL MENOP S, V40, P207; THORNEYCROFT IH, 1995, PROG CARDIOVASC DIS, V38, P243, DOI 10.1016/S0033-0620(95)80015-8; Trabal JF, 1997, MENOPAUSE, V4, P130; TRAPIDO EJ, 1984, J NATL CANCER I, V73, P1101; UDOFF L, 1995, OBSTET GYNECOL, V86, P306, DOI 10.1016/0029-7844(95)00115-8; WATTS NB, 1995, OBSTET GYNECOL, V85, P529, DOI 10.1016/0029-7844(94)00448-M; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; WEINSTEIN L, 1990, AM J OBSTET GYNECOL, V162, P1534, DOI 10.1016/0002-9378(90)90917-V; WHELAN EA, 1990, AM J EPIDEMIOL, V131, P625, DOI 10.1093/oxfordjournals.aje.a115546; WHITEHEAD MI, 1990, OBSTET GYNECOL, V75, pS59; Wild RA, 1996, OBSTET GYNECOL, V87, pS27, DOI 10.1016/0029-7844(95)00434-3; WREN BG, 1983, MATURITAS, V5, P135, DOI 10.1016/0378-5122(83)90009-9; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	110	51	53	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					605	616		10.7326/0003-4819-131-8-199910190-00010	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523222				2023-01-03	WOS:000083196600008
J	Wilson, AM; Sims, EJ; Orr, LC; Lipworth, BJ				Wilson, AM; Sims, EJ; Orr, LC; Lipworth, BJ			Differences in lung bioavailability between different propellants for fluticasone propionate	LANCET			English	Article								The lung bioavailability las adrenal suppression) of fluticasone propionate was about two-fold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a mu g equivalent may therefore be inadvisable.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.			McSwiggan, Linda/0000-0001-7168-0750				Ayres J., 1995, European Respiratory Journal, V8, p157S; CRIPPS AL, 1997, J AEROSOL MED, V10; Wilson AM, 1999, THORAX, V54, P20, DOI 10.1136/thx.54.1.20	3	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1357	1358		10.1016/S0140-6736(99)03581-3	http://dx.doi.org/10.1016/S0140-6736(99)03581-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533870				2023-01-03	WOS:000083149900019
J	Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J				Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J			A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary	ANNALS OF INTERNAL MEDICINE			English	Review							SEROTONIN REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; RANDOMIZED CLINICAL-TRIALS; LONG-TERM TREATMENT; ST-JOHNS WORT; PRIMARY-CARE; DOUBLE-BLIND; MAJOR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; DISCONTINUATION RATES	Background: Depressive disorders are persistent, recurring illnesses that cause great suffering for patients and their families. Purpose: To evaluate the benefits and adverse effects of newer pharmacotherapies and herbal treatments for depressive disorders in adults and adolescents. Data Sources: English-language and non-English-language literature from 1980 to January 1998 was identified from a specialized registry of controlled trials, meta-analyses, and experts. Study Selection: Randomized trials evaluating newer antidepressants (such as serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and St. John's wort) that reported clinical outcomes were selected. Data Extraction: Two persons independently abstracted data that were then synthesized descriptively; some data were pooled by using a random-effects model. Data Synthesis: Of 315 eligible trials, most evaluated antidepressants in adults with major depression, were conducted among outpatients, and examined acute-phase treatment. Newer antidepressants were more effective than placebo for major depression (relative benefit, 1.6 [95% CI, 1.5 to 1.7]) and dysthymia (relative benefit, 1.7 [CI, 1.3 to 2.3]). They were effective among older adults and primary care patients. Efficacy did not differ among newer agents or between newer and older agents. Hypericum (St. John's wort) was more effective than placebo for mild to moderate depression (risk ratio, 1.9 [Cl, 1.2 to 2.8]), but publication bias may have inflated the estimate of benefit. Newer and older antidepressants did not differ for overall discontinuation rates, but side effect profiles varied significantly. Data were insufficient for determining the efficacy of newer antidepressants for subsyndromal depression, depression with coexisting medical or psychiatric illness, or depression in adolescents. Conclusions: Newer antidepressants are clearly effective in treating depressive disorders in diverse settings. Because of similar efficacy, both newer and older antidepressants should be considered when making treatment decisions. Better information is urgently needed on the efficacy of newer antidepressants in patients with nonmajor depression and in special populations, including adolescents.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Kerrville, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Williams, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, 7703 Floyd Curl Dr,Mail Code 7879, San Antonio, TX 78229 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558; Noel, Polly/0000-0002-1519-7489	PHS HHS [290-97-0012] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ANGST J, 1995, J CLIN PSYCHOPHARM, V15, pS16, DOI 10.1097/00004714-199508001-00004; ANTON SF, 1994, PSYCHOPHARMACOL BULL, V30, P165; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEASLEY CM, 1992, INT CLIN PSYCHOPHARM, V6, P35, DOI 10.1097/00004850-199206006-00006; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGMANN R, 1993, TW NEUROLOGIE PSYCHI, P7235; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boyer P, 1996, EUR PSYCHIAT, V11, pS135, DOI 10.1016/0924-9338(96)85188-1; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; Brown C, 1995, GEN HOSP PSYCHIAT, V17, P414, DOI 10.1016/0163-8343(95)00072-0; BYRNE MM, 1989, ACTA PSYCHIAT SCAND, V80, P138, DOI 10.1111/j.1600-0447.1989.tb07194.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CHURCHILL R, 1998, SYSTEMATIC REV META, P2; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434; CONTE HR, 1986, ARCH GEN PSYCHIAT, V43, P471; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; Cucherat M, 1996, ENCEPHALE, V22, P378; DELINISTULA A, 1995, J AFFECT DISORDERS, V35, P21, DOI 10.1016/0165-0327(95)00034-K; Devane CL, 1996, J CLIN PSYCHIAT, V57, P55; DITZLER K, 1994, COMPLEMENT THER MED, V2, P5; Donoghue J, 1996, BRIT MED J, V313, P861; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; DUNBAR GC, 1995, PHARMACOLOGY, V51, P137, DOI 10.1159/000139327; EGGER M, 1997, BRIT MED J, V314, P629; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Entsuah AR, 1995, PSYCHOPHARMACOL BULL, V31, P759; FAWCETT J, 1995, J CLIN PSYCHIAT, V56, P37; FRANCHINI L, 1994, J AFFECT DISORDERS, V32, P225, DOI 10.1016/0165-0327(94)90085-X; Franchini L, 1997, J CLIN PSYCHIAT, V58, P104, DOI 10.4088/JCP.v58n0303; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE, P5; FREEMANTLE N, 1998, SELECTIVE SEROTONIN, P2; GOLDSTEIN DJ, 1993, CLIN PHARMACOL THER, V54, P245, DOI 10.1038/clpt.1993.144; GOODNICK PJ, 1995, J CLIN PSYCHIAT, V56, P128; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; GREENBERG RP, 1992, J CONSULT CLIN PSYCH, V60, P664, DOI 10.1037/0022-006X.60.5.664; GREENBERG RP, 1994, J NERV MENT DIS, V182, P547, DOI 10.1097/00005053-199410000-00003; HELLERSTEIN DJ, 1993, AM J PSYCHIAT, V150, P1169; HENRY JA, 1995, BRIT MED J, V310, P221, DOI 10.1136/bmj.310.6974.221; Hoffmann J, 1979, ZFA (Stuttgart), V55, P776; HORNIG M, 1998, ALTERNATIVE MED ALER, V1, P4; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; Hotopf M, 1996, BRIT J PSYCHIAT, V168, P404, DOI 10.1192/bjp.168.4.404; Hotopf M, 1997, BRIT J PSYCHIAT, V170, P120, DOI 10.1192/bjp.170.2.120; HOTOPF M, 1998, SYSTEMATIC REV TREAT, P2; Hunkeler E, 1998, INT J PSYCHIAT MED, V28, P389; IBOR JJL, 1993, EUR PSYCHIAT, V8, pS17; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; Kasper S, 1996, INT CLIN PSYCHOPHARM, V11, P35, DOI 10.1097/00004850-199609004-00005; Kasper S, 1995, INT CLIN PSYCHOPHARM, V10, P25, DOI 10.1097/00004850-199512004-00005; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick D, 1998, INT J PSYCHIAT MED, V28, P391; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KNIEBEL R, 1988, Z ALLG MED, V64, P689; LIMA MS, 1998, COMP DRUGS VERSUS PL, P2; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 1998, ST JOHNS WORT DEPRES, P2; Mandoki MW, 1997, PSYCHOPHARMACOL BULL, V33, P149; McCusker J, 1998, ARCH INTERN MED, V158, P705, DOI 10.1001/archinte.158.7.705; MONTGOMERY DE, 1995, MODAL ANAL, V10, P1; MONTGOMERY SA, 1995, INT CLIN PSYCHOPHARM, V9, P33, DOI 10.1097/00004850-199501004-00005; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P35, DOI 10.1097/00004850-199403001-00006; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; MONTGOMERY SA, 1993, INT CLIN PSYCHOPHARM, V8, P189, DOI 10.1097/00004850-199300830-00009; Mulrow CD, 1998, PSYCHOPHARMACOL BULL, V34, P409; MULROW CD, 1999, AHCPR PUBLICATION; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; *N ENGL EV BAS GUI, 1998, CHOIC ANT DEPR PRIM; PARNETTI L, 1993, DRUG INVEST, V6, P181, DOI 10.1007/BF03259242; PEDEN JG, 1995, TREATMENTS PSYCHIAT, P1330; PERSAD E, 1990, CAN J PSYCHIAT, V35, P175, DOI 10.1177/070674379003500214; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Puech A, 1997, INT CLIN PSYCHOPHARM, V12, P99, DOI 10.1097/00004850-199703000-00005; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REH C, 1992, THERAPIEWOCHE, V42, P1576; Rost K, 1998, INT J PSYCHIAT MED, V28, P398; SALZMANN E, 1995, NEUROPSYCHOBIOLOGY, V31, P68, DOI 10.1159/000119175; Schmidt U, 1993, Fortschr Med, V111, P339; SIMEON JG, 1990, PROG NEURO-PSYCHOPH, V14, P791, DOI 10.1016/0278-5846(90)90050-Q; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Smeraldi E, 1998, J AFFECT DISORDERS, V48, P47, DOI 10.1016/S0165-0327(97)00139-0; Sobin C, 1996, BRIT J PSYCHIAT, V169, P322, DOI 10.1192/bjp.169.3.322; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stahl S, 1997, ACTA PSYCHIAT SCAND, V96, P22, DOI 10.1111/j.1600-0447.1997.tb05955.x; Stassen HH, 1996, PHARMACOPSYCHIATRY, V29, P87, DOI 10.1055/s-2007-979551; Steffens D C, 1997, Depress Anxiety, V6, P10, DOI 10.1002/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9; STEGER W, 1985, Z ALLG MED, V61, P914; Szegedi A, 1997, PHARMACOPSYCHIATRY, V30, P97, DOI 10.1055/s-2007-979490; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; TOLLEFSON GD, 1994, J CLIN PSYCHOPHARM, V14, P163; TRINIDADE E, 1997, 19973E19974E CCOHTA; *US DEP HHS, 1993, AHCPR PUBL; Vanelle JM, 1997, BRIT J PSYCHIAT, V170, P345, DOI 10.1192/bjp.170.4.345; VANMOFFAERT M, 1989, NEW TRENDS EXPT CLIN, V5, P167; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; VORBACH EU, 1994, J GERIATR PSYCHIA S1, V7, P519; Wagner W, 1992, Drugs, V43 Suppl 2, P48; Warshaw MG, 1996, J CLIN PSYCHIAT, V57, P158; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; WILSON K, 1998, REV ANTIDEPRESSANT D, P2; Witte B, 1995, Fortschr Med, V113, P404; 1993, AM J PSYCHIAT S4, V150, pR3	114	275	283	0	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					743	756		10.7326/0003-4819-132-9-200005020-00011	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00011			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	308VT	11074910				2023-01-03	WOS:000086734100010
